<SEC-DOCUMENT>0001193125-21-158241.txt : 20210512
<SEC-HEADER>0001193125-21-158241.hdr.sgml : 20210512
<ACCEPTANCE-DATETIME>20210512060826
ACCESSION NUMBER:		0001193125-21-158241
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		36
FILED AS OF DATE:		20210512
DATE AS OF CHANGE:		20210512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vera Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001831828
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				812744449
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-255492
		FILM NUMBER:		21913351

	BUSINESS ADDRESS:	
		STREET 1:		170 HARBOR WAY
		STREET 2:		3RD FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-770-0077

	MAIL ADDRESS:	
		STREET 1:		170 HARBOR WAY
		STREET 2:		3RD FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d96328ds1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML><HEAD>
<TITLE>S-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>As filed with the Securities and Exchange Commission on May 12, 2021. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration No. 333-255492 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE
COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>  <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>AMENDMENT NO. 2
</B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B><I>THE SECURITIES ACT OF 1933
</I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>(Exact name of
registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">81-2744449</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>170 Harbor Way, 3rd Floor </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>South San Francisco,
California 94080 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">770-0077</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Marshall Fordyce, M.D. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Chief Executive Officer
and President </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>170 Harbor Way, 3rd Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>South San Francisco, California 94080 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(650) <FONT
STYLE="white-space:nowrap">770-0077</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service)
</B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Jodie Bourdet</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Carlton Fleming</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cooley LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>101 California Street, 5th Floor</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>San Francisco,
California 94111</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">693-2000</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Jonathan Wolter</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Chief Financial Officer</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>170 Harbor Way, 3rd
Floor</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>South San Francisco, California 94080</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">770-0077</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Heidi Mayon</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Jesse Nevarez</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Goodwin Procter LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>601 Marshall Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Redwood City, California
94063</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">752-3100</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as practicable after this registration statement becomes effective. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the
following box:&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is filed to register additional securities for an offering pursuant
to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT
STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company or an emerging growth company. See the definitions of &#147;large
accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="font-size:1px; font-family:ARIAL; font-size:8pt">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>TITLE OF EACH CLASS&nbsp;OF</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES TO BE REGISTERED</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000"><B>AMOUNT&nbsp;TO&nbsp;BE<BR>REGISTERED<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>PROPOSED&nbsp;MAXIMUM<BR>AGGREGATE&nbsp;OFFERING<BR>PRICE PER SHARE <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>PROPOSED</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>MAXIMUM</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>AGGREGATE<BR>OFFERING&nbsp;PRICE<SUP
STYLE="font-size:85%; vertical-align:top"> (2)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>AMOUNT&nbsp;OF</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION&nbsp;FEE&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Class A Common stock, par value $0.001 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="center">5,002,500</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="center">$16.00</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center">$80,040,000</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center">$8,733</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Includes 652,500 shares of Class A common stock that the underwriters have the option to purchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Estimated solely for purposes of calculating the amount of the registration fee pursuant to Rule 457(a) under the
Securities Act. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">The registration fee was previously paid by the Registrant in connection with the filing of its Registration Statement on
Form S-1 on April 23, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>The Registrant hereby amends this
Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in
accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine.
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#cc062a"><B>The information in this preliminary prospectus is not complete and may be changed. These
securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction
where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><FONT COLOR="#cc062a">SUBJECT TO COMPLETION, DATED MAY 12, 2021 </FONT></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>4,350,000 Shares </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g06h50.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Class A Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">This
is an initial public offering of shares of Class A common stock by Vera Therapeutics, Inc. We are offering 4,350,000 shares of our Class A common stock. The initial public offering price is expected to be between $14.00 and $16.00 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for our Class A common stock.&nbsp;We have applied to list our Class A common stock on The Nasdaq Global Market
under the symbol &#147;VERA.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; as defined under the federal
securities laws and, as such, have elected to comply with certain reduced reporting requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Following this offering, we will have two classes of common
stock: Class A common stock and Class B common stock. The rights of the holders of Class A common stock and Class B common stock are identical, except with respect to voting and conversion. Each share of Class A common stock will be entitled to one
vote and shares of Class B common stock will be non-voting, except as may be required by law. Each share of Class B common stock may be converted at any time into one share of Class A common stock at the option of its holder, subject to the
ownership limitations provided for in our amended and restated certificate of incorporation to become effective upon the closing of this offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts and commissions<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds to Vera Therapeutics, Inc., before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See the section titled &#147;Underwriting&#148; beginning on page 180 for a description of the compensation payable to the underwriters. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have granted the underwriters an option for a period of 30 days to purchase up to 652,500 additional shares of Class A common stock at the initial public offering
price, less the underwriting discounts and commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">At our request, the underwriters have reserved for sale, at the initial public offering price, up to 3% of
the shares of Class A common stock offered hereby to our directors, officers, employees, business associates and related persons through a directed share program. See the section titled &#147;Underwriting&#151;Directed Share Program&#148; for
additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investing in our Class A common stock involves a high degree of risk. See the section titled &#147;<A HREF="#tx96328_2">Risk
Factors</A>&#148; beginning on page&nbsp;14. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of
these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The underwriters expect
to deliver the shares to purchasers on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Evercore&nbsp;ISI</B></TD></TR>
</TABLE> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Prospectus dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_3">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_4">MARKET, INDUSTRY AND OTHER DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_6">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_7">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_8">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_9">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_10">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_11">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_12">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_13">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_14">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_15">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_16">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_17">CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_18">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_19">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_20">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_21">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#tx96328_22">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Through and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 (the 25th day after the date of this
prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an
underwriter and with respect to an unsold allotment or subscription. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we nor the underwriters have authorized anyone to provide you any information or make any representations
other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability
of, any other information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this
prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since
that date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For investors outside of the United States: we have not, and the underwriters have not, done anything that would permit this offering or possession or
distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe
any restrictions relating to, the offering of our securities and the distribution of this prospectus outside of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before
investing in our securities. You should read this entire prospectus carefully, including the sections in this prospectus titled &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations,&#148; and our financial statements and the related notes included elsewhere in this prospectus, before making an investment decision. Unless otherwise indicated, all references in this prospectus to &#147;Vera,&#148; the
&#147;company,&#148; &#147;we,&#148; &#147;our,&#148; &#147;us&#148; or similar terms refer to Vera Therapeutics, Inc. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Our
lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to
produce autoantibodies contributing to certain autoimmune diseases. We are conducting a Phase 2b clinical trial of atacicept in patients with immunoglobulin A nephropathy (IgAN), a disease with a high unmet medical need and no approved therapies.
IgAN is a serious and progressive autoimmune disease of the kidney that is driven by the production of immunogenic galactose-deficient IgA1 <FONT STYLE="white-space:nowrap">(Gd-IgA1).</FONT> IgAN patients with elevated
<FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> are at increased risk of kidney-related morbidity and mortality. As reported in a Phase 2a clinical trial of 16 patients conducted by Merck KGaA, Darmstadt, Germany, atacicept is the first and only
molecule currently in development to demonstrate a 60% reduction in plasma <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> in IgAN patients (75 mg dose, n=4 at 24 weeks), which we believe can be disease modifying. We plan to initiate patient
screening for our Phase 2b clinical trial in IgAN in the second quarter of 2021, and we expect to report topline results in the fourth quarter of 2022. In addition, we are evaluating additional diseases where atacicept&#146;s reduction of
autoantibodies may prove medically useful, including lupus nephritis (LN), a severe renal manifestation of systemic lupus erythematosus (SLE). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Product
Candidate: Atacicept </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Atacicept is a fully humanized fusion protein that impacts the <FONT STYLE="white-space:nowrap">B-cell</FONT> pathway, which has well
characterized implications in immunologic diseases. Specifically, atacicept contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines BLyS and APRIL. These cytokines
are members of the tumor necrosis factor family that promote <FONT STYLE="white-space:nowrap">B-cell</FONT> survival and autoantibody production associated with IgAN and other immunologic diseases. Dual blockade of BlyS and APRIL has been shown to
be more potent than blocking BLyS alone and has the benefit of targeting long-lived plasma cells, in addition to B cells, thus reducing autoantibody production, including <FONT STYLE="white-space:nowrap">Gd-IgA1,</FONT> IgA, IgG, and IgM. Therefore,
atacicept&#146;s mechanism acts directly on the source of many immunologic diseases, including IgAN and LN. Through an integrated analysis of randomized, double-blind, placebo-controlled clinical trials in over 1,500 patients to date, atacicept has
a well-characterized clinical safety profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Atacicept in IgAN </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
estimate there are approximately 126,000 biopsy-confirmed IgAN patients in the United States, 136,000 in the European Union, and 130,000 in Japan. Up to 50% of patients diagnosed with IgAN develop <FONT STYLE="white-space:nowrap">end-stage</FONT>
renal disease (ESRD) within 20 years from initial diagnosis, requiring dialysis or kidney transplant. ESRD causes considerable morbidity and impact on patients&#146; lives and represents a significant health economic burden, which was estimated to
be $49.2&nbsp;billion in the United States in 2018. Despite this high level of morbidity, there are currently no approved treatments indicated for IgAN. The current standard of care consists of <FONT STYLE="white-space:nowrap">off-label</FONT> use
of renin-angiotensin-aldosterone system (RAAS) inhibitors, including angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), as well as steroids. We estimate the U.S. market opportunity for novel therapeutics in
IgAN is approximately $4.0&nbsp;billion to $8.0&nbsp;billion annually, based </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
on the disease prevalence and the segment of IgAN patients at high risk of progressing to ESRD. In Europe and Japan, we estimate the annual market opportunity for novel IgAN therapeutics to be
$1.0&nbsp;billion and $600&nbsp;million, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Atacicept has been shown in clinical trials to reduce <FONT STYLE="white-space:nowrap">Gd-IgA1,</FONT> which
is central to the pathogenesis of IgAN, and therefore has the potential to be the first disease modifying therapy for IgAN due to its ability to act on core pathophysiology processes. Clinical trials of patients with IgAN have correlated higher
serum levels of <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> with greater severity of IgAN disease, suggesting that reduction in serum levels of <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> may slow disease progression. As published in Kidney
International, in a prospective study of 275 patients with IgAN, higher serum levels of aberrantly glycosylated IgA1 demonstrated correlation with a higher likelihood of developing progressive renal failure, as shown in Figure A below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Figure A: Renal Survival in IgAN patients with Four Quartile Serum <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> Levels </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g22p40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that atacicept&#146;s mechanism has the potential to drive clinical success by measures designed to assess efficacy in
IgAN and other immunologic diseases. BLyS inhibition has been clinically and commercially validated through the approval of Benlysta (belimumab) in both SLE and LN. Preclinical and clinical evidence supports that atacicept&#146;s mechanism of dual
inhibition of BLyS and APRIL may provide improved clinical outcomes by measures designed to assess efficacy compared to inhibiting either signal alone. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October
29, 2020, we entered into a worldwide, exclusive license to atacicept from Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, which advanced atacicept in randomized, double-blind, placebo-controlled clinical trials for several
autoimmune diseases in over 1,500 patients. We believe the large and <FONT STYLE="white-space:nowrap">well-characterized</FONT> clinical data set for atacicept provides a competitive advantage for us versus other emerging therapies in development,
many of which are either earlier in development and have clinical profiles that are not as well characterized or are characterized by the well-known acute and chronic side effects of corticosteroids that limit their medical use. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In IgAN, Ares conducted a randomized, double-blind, placebo-controlled Phase 2a clinical trial that enrolled 16
patients, known as JANUS. A&nbsp;clinically meaningful reduction in proteinuria was observed at week 24 in the atacicept group versus an increase in the placebo group, as shown in Figure B below. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Figure B: Proteinuria at Week 24 in the Phase 2a JANUS Trial </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g00c36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Atacicept 75 mg also showed a 60% of <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> reduction at 24 weeks (as shown in Figure C
below), the largest magnitude in reduction of <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> in IgAN patients by any molecule in development for IgAN. Clear dose-dependent reductions of serum <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> were
observed over the <FONT STYLE="white-space:nowrap">72-week</FONT> period studied, with atacicept 75 mg reducing <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> significantly (60%) and durably. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Figure C: Serum <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> Levels Over Time in the Phase 2a JANUS Trial </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g13v55.jpg" ALT="LOGO">
 </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are conducting a global, randomized, double-blind, placebo-controlled Phase 2b clinical trial in IgAN, which we
refer to as ORIGIN. The ORIGIN trial is designed to evaluate three subcutaneous weekly doses of atacicept (25 mg, 75 mg, and 150 mg) and their impact on the reduction of proteinuria as the primary endpoint. A significant reduction in proteinuria, as
measured by urine protein to creatinine ratio (UPCR) in a <FONT STYLE="white-space:nowrap">24-hour</FONT> urine collection, is associated with improved renal outcomes in patients with IgAN. UPCR is a surrogate endpoint endorsed by the U.S. Food and
Drug Administration (FDA) for primary glomerular diseases associated with significant proteinuria, including IgAN. The Phase 2b ORIGIN trial is powered to demonstrate a statistically significant difference between atacicept and placebo in decrease
of proteinuria. Secondary endpoints include the difference in kidney function between treated and placebo patients as measured by estimated glomerular filtration rate and reduction in <FONT STYLE="white-space:nowrap">Gd-IgA1.</FONT> We plan to
initiate patient screening for our Phase 2b clinical trial in the second quarter of 2021 and we expect to report topline results from ORIGIN in the fourth quarter of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Atacicept in LN </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are evaluating further development of atacicept as a
potential treatment for patients with LN, a severe renal manifestation of SLE. We estimate that there are approximately 110,000 LN patients in the United States, 69,000 in the European Union, and 22,000 in Japan. We estimate the market for novel LN
therapeutics annually to be approximately $2.0 to $5.0&nbsp;billion, $600&nbsp;million, and $200&nbsp;million in United States, Europe, and Japan, respectively. Significant unmet need for improved efficacy persists for these patients despite the
recent approval of the first two <FONT STYLE="white-space:nowrap">LN-specific</FONT> therapies. Fewer than half of patients treated for LN have a complete response to therapy, and among patients without a complete response, over half will have <FONT
STYLE="white-space:nowrap">non-functioning</FONT> kidneys within five years. Benlysta (belimumab), a BlyS-only inhibitor, is one of the two therapies now approved for patients with LN. Both BlyS and APRIL levels are increased in patients with SLE,
suggesting that dual inhibition by atacicept may be more potent than blocking BLyS alone and has the benefit of targeting plasma cells in addition to B cells. Merck KGaA, Darmstadt, Germany previously initiated a randomized, double-blind,
placebo-controlled Phase 2/3 clinical trial of atacicept in LN, the APRIL-LN trial, designed to evaluate the efficacy and safety of atacicept at 150 mg twice weekly for four weeks - then weekly - in patients with active LN. However, this trial was
terminated early due to two subjects developing hypogammaglobulinemia with induction therapy (MMF and CS) which continued to worsen when initiating atacicept and subsequently developed pneumonia. In a prior Phase 2 clinical trial of atacicept in SLE
also conducted by Merck KGaA, Darmstadt, Germany, despite missing its primary endpoint of improved SLE responder index 4 (SRI-4) at week 24, in the broader SLE study population, atacicept achieved positive clinical data on multiple measures within
the pre-specified High Disease Activity patient segment (defined as Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) <FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT> 10 at
screening), including reduction of renal flares, which we believe supports atacicept&#146;s applicability in LN. Because both preclinical and clinical evidence suggests atacicept&#146;s dual inhibition of BLyS and APRIL may provide improved clinical
outcomes, measured by endpoints designed to assess efficacy, than inhibiting either signal alone, we believe there is a strong rationale to conduct a clinical trial of atacicept in LN. We intend to discuss our development plans for LN with the FDA
and obtain feedback in the second half of 2021 and expect to initiate a Phase 2b or Phase 3 clinical trial in 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Patent Portfolio; Potential Market
Exclusivity </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of April 30, 2021, our licensed patent portfolio related to atacicept contains approximately 15 issued U.S. patents, as well as certain foreign
counterparts of a subset of these patents in several foreign countries, including countries within the European Patent Convention and the Eurasian Patent Organization. Because atacicept is a biologic, marketing approval would also provide 12 years
of market exclusivity from the approval date of a Biologics License Application in the United States. Additionally, we plan to seek orphan drug designation for atacicept in IgAN from the FDA and European Medicines Agency (EMA), which would allow us
to obtain regulatory exclusivity protection from the approval date for seven years in the United States and 10 years in the European Union. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Business Principles and Strategy </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our goal is to develop and commercialize transformative treatments for patients suffering from severe immunological diseases. We believe the successful translation of
biomedical science into innovative therapeutic products for patients with immunological diseases will enable outsized growth over the next decade and beyond. Specifically, our strategy is based on the following business principles: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Develop disease modifying medicines to improve patients&#146; lives. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Establish clear <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">line-of-sight</FONT></FONT> to
successful products. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Build a leading biotech company that delivers innovative medicines to patients. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These principles have guided us to the successful <FONT STYLE="white-space:nowrap">in-licensing</FONT> of atacicept from Merck KGaA, Darmstadt, Germany with worldwide
rights for development and commercialization in all indications. We take a gated-capital raise approach and scale product candidate investment and exposure in close step with key development milestones to ensure high return on development costs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The key elements of our strategy to achieve our goal include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Complete global development of atacicept in IgAN. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Advance atacicept in LN. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Explore additional disease areas where atacicept holds significant therapeutic promise. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Build and scale organizational capabilities to support commercialization of atacicept. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Expand our pipeline by acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> product candidates for
immunologic diseases with unmet needs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Team </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
were founded and are led by a team of experienced drug development professionals who have proven track records in clinical and commercial development and have led or been involved in the approvals of 10 medicines from Gilead Sciences. Inc. (Gilead)
and Genentech, Inc. (Genentech), including numerous drugs within Gilead&#146;s multi-billion blockbuster HIV and HCV franchises. Our Chief Executive Officer, Marshall Fordyce, M.D., brings more than 15 years of experience leading teams in clinical
translation, development, and commercialization of new treatments. Earlier in his career, Dr.&nbsp;Fordyce served as Gilead&#146;s Senior Director of Clinical Research where he contributed to seven new drug approvals and served as project lead for
Gilead&#146;s tenofovir alafenamide development program that led to five commercial products, including Genvoya and Descovy, which collectively generated over $12.0&nbsp;billion in worldwide sales in 2019. Our senior management team also includes:
Chief Medical Officer, Celia Lin, M.D., who joined from Genentech and was previously at Amgen Inc., where she led Phase 3 global trial execution in various therapeutic areas, as well as a regulatory filing in an orphan disease; Chief Development
Officer, Joanne Curley, Ph.D., who was formerly head of Portfolio Management at Gilead; Chief Business Officer, Lauren Frenz, who held positions of increasing responsibility within Gilead&#146;s commercial organization; Chief Financial Officer,
Jonathan Wolter, who is a partner at FLG Partners, LLC, and has served as Chief Financial Officer for multiple public and private companies; Senior Vice President, Development Operations, Tom Doan, who was formerly Executive Director of Clinical
Operations and Therapeutic Area Head of Inflammation and Respiratory at Gilead; Senior Vice President and Head of Product Development and Manufacturing, Tad Thomas, Ph.D., who was formerly Associate Vice President, Technical Operations at Codexis,
Inc. and held previous manufacturing leadership roles at Bayer HealthCare LLC and other biopharmaceutical companies; and Senior Vice President, Finance and Chief Accounting Officer, Joseph Young, who was formerly Senior Vice President, Finance and
Treasurer at Plexxikon Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Leading Life Sciences Investors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
conjunction with the license agreement with Ares, we completed an approximately $80.0&nbsp;million Series C redeemable convertible preferred stock financing led by Abingworth LLP. Investors included Sofinnova
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Investments, Longitude Capital, Fidelity Management&nbsp;&amp; Research Company LLC, Surveyor Capital (a Citadel company), Octagon Capital, Kleiner Perkins, GV (formerly Google Ventures), and
Alexandria Venture Investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Business </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Investing in our securities involves substantial risk. The risks, described under the section titled &#147;Risk Factors&#148; immediately following this prospectus
summary, may cause us to not realize the full benefits of our strengths or may cause us to be unable to successfully execute all or part of our strategy. Some of the more significant risks and challenges include, without limitation, the following:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We have not completed any clinical trials for our lead product candidate, atacicept, and have no products approved for
commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We have incurred net losses since inception, and we expect to continue to incur net losses for the foreseeable future.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Even if this offering is successful, we will require substantial additional capital to finance our operations.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We are substantially dependent on the success of our only product candidate, atacicept, which is currently in the early
stages of clinical development. If we are unable to complete development of, obtain regulatory approval for and commercialize atacicept in one or more indications and in a timely manner, our business, financial condition, results of operations and
prospects will be significantly harmed. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more
difficult or rendered impossible by multiple factors outside our control, including difficulties in identifying patients with IgAN and significant competition for recruiting such patients in clinical trials. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The incidence and prevalence for target patient populations of atacicept in specific indications are based on estimates
and third-party sources. If the market opportunities for atacicept, or any future product candidate we may develop, if and when approved, are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient
population, our revenue and ability to achieve profitability might be materially and adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Interim, initial, <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> and preliminary data from our clinical
trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We face significant competition, which may result in others discovering, developing or commercializing products before or
more successfully than us. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Changes in methods of atacicept manufacturing or formulation may result in additional costs or delays.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Atacicept, and any future product candidates we develop, may cause significant adverse events, toxicities or other
undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial
potential or result in significant negative consequences. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Even if atacicept, or any product candidate we develop in the future, receives regulatory approval, it could be subject to
significant post-marketing regulatory requirements and will be subject to continued regulatory oversight. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Biosimilars to atacicept may provide competition sooner than anticipated. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The outbreak of the novel coronavirus (COVID-19) could adversely impact our business, including our clinical trials.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our success depends on our ability to protect our intellectual property and our proprietary technologies. If we or our
potential licensors, licensees, or collaborators are unable to obtain or maintain patent protection with respect to atacicept and our other products, proprietary technologies and their uses, our business, financial condition, results of operations
and prospects could be significantly harmed. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If we breach our license agreement with Ares, an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, we
could lose the ability to continue the development and commercialization of atacicept. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may be required to make significant payments under our license agreement for atacicept. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our
ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Patent terms may be inadequate to protect our competitive position on atacicept or any future product candidates we may
develop for an adequate amount of time. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If third parties, on which we rely to conduct certain aspects of our nonclinical studies and clinical trials, do not
successfully carry out their contractual duties, comply with applicable regulatory requirements, or meet expected deadlines, we may not be able to obtain regulatory approval for, or commercialize, atacicept or future product candidates we may
develop, and our business, financial condition, results of operations and prospects could be significantly harmed. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of
our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of atacicept for clinical trials or our product for patients, if approved, could be delayed or prevented. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The price of our stock may be volatile, and you could lose all or part of your investment. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If the remediation of the material weakness in our internal control over financial reporting is not effective, or if we
experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately or timely report our financial condition or results of operations, which
may adversely affect investor confidence in us and, as a result, the value of our securities. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant
control over matters subject to stockholder approval. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law could
make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may be subject to securities litigation, which is expensive and could divert management attention.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate Information </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were initially incorporated
in Delaware in May 2016 under the name CDF Therapeutics, Inc. In October 2017, we changed our name to Trucode Gene Repair, Inc., and in April 2020, we changed our name to Vera Therapeutics, Inc. Our principal executive offices are located at 170
Harbor Way, 3rd Floor, South San Francisco, California 94080, and our telephone number is (650) <FONT STYLE="white-space:nowrap">770-0077.</FONT> Our website address is www.veratx.com. Information contained in, or accessible through, our website is
not a part of this prospectus, and the inclusion of our website address in this prospectus is only an inactive textual reference. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We use the VERA THERAPEUTICS word
mark, Vera Therapeutics logo and other marks as trademarks in the United States and other countries. This prospectus contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks
and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or <SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> symbols,
but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
not intend our use or display of other entities&#146; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Implications of Being an Emerging Growth Company and Smaller Reporting Company </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). We may take advantage of certain exemptions from
various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm under Section&nbsp;404 of the Sarbanes-Oxley Act of 2002
(the Sarbanes-Oxley Act), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any
golden parachute payments. In particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation related information that would be required if we were not an
emerging growth company. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock. We will remain an emerging growth company until the earliest of
(i)&nbsp;the last day of our first fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the completion of this offering; (iii)&nbsp;the date
on which we are deemed to be a &#147;large accelerated filer,&#148; under the rules of the SEC, which means the market value of equity securities that is held by non-affiliates exceeds $700.0 million as of the prior June 30th; and (iv)&nbsp;the date
on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the JOBS Act provides that an
emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of accounting standards that have different
effective dates for public and private companies until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, we will not be subject to the same requirements to adopt new or
revised accounting standards as other public companies that are not &#147;emerging growth companies.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are also a &#147;smaller reporting company&#148; as
defined in the Securities Exchange Act of 1934, as amended (Exchange Act). We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available
to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal
year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter.
Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and have reduced disclosure
obligations regarding executive compensation, and, similar to emerging growth companies, if we are a smaller reporting company with less than $100&nbsp;million in annual revenue, we would not be required to obtain an attestation report on internal
control over financial reporting issued by our independent registered public accounting firm. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE OFFERING </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL"><B>Class A common stock offered</B> </P></TD>
<TD>4,350,000&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL"><B>Underwriters&#146; option to purchase additional shares</B> <B>of Class&nbsp;A common stock</B> </P></TD>
<TD>We have granted the underwriters an option for a period of 30 days to purchase up to 652,500 additional shares of our Class A common stock at the initial offering price, less underwriting discounts and commissions. </TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL"><B>Total Class A and Class B common stock to be outstanding after this offering</B> </P></TD>
<TD>20,479,310&nbsp;shares (or 21,131,810 shares if the underwriters exercise their option to purchase additional shares in full) </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL"><B>Use of proceeds</B> </P></TD>
<TD>We estimate that the net proceeds from this offering will be approximately $57.6&nbsp;million (or approximately $66.7&nbsp;million if the underwriters&#146; option to purchase additional shares is exercised in full), after deducting underwriting
discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund the clinical development of atacicept in IgAN, LN and potential additional indications, and
the remaining for working capital and other general corporate purposes. See the section titled &#147;Use of Proceeds&#148; for additional information. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL"><B>Voting rights</B> </P></TD>
<TD>Following this offering, we will have two classes of common stock: Class&nbsp;A common stock and Class&nbsp;B common stock. The rights of the holders of Class&nbsp;A common stock and Class&nbsp;B common stock are identical, except with respect
to voting and conversion. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each share of Class&nbsp;A common stock will be entitled to one vote and shares of Class&nbsp;B common stock will be non-voting, except as may be required by law. Each share of Class&nbsp;B common stock may be converted
into one share of Class&nbsp;A common stock at the option of its holder, subject to the ownership limitations provided for in our amended and restated certificate of incorporation to become effective upon the closing of this offering. See the
section titled &#147;Description of Capital Stock&#148; for additional information. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL"><B>Risk factors</B> </P></TD>
<TD>See the section titled &#147;Risk Factors&#148; beginning on page&nbsp;14 and other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our securities. </TD></TR></TABLE>
 <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL"><B>Directed share program</B> </P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">At our request, the underwriters have reserved for sale, at the initial public offering price, up to 3% of the shares of Class&nbsp;A common stock offered hereby
to our directors, officers, employees, business associates and related persons through a directed share program. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:9.5pt; font-family:ARIAL">
Shares purchased through the directed share program will not be subject to a lock-up restriction, except in the case of shares purchased by any of our directors or officers and certain of our
employees and existing equity holders. The number of shares of Class A common stock available for sale to the general public will be reduced to the extent these individuals purchase such reserved shares. Any reserved shares not so purchased will be
offered by the underwriters to the general public on the same basis as the other shares of Class A common stock offered by this prospectus. See the section titled &#147;Underwriting&#151;Directed Share Program&#148; for additional information.
</P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL"><B>Proposed Nasdaq Global Market trading symbol</B> </P></TD>
<TD>&#147;VERA&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares of our Class A common stock and Class B common stock to be outstanding after this offering is based on
16,129,310 shares of Class A common stock and no&nbsp;shares of Class B common stock outstanding as of December&nbsp;31, 2020 (including (i) 15,774,014 shares issuable upon the conversion of all outstanding shares of our redeemable convertible
preferred stock as of December&nbsp;31, 2020 and (ii) 41,363 shares of unvested restricted common stock subject to repurchase as of such date), and excludes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1,855,507 shares of our Class A common stock issuable upon the exercise of outstanding stock options as of
December&nbsp;31, 2020 under our 2017 Equity Incentive Plan, as amended (2017 Plan), with a weighted-average exercise price of $2.99 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">484,956 shares of our Class A common stock issuable upon the exercise of outstanding stock options granted subsequent to
December&nbsp;31, 2020 under our 2017 Plan, with a weighted-average exercise price of $3.93 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1,762,009 shares of our Class A common stock reserved for future issuance under our 2021 Equity Incentive Plan (2021
Plan), which will become effective once the registration statement of which this prospectus forms a part is declared effective, as well as any future automatic annual increases in the number of shares of Class A common stock reserved for issuance
under our 2021 Plan and any shares of Class A common stock underlying outstanding stock awards granted under our 2017 Plan that expire or are repurchased, forfeited, cancelled or withheld, as more fully described in the section titled
&#147;Executive Compensation&#151;Equity Benefit Plans&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">220,251 shares of our Class A common stock reserved for issuance under our 2021 Employee Stock Purchase Plan (ESPP), which
will become effective once the registration statement of which this prospectus forms a part is declared effective, and any future automatic annual increases in the number of shares of Class A common stock reserved for future issuance under our ESPP;
and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">450,326 shares of our Class A common stock issuable upon the exercise of options to purchase shares of our Class A common
stock granted to certain of our officers, directors and employees under our 2021 Plan, which will become effective in connection with this offering, at an exercise price per share equal to the initial public offering price in this offering.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise indicated, this prospectus assumes or gives effect to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">11.5869-for-one</FONT></FONT> reverse stock split of
our common stock effected on May 7, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the automatic conversion of all outstanding shares of our redeemable convertible preferred stock as of December&nbsp;31,
2020 into an aggregate of 15,774,014 shares of our Class A common stock upon the closing of this offering; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">no exercise of the outstanding options described above; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">no exercise by the underwriters of their option to purchase 652,500 additional shares of Class A common stock from us in
this offering; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">no issuance of shares of Class B common stock upon the conversion of our redeemable convertible preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an assumed initial public offering price of $15.00 per share of Class A common stock, which is the midpoint of the price
range set forth on the cover page of this prospectus; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the filing and effectiveness of our amended and restated certificate of incorporation immediately after the closing of
this offering, and the adoption of our amended and restated bylaws upon the closing of this offering. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following tables set forth a summary of our financial data as of, and for the periods ended on, the periods indicated. We have derived the summary statements of
operations and comprehensive loss data for the years ended December&nbsp;31, 2019 and 2020, and balance sheet data as of December&nbsp;31, 2020, from our audited financial statements included elsewhere in this prospectus. Our historical results are
not necessarily indicative of the results that may be expected for any period in the future. You should read the following summary financial data together with the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition
and Results of Operations&#148; and our financial statements and the related notes included elsewhere in this prospectus. The summary financial data included in this section are not intended to replace the financial statements and are qualified in
their entirety by our financial statements and the related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Year Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(in thousands, except share</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>and per share data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gain on the issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,076</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income(expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per common share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(40.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(166.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average shares used to compute net loss per common share, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss per common share, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average shares used to compute pro forma net loss per common share, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,076,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note 2 to our financial statements included elsewhere in this prospectus for a description of how we compute basic and diluted net loss per share attributable to common stockholders. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The unaudited pro forma net loss per common share for the year ended December 31, 2020 was computed using the weighted-average number of shares of common stock outstanding, including the pro forma effect of the
conversion of all outstanding shares of redeemable convertible preferred stock into 15,774,014 shares of Class A common stock and no shares of Class B common stock, as if such conversion had occurred at the beginning of the period, or their issuance
dates, if later. The unaudited pro forma net loss per common share does not include the shares expected to be sold in, and related proceeds to be received from, the Company&#146;s initial public offering of Class A common stock. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO<BR>FORMA<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO FORMA</B><br><B>AS<BR>ADJUSTED<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">111,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(89,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma column in the balance sheet data gives effect to (i)&nbsp;the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of 15,774,014 shares of Class A
common stock and no shares of Class B common stock which will occur upon the closing of this offering and the related reclassification of the carrying value of our redeemable convertible preferred stock to permanent equity upon the closing of this
offering, and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation that will be in effect immediately after the closing of this offering. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma as adjusted column in the balance sheet data gives effect to (i)&nbsp;the items described in footnote (1)&nbsp;above and (ii)&nbsp;the issuance and sale of 4,350,000&nbsp;shares of our Class A common stock
in this offering at the assumed initial public offering price of $15.00 per share after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma as adjusted information is illustrative only and will depend on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the
assumed initial public offering price of $15.00 per share would increase or decrease, as applicable, each of cash and cash equivalents, working capital, total assets and total stockholders&#146; equity (deficit) by $4.0&nbsp;million, assuming that
the number of shares of Class A common stock offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each
increase or decrease of 1.0&nbsp;million shares in the number of shares of Class A common stock offered by us would increase or decrease, as applicable, each of cash and cash equivalents, working capital, total assets, and total stockholders&#146;
equity (deficit) by $14.0&nbsp;million, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets less current liabilities. See our financial statements and related notes included elsewhere in this prospectus for further details regarding our current assets and current
liabilities. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing in our Class A common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in
this prospectus, including our financial statements and the related notes and the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; before deciding whether to invest in our
securities. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our Class A common stock could decline,
and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks related to our financial position and need for additional capital </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have not completed any clinical trials for our lead product candidate, atacicept, and have no products approved for commercial sale, which may make it
difficult for you to evaluate our current business and predict our future success and viability. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical-stage biotechnology company and we have
no products approved for commercial sale, have not generated any revenue from product sales and have incurred losses since inception. To date, we have devoted substantially all of our resources and efforts to organizing and staffing our company,
business planning, executing partnerships, raising capital, acquiring, developing and securing our lead technology and product candidate, atacicept, and initiating a Phase 2b study to further evaluate atacicept in patients with IgAN. We have not yet
demonstrated our ability to successfully complete any clinical trials with respect to atacicept, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing
activities necessary for successful product commercialization. As a result, it may be more difficult for you to accurately predict our future success or viability than it could be if we had a longer operating history. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by
clinical-stage biotechnology companies in rapidly evolving fields. We may face difficulty transitioning from a company with a research focus to a company capable of successfully executing drug development activities and supporting commercial
operations. If we do not adequately address these risks and difficulties or successfully make such a transition, our business, financial condition, results of operations and prospects will be significantly harmed. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if this offering is successful, we will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed,
or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs of our only product or future commercialization efforts. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Developing treatments for immunological and inflammatory diseases, including conducting nonclinical studies and clinical trials, is a very time-consuming, expensive and
uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses will increase in connection with our ongoing activities, particularly as we continue to conduct
clinical trials of, and seek marketing approval for, atacicept. With only one product candidate in development, we anticipate incurring significant costs associated with the development of atacicept. Our expenses could increase beyond expectations
if we are required by the FDA, or any comparable foreign regulatory authority to perform clinical trials or nonclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also arise. In addition, if we obtain
marketing approval for atacicept, we expect to incur significant commercialization expenses related to drug sales, marketing, manufacturing and distribution. Because the design and outcome of our planned and anticipated clinical trials are highly
uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidate we develop. Following this offering, we also expect to incur additional costs associated
with operating as a public company. Accordingly, we will need to obtain substantial additional funding in order to maintain our continuing operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of
December&nbsp;31, 2020, we had $53.7&nbsp;million in cash and cash equivalents. Based on our current operating plans, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
be sufficient to fund our operating expenses and capital expenditures requirements for at least the next 18 months. Our estimate as to how long we expect the net proceeds from this offering,
together with our existing cash and cash equivalents, to be able to continue to fund our operating expenses and capital expenditures requirements is based on assumptions that may prove to be wrong, and we could use our available capital resources
sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.
Moreover, it is particularly difficult to estimate with certainty our future expenses given the dynamic nature of our business, the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the macro-economic environment generally. We
anticipate that our expenses will increase substantially if, and as, we: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continue our ongoing and planned research and development of our product candidate, atacicept, for the treatment of IgAN
and LN; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">initiate nonclinical studies and clinical trials for atacicept and any additional product candidates that we may pursue in
the future; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">seek to discover and develop additional product candidates and further expand our clinical product pipeline;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">seek regulatory approvals for any product candidates that successfully complete clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continue to scale up external manufacturing capacity with the aim of securing sufficient quantities to meet our capacity
requirements for clinical trials and potential commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establish a sales, marketing and distribution infrastructure to commercialize any approved product candidates and related
additional commercial manufacturing costs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">develop, maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets, and
know how; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acquire, develop or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">attract, hire and retain additional clinical, scientific, quality control, and manufacturing management and administrative
personnel; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">add clinical, operational, financial and management information systems and personnel, including personnel to support our
product development and planned future commercialization efforts; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">incur additional legal, accounting, investor relations and other expenses associated with operating as a public company.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to use the net proceeds from this offering to advance and expand our clinical and nonclinical development programs and for working
capital and other general corporate purposes. Advancing the development of atacicept and any future product candidates we may develop will require a significant amount of capital. The net proceeds from this offering and our existing cash and cash
equivalents will not be sufficient to fund all of the activities that are necessary to complete the development of atacicept. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will be required to obtain further
funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, which may dilute our stockholders or restrict our operating activities. Adequate additional financing may not be
available to us on acceptable terms, or at all. Market volatility, including as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, could also adversely impact our ability to access capital as and when needed. Our failure to
raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our
research-stage programs, clinical trials or future commercialization efforts. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have incurred net losses since inception, and we expect to continue to incur
net losses for the foreseeable future. In addition, we may be unable to continue as a going concern over the long-term. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have incurred net losses in each
reporting period since the commencement of our operations, have not generated any revenue from product sales to date and have financed our operations principally through private financings. We have incurred net losses of $11.9&nbsp;million and
$53.4&nbsp;million for the years ended December&nbsp;31, 2020 and 2019. We had an accumulated deficit of $91.4&nbsp;million as of December&nbsp;31, 2020. Our losses have resulted principally from expenses incurred in research and development and
from management and administrative costs and other expenses that we have incurred while building our business infrastructure, a significant portion of which were incurred </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
resulting from our efforts to develop <FONT STYLE="white-space:nowrap">gamma-PNA</FONT> chemistry and triplex gene editing for therapeutic use, which we discontinued in September 2020. Our only
product candidate, atacicept, is in early-stage clinical trials. As a result, we expect that it will be several years, if ever, before we have a commercialized product and generate revenue from product sales. Even if we succeed in receiving
marketing approval for and commercializing atacicept in one of our lead indications, we expect that we will continue to incur substantial research and development and other expenses as we continue the clinical development programs for atacicept in
other indications. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to continue to incur increased expenses and operating losses for the foreseeable future as we continue our research and development
efforts and seek to obtain regulatory approval for atacicept. The net losses we incur may fluctuate significantly from quarter to quarter such that a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT>
comparison of our results of operations may not be a good indication of our future performance. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior
losses and expected future losses have had, and will continue to have, an adverse effect on our working capital. In any particular period, our operating results could be below the expectations of securities analysts or investors, which could cause
our stock price to decline. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our audited financial statements for the year ended December&nbsp;31, 2020 included elsewhere in this prospectus have been
prepared assuming we will continue as a going concern. However, we have incurred losses and negative cash flows from operations. As a development stage company, we expect to incur significant and increasing losses until regulatory approval is
granted for atacicept. Regulatory approval is not guaranteed and may never be obtained. As a result, these conditions raise substantial doubt about our ability to continue as a going concern over the long-term. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have never generated revenue from product sales and may never be profitable. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with our collaboration partners, to successfully complete
the development of, and obtain the regulatory approvals necessary to commercialize, atacicept and any future product candidates we may develop. We do not anticipate generating revenue from product sales for the next several years, if ever. Our
ability to generate revenue from product sales depends heavily on our and our current and potential future collaborators&#146; success in: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">completing clinical development of product candidates and programs and identifying and developing new product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">seeking and obtaining marketing approvals for any product candidates that we develop; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">launching and commercializing product candidates for which we obtain marketing approval by establishing a sales force,
marketing, medical affairs and distribution infrastructure or, alternatively, collaborating with a commercialization partner; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">achieving adequate access and reimbursement by government and third-party payors for product candidates that we develop;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate, in both
amount and quality, products and services to support clinical development and the market demand for product candidates that we develop, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining market acceptance of product candidates that we develop as viable treatment options; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">addressing any competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">maintaining our rights under our existing license agreement with Ares and any similar agreements we may enter into in the
future; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing
our obligations in such collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">maintaining, protecting, enforcing and expanding our portfolio of intellectual property rights, including patents, trade
secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">defending against third-party interference, infringement or other intellectual property-related claims, if any; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">attracting, hiring and retaining qualified personnel. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if atacicept or any future product candidate that we may develop is approved for commercial sale, we anticipate
incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the FDA or comparable foreign regulatory authorities to perform clinical trials or
nonclinical studies in addition to those that we currently anticipate. Even if we are able to generate revenue from the sale of any approved products, we may not be able to reach or sustain profitability, and may need to obtain additional funding to
continue operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks related to the discovery, development and commercialization of our product candidate </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are substantially dependent on the success of our only product candidate, atacicept, which is currently in the early stages of clinical development. If we are
unable to complete development of, obtain regulatory approval for and commercialize atacicept in one or more indications and in a timely manner, our business, financial condition, results of operations and prospects will be significantly harmed.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our future success is heavily dependent on our ability to timely complete clinical trials, obtain marketing approval for and successfully commercialize
atacicept, our only product candidate. We expect that a substantial portion of our efforts and expenses over the next several years will be devoted to the development of atacicept in our ongoing clinical trials in patients with IgAN, as well as our
efforts to evaluate atacicept in LN. We are investing significant efforts and financial resources in the research and development of atacicept, which will require additional clinical development, evaluation of clinical, nonclinical and manufacturing
activities, marketing approval from government regulators, and significant marketing efforts before we can generate any revenues from product sales. We are not permitted to market or promote atacicept before we receive marketing approval from the
FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals. Should our planned clinical development of atacicept in patients with IgAN fail to be completed in a timely manner or at all, we will need to rely
on clinical development of atacicept in additional indications, which will require more time and resources to obtain regulatory approval and proceed with commercialization, and may ultimately be unsuccessful. We cannot assure you that our planned
clinical development programs for atacicept will be completed in a timely manner, or at all, or that we will be able to obtain approval for&nbsp;atacicept&nbsp;from the FDA or comparable foreign regulatory authorities. If we are unable to complete
development of, obtain regulatory approval for and commercialize atacicept in one or more indications and in a timely manner, our business, financial condition, results of operations and prospects will be significantly harmed. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial
results. Failure can occur at any stage of clinical development. We have never completed a clinical trial for atacicept or submitted a Biologics License Application (BLA) to the FDA or similar drug approval filings to comparable foreign authorities.
If we are ultimately unable to obtain regulatory approval for atacicept, we will be unable to generate product revenue and our business, financial condition, results of operations and prospects will be significantly harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial
process. The results of nonclinical studies and early clinical trials of atacicept and any future product candidates we may develop may not be predictive of the results of subsequent clinical trials. We have a limited operating history and to date
have not demonstrated our ability to complete large scale clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Product candidates in later stages of clinical trials may fail to show the desired
safety and efficacy traits despite having progressed through nonclinical studies and initial clinical trials. For example, atacicept has been the subject of clinical trials by prior sponsors, including a Phase 2 trial in SLE, that missed its primary
endpoint in the overall study population. In the future, clinical trial failures may result from a multitude of factors including flaws in trial design, dose selection, placebo effect and patient enrollment criteria. A number of companies in the
biotechnology industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we or any
potential future collaborator may decide, or regulators may require us, to conduct additional clinical trials or nonclinical studies. In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may
not interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval. Any future delays or abandonment could harm our business, financial condition, results of operations and prospects.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Even if our clinical trials are completed as planned, we cannot be certain that their results will support our proposed indications. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our future clinical trials may not be successful. If any product candidate is found to be unsafe or lack efficacy, we will not be able to obtain regulatory approval for
it and our business, financial condition, results of operations and prospects may be significantly harmed. In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product
candidate due to numerous factors, including changes in trial protocols, differences in composition of the patient populations, adherence to the dosing regimen and other trial protocols and the dropout rate among clinical trial participants.
Patients treated with atacicept or product candidates we may develop in the future may also be undergoing surgical, radiation and chemotherapy treatments and may be using other approved products or investigational new drugs, which can cause side
effects or adverse events that are unrelated to atacicept or product candidates we may develop. As a result, assessments of efficacy can vary widely for a particular patient, and from patient to patient and site to site within a clinical trial. This
subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes. We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain marketing
approval to market atacicept or any future product candidates we may develop. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not know whether our current clinical trial of atacicept or any future clinical
trials we may conduct will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market atacicept or any future product candidates we may develop. Most product candidates that begin clinical trials are never
approved by regulatory authorities for commercialization. If we are unable to bring atacicept or any future product candidates to market, our ability to create long-term shareholder value will be limited. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we may rely in part on nonclinical, clinical and quality data generated by contract research organizations (CROs) and other third parties for regulatory
submissions for atacicept. While we have or will have agreements governing these third parties&#146; services, we have limited influence over their actual performance. If these third parties do not make data available to us, or, if applicable, make
regulatory submissions in a timely manner, our development programs may be significantly delayed, and we may need to conduct additional studies or collect additional data independently. In either case, our development costs would increase. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, nonclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates
performed satisfactorily in nonclinical studies and clinical trials nonetheless failed to obtain FDA or comparable foreign regulatory authority approval. We cannot guarantee that the FDA or foreign regulatory authorities will interpret trial results
as we do, and more trials could be required before we are able to submit an application seeking approval of atacicept or any future product candidates we may develop. To the extent that the results of the trials are not satisfactory to the FDA or
foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of atacicept or any future
product candidates we may develop. Even if regulatory approval is secured for atacicept, the terms of such approval may limit the scope and use of atacicept, which may also limit its commercial potential. Furthermore, the approval policies or
regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval, which may lead to the FDA or comparable foreign regulatory authorities delaying, limiting
or denying approval of atacicept, including and any other indication we are seeking for approval under atacicept. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Delays in clinical trials are common and
have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval and commence product sales. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may experience delays in clinical trials of atacicept or any future product candidate we may develop. Our planned clinical trials may not begin on time, have an
effective design, enroll a sufficient number of patients, or be completed on schedule, if at all. Our clinical trials can be delayed for a variety of reasons, including delays related to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on trial
design; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to
extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining approval from one or more institutional review boards (IRBs); </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of
additional subjects, or withdrawing their approval of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes to clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">clinical sites deviating from trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">study conduct issues, which could confound the clinical endpoints and/or data; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">manufacturing sufficient quantities of clinical trial material to supply the clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">subjects failing to enroll or remain in our trial at the rate we expect, or failing to return for post- treatment <FONT
STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in enrollment due to low prevalence or incidence rates of subjects with the applicable disease;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in enrollment by subjects, or completion of the trial by subjects, due to the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">subjects choosing an alternative treatment for the indication for which we are developing atacicept, or participating in
competing clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">lack of adequate funding to continue the clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">subjects experiencing severe or unexpected drug-related adverse effects; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory authorities imposing a clinical hold; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">occurrence of serious adverse events in trials of the same class of agents conducted by other companies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">shutdowns, either temporarily or permanently, of any facility manufacturing atacicept or any future product candidate we
may develop or any of their components, including by order from the FDA or comparable foreign regulatory authorities due to violations of current good manufacturing practice (cGMP), regulations or other applicable requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing
our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices (GCP) or other regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">third-party contractors not performing data collection or analysis in a timely or accurate manner; or
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory
authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may increase the likelihood that we encounter
such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. For example, in 2020 some hospitals delayed initiating clinical trials due to their focus on treating <FONT
STYLE="white-space:nowrap">COVID-19</FONT> patients. Manufacturing timelines for drug product could be delayed, for example, due to a global shortage of syringes. We could also encounter delays if a clinical trial is suspended or terminated by us,
by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due
to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory
authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate
funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial
protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, conducting clinical trials in
foreign countries, as we may do for atacicept or product candidates we may develop in the future, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries
to adhere to clinical protocol as a result of differences in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign
countries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we experience delays in the completion of, or termination of, any clinical trial of atacicept or any product candidates we may develop in the future,
the commercial prospects of atacicept or any product candidates we may develop in the future will be harmed, and our ability to generate product revenues from atacicept or any product candidates we may develop in the future will be delayed.
Moreover, any delays in completing our clinical trials will increase our costs, slow down atacicept&#146;s or any product candidates we may develop in the future&#146;s development and approval process and jeopardize our ability to commence product
sales and generate revenues. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion
of, clinical trials may also ultimately lead to the denial of regulatory approval of atacicept or any product candidates we may develop in the future. Any delays in our clinical trials that occur as a result could shorten any period during which we
may have the exclusive right to commercialize atacicept or any product candidates we may develop in the future and our competitors may be able to bring products to market before we do, and the commercial viability of atacicept or any product
candidates we may develop in the future could be significantly reduced. Any of these occurrences may significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by
multiple factors outside our control, including difficulties in identifying patients with IgAN and significant competition for recruiting such patients in clinical trials. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Identifying and qualifying patients to participate in our clinical trials is critical to our success. We may encounter delays in enrolling, or be unable to enroll, a
sufficient number of patients to complete any of our clinical trials, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. In particular, as a result of the inherent difficulties in
diagnosing IgAN and the significant competition for recruiting patients with IgAN in clinical trials, there may be delays in enrolling the patients we need to complete clinical trials on a timely basis, or at all. Although we have engaged certain
third-party investigators to assist with patient enrollment for our Phase&nbsp;2b clinical trial, there can be no assurance that we will be able to maintain our relationships with such third parties or that such third parties will be successful in
helping us identify patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Factors that may generally affect patient enrollment include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the size and nature of the patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the number and location of clinical sites we enroll; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">competition with other companies for clinical sites or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the drug background and clinical experience (e.g., safety profile, risk/benefit assessment, mechanism of action, known
proof of concept); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the eligibility and exclusion criteria for the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the design of the clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">inability to obtain and maintain patient consents; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">risk that enrolled participants will drop out before completion; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential advantages of the drug
being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
addition, if any significant adverse events or other side effects are observed in any of our future clinical trials or other sponsor development programs of similar mechanism of action that may result in a drug class effect, it may make it more
difficult for us to recruit patients to our clinical trials and patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. Our inability to enroll a
sufficient number of patients for our clinical trials would result in significant delays, which would increase our costs and have an adverse effect on our company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may develop atacicept, and potentially future product candidates, in combination with other therapies, which
exposes us to additional risks. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may develop atacicept and future product candidates in combination with one or more currently approved therapies. Even
if atacicept, or any product candidate we develop, were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory
authorities outside of the United States could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. This could result in our
own products being removed from the market or being less successful commercially. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also evaluate atacicept or any other future product candidates in
combination with one or more other therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the United States. We will not be able to market and sell atacicept or any product candidate we
develop in combination with any such unapproved therapies that do not ultimately obtain marketing approval. If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs or revoke their approval of, or if
safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with atacicept or any other product candidate we develop, we may be unable to obtain approval of or market atacicept or any other product
candidate we develop. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The incidence and prevalence for target patient populations of atacicept in specific indications are based on estimates and third-party
sources. If the market opportunities for atacicept, or any future product candidate we may develop, if and when approved, are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our
revenue and ability to achieve profitability might be materially and adversely affected. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Periodically, we make estimates regarding the incidence and
prevalence of target patient populations for particular diseases based on various third-party sources and internally generated analysis and use such estimates in making decisions regarding our drug development strategy, including acquiring <FONT
STYLE="white-space:nowrap">or&nbsp;in-licensing&nbsp;product</FONT> candidates and determining indications on which to focus in nonclinical or clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
incidence and prevalence for target patient populations of atacicept in specific indications are based on estimates and third-party sources.<B><I> </I></B>These estimates may be inaccurate or based on imprecise data. For example, the total
addressable market opportunity will depend on, among other things, acceptance of our drugs by the medical community and patient access, drug pricing and reimbursement. The number of patients in the addressable markets may turn out to be lower than
expected, patients may not be otherwise amenable to treatment with our drugs, or new patients may become increasingly difficult to identify or gain access to. If the market opportunities for atacicept, or any future product candidate we may develop,
if and when approved, are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve and sustain profitability might be materially and adversely
affected. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interim, initial, <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> and preliminary data from our clinical trials that we announce or
publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, we may publicly disclose preliminary or <FONT STYLE="white-space:nowrap">top-line</FONT> data from our nonclinical studies and clinical trials, which
is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make
assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the <FONT STYLE="white-space:nowrap">top-line</FONT>
or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. <FONT
STYLE="white-space:nowrap">Top-line</FONT> data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, <FONT
STYLE="white-space:nowrap">top-line</FONT> data should be viewed with caution until the final data are available. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, we may also disclose interim
data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim
data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock after this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh
the importance of data differently, which could impact the value of our particular program, the approvability or commercialization of our particular product candidate or product and our company in general. In addition, the information we choose to
publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our
disclosure. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the interim, <FONT STYLE="white-space:nowrap">top-line,</FONT> or preliminary data that we report differ from actual results, or if others,
including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, atacicept or any future product candidates we may develop may be harmed, which could significantly harm our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We face significant competition, which may result in others discovering, developing or
commercializing products before or more successfully than us. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biotechnology industry is intensely competitive and subject to rapid and significant
technological change. Our competitors include multinational pharmaceutical companies, specialized biotechnology companies and universities and other research institutions. There are currently no approved therapies for IgAN and current <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> consists of treatment with renin-angiotensin-aldosterone system inhibitors, including angiotensin-converting enzyme inhibitors or angiotensin II receptor
blockers, to control blood pressure, or steroids with or without other immunosuppressive agents to <FONT STYLE="white-space:nowrap">non-specifically</FONT> reduce inflammation. We do not expect to compete directly with these <FONT
STYLE="white-space:nowrap">non-specific</FONT> approaches, but rather atacicept may be an appropriate option where these therapies are not well tolerated and/or where a patient&#146;s disease progression remains uncontrolled despite these
approaches. Among emerging therapies, we consider our most direct competitors with respect to atacicept in IgAN to be the programs in Phase 3 clinical development: Calliditas Therapeutics AB, Novartis Pharmaceuticals Corporation (Novartis), Omeros
Corporation, Travere Therapeutics, Inc., and Chinook Therapeutics Inc., and the following companies with programs in Phase 2 of clinical development: Chinook Therapeutics Inc., Alnylam Pharmaceuticals Inc., Apellis Pharmaceuticals, Inc., Reata
Pharmaceuticals, Inc., RemeGen Co., Ltd., Visterra, Inc., Ionis Pharmaceuticals, Inc., Alexion Pharmaceuticals Inc. (Alexion), and DiaMedica Therapeutics, Inc. There is also a potential that SGLT2 inhibitors, including AstraZeneca plc&#146;s
(AstraZeneca) farxiga, which has completed Phase 3 clinical development, and C.H. Boehringer Sohn AG&nbsp;&amp; Ko. KG&#146;s (Boehringer) jardiance, which is undergoing Phase 3 clinical development, will be approved broadly for chronic kidney
disease and used in IgAN. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In LN, prior to December 2020, there had been no approved therapies, and the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">standard-of-care</FONT></FONT> has consisted of a number of <FONT STYLE="white-space:nowrap">non-specific</FONT> therapies, including MMF, steroids, CYC, rituxumab, calcineurin inhibitors, AZA, and HCQ, dependent on class
of disease and whether a patient was cycling through the induction or maintenance phase of therapy. We expect that these paradigms will evolve with the recent FDA approvals of GlaxoSmithKline plc&#146;s Benlysta (belimumab) and Aurinia
Pharmaceuticals Inc.&#146;s Lupkynis (voclosporin), both of which we consider to be direct competitors. Our competitors include the following companies with programs in Phase 3 clinical development: Roche Holding AG and Novartis, and the following
companies with programs in Phase 2 clinical development: BeiGene Ltd., Janssen Pharmaceuticals, Inc., AstraZeneca, Alexion, Omeros Corporation, Kezar Life Science Inc., Bristol Myers Squibb, Boehringer, and Novartis. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of our competitors have significantly greater financial, technical, human and other resources than we do and may be better equipped to develop, manufacture and
market technologically superior products. In addition, many of these competitors have significantly greater experience than we have in undertaking nonclinical studies and human clinical trials of new pharmaceutical products and in obtaining
regulatory approvals of human therapeutic products. Accordingly, our competitors may succeed in obtaining FDA approval for superior products. Many of our competitors have established distribution channels for the commercialization of their products,
whereas we have no such channel or capabilities. In addition, many competitors have greater name recognition and more extensive collaborative relationships. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in
even more </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our competitors may obtain regulatory approval of their products more rapidly than we do or may obtain patent
protection or other intellectual property rights that limit our ability to develop or commercialize our product candidate or any future product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely
used and less costly or have a better safety profile than our products and these competitors may also be more successful than we are in manufacturing and marketing their products. If we are unable to compete effectively against these companies, then
we may not be able to commercialize our product candidate or any future product candidates or achieve a competitive position in the market. This would adversely affect our ability to generate revenue. Our competitors also compete with us in
recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our
programs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in methods of atacicept manufacturing or formulation may result in additional costs or delays. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As atacicept progresses through preclinical to late-stage clinical trials to marketing approval and commercialization, it is common that various aspects of the
development program, such as manufacturing methods and formulation, and manufacturing sites are altered along the way in an effort to optimize yield, manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes
carry the risk that they will not achieve these intended objectives. Any of these changes could cause atacicept to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered
materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of atacicept and jeopardize our ability to
commercialize atacicept, if approved, and generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks related to regulatory approval and other legal compliance matters </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately
unable to obtain regulatory approval for atacicept or any future product candidates we may develop, our business, financial condition, results of operations and prospects will be significantly harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The time required to obtain approval by the FDA and comparable foreign authorities typically takes many years following the commencement of clinical trials. In
addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Applications for atacicept could fail to receive regulatory approval for many reasons, including the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design, implementation or results of our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA or comparable foreign regulatory authorities may determine that atacicept is not safe and effective, only
moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety
in the full population for which we seek approval, resulting in a restrictive label and limiting commercial use; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from nonclinical studies
or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the data collected from clinical trials of atacicept may not be sufficient to support the submission of a BLA, or other
submission or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that atacicept&#146;s risk-benefit
ratio for its proposed indication is acceptable; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and
specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a
manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This lengthy approval process, as well as the unpredictability of the results of
clinical trials, may result in our failing to obtain regulatory approval to market atacicept, which would significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, even if we obtain approval of atacicept for a lead indication, regulatory authorities may not approve atacicept for other indications, may impose
significant limitations in the form of narrow indications, warnings, or a Risk Evaluation and Mitigation Strategy (REMS). Certain regulatory authorities may grant approval contingent on the performance of costly post-marketing clinical trials or may
approve atacicept with a label that does not include the labeling claims necessary or desirable for successful commercialization of our product candidates. In addition, if we are unable to obtain regulatory approval of atacicept, or if regulatory
approval results in a limited label, our business, financial condition, results of operation and prospects will be significantly harmed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if approved,
atacicept may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if atacicept receives regulatory approval, it may not gain adequate market acceptance among physicians, patients, healthcare payors and others in the medical
community. The degree of market acceptance would depend on a number of factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing of market introduction of the product candidate as well as competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the clinical indications for which the product candidate is approved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on the use of atacicept, such as boxed warnings or contraindications in labeling, or a REMS, if any, which
may not be required of alternative treatments and competitor products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential and perceived advantages of product candidates over alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the cost of treatment in relation to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our pricing and the availability of coverage and adequate reimbursement by third-party payors, including government
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the availability of atacicept for use as a combination therapy; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">relative convenience and ease of administration; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the effectiveness of sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">inclusion or exclusion of atacicept from treatment guidelines established by various physician groups;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">unfavorable publicity relating to atacicept or similar approved products or product candidates in development by third
parties; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the approval of other new therapies for the same indications. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Sales of medical products also depend on the willingness of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians
that the products are safe, therapeutically effective and accessible to patients. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of influential physicians can
affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#146; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that our
product is safe, therapeutically effective and cost effective as compared with competing treatments. If any product candidate is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient
revenue from such product candidate and may not be able to achieve or sustain profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our business entails a significant risk of product liability and if we are unable to obtain sufficient
insurance coverage, such inability could significantly harm our business, financial condition, results of operations and prospects. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business exposes us
to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing
products, such claims could result in an FDA or other regulatory authority investigation of the safety and effectiveness of our product, our manufacturing processes and facilities or our marketing programs. FDA or other regulatory authority
investigations could potentially lead to a recall of our product or more serious enforcement action, limitations on the approved indications for which it may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual
outcome, liability claims may also result in decreased demand for our product, injury to our reputation, costs to defend the related litigation, a diversion of management&#146;s time and our resources and substantial monetary awards to trial
participants or patients. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing atacicept, if approved. Any insurance we have or may obtain
may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to
protect us against losses caused by product liability claims that could significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Atacicept, and any future product candidates we develop, may cause significant adverse events, toxicities or other undesirable side effects when used alone or in
combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative
consequences. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with the use of
atacicept or any future product candidates we may develop. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by atacicept or any
future product candidates we may develop could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign
regulatory authorities. For example, Merck KGaA, Darmstadt, Germany previously conducted <FONT STYLE="white-space:nowrap">APRIL-LN,</FONT> a study aimed to evaluate the efficacy and safety of atacicept in patients with active LN, receiving newly
initiated corticosteroids (CS) and mycophenolate mofetil (MMF). Two weeks before the initiation of atacicept, significant decreases in IgG levels began unexpectedly with initiation of MMF and high-dose CS, and persisted upon initiation of atacicept,
which led to trial termination. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may significantly harm
our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If atacicept or any future product candidates we may develop are associated with
undesirable side effects or have unexpected characteristics in nonclinical studies or clinical trials when used alone or in combination with other approved products or investigational new drugs, we may need to interrupt, delay or abandon their
development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects
could also affect patient recruitment or the ability of enrolled subjects to complete a trial, or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected
product candidate and may significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patients in our ongoing and planned clinical
trials may in the future suffer significant adverse events or other side effects not observed in our nonclinical studies or previous clinical trials. atacicept or any future product candidates we may develop, may be used as chronic therapies or be
used in pediatric populations, for which safety concerns may be particularly scrutinized by regulatory agencies. In addition, if atacicept or any future product candidates we may develop, are used in combination with other therapies, atacicept or
any future product candidates we may develop may exacerbate adverse events associated with the therapy and it may not be possible to determine whether it was caused by our product or the one with which it was combined. Patients treated with
atacicept or any future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
candidates we may develop, may also be undergoing surgical, radiation. chemotherapy or other treatments, which can cause side effects or adverse events that are unrelated to atacicept or any
future product candidates we may develop, but may still impact the success of our clinical trials. The inclusion of patients with advanced disease in our clinical trials may result in deaths or other adverse medical events due to other therapies or
medications that such patients may be using or due to the gravity of such patients&#146; illnesses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If significant adverse events or other side effects are
observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product
candidate altogether. We, the FDA, other comparable regulatory authorities or an IRB may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to
unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their
further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these
developments could significantly harm our business, financial condition, results of operations and prospects </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, if atacicept obtains marketing approval,
toxicities associated with atacicept and not seen during clinical testing may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional contraindications, warnings and precautions being added
to the drug label, significant restrictions on the use of the product or the withdrawal of the product from the market. We cannot predict whether atacicept will cause toxicities in humans that would preclude or lead to the revocation of regulatory
approval based on nonclinical studies or early-stage clinical trials. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Obtaining and maintaining regulatory approval of atacicept, or any product candidate we
develop in the future, in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of atacicept, or any product candidate we develop in the future, in other jurisdictions. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Obtaining and maintaining regulatory approval of atacicept, or any product candidate we develop in the future, in one jurisdiction does not guarantee that we will be
able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA or other foreign regulatory authority grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions
must also approve the marketing approval of the product candidate in their countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval
procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional nonclinical studies or clinical trials as clinical trials conducted in one
jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In
some cases, the price that we intend to charge for our product is also subject to approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Obtaining foreign regulatory approvals and establishing and maintaining
compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product in certain countries. If we or any future collaborator fail to comply with
the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of atacicept, or any product candidate we develop in the
future, will be harmed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if atacicept, or any product candidate we develop in the future, receives regulatory approval, it could be subject to
significant post-marketing regulatory requirements and will be subject to continued regulatory oversight. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any regulatory approvals that we may receive for
atacicept, or any product candidate we develop in the future, will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the marketed product, may contain significant limitations related
to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve atacicept, which
could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the FDA or applicable foreign regulatory authorities approve atacicept or any product candidate we develop in the future, the manufacturing processes, labeling, packaging, distribution, adverse
event reporting, storage, advertising, promotion, import, export and recordkeeping for atacicept will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information
and reports, registration, as well as <FONT STYLE="white-space:nowrap">on-going</FONT> compliance with cGMPs and GCP for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject
to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as
adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or
withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory requirements may subject our company to administrative or judicially imposed sanctions,
including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays in or the rejection of product approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned
trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on the products, manufacturers or manufacturing process; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">warning letters; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">civil and criminal penalties; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">injunctions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">suspension or withdrawal of regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product seizures, detentions or import bans; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">voluntary or mandatory product recalls and publicity requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">total or partial suspension of production; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">imposition of restrictions on operations, including costly new manufacturing requirements. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The occurrence of any event or penalty described above may inhibit our ability to commercialize atacicept, or any product candidate we may develop in the future, and
generate revenue and could require us to expend significant time and resources in response and could generate negative publicity. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA&#146;s and other
regulatory authorities&#146; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of atacicept or any product candidate we may develop in the future. If we are slow or
unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not be able to
achieve or sustain profitability. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or
administrative or executive action, either in the United States or abroad. If these actions impose constraints on FDA&#146;s or foreign regulatory authorities&#146; ability to engage in oversight and implementation activities in the normal course,
it may significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are currently seeking orphan drug designation for
atacicept for the treatment of IgAN, but even if designated we may not ultimately realize the potential benefits of orphan drug designation. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are
currently seeking orphan drug designation from the FDA and EMA for&nbsp;atacicept for the treatment of IgAN. Under the Orphan Drug Act, the FDA may designate a drug product as an orphan drug if it is intended to treat a rare disease or condition,
defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States but where there is no reasonable expectation to recover the costs of developing and marketing a treatment
drug in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and application fee waivers. After the FDA grants
orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. However, orphan drug designation neither shortens the development time nor regulatory review time of a product candidate nor
gives the candidate any advantage in the regulatory review or approval process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the
product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical
superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity for the orphan patient population. Exclusive marketing rights in the United States may also be unavailable if we or our
collaborators seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective. Even if we obtain orphan drug designation, we may not
be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain orphan drug exclusivity for a product candidate, that exclusivity
may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA
concludes that the later drug is clinically superior in that it is safer, more effective, or makes a major contribution to patient care. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similarly, in Europe, a
medicinal product may receive orphan designation under Article 3 of Regulation (EC) 141/2000. This applies to products that are intended for a life-threatening or chronically debilitating condition and either (1)&nbsp;such condition affects no more
than five in 10,000 persons in the EU when the application is made, or (2)&nbsp;the product, without the benefits derived from orphan status, would be unlikely to generate sufficient returns in the EU to justify the necessary investment in its
development. Moreover, in order to obtain orphan designation in the EU it is necessary to demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU or, if such a
method exists, the product will be of significant benefit to those affected by the condition. In the EU, orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and applicants can benefit from
specific regulatory assistance and scientific advice. Products receiving orphan designation in the EU can receive 10 years of market exclusivity, during which time no &#147;similar medicinal product&#148; for the same indication may be placed on the
market. A &#147;similar medicinal product&#148; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication.
An orphan product can also obtain an additional two years of market exclusivity in the EU for pediatric studies. However, the <FONT STYLE="white-space:nowrap">10-year</FONT> market exclusivity may be reduced to six years if, at the end of the fifth
year, it is established that the product no longer meets the criteria for orphan designation&#151;for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be
granted to a similar medicinal product for the same indication at any time if: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically
superior; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the first marketing authorization holder for the authorized product consents to a second orphan medicinal product
application; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the marketing authorization holder for the authorized product cannot supply enough orphan medicinal product.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we do not receive or maintain orphan drug designation for atacicept for the treatment of IgAN, it could limit our ability to realize revenues.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are
unable to obtain such approval, we may be required to conduct additional nonclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals.
Even if we receive accelerated approval from the FDA or comparable foreign regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA or comparable
foreign regulatory authorities may seek to withdraw any accelerated approval. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may in the future seek an accelerated approval for atacicept or future
product candidates we may develop. For example, if the results from our planned Phase 2b trial of atacicept in patients with IgAN are positive, we may seek accelerated approval with the FDA based on this trial, which we may not be granted. Under the
accelerated approval </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available
therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive
therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement,
radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. For example, UPCR is an accepted surrogate primary endpoint for clinical trials in IgAN, which could
allow for a faster path to commercialization than rate of change/slope in GFR. We may seek accelerated approval based on the UPCR endpoint. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on
irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over
available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. Use of the accelerated approval pathway would entail submission of a BLA under Subpart E of the FDA
regulations with the UPCR surrogate endpoint data while conducting the Phase 3 trial to collect change/slope in GFR data. If granted, accelerated approval is usually contingent on the sponsor&#146;s agreement to complete ongoing trials and/or
conduct, in a diligent manner, additional post- approval confirmatory studies to verity and describe the drug&#146;s clinical benefit. Additionally, unless and until converted to full approval at the time of satisfying the conditions of any
accelerated approval letter, the sponsor must submit any promotional materials for the accelerated approval drug to FDA at least 30 days prior to use. Third-party payors may refuse to provide coverage or reimbursement for the drug until the
confirmatory studies are complete. Additionally, if such post-approval studies fail to confirm the drug&#146;s clinical benefit, the FDA may withdraw its approval of the drug. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to seeking accelerated approval for atacicept, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated
approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a BLA, for accelerated approval or any other form of expedited development, review or approval. Similarly, there can
be no assurance that after subsequent FDA feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit
an application for accelerated approval or receive an expedited regulatory designation (e.g., breakthrough therapy designation) for atacicept, there can be no assurance that such submission or application will be accepted or that any expedited
development, review or approval will be granted on a timely basis, or at all. The FDA or comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any
type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for atacicept would result in a longer time period to commercialization of such product candidate, could increase the cost of development
of atacicept and could harm our competitive position in the marketplace. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Biosimilars to atacicept may provide competition sooner than anticipated.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, ACA), signed into law
on March&nbsp;23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT
STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed
by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of
exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#146;s own preclinical data and data from adequate and well-controlled
clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the <FONT STYLE="white-space:nowrap">12-year</FONT>
period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also
been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for <FONT
STYLE="white-space:nowrap">non-biological</FONT> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any approved products are subject to biosimilar competition sooner than we expect, we will face significant pricing pressure and our commercial opportunity will be
limited. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Any product candidate we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to seek approval to market atacicept in both the United States, in the EU and in certain foreign jurisdictions. If we obtain approval in one or
more foreign jurisdictions for atacicept, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the European Union, the pricing of drugs is subject to governmental control and other
market regulations which could put pressure on the pricing and usage of atacicept. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In
addition, market acceptance and sales of atacicept will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for atacicept and may be affected by existing and future healthcare reform measures. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The availability and extent of coverage and adequate reimbursement by third-party payors, including government health administration authorities, private health
coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. If we obtain marketing approval of atacicept, or any future product candidate we may develop, sales
of such product will depend substantially, both in the United States and internationally, on the extent to which the costs of the product will be covered and reimbursed by third-party payors. If reimbursement is not available, or is available only
at inadequate levels, we may not be able to successfully commercialize atacicept or any future product candidates we may develop. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or
maintain pricing sufficient to realize an adequate return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not
available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, for example, principal
decisions about reimbursement for new products are typically made by the Centers for Medicare&nbsp;&amp; Medicaid Services (CMS) an agency within the U.S. Department of Health and Human Services. CMS decides whether and to what extent a new product
will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#146;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#146;s determination to provide coverage for
a product candidate does not assure that other payors will also provide coverage for the product candidate. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs,
including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to
the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. As a result, the coverage determination
process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our product to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be
applied consistently or obtained in the first instance. Factors payors consider in determining reimbursement are based on whether the product is: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">neither experimental nor investigational. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Governmental payors, as well as
other third-party payors, including pharmacy benefit managers, have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and requiring substitutions of generic products and/or biosimilars.
Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly examining the medical
necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product
candidates on an approved list, known as a formulary, which might not include all <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the
medical necessity and cost effectiveness of our product. Nonetheless, atacicept or any future product candidates we may develop may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be
available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Outside the United States,
international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue
to put pressure on the pricing and usage of therapeutics such as atacicept or any future product candidates we may develop. In many countries, particularly the countries of the European Union, medical product prices are subject to varying price
control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing approval. To obtain reimbursement or pricing approval in some
countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of atacicept or any future product candidates we may develop to other available therapies. In general, product prices under such systems are substantially
lower than in the United States. Other countries allow companies to fix their own prices for products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that
we are able to charge for atacicept or any future product candidates we may develop. Accordingly, in markets outside the United States, the reimbursement for any product that we commercialize may be reduced compared with the United States and may be
insufficient to generate commercially reasonable revenue and profits. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are unable to establish or sustain coverage and adequate reimbursement for any product
candidates that we commercialize from third-party payors, the adoption of those products and potential sales revenue would be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if
approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for a product for which we receive regulatory approval, less favorable coverage policies
and reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may face difficulties from changes to current regulations and future legislation. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of atacicept or any
future product candidates we may develop. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to
adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not be able to achieve or
sustain profitability. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, the ACA was passed in March 2010, which, among other things, subjected biologic products to potential competition by lower-cost
biosimilars; addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed
by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and
taxes for certain branded prescription drugs; created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of
January&nbsp;1, 2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition
for the manufacturer&#146;s outpatient drugs to be covered under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Medicare Part D; and provided incentives to programs that increase the federal government&#146;s comparative effectiveness research. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA. For example, various
portions of the ACA are currently undergoing legal and constitutional challenges in the United States Supreme Court. On February 10, 2021, the Biden administration withdrew the federal government&#146;s support for overturning the ACA. Further,
although the Supreme Court has not yet ruled on the constitutionality of the ACA, on January&nbsp;28, 2021, President Biden issued an executive order to initiate a special enrollment period coverage through the ACA marketplace, which began on
February 15, 2021 and will remain open through August 15, 2021. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others,
reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is also unclear how the
Supreme Court ruling, other such litigation and the healthcare reform measures of the Biden administration will impact the ACA and our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, other
legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011, which
began in 2013, and due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, will remain in effect through 2030, unless additional congressional action is taken.
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic relief legislation suspended the 2% Medicare sequester from May&nbsp;1, 2020 through December 31, 2021. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare
payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding,
which could have an adverse effect on customers for our product candidates, if approved, and, accordingly, our financial operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, there has been
heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted
federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for
products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July&nbsp;24, 2020 and
September&nbsp;13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#146;s proposals. In response, the FDA released a final rule on
September&nbsp;24, 2020, which went into effect on November&nbsp;30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November&nbsp;20, 2020 CMS issued an Interim Final Rule implementing
the Most Favored Nation (MFN) Model under which Medicare Part B reimbursement rates will be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development
countries with a similar gross domestic product per capita. The MFN Model regulations mandate participation by identified Part B providers and would have applied to all U.S. states and territories for a seven-year period beginning January&nbsp;1,
2021, and ending December&nbsp;31, 2027. However, in response to a lawsuit filed by several industry groups, on December&nbsp;28, the U.S. District Court for the Northern District of California issued a nationwide preliminary injunction enjoining
government defendants from implementing the MFN Rule pending completion of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">notice-and-comment</FONT></FONT> procedures under the Administrative Procedure Act. On January&nbsp;13,
2021, in a separate lawsuit brought by industry groups in the U.S. District of Maryland, the government defendants entered a joint motion to stay litigation on the condition that the government would not appeal the preliminary injunction granted in
the U.S. District Court for the Northern District of California and that performance for any final regulation stemming from the MFN Interim Final Rule shall not commence earlier than 60 days after publication of that regulation in the Federal
Register. Further, authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. If implemented, importation of drugs from Canada and the MFN Model may materially and adversely affect the price we receive for
any of our product candidates. Additionally, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy
benefit managers, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale,</FONT></FONT> as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to an order entered by the U.S.
District Court for the District of Columbia, the portion of the rule eliminating safe harbor protection for certain rebates related to the sale or purchase of a pharmaceutical product from a manufacturer to a plan sponsor under Medicare Part D has
been delayed to January&nbsp;1, 2023. Further, implementation of this change and new safe harbors for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> reductions in price for prescription pharmaceutical
products and pharmacy benefit manager service fees have also been delayed until January 1, 2023. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological
product pricing, including price or patient reimbursement-constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other
countries and bulk purchasing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous
coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, achieve and sustain profitability or commercialize atacicept or any future product candidates we may develop. It is
possible that additional governmental action is taken in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Legislative and regulatory
proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or
interpretations will be changed, or what the impact of such changes on the marketing approvals of atacicept or any future product candidates we may develop, if any, may be. In addition, increased scrutiny by Congress of the FDA&#146;s approval
process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, FDA regulations and guidance may be revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new
regulations or guidance, or revisions or reinterpretations of existing regulations or guidance, may impose additional costs or lengthen FDA review times for atacicept or future product candidates we may develop. We cannot determine how changes in
regulations, statutes, policies, or interpretations when and if issued, enacted or adopted, may affect our business in the future. Such changes could, among other things, require: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">additional clinical trials to be conducted prior to obtaining approval; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes to manufacturing methods; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">recalls, replacements, or discontinuance of one or more of our products; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">additional recordkeeping. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Such changes would likely require substantial time and impose significant costs, or could reduce the potential commercial value of atacicept or future product
candidates we may develop, and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any other products would harm our business, financial
condition, and results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our relationships with healthcare professionals, clinical investigators, CROs and third party payors in connection with
our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and privacy and security laws (including health information privacy and
security laws), which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future
earnings. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of our product candidate for which we
obtain marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and
regulations that may constrain the business or financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
arrangements and relationships through which we market, sell and distribute our product for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and
regulations include the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully
soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service,
for which payment may be made under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have
committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False
Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the federal false claims laws, including the civil False Claims Act, which can be enforced by private citizens through
civil whistleblower or qui tam actions, and civil monetary penalties laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or
fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) prohibits, among other things, executing
or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH) and their
implementing regulations, also imposes obligations, including mandatory contractual terms, certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates and subcontractors that
perform services for them that involve the use, or disclosure of, individually identifiable health information with respect to safeguarding the privacy, security and transmission of individually identifiable health information;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and
medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding payments and other transfers of value to physicians
(defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. Beginning in 2022,
applicable manufacturers also will be required to report information regarding payments and other transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered
nurse anesthetists and certified nurse midwives during the previous year; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or
marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Some state laws require biotechnology companies to comply with the biotechnology industry&#146;s voluntary compliance guidelines and the relevant compliance guidance
promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Some state laws require
biotechnology companies to report information on the pricing of certain drug products. Some state and local laws require the registration of pharmaceutical sales representatives. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Much like the federal Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the
prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to induce or reward improper performance generally is governed by the
national anti-bribery laws of EU Member States, and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Bribery Act 2010 in the UK. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for
human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are
inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the UK despite its departure from the EU. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification
and approval by the physician&#146;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional
codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve <FONT
STYLE="white-space:nowrap">on-going</FONT> substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud
and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal
and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages,
reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources.
Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business
is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, and policies related to data privacy and security,
and our actual or perceived failure to comply with such obligations could harm our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business is subject to stringent and evolving U.S. and
foreign laws, rules, and regulations and contractual obligations relating to data privacy and security, including the collection, use, processing, disclosure, retention and security of personal information. The regulatory frameworks for data privacy
and security are evolving and may result in increasing regulatory and public scrutiny and escalating levels of enforcement and sanctions, including monetary penalties and prohibitions on processing personal information that could require us to
change our business practices. Interpretation of these frameworks is likely to remain uncertain and potentially inconsistent for the foreseeable future. This evolution may create uncertainty in our business, affect our ability (or the ability of our
collaborators, service providers, and contractors) to operate in certain jurisdictions or to collect, store, process, transfer, use or share personal information. This evolution could also necessitate the acceptance of more onerous obligations in
our contracts and impose additional costs on us. Our efforts to bring our practices (and those of our collaborators, service providers, and contractors) into compliance with these obligations may not succeed for a variety of reasons, including due
to internal or external factors such as resource allocation limitations or a lack of vendor cooperation. Noncompliance could result in the commencement of legal proceedings against us by governmental and regulatory entities, collaborators, data
subjects or others. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Among the most stringent of these laws is the General Data Protection Regulation ((EU) 2016/679) (GDPR), which applies to the processing of
personal information about clinical trials participants and other individuals in the EU and the United Kingdom. Companies that violate the GDPR can face private litigation, prohibitions on data processing and fines of up to the greater of
20&nbsp;million Euros or 4% of their worldwide annual revenue. The GDPR requires us to give detailed disclosures about how we collect, use and share personal information; ensure any consents relied on to process personal information (including
special categories of personal data, such as health data) meet the stricter GDPR requirements; contractually impose data protection requirements on vendors entrusted with personal information; maintain adequate data security measures; notify
regulators and affected individuals of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
certain data breaches; meet extensive privacy governance and documentation requirements; and honor individuals&#146; data protection rights, including their rights to access, correct and delete
their personal information. European data protection authorities may interpret the GDPR and national laws implementing it differently and impose additional requirements or obligations on us, which further contribute to the complexity of processing
personal information in or from Europe. Guidance on implementation and compliance with the GDPR is often updated or otherwise revised. The GDPR may increase our responsibility and liability in relation to personal information that we process, and we
may be required to implement additional mechanisms to comply with the GDPR. These mechanisms may be onerous and, if our efforts to comply with GDPR or other applicable European data protection laws and regulations are not successful, our business in
Europe could be adversely affected. In addition, further to the United Kingdom&#146;s (UK) exit from the EU on January&nbsp;31, 2020, the GDPR ceased to apply in the UK at the end of the transition period on December&nbsp;31, 2020. However, as of
January&nbsp;1, 2021, the UK&#146;s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December&nbsp;31, 2020 but subject to certain UK specific amendments) into UK law (referred to as the &#145;UK GDPR&#146;). The UK GDPR
and the UK Data Protection Act 2018 set out the UK&#146;s data protection regime, which is independent from but aligned to the European&#146;s data protection regime. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> with the UK GDPR may result
in monetary penalties of up to &pound;17.5&nbsp;million or 4% of worldwide revenue, whichever is higher. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">European data protection laws also generally prohibit the
transfer of personal information from Europe to the United States and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal information. One of the primary safeguards used
for transfers of personal information from the European Union and Switzerland to the United States until recently was the Privacy Shield framework administered by the U.S. Department of Commerce, which was invalidated by a decision of the European
Union&#146;s highest court in July 2020. The same decision also cast doubt on the viability of one of the primary alternatives to the Privacy Shield, namely, the European Commission&#146;s Standard Contractual Clauses, as a vehicle for such
transfers. Similarly, the Swiss Federal Data Protection and Information Commissioner has opined that the Privacy Shield is inadequate for transfers of data from Switzerland to the U.S. and raised similar questions regarding the Standard Contractual
Clauses. At present, there are few, if any, viable alternatives to the Standard Contractual Clauses and, therefore, there is uncertainty regarding how to lawfully transfer personal information from Europe or the UK to the U.S. and other third
countries. Failure to comply with the GDPR&#146;s cross-border data restrictions may increase our exposure to its heightened sanctions, restrict our clinical trial activities in Europe, and limit our ability to collaborate with CROs, service
providers and other companies subject to European and UK data protection laws. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, it is unclear whether the transfer of personal information from the EU
to the United Kingdom will continue to remain lawful under the GDPR in light of Brexit. Pursuant to a post-Brexit trade deal between the United Kingdom and the EU, transfers of personal information from the European Economic Area to the United
Kingdom are not considered restricted transfers under the GDPR for a period of up to six months from January&nbsp;1,&nbsp;2021. However, unless the EU Commission makes an adequacy finding with respect to the United Kingdom before the end of that
period, the United Kingdom will be considered a &#147;third country&#148; under the GDPR and transfers of European personal information to the United Kingdom will require an approved compliance mechanism to render such transfers lawful under the
GDPR. Although the United Kingdom&#146;s primary data protection legislation is designed to be consistent with the GDPR, uncertainty remains regarding how data transfers to and from the United Kingdom will be regulated after Brexit. This uncertainty
and any restrictions on data transfers between the UK and the EU may further limit our ability to do business in the region. Additionally, other countries outside of Europe have enacted or are considering enacting similar cross-border data transfer
restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Privacy
and data security laws in the United States are also increasingly complex and changing rapidly. Just over a month after the GDPR took effect, the California legislature passed the California Consumer Privacy Act of 2018 (CCPA), which took effect on
January&nbsp;1, 2020. The CCPA gives California residents certain rights similar to the individual rights given under the GDPR (including the right to access and delete their personal information, <FONT STYLE="white-space:nowrap">opt-out</FONT> of
certain personal information sharing, and receive detailed information about how their personal information is used), and provides for civil penalties for violations. Since the enactment of the CCPA, new privacy and data security laws have been
proposed in more than half of the states and in United States Congress, reflecting a trend toward more stringent privacy legislation in the United States that may increase our compliance costs and our exposure to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
liability. Further, a new California privacy law, the California Privacy Rights Act (CPRA) was passed by California voters on November&nbsp;3, 2020. The CPRA will create additional obligations
with respect to processing and storing personal information that are scheduled to take effect on January&nbsp;1, 2023 (with certain provisions having retroactive effect to January&nbsp;1, 2022). While certain clinical trials activities are exempt
from the CCPA&#146;s requirements, other personal information that we handle may be subject to the CCPA, which may increase our compliance costs, exposure to regulatory enforcement action and other liabilities. All of these evolving compliance and
operational requirements impose significant costs that are likely to increase over time, may require us to modify our data processing practices and policies, divert resources from other initiatives and projects, including increased costs related to
insurance, cybersecurity and information technology, and could restrict the way products and services involving data are offered, all of which could significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could
significantly harm our business, financial condition, results of operations or prospects. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are subject to numerous environmental, health and safety laws
and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and
biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the
event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal
fines and penalties. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees
resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in
connection with our storage or disposal of hazardous and flammable materials, including chemicals and biological materials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we may incur substantial
costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws
and regulations also may result in substantial fines, penalties or other sanctions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our business activities may be subject to the U.S. Foreign Corrupt
Practices Act (FCPA) and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal
requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we expand our operations outside of
the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption
laws, regulations or rules of other countries in which we operate. The FCPA generally prohibits companies and their employees and third party intermediaries from offering, promising, giving or authorizing the provision of anything of value, either
directly or indirectly, to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and
records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with
public officials, including officials of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments. Additionally, in many other countries, hospitals owned and operated by the government, and doctors and other hospital employees would be
considered foreign officials under the FCPA. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees,
agents or contractors, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal
sanctions against us, our officers or our employees, disgorgement, and other sanctions and remedial measures, and prohibitions on the conduct of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
business. Any such violations could include prohibitions on our ability to offer our product in one or more countries and could materially damage our reputation, our brand, our international
activities, our ability to attract and retain employees and our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our product and activities may be subject to U.S. and foreign export
controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our product, or our failure to obtain any required import or export authorization for our product, when applicable, could harm our
international sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our product may create delays in the introduction of our product in international markets or, in some cases, prevent the
export of our product to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to
comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in
the enforcement or scope of existing regulations, or in the countries, persons, or product targeted by such regulations, could result in decreased use of our product by, or in our decreased ability to export our product to existing or potential
customers with international operations. Any decreased use of our product or limitation on our ability to export or sell access to our product would likely significantly harm our business, financial condition, results of operations and prospects.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are subject to various laws relating to foreign investment and the export of certain technologies, and our failure to comply with these laws or adequately
monitor the compliance of our suppliers and others we do business with could subject us to substantial fines, penalties and even injunctions, the imposition of which on us could have a material adverse effect on the success of our business.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are subject to U.S. laws that regulate foreign investments in U.S. businesses and access by foreign persons to technology developed and produced in the
United States. These laws include Section&nbsp;721 of the Defense Production Act of 1950, as amended by the Foreign Investment Risk Review Modernization Act of 2018, and the regulations at 31 C.F.R. Parts&nbsp;800 and 801, as amended, administered
by the Committee on Foreign Investment in the United States; and the Export Control Reform Act of 2018, which is being implemented in part through Commerce Department rulemakings to impose new export control restrictions on &#147;emerging and
foundational technologies&#148; yet to be fully identified. Application of these laws, including as they are implemented through regulations being developed, may negatively impact our business in various ways, including by restricting our access to
capital and markets; limiting the collaborations we may pursue; regulating the export our products, services, and technology from the United States and abroad; increasing our costs and the time necessary to obtain required authorizations and to
ensure compliance; and threatening monetary fines and other penalties if we do not. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks related to employee matters, managing our growth and other risks
related to our business </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The outbreak of the novel coronavirus disease, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> could adversely impact our
business, including our clinical trials. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2020, the World Health Organization declared the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
outbreak a pandemic, and since such time, actions taken around the world to help mitigate the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> have included varying restrictions on travel, quarantines in certain areas, and forced closures
for several types of public places and businesses The outbreak and government measures taken in response have had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been
disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. The effects of government
orders and our work-from-home could slow our productivity or disrupt our business in the future, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business
in the ordinary course. In response to the spread of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> we have closed our executive offices with our administrative employees continuing their work outside of our offices and limited the number of
staff in any given research and development laboratory. As a result of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we may experience additional disruptions that could severely impact our business, preclinical studies and
clinical trials, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays or difficulties in enrolling and retaining patients in our clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and
clinical site staff; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving
as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel
imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical trial endpoints; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval
timelines; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">limitations on our business operations by the local, state, or federal government that could impact our ability to sell or
deliver our instruments and consumables; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">interruption of, or delays in receiving, supplies of atacicept from our contract manufacturing organizations (CMO) due to
staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">interruption of or delays in receiving products and supplies from the third parties we rely on to, among other things,
manufacture components of our instruments, due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems, which may impair our ability to sell our products and consumables; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">interruptions in nonclinical studies due to restricted or limited operations at our laboratory facility;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">business disruptions caused by workplace, laboratory and office closures and an increased reliance on employees working
from home, travel limitations, cyber security and data accessibility limits, or communication or mass transit disruptions; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">limitations on employee resources that would otherwise be focused on the conduct of our nonclinical studies and clinical
trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">interruption or delays to our sourced discovery and clinical activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Three vaccines for <FONT STYLE="white-space:nowrap">COVID-19</FONT> were granted Emergency Use Authorization by the FDA in late 2020 and early 2021, and more are likely
to be authorized in the coming months. The resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more
difficult to obtain materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">It is uncertain
when restrictions will be fully lifted, and if so, when we will be able to resume <FONT STYLE="white-space:nowrap">pre-pandemic</FONT> work routines. Imposition of government orders, including quarantine and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> orders related to <FONT STYLE="white-space:nowrap">COVID-19</FONT> or other infectious diseases, is expected to continue to impact personnel at our and our third-party manufacturing
facilities for the foreseeable future. The ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to rapidly evolve. The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to impact our
business, clinical development, including our ongoing and planned preclinical studies and clinical trials, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread
of the disease, the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other
countries to contain and treat the disease, including the effectiveness and timing of vaccination programs in the United States and worldwide. Accordingly, we do not yet know the full extent of potential delays or impacts on our business, our
clinical and regulatory activities, healthcare systems or the global economy as a whole. However, these effects could have negative impacts on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, to the extent the evolving <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to adversely affects our business and results of operations,
it may also have the effect of heightening many of the other risks and uncertainties described in this &#147;Risk Factors&#148; section. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our success is highly dependent on our ability to attract and retain highly skilled executive officers and
employees and key consultants. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel,
and we face significant competition for experienced personnel. We are highly dependent on the management, research and development, clinical, financial and business development expertise of our executive officers, as well as the other members of our
scientific and clinical teams, including certain key consultants. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, although we have employment offer letters with each of our executive officers, each
of them may terminate their employment with us at any time. We do not maintain &#147;key person&#148; insurance for all of our executives or employees. If we do not succeed in attracting and retaining qualified personnel, particularly at the
management level, it could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable
replacements in a timely manner. The competition for qualified personnel in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the future success of our business.
We could in the future have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a
longer history in the industry than we do. They also may provide more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we
are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize atacicept or any other product candidate will be limited and the potential for successfully growing our
business will be harmed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market
atacicept or any product candidate we may develop in the future, we may not be able to successfully sell or market atacicept or any future product candidate we may develop in the future that obtained regulatory approval. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently do not have, and have never had, a marketing or sales team. In order to commercialize any product candidates, if approved, we must build marketing, sales,
distribution, managerial and other <FONT STYLE="white-space:nowrap">non-technical</FONT> capabilities or make arrangements with third parties to perform these services for each of the territories in which we may have approval to sell or market
atacicept or any future product candidate we may develop. We may not be successful in accomplishing these required tasks. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Establishing an internal sales or
marketing team with technical expertise and supporting distribution capabilities to commercialize atacicept or any product candidate we may develop in the future will be expensive and time-consuming, and will require significant attention of our
executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could adversely impact the commercialization of atacicept or any product candidate we may develop in the future that
we obtain approval to market, if we do not have arrangements in place with third parties to provide such services on our behalf. Alternatively, if we choose to collaborate, either globally or on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">territory-by-territory</FONT></FONT> basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales
force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration. If we are unable to enter into such arrangements when needed, on acceptable terms, or at
all, we may not be able to successfully commercialize atacicept or any product candidate we may develop in the future which may receive regulatory approval or any such commercialization may experience delays or limitations. If we are unable to
successfully commercialize our approved product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products
on our own or together with suitable collaborators. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never commercialized a product candidate, and we currently have no sales force, marketing or
distribution capabilities. To achieve commercial success for a product candidate, which we may license to others, we will rely on the assistance and guidance of those collaborators. For any product candidates for which we retain
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
commercialization rights, we will have to develop our own sales, marketing and supply organization or outsource these activities to a third party. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As an organization, we have never commercialized a product candidate. Factors that may affect our ability to commercialize atacicept or any future product candidate we
may develop, on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, obtaining access to or persuading adequate numbers of physicians to prescribe atacicept or any future product candidates we may
develop and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization will be expensive and time-consuming and could delay the launch of atacicept or any future
product candidate we may develop. We may not be able to build an effective sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of
atacicept or any future product candidate we may develop, we may not generate revenues from such product candidate or be able to achieve or sustain profitability. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing
this growth. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of April 30, 2021, we had 12 full-time employees, including eight employees engaged in research and development. In order to successfully
implement our development and commercialization plans and strategies, and as we transition into operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel. Future growth would
impose significant added responsibilities on members of management, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">identifying, recruiting, integrating, maintaining and motivating additional employees; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">managing our internal development efforts effectively, including the clinical, FDA and other comparable foreign regulatory
agencies&#146; review process for atacicept and any other future product candidates we may develop, while complying with any contractual obligations to contractors and other third parties we may have; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">improving our operational, financial and management controls, reporting systems and procedures. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we expect to be conducting multiple clinical trials of atacicept for several different indications concurrently. Given the small size of our organization,
we may encounter difficulties managing multiple clinical trials at the same time, which could negatively affect our ability to manage growth of our organization, particularly as we take on additional responsibility associated with being a public
company. Our future financial performance and our ability to successfully develop and, if approved, commercialize, atacicept and any other future product candidates will depend, in part, on our ability to effectively manage any future growth, and
our management may also have to divert a disproportionate amount of its attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities in order to devote a substantial amount of time to
managing these growth activities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent
organizations, advisors and consultants to provide certain services, including key aspects of clinical development and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be
available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by third party service
providers is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of atacicept and any other future product candidates we may develop or otherwise advance our
business. We cannot assure you that we will be able to manage our existing third party service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are not able to effectively expand our organization by hiring new employees and/or engaging additional third party service providers, we may not be able to
successfully implement the tasks necessary to further develop and commercialize atacicept and any other future product candidates we may develop and, accordingly, may not achieve our research, development and commercialization goals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We or the third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural
disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our headquarters is located in
South San Francisco, California, which in the past has experienced severe earthquakes and fires. If these earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control prevented us from using all or a
significant portion of our research facility, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may
incur substantial expenses as a result of the absence or limited nature of our internal or third-party service provider disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance,
could have a material adverse effect on our business. Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If
such an event were to affect our supply chain, it could have an adverse effect on our ability to conduct our clinical trials, our development plans and business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comprehensive tax reform legislation could adversely affect our business and financial condition. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations
and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Cuts and Jobs Act of 2017 (Tax Act) enacted many significant
changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example,
the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) signed into law on March&nbsp;27, 2020, modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act or
any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform
legislation could have a material impact on the value of our deferred tax assets, could result in significant <FONT STYLE="white-space:nowrap">one-time</FONT> charges, and could increase our future U.S. tax expense. Among the changes made by the Tax
Act were a reduction of the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions generally referred to as &#147;orphan drugs&#148;. We continue to examine the impact this
tax reform legislation may have on our business. We urge investors to consult with their legal and tax advisers regarding the implications of the Tax Act and potential changes in U.S. tax laws on an investment in our Class A common stock. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have incurred losses during our history, we expect to continue to incur significant losses for the foreseeable future, and we may never achieve profitability As of
December&nbsp;31, 2020, we had federal and state net operating loss carryforwards of $10.2&nbsp;million and $3.5&nbsp;million, respectively, that will begin expiring in the year 2037 and 2036, respectively, if not utilized. We also have
$33.8&nbsp;million of federal net operating loss carryforwards as of December&nbsp;31, 2020, that do not expire as a result of recent tax law changes. Our net operating loss (NOL) carryforwards are subject to review and possible adjustment by the
U.S. and state tax authorities. Our NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. NOLs generated in tax years ending
on or prior to December&nbsp;31, 2017 are only permitted to be carried forward for 20 taxable years under applicable U.S. federal tax law. Under the Tax Act, as modified by the CARES Act, NOLs arising in tax years beginning after December&nbsp;31,
2017, and before January&nbsp;1, 2021 may be carried back to each of the five tax years preceding the tax year of such loss, and NOLs arising in tax years beginning after December&nbsp;31, 2020 may not be carried back. Moreover, under the Tax Act as
modified by the CARES Act, federal NOLs generated in tax years ending after December&nbsp;31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs may be limited to 80% of current year taxable income for tax years
beginning after December&nbsp;31, 2020. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, California
recently imposed limits on the usability of California state NOL carryforwards to offset taxable income in taxable years beginning after 2019 and before 2023. It is generally uncertain if and to what extent various states will conform to the Tax Act
or the CARES Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes
an &#147;ownership change&#148; (generally defined as a cumulative change in our ownership by <FONT STYLE="white-space:nowrap">&#147;5-percent</FONT> shareholders&#148; that exceeds 50 percentage points over a rolling three-year period), the
corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and certain other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset its post-change income and taxes may be limited. Similar
rules may apply under state tax laws. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of this offering or subsequent shifts in our stock ownership, some of which are
outside our control. We have not conducted any studies to determine annual limitations, if any, that could result from such changes in the ownership. Our ability to utilize those NOLs could be limited by an &#147;ownership change&#148; as described
above and consequently, we may not be able to utilize a material portion of our NOLs and certain other tax attributes, which could have an adverse effect on our cash flows and results of operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A variety of risks associated with marketing atacicept or any future product candidate we may develop internationally could significantly harm our business,
financial condition, results of operations and prospects. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to seek regulatory approval of atacicept or any future product candidates we may develop
outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">differing regulatory requirements and reimbursement regimes in foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">foreign taxes, including withholding of payroll taxes; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other
obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">difficulties staffing and managing foreign operations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential liability under the FCPA or comparable foreign regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not
respect and protect intellectual property rights to the same extent as the United States; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including war and
terrorism. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These and other risks associated with our international operations may significantly harm our business, financial condition, results
of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks related to our intellectual property </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our success depends on our ability to protect our intellectual property and our proprietary technologies. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial success depends in part on our and our current or future licensors&#146;, licensees&#146; or collaborators&#146; ability to obtain and maintain
proprietary or intellectual property protection in the United States and other countries for atacicept, any future product candidates that we may develop and technologies related to their various uses. We generally seek to protect our proprietary
position by, among other things, filing patent applications in the United States and abroad related to our proprietary technologies, and their manufacture and uses that are important to our business, as well as inventions and improvements that are
important to the development and implementation of our business. Our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications in both United States and certain foreign jurisdictions relate to atacicept and other
products. There can be no assurance that the claims of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, or any patent application that issues as a patent, will exclude others from making, using or selling our product
candidate or any future product candidates or products that are substantially similar to our product candidate or any future product candidates. We also rely on trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing
technological innovation to develop and maintain our proprietary and intellectual property position. We may seek to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
protect our proprietary position by acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> additional relevant issued patents or pending applications from third parties. If we or our
potential licensors, licensees or collaborators are unable to obtain or maintain patent protection with respect to atacicept and our other products, proprietary technologies and their uses, our business, financial condition, results of operations
and prospects could be significantly harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pending patent applications cannot be enforced against third parties practicing the technology claimed in such
applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent
applications or our current or future licensors&#146;, licensees&#146; or collaborators&#146; patent applications will result in additional patents being issued or that issued patents will afford sufficient protection against competitors with
similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, in the
future, some of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications may be <FONT STYLE="white-space:nowrap">co-owned</FONT> with third parties. If we are unable to obtain exclusive licenses to any such <FONT
STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such patents or patent applications, then such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other third parties, including our competitors, and
our competitors could market competing products and technology. In addition, we may need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> in order to enforce such patents against third parties, and such cooperation may
not be provided to us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties
before various patent offices or in courts. Thus, the degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any
competitive advantage. These uncertainties and/or limitations in our ability to properly protect the intellectual property rights relating to atacicept or any future product candidates we may develop could significantly harm our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot be certain that the claims in our U.S. pending patent applications and corresponding international
applications will be considered patentable by the United States Patent and Trademark Office (USPTO) courts in the United States or by the patent offices and courts in foreign countries , nor can we be certain that the claims in our issued patent(s)
will not be found invalid or unenforceable if challenged. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent application process is subject to numerous risks and uncertainties, and there can be no
assurance that we or any of our potential future collaborators will be successful in protecting atacicept or any future product candidates we may develop by obtaining and defending patents. These risks and uncertainties include the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">patent applications must be filed in advance of certain events (e.g., third party filings, certain sales or offers for
sale, or other activities that might be legally deemed to be public disclosures) and we might not be aware of such events or otherwise might not succeed in filing applications before they occur; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary,
fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">patent applications may not result in any patents being issued; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not
provide any competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of
patent protection both inside and outside the United States; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts,
allowing foreign competitors a better opportunity to create, develop and market competing product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent prosecution process is
also expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection
may be commercially advantageous. It is also possible that we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection, for example, if patentable aspects are publicly disclosed, by us
or a third party, such as by public use, sale or offer for sale, or publication. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, although we enter into
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, outside scientific collaborators,
CROs, third-party manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent
protection. Further, although we require our employees, commercial contractors, and certain consultants and investigators to enter into invention assignment agreements that grant us ownership of any discoveries or inventions made by them while in
our employ, we cannot guarantee that we have entered into such agreements with each party, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach such agreements and claim ownership in
intellectual property that we believe is owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> by us. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in
the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our owned or any licensed
patents or pending patent applications, or that we were the first to file for patent protection of such inventions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Given the amount of time required for the
development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with
sufficient rights to exclude others from commercializing products similar or identical to ours. Should any of the above events occur, it could significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we breach our license agreement with Ares, an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, we could lose the ability to continue the
development and commercialization of atacicept. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are dependent on patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology
licensed or sublicensed to us from Ares. Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidate or any future product candidates and use our and our licensor&#146;s proprietary technologies
without infringing the proprietary rights of third parties. Ares may have the right to terminate the license agreement in full in the event we materially breach or default in the performance of any of the obligations under the license agreement. A
termination of the license agreement with Ares could result in the loss of significant rights and could harm our ability to commercialize our product candidates. Additionally, certain patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and
proprietary technology of third parties, including certain composition of matter patents, are sublicensed to us from Ares and in the event the agreement between Ares and any such third party terminates, expires or is in dispute, it could result in
the loss of significant rights and could harm our ability to commercialize our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Disputes may also arise between us and Ares, an affiliate of
Merck KGaA, Darmstadt, Germany, as well as any future potential licensors, regarding intellectual property subject to a license agreement, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not
subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our product candidate and what activities satisfy those diligence obligations; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint creation or use
of intellectual property by our licensors and us and our partners. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If disputes over intellectual property that we have licensed prevent or impair
our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we acquired worldwide, exclusive rights to atacicept pursuant to our license agreement (Ares Agreement)
with Ares, under which we currently license intellectual property. The Ares Agreement is complex, and certain provisions may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could
narrow what we believe to be the scope of our rights to the relevant intellectual property, or increase what we believe to be our financial or other obligations under the Ares Agreement, either of which could have an adverse effect on our business,
financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangement on commercially acceptable terms, we may be
unable to successfully develop and commercialize the affected product candidates, which could have an adverse effect on our business, financial conditions, results of operations, and prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we
own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be required to make significant payments under our license agreement for atacicept. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Ares Agreement, in consideration for the license, we issued 22,171,553 shares of our Series&nbsp;C redeemable convertible preferred stock to Ares at the time
of the initial closing of our Series C redeemable convertible preferred stock financing in October 2020. As additional consideration for the license, we paid Ares $25.0&nbsp;million upon delivery and initiation of the transfer of specified
information and materials and we are required to pay Ares aggregate milestone payments of up to $176.5&nbsp;million upon the achievement of specified BLA filing or regulatory approval and aggregate milestone payments of up to $515&nbsp;million upon
the achievement of specified commercial milestones. Commencing on the first commercial sale of licensed products, we are obligated to pay tiered royalties of low double-digit to <FONT STYLE="white-space:nowrap">mid-teen</FONT> percentages on annual
net sales of the products covered by the license. In the event we sublicense our rights under the Ares Agreement, we are obligated to pay Ares a percentage ranging from the <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> to the low
double-digits of specified sublicensing income received. If milestone or other <FONT STYLE="white-space:nowrap">non-royalty</FONT> obligations become due, we may not have sufficient funds available to meet our obligations, which will adversely
affect our business operations and financial condition. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our
patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
patent positions of biotechnology companies generally are highly uncertain, involve complex legal and factual questions for which important legal principles remain unsolved and have been the subject of much litigation in recent years. As a result,
the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect atacicept or which effectively prevent
others from commercializing competitive technologies and product candidates. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, many countries restrict the
patentability of methods of treatment of the human body. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, the coverage claimed in a patent application can be significantly reduced before a patent is
issued, and its scope can be reinterpreted after issuance. Legal standards relating to valid and enforceable claim scope are unsettled in the United States and elsewhere and disputes challenging or <FONT STYLE="white-space:nowrap">re-defining</FONT>
scope are common in the biopharmaceutical industry. Even if patent applications we own or <FONT STYLE="white-space:nowrap">in-license</FONT> currently or in the future issue as patents, they may not issue in a form that will provide us with any
meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> may be challenged or
circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether atacicept or any future product candidates we may develop will be protectable or remain protected by
valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in <FONT STYLE="white-space:nowrap">a&nbsp;non-infringing&nbsp;manner</FONT>
which could significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The issuance of a patent is not conclusive as to its
inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The process by which patent applications are examined and considered for issuance as patents involves consideration
by the relevant patent office of &#147;prior art&#148; relative to the invented technology. Different countries have different rules about what information or events can be considered &#147;prior art,&#148; and different requirements regarding when
a patent application must be filed relative to any particular piece of potential prior art. Moreover, legal decisions can <FONT STYLE="white-space:nowrap">re-interpret</FONT> or change whether particular information or events are considered to be
&#147;prior art.&#148; Still further, in the United States, patent applicants are required to notify the USPTO of any material &#147;prior art&#148; of which they are aware for the patent examiner to consider in addition to independent searches that
the patent examiner is required to do. Also, in the United States and certain other jurisdictions, third parties are entitled to submit prior art to patent offices for consideration during examination. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may not be aware of certain relevant prior art, may fail to identify or timely cite certain prior art, or may not be able to convince a patent examiner that our
patent(s) should issue in light of the art. Also, we cannot be certain that all relevant art will be or was identified during examination of a patent application so that, even if a patent issues, it may be susceptible to challenge that it is not
valid over art that was not considered during its examination. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may be subject to a
<FONT STYLE="white-space:nowrap">third-party&nbsp;pre-issuance&nbsp;submission</FONT> of prior art to the USPTO or other jurisdictions, or become involved in post-grant challenges such as opposition, derivation, revocation, reexamination, post-grant
review (PGR) and<I>&nbsp;inter partes</I>&nbsp;review (IPR), or other similar proceedings, or in litigation, challenging our patent rights, including by challenging the validity or the claim of priority of our patents. An adverse determination in
any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize atacicept or any future product candidates we may develop and compete directly
with us, without payment to us. Such challenges may result in loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or
commercializing similar or identical technology and products, or limit the duration of the patent protection of atacicept or any future product candidates we may develop. The outcome following legal assertions of invalidity and unenforceability is
unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, including art of which we were unaware, and art which was not raised during prosecution of any of our patents or patent
applications. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our technology or platform, or any product candidates that we may
develop. Such a loss of patent protection would significantly impact our business, financial condition, results of operations and prospects. Such proceedings also may result in substantial cost and require significant time from our scientists and
management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from
collaborating with us to license, develop, or commercialize current or future product candidates or could embolden competitors to launch products or take other steps that could disadvantage us in the marketplace or draw us into additional expensive
and time consuming disputes. Should any of these events occur, it could significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately
protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may not be able to detect infringement of our issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">others may be able to develop products that are similar to atacicept, or any future product candidates we may develop, but
that are not covered by the claims of the patents that we may <FONT STYLE="white-space:nowrap">in-license</FONT> in the future or own; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our competitors may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to
make, use and sell atacicept or any future product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we, or our current or future collaborators or license partners, might not have been the first to make the inventions
covered by the issued patents or patent applications that we may <FONT STYLE="white-space:nowrap">in-license</FONT> in the future or own; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we, or our current or future collaborators or license partners, might be found not have been the first to file patent
applications covering certain of our or their inventions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">it is possible that the pending patent applications we may <FONT STYLE="white-space:nowrap">in-license</FONT> in the
future or own will not lead to issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">it is possible that there are prior public disclosures that could invalidate our patents, or parts of our patents, for
which we are not aware; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">issued patents that we hold rights to may be held invalid or unenforceable, as a result of legal challenges by our
competitors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">issued patents may not have sufficient term or geographic scope to provide meaningful protection; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then
use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the patents of others may have an adverse effect on our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">we may choose not to file a patent in order to maintain certain trade secrets, and a third party may subsequently file a
patent covering such intellectual property. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Should any of these events occur, it could significantly harm our business, financial condition,
results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our commercial success depends significantly on our ability to operate without infringing, misappropriating or otherwise
violating the patents and other proprietary rights of third parties. Claims by third parties that we infringe, misappropriate or otherwise violate their proprietary rights may result in liability for damages or prevent or delay our developmental and
commercialization efforts. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial success depends in part on avoiding infringement, misappropriation or other violations of the patents and
proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe, misappropriate or otherwise violate patents or other intellectual property rights owned or controlled
by third parties. A finding by a court or administrative body that we infringe the claims of issued patents owned by third parties could preclude us from commercializing atacicept or any future product candidates we may develop. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import atacicept or any future
product candidates we may develop and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual
property rights in the biotechnology industry, including patent infringement lawsuits, and proceedings, such as oppositions, reexaminations, IPR proceedings and PGR proceedings, before the USPTO and/or corresponding foreign patent offices. In
addition, many companies in intellectual property-dependent industries, including the biotechnology industry, have employed intellectual property litigation as a means to gain an advantage over their competitors. Numerous third-party U.S. and
foreign issued patents and pending patent applications may exist in the fields in which we are developing atacicept or any future product candidates we may develop. There may be third-party patents or patent applications with claims to compositions,
formulations, methods of manufacture or methods for treatment related to the use or manufacture of atacicept or any future product candidates we may develop. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">It is
possible that one or more organizations will hold patent rights to which we will need a license. If those organizations refuse to grant us a license to such patent rights on reasonable terms, we may be unable to develop, manufacture, market, sell
and commercialize products or services or perform research and development or other activities covered by these patents. In the event that any of these patents were to issue and be asserted against us, we believe that we would have defenses against
any such assertion, including that such patents are not valid. However, if such defenses to such assertion were unsuccessful, we could be liable for damages, which could be significant and include treble damages and attorneys&#146; fees if we are
found to willfully infringe such patents. We could also be required to obtain a license to such patents, which may not be available on commercially reasonable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
terms or at all. If we are unable to obtain such a license, we could be precluded from commercializing any product candidates that were ultimately held to infringe such patents. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As the biotechnology industry expands and more patents are issued, the risk increases that atacicept, or any future product candidates we may develop, may be subject to
claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published, we may be unaware of third-party patents that may be
infringed by commercialization of atacicept, or any future product candidates we may develop, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent
applications can take many years to issue, there may be currently-pending patent applications that may later result in issued patents that atacicept or any future product candidates we may develop may infringe. In addition, identification of
third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims.
There is also no assurance that there is not prior art of which we are aware, but which we do not believe is relevant to our business, which may, nonetheless, ultimately be found to limit our ability to make, use, sell, offer for sale or import our
products that may be approved in the future, or impair our competitive position. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Still further, we cannot rely on our
experience that third parties have not so far alleged that we infringe their patent rights, as provisions of U.S. patent laws provide a safe harbor from patent infringement for therapeutic products under clinical development. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any claims of patent infringement, misappropriation or other violations asserted by third parties would be time consuming and could: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">result in costly litigation that may cause negative publicity; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">divert the time and attention of our technical personnel and management; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">cause development delays; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">prevent us from commercializing atacicept or any future product candidates we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">require us to develop <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology, which may not be possible on a
cost-effective basis; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">subject us to significant liability to third parties; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or
at all, or which might be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which could result in our competitors gaining access to the same technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any patent-related legal action against us claiming damages or seeking to enjoin commercial activities relating to our products, or processes could subject us to
significant liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or market atacicept or any future product candidates we may develop. Defense of these claims,
regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under
any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or a future strategic partner were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining
access to the same intellectual property. In addition, we cannot be certain that we could redesign atacicept or any future product candidates we may develop processes to avoid infringement, if necessary. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing
atacicept or any future product candidates we may develop, which could significantly harm our business, financial condition and operating results. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity
and could prohibit us from marketing or otherwise commercializing atacicept and future product candidates and technologies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Parties making claims against us may be
able to sustain the costs of complex patent litigation more effectively than we can. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a
risk that some of our confidential information could be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have an adverse effect on our ability to raise additional funds or
otherwise significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be successful in obtaining or maintaining
necessary rights from third parties that we identify as necessary for future product candidates we may develop through acquisitions <FONT STYLE="white-space:nowrap">and&nbsp;in-licenses.</FONT> </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because our development programs may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our
ability to <FONT STYLE="white-space:nowrap">acquire,&nbsp;in-license,&nbsp;or</FONT> use these third-party proprietary rights. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While we may have <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents that cover atacicept, it is possible that third parties may have blocking patents that prevent us from marketing, manufacturing or commercializing our patented products and practicing our <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patented technology. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may be unsuccessful in acquiring
<FONT STYLE="white-space:nowrap">or&nbsp;in-licensing&nbsp;compositions,</FONT> methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for practicing inventions claimed by our patents,
including the manufacture, sale and use of atacicept and any future product candidates we may develop. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may
pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater
clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property
rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights
we have, we may have to abandon development of the relevant program or product candidate, which could significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents could be
found invalid or unenforceable if challenged in court. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competitors or other third parties may infringe, misappropriate or otherwise violate our
intellectual property rights. To prevent infringement or unauthorized use, we may be required to file infringement or other intellectual property claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a
court may decide that a patent we may <FONT STYLE="white-space:nowrap">in-license</FONT> in the future or own is not valid, is unenforceable, and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the
grounds that our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents do not cover the technology in question. If we or any of our potential future collaborators were to initiate legal proceedings against a third party to enforce a
patent directed at atacicept or any future product candidates we may develop, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims
alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, <FONT
STYLE="white-space:nowrap">non-enablement,</FONT> or obviousness-type double patenting. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from
the USPTO or made a misleading statement during prosecution. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we may lose
at least part, and perhaps all, of the patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating
with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not
protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may
cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available
for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Our competitors may be able to sustain the costs of
such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete
in the marketplace. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal
proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Should any of these events occur, it could significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of
hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be
diminished. Accordingly, the market price of shares of our Class&nbsp;A common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could significantly harm our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Derivation proceedings may be </I></B><B><I>necessary</I></B><B><I> to determine priority of inventions, and
an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party</I></B>. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Derivation
proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the
related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of derivation proceedings may fail
and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have an adverse effect on our ability to raise the funds necessary to
continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring atacicept or any future product candidates to market.
Should any of these events occur, it could significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Patent reform
legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our patents. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in
the biotechnology industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. Our ability to obtain patents is highly
uncertain because, to date, some legal principles remain unresolved, and there has not been a consistent policy regarding the breadth or interpretation of claims allowed in patents in the United States. Furthermore, the specific content of patents
and patent applications that are necessary to support and interpret patent claims is highly uncertain due to the complex nature of the relevant legal, scientific, and factual issues. Changes in either patent laws or interpretations of patent laws in
the United States and other countries may diminish the value of our intellectual property or narrow the scope of our patent protection. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, the United States
has enacted and implemented wide-ranging patent reform legislation and the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the
rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign
jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patent and the patents we might obtain or license in the future. An inability
to obtain, enforce, and defend patents covering our proprietary technologies (including atacicept) would adversely affect our business prospects and financial condition. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similarly, changes in patent laws and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the
relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we may obtain in the future. Further, the laws of some foreign countries do not protect proprietary rights to
the same extent or in the same manner as the laws of the United States and Europe. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. For example, if the
issuance in a given country of a patent covering an invention is not followed by the issuance in other countries of patents covering the same invention, or if any judicial interpretation of the validity, enforceability or scope of the claims or the
written description or enablement, in a patent issued in one country is not similar to the interpretation given to the corresponding patent issued in another country, our ability to protect our intellectual property in those countries may be
limited. Changes in either patent laws or in interpretations of patent laws in the United States and other countries may materially diminish the value of our intellectual property or narrow the scope of our patent protection. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">It is possible that we do not transfer or perfect ownership of all patents, patent applications or other intellectual property. This possibility includes the risk that
we do not identify all inventors, or identify incorrect inventors, which may lead to claims disputing inventorship or ownership of our patents, patent applications or other intellectual property by former employees or other third parties. There is
also a risk that we do not establish an unbroken chain of title from inventors to us. Errors in inventorship or ownership can sometimes also impact priority claims. If we were to lose ability to claim priority for certain patent filings, intervening
art or other events may preclude us from issuing patents. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Litigation may be necessary to defend against these and other claims challenging inventorship or
ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could significantly harm our business, financial condition, results of operations and
prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Patent terms may be inadequate to protect our competitive position on atacicept or any future product candidates we may develop for an adequate amount of time.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patents have a limited lifespan. Generally, issued patents are granted a term of 20 years from the earliest claimed
<FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Various extensions may be available, but there can be no assurance that any such extensions will be obtained, and the life of a patent, and the protection it affords, is limited.
In certain instances, patent term can be adjusted to recapture a portion of delay by the USPTO in examining the patent application (patent term adjustment) or extended to account for term effectively lost as a result of the FDA regulatory review
period (patent term extension), or both. There is a risk that we may take action that detracts from any accrued patent term adjustment. Even if patents covering atacicept or any future product candidates we may develop are obtained, once the patent
life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or
shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our earliest <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents may expire before, or soon after, our first product achieves marketing approval in the United
States or foreign jurisdictions. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could also have a similar material adverse effect on our business,
financial condition, prospects and results of operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any of the foregoing could significantly harm our business, financial condition, results of operations
and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of
time, and if we do not obtain protection under the Hatch-Waxman Amendments and similar <FONT STYLE="white-space:nowrap">non-United</FONT> States legislation for extending the term of patents covering each of our product candidates, our business may
be significantly harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting
such candidates might expire before or shortly after such candidates are commercialized. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our United States patents may be eligible
for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the European Union. The Hatch-Waxman Amendments permit a patent term
extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a
patent beyond a total of 14 years from the date of product approval. Only one patent may be extended per approved drug product, and only those claims covering the approved drug product, a method for using it, or a method for manufacturing it may be
extended. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension
could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be impacted and our competitors
may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced and could have a material adverse effect on our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries
outside the United States may be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States.
Consequently, we will not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other
jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection,
but enforcement is not as strong as that in the United States. These infringing products may compete with atacicept or any future product candidates we may develop, without any available recourse. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The laws of some other countries do not protect intellectual property rights to the same extent as the laws of the United States. Patent protection must ultimately be
sought on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection
in certain countries, and we will not have the benefit of patent protection in such countries. In addition, the legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual
property protection, especially those relating to biopharmaceuticals. As a result, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. Because the legal systems of
many foreign countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceutical products, it could be difficult for us to stop the infringement, misappropriation or
violation of our patents or our licensors&#146; patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our intellectual property and other proprietary rights in foreign jurisdictions could result in
substantial costs and divert our efforts and attention from other aspects of our business, could put our patents or the patents of our licensors at risk of being invalidated or interpreted narrowly, could put our patent applications or the patent
applications of our licensors at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially
meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the
enforceability of patents against government agencies or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third
parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be significantly harmed. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">In addition, recordation of licenses with respect to exclusively licensed patent rights outside of the United States is potentially costly and we might fail to record
such rights timely. If we fail to timely record our patent rights, third parties may try to seek licenses from the patent owners, or we may not be able to recover full damages for patent infringement in jurisdictions where we have no such
recordations, any of which could significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Obtaining and maintaining our
patent protection depends on compliance with various procedural, documentary, fee payment, and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated <FONT
STYLE="white-space:nowrap">for&nbsp;non-compliance&nbsp;with</FONT> these requirements. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Periodic maintenance fees, renewal fees, annuity fees and various
other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or patent applications. We have systems in place to remind us to pay these
fees, and we rely on our outside patent annuity service to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions
during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to
the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an
event were to occur, potential competitors might be able to enter the market with similar or identical products or technology, which could significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business,
financial condition, results of operations and prospects could be significantly harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to use registered or unregistered trademarks or trade
names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these
trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build
brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered
or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business, financial condition, results of
operations and prospects may be significantly harmed. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in
substantial costs and diversion of resources and could significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, any
proprietary name we propose to use with our current or future products in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of
proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort
to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business, financial condition, results of operations, prospects and competitive position
would be significantly harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we rely on the protection of our trade secrets, including
<FONT STYLE="white-space:nowrap">unpatented&nbsp;know-how,&nbsp;technology</FONT> and other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and
<FONT STYLE="white-space:nowrap">unpatented&nbsp;know-how,&nbsp;including</FONT> entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot
guarantee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology or processes. Further, we cannot provide any assurances
that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, or claim ownership in intellectual property that we believe is owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> by us. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective.
In addition, we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In
addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, if any of our trade secrets were to be
lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection
for our trade secrets, the value of this information may be greatly reduced, and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of
our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized. Any of the foregoing could significantly harm our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to claims that we or our employees have wrongfully used or disclosed alleged confidential
information or trade secrets. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into and may enter in the future <FONT STYLE="white-space:nowrap">into&nbsp;non-disclosure&nbsp;and</FONT>
confidentiality agreements to protect the proprietary positions of third parties, such as outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors, potential partners, lessees of shared multi-company property and
other third parties. Many of our employees and consultants were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology companies, including our competitors or potential
competitors. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to
assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#146; former employers or
other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our future patents or patent applications. Defense of such matters, regardless of their merit, could involve substantial
litigation expense and be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions. Moreover, intellectual property litigation, regardless of its outcome, may cause negative
publicity and could prohibit us from marketing or otherwise commercializing atacicept or any future product candidates or technologies we may develop. Failure to defend against any such claim could subject us to significant liability for monetary
damages or prevent or delay our developmental and commercialization efforts, and cause us to lose valuable intellectual property rights or personnel, which could significantly harm our business, financial condition, results of operations and
prospects. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Parties making claims against us may be able to sustain the costs of complex intellectual property litigation more effectively than we can. Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation
and continuation of any litigation could have an adverse effect on our ability to raise additional funds or otherwise significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our rights to develop and commercialize our technology and product candidate may be subject, in part, to the terms and conditions of licenses granted to us by
others. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may enter into license agreements in the future with others to advance our research or allow commercialization of atacicept or any future
product candidates we may develop. These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our
technology and products in the future. As a result, we may not be able to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
prevent competitors from developing and commercializing competitive products in territories included in our licenses. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we fail to comply with our obligations under any such license agreements, including obligations to make various milestone payments and royalty payments and other
obligations, the licensor may have the right to terminate the license. If these agreements are terminated, we could lose intellectual property rights that are important to our business, be liable for any damages to such licensors or be prevented
from developing and commercializing our product candidates, and competitors could have the freedom to seek regulatory approval of, and to market, products identical to ours. Termination of these agreements or reduction or elimination of our rights
under these agreements may also result in our being required to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or
technology, or impede, delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements. It is possible that we may be unable to obtain any additional licenses at a reasonable cost or on
reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our product candidates or the methods for manufacturing them or to develop or license replacement technology, all of which may not be
feasible on a technical or commercial basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, subject to the terms of any such license agreements, we may not have the right to control the
preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the technology that we license from third parties. In such an event, we cannot be certain that these patents and patent applications
will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business, including the payment of all applicable fees for patents covering our product candidates. If our licensors fail to
prosecute, maintain, enforce and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our products that are subject
of such licensed rights could be adversely affected. Further, we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control the prosecution of patents and patent
applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by the actions or inactions of our licensees, our licensors and their counsel that took place prior to the date upon which we assumed control
over patent prosecution. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our licensors may have relied on third party consultants or collaborators or on funds from third parties such that our licensors are not
the sole and exclusive owners of the patents <FONT STYLE="white-space:nowrap">we&nbsp;in-licensed.&nbsp;If</FONT> other third parties have ownership rights to <FONT STYLE="white-space:nowrap">our&nbsp;in-licensed&nbsp;patents,</FONT> they may be
able to license such patents to our competitors, and our competitors could market competing products and technology. This could have an adverse effect on our competitive position, business, financial condition, results of operations and prospects.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may need to obtain additional licenses from existing licensors and others to advance our research or allow commercialization of product candidates we develop.
It is possible that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may <FONT STYLE="white-space:nowrap">be&nbsp;non-exclusive,&nbsp;thereby</FONT>
giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or
license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could significantly harm our
business, financial condition, results of operations and prospects significantly. We cannot provide any assurances that third party patents do not exist which might be enforced against our current technology, manufacturing methods, product
candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third
parties, which could be significant. Should any of these events occur, it could significantly harm our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to comply with our obligations in the agreements under which we license intellectual property rights
from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Disputes may arise between us and our past, current or future licensors regarding intellectual property subject to a license agreement, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not
subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our right to sublicense patents and other rights to third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our right to transfer or assign the license; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the agreements under which we license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be
susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we
believe to be our financial or other obligations under the relevant agreement, either of which could significantly harm our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we
have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could significantly harm
our business, financial condition and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements
and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products and technology covered by these license agreements. If <FONT STYLE="white-space:nowrap">these&nbsp;in-licenses&nbsp;are</FONT>
terminated, or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. This could significantly harm our competitive position,
business, financial condition and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Intellectual property discovered through government funded programs may be subject to federal regulations such
as <FONT STYLE="white-space:nowrap">&#147;march-in&#148;</FONT> rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> manufacturers. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may develop, acquire, or license intellectual property rights that have been generated through
the use of U.S. government funding or grants. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">non-transferable,</FONT> irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under
certain limited circumstances, to require us to grant exclusive, partially exclusive, or <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses to any of these inventions to a third party if it determines that: (1)&nbsp;adequate steps have
not been taken to commercialize the invention; (2) government action is necessary to meet public health or safety needs; or (3) government action is necessary to meet requirements for public use under federal regulations (also referred to as <FONT
STYLE="white-space:nowrap">&#147;march-in</FONT> rights&#148;). If the U.S. government exercised its <FONT STYLE="white-space:nowrap">march-in</FONT> rights in our future intellectual property rights that are generated through the use of U.S.
government funding or grants, we could be forced to license or sublicense intellectual property developed by us or that we license on terms unfavorable to us, and there can be no assurance that we would receive compensation from the U.S. government
for the exercise of such rights. The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property
within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government
requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential
licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract <FONT
STYLE="white-space:nowrap">with&nbsp;non-U.S.&nbsp;product</FONT> manufacturers for products covered by such intellectual property. Any exercise by the government of any of the foregoing rights could harm our competitive position, business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks related to our dependence on third parties </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct certain aspects of our nonclinical
studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or
commercialize atacicept or future product candidates we may develop and our business, financial condition, results of operations and prospects could be significantly harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs, to conduct certain aspects of
our nonclinical studies and clinical trials and to monitor and manage data for our ongoing nonclinical and clinical programs. We rely on these parties for execution of our nonclinical studies and clinical trials, and control only certain aspects of
their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not
relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for
atacicept in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties or our CROs fail to comply with applicable
GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot
assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under
cGMP regulations. Failure to comply and maintain adequate documentation with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be adversely affected if any of
these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, these
investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to atacicept and clinical trials. These third parties may also have relationships
with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If independent investigators or CROs fail to
devote sufficient resources to the development of atacicept, or if CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data
they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or
successfully commercialize atacicept. As a result, our results of operations and the commercial prospects for atacicept would be harmed, our costs could increase and our ability to generate revenues could be delayed or precluded entirely, and our
business, financial condition, results of operations and prospects could be significantly harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our CROs have the right to terminate their agreements with us in
the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials
warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. In addition, our CROs could fail to perform, we could terminate their agreements or they could go out of business. If our
relationships with our CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding CROs involves substantial cost and requires management time and focus, and
could delay development and commercialization of atacicept or any future product candidate we may develop. In addition, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
there is a natural transition period when a new CRO commences work. As a result, delays occur, which can negatively impact our ability to meet our desired clinical development timelines. Though
we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business and financial
condition. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and government measures taken in response have also had a significant impact on our CROs,
and we expect that they will face further disruption which may affect our ability to initiate and complete our nonclinical studies and clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of
our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires
management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may
lack the capacity to absorb higher workloads or take on additional capacity to support our needs. There can be no assurance that we will not encounter challenges or delays with CROs in the future or that these delays or challenges will not
significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We contract with third parties for the manufacture of atacicept
for our ongoing clinical trials, and expect to continue to do so for additional clinical trials and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of atacicept or other
drugs necessary for the development or commercialization of atacicept or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not currently have the infrastructure or internal capability to manufacture supplies of atacicept for use in development and commercialization. We rely, and
expect to continue to rely, on third-party manufacturers for the production of atacicept for clinical trials under the guidance of members of our organization. We do not have long-term supply agreements for atacicept. Furthermore, the raw materials
for atacicept are sourced, in some cases, from a single-source supplier. If we were to experience an unexpected loss of supply of atacicept for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could
experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. For example, the extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts our
ability to procure sufficient supplies for the development of atacicept in the future will depend on the severity and duration of the spread of the virus, and the actions undertaken to contain <FONT STYLE="white-space:nowrap">COVID-19</FONT> or
treat its effects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to continue to rely on third-party manufacturers for the commercial supply of atacicept, if we obtain marketing approval. We may be
unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional
risks, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the failure of the third party to manufacture atacicept according to our schedule, or at all, including if our third-party
contractors give greater priority to the supply of other products over atacicept or otherwise do not satisfactorily perform according to the terms of the agreements between us and them; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">disruptions resulting from the impact of public health pandemics or epidemics (including, for example, the ongoing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or
inconvenient for us; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the breach by the third-party contractors of our agreements with them; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the failure of third-party contractors to comply with applicable regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the failure of the third party to manufacture atacicept according to our specifications; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or
placebo not being properly identified; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug
supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the misappropriation of our proprietary information, including our trade secrets and
<FONT STYLE="white-space:nowrap">know-how.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not have control over all aspects of the manufacturing process of, and are dependent on,
our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory
requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or
maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a
comparable foreign regulatory authority does not approve these facilities for the manufacture of atacicept, or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly
impact our ability to develop, obtain marketing approval for or market atacicept, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us,
including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly
and adversely affect supplies of atacicept or other drugs necessary for the development or commercialization of atacicept and significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, if the third-party providers of therapies or therapies in development used in combination with atacicept are unable to produce sufficient quantities for
clinical trials or for commercialization of atacicept, or if the cost of combination therapies are prohibitive, our development and commercialization efforts would be impaired, which would significantly harm our business, financial condition,
results of operations and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our current and anticipated future dependence upon others for the manufacture of atacicept or other drugs necessary for the
development or commercialization of atacicept may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter
such difficulties, our ability to provide adequate supply of atacicept for clinical trials or our product for patients, if approved, could be delayed or prevented. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Manufacturing drugs, especially in large quantities, is complex and may require the use of innovative technologies. Each lot of an approved drug product must undergo
thorough testing for identity, strength, quality, purity and potency. Manufacturing drugs requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary.
Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the
manufacturing process, we may be required to provide nonclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are
discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and significantly harm our business, financial
condition, results of operations and prospects. The use of biologically derived ingredients can also lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination. If our
manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization as a result of these challenges, or otherwise, our development and commercialization efforts would be impaired, which would significantly harm our
business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements,
dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, we may evaluate various
acquisition opportunities and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks,
including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">increased operating expenses and cash requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the assumption of contingent liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the issuance of our equity securities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated
with integrating new personnel; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the diversion of our management&#146;s attention from our existing programs and initiatives in pursuing such a strategic
merger or acquisition; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and
their existing products or product candidates and marketing approvals; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in
undertaking the acquisition or even to offset the associated acquisition and maintenance costs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, if we undertake acquisitions or
pursue partnerships in the future, we may issue dilutive securities, assume or incur debt obligations, incur large <FONT STYLE="white-space:nowrap">one-time</FONT> expenses and acquire intangible assets that could result in significant future
amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities, and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may enter into collaborations with third parties for the development and commercialization of atacicept. If those collaborations are not successful, we
may not be able to capitalize on the market potential of atacicept. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the future, we may partner with third-party collaborators for the development and
commercialization of atacicept. Our likely collaborators for any future collaboration arrangements would likely include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical
companies and biotechnology companies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will likely have, limited control over the amount and timing of resources that our collaborators dedicate to the
development or commercialization of atacicept. Our ability to generate revenues from these arrangements will depend on our collaborators&#146; abilities and efforts to successfully perform the functions assigned to them in these arrangements.
Collaborations involving atacicept or any future product candidate could pose numerous risks to us, including the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these
collaborations and may not perform their obligations as expected; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators may deemphasize or not pursue development and commercialization of atacicept or may elect not to continue or
renew development or commercialization programs based on clinical trial results, changes in the collaborators&#146; strategic focus, including as a result of a sale or disposition of a business unit or development function, or available funding or
external factors such as an acquisition that diverts resources or creates competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial
or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly
with atacicept if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a collaborator with marketing and distribution rights to multiple products may not commit sufficient resources to the
marketing and distribution of our product relative to other products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborators may not properly obtain, maintain, defend or enforce our intellectual property rights or may use our
proprietary information and intellectual property in such a way as to invite litigation or other intellectual property related proceedings that could jeopardize or invalidate our proprietary information and intellectual property or expose us to
potential litigation or other intellectual property related proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">disputes may arise between the collaborators and us that result in the delay or termination of the research, development
or commercialization of atacicept or that result in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further
development or commercialization of the applicable product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient
manner or at all; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">if a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our drug
development or commercialization program could be delayed, diminished or terminated. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we decide to establish collaborations in the
future, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our drug development programs and the potential commercialization of atacicept or any future product candidates we may develop will require substantial additional cash
to fund expenses. We may continue to seek to selectively form collaborations to expand our capabilities, potentially accelerate research and development activities and provide for commercialization activities by third parties. Any of these
relationships may require us to incur <FONT STYLE="white-space:nowrap">non-recurring</FONT> and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and
business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we seek collaborations in the future, we will face significant competition in seeking appropriate collaborators and the negotiation process is
time-consuming and complex. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration
and the proposed collaborator&#146;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for
the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of intellectual property and
industry and market conditions generally. The potential collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more
attractive than the one with us for atacicept or any future product candidates we may develop. Further, we may not be successful in our efforts to establish a collaboration or other alternative arrangements for future product candidates because they
may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of
potential future collaborators. Even if we are successful in entering into a collaboration, the terms and conditions of that collaboration may restrict us from entering into future agreements on certain terms with potential collaborators. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If and when we seek to enter into additional collaborations, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are
unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or
marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to
obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop atacicept or any future product candidates we may develop or bring them to market
and generate product revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks related to this offering and ownership of our Class A common stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>There has been no prior public market for our Class A common stock. We do not know whether an active, liquid and orderly trading market will develop for our Class
A common stock or what the market price of our Class A common stock will be, and as a result, it may be difficult for you to sell your shares of our Class A common stock. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, no public market for shares of our Class A common stock existed and an active trading market for our Class A common stock may never develop or
be sustained following this offering. We will determine the initial public offering price for our Class A common stock through negotiations with the underwriters, and the negotiated price may not be indicative of the market price of our Class A
common stock after this offering. The market value of our Class A common stock may decrease from the initial public offering price. As a result of these and other factors, you may be unable to resell your shares of our Class A common stock at or
above the initial public offering price. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair
market value of your shares. Furthermore, an inactive market may also impair our ability to raise capital by selling shares of our Class A common stock and may impair our ability to enter into strategic collaborations or acquire companies,
technologies or other assets by using our shares of Class&nbsp;A common stock as consideration. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The price of our stock may be volatile, and you could lose
all or part of your investment. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading price of our Class A common stock following this offering is likely to be highly volatile and subject to wide
fluctuations in response to various factors, some of which we cannot control. The stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been
unrelated or disproportionate to the operating performance of these companies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Broad market and industry factors may negatively affect the market price of our
Class A common stock, regardless of our actual operating performance. In addition to the factors discussed in this &#147;Risk Factors&#148; section and elsewhere in this prospectus, these factors include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developments associated with our license with Ares, an affiliate of Merck KGaA, Darmstadt, Germany, including any
termination or other change in our relationship with Ares or Merck KGaA, Darmstadt, Germany; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing and results of nonclinical studies and clinical trials of atacicept or any future product candidates we may
develop or those of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the success of competitive products or announcements by potential competitors of their product development efforts;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory actions with respect to our product candidate or our competitors&#146; products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">actual or anticipated changes in our growth rate relative to our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures,
collaborations or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the results of our efforts to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire additional product candidates
or products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities
analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">market conditions in the pharmaceutical and biotechnology sector; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">announcement or expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sales of our securities by us, our insiders or our other stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expiration of market <FONT STYLE="white-space:nowrap">stand-off</FONT> or <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">general economic, industry and market conditions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the trading prices for common stock of other biotechnology companies have been highly volatile as a
result of factors unrelated to the specific company or its technology, as well as due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak continues to rapidly evolve. The
extent to which the outbreak may impact our business, nonclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The realization of any of the above risks or any of a broad range of other risks, including those described in this &#147;Risk Factors&#148; section, could have a
dramatic and adverse impact on the market price of our Class A common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have identified a material weakness in our internal control over financial
reporting. If our remediation of this material weakness is not effective, or if we experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to
accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our Class A common stock. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the completion of this offering, we have been a private company with limited accounting personnel to adequately execute our accounting processes and other
supervisory resources with which to address our internal control over financial reporting. In connection with the audit of our financial statements as of and for the years ended December&nbsp;31, 2019 and 2020, we identified a material weakness in
our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our
financial statements will not be prevented or detected on a timely basis. The material weakness related to a lack of sufficient number of qualified personnel within our accounting function to adequately segregate duties, to perform sufficient
reviews and approval of manual journal entries posted to the general ledger and to consistently execute review procedures over general ledger account reconciliations, financial statement preparation and accounting for
<FONT STYLE="white-space:nowrap">non-routine</FONT> transactions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are implementing measures designed to improve our internal control over financial reporting to
remediate this material weakness, including the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We are formalizing our internal control documentation and strengthening supervisory reviews by our management; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We are in the process of adding additional accounting personnel and segregating duties amongst accounting personnel.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot assure you that the measures we have taken to date, and are continuing to implement, will be sufficient to remediate the material
weakness we have identified or avoid potential future material weaknesses. If the steps we take do not correct the material weakness in a timely manner, we will be unable to conclude that we maintain effective internal control over financial
reporting. Accordingly, there could continue to be a reasonable possibility that a material misstatement of our financial statements would not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a public company, we will be required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls.
Section&nbsp;404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and, beginning with our fifth annual report following this offering, which will be our year ending
December&nbsp;31, 2024, provide a management report on internal control over financial reporting. The Sarbanes-Oxley Act also requires that our management report on internal control over financial reporting be attested to by our independent
registered public accounting firm, to the extent we are no longer an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). We do not expect our independent registered public accounting firm to
attest to our management report on internal control over financial reporting for so long as we are an emerging growth company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are in the process of designing
and implementing the internal control over financial reporting required to comply with this obligation, which process will be time consuming, costly and complicated. If we identify any additional material weaknesses in our internal control over
financial reporting, if we are unable to comply with the requirements of Section&nbsp;404 in a timely manner, if we are unable to assert that our internal control over financial reporting is effective, or when required in the future, if our
independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the accuracy and completeness of our financial reports and the market price of our Class A common stock could be adversely affected, and we could become subject to investigations by the stock
exchange on which our securities are listed, the SEC, or other regulatory authorities, which could require additional financial and management resources. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our
quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">timing and variations in the level of expense related to the ongoing development of atacicept or future development
programs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">timing and status of enrollment for our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">impacts from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on us or third parties with which we engage;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">results of clinical trials, or the addition or termination of clinical trials or funding support by us or potential future
partners; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive
under potential future arrangements or the termination or modification of any such potential future arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any intellectual property infringement, misappropriation or violation lawsuit or opposition, interference or cancellation
proceeding in which we may become involved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">additions and departures of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic
investments or changes in business strategy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">if atacicept or any future product candidate we may develop receive regulatory approval, the timing and terms of such
approval and market acceptance and demand for such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing and cost to establish a sales, marketing and distribution infrastructure to commercialize any products for
which we may obtain marketing approval and intend to commercialize on our own or jointly with current or future collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">regulatory developments affecting atacicept or any future product candidate we may develop or those of our competitors;
and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">changes in general market and economic conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our Class&nbsp;A common stock could decline
substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and
should not be relied upon as an indication of our future performance. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our principal stockholders and management own a significant percentage of our stock and
will be able to exert significant control over matters subject to stockholder approval. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, our executive officers, directors, holders
of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 89.8% of our voting stock and, upon the closing of this offering, that same group will beneficially own a significant percentage of our outstanding
voting stock. Therefore, even after this offering these stockholders will be able to significantly influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example,
these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition
proposals or offers for our Class A common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders
and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their shares, and might affect the prevailing market price for our Class A common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If you purchase shares of our Class A common stock in our initial public offering, you will experience
substantial and immediate dilution. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The initial public offering price is substantially higher than the net tangible book value per share of our
outstanding Class A common stock immediately following the closing of this offering. Based on the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, if
you purchase shares of our Class A common stock in this offering, you will experience substantial and immediate dilution in the pro forma as adjusted net tangible book value per share of $9.74&nbsp;per share as of December&nbsp;31, 2020. That is
because the price that you pay will be substantially greater than the pro forma net tangible book value per share of the Class A common stock that you acquire. This dilution is due in large part to the fact that our earlier investors paid
substantially less than the initial public offering price when they purchased their shares of our capital stock. You will experience additional dilution when those holding stock options or warrants exercise their right to purchase Class A common
stock under our equity incentive plans or when we otherwise issue additional shares of Class A common stock. See the section titled &#147;Dilution.&#148; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Sales of a substantial number of shares of our Class A common stock in the public market could cause our stock price to fall. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our Class A common stock price could decline as a result of sales of a large number of shares of Class A common stock after this offering or the perception that these
sales could occur. These sales, or the possibility that these sales may occur, might also make it more difficult for us to sell equity securities in the future at a time and price that we deem appropriate. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the closing of this offering, 20,479,310 shares of Class A common stock (including (i) 15,774,014 shares of Class A common stock issuable upon the conversion of
all outstanding shares of our redeemable convertible preferred stock as of December&nbsp;31, 2020 and (ii) 41,363 shares of unvested restricted Class A common stock subject to repurchase as of such date) and no shares of Class B common stock
(together with Class A common stock, referred to herein as common stock) will be outstanding (21,131,810&nbsp;shares if the underwriters exercise their option to purchase additional shares of Class A common stock from us in full), based on the
number of shares of Class A common stock outstanding as of December&nbsp;31, 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All shares of Class A common stock expected to be sold in this offering will be
freely tradable without restriction or further registration under the Securities Act of 1933, as amended (Securities Act), unless held by our &#147;affiliates&#148; as defined in Rule 144 under the Securities Act. The resale of the remaining
16,129,310 shares of Class A common stock and no shares of Class B common stock, or 78.8% and 0% of all of our outstanding shares of common stock, respectively, following this offering, is currently prohibited or otherwise restricted as a result of
securities law provisions, market standoff agreements entered into by certain of our stockholders with us or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by our stockholders with the underwriters in connection with this
offering. However, subject to applicable securities law restrictions, these shares will be able to be sold in the public market beginning 181 days after the date of this prospectus. The representatives of the underwriters may release some or all of
the shares of common stock subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time in their sole discretion and without notice, which would allow for earlier sales of shares in the public market. Shares issued upon the
exercise of stock options and warrants outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable
vesting schedules, market <FONT STYLE="white-space:nowrap">stand-off</FONT> agreements and/or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, as well as Rules 144 and 701 under the Securities Act. For more information, see the section
titled &#147;Shares Eligible for Future Sale&#148; herein. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the closing of this offering, the holders of approximately 15,774,014 shares of Class A common
stock and Class B common stock, or 77.0% of our outstanding shares of common stock following this offering, assuming no exercise of the underwriters&#146; option to purchase additional shares, will have rights, subject to certain conditions, to
require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or our other stockholders. We also intend to register the offer and sale of all shares
of common stock that we may issue under our equity compensation plans. Once we register the offer and sale of shares for the holders of registration rights and shares that may be issued under our equity incentive plans, these shares will be able to
be sold in the public market upon issuance, subject to applicable securities laws and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described under the section titled &#147;Underwriters&#148; herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, in the future, we may issue additional shares of common stock, or other equity or debt securities
convertible into common stock, in connection with a financing, acquisition, employee arrangement or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our common stock to
decline. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to atacicept
or future product candidates we may develop on unfavorable terms to us. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may seek additional capital through a variety of means, including through public
or private equity, debt financings or other sources, including <FONT STYLE="white-space:nowrap">up-front</FONT> payments and milestone payments from strategic collaborations. To the extent that we raise additional capital through the sale of equity
or convertible debt or equity securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Such financing may result in dilution to stockholders,
imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through <FONT STYLE="white-space:nowrap">up-front</FONT> payments or milestone payments pursuant to
strategic collaborations with third parties, we may have to relinquish valuable rights to atacicept or future product candidates we may develop, or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due
to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are an
&#147;emerging growth company,&#148; and a &#147;smaller reporting company&#148; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our Class&nbsp;A common
stock less attractive to investors. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act. For as long as we continue to be an emerging
growth company, we intend to take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim
financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of
2002 (Sarbanes-Oxley Act); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board
regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy
statements; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and
stockholder approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot predict if investors will find our Class&nbsp;A common
stock less attractive because we may rely on these exemptions. If some investors find our Class&nbsp;A common stock less attractive as a result, there may be a less active trading market for our Class&nbsp;A common stock and our stock price may be
more volatile. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will remain an emerging growth company until the earliest to occur of: (1)&nbsp;the last day of the fiscal year in which we have more than
$1.07&nbsp;billion in annual revenue; (2)&nbsp;the date we qualify as a &#147;large accelerated filer,&#148; with at least $700&nbsp;million of equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> (3)&nbsp;the date on
which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period; and (4)&nbsp;the last day of the fiscal year ending after the fifth anniversary of our
initial public offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those
standards apply to private companies. We intend to take advantage of the extended transition period for adopting new or revised accounting standards under the JOBS Act as an emerging growth company. As a result of this election, our financial
statements may not be comparable to companies that comply with public company effective dates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act (Section 404)
we will be required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
financial reporting issued by our independent registered public accounting firm. However, while we remain an EGC or a smaller reporting company with less than $100&nbsp;million in annual revenue,
we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. We could be an EGC for up to five years. To achieve compliance with Section&nbsp;404
within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources,
potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that
controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting
firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section&nbsp;404. This could result in an adverse reaction in the financial markets due to a loss of
confidence in the reliability of our financial statements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, we are also a &#147;smaller reporting company,&#148; as defined in the Exchange Act. We
may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these
scaled disclosures for so long as our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million measured on the last business day of our
second fiscal quarter, or our annual revenue is less than $100&nbsp;million during the most recently completed fiscal year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million measured on the last business day of our second fiscal quarter. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Investors may
find our Class A common stock less attractive as a result of our reliance on these exemptions. If some investors find our Class A common stock less attractive as a result, there may be a less active trading market for our Class A common stock and
our stock price may be more volatile. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our management team has broad discretion to use the net proceeds from this offering and its investment of these
proceeds may not yield a favorable return. They may invest the net proceeds from this offering in ways with which investors disagree. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to use a
portion of the net proceeds from this offering to advance and expand our clinical and nonclinical development programs and for working capital and for other general corporate purposes, which may include the hiring of additional personnel, capital
expenditures and the costs of operating as a public company. See the section titled &#147;Use of Proceeds.&#148; However, within the scope of our plan, and in light of the various risks to our business, including those discussed in this &#147;Risk
Factors&#148; section and elsewhere in this prospectus, our management will have broad discretion over the use of net proceeds from this offering, and could spend the net proceeds in ways our stockholders may not agree with or that do not yield a
favorable return, if at all. If we do not invest or apply the net proceeds from this offering in ways that improve our operating results, we may fail to achieve expected financial results, which could cause our stock price to decline. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We do not currently intend to pay dividends on our Class A common stock and, consequently, your ability to achieve a return on your investment will depend on
appreciation of the value of our Class A common stock. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never declared or paid any cash dividends on our equity securities. We currently anticipate
that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any
appreciation in the value of our Class A common stock, which is not certain. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Provisions in our amended and restated certificate of incorporation and amended
and restated bylaws and Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation and amended and restated bylaws that will become effective upon the closing of this offering may discourage, delay
or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that
investors might be willing to pay in the future for shares of our Class A common stock, thereby depressing the market price of our Class A common stock. In addition, because our board of directors is responsible for appointing the members of our
management team, these provisions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors.
Among other things, these provisions: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establish a classified board of directors such that not all members of the board are elected at one time;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">limit the manner in which stockholders can remove directors from the board; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and
nominations to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our
stockholders by written consent; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">prohibit our stockholders from calling a special meeting of our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">prohibit cumulative voting; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a
stockholder rights plan, or <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;poison pill,&#148; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by
our board of directors; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">require the approval of the holders of at least 66 2/3% of the votes that all our stockholders would be entitled to cast
to amend or repeal certain provisions of our amended and restated certificate of incorporations or amended and restated bylaws. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, because
we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law (DGCL), which prohibits a person who owns 15% or more of our outstanding voting stock from merging or combining with us
for a period of three years after the date of the transaction in which the person acquired 15% or more of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions could discourage potential
acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our Class A common stock, including transactions that may be in your best
interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our stock. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our amended
and restated certificate of incorporation will provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States will be the exclusive forums for substantially all disputes between us and our
stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation will provide that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the
State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any
appellate court therefrom is the sole and exclusive forum for the following claims or causes of action under the Delaware statutory or common law: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any derivative claim or cause of action brought on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any claim or cause of action for a breach of fiduciary duty owed by any of our current or former directors, officers, or
other employees to us or our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any claim or cause of action against us or any of our current or former directors, officers or other employees arising out
of or pursuant to any provision of the DGCL, our amended and restated certificate of incorporation, or our bylaws (as each may be amended from time to time); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our amended and restated
certificate of incorporation or our amended and restated bylaws (as each may be amended from time to time, including any right, obligation, or remedy thereunder); </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any claim or cause of action as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware;
and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any claim or cause of action against us or any of our current or former directors, officers, or other employees governed
by the internal-affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#146;s having personal jurisdiction over the indispensable parties named as defendants. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This choice of forum provision would not apply to claims or causes of action brought to enforce a duty </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">or liability created by the Securities Act, the Exchange Act or any other claim for which the federal courts have </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">exclusive jurisdiction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To prevent having to litigate claims in multiple
jurisdictions and the threat of inconsistent or contrary rulings by </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">different courts, among other considerations, our amended and restated certificate of
incorporation will further provide that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action
asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other
professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. While the Delaware courts have determined that such choice of
forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and
enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that
the provisions will be enforced by a court in those other jurisdictions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These exclusive forum provisions may limit a stockholder&#146;s ability to bring a claim
in a judicial forum that it finds </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our
directors, officers and other employees. If a court were to find the exclusive forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant
additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business, financial condition, results of operations and prospects </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General Risk Factors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our information technology systems, or those of
any of our CROs, manufacturers, other contractors, consultants, third party vendors, collaborators, or potential future collaborators, may fail or suffer cybersecurity incidents, breaches or other unauthorized or improper access to, use of, or
destruction of our proprietary or confidential data, employee data, or personal information, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations, or otherwise
harm our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the course of our business, we collect, store and transmit proprietary, confidential and sensitive information, including personal
information. The information and data processed and stored in our technology systems, and those of our research collaborators, CROs, contractors, consultants, and other third parties on which we depend to operate our business, may be vulnerable to
security breaches, loss, damage, corruption, unauthorized access, use or disclosure, or misappropriation. Such incidents may also result from errors or malfeasance by our personnel or the personnel of the third parties we work with, malware,
viruses, software vulnerabilities, hacking, denial of service attacks, social engineering (including phishing), ransomware, credential stuffing or other cyberattacks, including attacks by state-sponsored organizations or sophisticated groups of
hackers. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While we have developed systems and processes designed to protect the integrity, confidentiality and security of the confidential and personal information
under our control, we cannot assure you that any security measures that we or our third party service providers have implemented will be effective in preventing cybersecurity incidents. There are many different cybercrime and hacking techniques and
as such techniques continue to evolve, we may be unable to anticipate attempted security breaches, identify them before our information is exploited, or react in a timely manner. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, as a result of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, certain functional areas of our workforce remain in a remote work
environment and outside of our corporate network security protection boundaries, which imposes additional risks to our business, including increased risk of industrial espionage, phishing and other cybersecurity attacks, and unauthorized
dissemination of proprietary or confidential information, any of which could have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Despite our efforts to strengthen security and authentication measures, we have experienced an overall increase in
cybersecurity incidents, none of which have caused material disruption to our business, or to our knowledge, involved a material security breach. However, we or the third parties we rely on could experience a material system failure, security breach
or other cybersecurity incident in the future, which could interrupt our operations disrupt our development programs and have a material adverse effect on our business, financial condition and results of operations. For example, the loss of clinical
trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our
product candidates, to analyze clinical trial samples and to conduct clinical trials, and cybersecurity incidents experienced by these third parties could have a material adverse effect on our business. Security breaches and other cybersecurity
incidents affecting us or the third parties we rely on could also result in substantial remediation costs and expose us to litigation, regulatory enforcement action, fines, penalties, and other liabilities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot be certain that our insurance coverage will be adequate for data security liabilities actually incurred, will continue to be available to us on economically
reasonable terms, or at all, or that any insurer will not deny coverage as to any future claim. The successful assertion of one or more large claims against us that exceed available insurance coverage, or the occurrence of changes in our insurance
policies, including premium increases or the imposition of large deductible <FONT STYLE="white-space:nowrap">or&nbsp;co-insurance&nbsp;requirements,</FONT> could adversely affect our reputation, business, financial condition and results of
operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is
accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and
procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake.
Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system,
misstatements due to error or fraud may occur and not be detected. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Future changes in financial accounting standards or practices may cause adverse and
unexpected revenue fluctuations and adversely affect our reported results of operations. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Future changes in financial accounting standards may cause
adverse, unexpected revenue fluctuations and affect our reported financial position or results of operations. Financial accounting standards in the United States are constantly under review and new pronouncements and varying interpretations of
pronouncements have occurred with frequency in the past and are expected to occur again in the future. As a result, we may be required to make changes in our accounting policies. Those changes could affect our financial condition and results of
operations or the way in which such financial condition and results of operations are reported. We intend to invest resources to comply with evolving standards, and this investment may result in increased general and administrative expenses and a
diversion of management time and attention from business activities to compliance activities. See the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Recent Accounting
Pronouncements.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The requirements of being a public company may strain our resources, result in more litigation and divert management&#146;s attention.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a public company, we will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and
Consumer Protection Act the listing requirements of The Nasdaq Stock Market LLC and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will increase our legal and financial compliance
costs, make some activities more difficult, time consuming or costly and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and
operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
internal control over financial reporting. We are required to disclose changes made in our internal control and procedures on a quarterly basis. In order to maintain and, if required, improve our
disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#146;s attention may be diverted from other business
concerns, which could significantly harm our business, financial condition, results of operations and prospects. We may also need to hire additional employees or engage outside consultants to comply with these requirements, which will increase our
costs and expenses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for
public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a
result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to
disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#146;s time and
attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their
application and practice, regulatory authorities may initiate legal proceedings against us and our business, financial condition, results of operations and prospects may be harmed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These rules and regulations may make it more expensive for us to obtain director and officer liability insurance and, in the future, we may be required to accept
reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and
compensation committee, and qualified executive officers. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">By disclosing information in this prospectus and in future filings required of a public company, our
business and financial condition will become more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If those claims are successful, our business could be seriously harmed. Even
if the claims do not result in litigation or are resolved in our favor, the time and resources needed to resolve them could divert our management&#146;s resources and seriously harm our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to securities litigation, which is expensive and could divert management attention. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The market price of our Class A common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been
subject to securities class action litigation and shareholder derivative actions. We may be the target of these types of litigation and claims in the future. These claims and litigation against us could result in substantial costs and divert our
management&#146;s attention from other business concerns, which could seriously harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or
our market, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading market for our Class A common stock will be influenced by the research and
reports that securities or industry analysts publish about us, our business or our market. We do not currently have and may never obtain research coverage by securities or industry analysts. If no or few securities or industry analysts commence
coverage of us, the stock price would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our
intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports
on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus contains forward-looking statements. All statements other than statements of historical facts contained in this prospectus, including statements
regarding our future results of operations and financial position, business strategy, product candidates, planned nonclinical studies and clinical trials, results of nonclinical studies, clinical trials, research and development costs, regulatory
approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in
some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;would,&#148;
&#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;project,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential,&#148; or
&#147;continue&#148; or the negative of these terms or other similar expressions. Forward-looking statements contained in this prospectus include, but are not limited to, statements about: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our financial performance; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the sufficiency of our existing cash to fund our future operating expenses and capital expenditure requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional
financing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope, progress, results and costs of developing atacicept or any other product candidates we may develop, and
conducting nonclinical studies and clinical trials, including our atacicept Phase 2b clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing and costs involved in obtaining and maintaining regulatory approval of atacicept or any other product
candidates we may develop, and the timing or likelihood of regulatory filings and approvals, including our expectation to seek special designations for our product candidates for various diseases; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our plans relating to commercializing atacicept and any other product candidates we may develop, if approved, including
the geographic areas of focus and our ability to grow a sales team; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the ability to license additional intellectual property relating to any future product candidates and to comply with our
existing license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the impact of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business and operations,
including enrollment in our clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the implementation of our strategic plans for our business and atacicept or any other product candidates we may develop;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the size of the market opportunity for atacicept or any other product candidates we may develop in each of the diseases we
target; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our reliance on third parties to conduct nonclinical research activities, and for the manufacture of atacicept and any
other product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the beneficial characteristics, safety, efficacy and therapeutic effects of atacicept and any other product candidates we
may develop; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our estimates of the number of patients in the United States who suffer from the diseases we target and the number of
subjects that will enroll in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the progress and focus of our current and future clinical trials, and the reporting of data from those trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to advance product candidates into and successfully complete clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the ability of our clinical trials to demonstrate the safety and efficacy of atacicept and any other product candidates we
may develop, and other positive results; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developments relating to our competitors and our industry, including competing product candidates and therapies;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our plans relating to the further development and manufacturing of atacicept and any other product candidates we may
develop, including additional indications that we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">existing regulations and regulatory developments in the United States and other jurisdictions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our potential and ability to successfully manufacture and supply atacicept and any other product candidates we may develop
for clinical trials and for commercial use, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the rate and degree of market acceptance of atacicept and any other product candidates we may develop, as well as the
pricing and reimbursement of atacicept and any other product candidates we may develop, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our continued reliance on third parties to conduct additional clinical trials of atacicept and any other product
candidates we may develop, and for the manufacture of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our plans and ability to obtain and protect intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope of protection we are able to establish and maintain for intellectual property rights, including atacicept and
any other product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to retain the continued service of our key personnel and to identify, hire, and then retain additional
qualified personnel; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our expectations regarding the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business and
operations, including clinical trials, manufacturing suppliers, collaborators, use of CROs and employees; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act and as
a smaller reporting company under the Exchange Act; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our anticipated use of our existing cash and cash equivalents and the proceeds from this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial
trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of
the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described in the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to
risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be
achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein
until after we distribute this prospectus, whether as a result of any new information, future events or otherwise. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, statements that &#147;we
believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable
basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These
statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_4"></A>MARKET, INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We obtained the industry, market and competitive position data used throughout this prospectus from our own internal estimates and research, as well as from
independent market research, industry and general publications and surveys, governmental agencies and publicly available information in addition to research, surveys and studies conducted by third parties. Internal estimates are derived from
publicly available information released by industry analysts and third-party sources, our internal research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market, which
we believe to be reasonable. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of
this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. In addition, while we believe the industry, market and competitive position data included in this
prospectus is reliable and based on reasonable assumptions, such data involve risks and uncertainties and are subject to change based on various factors, including those discussed in the section titled &#147;Risk Factors.&#148; These and other
factors could cause results to differ materially from those expressed in the estimates made by the independent parties or by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that we will receive net proceeds from this offering of approximately $57.6&nbsp;million (or approximately $66.7 million if the underwriters&#146; option
to purchase 652,500 additional shares of our Class A common stock is exercised in full) based on the assumed initial public offering price of $15.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses
payable by us. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each $1.00 increase or decrease in the assumed initial public offering price of $15.00 per share would increase or decrease, as applicable, the
net proceeds to us from this offering by approximately $4.0 million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting underwriting discounts and commissions and
estimated offering expenses payable by us. Similarly, each increase or decrease of 1.0&nbsp;million shares in the number of shares of Class A common stock offered by us would increase or decrease, as applicable, the net proceeds to us from this
offering by approximately $14.0 million, assuming the initial public offering price of $15.00 per share remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The principal purposes of this offering are to obtain additional capital to support our operations, establish a public market for our Class A common stock and
facilitate our future access to the public capital markets.</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently intend to use the net proceeds we receive from this offering, together with our existing
cash and cash equivalents, as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approximately $30.0 million to $35.0 million to complete our current Phase 2b clinical trial of atacicept in IgAN;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approximately $15.0 million to $20.0 million to initiate a Phase 2b or Phase 3 clinical trial for atacicept in patients
with LN; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the remainder for research and development activities, including developing atacicept in potential additional indications,
general corporate purposes, including working capital, operating expenses and capital expenditures. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also use a portion of the remaining
net proceeds and our existing cash and cash equivalents to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in complementary businesses, technologies, products or assets. However, we have no current commitments or obligations
to do so. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe, based on our current operating plan, that the net proceeds from this offering, together with our existing cash and cash equivalents, will be
sufficient to fund our operations for at least the next 18&nbsp;months. In particular, we expect that the net proceeds from this offering will allow us to complete our current Phase 2b clinical trial for atacicept in patients with IgAN, and initiate
a Phase 2b or Phase 3 clinical trial for atacicept in patients with LN. However, our expected use of proceeds from this offering described above represents our current intentions based on our present plans and business condition. As of the date of
this prospectus, we cannot predict with certainty all of the particular uses for the proceeds to be received upon the closing of this offering or the actual amounts that we will spend on the uses set forth above. The net proceeds from this offering,
together with our cash and cash equivalents, will not be sufficient for us to fund atacicept in IgAN or LN through regulatory approval, and we will need to raise additional capital to complete the development and commercialization of atacicept in
IgAN, LN, and any future product candidates we may develop. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The amounts and timing of our actual expenditures will depend on numerous factors, including the time
and cost necessary to conduct our planned clinical trials, the results of our planned clinical trials and other factors described in the section titled &#147;Risk Factors&#148; in this prospectus, as well as the amount of cash used in our operations
and any unforeseen cash needs. Therefore, our actual expenditures may differ materially from the estimates described above. We may find it necessary or advisable to use the net proceeds for other purposes. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will have broad discretion over how to use the net proceeds to us from this offering. We intend to invest the net proceeds to us from the offering that are not used
as described above in short-term, investment-grade, interest-bearing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock. We intend to retain all available funds and future
earnings, if any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination regarding the declaration and payment of dividends, if any, will be at
the discretion of our board of directors, subject to applicable laws, and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other
factors our board of directors may deem relevant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our ability to pay cash dividends on our capital stock in the future may be limited by the terms of
any future debt or preferred securities we issue or any credit facilities we enter into. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth our cash and cash equivalents and capitalization as of December&nbsp;31, 2020 on: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a pro forma basis, giving effect to the (i)&nbsp;automatic conversion of all outstanding shares of our redeemable
convertible preferred stock into an aggregate of 15,774,014 shares of our Class A common stock which will occur upon the closing of this offering, and the related reclassification of the carrying value of our redeemable convertible preferred stock
to permanent equity upon the closing of this offering, and (ii)&nbsp;filing and effectiveness of our amended and restated certificate of incorporation that will be in effect immediately after the closing of this offering; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a pro forma as adjusted basis, giving effect to the (i)&nbsp;pro forma adjustments set forth above and (ii)&nbsp;our
receipt of net proceeds from the sale of 4,350,000 shares of Class A common stock in this offering at the assumed initial public offering price of $15.00 per share, after deducting underwriting discounts and commissions and estimated offering
expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The pro forma as adjusted information below is illustrative only, and our capitalization following the closing of this
offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You should read this table
together with the sections titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; &#147;Description of Capital Stock&#148; and our financial statements and related notes included elsewhere in
this prospectus. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF DECEMBER&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(In thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO<BR>FORMA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO<BR>FORMA<BR>AS<BR>ADJUSTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">111,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred stock, $0.001 par value; 182,772,372 shares authorized, issued and
outstanding as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stockholders&#146; deficit (equity)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Class A Common stock, $0.001 par value; 273,986,920 shares authorized and 355,296 shares issued and
outstanding as of December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Class B Common stock, $0.001 par value; 21,593,607 shares authorized and no shares issued and outstanding
as of December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share would increase (decrease) each of our pro forma as adjusted cash and cash
equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity (deficit) and total capitalization by approximately $4.0 million, assuming the number of shares offered by us, as set forth on the cover
page of this prospectus, remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0&nbsp;million shares in the number of shares Class A
common stock offered by us would increase (decrease) each of our pro forma as adjusted cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity (deficit) and total capitalization
by approximately $14.0 million, assuming the assumed initial public offering price of $15.00 per share remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares in the table above, pro forma and pro forma as adjusted, assumes no issuance of Class B common
stock in connection with this offering, and excludes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1,855,507 shares of our Class A common stock issuable upon the exercise of outstanding stock options as of
December&nbsp;31, 2020 under our 2017 Plan, with a weighted-average exercise price of $2.99 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">484,956 shares of our Class A common stock issuable upon the exercise of outstanding stock options granted subsequent to
December&nbsp;31, 2020 under our 2017 Plan, with a weighted-average exercise price of $3.93 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1,762,009 shares of our Class A common stock reserved for future issuance under our 2021 Plan, which will become effective
once the registration statement of which this prospectus forms a part is declared effective, as well as any future automatic annual increases in the number of shares of Class A common stock reserved for issuance under our 2021 Plan and any shares
underlying outstanding stock awards granted under our 2017 Plan, that expire or are repurchased, forfeited, cancelled or withheld, as more fully described in the section titled &#147;Executive Compensation&#151;Equity Benefit Plans&#148;;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">220,251 shares of our Class A common stock reserved for issuance under our 2021 Employee Stock Purchase Plan (ESPP), which
will become effective once the registration statement of which this prospectus forms a part is declared effective, and any future automatic annual increases in the number of shares of Class A common stock reserved for future issuance under our ESPP;
and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">450,326 shares of our Class A common stock issuable upon the exercise of options to purchase shares of our Class A common
stock granted to certain of our officers, directors and employees under our 2021 Plan, which will become effective in connection with this offering, at an exercise price per share equal to the initial public offering price in this offering.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_8"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you invest in our Class A common stock in this offering, your interest will be diluted to the extent of the difference between the initial public offering price per
share of Class A common stock and the pro forma as adjusted net tangible book value per share immediately after this offering. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2020, we
had a historical net tangible book deficit of $(89.3)&nbsp;million, or $(251.47) per share of common stock based on the 355,296&nbsp;shares of common stock outstanding as of such date, including 41,363&nbsp;shares subject to repurchase as of such
date. Our historical net tangible book value per share represents total tangible assets less total liabilities and convertible preferred stock, which is not included within permanent equity, divided by the number of shares of Class A common stock
outstanding as of December&nbsp;31, 2020, including 41,363&nbsp;shares of Class&nbsp;A common stock subject to repurchase as of such date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our pro forma net
tangible book value as of December&nbsp;31, 2020 was $50.2&nbsp;million, or $3.11 per share. Pro forma net tangible book value per share represents the amount of our total tangible assets less our total liabilities, divided by 16,129,310&nbsp;shares
of all common stock outstanding as of such date, after giving effect to (i)&nbsp;the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of 15,774,014 shares of our Class&nbsp;A common stock and the
related reclassification of the carrying value of our convertible preferred stock to permanent equity upon the closing of this offering, and (ii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation that will be
in effect immediately after the closing of this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After giving effect to the sale by us of 4,350,000&nbsp;shares of Class A common stock in this offering
at the assumed initial public offering price of $15.00 per share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of December&nbsp;31,
2020 would have been $107.8&nbsp;million, or $5.26 per share. This amount represents an immediate increase in pro forma as adjusted net tangible book value of $2.15 per share to our existing stockholders and an immediate dilution in pro forma as
adjusted net tangible book value of $9.74 per share to investors purchasing Class A common stock in this offering. We determine dilution by subtracting the pro forma as adjusted net tangible book value per share after this offering from the amount
of cash paid by an investor for a share of Class&nbsp;A common stock in this offering. The following table illustrates this dilution on a per share basis: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Historical net tangible book deficit per share as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(251.47</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma increase in historical net tangible book value per share attributable to the pro forma
transactions described in the preceding paragraphs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">254.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net tangible book value per share as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in pro forma as adjusted net tangible book value per share attributable to investors purchasing
shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dilution in pro forma as adjusted net tangible book value per share to investors purchasing shares in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The dilution information discussed above is illustrative only and may change based on the actual initial public offering price and other terms of this offering. Each
$1.00 increase or decrease in the assumed initial public offering price of $15.00 per share would increase or decrease, as applicable, our pro forma as adjusted net tangible book value per share after this offering by $0.20 per share and increase or
decrease, as applicable, the dilution to investors purchasing shares in this offering by $0.80 per share, in each case assuming the number of shares of Class&nbsp;A common stock offered by us, as set forth on the cover page of this prospectus,
remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, an increase of 1.0 million in the number of shares of common stock offered by us would increase the pro forma as
adjusted net tangible book value after this offering by $0.41 per share and decrease the dilution per share to new investors participating in this offering by $0.41 per share, and a decrease of 1.0 million shares of common stock
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
offered by us would decrease the pro forma as adjusted net tangible book value by $0.44 per share, and increase the dilution per share to new investors in this offering by $0.44 per share, in
each case assuming the assumed initial public offering price of $15.00 per share remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the underwriters exercise their option to purchase additional shares of Class A common stock in full, the pro forma net tangible book value per share, as adjusted to
give effect to this offering, would be $5.53 per share, and the dilution in pro forma net tangible book value per share to investors in this offering would be $9.47 per share. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The foregoing discussion and tables above assumes no issuance of Class B common stock in connection with this offering, and excludes: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1,855,507 shares of our Class A common stock issuable upon the exercise of outstanding stock options as of
December&nbsp;31, 2020 under our 2017 Plan, with a weighted-average exercise price of $2.99 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">484,956 shares of our Class A common stock issuable upon the exercise of outstanding stock options granted subsequent to
December&nbsp;31, 2020 under our 2017 Plan, with a weighted-average exercise price of $3.93 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1,762,009 shares of our Class A common stock reserved for future issuance under our 2021 Plan, which will become effective
once the registration statement of which this prospectus forms a part is declared effective, as well as any future automatic annual increases in the number of shares of common stock reserved for issuance under our 2021 Plan and any shares underlying
outstanding stock awards granted under our 2017 Plan that expire or are repurchased, forfeited, cancelled or withheld, as more fully described in the section titled &#147;Executive Compensation&#151;Equity Benefit Plans&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">220,251 shares of our Class A common stock reserved for issuance under our ESPP, which will become effective once the
registration statement of which this prospectus forms a part is declared effective, and any future automatic annual increases in the number of shares of common stock reserved for future issuance under our ESPP; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">450,326 shares of our Class A common stock issuable upon the exercise of options to purchase shares of our Class A common
stock granted to certain of our officers, directors and employees under our 2021 Plan, which will become effective in connection with this offering, at an exercise price per share equal to the initial public offering price in this offering.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that any outstanding options are exercised or new options are issued under our stock-based compensation plans, or we issue
additional shares of Class A common stock and Class B common stock in the future, there will be further dilution to investors participating in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following discussion
should be read in conjunction with our financial statements and related notes thereto included elsewhere in this prospectus. In addition to historical information, this discussion contains forward-looking statements that involve risks, uncertainties
and assumptions that could cause actual results to differ materially from management&#146;s expectations. Factors that could cause such differences are discussed in the sections titled &#147;Special Note Regarding Forward-Looking Statements&#148;
and &#147;Risk Factors.&#148; We are not undertaking any obligation to update any forward-looking statements or other statements we may make in the following discussion or elsewhere in this document even though these statements may be affected by
events or circumstances occurring after the forward-looking statements or other statements were made. Therefore, no reader of this document should rely on these statements being current as of any time other than the time at which this document is
declared effective by the SEC. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical stage
biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Our lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once
weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. We are conducting a Phase 2b clinical
trial of atacicept in patients with immunoglobulin A nephropathy (IgAN), a disease with a high unmet medical need and no approved therapies. IgAN is a serious and progressive autoimmune disease of the kidney that is driven by the production of
immunogenic galactose-deficient IgA1 <FONT STYLE="white-space:nowrap">(Gd-IgA1).</FONT> IgAN patients with elevated <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> are at increased risk of kidney-related morbidity and mortality. As reported in a
Phase 2a clinical trial of 16 patients conducted by Merck KGaA, Darmstadt, Germany, atacicept is the first and only molecule currently in development to demonstrate a 60% reduction in plasma <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> in IgAN
patients (75 mg dose, n=4 at 24 weeks), which we believe can be disease modifying. We plan to initiate patient screening for our Phase 2b clinical trial in IgAN in the second quarter of 2021, and we expect to report topline results in the fourth
quarter of 2022. In addition, we are evaluating additional diseases where atacicept&#146;s reduction of autoantibodies may prove medically useful, including lupus nephritis (LN), a severe renal manifestation of systemic lupus erythematosus (SLE).
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our inception, we have devoted substantially all of our resources to our research and development efforts,
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not have any product candidates approved for commercial sale, and we have not generated any revenue from product sales. Our ability to generate revenue sufficient
to achieve profitability, if ever, will depend on the successful development and eventual commercialization of one or more of our product candidates, which we expect, if they ever occur, will take a number of years. We also do not own or operate,
and currently have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for nonclinical and clinical testing, as well as for commercial
manufacturing if any of our product candidates obtain marketing approval. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment,
and personnel while also enabling us to focus our expertise and resources on the development of our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, we have funded our operations
primarily through proceeds from the sale of shares of our Class A common stock, redeemable convertible preferred stock and convertible promissory notes. As of December&nbsp;31, 2020, we had $53.7&nbsp;million in unrestricted cash and cash
equivalents. Based on our current operating plan, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will be sufficient to fund our planned operating expenses and capital expenditure
requirements for at least the next 18 months. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have incurred significant operating losses since the commencement of our operations. Our net losses were
$11.9&nbsp;million and $53.4&nbsp;million for the years ended December&nbsp;31, 2019 and 2020, and we expect to incur significant and increasing losses for the foreseeable future as we continue to advance our product candidate, atacicept, and as we
transition to operating as a public company. Our net losses may fluctuate significantly from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
period to period, depending on the timing of expenditures on our research and development activities. As of December&nbsp;31, 2020, we had an accumulated deficit of $91.4&nbsp;million. Our
primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures and general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these
expenses, as reflected in the change in our outstanding accounts payable and other current liabilities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to continue to incur net operating losses for at
least the next several years, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. We expect our expenses and capital requirements will increase significantly
in connection with our ongoing activities as we: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continue our ongoing and planned research and development of our product candidate, atacicept, for the treatment of iGAN
and LN; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">initiate nonclinical studies and clinical trials for atacicept and any additional product candidates that we may pursue in
the future; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">seek to discover and develop additional product candidates and further expand our clinical product pipeline;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">seek regulatory approvals for any product candidates that successfully complete clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">continue to scale up external manufacturing capacity with the aim of securing sufficient quantities to meet our capacity
requirements for clinical trials and potential commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">establish a sales, marketing and distribution infrastructure to commercialize any approved product candidates and related
additional commercial manufacturing costs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">develop, maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets and
know how; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">acquire, develop or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">attract, hire and retain additional clinical, scientific, quality control, and manufacturing management and administrative
personnel; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">add clinical, operational, financial and management information systems and personnel, including personnel to support our
product development and planned future commercialization efforts; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">incur additional legal, accounting, investor relations and other expenses associated with operating as a public company.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also expect to increase the size of our administrative function to support the growth of our business. Our net losses may fluctuate
significantly from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of our
clinical trials and our expenditures on other research and development activities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will require substantial additional funding to develop our product candidates
and support our continuing operations. Until such time that we can generate significant revenue from product sales or other sources, if ever, we expect to finance our operations through the sale of equity, debt financings, or other capital sources,
which could include income from collaborations, strategic partnerships, or marketing, distribution, licensing or other strategic arrangements with third parties, or from grants. We may be unable to raise additional funds or to enter into such
agreements or arrangements on favorable terms, or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial
markets in the United States and worldwide resulting from the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and otherwise. Our failure to obtain sufficient funds on acceptable terms when needed could have a material adverse
effect on our business, results of operations or financial condition, including requiring us to have to delay, reduce or eliminate our product development or future commercialization efforts. Insufficient liquidity may also require us to relinquish
rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our
development efforts. We cannot provide assurance that we will ever be profitable or generate positive cash flow from operating activities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT
STYLE="white-space:nowrap">Covid-19</FONT> Pandemic </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since it was reported to have surfaced in December 2019, a novel strain of <FONT
STYLE="white-space:nowrap">coronavirus&nbsp;(COVID-19)&nbsp;has</FONT> spread across the world and has been declared a pandemic by the World Health Organization. Efforts to contain the spread </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">of&nbsp;COVID-19&nbsp;have</FONT> intensified and governments around the world, including in the United States, Europe and Asia, have implemented travel
restrictions, social distancing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">requirements,&nbsp;stay-at-home&nbsp;orders</FONT></FONT> and have delayed the commencement <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">of&nbsp;non-COVID-19-related&nbsp;clinical</FONT></FONT></FONT> trials, among other restrictions. As a result, the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has
presented a substantial public health and economic challenge around the world and is affecting our employees, patients, communities and business operations, as well as contributing to significant volatility and negative pressure on the U.S. economy
and in financial markets.</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of the outbreak, many companies have experienced disruptions in their operations and in markets served. To date, we have
initiated some and may take additional temporary precautionary measures intended to help ensure our employees&#146; well-being and minimize business disruption. For the safety of our employees and their families, we have temporarily reduced the
presence of our employees in our facilities. Certain of our third-party service providers have also experienced shutdowns or other business disruptions. We are continuing to assess the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic on our current and future business and operations, including our expenses and planned clinical trial and other development timelines, as well as on our industry and the healthcare system. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic,</FONT> or similar pandemics and outbreaks, we have and may in the future experience
severe disruptions, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">interruption of or delays in receiving products and supplies from the third parties we rely on to, among other things,
manufacture components of our instruments, due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems, which may impair our ability to sell our products and consumables; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">limitations on our business operations by the local, state, or federal government that could impact our ability to sell or
deliver our instruments and consumables; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">business disruptions caused by workplace, laboratory and office closures and an increased reliance on employees working
from home, travel limitations, cybersecurity and data accessibility limits, or communication or mass transit disruptions; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">limitations on employee resources that would otherwise be focused on the conduct of our activities, including because of
sickness of employees or their families or the desire of employees to avoid contact with large groups of people. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparisons of the Years Ended December&nbsp;31, 2019 and 2020 </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
following table summarizes our results of operations for the periods presented. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(dollars in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,290</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,206</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,916</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">520</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,410</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,039</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(371</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8)</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,996</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,735</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.37em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,241</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,280</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(95)</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gain on issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,076</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,076</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.37em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,279</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,184)</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(41,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">351</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Not meaningful </TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses represent a substantial portion of our operating expenses. Our research and development expenses consist primarily of direct and
indirect expenses incurred in connection with the discovery and development of our product candidates. Through September 2020, our research and development expenses were incurred resulting from our efforts to develop
<FONT STYLE="white-space:nowrap">gamma-PNA</FONT> chemistry and triplex gene editing for therapeutic use. Since October 2020, we have been engaged in the development of atacicept. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses are recorded as expense in the period they are incurred, and payments we make prior to the receipt of goods or services to be used in
research and development efforts are deferred as prepaid expenses until the goods or services are received and used. The cost incurred in obtaining technology licenses, including initial and subsequent milestone payments incurred under our licensing
agreements, are recorded as expense in the period in which they are incurred, as the licensed technology, method or process has no alternative future uses other than for our research and development activities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our research and development expenses incurred during the respective periods. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(dollars in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Direct preclinical and clinical expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Consulting and outside services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56)</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">License</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Indirect preclinical and clinical expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Compensation and related benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7)</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Facilities, depreciation and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">520</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Not meaningful </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses increased by $37.9&nbsp;million, or 520%, to $45.2&nbsp;million in 2020 from
$7.3&nbsp;million in 2019. The increase was primarily due to payments made to Ares pursuant to our exclusive license of atacicept, consisting of an initial payment of $13.1&nbsp;million payable in shares of our Series C redeemable convertible
preferred stock and subsequent cash milestone payments of $25.0&nbsp;million, and an increase of $0.4&nbsp;million in consulting and outside services expense resulting primarily from services commenced by clinical research organizations to initiate
the Phase 2b clinical trial of atacicept, which were partially offset by decreases of $0.8&nbsp;million of equipment expense, as we recorded such expense through September 2020 at which time we ceased using our laboratory equipment for preclinical
activities, and $0.2&nbsp;million of compensation and benefits expense, resulting from our ceasing use of laboratory equipment and reducing our preclinical workforce in September 2020. Facilities, depreciation and other expenses of $2.9&nbsp;million
in 2020 include an impairment charge of $1.0&nbsp;million resulting from our disposal of furniture and laboratory equipment associated with the preclinical activities that we ceased in September 2020. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>General and Administrative </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses
consist primarily of compensation and personnel-related expenses, including stock-based compensation, for our personnel in executive management, legal, finance, human resources, and other administrative functions. General and administrative expenses
also include professional fees paid for accounting, auditing, legal, tax and consulting services, and other general overhead costs to support our operations. General and administrative expenses are recorded as expense in the period they are
incurred, and payments we make prior to the receipt of goods or services to be used for general and administrative purposes efforts are deferred as prepaid expenses until the goods or services are received and used. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(dollars in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019 </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(371</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses decreased by $0.4&nbsp;million, or 8%, to $4.0&nbsp;million in 2020 from $4.4&nbsp;million in 2019, due primarily to lower rent
expense of $0.7&nbsp;million and lower compensation and benefits of $0.1&nbsp;million resulting from our ceasing preclinical activities during the year. These decreases were partially offset by an increase in professional services of
$0.3&nbsp;million and an impairment charge of $0.1&nbsp;million associated with the disposal of office equipment. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Restructuring Costs </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Restructuring costs primarily consist of contract termination costs related to leases and employee termination costs. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(dollars in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,735</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:ARIAL">Restructuring costs increased by $2.7&nbsp;million, or 1,048%, to $3.0&nbsp;million in 2020 from $0.3&nbsp;million in 2019, due primarily due to our
restructuring in September 2020, which resulted in our termination of certain of our employees, vacating leased facilities, and ceasing use of leased equipment that had been focused on our preclinical research and development activities.
Restructuring costs in 2019 resulted from vacating our lab and office facilities in Massachusetts. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Total Other Income (Expense) </I></B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(dollars in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,279</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,184</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The decrease of ($1.3) million in total other income (expense) to ($1.2) million other (expense) in 2020 from
$0.1&nbsp;million other income in 2019 resulted from a loss due to an increase of $1.1 million in the fair value of our convertible notes for which we elected to account for at fair value, a $0.1&nbsp;million increase in interest expense
attributable to the issuance of such notes, which converted into shares of our Series C redeemable convertible preferred stock during 2020, and a $0.2&nbsp;million decrease in interest income due a lower level of available cash invested in 2020.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, we have funded our operations
primarily through the issuance and sale of redeemable convertible preferred stock and convertible notes. From our inception through December&nbsp;31, 2020, we have raised aggregate net cash proceeds of $141.6&nbsp;million from the issuance and sale
of redeemable convertible preferred stock and convertible notes. Since the date of our incorporation, we have not generated any revenue from product sales and have incurred substantial operating losses and negative cash flows from operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We use our cash to fund operations, primarily to fund our research and development efforts, clinical trials, establishing and maintaining our intellectual property
portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. Cash used to fund operating expenses is affected by the timing of when we pay these expenses, as reflected in the change in our
outstanding accounts payable, accrued expenses and prepaid assets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We anticipate that we will continue to incur net losses for the foreseeable future as we
continue research and development activities of atacicept, hire additional staff, including clinical, operational, financial and management personnel, and incur additional expenses associated with operating as a public company. We expect to incur
significant expenses and operating losses for the foreseeable future as we advance our clinical development activities. We expect that our research and development and general and administrative costs will increase in connection with conducting
additional clinical trials and clinical trials for our current and future research programs and product candidates, contracting with third parties to support nonclinical studies and clinical trials, expanding our intellectual property portfolio, and
providing general and administrative support for our operations. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements, or other
sources. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2020, we had unrestricted cash and cash equivalents balance of $53.7&nbsp;million. We expect that our existing cash and cash
equivalents, together with the proceeds from this offering, will be sufficient to fund our operations through at least the next 18 months. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash Flows
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our cash flows for the periods indicated. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,551</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating Activities </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2020, we used $34.8&nbsp;million of cash used in operating activities, attributable to a net loss of $53.4&nbsp;million, partially offset by <FONT
STYLE="white-space:nowrap">non-cash</FONT> expenses of $13.1&nbsp;million resulting from a license payment made in shares of redeemable convertible preferred stock, an increase of $2.4&nbsp;million in the liability for restructuring, net of cash
paid, a net change of $0.1&nbsp;million in our net operating assets and liabilities, and $2.9&nbsp;million of other <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses, of which $1.2&nbsp;million was an impairment charge associated with the
disposal of property, equipment and intangible assets, $1.1&nbsp;million was attributable to the change in fair value on convertible notes payable, $0.3&nbsp;million of stock-based compensation and $0.3&nbsp;million of depreciation and amortization.
The net change of $0.1&nbsp;million in our net operating assets and liabilities resulted primarily from a $0.5&nbsp;million decrease in other liabilities, a $0.6&nbsp;million increase in accounts payable and a $0.1&nbsp;million decrease in other
assets, which were partially offset by a $0.1&nbsp;million increase in prepaid expense and other assets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2019, we used $10.3&nbsp;million of cash in operating
activities, attributable to a net loss of $11.9&nbsp;million, partially offset by a net change in our net operating assets and liabilities of $0.5&nbsp;million, the accrual for restructuring costs, net of cash paid, of $0.2&nbsp;million, and <FONT
STYLE="white-space:nowrap">non-cash</FONT> expenses of $0.9&nbsp;million, of which $0.5&nbsp;million was for depreciation and amortization, $0.3&nbsp;million was for stock-based compensation and $0.1&nbsp;million was for the loss on disposal of
property and equipment. The change in our net operating assets and liabilities resulted primarily from a decrease in prepaid expenses and other current assets of $0.3&nbsp;million, a decrease in grants receivable of $0.2&nbsp;million, an increase in
accrued and other current liabilities of $0.1&nbsp;million, and an increase in other liabilities of $0.3&nbsp;million, which were partially offset by a decrease in accounts payable of $0.3&nbsp;million. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Investing Activities </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2020, we used $42,000 of cash for investing
activities as a result of the purchase of $0.1&nbsp;million of equipment, partially offset by our receipt of proceeds in the amount of $57,000 from the sale of equipment. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2019, we used $0.1&nbsp;million of cash for investing activities, resulting from the purchase of property and equipment used for research and development activities
and for general and administrative operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Financing Activities </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2020, our financing activities provided $85.3&nbsp;million of cash resulting from $79.6&nbsp;million in proceeds from our issuance of Series C redeemable convertible
preferred stock, net of issuance costs, proceeds of $5.6&nbsp;million from our issuance of convertible notes payable that were converted into Series C redeemable convertible preferred stock, and proceeds of $0.2&nbsp;million from the exercise of
stock options to purchase Class A common stock, partially offset by the payment of $0.1&nbsp;million of capital lease obligations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2019, cash used in financing
activities was $0.1&nbsp;million. This was attributable to the payment of capital lease obligations totaling $0.2&nbsp;million, partially offset by the proceeds from the exercise of stock options totaling $0.1&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Contractual Obligations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our contractual
obligations as of December&nbsp;31, 2020. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAYMENTS DUE BY PERIOD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LESS&nbsp;THAN<BR>1 YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">1-3&nbsp;YEARS</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">3-5&nbsp;YEARS</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MORE&nbsp;THAN<BR>5 YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We enter into agreements in the normal course of business with various third parties for preclinical, clinical and other services. These contracts are generally
cancellable without material penalty upon written notice. Payments associated with these agreements are not included in this table of contractual obligations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
operating lease obligations reflect our lease obligations for our office and laboratory space in Woburn, Massachusetts and our office and life science research space in South San Francisco, California. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During 2019, we vacated our leased facilities in Woburn, Massachusetts and recorded a discounted lease-related
restructuring liability, which was calculated as the present value of the estimated future facility costs for which we would obtain no future economic benefit over the remaining term of the lease, which ends in July 2021. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During 2020, we vacated the leased facilities in South San Francisco. Our total future minimum commitment due pursuant to this lease is $11.1&nbsp;million. In November
2020, we entered into a <FONT STYLE="white-space:nowrap">non-cancellable</FONT> sublease agreement for the facility, under the terms of which we are entitled to receive $8.8&nbsp;million in lease payments over the term of the sublease, which ends
concurrently with the original lease in September 2025. As tenant, we remain responsible for the $11.1 million minimum lease commitment on the facilities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
addition to the office leases, we have future minimum lease payments of $0.6&nbsp;million for leases on research and laboratory equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Internal control over
financial reporting </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the preparation of our financial statements for 2020, we determined a material weakness in our internal control over financial reporting
existed during 2019, which material weakness remained unremediated as of December&nbsp;31, 2020. See the section titled &#147;Risk Factors&#151;We have identified a material weakness in our internal control over financial reporting. Although we have
already taken some steps to remediate this material weakness, if we are unable to remediate the material weakness, or if we identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls,
we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT
STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since the date of our incorporation, we have not engaged in any
<FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical Accounting Policies, Significant Judgments and Use of Estimates </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with
United States generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets
and liabilities, at the date of the financial statements, as well as revenue and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under
the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different
assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#146;s judgments and
estimates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While our significant accounting policies are described in the notes to our financial statements, we believe that the following critical accounting
policies are most important to understanding and evaluating our reported financial results. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research Contract Costs and Accruals </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We enter into various research and development and other agreements with commercial firms, researchers and others for provisions of goods and services from time to
time. These agreements are generally cancellable, and the related costs are recorded as research and development expenses as incurred. We record accruals for estimated ongoing research and development costs. When evaluating the adequacy of the
accrued liabilities, we analyze progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the
end of any reporting period. Actual results could differ materially from our estimates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We maintain a stock-based compensation plan as a long-term incentive for employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, consultants and
advisors. The plan allows for the issuance of a variety of equity incentive awards, including incentive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
stock options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options and restricted stock awards. We account for stock-based compensation by measuring and recognizing compensation
expense for all share-based awards made to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> based on estimated grant-date fair values. We use the straight-line method to allocate compensation cost to reporting periods over the
requisite service period, which is generally the vesting period. We recognize actual forfeitures by reducing the stock-based compensation expense in the same period as the forfeitures occur. We estimate the fair value of share-based awards to
employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> using the Black-Scholes model. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Estimating the fair value of equity-settled awards as of the
grant date using the Black-Scholes option pricing model is affected by assumptions regarding a number of complex variables. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation is
recognized. These inputs are subjective and generally require significant analysis and judgment to develop. These inputs are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Fair value of common stock&#151;See the subsection titled &#147;Fair Value of Common Stock&#148; below.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Expected term&#151;The expected term represents the average period that our options granted are expected to be outstanding
and is determined using the simplified method (based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the weighted-average vesting date and the end of the contractual term). We have very limited historical information to develop
reasonable expectations about future exercise patterns and post-vesting employment termination behavior for our stock option grants. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Expected volatility&#151;Since we are a privately-held company and do not have any trading history for our common stock,
the expected volatility was estimated based on the historical average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen
based on their similar size, life cycle stage, or area of specialty. We will continue to apply this process until enough historical information regarding the volatility of our own stock price becomes available. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Risk-free interest rate&#151;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the
time of grant for periods corresponding with the expected term of the options. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Expected dividend yield&#151;We have never paid dividends on our common stock and have no plans to pay dividends on our
common stock. Therefore, we used an expected dividend yield of zero. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will continue to use judgment in evaluating the expected volatility,
expected terms, and interest rates utilized for our stock-based compensation calculations on a prospective basis. Assumptions we used in applying the Black-Scholes option-pricing model to determine the estimated fair value of our stock options
granted involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our equity-based compensation could be materially
different. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to incur stock-based compensation of approximately $3.0 million to $3.2 million over the next three to four years as a result of all
compensatory equity issuances made in fiscal year 2021. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to incur stock-based compensation of approximately $0.9 million to $1.1 million in fiscal year
2022 as a result of all compensatory equity issuances made in fiscal year 2021. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The intrinsic value of all outstanding options as of December&nbsp;31, 2020 was
$22.2 million, $21.9 million of which related to unvested options as of such date, based on the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fair Value of Common Stock </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Historically, for all periods prior to
this initial public offering, the fair values of the shares of our common stock underlying our share-based awards were determined on each grant date by our board of directors with input from management and the assistance of an independent
third-party valuation specialist. Given the absence of a public trading market of our common stock, and in accordance with the American Institute of Certified Public Accountants Practice Aid, <I>Valuation of Privately-Held-Company Equity Securities
Issued as Compensation</I> (Practice Aid), our board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of our common stock at each grant date. These
factors include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">external market conditions affecting the proteomics and genomics biotechnology industry and trends within the industry;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our stage of development; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the rights, preferences and privileges of our redeemable convertible preferred stock relative to those of our common
stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the prices at which we sold shares of our redeemable convertible preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">actual operating results and projected financial performance, including our levels of available capital resources;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the progress of our research and development efforts and business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">equity market conditions affecting comparable public companies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">general U.S. market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the lack of marketability of our common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In valuing our common stock, the fair value of our business, or enterprise value, was determined using various valuation methods, including combinations of income,
market and asset approaches with input from management. The income approach determines value by using one or more methods that convert anticipated economic benefits into a present single amount. The application of the income approach establishes
value by methods that discount or capitalize earnings or cash flow, by a discount or capitalization rate that reflects investors&#146; rate of return expectations, market conditions, and the relative risk of the subject investment. The market
approach involves identifying and evaluating comparable public companies and acquisition targets that operate in the same industry or which have similar operating characteristics as the subject company. From the comparable companies, publicly
available information is used to extrapolate market-based valuation multiples that are applied to historical or prospective financial information in order to derive an indication of value. The asset approach determines the value of the underlying
assets and liabilities of a business as a means of determining the value of the business in aggregate. This approach can include the value of both tangible and intangible assets. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Practice Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value
of common stock at each valuation date. In accordance with the Practice Aid, we considered the following methods: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Option Pricing Method (OPM). Under the OPM, shares are valued by creating a series of call options with exercise prices
based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the redeemable convertible preferred stock and common stock are inferred by analyzing these options. This method is appropriate to use when
the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Probability-Weighted Expected Return Method (PWERM). The PWERM is a scenario-based analysis that estimates value per share
based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class. This method is generally most
appropriate to use when the time to a liquidity event is short, making the range of possible future outcomes relatively easy to predict. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on
our early stage of development and other relevant factors, we determined that the OPM was the most appropriate method for allocating our enterprise value to determine the estimated fair value of our common stock for valuations during 2019 and early
2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Beginning in March 2020, we used a hybrid method to determine the estimated fair value of our common stock, which included both the OPM and PWERM models.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Application of these approaches involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding our
expected future revenue, expenses, and cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of future events. Changes in any or all of these estimates and assumptions, or the relationships between
those assumptions, impact our valuations as of each valuation date and may have a material impact on the valuation of common stock. The assumptions underlying these valuations represent our management&#146;s best estimate, which involve inherent
uncertainties and the application of management judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation could be materially different. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the completion of this offering, the fair value of each share of the underlying common stock will be determined
based on the closing price as reported on the date of grant on the primary stock exchange on which our common stock is traded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Emerging Growth Company Status
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting
standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for emerging growth companies include presentation of
only two years audited financial statements in a registration statement for an initial public offering, an exemption from the requirement to provide an auditor&#146;s report on internal controls over financial reporting pursuant to the
Sarbanes-Oxley Act, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements. We have
elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that (i)&nbsp;we are no longer an emerging growth
company or (ii)&nbsp;we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting
pronouncements as of public company effective dates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will remain an emerging growth company under the JOBS Act until the earliest of (i)&nbsp;the last day of
our first fiscal year in which we have total annual gross revenue of $1.07&nbsp;billion or more, (ii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt instruments
during the previous three fiscal years, (iii)&nbsp;the date on which we are deemed a &#147;large accelerated filer&#148; under the rules of the SEC with at least $700.0&nbsp;million of outstanding equity securities held by <FONT
STYLE="white-space:nowrap">non-affiliates,</FONT> or (iv)&nbsp;the last day of the fiscal year following the fifth anniversary of completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See Note 2 to our financial statements
included elsewhere in this prospectus for more information about recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one yet, of their potential impact on our financial condition of results
of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quantitative and Qualitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interest Rate Risk </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2020, we had cash and
cash equivalents of $53.7&nbsp;million, which cash equivalents consisted of money market funds. Such interest-earning instruments carry a degree of interest rate risk. The goals of our investment policy are liquidity and capital preservation; we do
not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate exposure. We believe that we do not have any material exposure to changes in the fair value of these
assets as a result of changes in interest rates due to the short-term nature of our cash, cash equivalents, restricted cash, and investments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical stage biotechnology company focused on
developing and commercializing transformative treatments for patients with serious immunological diseases. Our lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B
lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. We are conducting a Phase 2b clinical trial of atacicept in
patients with immunoglobulin A nephropathy (IgAN), a disease with a high unmet medical need and no approved therapies. IgAN is a serious and progressive autoimmune disease of the kidney that is driven by the production of immunogenic
galactose-deficient IgA1 <FONT STYLE="white-space:nowrap">(Gd-IgA1).</FONT> IgAN patients with elevated <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> are at increased risk of kidney-related morbidity and mortality. As reported in a Phase 2a
clinical trial of 16 patients conducted by Merck KGaA, Darmstadt, Germany, atacicept is the first and only molecule in development to demonstrate a 60% reduction in plasma <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> in IgAN patients (75 mg dose,
n=4 at 24 weeks), which we believe can be disease modifying. We plan to initiate patient screening for our Phase 2b clinical trial in IgAN in the second quarter of 2021, and we expect to report topline results in the fourth quarter of 2022. In
addition, we are evaluating additional diseases where atacicept&#146;s reduction of autoantibodies may prove medically useful, including lupus nephritis (LN), a severe renal manifestation of systemic lupus erythematosus (SLE). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate there are approximately 126,000 biopsy-confirmed IgAN patients in the United States, 136,000 in the European Union, and 130,000 in Japan. Up to 50% of
patients diagnosed with IgAN develop <FONT STYLE="white-space:nowrap">end-stage</FONT> renal disease (ESRD) within 20 years from initial diagnosis, requiring dialysis or kidney transplant. ESRD causes considerable morbidity and impact on
patients&#146; lives and represents a significant health economic burden, which was estimated to be $49.2&nbsp;billion in the United States in 2018. Despite this high level of morbidity, there are currently no approved treatments indicated for IgAN.
The current standard of care consists of <FONT STYLE="white-space:nowrap">off-label</FONT> use of renin-angiotensin-aldosterone system (RAAS) inhibitors, including angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers
(ARBs), as well as steroids. We estimate the U.S. market opportunity for novel therapeutics in IgAN is approximately $4.0&nbsp;billion to $8.0&nbsp;billion annually, based on the disease prevalence and the segment of IgAN patients at high risk of
progressing to ESRD. In Europe and Japan, we estimate the annual market opportunity for novel IgAN therapeutics to be $1.0&nbsp;billion and $600&nbsp;million, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Atacicept has been shown in clinical trials to reduce <FONT STYLE="white-space:nowrap">Gd-IgA1,</FONT> which is central to the pathogenesis of IgAN, and therefore has
the potential to be the first disease modifying therapy for IgAN due to its ability to act on core pathophysiology processes. We believe that atacicept&#146;s mechanism has the potential to drive clinical success by measures designed to assess
efficacy in IgAN and other immunologic diseases. BLyS inhibition has been clinically and commercially validated through the approval of Benlysta (belimumab) in both SLE and lupus nephritis (LN). Preclinical and clinical evidence supports that
atacicept&#146;s mechanism of dual inhibition of BLyS and APRIL may provide improved clinical outcomes, measured by endpoints designed to assess efficacy, than inhibiting either signal alone. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have worldwide, exclusive rights to atacicept from Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, pursuant to a license agreement (Ares
Agreement), which advanced atacicept in randomized, double-blind, placebo-controlled clinical trials for several autoimmune diseases in over 1,500 patients, in which it was well tolerated. In IgAN, Ares conducted arandomized, double-blind,
placebo-controlled Phase 2a trial, known as JANUS. Results from the JANUS trial showed a dose-dependent effect of atacicept 25mg and 75mg weekly on serum <FONT STYLE="white-space:nowrap">Gd-IgA1,</FONT> proteinuria and key biomarkers, including
serum immunoglobulin levels. Atacicept was observed to be generally well tolerated. Specifically, the atacicept 75 mg dose arm demonstrated a 60% reduction in serum <FONT STYLE="white-space:nowrap">Gd-IgA1.</FONT> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are conducting a global, randomized, double-blind, placebo-controlled Phase 2b clinical trial in IgAN, which we refer to as ORIGIN. The ORIGIN trial is designed to
evaluate three subcutaneous weekly doses of atacicept (25 mg, 75 mg, and 150 mg) and their impact on the reduction of proteinuria as the primary endpoint. A significant reduction in proteinuria, as measured by urine protein to creatinine ratio
(UPCR) in a <FONT STYLE="white-space:nowrap">24-hour</FONT> urine collection, is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">associated with improved renal outcomes in patients with IgAN. UPCR is a surrogate endpoint endorsed by the U.S. Food
and Drug Administration (FDA) for primary glomerular diseases associated with significant proteinuria, including IgAN. The ORIGIN trial is powered to demonstrate a statistically significant difference between atacicept and placebo in decrease of
proteinuria. Secondary endpoints include the difference in kidney function between treated and placebo patients as measured by estimated glomerular filtration rate (eGFR) and reduction in <FONT STYLE="white-space:nowrap">Gd-IgA1.</FONT> We plan to
initiate patient screening for our Phase 2b clinical trial in the second quarter of 2021. We expect to report topline results from ORIGIN in the fourth quarter of 2022. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are evaluating further development of atacicept as a potential treatment for patients with LN, a severe renal manifestation of SLE. We estimate that there are
approximately 110,000 LN patients in the United States, 69,000 in the European Union, and 22,000 in Japan. We estimate the market for novel LN therapeutics annually to be approximately $2.0 to $5.0&nbsp;billion, $600&nbsp;million, and
$200&nbsp;million in United States, Europe, and Japan, respectively. Significant unmet need for improved efficacy persists for these patients despite the recent approval of the first two <FONT STYLE="white-space:nowrap">LN-specific</FONT> therapies.
Fewer than half of patients treated for LN have a complete response to therapy, and among patients without a complete response, over half will have <FONT STYLE="white-space:nowrap">non-functioning</FONT> kidneys within five years. Benlysta
(belimumab), a BlyS-only inhibitor, is one of the two therapies now approved for patients with LN. Both BlyS and APRIL levels are increased in patients with SLE, suggesting that dual inhibition by atacicept may be more potent than blocking BLyS
alone and has the benefit of targeting plasma cells in addition to B cells. Merck KGaA, Darmstadt, Germany previously initiated a randomized, double-blind, placebo-controlled Phase 2/3 clinical trial of atacicept in LN, the APRIL-LN trial, aimed to
evaluate the efficacy and safety of atacicept at 150 mg twice weekly for four weeks - then weekly - in patients with active LN. However, this trial was terminated early due to two subjects developing hypogammaglobulinemia with induction therapy (MMF
and CS) which continued to worsen when initiating atacicept and subsequently developed pneumonia. In a prior Phase 2 clinical trial of atacicept in SLE also conducted by Merck KGaA, Darmstadt, Germany, despite missing its primary endpoint in the
broader SLE study population, atacicept achieved positive clinical data on multiple measures within the pre-specified High Disease Activity patient segment (defined as Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) <FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT> 10 at screening), including reduction of renal flares, which we believe supports atacicept&#146;s applicability in LN. Because both preclinical and clinical
evidence suggests atacicept&#146;s dual inhibition of BLyS and APRIL may provide improved clinical outcomes, measured by endpoints designed to assess efficacy, than inhibiting either signal alone, we believe there is a strong rationale to conduct a
clinical trial of atacicept in LN. We intend to discuss our development plans for LN with the FDA and obtain feedback in the second half of 2021 and expect to initiate a Phase 2b or Phase 3 clinical trial in 2022. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of April 30, 2021 our licensed patent portfolio related to atacicept contains approximately 15 issued U.S. patents, as well as certain foreign counterparts of a
subset of these patents in several foreign countries, including countries within the European Patent Convention and the Eurasian Patent Organization. Because atacicept is a biologic, marketing approval would also provide 12 years of market
exclusivity from the approval date of a Biologics License Application (BLA) in the United States. Additionally, we plan to seek orphan drug designation for atacicept in IgAN from the FDA and European Medicines Agency (EMA), which would allow us to
obtain regulatory exclusivity protection from the approval date for seven years in the United States and 10 years in the European Union. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were founded and are
led by a team of experienced drug development professionals who have proven track records in clinical and commercial development and have led or been involved in the approvals of 10 medicines from Gilead Sciences. Inc. (Gilead) and Genentech, Inc.
(Genentech), including numerous drugs within Gilead&#146;s multi-billion blockbuster HIV and HCV franchises. Our Chief Executive Officer, Marshall Fordyce, M.D., brings more than 15 years of experience leading teams in clinical translation,
development, and commercialization of new treatments. Earlier in his career, Dr.&nbsp;Fordyce served as Gilead&#146;s Senior Director of Clinical Research where he contributed to seven new drug approvals and served as project lead for Gilead&#146;s
tenofovir alafenamide development program that led to five commercial products, including Genvoya and Descovy, which collectively generated over $12.0&nbsp;billion in worldwide sales in 2019. Our senior management team also includes: Chief Medical
Officer, Celia Lin, M.D., who joined from Genentech and was previously at Amgen Inc., where she led Phase 3 global trial execution in various therapeutic areas, as well as a regulatory filing in an orphan disease; Chief Development Officer, Joanne
Curley, Ph.D., who was formerly head of Portfolio Management at Gilead; Chief Business Officer, Lauren Frenz, who held positions of increasing responsibility within Gilead&#146;s commercial organization; Chief Financial
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Officer, Jonathan Wolter, who is a partner at FLG Partners, LLC, and has served as Chief Financial Officer for multiple public and private companies; Senior Vice President, Development
Operations, Tom Doan, who was formerly Executive Director of Clinical Operations and Therapeutic Area Head of Inflammation and Respiratory at Gilead; Senior Vice President and Head of Product Development and Manufacturing, Tad Thomas, Ph.D., who was
formerly Associate Vice President, Technical Operations at Codexis, Inc. and held previous manufacturing leadership roles at Bayer HealthCare LLC and other biopharmaceutical companies; and Senior Vice President, Finance and Chief Accounting Officer,
Joseph Young, who was formerly Senior Vice President, Finance and Treasurer at Plexxikon Inc. In conjunction with the Ares Agreement, we completed an approximately $80.0&nbsp;million Series C redeemable convertible preferred stock financing led by
Abingworth LLP. Other investors included Sofinnova Investments, Longitude Capital, Fidelity Management&nbsp;&amp; Research Company LLC, Surveyor Capital (a Citadel company), Octagon Capital, Kleiner Perkins, GV (formerly Google Ventures), and
Alexandria Venture Investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Business Principles and Strategy </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our goal is to develop and commercialize transformative treatments for patients suffering from severe immunological diseases. We believe the successful translation of
biomedical science into innovative therapeutic products for patients with immunological diseases will enable outsized growth over the next decade and beyond. Specifically, our strategy is based on the following business principles: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Develop disease modifying medicines to improve patients&#146; lives. </B>Our team seeks to bring transformative medical
products to patients with severe immunological diseases, who often receive steroids for treatment. The <FONT STYLE="white-space:nowrap">non-specific</FONT> immunologic effect of steroids, with known acute and chronic side effects, present an
important opportunity for innovation. We aim to develop and commercialize disease modifying drugs that target the source of disease, minimize side effects, and have high potential to meaningfully change standard medical care and improve
patients&#146; lives. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Establish clear <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">line-of-sight</FONT></FONT> to
successful products. </B>We apply our deep drug development experience, scientific rigor, and disciplined decision making to establish clear <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">line-of-sight</FONT></FONT> along the full
spectrum of drug development. We pursue biologic targets, product candidates, and disease indications with a <FONT STYLE="white-space:nowrap">de-risked</FONT> profile and capital efficient development pathway, and optimize for high probability of
clinical, regulatory, and commercial success. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Build a leading biotech company that delivers innovative medicines to patients.</B> We believe our team&#146;s
expertise and our business culture are fundamental to our success. Our Research and Development team is led by experienced drug development executives with proven track records in clinical and commercial development who have led or been involved in
the approvals of more than 12 medicines from leading companies, including Gilead Sciences and Genentech. We leverage our team&#146;s <FONT STYLE="white-space:nowrap">know-how</FONT> with additional outsourced resources and enable focused clinical
development of our product candidates with the goal to improve patients&#146; lives. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These principles have guided us to the successful <FONT
STYLE="white-space:nowrap">in-licensing</FONT> of atacicept from Ares with worldwide rights for development and commercialization in all indications. We take a gated-capital raise approach and scale product candidate investment and exposure in close
step with key development milestones to ensure high return on development costs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The key elements of our strategy to achieve our goal include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Complete global development of atacicept in IgAN. </B>We plan to initiate patient screening for our Phase 2b clinical
trial in IgAN in the second quarter of 2021. We expect to report topline results from ORIGIN in the fourth quarter of 2022. If these data are positive, we plan to seek an accelerated approval path in the United States by the FDA and in the European
Union by the EMA while initiating a pivotal Phase 3 clinical trial in 2023. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Advance atacicept in lupus nephritis (LN).</B> LN is a frequent but devastating complication of SLE. The recent FDA
approval of the anti-BLyS antibody, Benlysta (belimumab), provides clinical and regulatory precedent upon which to build our program. We believe that atacicept could offer a significant efficacy advantage for LN patients with its dual anti-APRIL and
anti-BlyS mechanism. We intend to discuss our development plans for LN with the FDA and obtain feedback in the second half of 2021 and expect to initiate a Phase 2b or Phase 3 clinical trial in 2022. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Explore additional disease areas where atacicept holds significant therapeutic promise. </B>By targeting APRIL and
BLyS, atacicept&#146;s ability to reduce disease causing autoantibodies may provide clinical benefit. We intend to explore additional immunologic diseases where BLyS and APRIL are abnormally elevated, or where autoantibodies play an important role.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Build and scale organizational capabilities to support commercialization of atacicept.</B> Under the leadership of our
experienced management team, we plan to build a specialized commercial organization to launch atacicept in the United States and other key markets, if approved. Within certain <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> markets, we may consider
strategic collaborations for commercialization. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Expand our pipeline by acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> product candidates for
immunologic diseases with unmet needs.</B> We believe our expertise and track record will enable us to identify and acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional product candidates that represent opportunities to expand
the potential value of our pipeline. We will leverage our lean clinical development operation to bring to market additional product candidates to address immunologic diseases </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Atacicept in IgAN </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are developing atacicept as a potential treatment for
patients with IgAN, a disease with a high unmet medical need and currently no approved therapies. IgAN is a serious and progressive autoimmune disease of the kidney, that is driven by the production of pathogenic
<FONT STYLE="white-space:nowrap">Gd-IgA1.</FONT> IgAN patients with elevated <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> are at increased risk of kidney-related morbidity and mortality. As reported in the Phase 2a JANUS trial, atacicept is the
first and only molecule in development to demonstrate a 60% reduction in plasma <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> in IgAN patients, suggesting atacicept targets the source of disease in these patients. Based on these encouraging
results, we are initiating the randomized, double-blind, placebo-controlled Phase 2b ORIGIN trial to further evaluate the efficacy and safety of atacicept in patients with IgAN. We expect to report topline results in the fourth quarter of 2022, and
if positive, we plan to seek an accelerated approval path in the United States by the FDA and in the European Union by the EMA while initiating a pivotal Phase 3 clinical trial in 2023. We believe that atacicept has the potential to be the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> and the leading B cell-targeted therapy for IgAN. Up to 50% of confirmed IgAN patients progress to ESRD, requiring dialysis or kidney transplant. ESRD causes
significant morbidity and impact on patients&#146; lives and represents a significant health economic burden estimated to be over $40.0&nbsp;billion annually in the United States. Despite this high level of morbidity, there is currently no approved
treatment indicated for IgAN. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Pathophysiology of IgAN </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The IgA antibody plays a key role in the immune system by protecting the body from foreign substances such as bacteria and viruses. Patients with IgAN produce elevated
levels of <FONT STYLE="white-space:nowrap">Gd-IgA1.</FONT> This abnormal glycosylation pattern of IgA1 is of central importance to the disease etiology. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As shown
in Figure 1 below, a multi-step process leads to the ultimate development of progressive renal injury. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 1: IgAN
Pathophysiology&#151;Overview </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g96a22.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">


<IMG SRC="g96328g08a11.jpg" ALT="LOGO">
&#8201;&#8201;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">B cells, which mature into plasma cells, are abnormally primed in the Peyer&#146;s patch region of the ileum of the intestines, potentially due to a combination of genetic predisposition and environmental, bacterial or dietary
factors. BLyS promotes B cell maturation and survival, increasing the number of disease causing B cells.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">


<IMG SRC="g96328g09a11.jpg" ALT="LOGO">
&#8201;&#8201;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">APRIL, a factor important for plasma cell survival, becomes upregulated, resulting in increased numbers of disease-causing plasma cells.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">


<IMG SRC="g96328g10a11.jpg" ALT="LOGO">
&#8201;&#8201;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">APRIL increases the number of plasma cells and increases antibody class switching, which is a mechanism that changes cells production from one immunoglobulin to another, causing an increase in the production of immunogenic <FONT
STYLE="white-space:nowrap">Gd-IgA1.</FONT> (See &#147;Hit 1&#148; in Figure 2 below.)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">


<IMG SRC="g96328g11a11.jpg" ALT="LOGO">
&#8201;&#8201;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">The <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> antibodies are immunogenic when found in the systemic circulation, which triggers autoantibodies, or antibodies created by the body in response to a constituent of its own tissue.
(See &#147;Hit 2&#148; in Figure 2 below.)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">


<IMG SRC="g96328g12a11.jpg" ALT="LOGO">
&#8201;&#8201;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Autoantibodies against <FONT STYLE="white-space:nowrap">Gd-IgA</FONT> lead to the formation of pathogenic immune complexes, or clusters of antibodies. (See &#147;Hit 3&#148; in Figure 2
below.)</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">


<IMG SRC="g96328g06a11.jpg" ALT="LOGO">
&#8201;&#8201;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Pathogenic immune complexes are deposited and become trapped in the kidney&#146;s glomeruli and initiate an inflammatory response that damages the membranes, resulting in protein and blood leaking into the urine. (See &#147;Hit
4&#148; in Figure 2 below.)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">


<IMG SRC="g96328g07a11.jpg" ALT="LOGO">
&#8201;&#8201;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">As the glomeruli are destroyed, the kidney&#146;s ability to remove waste products from the blood is reduced, which can result in potentially life-threatening complications that lead to the need for dialysis or kidney transplant in
many patients.</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similarly, IgAN has also been described as having a
<FONT STYLE="white-space:nowrap">multi-hit</FONT> pathogenesis, as shown in Figure 2 below, and referenced in the steps <FONT STYLE="white-space:nowrap">3-6</FONT> above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 2: IgAN Pathophysiology&#151;Downstream Effects of Elevated
<FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g01x89.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> is Central to the Pathogenesis of IgAN </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> is a subclass of IgA antibodies that lack units of galactose, a type of sugar, at the
<FONT STYLE="white-space:nowrap">O-linked</FONT> glycans of their hinge region, as shown in Figure 3 below. The hinge region is a stretch of amino acids in the IgA antibody. Circulating immune complex&#151;containing
<FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> proteins have been shown to be the target antigens for immunoglobulin G (IgG) antibodies with specificity for the hinge region. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 3: Components of <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g03c36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A histopathological hallmark of IgAN is deposition of Gd&#151;IgA1 in the glomerular mesangium, either alone or in combination with
IgG and/or immunoglobulin M (IgM). Sampling of the serum of subjects with IgAN has confirmed the presence of elevated levels of circulating immune complex&#151;containing <FONT STYLE="white-space:nowrap">Gd-IgA1.</FONT> </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials of patients with IgAN have correlated higher serum levels of <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> with greater severity of IgAN disease,
suggesting that reduction in serum levels of <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> may slow disease progression. Compared with healthy subjects, patients with IgAN have an increase in the proportion of
<FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> <FONT STYLE="white-space:nowrap">O-glycoforms</FONT> in the serum. As published </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
in Kidney International, in a prospective study of 275 patients with IgAN, higher serum levels of aberrantly glycosylated IgA1 demonstrated correlation with a higher likelihood of developing
progressive renal failure, as shown in Figure 4 below. A separate clinical trial of patients with IgAN of varying severity found that higher titers of autoantibodies specific for <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> corresponded to both
absolute renal risk score and risk of <FONT STYLE="white-space:nowrap">end-stage</FONT> renal disease or death. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 4: Renal Survival in IgAN
Patients with Four Quartile Serum <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> Levels </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g22p40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, high serum APRIL levels correlate with increased expression of serum Gd&#151;IgA1 in IgAN patients and high serum BLyS
levels are associated with more severe clinical features, as well as more severe histopathological features. For these reasons, we believe a fusion protein that blocks both BLyS and APRIL, which has the potential to reduce levels of <FONT
STYLE="white-space:nowrap">Gd-IgA1</FONT> in serum, would address the upstream source of IgAN, and represent the first disease-modifying approach for IgAN. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Disease Burden, Diagnosis, and Predictors of Disease Progression </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">IgAN is a rare disease in the United States and European Union and is also the predominant cause of primary glomerulonephritis. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patients with IgAN are diagnosed throughout life, but most commonly in the second and third decade. There are three common ways in which patients present: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">40-50%</FONT> present with one or more episodes of gross (visible) hematuria, often
linked to an upper respiratory tract infection. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">30-40%</FONT> present with microscopic hematuria and mild proteinuria, which is detected
in a routine physical or during chronic kidney disease evaluation. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Less than 10% present with either nephrotic syndrome or an acute, rapidly progressive glomerulonephritis with symptoms
including edema, hypertension, renal insufficiency, and hematuria. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once IgAN is suspected based on clinical history and laboratory data, kidney
biopsy, which is the gold standard for IgAN diagnosis, is performed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>IgAN Market Opportunity </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate there are approximately 126,000 biopsy-confirmed IgAN patients in the United States, 136,000 in the European Union, and 130,000 in Japan, and that growth in
the diagnosed prevalent population is due to overall population growth. Underlying genetic differences may contribute to the significantly higher rate in Japan. As therapies become commercially available, however, an increase in diagnosis rate or
longer time to progression, due to better treatments, may increase the diagnosed population over time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate the U.S. market opportunity for novel therapeutics in IgAN is approximately $4.0&nbsp;billion to
$8.0&nbsp;billion annually, based on the prevalence of the disease in the United States and the segment of IgAN patients at high risk of progressing to ESRD. In Europe and Japan, we estimate the annual market opportunity for novel IgAN therapeutics
to be $1.0&nbsp;billion and $600&nbsp;million, respectively. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Current Standard of Care for IgAN Patients </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are currently no approved therapies indicated for IgAN, However, the two following general approaches are typically employed for the treatment of patients with
IgAN: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">Non-specific</FONT> measures to slow progression, including blood pressure control, and
in patients with proteinuria, RAAS inhibitors, including ACE inhibitors or ARBs. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Steroids with or without other immunosuppressive agents to <FONT STYLE="white-space:nowrap">non-specifically</FONT> reduce
inflammation as a result of immune complex deposition in the glomeruli. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Treatment is selected based on perceived risk of progressive kidney
disease, and clinical measures such as hematuria, proteinuria, and eGFR are used to monitor patients while on treatment. The current standard of care is seen as insufficient by physicians and patients; these treatment approaches have limited
clinical efficacy and are not well tolerated. Approximately 50% of patients fail to achieve controlled UPCR on ACE inhibitors, ARBS, or steroids. The use of steroids may cause significant side effects, including serious infections, high blood
pressure, weight gain, diabetes, and osteoporosis. As such, there is a high unmet medical need for targeted therapies that impact the underlying disease pathophysiology and more tolerable, steroid-sparing treatment options for IgAN patients. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Emerging Therapies in Development </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Though there are no currently
approved therapies indicated for IgAN, there are several treatments in clinical development. The multistep IgAN pathogenesis hypothesis offers potential target points and approaches for therapeutic intervention. Most therapeutic candidates in
clinical development have employed various approaches to target inflammation and the downstream effects. Atacicept is the first and only agent currently in development that has demonstrated a 60% reduction of
<FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> in IgAN patients, the upstream source of IgAN pathogenesis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These agents can be grouped mechanistically into the
following categories: glucocorticoid receptor agonists, endothelin receptor antagonists (ERAs), complement inhibitors, <FONT STYLE="white-space:nowrap">B-cell</FONT> modulators, and a variety of other approaches that are earlier in development. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Glucocorticoid Receptor Agonists.</I></B> Glucocorticoid receptor agonists are a well-known class of molecules that have broad anti-inflammatory effects, and well
established acute and chronic side effects. Though reduction in the risk of eGFR decline was shown in clinical trials, there is no consensus on whether glucocorticoid may improve renal survival. The glucocorticoid, budesonide, has been reformulated
to concentrate steroid effects locally on the gut mucosa, theoretically suppressing the abnormal <FONT STYLE="white-space:nowrap">B-cell</FONT> activity reducing systemic steroid toxicity. Currently in a Phase 3 clinical trial in IgAN, reformulated
budesonide has demonstrated statistically meaningful reduction of proteinuria, though systemic steroid side effects have been observed in prior clinical trials and the ongoing Phase 3 clinical trial. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>ERAs.</I></B> Aberrant endothelin signaling is implicated in structural podocyte changes and increased mesangial proliferation in chronic kidney diseases,
including IgAN. ERAs block endothelin-induced cell proliferation hence may reduce renal perfusion pressure and proteinuria. Since this mechanism of action works downstream of disease related immune activities, it is not expected to reduce <FONT
STYLE="white-space:nowrap">Gd-IgA1</FONT> or the resulting immune complexes that cause the disease. Several ERAs, which have previously been approved for the treatment of pulmonary arterial hypertension and erectile dysfunction and make use of a
vasodilatory effect, are currently in Phase 3 development and have been shown to reduce proteinuria in patients with IgAN. However, ERAs have been associated with edema, significant liver toxicity and increased risk of heart failure. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Complement Inhibitors. </I></B>Increased complement activation is commonly observed in patients with IgAN. It is hypothesized that immune-complex deposition in
glomeruli may contribute to complement activation, though the exact mechanism is not well understood. Several agents that inhibit complement activation are in clinical development for IgAN. Modest reduction of proteinuria has been observed in early
clinical trials. As complement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
inhibition works downstream of immune complex formation, these agents are not expected to impact the upstream cause of disease and reduce <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> or the
resulting immune complexes that cause inflammation and complement activation in the kidney. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">B-cell</FONT>
Modulators.</I></B> <FONT STYLE="white-space:nowrap">B-cell</FONT> modulators, including atacicept, are an important category of emerging therapies for IgAN. The disease causing <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> is predominantly
produced by B cells and plasma cells. Therefore, control of <FONT STYLE="white-space:nowrap">B-cell</FONT> activation may reduce production of <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> and the downstream formation of autoantibodies and immune
complex. Interestingly, product candidates that modulate B cells through other single-target mechanisms, such as rituximab (CD20 alone), or blisibimod (BlyS alone), have been studied in patients with IgAN and have not shown a meaningful reduction of
<FONT STYLE="white-space:nowrap">Gd-IgA1.</FONT> Preclinical models have shown that dual inhibition of BlyS and APRIL offers improved suppression of B cell activities than blocking BlyS or APRIL alone. Atacicept blocks both BlyS and APRIL, and has
shown substantial reduction (60%) in <FONT STYLE="white-space:nowrap">Gd-IgA1.</FONT> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Solution: Atacicept </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Atacicept is a fusion protein that blocks both BLyS and APRIL, which play key roles in the upstream pathway that causes IgAN, and is dosed once weekly via subcutaneous
injection. As a result, we believe atacicept has the potential to be the first disease modifying therapy for IgAN. Through an integrated analysis of randomized, double-blind, placebo-controlled clinical trials in over 1,500 patients to date,
atacicept has a well-characterized clinical safety profile. In a Phase 2a clinical trial in patients with IgAN, atacicept substantially reduced <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> and demonstrated a clinically meaningful reduction in
proteinuria and eGFR parameters at week 24. We plan to initiate patient screening for our Phase 2b clinical trial in IgAN in the second quarter of 2021, and we expect to report topline results in the fourth quarter of 2022. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Approach to IgAN: Reducing <FONT STYLE="white-space:nowrap">Gd-IgA1,</FONT> the Source of Autoantibodies </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Atacicept is a fully humanized fusion protein that impacts the <FONT STYLE="white-space:nowrap">B-cell</FONT> pathway, which has well characterized implications in
immunologic diseases. Specifically, as shown in Figure 5 below, atacicept contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines BLyS and APRIL. These cytokines
are members of the tumor necrosis factor family that promote <FONT STYLE="white-space:nowrap">B-cell</FONT> survival and autoantibody production associated with IgAN and other immunologic diseases. Dual blockade of BlyS and APRIL by TACI has been
shown to be more potent than blocking BLyS alone and has the benefit of targeting long-lived plasma cells, in addition to B cells, thus reducing autoantibody production, including <FONT STYLE="white-space:nowrap">Gd-IgA1,</FONT> IgA, IgG, and IgM.
Therefore, atacicept&#146;s mechanism acts directly on the source of IgAN, which we believe will significantly mitigate the downstream effects of the disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 5: Atacicept Blocks Both BLyS and APRIL </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g27a75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Atacicept: Potential to Address the Core Processes Underlying IgAN Pathogenesis </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Atacicept&#146;s specific actions on IgAN disease pathogenesis are shown in Figure 6 below. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 6: Atacicept Impact on IgAN Pathogenesis </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g10g01.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">


<IMG SRC="g96328g01a11.jpg" ALT="LOGO">
&#8201;&#8201;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Atacicept blocks BLyS, a factor important for B cell survival and maturation, resulting in reduced numbers of disease-causing B cells.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">


<IMG SRC="g96328g02a11.jpg" ALT="LOGO">
&#8201;&#8201;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Atacicept blocks APRIL, a factor important for Plasma cell survival, resulting in reduced numbers of disease-causing plasma cells.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">


<IMG SRC="g96328g03a11.jpg" ALT="LOGO">
&#8201;&#8201;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Reductions in plasma cells and in antibody class switching to IgA reduces production of immunogenic <FONT STYLE="white-space:nowrap">Gd-IgA.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">


<IMG SRC="g96328g04a11.jpg" ALT="LOGO">
&#8201;&#8201;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Reductions in B cells, plasma cells, and <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> work together to cause a reduction in production of autoantibodies to <FONT STYLE="white-space:nowrap">Gd-IgA1.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">


<IMG SRC="g96328g05a11.jpg" ALT="LOGO">
&#8201;&#8201;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Therefore, formation of pathogenic immune complexes is greatly reduced.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">


<IMG SRC="g96328g06a11.jpg" ALT="LOGO">
&#8201;&#8201;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">This in turn, reduces immune complex deposition in glomeruli and reduces complement activation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">


<IMG SRC="g96328g07a11.jpg" ALT="LOGO">
&#8201;&#8201;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ultimately, progressive renal injury is reduced, which we believe will significantly lower the morbidity and mortality associated with IgAN.</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Atacicept&#146;s disease modifying mechanism addresses the upstream processes that cause IgAN, while most other molecules in development
act downstream. Therefore, we believe that the clinical outcomes of atacicept, measured by measures designed to assess efficacy and durability will be favorable to competitors, with a demonstrated tolerability profile. Once weekly subcutaneous
dosing also provides an attractive target product profile for patients. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Atacicept in IgAN: Clinical Development </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Atacicept was the subject of a collaboration agreement between ZymoGenetics, Inc. in 2001 and licensed on an exclusive basis to Ares in 2008. It was advanced by Ares in
clinical trials for several autoimmune disease, including rheumatoid arthritis (RA), multiple sclerosis, SLE, and IgAN, and in totality studied in double-blind placebo-controlled clinical trials in over 1,50(0 subjects to date. Safety, tolerability,
pharmacokinetics, pharmacodynamics, and clinical efficacy of the weekly 25 mg, 75 mg, and 150 mg doses administered subcutaneously have been studied. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the Phase
2a JANUS clinical trial conducted by Merck KGaA, Darmstadt, Germany in patients with IgAN, atacicept (25 mg and 75 mg doses) reduced <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> by 60% in IgAN patients. Atacicept has been the first and only
molecule observed to reduce <FONT STYLE="white-space:nowrap">Gd-IgA1,</FONT> the presumed upstream source of the disease, by this magnitude in IgAN patients. The 150 mg dose was not studied in the JANUS study. A clinically meaningful reduction in
proteinuria and eGFR parameters was observed at week 24 for both the 25 mg and 75 mg doses. The clinically significant and robust reduction in <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> provides important corroborative evidence of the potential
benefit of atacicept for patients with IgAN. Based on this encouraging data, we are initiating a Phase 2b ORIGIN clinical trial in IgAN to test 25 mg, 75&nbsp;mg, and 150 mg of atacicept with endpoints of proteinuria, eGFR and <FONT
STYLE="white-space:nowrap">Gd-IgA1</FONT> planned from week 12 though week 96. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe atacicept has the potential to be the first disease modifying therapy for
IgAN. We believe the large and established clinical data set for atacicept provides a competitive advantage for us versus other emerging therapies in development, many of which are either earlier in development and have clinical profiles that are
not as well characterized or are characterized by the well-known acute and chronic side effects of corticosteroids that limit their medical use. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Phase 2a JANUS
Trial of Atacicept in Patients with IgAN </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Phase 2a JANUS trial was a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety
of atacicept in IgAN. The trial enrolled 16 subjects with IgAN and persistent proteinuria who were on a stable and optimized dose of ACEi and/or ARB. The JANUS trial design is shown in Figure 7 below and the baseline patient characteristics shown in
Figure 8 below. Results showed a dose dependent effect of atacicept 25mg and 75mg weekly on proteinuria as well as key biomarkers including serum immunoglobulin levels, and <FONT STYLE="white-space:nowrap">Gd-IgA1,</FONT> and atacicept was observed
to be generally well tolerated. The JANUS trial was terminated earlier than planned due to Ares&#146; decision to deprioritize the program and therefore the sample size was truncated to 16 subjects, the 150 mg dose arm was not enrolled, and there
was limited long-term follow up after week 24. Trial termination was not related to safety or efficacy. Due to the small sample size of JANUS, the results should be interpreted with caution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 7: Phase 2a JANUS Trial Design </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g27d13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 8: Phase 2a JANUS Trial Baseline Characteristics </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g63g07.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><U>Atacicept Dose-Related Effects Within Target Weekly Dose Ranges </U></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A clinically meaningful reduction in proteinuria parameters was observed at week 24 in the atacicept group. The median percent change for UPCR and total protein by
24-hour urine collection decreased from baseline to week 24 for the atacicept 25 mg and 75 mg groups and increased for the placebo group, as shown in Figure 9 below. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 9: Proteinuria at Week 24 in the Phase 2a JANUS Trial </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g00c36.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After week 24, a persistent reduction in UPCR and total protein by 24-hour urine collection was observed in the atacicept 25 mg
group. The results for the 75 mg group after week 24 were inconclusive, however, because of confounding factors related to low subject numbers and changes in <FONT STYLE="white-space:nowrap">co-morbid</FONT> disease and treatments, such as diabetes
and hypertension, that affected four of the five subjects. All five subjects showed an initial decrease of proteinuria parameters. The one subject without trial management issues after week 24 showed a persistent reduction in UPCR and total protein
at weeks 48 and 72. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As seen in Figure 10 below, atacicept also showed stable eGFR for greater than one year versus expected 25% decline,
as was shown in the placebo arm. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 10: eGFR Over Time in the Phase 2a JANUS Trial </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g05v45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Atacicept 75 mg also showed a 60% of <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> reduction at 24 weeks, the largest magnitude in
reduction in of any molecule in development in IgAN patients, and dose-dependent reduction in serum IgA, IgG, and IgM, as shown in Figure 11 below. Clear dose-dependent reductions of serum <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> were
observed over the <FONT STYLE="white-space:nowrap">72-week</FONT> period studied (as shown in Figure 12 below), with atacicept 75 mg reducing <FONT STYLE="white-space:nowrap">Gd-IgA</FONT> significantly (60%) and durably. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 11: Median Change from Baseline (%) in Immunoglobulin Levels at Week 24 in the Phase 2a JANUS Trial </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g02w97.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 12: Serum <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> Levels Over Time in the Phase 2a
JANUS Trial </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g13v55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As the number of subjects included in the Phase 2a JANUS trial in IgAN for atacicept 25 mg and 75 mg was limited, further
investigation of these doses is warranted in a larger cohort, while also evaluating the safety and efficacy of atacicept 150 mg in IgAN, to ensure the optimal dose of atacicept is selected for a Phase 3 clinical trial. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><U>Atacicept Safety and Tolerability Profile in the JANUS Trial</U> </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Atacicept 25
mg and 75 mg weekly were observed to be generally well tolerated in the Phase 2a JANUS trial, with treatment-emergent adverse events (TEAEs) shown in Figure 13 below. Among the 11 atacicept treated patients, there was no TEAE leading to death and
only one patient in the 25 mg weekly cohort discontinued treatment due to injection site pruritus. Most TEAEs were graded as mild and were related to injection site events such as injection site bruising and erythema. The one severe TEAE event of
cervical spinal stenosis was reported by a patient in the 25 mg weekly cohort during the safety follow-up period, and was deemed not drug related. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 13: Overview of Treatment-emergent Adverse Events by Severity in the Phase 2a JANUS Trial </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g77q21.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><U>Atacicept Safety and Tolerability Profile: Integrated Analysis</U> </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Though there was a limited number of patients in the JANUS trial, in an integrated safety analysis in clinical trials of over 1,500 patients in a number of indications
atacicept was well tolerated, shown in Figure 14 below. Serious TEAEs reported in the highest proportions were those in infections and infestations (placebo 3.9% versus atacicept 4.4%), musculoskeletal and connective tissue disorders (placebo 1.9%
versus atacicept 1.3%), and nervous system disorders (placebo 2.1% versus atacicept 1.2%). The most frequently reported TEAE was pneumonia (placebo 1.2% versus atacicept 1.3%). We believe that this large and established data set is a competitive
advantage for us versus other emerging therapies in development, many of which lack extensive safety data. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 14. Integrated Safety Analysis:
Summary of Treatment-Emergent Adverse Events &gt; 5% in Any Arm, by Dose </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g03p94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The safety profile of atacicept 25 mg, 75 mg, and 150 mg has been characterized in healthy subjects and subjects with RA, multiple
sclerosis, optic neuritis, SLE, IgAN, and <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies, and is considered acceptable in IgAN. Over 1,940 subjects have been enrolled in 22 clinical trials, of which, over 1,425 subjects have received at
least one dose of atacicept. In the three Phase 2/3 clinical trials, 590 subjects with SLE and 11 subjects with IgAN have received at least one dose of atacicept. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the most recent atacicept Phase 2 SLE clinical trial, ADDRESS II, the frequencies of treatment-emergent adverse events were infections and infestations were similar
among atacicept 75 mg, 150 mg, and placebo. There was no correlation between infections and reduced levels of IgG, IgM, or IgA or reduced na&iuml;ve B cell or plasma cell numbers. No association was found between decreases in IgG and risk of serious
or severe infection. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe the benefit-risk balance of atacicept to be favorable for further development in IgAN and certain additional autoimmune diseases,
and we intend to explore additional immunologic diseases where BLyS and APRIL are abnormally elevated, or where autoantibodies play an important role. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Planned Phase 2b ORIGIN Clinical Trial Design </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">ORIGIN, our planned Phase 2b randomized, double-blinded, placebo-controlled, dose-ranging trial, will aim to evaluate the efficacy and safety of atacicept in subjects
with IgAN. The clinical trial consists of a <FONT STYLE="white-space:nowrap">36-week</FONT> double-blind treatment period, followed by a <FONT STYLE="white-space:nowrap">60-week</FONT> open-label treatment period and a
<FONT STYLE="white-space:nowrap">26-week</FONT> safety <FONT STYLE="white-space:nowrap">follow-up</FONT> period. The trial will assess multiple doses (25 mg, 75 mg, and 150 mg) of once weekly subcutaneous injections of atacicept by prefilled syringe
versus placebo on impact of renal function as measured by proteinuria. The primary endpoint is change from baseline in UPCR at 24 weeks based on <FONT STYLE="white-space:nowrap">24-hour</FONT> urine collection, with a secondary endpoint of UPCR at
36 weeks. Other endpoints include change from baseline in UPCR at 12, 48, 96 weeks, change from baseline in eGFR at 12, 24, 36, 48, 96 weeks, change from baseline in IgA, IgG, IgM, C3, C4, and <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> levels
at 12, 24, 36, 48, and 96 weeks, number of participants with adverse events during the double-blind treatment period through 36 weeks, and the serum concentration of atacicept through study completion. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 15. Phase 2b ORIGIN Trial Design </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g04e10.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">UPCR is an accepted surrogate primary endpoint for clinical
trials in IgAN, which allows for a faster path to commercialization than rate of change/slope in GFR, which is measured at or after week 110. The recommendation for usage of this surrogate endpoint was put forward by the ASN, partnering with the FDA
under the auspices of the Kidney Health Initiative, and the EMA, and has now been implemented in five Phase 3 clinical trials in IgAN. Accelerated and/or conditional approval may be granted on the UPCR endpoint, with full approval to be granted upon
longer-term data demonstrating stabilization of eGFR with treatment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are initiating the Phase 2b ORIGIN trial and expect to enroll a total of 105 patients at
multiple global sites, commencing in the second quarter of 2021. We expect to report topline results from ORIGIN in the fourth quarter of 2022. If these data are positive, we plan to seek an accelerated approval path in the United States by the FDA
and in the European Union by the EMA while initiating a pivotal Phase 3 clinical trial in 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Atacicept in LN: A Severe Renal Manifestation of SLE </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are evaluating further development of atacicept as a potential treatment for patients with LN, a severe renal manifestation of SLE. We estimate that there are
approximately 110,000 LN patients in the United States, 69,000 in the European Union, and 22,000 in Japan. Significant unmet need for improved efficacy persists for these patients despite the recent approval of the first two <FONT
STYLE="white-space:nowrap">LN-specific</FONT> therapies. Fewer than half of patients treated for LN have a complete response to therapy, and among patients without a complete response, over half will have
<FONT STYLE="white-space:nowrap">non-functioning</FONT> kidneys within five years. Benlysta (belimumab), a BlyS-only inhibitor, is one of the two therapies now approved for patients with LN. Both BlyS and APRIL levels are increased in patients with
SLE, suggesting that dual inhibition by atacicept may be more potent than blocking BLyS alone and has the benefit of targeting plasma cells in addition to B cells. Merck KGaA, Darmstadt, Germany previously initiated a randomized, double-blind,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
placebo-controlled Phase 2/3 clinical trial of atacicept in LN, the APRIL-LN trial, aimed to evaluate the efficacy and safety of atacicept at 150 mg twice weekly for four weeks - then weekly - in
patients with active LN. However, this trial was terminated early due to two subjects developing hypogammaglobulinemia with induction therapy (MMF and CS) which continued to worsen when initiating atacicept and subsequently developed pneumonia. In a
prior Phase 2 clinical trial of atacicept in SLE also conducted by Merck KGaA, Darmstadt, Germany, despite missing its primary endpoint of improved SLE responder index 4 (SRI- 4) at week 24, in the broader SLE study population, atacicept achieved
positive clinical data on multiple measures within the prespecified High Disease Activity patient segment, including reduction of renal flares, which we believe supports atacicept&#146;s applicability in LN. Because both preclinical and clinical
evidence suggests atacicept&#146;s dual inhibition of BLyS and APRIL may provide improved clinical outcomes, measured by endpoints designed to assess efficacy, than inhibiting either signal alone, we believe there is a strong rationale to conduct a
clinical trial of atacicept in LN. We intend to discuss our development plans for LN with the FDA and obtain feedback in the second half of 2021 and expect to initiate a Phase 2b or Phase 3 clinical trial in 2022. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Pathophysiology of LN </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">LN is a severe renal manifestation of SLE
(also referred to as lupus). SLE is a chronic and disabling autoimmune disease in which the body&#146;s own immune system attacks itself. SLE predominantly affects women and is more prevalent in women of color. When LN is diagnosed in a patient,
mortality risk dramatically increases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">LN pathogenesis involves a variety of disease-causing mechanisms, including the formation of immune deposits within the
kidneys that are primarily due to anti-double stranded DNA (anti-dsDNA) antibodies, which atacicept has been shown to reduce in a dose-dependent manner. However, there are also instances in which induction of LN by anti-dsDNA may not require immune
complex formation &#151; autoreactive plasma cells in the kidney may be another cause of nephritis. Certain genes and genetic factors may also predispose patients. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>LN Disease Burden and Diagnosis </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">LN has a strong influence on
morbidity and mortality within SLE, with up to 26% of patients progressing to ESRD within 15 to 20 years from initial diagnosis. LN is characterized by abnormal proteinuria, hematuria, and impaired kidney function. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Diagnosed SLE patients are routinely monitored by rheumatologists, who will refer to nephrologists upon suspicion of renal manifestations. In the United States and
European Union, LN patients without a prior SLE diagnosis will typically first present to a primary care physician (U.S.) or internist (EU) with hematuria or proteinuria before ultimate referral to a nephrologist. For confirmatory diagnosis,
nephrologists perform renal biopsy &#151; of which the results are analyzed to determine histologic class and relevant treatment course. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">LN patients are segmented
in Class&nbsp;I &#151; VI based on histopathology and degree of renal impairment, and this classification drives treatment decisions. Class&nbsp;I, or Minimal mesangial LN, is rarely diagnosed as these patients have normal urinalysis and therefore
biopsy is not typically performed. Class&nbsp;II, Mesangial proliferative LN, refers to microscopic hematuria and/or proteinuria. Patients with Class&nbsp;III, or Focal LN, tend to have both hematuria and proteinuria, and may have hypertension,
decreased eGFR, and nephrotic syndrome. Class&nbsp;IV, or Diffuse LN, is the most commonly diagnosed and severe form of LN, with patients exhibiting hematuria, proteinuria, nephrotic syndrome, hypertension, and decreased eGFR. Patients with
Class&nbsp;V, or lupus membranous nephropathy, tend to have nephrotic syndrome, may have microscopic hematuria and hypertension, but normal UPCR. Class&nbsp;VI, or advanced sclerosing LN, refers to a slow progression of kidney dysfunction correlated
with proteinuria. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As shown in Figure 16 below, LN typically develops early in the disease course, though the rate of SLE patients that
develop LN increases over time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 16: LN Progression </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g07g61.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>LN Market Opportunity </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According
to the Centers for Disease Control and Prevention, there are approximately 322,000 people living with SLE in the United States. Approximately half of individuals living with SLE develop LN within 15 years of their initial diagnosis, as shown in
Figure 16 above. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that there are approximately 110,000 LN patients in the United States, 69,000 in the European Union, and 22,000 in Japan at present.
In the United States, higher prevalence rates occur in the heterogeneous population, as both SLE and LN occur more frequently among <FONT STYLE="white-space:nowrap">non-Caucasian</FONT> patients &#151; with the highest frequency of LN occurring in
Black and Hispanic populations after adjustment for socioeconomic factors. In all three geographies, women account for the majority of LN cases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on primary
market research with physicians and payors and extensive secondary research, we estimate the market for novel LN therapeutics annually to be approximately $2.0 to $5.0&nbsp;billion, $600&nbsp;million, and $200&nbsp;million in United States, Europe,
and Japan, respectively. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Current Standard of Care for LN Patients </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Current LN treatment is largely cyclical, with induction versus maintenance therapy dictated by the severity of disease and frequency of flares. Treatment is driven by
histologic class and can be influenced by the treatments that the patient has been on since SLE diagnosis. Class&nbsp;I and II LN do not generally need <FONT STYLE="white-space:nowrap">LN-specific</FONT> treatment. Within <FONT
STYLE="white-space:nowrap">Class&nbsp;III-V,</FONT> patients tend to receive induction therapy for approximately one year to achieve complete or partial remission. Induction therapy for <FONT STYLE="white-space:nowrap">Class&nbsp;III-IV</FONT>
patients include several immunosuppressive agents, such as mycophenolate mofetil (MMF) &plusmn; corticosteroids or cylophosphamide (CYC) &plusmn; corticosteroids in the first line of treatment, switching to either CYC or MMF in the second line,
whichever was not administered first line. Third line induction therapy has generally consisted of rituximab for <FONT STYLE="white-space:nowrap">Class&nbsp;III-V</FONT> patients. For induction therapy of Class&nbsp;V LN patients, patients typically
receive MMF &plusmn; steroids in the first line, a calcineurin inhibitor in the second line, and rituximab for third line. Maintenance therapy, which typically consists of MMF, azathioprine (AZA), or hydroxychloroquine (HCQ), is typically prescribed
to well controlled patients after any line of induction to reduce flares. Immunosuppressive therapy is unlikely to be beneficial for Class&nbsp;VI, or advanced sclerosing LN. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patients on maintenance still experience flares approximately every year, resulting in cycling back to induction therapy. Many of the therapies used in the treatment
paradigm today have limited efficacy and poor tolerability profiles &#151; and therefore there is significant unmet need for safe and specific therapies that have a direct impact on LN disease activity without a high risk of infection. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Recently Approved and Emerging Therapies in Development </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Until
recently, there were no approved therapies for the treatment of LN. In December 2020, the FDA approved Benlysta (belimumab), an anti-BLyS antibody, for treatment of adult patients with active LN who are receiving standard therapy. In January 2021,
the FDA approved Lupkynis (voclosporin), a calcineurin inhibitor, to be used in combination with a background immunosuppressive therapy regimen for adult patients with active LN. Clinical guidelines on how these two medicines may be incorporated
into standard of care remain to be updated. In addition </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
to Benlysta (belimumab) and Lupkynis (voclosporin), there are several other cytokine inhibitors and complement inhibitors in development for LN. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">B-cell</FONT> Modulators.</I></B><I> </I>Benlysta (belimumab) is an anti-BLyS antibody, belonging to the class of <FONT
STYLE="white-space:nowrap">B-cell</FONT> modulators. Within the <FONT STYLE="white-space:nowrap">B-cell</FONT> modulator class, there is a desire for different mechanisms to target the complex pathophysiology of LN. The results shared to date for
these agents reveal statistically significant efficacy, but only achieve complete response rates in fewer than 50% of the patients studied. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Calcineurin
Inhibition.</I></B> Lupkynis (voclosporin) is a calcineurin inhibitor, a mechanism which has been commonly used in generic form as induction therapy for Class&nbsp;V patients. Calcineurin inhibition has been shown to reduce cytokine activation of <FONT
STYLE="white-space:nowrap">T-cells</FONT> and protect against proteinuria, however it may pose serious infection risks and nephrotoxicity is a known class effect. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cytokine Inhibitors.</I></B><I> </I>The other cytokine inhibitors under investigation offer blockade of key
<FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines (IL17A, IL23, Type 1 IFNs) involved in the pathogenesis of LN, however they are early in their development. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Complement Pathway Inhibitors.</I></B><I> </I>Complement pathway inhibitors are also early in their development, but unlikely to be disease modifying, since
complement activation is one result of the inflammation caused by immune-complex deposition in the kidneys, downstream of key steps in disease pathophysiology. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Solution: Atacicept / Scientific Rationale in LN </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Targeting
both BLyS and APRIL is key to reduce autoantibodies produced by B cells and plasma cells in LN.</B> Autoantibodies play a large role in the pathogenesis of LN. Autoantibodies target tissue or form immune complexes, leading to tissue and organ
damage. Both short-lived and long-lived plasma cells are responsible for generating high levels of autoantibodies in LN. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Short-lived plasma blasts are the main B
cell effector subset dependent on activation of various of B cell receptors such as TACI, BCMA and BLyS. Therefore, B cell blocking agents such as rituxan (anti-CD20) and Benlysta (belimumab) (anti-BLyS) can reduce short-lived plasma cells and the
resulting autoantibody production. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Long-lived plasma cells are in bone marrow and inflammatory tissue niches, and form antibodies in the absence of <FONT
STYLE="white-space:nowrap">B-cell</FONT> activation. Inflammatory tissue has high levels of BLyS and APRIL, which serve to maintain long-lived plasma cells. Inhibiting APRIL blocks long-lived nonproliferating plasma cell activities to further reduce
autoantibody formations in LN. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Atacicept contains the soluble TACI receptor that binds to the cytokines BLyS and APRIL and prevents their interaction with TACI,
BCMA and BlyS receptors <FONT STYLE="white-space:nowrap">(BLyS-R</FONT> is also known as <FONT STYLE="white-space:nowrap">BAFF-R).</FONT> Atacicept thus inhibits survival of immature and mature B cells and antibody-producing plasma cells and
prevents immunoglobulin class switching. In contrast to a range of available biologics directed at B cells only, we believe atacicept has a prompt and marked effect on antibody production by inhibiting both short-lived and long-lived plasma cells.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Preclinical evidence indicates that dual inhibition of BLyS and APRIL is superior to either BLyS or APRIL alone. </B>Animal models of kidney disease have
confirmed that atacicept reduces plasma cell numbers and reduces autoantibodies more effectively than BLyS and APRIL antibodies given individually. In a mouse model of collagen-induced arthritis, soluble atacicept inhibited development of
collagen-specific antibodies and reduced the incidence of the disease better than BLyS (also known as BAFF) agents alone. In a mouse model of SLE, soluble atacicept decreased the number of B cells, increased survival time and reduced severity of
disease symptoms. Furthermore, in a mouse model of SLE, atacicept administered after onset of autoimmunity decreased the number of bone marrow plasma cells and slowed down further formation of autoantibodies. Atacicept prevented renal damage during
a <FONT STYLE="white-space:nowrap">12-week</FONT> treatment period regardless of autoantibody levels, while BLyS-only inhibitor did not. Atacicept also decreased established plasma cells in an immunization model better than single inhibitors of BLyS
or APRIL. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>In patients with active SLE, targeting BLyS and APRIL (atacicept) appears to have improved clinical outcomes, measured by endpoints designed to assess
efficacy, than BLyS alone (Benlysta (belimumab)).</B> While Atacicept and Benlysta (belimumab) have not been studied <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> in clinical trials, each has been
studied in similar </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
populations of patients with SLE, and results of a Phase 2 clinical trial of 150 mg of atacicept compared favorably to published reports on changes in symptom response index <FONT
STYLE="white-space:nowrap">(SRI-4)</FONT> of belimumab. In a Phase 2 clinical trial of atacicept, the magnitude of efficacy as measured by the difference between treatment and placebo by <FONT STYLE="white-space:nowrap">SRI-4</FONT> at 24 weeks was
approximately 39% (25% placebo,&nbsp;64% atacicept 75 mg,&nbsp;65% atacicept 150 mg, both p=0.005). For Benlysta (belimumab), in a Phase 3 clinical trial of SLE patients, a published analysis of patients with HDA and serologically active disease,
clinical efficacy for Benlysta (belimumab) 10 mg/kg showed a difference between treatment and placebo by <FONT STYLE="white-space:nowrap">SRI-4</FONT> at 24 weeks of approximately 12%. However, as this data is based on a cross-trial comparison and
not a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> clinical trial, such data may not be directly comparable due to differences in study protocols, conditions and patient populations. Accordingly,
cross-trial comparisons may not be reliable predictors of the relative efficacy or other benefits of atacicept compared to other product candidates that may be approved or that are in development. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In SLE, atacicept consistently demonstrated improved clinical outcomes, measured by endpoints designed to assess efficacy, in SLE patients with HDA <FONT
STYLE="white-space:nowrap">(SLEDAI-2K</FONT> <FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT>10) versus placebo across additional clinical measures and consistent across all SRI <FONT
STYLE="white-space:nowrap">cut-offs,</FONT> as well as using the separate clinical assessment, BILAG-based Combined Lupus Assessment (BICLA). In the HDA population in ADDRESS II, the BICLA delta at week 24 was 20% (atacicept 150 mg 49%, placebo
29.2%, p=0.035), which compares very favorably to BICLA data from other late-stage SLE clinical trials, such as anifrolumab (week 24 BICLA in 16%) and ustekinumab (2%). We believe that based on these results, we believe an improved clinical benefit
may be observed in patients with LN. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Prior Clinical Development of Atacicept in LN </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Merck KGaA, Darmstadt, Germany conducted a randomized, double-blind, placebo-controlled Phase 2/3 clinical trial of atacicept in LN, the
<FONT STYLE="white-space:nowrap">APRIL-LN</FONT> trial, aimed to evaluate the efficacy and safety of atacicept in patients with active LN. As per trial protocol, patients initiated high-dose corticosteroids (CS) (the lesser of 0.8 mg/kg/day or 60
mg/day prednisone) and mycophenolate mofetil MMF (1 g daily, increased by 1 g/day each week to 3 g daily) at the time of screening (day <FONT STYLE="white-space:nowrap">-14).</FONT> From day 1, atacicept (150 mg, subcutaneously, twice weekly for
four weeks, then weekly) was initiated with MMF along with a tapered dose of CS.</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Four of the six enrolled LN subjects developed decreases in the serum IgG levels
following the initiation of MMF and CS in the setting of significant proteinuria, which are contributing factors of hypogammaglobulinemia. After initiation of atacicept, serum IgG levels further reduced; two subjects developed severe
hypogammaglobulinemia, defined as IgG &lt;3 g/L and pneumonia. These two subjects recovered after treatment discontinuation and received antibiotics therapy. This trial was terminated. Based on the detailed assessment of results from this trial,
plans to develop atacicept for the treatment of LN will explore alternatives to the induction regimen studied previously, including not dosing atacicept 150 mg twice weekly; clearly defining the dosing regimen for CS and MMF; and closely monitoring
immunoglobulin levels during induction therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Evaluation of Safety and Efficacy Profile of Atacicept In SLE </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Atacicept 75 mg and 150 mg, dosed once per week with subcutaneous auto-injection, have demonstrated improved clinical outcomes, measured by endpoints designed to assess
efficacy, in subjects with SLE in the Phase 2 <FONT STYLE="white-space:nowrap">APRIL-SLE</FONT> and ADDRESS II trials. In these trials, autoantibody titers were significantly reduced, and prespecified and post hoc analyses revealed prevention of
flare and reduction of active disease with atacicept treatment, despite the fact that the primary endpoints in these trials were not met. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In ADDRESS II, SLE
subjects with HDA (SLEDAI-2K <FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT> 10) had an increase in SLE Responder Index <FONT STYLE="white-space:nowrap">(SRI)-6</FONT> response, attainment of low
disease activity (LDA), or <FONT STYLE="white-space:nowrap">SLEDAI-2K</FONT> <FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT></FONT> 2, and a reduction of the risk of a first new severe flare (defined by
SLEDAI Flare Index (SFI) or by BILAG A) when treated with atacicept 150 mg. Furthermore, the 024 long-term extension (LTE) trial showed durability of these effects through a median duration of treatment of 96 weeks. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the release of the HDA data, Merck KGaA, Darmstadt, Germany pursued the planning and initiation of a global Phase 3 registrational program for atacicept 150
mg once per week in SLE. This program, including two large Phase 3 randomized placebo-controlled trials of atacicept 150 mg compared to placebo, were reviewed by FDA via
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-phase</FONT></FONT> 2 communication and scientific advice communication with EMA, prior to Merck KGaA, Darmstadt, Germany terminating the SLE program and the IgAN program for
business strategy reasons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Phase 2 SLE Clinical Trial In Patients With SLE For 52 Weeks </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">ADDRESS II, a Phase 2b SLE trial of 306 patients, evaluated the efficacy and safety of atacicept at two subcutaneous doses (150 mg and 75 mg) versus placebo over the
course of 24 weeks, with a LTE arm continuing an additional 96 weeks. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Atacicept demonstrated consistent reductions in IgG, IgA, and IgM serum levels, and
reductions in anti-dsDNA antibodies, as well as improvements in serum C3 and C4 levels, as shown in Figure 17 below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 17: Atacicept Impact
on Key Biomarkers in the Phase 2 ADDRESS II Trial </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g03t13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Though atacicept missed its primary endpoint of <FONT STYLE="white-space:nowrap">SRI-6</FONT> reduction versus placebo in all comers,
in a <FONT STYLE="white-space:nowrap">pre-specified</FONT> analysis within HDA patients, which comprised approximately half of those enrolled, atacicept 150 mg showed improved clinical outcomes, measured by multiple endpoints designed to assess
efficacy, including a 26% improvement (p=0.005) by <FONT STYLE="white-space:nowrap">SRI-6</FONT> versus placebo, flare risk reduction, and serologic marker normalization. <FONT STYLE="white-space:nowrap">SRI-6</FONT> response is defined as <FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT><FONT STYLE="white-space:nowrap">6-point</FONT> reduction in the SELENA-SLEDAI score, and no new BILAG A organ domain score or two new BILAG B organ domain
scores, and no worsening <FONT STYLE="white-space:nowrap">(&lt;0.30-point</FONT> increase) in Physician&#146;s Global Assessment score. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 18: <FONT STYLE="white-space:nowrap">SRI-6</FONT> Response Among HDA Patients in the Phase 2
ADDRESS II Trial </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g53o82.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Also among this HDA patient segment, significantly more patients on the atacicept 150 mg arm reached LDA, as measured by <FONT
STYLE="white-space:nowrap">SLEDAI-2K</FONT> &lt;= 2, as shown in Figure 19 below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 19: HDA Patients Reaching LDA in the Phase 2 ADDRESS II
Trial </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g26s28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, Figure 20 below demonstrates the durable clinical outcomes observed in the HDA segment: more patients reached LDA by
multiple measures at both week 24 and week 48. Significantly more patients treated with atacicept 150 mg once weekly versus placebo demonstrated clinical improvement (as shown by <FONT STYLE="white-space:nowrap">SRI-6),</FONT> achieved LDA, and
remission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 20: Durable Clinical Outcomes Observed in HDA Patients in the Phase 2 ADDRESS II Trial
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g80a43.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that the clinical outcomes, measured by endpoints designed to assess efficacy, demonstrated on multiple measures within
the HDA segment of the SLE population in the ADDRESS II trial &#150; and a favorable tolerability profile observed in ADDRESS II, as well as the integrated safety analysis in over 1,500 patients &#150; provide the foundation of our rationale for
developing atacicept further in LN, a severe renal manifestation of SLE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Exclusive License Agreement with Ares Trading S.A. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October&nbsp;29, 2020, we entered into an Exclusive License Agreement with Ares, an affiliate of Merck KGaA, Darmstadt, Germany (Ares Agreement), pursuant to which
Ares granted us an exclusive worldwide license to certain patents and related <FONT STYLE="white-space:nowrap">know-how</FONT> to research, develop, manufacture, use and commercialize therapeutic products containing atacicept or any other compound
that is covered by a claim of such licensed patents. Pursuant to the Ares Agreement, Ares also transferred inventory of licensed product to us for use in our clinical development of atacicept. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Per the Ares Agreement, we have obligations to use commercially reasonable efforts to develop at least one licensed product, to launch at least one licensed product in
a major market country within a specified time frame after receiving marketing approval for such product and to maintain sufficient resources to manufacture and supply licensed products to meet the market demand in each country for which a licensed
product has received marketing approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In consideration for the rights granted under the Ares Agreement, we issued 22,171,553 shares of our Series&nbsp;C
redeemable convertible preferred stock to Ares at the time of the initial closing of our Series C redeemable convertible </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
preferred stock financing in October 2020, representing ownership of approximately 10% on a fully diluted basis. As additional consideration under the Ares Agreement, we paid Ares
$25.0&nbsp;million upon delivery and initiation of the transfer of specified information and supply of drug product and drug substance and we are required to pay Ares aggregate milestone payments of up to $176.5&nbsp;million upon the achievement of
specified BLA filing or regulatory approvals in the United States, Europe and Japan (the first of which consists of a $15.0&nbsp;million payment upon filing of the BLA), and aggregate milestone payments of up to $515&nbsp;million upon the
achievement of specified commercial milestones. Commencing on the first commercial sale of licensed products, we are obligated to pay tiered royalties of low double-digit to <FONT STYLE="white-space:nowrap">mid-teen</FONT> percentages on annual net
sales of the products covered by the license. Our obligation to pay royalties will expire on a licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the latest of (i)&nbsp;15 years after the first commercial sale of such licensed product in such country; (ii)&nbsp;the expiration of the last valid claim of a licensed patent
that covers such licensed product in, or its use, importation or manufacture with respect to, such country; and (iii)&nbsp;expiration of all applicable regulatory exclusivity periods in such country with respect to such licensed product. In the
event we sublicense our rights under the Ares Agreement, we are obligated to pay Ares a percentage ranging from the mid single-digit to the low double-digits of specified sublicensing income received. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The term of the Ares Agreement will expire on a licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis upon the expiration of our obligation to pay royalties to Ares with respect to such licensed product in such country. We have the right to
terminate the Ares Agreement at will upon a specified notice period, provided that such termination is not within two years of the effective date of the Ares Agreement. Ares has the right to terminate the Ares Agreement in the event we challenge the
validity of the licensed patents. Additionally, either party can terminate the Ares Agreement for the other party&#146;s uncured material breach or bankruptcy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual Property </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our success depends in part upon our ability to
protect our core technology and intellectual property. To protect our intellectual property rights, we rely on patents, trademarks, copyrights and trade secret laws, confidentiality procedures, and employee disclosure and invention assignment
agreements. Our intellectual property is critical to our business and we strive to protect it through a variety of approaches, including by obtaining and maintaining patent protection in the United States and internationally for our product
candidate, and other inventions that are important to our business. For our product candidates, we generally intend to pursue patent protection covering compositions of matter, including new formulations, methods of making and methods of use. As we
continue the development of our product candidates, we intend to identify additional means of obtaining patent protection that would potentially enhance commercial success, including through claims covering additional methods of use. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of October&nbsp;29, 2020, we have licensed, including sublicenses, from Ares, an affiliate of Merck KGaA, Darmstadt, Germany, a patent portfolio related to atacicept
that contains approximately fifteen issued U.S. patents, as well as certain foreign counterparts of a subset of these patents in foreign countries, including Australia, Brazil, Canada, China, Hong Kong, Israel, India, Japan, Mexico, New Zealand,
Ukraine, Singapore, South Korea, South Africa, and countries within the European Patent Convention and the Eurasian Patent Organization. The issued patents are expected to expire between 2022 and 2029, with patents covering the composition of matter
of atacicept expiring in 2022. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In regards to atacicept, we <FONT STYLE="white-space:nowrap">in-license</FONT> a patent family that includes one issued U.S. patent
with claims covering a method of purifying atacicept and over 10 foreign patents granted in various jurisdictions including Australia, China, Europe, Israel, and Mexico. The U.S. patent is expected to expire in 2028 and the foreign patents are
expected to expire in 2027. We also <FONT STYLE="white-space:nowrap">in-license</FONT> a patent family that includes one issued U.S. patent with claims covering a formulation of atacicept and six foreign patents granted in various jurisdictions such
as Australia, Canada, China, and Europe. The U.S. patent is expected to expire in 2029, without taking into account any patent term extension, and the foreign patents are expected to expire in 2028. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because atacicept is a biologic, marketing approval would also provide 12 years of market exclusivity from the approval date of a BLA in the United States. We are
currently seeking orphan drug designation for atacicept in IgAN from the FDA and EMA, which, if secured, would provide seven and ten years, in the United States and European Union, respectively, of regulatory exclusivity protection from the approval
date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to patents, we may rely upon unpatented trade secrets and
<FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. We
seek to protect our proprietary information, in part, by executing confidentiality agreements with our collaborators and scientific advisors, and <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality, and invention assignment
agreements with our employees and consultants. We have also executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. The confidentiality agreements we enter into are designed to protect our
proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the respective counterparty. We cannot guarantee,
however, that we have executed such agreements with all applicable counterparties, such agreements will not be breached, or that these agreements will afford us adequate protection of our intellectual property and proprietary rights. For more
information, see &#147;Risk Factors&#151;Risks Related to Our Intellectual Property.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, we seek trademark protection in the United States and
internationally where available and when we deem appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Manufacturing and Supply </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We manage a number of external commercial manufacturing organizations (CMOs) to develop and manufacture our product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Atacicept is a fully humanized fusion protein that impacts the <FONT STYLE="white-space:nowrap">B-cell</FONT> pathway, which has well characterized implications in
immunologic diseases. The human <FONT STYLE="white-space:nowrap">IgG1-Fc</FONT> was modified to reduce the Fc binding to the C1q component of complement and the interaction with Fc receptors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Atacicept is manufactured following Current Good Manufacturing Procedures (cGMP) using a process that is similar to that used routinely for production of monoclonal
antibodies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The atacicept drug product is available as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ready-to-use</FONT></FONT> injection
solution in a prefilled syringe (PFS) at strengths of 25 mg/mL, 75 mg/mL, or 150 mg/mL of trial drug. Each atacicept PFS is designed to deliver a 1 mL solution of drug product. The drug product formulation is composed of atacicept as the active
substance, a sugar as a stabilizing agent, and sodium acetate as a buffer. All formulation components are pharmacopeia grade. An atacicept drug product presentation in a prefilled autoinjector has been developed and will be implemented for future
clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Ares Agreement includes the transfer of all existing inventory of atacicept drug substance and drug product, for our use in planned and future
clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We acquired approximately 35,000 PFS of atacicept, representing all three strengths, 25 mg, 75 mg, and 150 mg, of atacicept and approximately
25,000 PFS of placebo, as part of the Ares Agreement. This drug product will be used to initiate the Phase 2b ORIGIN trial. Additionally, we will acquire 6 kg of atacicept drug substance. As part of the Ares Agreement, in the first quarter of 2022,
Ares will convert the 6 kg of drug substance into drug product to supply both the ongoing Phase 2b ORIGIN trial and to support our future clinical trials through the first quarter in 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commercialization Plans </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate the market opportunity for novel
therapeutics in IgAN across the United States, Europe, and Japan to be approximately $5.6&nbsp;billion to $9.6&nbsp;billion annually, based on our assumptions, secondary research, and primary market research with physicians and payors. In order to
capitalize on this opportunity, we plan to build a specialty commercial infrastructure focused on IgAN, engaging treating physicians, including nephrologists, educating and engaging patients, and ensuring market access for patients. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For novel therapeutics in LN, we estimate the market opportunity across the United States, Europe, and Japan to be $2.8&nbsp;billion to $5.8&nbsp;billion annually,
based on a similar methodology. If we receive regulatory approval for atacicept in both IgAN and LN, we plan to assess call point overlap for the two indications and selectively build out our future commercial infrastructure to address any gaps to
optimize our coverage of LN treating physicians. We also plan to build out <FONT STYLE="white-space:nowrap">LN-specific</FONT> patient and market access programs, leveraging synergies where possible. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Through with the Ares Agreement, we were granted worldwide rights to the development and commercialization of
atacicept in all indications. We intend to commercialize atacicept ourselves in the United States and other key markets, if approved. Within certain <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> markets, we may consider strategic collaborations to
facilitate commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Competition </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biotechnology and
pharmaceutical industries are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. This is also true for the development and commercialization of treatments for immunologic diseases.
Though we believe that our focus, experienced team, scientific knowledge, and intellectual property provide us with competitive advantages, we face competition from a number of sources, including large and small biopharmaceutical companies,
universities, and other research institutions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are currently no approved therapies for IgAN and current <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">standard-of-care</FONT></FONT> consists of treatment with RAAS inhibitors, including ACE inhibitors or ARBs, to control blood pressure, or steroids with or without other immunosuppressive agents to <FONT
STYLE="white-space:nowrap">non-specifically</FONT> reduce inflammation. Atacicept, if and when approved and successfully commercialized, may compete with these existing approaches and with any new therapies that may become available in the future.
Among emerging therapies, we consider our most direct competitors with respect to atacicept in IgAN to be the programs in Phase 3 clinical development: Calliditas Therapeutics AB, Novartis Pharmaceuticals Corporation (Novartis), Omeros Corporation,
Travere Therapeutics, Inc., and Chinook Therapeutics Inc., and the following companies with programs in Phase 2 of clinical development: Chinook Therapeutics Inc., Alnylam Pharmaceuticals Inc., Apellis Pharmaceuticals, Inc., Reata Pharmaceuticals,
Inc., RemeGen Co., Ltd., Visterra, Inc., Ionis Pharmaceuticals, Inc., Alexion Pharmaceuticals Inc. (Alexion), and DiaMedica Therapeutics, Inc. There is also a potential that SGLT2 inhibitors, including AstraZeneca plc&#146;s (AstraZeneca) farxiga,
which has completed Phase 3 clinical development, and C.H. Boehringer Sohn AG&nbsp;&amp; Ko. KG&#146;s (Boehringer) jardiance, which is undergoing Phase 3 clinical development, will be approved broadly for chronic kidney disease and used in IgAN.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In LN, prior to December 2020, there had been no approved therapies, and the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> has consisted of a number of <FONT STYLE="white-space:nowrap">non-specific</FONT> therapies, including MMF, steroids, CYC, rituxumab, calcineurin
inhibitors, AZA, and HCQ, dependent on class of disease and whether a patient was cycling through the induction or maintenance phase of therapy. We expect that these paradigms will evolve with the recent FDA approvals of GlaxoSmithKline plc&#146;s
Benlysta (belimumab) and Aurinia Pharmaceuticals Inc.&#146;s Lupkynis (voclosporin), both of which we consider to be direct competitors. Our competitors include the following companies with programs in Phase 3 clinical development: Roche Holding AG
and Novartis, and the following companies with programs in Phase 2 clinical development: BeiGene Ltd., Janssen Pharmaceuticals, Inc., AstraZeneca, Alexion, Omeros Corporation, Kezar Life Science Inc., Bristol Myers Squibb, Boehringer, and Novartis.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of our competitors have significantly greater financial, technical, human and other resources than we do and may be better equipped to develop, manufacture
and market technologically superior products. In addition, many of these competitors have significantly greater experience than we have in undertaking nonclinical studies and human clinical trials of new pharmaceutical products and in obtaining
regulatory approvals of human therapeutic products. Accordingly, our competitors may succeed in obtaining FDA approval for superior products. Many of our competitors have established distribution channels for the commercialization of their products,
whereas we have no such channel or capabilities. In addition, many competitors have greater name recognition and more extensive collaborative relationships. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in
even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our competitors may obtain regulatory approval of their products more rapidly than we do or may obtain patent protection or other intellectual property rights that
limit our ability to develop or commercialize our product candidate or any future product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile
than our products and these competitors may also be more successful than we are in manufacturing and marketing their products. If we are unable to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
compete effectively against these companies, then we may not be able to commercialize our product candidate or any future product candidates or achieve a competitive position in the market. This
would adversely affect our ability to generate revenue. Our competitors also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and patient registration for
clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Government Regulation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Government authorities in the United States at the federal, state and local level and in other countries and jurisdictions, including the European Union, extensively
regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and
export and import of drug and biological products, such as our investigational medicines and any future investigational medicines. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and
efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Regulatory Approval in the United States </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States,
pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug and Cosmetic Act (FDCA), and other federal and state statutes and regulations, govern, among other things, the research, development, testing,
manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post- approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Biological products used for the prevention,
treatment or cure of a disease or condition of a human being are subject to regulation under the FDCA, except the section of the FDCA that governs the approval of a new drug application (NDA). Biological products are approved, or licensed, for
marketing under provisions of the Public Health Service Act (PHSA) via a BLA. The application process and requirements for approval of BLAs for originator biological products are similar to those for NDAs for new chemical entities, and biologics are
associated with similar approval risks and costs as drugs. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to approve pending NDAs or
BLAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our investigational medicines and any future investigational medicines must be approved by the FDA pursuant to a BLA before they may be legally marketed in the United
States. The process generally involves the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">completion of extensive preclinical laboratory and animal studies in accordance with applicable regulations, including
studies conducted in accordance with good laboratory practices (GLP) requirements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">submission to the FDA of an Investigational New Drug Application (IND), which must become effective before human clinical
trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approval of the protocol and related documents by an institutional review board (IRB) or independent ethics committee at
each clinical trial site before each clinical trial may be commenced; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performance of adequate and well controlled human clinical trials in accordance with applicable IND regulations, good
clinical practices (GCP) requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preparation of and submission to the FDA of a BLA for marketing approval that includes sufficient evidence of establishing
the safety, purity, and potency of the proposed biological product for its intended indication, including from results of nonclinical testing and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">payment of any user fees for FDA review of the BLA; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a determination by the FDA within 60 days of its receipt of a BLA to accept the filing for review; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of one or more FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections of the
manufacturing facility or facilities where the biologic, or components thereof, will be produced to assess compliance with current good manufacturing processes (cGMP) requirements to assure that the facilities, methods and controls are adequate to
preserve the biologic&#146;s identity, strength, quality and purity; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of any potential FDA audits of the clinical trial sites that generated the data in support of the
BLA to assure compliance with GCPs and integrity of the clinical data; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">FDA review and approval of the BLA, including consideration of the views of any FDA advisory committee; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">compliance with any post-approval requirements, including a Risk Evaluation and Mitigation Strategy (REMS), where
applicable, and post- approval studies required by the FDA as a condition of approval. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The preclinical and clinical testing and approval process
requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, or at all. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Preclinical Studies </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before testing any biological product candidates
in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as in vitro and animal studies to assess the potential for adverse events and
in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to beginning the first clinical trial with a product candidate in the United States, an IND must be submitted to the FDA and the FDA must allow the IND to
proceed. An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA allowance that such investigational product may be
administered to humans in connection with such trial. Such authorization must be secured prior to interstate shipment and administration. In support of a request for an IND, applicants must submit a protocol for each clinical trial and any
subsequent protocol amendments must be submitted to the FDA as part of the IND. An IND sponsor must also submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature
and plans for clinical trials, among other things, to the FDA as part of an IND. Some long-term preclinical testing may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that
time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin.
As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical Trials </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified
investigators, generally physicians not employed by or under the trial sponsor&#146;s control. Clinical trials must be conducted: (i)&nbsp;in compliance with federal regulations; (ii)&nbsp;in compliance with GCPs, an international standard meant to
protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors; as well as (iii)&nbsp;under protocols detailing, among other things, the objectives of the trial, the parameters to be used in
monitoring safety and the effectiveness criteria to be evaluated in the trial. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to
individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal
representative and must monitor the clinical trial until completed. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the
clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the product candidate has been associated with unexpected serious harm to patients. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee (DSMB). This
group provides authorization as to whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results
to public registries. Information about certain clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. Information related to the product, patient
population, phase of investigation, clinical trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Disclosure of the results of these clinical trials can be delayed in certain
circumstances for up to two years after the date of completion of the trial. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A sponsor who wishes to conduct a clinical trial outside of the United States may, but
need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA will accept a well-
designed and well-conducted foreign clinical trial not conducted under an IND if the clinical trial was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials are generally conducted in three sequential phases, known as Phase 1, Phase 2 and Phase&nbsp;3: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are
initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacokinetics, pharmacologic action, side effect tolerability, safety of the product
candidate, and, if possible, early evidence of effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 2 clinical trials generally involve studies in disease-affected patients to evaluate proof of concept and/or
determine the dosing regimen(s) for subsequent investigations. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation
of efficacy is conducted. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the
data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product labeling. In most cases, the FDA
requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the biologic. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These Phases may overlap or be
combined. For example, a Phase 1/2 clinical trial may contain both a dose-escalation stage and a dose-expansion stage, the latter of which may confirm tolerability at the recommended dose for expansion in future clinical trials. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A single Phase&nbsp;3 or Phase 2 trial with other confirmatory evidence may be sufficient in rare instances to provide substantial evidence of effectiveness (generally
subject to the requirement of additional post-approval studies). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In some cases, FDA may require, or firms may voluntary pursue, post-approval clinical trials,
sometimes referred to as Phase 4 clinical trials, after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety
<FONT STYLE="white-space:nowrap">follow-up.</FONT> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all
clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the
investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or <I>in vitro</I> testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of
a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The
sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s initial receipt of the information. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Phase 1, Phase 2, Phase 3 and other types of clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor
may suspend or terminate a clinical trial at any time on various grounds, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements or a finding that the patients are being exposed to an unacceptable health risk.
Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical
characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of
the product and, among other things, companies must develop methods for testing the identity, strength, quality, potency and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be
conducted to demonstrate that the investigational medicines do not undergo unacceptable deterioration over their shelf life. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>FDA Review Processes
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following completion of the clinical trials, the results of preclinical studies and clinical trials are submitted to the FDA as part of a BLA, along with
proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the
investigational product to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic or drug may be marketed in the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
cost of preparing and submitting a BLA is substantial. Under the Prescription Drug User Fee Act (PDUFA), each BLA must be accompanied by a substantial user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are
available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also
includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. The applicant under an approved BLA is also subject to an annual program fee. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Within 60
days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the FDA accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable
at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review to determine if it is substantially complete before
the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product
is safe, pure and potent, for its intended use, and whether the product is being manufactured in accordance with cGMP to ensure its continued safety, purity and potency. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months, from the filing date, in which to complete its initial review of an original BLA
for a new molecular entity and respond to the applicant, and six months from the filing date of an original BLA designated for priority review. The review process for both standard and priority review may be extended by the FDA for three additional
months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and the review process can be
extended by FDA requests for additional information or clarification. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before approving a BLA, the FDA will conduct a
<FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the
manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA also may audit data from clinical trials to ensure compliance with GCP requirements and the integrity of the data supporting safety and efficacy. Additionally,
the FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation
as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it generally follows such recommendations when making decisions on approval. The FDA likely
will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the FDA evaluates a BLA, it will issue either an approval letter or a Complete Response Letter. An approval
letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved
in its present form. A Complete Response Letter generally outlines the deficiencies in the BLA and may require additional clinical data, additional pivotal clinical trial(s) and/or other significant and time-consuming requirements related to
clinical trials, preclinical studies or manufacturing in order for FDA to reconsider the application. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or
withdraw the application or request an opportunity for a hearing. The FDA has committed to reviewing such resubmissions in two or six months, depending on the type of information included. Even if such data and information are submitted, the FDA may
decide that the BLA does not satisfy the criteria for approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a product receives regulatory approval, the approval may be significantly limited to specific
diseases and dosages or the indications for use may otherwise be limited, including to subpopulations of patients, which could restrict the commercial value of the product. Furthermore, as a condition of BLA approval, the FDA may require a REMS to
help ensure that the benefits of the biologic outweigh the potential risks to patients. A REMS can include medication guides, communication plans for healthcare professionals and elements to assure a product&#146;s safe use (ETASU). An ETASU can
include, but is not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring and the use of patient-specific registries. The requirement for
a REMS can materially affect the potential market and profitability of the product. Moreover, the FDA may require substantial post-approval testing and surveillance to monitor the product&#146;s safety or efficacy. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Orphan Drug Designation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Orphan Drug Act, the FDA may grant
orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the
United States but for which there is no reasonable expectation that the cost of developing and making the product for this type of disease or condition will be recovered from sales of the product in the United States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential
orphan use are disclosed publicly by the FDA. Orphan drug designation on its own does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is
entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years from the date of such approval, except in limited circumstances, such as a
showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care, or in instances of drug supply issues. A designated orphan drug may not
receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Orphan drug exclusivity may be lost if the FDA later determines that the request for designation was materially
defective. Further, competitors may receive approval of either a different product for the same indication or the same product for a different indication. In the latter case, because healthcare professionals are free to prescribe products for <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, the competitor&#146;s product could be used for the orphan indication despite another product&#146;s orphan exclusivity. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Expedited Development and Review Programs </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA is authorized to
designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Fast track designation may be granted for products that are intended to treat a serious or life-threatening disease or condition for which there is no effective
treatment and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor of a new
biologic candidate can request the FDA to designate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the candidate for a specific indication for fast track status concurrent with, or after, the submission of the IND for the candidate. The FDA must determine if the biologic candidate qualifies
for fast track designation within 60 days of receipt of the sponsor&#146;s request. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a fast track product&#146;s BLA before
the application is complete. This &#147;rolling review&#148; is available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The sponsor must also provide, and
the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of
FDA programs intended to expedite development and review, such as priority review and accelerated approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Breakthrough therapy designation may be granted for
products that are intended, alone or in combination with one or more other products, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently
approved therapies on one or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new biologic candidate may request that the FDA designate the candidate for a specific indication as a breakthrough therapy
concurrent with, or after, the submission of the IND for the biologic candidate. The FDA must determine if the biological product qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#146;s request. The FDA may
take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process, providing timely advice to the product sponsor regarding development and approval, involving more senior
staff in the review process, assigning a cross-disciplinary project lead for the review team and taking other steps to design the clinical trials in an efficient manner. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Priority review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement
in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review. Under priority review, the
FDA&#146;s goal is to review an application in six months once it is filed, compared to ten months for a standard review. Priority review designation does not change the standard for approval or the quality of evidence necessary to support approval.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accelerated approval may be granted for products that are intended to treat a serious or life-threatening condition and that generally provide a meaningful
therapeutic advantage to patients over existing treatments. A product eligible for accelerated approval may be approved on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that
can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the
condition and the availability or lack of alternative treatments. In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels,
functions or survives. The accelerated approval pathway is most often used in settings in which the course of a disease is long, and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on
the surrogate or intermediate clinical endpoint occurs rapidly. Use of the accelerated approval pathway entails submission of a BLA with the surrogate or intermediate clinical endpoint data while continuing to conduct the trial(s) to completion and
is contingent on a sponsor&#146;s agreement to complete and/or conduct additional post-approval confirmatory studies to verify and describe the product&#146;s clinical benefit. These confirmatory trials must be completed with due diligence and, in
some cases, the FDA may require that the trial be designed, initiated and/or fully enrolled prior to approval. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, would allow the FDA to
withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time
period for FDA review or approval may not be shortened. Furthermore, fast track designation, breakthrough therapy designation, priority review and accelerated approval do not change the standards for approval, but may expedite the development or
approval process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Additional Controls for Biologics </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes
cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health
needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is
required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release
protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral vaccines,
before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency and effectiveness of biological products. As with drugs, after
approval of biologics, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Combination Products </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A combination product is a product comprised of
two or more regulated components, e.g., drug and medical device, that are physically combined and produced as a single entity, packaged together in a single package, or packaged separately but intended to be labeled for use together. Atacicept in a
prefilled autoinjector would be such a combination of therapeutic and delivery device. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">FDA is divided into various branches, or Centers, by product type. Different
Centers typically review drug, biologic, or device applications. In order to review an application for a combination product, FDA must decide which Center should be responsible for the review. FDA regulations require that FDA determine the
combination product&#146;s primary mode of action, or PMOA, which is the single mode of a combination product that provides the most important therapeutic action of the combination product. The Center that regulates that portion of the product that
generates the PMOA becomes the lead evaluator. If there are two independent modes of action, neither of which is subordinate to the other, FDA makes a determination as to which Center to assign the product based on consistency with other combination
products raising similar types of safety and effectiveness questions or to the Center with the most expertise in evaluating the most significant safety and effectiveness questions raised by the combination product. When evaluating an application, a
lead Center may consult other Centers but still retain complete reviewing authority, or it may collaborate with another Center, by which the Center assigns review of a specific section of the application to another Center, delegating its review
authority for that section. Typically, FDA requires a single marketing application submitted to the Center selected to be the lead evaluator, although the agency has the discretion to require separate applications to more than one Center. We believe
that our prefilled autoinjector would have a biologic PMOA. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Pediatric Information </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Pediatric Research Equity Act (PREA), BLAs or supplements to BLAs must contain data to assess the safety and effectiveness of the biological product for the
claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA may grant full or partial waivers, or deferrals,
for submission of data. Unless otherwise required by regulation, PREA generally does not apply to any biological product for an indication for which orphan designation has been granted. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Best Pharmaceuticals for Children Act (BPCA) provides a <FONT STYLE="white-space:nowrap">six-month</FONT> extension of any exclusivity&#151;patent or <FONT
STYLE="white-space:nowrap">non-patent&#151;for</FONT> a biologic if certain conditions are met. Conditions for exclusivity include the FDA&#146;s determination that information relating to the use of a new biologic in the pediatric population may
produce health benefits in that population, FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as
priority applications, with all of the benefits that designation confers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once a BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and
promotion of biologics, including standards and regulations for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, <FONT STYLE="white-space:nowrap">off-label</FONT> promotion,
industry-sponsored scientific and educational activities and promotional activities involving the Internet. Biologics may be marketed only for the approved indications and in a manner consistent with the provisions of the approved labeling. Although
physicians may prescribe products for <FONT STYLE="white-space:nowrap">off-label</FONT> uses as the FDA and other regulatory agencies do not regulate a physician&#146;s choice of drug treatment made in the physician&#146;s independent medical
judgment, they do restrict promotional communications from companies or their sales force with respect to <FONT STYLE="white-space:nowrap">off-label</FONT> uses of products for which marketing clearance has not been issued. Companies may only share
truthful and not misleading information that is otherwise consistent with a product&#146;s FDA approved labeling. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Adverse event reporting and submission of
periodic safety summary reports is required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase 4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place
conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, biological product manufacture, packaging and labeling procedures must continue to conform to cGMPs after approval. Biologic
manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the
agency inspects a biologic product&#146;s manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality-control to maintain compliance with
cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with required regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems
are subsequently discovered. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not
maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes or failure to
comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical trials to assess new safety risks or imposition of distribution or other restrictions
under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the
product from the market or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">fines, warning or other enforcement-related letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license
approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">product seizure or detention, or refusal to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>U.S. Marketing Exclusivity </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Biologics Price Competition and
Innovation Act of 2009 (BPCIA) created an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Biosimilarity,
which requires that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the biological product and the
reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that
the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched
after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A reference biological product is granted 12 years of data exclusivity from the time of first licensure of the
product and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. &#147;First licensure&#148;
typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the
licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest or other related entity) for a change (not including a
modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological
product that does not result in a change in safety, purity or potency. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Regulatory Approval in the European Union </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The EMA is a decentralized scientific agency of the European Union. It coordinates the evaluation and monitoring of centrally authorized medicinal products. It is
responsible for the scientific evaluation of applications for EU marketing authorizations, as well as the development of technical guidance and the provision of scientific advice to sponsors. The EMA decentralizes its scientific assessment of
medicines by working through a network of about 4,500 experts throughout the European Union, nominated by the Member States. The EMA draws on resources of over 40 national competent authorities of European Union Member States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The process regarding approval of medicinal products in the European Union follows roughly the same lines as in the United States and likewise generally involves
satisfactorily completing each of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the applicable EU
Good Laboratory Practice regulations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">submission to the relevant national competent authorities of a clinical trial application (CTA) for each trial in humans,
which must be approved by such national authorities and at least one independent ethics committee before the trial may begin in each country where patient enrollment is planned; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">performance of adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each
proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">submission to the relevant competent authorities of a marketing authorization application (MAA) which includes the data
supporting safety and efficacy as well as detailed information on the manufacture and composition of the product in clinical development and proposed labelling; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">satisfactory completion of an inspection by the relevant national authorities of the manufacturing facility or facilities,
including those of third parties, at which the product is produced to assess compliance with strictly enforced cGMP; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">potential audits of the <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical trial sites that generated the
data in support of the MAA; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">review and approval by the relevant competent authority of the MAA before any commercial marketing, sale or shipment of
the product. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Preclinical Studies </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Preclinical
tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animal studies, in order to assess the quality and potential safety and efficacy of the product. The conduct of the
preclinical tests and formulation of the compounds for testing must comply with the relevant international, E.U. and national legislation, regulations and guidelines. The results of the preclinical tests, together with relevant manufacturing
information and analytical data, are submitted as part of the CTA. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical Trials </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Clinical Trials Directive 2001/20/EC, as amended (Clinical Trials Directive), a system for the approval of clinical trials in the European Union has
been implemented through national legislation of the member states. Under this system, approval must be obtained from the national competent authority of each European Union Member State in which a clinical trial is planned to be conducted. To this
end, a CTA is submitted, which must be supported by an investigational medicinal product dossier and further supporting information prescribed by the Clinical Trials Directive and other applicable guidance documents including but not being limited
to the clinical trial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
protocol. Furthermore, a clinical trial may only be started after an independent ethics committee has issued a favorable opinion on the CTA in that country. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2014, the EU adopted a new Clinical Trials Regulation (EU) No 536/2014, which is set to replace the current Clinical Trials Directive. The Regulation
introduces an authorization procedure based on a single submission via a single E.U. portal, an assessment procedure leading to a single decision, as well as transparency requirements (the proactive publication of clinical trial data in the E.U.
database). It is expected that the new Regulation will apply following confirmation of full functionality of the Clinical Trials Information System (CTIS), the centralized EU portal and database for clinical trials foreseen by the Regulation,
through an independent audit, currently expected to occur in December 2021. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Manufacturing and import into the E.U. of investigational medicinal products for use in
clinical trials is subject to the holding of appropriate authorizations and must be carried out in accordance with cGMP. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Review and Approval </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Authorization to market a product in the European Economic Area (EEA), comprising the European Union Member States plus Norway, Iceland and Liechtenstein, proceeds
under one of four procedures: a centralized authorization procedure, a mutual recognition procedure, a decentralized procedure or a national procedure. Since our products by their virtue of being antibody-based biologics fall under the centralized
procedure, only this procedure will be described here. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain drugs, including medicinal products developed by means of biotechnological processes, must be
approved via the centralized authorization procedure for marketing authorization. The centralized procedure is also mandatory for orphan medicinal products, advanced-therapy medicinal products (i.e.&nbsp;gene-therapy, somatic cell-therapy or
tissue-engineered medicines) and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The
centralized procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public
health. A successful application under the centralized authorization procedure results in a marketing authorization from the European Commission, which is automatically valid throughout the EEA. The other European Economic Area member states (namely
Norway, Iceland and Liechtenstein) are also obligated to recognize the European Commission decision. The EMA and the European Commission administer the centralized authorization procedure. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the centralized authorization procedure, the Committee for Medicinal Products for Human Use (CHMP) serves as the scientific committee that renders opinions about
the safety, efficacy and quality of human medicinal products on behalf of the EMA. The CHMP is composed of experts nominated by each member state&#146;s national drug authority, with one of them appointed to act as Rapporteur for the <FONT
STYLE="white-space:nowrap">co-ordination</FONT> of the evaluation with the possible assistance of a further member of the CHMP acting as a <FONT STYLE="white-space:nowrap">Co-Rapporteur.</FONT> After approval, the Rapporteur(s) continue to monitor
the product throughout its life cycle. The CHMP is required to issue an opinion within 210 days of receipt of a valid application, though the clock is stopped if it is necessary to ask the applicant for clarification or further supporting data.
Clock stops may extend the timeframe of evaluation of a marketing authorization application considerably beyond 210 days. The process is complex and involves extensive consultation with the regulatory authorities of Member States and a number of
experts. Once the procedure is completed, a European Public Assessment Report is produced. If the CHMP concludes that the quality, safety and efficacy of the medicinal product is sufficiently proven, it adopts a positive opinion. The CHMP&#146;s
opinion is sent to the European Commission, which uses the opinion as the basis for its decision whether or not to grant a marketing authorization. The European Commission&#146;s decision is issued within 67 days of receipt of the CHMP&#146;s
recommendation. If the opinion is negative, information is given as to the grounds on which this conclusion was reached. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After a drug has been authorized and
launched, it is a condition of maintaining the marketing authorization that all aspects relating to its quality, safety and efficacy must be kept under review. Sanctions may be imposed for failure to adhere to the conditions of the marketing
authorization. In extreme cases, the authorization may be revoked, resulting in withdrawal of the product from sale. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Now that the UK (which comprises Great Britain and Northern Ireland) has left the EU, Great Britain will no longer be
covered by centralized MAs (under the Northern Irish Protocol, centralized MAs will continue to be recognized in Northern Ireland). All medicinal products with a current centralized MA were automatically converted to Great Britain MAs on
January&nbsp;1, 2021. For a period of two years from January&nbsp;1, 2021, the Medicines and Healthcare products Regulatory Agency (MHRA), the UK medicines regulator, may rely on a decision taken by the European Commission on the approval of a new
marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain MA. A separate application will, however, still be required. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Conditional Approval and Accelerated Assessment </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As per Article 14(7)
of Regulation (EC) 726/2004, a medicine that would fulfill an unmet medical need may, if its immediate availability is in the interest of public health, be granted a conditional marketing authorization on the basis of less complete clinical data
than are normally required, subject to specific obligations with defined timelines being imposed on the authorization holder. The list of these obligations shall be made publicly accessible. In order for a conditional marketing authorization to be
granted, the CHMP must find that all of the following criteria are met: (i)&nbsp;the benefit-risk balance of the medicine is positive; (ii)&nbsp;it is likely that the applicant will be able to provide comprehensive data post-authorization;
(iii)&nbsp;the medicine fulfils an unmet medical need; and (iv)&nbsp;the benefit of the medicine&#146;s immediate availability to patients is greater than the risk inherent in the fact that additional data are still required. Such an authorization
shall be valid for one year, on a renewable basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When an application is submitted for a marketing authorization in respect of a drug for human use which is of
major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation, the applicant may request an accelerated assessment procedure pursuant to Article 14(9) of Regulation (EC) 726/2004. Under the
accelerated assessment procedure, the CHMP is required to issue an opinion within 150 days of receipt of a valid application, subject to clock stops, but it is possible that the CHMP may revert to the standard time limit for the centralized
procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment. We believe that some of the disease indications in which our product candidates are currently being or may be developed in the future
qualify for this provision, and we will take advantage of this provision as appropriate. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Period of Authorization and Renewals </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A marketing authorization is initially valid for five years and may then be renewed on the basis of a <FONT STYLE="white-space:nowrap">re-evaluation</FONT> of the
risk-benefit balance by the EMA or by the national competent authority of the authorizing Member State (where the centralized procedure is not used). To this end, the marketing authorization holder shall provide the EMA or the competent authority
with a version of the file in respect of quality, safety and efficacy, including all variants introduced since the marketing authorization was granted, at least six months before expiry of the initial five year period. Once renewed, the marketing
authorization shall be valid for an unlimited period, unless the European Commission or the relevant national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any
authorization which is not followed by the actual placing of the drug on the EEA market (if the centralized procedure is used) or on the market of the authorizing Member State (if the centralized procedure is not used) within three years after
authorization shall cease to be valid (the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;sunset clause&#148;). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Without prejudice to the law on the
protection of industrial and commercial property, marketing authorizations for innovative medicinal products benefit from an 8+2+1 year period of regulatory protection. This regime consists of a regulatory data protection period of eight years plus
a concurrent market exclusivity of 10 years plus an additional market exclusivity of one further year if, during the first eight years of those 10&nbsp;years, the marketing approval holder obtains an approval for one or more new therapeutic
indications which, during the scientific evaluation prior to their approval, are determined to bring a significant clinical benefit in comparison with existing therapies. Under the current rules, a third party making a generic or biosimilar
application may not reference the preclinical and clinical data of the reference product until the expiry of eight years after first approval of the reference product, and the third party may only market a generic or biosimilar version of the
reference product after 10 (or 11) years have lapsed since the first authorization of the reference product. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Orphan Drug Designation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulation (EC) 141/2000 states that a drug shall be designated as an orphan drug if its sponsor can establish (i)&nbsp;that it is intended for the diagnosis,
prevention or treatment of a life-threatening or chronically debilitating </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
condition; ; (ii) either such condition affects not more than five in 10,000 persons in the European Union when the application is made, or, without incentives, it is unlikely that the marketing
of the drug in the European Union would generate sufficient return to justify the necessary investment in its development; and (iii)&nbsp;that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question
that has been authorized in the European Union or, if such method exists, the drug will be of significant benefit to those affected by that condition. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulation
(EC) 847/2000 sets out provisions for the implementation of the criteria for the designation of orphan drugs. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the
product. Marketing authorization for an orphan drug leads to a <FONT STYLE="white-space:nowrap">10-year</FONT> period of market exclusivity, which means that no similar medicinal product can be authorized in the same indication. A &#147;similar
medicinal product&#148; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. This period may,
however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify continued
market exclusivity. In addition, derogation from market exclusivity may be granted on an individual basis in very select cases, such as with consent from the marketing authorization holder, inability to supply sufficient quantities of the authorized
product or demonstration of &#147;clinically relevant superiority&#148; by a similar medicinal product. Medicinal products designated as orphan drugs pursuant to Regulation (EC) 141/2000 are eligible for incentives made available by the European
Union and by the Member States to support research into, and the development and availability of, orphan drugs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the MAA of a medicinal product designated as an
orphan drug pursuant to Regulation (EC) 141/2000 includes the results of all studies conducted in compliance with an agreed pediatric investigation plan, and a corresponding statement is subsequently included in the marketing authorization granted,
the <FONT STYLE="white-space:nowrap">10-year</FONT> period of market exclusivity will be extended to 12 years. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>European and United Kingdom Data Collection
and Processing </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The collection, use, disclosure and other processing of health-related and other personal information about clinical trials participants and
other individuals in Europe is governed by the General Data Protection Regulation (GDPR) (and in the United Kingdom (UK), is governed by the European Union (Withdrawal) Act 2018 and the UK Data Protection Act 2018 (UK GDPR)). The GDPR and UK GDPR
require companies to give detailed disclosures about how they collect, use and share personal information; ensure any consents relied on to process personal information (including special categories of personal data, such as health data) meet the
stricter GDPR requirements; contractually impose data protection measures on vendors entrusted with personal information; maintain adequate data security measures; notify regulators and affected individuals of certain data breaches; meet extensive
privacy governance and documentation requirements; honor individuals&#146; data protection rights, including their rights to access, correct and delete their personal information; and refrain from transferring personal information from Europe or the
UK to most other countries unless specific safeguards can be implemented. Companies that violate the GDPR or UK GDPR can face private litigation, prohibitions on data processing and heavy fines. Complying with the GDPR and UK GDPR may be costly and
require us to limit our activities in Europe. If our efforts to comply are not successful, we may face litigation, reputational harm, significant penalties and other liabilities. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Marketing </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Much like the Anti-Kickback Statute prohibition in the
United States, as described below, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the E.U. The
provision of benefits or advantages to induce or reward improper performance generally is governed by the national anti-bribery laws of European Union member states and the Bribery Act 2010 in the UK. Infringement of these laws could result in
substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them,
no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines
Regulations 2012 and so remains applicable in the UK despite its departure from the EU. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Payments made to physicians in certain European Union member states must be publicly disclosed. Moreover, agreements
with physicians often must be the subject of prior notification and approval by the physician&#146;s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union member states. These
requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the European Union member states. Failure to comply with these requirements could result in reputational risk, public reprimands,
administrative penalties, fines or imprisonment. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Brexit and the Regulatory Framework in the United Kingdom </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2016, the electorate in the UK voted in favor of leaving the EU (commonly referred to as &#147;Brexit&#148;). Thereafter, in March 2017, the country formally
notified the EU of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty and the UK formally left the EU on January&nbsp;31, 2020. A transition period began on February&nbsp;1, 2020, during which EU pharmaceutical law remained
applicable to the UK, which ended on December&nbsp;31, 2020. Since the regulatory framework in the UK covering the quality, safety and efficacy of medicinal products, clinical trials, marketing authorization, commercial sales and distribution of
medicinal products is derived from EU Directives and Regulations, Brexit could materially impact the future regulatory regime which applies to products and the approval of product candidates in the UK, as UK legislation now has the potential to
diverge from EU legislation. It remains to be seen how Brexit will impact regulatory requirements for product candidates and products in the UK in the long-term. The MHRA, the UK medicines and medical devices regulator, has recently published
detailed guidance for industry and organizations to follow from January&nbsp;1, 2021 now the transition period is over, which will be updated as the UK&#146;s regulatory position on medicinal products evolves over time. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>International Regulation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to regulations in the United
States and Europe, a variety of foreign regulations govern clinical trials, commercial sales and distribution of product candidates. The approval process varies from country to country and the time to approval may be longer or shorter than that
required for FDA or European Commission approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Healthcare Laws and Regulations and Legislative Reform </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Healthcare Laws and Regulations </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Healthcare providers and third-party
payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our operations, including any arrangements with healthcare providers, physicians, third-party payors and
customers may expose us to broadly applicable fraud and abuse and other healthcare laws that may affect the business or financial arrangements and relationships through which we would market, sell and distribute our products. The healthcare laws
that may affect our ability to operate include, but are not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The federal Anti-Kickback Statute, which prohibits any person or entity from, among other things, knowingly and willfully
soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service
reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value. The federal Anti-Kickback Statute has
also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand. There are a number of statutory exceptions and regulatory safe harbors
protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Additionally, the intent standard under the federal Anti-Kickback Statute was
amended by the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, Affordable Care Act), to a stricter standard such that a person or entity does not need to have actual
knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the Affordable Care Act codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Federal civil and criminal false claims laws, such as the False Claims Act, which can be enforced by private citizens
through civil qui tam actions, and civil monetary penalty laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
for payment of federal funds, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an
obligation to pay money to the federal government. For example, pharmaceutical companies have been prosecuted under the False Claims Act in connection with their alleged <FONT STYLE="white-space:nowrap">off-label</FONT> promotion of drugs,
purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal
healthcare programs for the product. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. As a result of a
modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#147;any request or demand&#148; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the False Claims Act
even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Health Insurance Portability and Accountability Act of 1996 (HIPAA), among other things, imposes criminal liability
for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal
investigation of a healthcare offense, and creates federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or
representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">HIPAA, as amended by Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH), and their
implementing regulations, which impose privacy, security and breach reporting obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain
healthcare providers, known as covered entities, and their respective business associates and subcontractors that perform services for them that involve individually identifiable health information. HITECH also created new tiers of civil monetary
penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce HIPAA laws
and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The federal transparency requirements under the Physician Payments Sunshine Act, created under the Affordable Care Act,
which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children&#146;s Health Insurance Program to report annually to CMS information related to
payments and other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their
immediate family members. Beginning in 2022, applicable manufacturers also will be required to report information regarding payments and other transfers of value provided during the previous year to physician assistants, nurse practitioners,
clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">State and foreign laws that are analogous to each of the above federal laws, such as anti-kickback and false claims laws,
that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> <FONT STYLE="white-space:nowrap">third-party</FONT> payors, including private
insurers. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">State and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the
pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other healthcare
providers; state laws that require the reporting of marketing expenditures or drug pricing, including information pertaining to and justifying price increases; state and local laws that require the registration of pharmaceutical sales
representatives; state laws that prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals; state laws that </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
require the posting of information relating to clinical trials and their outcomes; and other federal, state and foreign laws that govern the privacy and security of health information or
personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure and protection of health-related and other personal information,
many of which differ from each other in significant ways and often are not <FONT STYLE="white-space:nowrap">pre-empted</FONT> by HIPAA, thus requiring additional compliance efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our operations are found to be in violation of any of these laws or any other current or future healthcare laws that may apply to us, we may be subject to
significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and
future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the
curtailment or restructuring of our operations, any of which could substantially disrupt our operations. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot
be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#146;s attention from the operation of our business, even if our defense is
successful. In addition, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or
administrative sanctions, including exclusions from government funded healthcare programs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Legislative Reform </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We operate in a highly regulated industry, and new laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, related
to healthcare availability, the method of delivery and payment for healthcare products and services could negatively affect our business, financial condition and prospects. There is significant interest in promoting healthcare reforms, and it is
likely that federal and state legislatures within the United States and the governments of other countries will continue to consider changes to existing healthcare legislation. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In 2010, the U.S. Congress
enacted the Affordable Care Act, which included changes to the coverage and reimbursement of drug products under government healthcare programs such as: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">established a branded prescription drug fee that pharmaceutical manufacturers of certain branded prescription drugs must
pay to the federal government; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new entities to
the program; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">established a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s
outpatient drugs to be covered under Medicare Part D; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">extended manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in
Medicaid managed care organizations; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to
additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for
certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">established a Center for Medicare and Medicaid Innovation at the CMS to test innovative payment and service delivery
models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">created a licensure framework for <FONT STYLE="white-space:nowrap">follow-on</FONT> biologic products.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There have been executive, judicial and congressional challenges to certain aspects of the Affordable Care Act as well as efforts to repeal or
replace certain aspects of the Affordable Care Act. For example, the U.S. Supreme Court is currently reviewing the constitutionality of the Affordable Care Act, but it is unknown when a decision will be reached. On February 10, 2021, the Biden
administration withdrew the federal government&#146;s support for overturning the Affordable Care Act. Further, although the Supreme Court has not yet ruled on the constitutionality of the Affordable Care Act, on January&nbsp;28, 2021, President
Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace, which began on February 15, 2021 and will remain open through August 15, 2021.
The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that
include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is unclear how the Supreme Court ruling, other such litigation, and the
healthcare reform measures of the Biden administration will impact the Affordable Care Act. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, there have been and continue to be a number of initiatives
at the United States federal and state levels that seek to reduce healthcare costs. In 2011, the U.S. Congress enacted the Budget Control Act, which included provisions intended to reduce the federal deficit. The Budget Control Act resulted in the
imposition of 2% reductions in Medicare payments to providers beginning in 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 with the exception of a temporary suspension from May&nbsp;1, 2020
through December 31, 2021 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, absent additional congressional action. If government spending is further reduced, anticipated budgetary shortfalls may also impact the ability of
relevant agencies, such as the FDA, to continue to function at current levels, which may impact the ability of relevant agencies to timely review and approve research and development, manufacturing and marketing activities, which may delay our
ability to develop, market and sell any product candidates we may develop. In addition, any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented, or any
significant taxes or fees that may be imposed on us, as part of any broader deficit reduction effort or legislative replacement to the Budget Control Act, could have an adverse impact on our anticipated product revenues. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in
several congressional inquiries and proposed legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient assistance programs and reform government program
reimbursement methodologies for drug products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For
example, on July&nbsp;24, 2020 and September&nbsp;13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#146;s proposals. As a result, the FDA
released a final rule on September&nbsp;24, 2020, effective November&nbsp;30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November&nbsp;20, 2020, the U.S. Department of
Health&nbsp;&amp; Human Services (HHS) finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless
the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January&nbsp;1, 2022 to January&nbsp;1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for
price reductions reflected at the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale,</FONT></FONT> as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the
implementation of which have also been delayed until January 1, 2023. On November&nbsp;20, 2020, the Centers for Medicare&nbsp;&amp; Medicaid Services (CMS) issued an interim final rule implementing the Trump administration&#146;s Most Favored
Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January&nbsp;1, 2021. On December&nbsp;28, 2020, the U.S. District
Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. It is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. Individual states in the United States have also become increasingly active in
passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and
transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what
pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. It is difficult to predict the future legislative landscape in healthcare and the effect on our business, results of operations,
financial condition and prospects. However, we expect that additional state and federal healthcare reform measures will be adopted in the future, particularly in light of the new presidential administration. Further, it is possible that additional
governmental action is taken in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Environmental, Health and Safety Laws and
Regulations </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We and our third-party contractors are subject to numerous environmental, health and safety laws and regulations, including those governing
laboratory procedures and the use, generation, manufacture, distribution, storage, handling, treatment, remediation and disposal of hazardous materials and wastes. Hazardous chemicals, including flammable and biological materials, are involved in
certain aspects of our business, and we cannot eliminate the risk of injury or contamination from the use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials and wastes. In particular, our product
candidates use PBDs, which are highly potent cytotoxins that require special handling by our and our contractors&#146; staff. In the event of contamination or injury, or failure to comply with environmental, health and safety laws and regulations,
we could be held liable for any resulting damages, fines and penalties associated with such liability could exceed our assets and resources. Environmental, health and safety laws and regulations are becoming increasingly more stringent. We may incur
substantial costs in order to comply with current or future environmental, health and safety laws and regulations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Pharmaceutical Coverage, Pricing and
Reimbursement </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The availability and extent of coverage and adequate reimbursement by governmental and private third-party payors are essential for most
patients to be able to afford expensive medical treatments. In both domestic and foreign markets, sales of our product candidates will depend substantially on the extent to which the costs of our product candidates will be covered by third- party
payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors decide which products will be covered and establish reimbursement levels for those products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#146;s determination that use of a product is:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Obtaining coverage approval and reimbursement for a product from a government or other third-party payor is a time-consuming and costly process that could require us to
provide supporting scientific, clinical and cost- effectiveness data for the use of our products to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement at a satisfactory level. If
coverage and adequate reimbursement of our future products, if any, are unavailable or limited in scope or amount, such as may result where alternative or generic treatments are available, we may be unable to achieve or sustain profitability.
Adverse coverage and reimbursement limitations may hinder our ability to recoup our investment in our product candidates, even if such product candidates obtain regulatory approval. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. There is no uniform policy for coverage and
reimbursement in the United States and, as a result, coverage and reimbursement can differ significantly from payor to payor. In the United States, the principal decisions about </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
reimbursement for new medicines are typically made by the CMS, which decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors often, but not
always, follow the CMS&#146;s decisions regarding coverage and reimbursement. It is difficult to predict what third-party payors will decide with respect to coverage and reimbursement for fundamentally novel products such as ours, as there is no
body of established practices and precedents for these new products. Further, one payor&#146;s determination to provide coverage and adequate reimbursement for a product does not assure that other payors will also provide coverage and adequate
reimbursement for that product. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our product candidates. There can be no assurance that our product candidates will be
considered medically necessary or cost-effective. Therefore, it is possible that any of our product candidates, even if approved, may not be covered by third-party payors or the reimbursement limit may be so restrictive that we cannot commercialize
the product candidates profitably. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Reimbursement agencies in Europe may be more restrictive than payors in the United States. In Europe, pricing and reimbursement
schemes vary widely from country to country. For example, some countries provide that products may be marketed only after an agreement on reimbursement price has been reached. Such pricing negotiations with governmental authorities can take
considerable time after receipt of marketing approval for a product. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Other
countries require the completion of additional health technology assessments that compare the cost- effectiveness of a particular product candidate to currently available therapies. In addition, the European Union provides options for its member
states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product,
may adopt a system of direct or indirect controls on the profitability of the company placing the product on the market or monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Reference pricing used by
various European Union member states and parallel distribution, or arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced member states, can further reduce prices. Furthermore, many countries in the European Union have
increased the amount of discounts required on pharmaceutical products, and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in
the European Union. The downward pressure on healthcare costs in general, and prescription products in particular, has become increasingly intense. As a result, there are increasingly higher barriers to entry for new products. There can be no
assurance that any country that has reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries. Accordingly, the reimbursement for any
products in Europe may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore,
the containment of healthcare costs has become a priority of foreign and domestic governments as well as private third-party payors. The prices of drugs have been a focus in this effort. Governments and private third-party payors have attempted to
control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably. We also expect to experience pricing pressures due to the trend towards managed
healthcare, the increasing influence of health maintenance organizations and additional legislative changes. These and other cost-control initiatives could cause us to decrease the price we might establish for products, which could result in
lower-than-anticipated product revenues. In addition, the publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If
pricing is set at unsatisfactory levels or if coverage and adequate reimbursement of our products is unavailable or limited in scope or amount, our revenues and the potential profitability of our product candidates in those countries would be
negatively affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees and Human Capital Resources </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have a
total of eight full time employees and 21 consultants on a part-time basis. Vera has in the past, and may in the future, retain additional expert consultants if required in connection with the Company&#146;s plans. We are not a party to any
collective bargaining agreements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Attracting, hiring, and retaining highly qualified individuals are key to our success. To do so, we believe we offer competitive
compensation packages - inclusive of base salary, bonus, and equity, and benefits. We also sought to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
establish a values-based culture centered around our core values of <I>teamwork</I>, <I>accountability</I>, and <I>empathy </I>for patients to enhance the working environment for our current
employees and to attract our desired candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Facilities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have
leased 24,606 square feet of office and lab space at 170 Harbor Way in South San Francisco, CA. This space is currently subleased to Vaxart, Inc. through September&nbsp;30, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> Impact on Facilities </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are operating virtually to align with local <FONT STYLE="white-space:nowrap">COVID-19</FONT> guidelines, which we believe meets our operational needs for the time
being as a clinical-stage organization. We plan to reassess our facilities needs on a quarterly basis and anticipate a future lease or flexible arrangement for office-only space. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal Proceedings </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, we may become involved in legal
proceedings or be subject to claims arising in the ordinary course of our business. We are not currently a party to any material legal proceedings. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense
and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers, Key Employees and Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets
forth information regarding our executive officers, key employees and directors, including ages as of April&nbsp;30, 2021. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>AGE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>POSITION</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Executive Officers:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Marshall Fordyce, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">47</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Celia Lin, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">46</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Joanne Curley, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Development Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jonathan Wolter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">70</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Other Key Employees</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lauren Frenz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">36</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Business Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tom Doan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">49</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President, Development Operations&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Joseph Young</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">49</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Senior Vice President, Finance and Chief Accounting Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tad Thomas, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">61</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Senior Vice President and Head of Product</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Development and
Manufacturing</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kurt von Emster, C.F.A.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP> <SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">53</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairperson of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Andrew Cheng, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP><SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">54</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Beth Seidenberg, M.D.<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">64</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Maha Katabi, Ph.D., C.F.A. <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP><SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">47</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Patrick Enright<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Scott Morrison<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">63</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the compensation committee. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the nominating and corporate governance committee. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the audit committee. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Marshall Fordyce, M.D. </I></B>is our founder and has served as our Chief Executive Officer and President and as a member of our board of directors since May
2016. From April 2011 to July 2016, Dr.&nbsp;Fordyce held a number of senior leadership roles at Gilead Sciences, Inc. (Gilead), a biotechnology company, including Director of Clinical Research and Senior Director of Clinical Research, where he was
responsible for leading teams in clinical translation, development and commercialization of new treatments. In April 2012, Dr.&nbsp;Fordyce joined the Albert and Mary Lasker Foundation, a foundation supporting biomedical research, as a <FONT
STYLE="white-space:nowrap">non-executive</FONT> director and continues in that role. Dr.&nbsp;Fordyce received a B.A. in medical anthropology from Harvard University and an M.D. from Harvard Medical School. We believe Dr.&nbsp;Fordyce is qualified
to serve on our board of directors due to his extensive experience in the biotechnology industry in senior leadership roles, as well as the perspective and experience he brings as our President and Chief Executive Officer. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Celia Lin, M.D. </I></B>has served as our Chief Medical Officer since February 2021. From August 2015 to February 2021, Dr. Lin was Senior Medical Director at
Genentech. She was responsible for late stage development and regulatory approval for a novel product in an orphan disease. She also served as Global Development Lead for a BTK inhibitor in multiple sclerosis, and led other programs including
monoclonal antibodies, bispecifics, and complement inhibitors in various therapeutic areas such as respiratory, allergy, nephrology, infectious disease and inflammation. Dr.&nbsp;Lin previously served as Medical Director in Clinical Development and
Medical Affairs at Amgen, from April 2012 to August 2015, leading teams and activities related to the approval and commercialization of two osteoporosis therapies. Dr.&nbsp;Lin is a board certified physician. Prior to joining industry, she was on
faculty at UCSF. She received her B.S. from UCLA and her M.D. from University of Rochester School of Medicine. She trained in internal medicine at Boston Medical Center and in rheumatology at UCLA and Washington University in St. Louis where she
also was a post-doctoral fellow. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Joanne Curley, Ph.D. </I></B>has served as our Chief Development Officer since March 2020. From June 2005 until March 2020,
Dr.&nbsp;Curley held a number of senior leadership roles at Gilead, a biotechnology company, including Senior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Director, Project and Portfolio Management and Vice President, Project and Portfolio Management, where she was responsible for developing products from research through regulatory approval. From
2002 to 2005, Dr.&nbsp;Curley served as a staff scientist at Nektar Therapeutics, a pharmaceutical company. Dr.&nbsp;Curley received a B.Sc. in physics and chemistry from Trinity College, Ireland, a Ph.D. in polymer science and engineering from the
University of Massachusetts, Amherst, and did a post-doctorate at Massachusetts Institute of Technology and Harvard Medical School focused on long-acting biodegradable formulations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Jonathan Wolter </I></B>has served as our Chief Financial Officer since March 2020 through his capacity as a partner at FLG Partners, LLC, a Silicon Valley chief
financial officer services firm. Mr.&nbsp;Wolter joined FLG Partners, where he is a partner, in July 2004. Through FLG Partners, Mr.&nbsp;Wolter has served public and private company clients as both permanent and interim chief financial officer. In
connection with his role at FLG Partners, Mr.&nbsp;Wolter has been engaged by SmartRent.com, Inc., a smart home automation company, as Chief Financial Officer since August 2020. From June 2019 to March 2020, Mr.&nbsp;Wolter served as interim Chief
Financial Officer at Amyris, Inc., a biotechnology company. From September 2017 to October 2019, Mr.&nbsp;Wolter served as Chief Financial Officer of Soleno Therapeutics, Inc., a biopharmaceutical company. From January 2016 to April 2019,
Mr.&nbsp;Wolter served as Chief Financial Officer of Verana Health, Inc., a private technology company that partners with medical associations to assemble clinical databases in medicine. Mr.&nbsp;Wolter received a B.S. in business administration
from the University of California, Berkeley and is a certified public accountant (inactive). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Key Employees </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Lauren Frenz </I></B>has served as our Chief Business Officer since April 2020. Ms.&nbsp;Frenz previously served as our Senior Vice President of Corporate
Strategy and Finance from August 2017 to April 2020. From June 2012 to July 2017, Ms.&nbsp;Frenz served in positions of increasing responsibility at Gilead, a biotechnology company, in the US Sales&nbsp;&amp; Marketing and Global Commercial
Planning&nbsp;&amp; Operations organizations in multiple therapeutic areas. At Gilead, she most recently led healthcare provider marketing for multiple blockbuster HIV therapies. Prior to Gilead, Ms.&nbsp;Frenz worked at SVB Leerink, an investment
bank specializing in healthcare and life sciences, in their Strategic Advisory Group, devising business development, commercial, and portfolio management strategies for biotech and pharmaceutical companies. Ms.&nbsp;Frenz received an M.B.A. from
Harvard Business School and an A.B. in psychology with a certificate in neuroscience from Princeton University. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Tom Doan </I></B>has served as our Senior
Vice President, Development Operations since March 2020. From April 2007 to March 2020, Mr.&nbsp;Doan held a number of senior leadership roles at Gilead, a biotechnology company, where he was responsible for clinical operations for multiple
successful drug market filings and approvals, including most recently Executive Director, Clinical Operations, Therapeutic Area Head, Inflammation/Respiratory. From October 2003 until April 2007, Mr.&nbsp;Doan served as Clinical Trial Manager and
Senior Clinical Trial Manager, BioOncology, at Genentech, a biotechnology company. From September 1999 until October 2003, Mr.&nbsp;Doan served as Clinical Research Manager and Clinical Research Associate, at Cato Research, LLC, a clinical research
organization. Mr.&nbsp;Doan received a B.S. in Fisheries Biology from Humboldt State University. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Joseph Young </I></B>has served as our Senior Vice
President, Finance since March 2021 and our Chief Accounting Officer since May 2021. From April 2006 to July 2020, Mr.&nbsp;Young held a number of senior leadership roles at Plexxikon Inc., a biotechnology company, and wholly-owned subsidiary of
Daiichi-Sankyo Co., Ltd. since its acquisition of Plexxikon in 2011, including most recently Senior Vice President, Finance and Treasurer, where he was responsible for all accounting, finance and treasury operations, in addition to oversight of
other business functions. From August 2005 to April 2006, Mr.&nbsp;Young served as Associate Director, Internal Controls Compliance at VaxGen, Inc., a biotechnology company. From February 1999 to August 2005, Mr.&nbsp;Young held management roles at
Cerus Corporation, a biotechnology company, including most recently Controller. From October 1994 to January 1999, Mr.&nbsp;Young was an auditor at Ernst&nbsp;&amp; Young LLP. Mr.&nbsp;Young received a B.A. in Business-Economics from the University
of California, Los Angeles and an M.B.A. from the University of California, Berkeley&#151;Haas School of Business, and is a Certified Public Accountant (inactive status). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Tad Thomas, Ph.D. </I></B>has served as our Senior Vice President and Head of Product Development and Manufacturing since April 2021. From March 2019 to April
2021, Dr. Thomas served as Associate Vice President, Technical Operations at Codexis, Inc., a biotechnology company, where he was responsible for overseeing preclinical development for biotherapeutic products and management of external contract
manufacturing partnerships. From July 2013 to March 2019, Dr. Thomas served as Director and Global Lead, Biologics Process Transfer and Launch at Bayer HealthCare LLC, a pharmaceutical and life sciences company, where he was responsible for leading
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
manufacturing site process transfers of clinical phase projects and leading the teams that drafted the Quality (CMC) sections of the successful marketing applications for Kovaltry and Jivi. Dr.
Thomas received a B.A. in Biochemistry from the University of California, Berkeley, a Ph.D. in Biochemistry &amp; Biophysics from the University of California, Davis, and completed a post-doctoral fellowship at the Harvard Medical School and Brigham
and Women&#146;s Hospital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Kurt von Emster, C.F.A. </I></B>has served on our board of directors since October 2020. Mr.&nbsp;von Emster currently serves as Managing Partner at Abingworth
LLP, a venture capital firm, where he has been employed as a Partner since January 2015. Mr.&nbsp;von Emster has served as a member of the board of directors of Tizona Therapeutics, Inc, a biotechnology company, since December 2020, Trishula
Therapeutics, Inc., an immunotherapy company, since December 2020, Orbus Therapeutics, Inc., a pharmaceutical company, since July 2020, SFJ Pharmaceuticals, Inc., a specialty pharmaceutical company, since April 2020, Jasper Therapeutics, Inc., a
biotechnology company, since November 2019, Vaxcyte Inc. (Vaxcyte), a biopharmaceutical vaccine company, since July 2015, and CymaBay Therapeutics, Inc., a biotechnology company, since April 2009. Mr.&nbsp;von Emster previously served on the board
of directors of the following companies: CRISPR Therapeutics, Inc. from March 2015 to June 2019, Kesios Therapeutics Ltd. from November 2015 to January 2017, Cytos Biotechnology AG from November 2012 to January 2016 (merged and renamed Kuros
Biosciences AG in January 2016), Aurinia Pharmaceuticals Inc. from February 2014 to March 2015, Facet Biotech Corporation (acquired by Abbott Laboratories in April 2010) from February 2009 to April 2010, and Somaxon Pharmaceuticals, Inc. (acquired
by Pernix Therapeutics Holdings, Inc. in March 2013) from August 2005 to March 2013. In addition, Mr.&nbsp;von Emster <FONT STYLE="white-space:nowrap">co-founded</FONT> venBio LLC, a health-care focused investment firm, in 2009, and served as
Partner until 2014. Prior to that, Mr.&nbsp;von Emster was General Partner at MPM Capital, Inc., a biotechnology private equity firm, from 2000 to 2009. Mr.&nbsp;von Emster was also a Biotechnology and Healthcare Analyst and Portfolio Manager at
Franklin Templeton Group from 1989 to 2000. Mr.&nbsp;von Emster received a B.S. in Business and Economics from the University of California, Santa Barbara and is a Chartered Financial Analyst (C.F.A.). We believe Mr.&nbsp;von Emster&#146;s
experience in the biotechnology industry, as well as his experience as a member on the boards of directors of multiple companies in the industry, qualifies him to serve on our board of directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Andrew Cheng, M.D., Ph.D. </I></B>has served as a member of our board of directors since May 2017. Dr.&nbsp;Cheng has served as the President and Chief Executive
Officer, as well as a director, of Akero Therapeutics, Inc., a biotechnology company, since September 2018. In August 2019, Dr.&nbsp;Cheng joined Arbutus Biopharma Corporation, a biopharmaceutical company, as a
<FONT STYLE="white-space:nowrap">non-executive</FONT> director and continues in that role. Before joining Akero, Dr.&nbsp;Cheng was at Gilead, a biotechnology company, as Chief Medical Officer from March 2018 to September 2018, Executive Vice
President from February 2015 to September 2018, and Senior Vice President from February 2009 to February 2015. From April 2018 to November 2018, Dr.&nbsp;Cheng served on the board of directors of Syntimmune, Inc., a biotechnology company, which was
acquired by Alexion Pharmaceuticals Inc. Dr.&nbsp;Cheng holds a B.A. in biology from the Johns Hopkins University and an M.D. and Ph.D. in cellular and molecular biology from Columbia University College of Physicians and Surgeons. He completed his
internal medicine residency at UCLA and was board certified in internal medicine. We believe Dr.&nbsp;Cheng is qualified to serve as a member of our board of directors due to his extensive experience in clinical development across multiple
therapeutic areas. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Beth Seidenberg, M.D. </I></B>has served as a member of our board of directors since June 2016. Dr.&nbsp;Seidenberg is a founding Managing
Director of Westlake Village BioPartners, a venture capital firm, a position she has held since September 2018. Dr.&nbsp;Seidenberg has been a Partner at Kleiner Perkins, a venture capital firm, since May 2005, where she primarily focuses on life
sciences investing. Prior to joining Kleiner Perkins, Dr.&nbsp;Seidenberg was the Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen, a biotechnology company. In addition, Dr.&nbsp;Seidenberg was a senior executive
in research and development at Bristol Myers Squibb Company, a biopharmaceutical company, and Merck&nbsp;&amp; Co., Inc. Dr.&nbsp;Seidenberg has served on the board of directors of Atara Biotherapeutics, Inc. since August 2012. Dr.&nbsp;Seidenberg
has served on the board of directors of Progyny, Inc. since May 2010. From February 2008 until September 2019 she served on the board of directors of Epizyme, Inc., from June 2011 to February 2019 she served on the board of directors of Tesaro,
Inc., and from December 2012 to June 2018 she served on the board of directors of ARMO BioSciences, Inc. Dr.&nbsp;Seidenberg received a B.S. from Barnard College and an M.D. from the University of Miami School of Medicine and completed her
post-graduate training at the Johns Hopkins University, George Washington University and the National Institutes of Health. We believe that Dr.&nbsp;Seidenberg is qualified to serve on our board of directors because of her extensive experience in
the life sciences industry as a senior executive and venture capitalist, as well as her training as a physician. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Maha Katabi, Ph.D. </I></B>has served as a member of our board of directors since October 2020. Dr. Katabi is a
General Partner at Sofinnova Investments, a venture capital firm, since March 2020. She joined Sofinnova as a Partner in April 2019. Prior to joining Sofinnova, Dr. Katabi was a founding Managing Partner at Oxalis Capital, a venture capital firm,
from August 2018 until April 2019. From September 2008 until January 2018, Dr. Katabi was a Partner, Private Equity at Sectoral Asset Management, an investment advisor exclusively focused on the global healthcare sector. She was the portfolio
manager of a family of funds investing in small cap and private biotech companies She held these positions since July 2012, and joined Sectoral in 2008 as Investment Manager. Prior to joining Sectoral in 2008, Dr. Katabi was a Vice President at
Ventures West from 2004to 2008, where she focused on early-stage venture investments in the life sciences industry. She started her venture capital career in 1999 with T2C2 Capital Bio, a seed fund focused on university start-ups. Dr. Katabi has
served as a member of the board of directors of several private companies, and currently serves as a director of Aerovate Therapeutics, Inc., Amplyx Pharmaceuticals, Inc., Gyroscope Therapeutics Limited, Northsea Therapeutics B.V., Quanta
Therapeutics, Inc., and Sofinnova Investments, Inc. She received a Ph.D. in Pharmacology in 1999 at McGill University and her CFA charter in 2011. We believe that Dr. Katabi is qualified to serve on our board of directors due to her experience as a
biopharmaceutical and biotechnology public and private company investor. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Patrick Enright </I></B>has served on our board of directors since October 2020.
Since July 2007, Mr.&nbsp;Enright has served as a Managing Director of Longitude Capital, a venture capital firm, of which he is a founder. From 2002 through 2006, Mr.&nbsp;Enright was a Managing Director of Pequot Ventures, a venture capital
investment firm, where he <FONT STYLE="white-space:nowrap">co-led</FONT> the life sciences investment practice. Mr.&nbsp;Enright currently serves on the boards of Aptinyx Inc. (APTX), Jazz Pharmaceuticals plc (JAZZ) and other private companies as
well as the National Venture Capital Association (NVCA). Selected prior board memberships include Aimmune Therapeutics, Inc. (AIMT, acquired by Nestl&eacute;), Esperion Therapeutics, Inc. (ESPR) and Vaxcyte (PCVX). Mr.&nbsp;Enright received a B.S.
in Biological Sciences from Stanford University and an M.B.A. from the Wharton School of the University of Pennsylvania. We believe that Mr.&nbsp;Enright is qualified to serve on our board of directors due to his experience serving on the board of
directors of clinical-stage biotechnology companies and his investment experience in the life sciences industry. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Scott Morrison </I></B>has served on our
board of directors since April 2020. From 1996 to December 2015, Mr.&nbsp;Morrison was a partner with Ernst&nbsp;&amp; Young LLP, a public accounting firm, where he also served as U.S. Life Sciences Leader from 2002 to December 2015.
Mr.&nbsp;Morrison has served on the board of directors of Corvus Pharmaceuticals Inc., a biopharmaceutical company, since December 2015, IDEAYA Biosciences, Inc., a biotechnology company, since July 2018, Audentes Therapeutics, Inc., a biotechnology
company, from December 2015 through its sale to Astellas Pharma Inc. on January&nbsp;15, 2021, Global Blood Therapeutics, Inc., a biopharmaceutical company, since December 2015, and Escape Bio, Inc., a biotechnology company, since October 2020.
Mr.&nbsp;Morrison has also held roles on the boards of directors of numerous other life sciences industry organizations. Mr.&nbsp;Morrison has previously served on the boards of directors of the Life Sciences Foundation, the California Life Sciences
Association, the Biotech Institute and the Emerging Companies Section of the Biotechnology Innovation Organization. He holds a B.S. in Business Administration from the University of California, Berkeley and is a certified public accountant
(inactive). Our board of directors believes that Mr.&nbsp;Morrison&#146;s 40 years of experience serving life sciences companies and in public accounting as well as many years of governance experience qualifies him to serve on our board of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Family Relationships </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are no family relationships
among any of our executive officers or directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Composition of Our Board of Directors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business and affairs are organized under the direction of our board of directors, which currently consists of seven members with no vacancies. The primary
responsibilities of our board of directors are to provide oversight, strategic guidance, counseling and direction to our management. Our board of directors meets on a regular basis and additionally as required. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain members of our board of directors were elected under the provisions of our Amended and Restated Voting Agreement entered into in October 2020 (Voting
Agreement), which will terminate upon the closing of this offering. Under the terms of our Voting Agreement, the stockholders who are party to the Voting Agreement have agreed to vote their respective shares to elect: (i)&nbsp;one director
designated by Abingworth Bioventures 8 LP, currently Mr. von </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Emster; (ii)&nbsp;one director designated by Sofinnova Venture Partners X, L.P., currently Dr. Katabi, Ph.D.; (iii)&nbsp;one director designated by Longitude Venture Partners IV, L.P., currently
Mr. Enright; (iv)&nbsp;one director designated by the holders of our Class A common stock, who shall be our then-current Chief Executive Officer, currently Dr.&nbsp;Fordyce,&nbsp;M.D.; and (v)&nbsp;three directors designated by a majority of the
other members of the board of directors, currently Dr.&nbsp;Cheng, M.D., Ph.D., Dr. Seidenberg, M.D. and Mr. Morrison. The Voting Agreement will terminate upon the closing of this offering, and upon the closing of the offering no stockholder will
have any special rights regarding the election or designation of the members of our board of directors. Our current directors elected to our board of directors pursuant to the Voting Agreement will continue to serve as directors until their
successors are duly elected and qualified by holders of our Class A common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors may establish the authorized number of directors from time
to time by resolution. In accordance with our amended and restated certificate of incorporation to be filed in connection with this offering, immediately after this offering, our board of directors will be divided into three classes with staggered
three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors will
be divided among the three classes as follows: </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Class&nbsp;I directors will be Dr. Fordyce, M.D. and Dr. Seidenberg, M.D., and their terms will expire at the annual
meeting of stockholders to be held in 2022; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Class&nbsp;II directors will be Mr. von Emster, Dr. Katabi Ph.D., and Mr. Enright, and their terms will expire at the
annual meeting of stockholders to be held in 2023; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Class&nbsp;III directors will be Dr. Cheng M.D., Ph.D. and Mr. Morrison, and their terms will expire at the annual
meeting of stockholders to be held in 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect that any additional directorships resulting from an increase in the number of directors
will be distributed among the three classes so that, as nearly as possible, each class will consist of one third of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a
change of our management or a change in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director Independence </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the listing requirements and rules of The Nasdaq Stock Market LLC (Nasdaq Listing Rules), independent directors must comprise a majority of our board of directors
as a listed company within one year of the listing date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors has undertaken a review of the independence of each director. Based on information
provided by each director concerning her or his background, employment and affiliations, including family relationships, our board of directors has determined that Dr. Cheng, M.D., Ph.D., Dr. Seidenberg, M.D., Mr. von Emster,
Dr.&nbsp;Katabi,&nbsp;Ph.D., Mr. Enright, and Mr. Morrison do not have relationships that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is
&#147;independent&#148; as that term is defined under the Nasdaq Listing Rules. Our board of directors has determined that Dr.&nbsp;Fordyce, by virtue of his position as our President and Chief Executive Officer, is not independent under applicable
rules and regulations of the U.S. Securities and Exchange Commission (SEC) and the Nasdaq Listing Rules. In making these determinations, our board of directors considered the current and prior relationships that each
<FONT STYLE="white-space:nowrap">non-employee</FONT> director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our shares by
each <FONT STYLE="white-space:nowrap">non-employee</FONT> director and the transactions described in the section titled &#147;Certain Relationships and Related Person Transactions.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Committees of Our Board of Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors has established
an audit committee, a compensation committee and a nominating and corporate governance committee. The composition and responsibilities of each of the committees of our board of directors are described below. Members serve on these committees until
their resignation or until otherwise determined by our board of directors. Each committee has adopted a written charter that satisfies the application rules and regulation of the SEC and the Nasdaq Listing Rules, which we will post to our website at
www.veratx.com upon the closing of this offering. Information contained on, or accessible through, our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is only an inactive textual reference. Our
board of directors may establish other committees as it deems necessary or appropriate from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audit committee currently consists of Mr.&nbsp;Morrison, Mr.&nbsp;von Emster and Dr.&nbsp;Seidenberg M.D., each of whom our board of directors has determined
satisfies the independence requirements under the Nasdaq Listing Rules and Rule <FONT STYLE="white-space:nowrap">10A-3(b)(1)</FONT> of the Securities Exchange Act of 1934, as amended (Exchange Act). With respect to Mr. von Emster specifically, our
board of directors has determined that he is independent even though he falls outside the &#147;safe harbor&#148; definition set forth in Rule 10A- 3(e)(1)(ii) under the Exchange Act. Mr. von Emster has not accepted directly or indirectly any
consulting, advisory or other compensatory fee from us, and while he is a Managing Partner of Abingworth LLP, he shares, but does not control, voting and investment power over the shares held by Abingworth Bioventures 8 LP, which is an affiliate of
Abingworth LLP and owns in excess of 10% of our outstanding common stock prior to this offering. As a result of this facts and circumstances analysis, our board of directors has determined in good faith that Mr. von Emster is not an &#147;affiliated
person&#148; of us who would fail to satisfy the applicable independence requirements for audit committee members. The chair of our audit committee is Mr.&nbsp;Morrison, who our board of directors has determined is an &#147;audit committee financial
expert&#148; within the meaning of SEC regulations. Each member of our audit committee can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, the board of directors
has examined each audit committee member&#146;s scope of experience and the nature of their employment in the corporate finance sector. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The primary purpose of the
audit committee is to discharge the responsibilities of our board of directors with respect to our corporate accounting and financial reporting processes, systems of internal control and financial-statement audits, and to oversee our independent
registered accounting firm. Specific responsibilities of our audit committee include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">helping our board of directors oversee our corporate accounting and financial reporting processes; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">managing the selection, engagement, qualifications, independence and performance of a qualified firm to serve as the
independent registered public accounting firm to audit our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with
management and the independent accountants, our interim and <FONT STYLE="white-space:nowrap">year-end</FONT> operating results; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">monitoring and assessing, and overseeing the reporting of, any material cybersecurity breaches and associated risks;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing related person transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">obtaining and reviewing a report by the independent registered public accounting firm at least annually, that describes
our internal quality control procedures, any material issues with such procedures, and any steps taken to deal with such issues when required by applicable law; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">approving, or, as permitted, <FONT STYLE="white-space:nowrap">pre-approving,</FONT> audit and permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the independent registered public accounting firm. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Compensation
Committee </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our compensation committee currently consists of Mr.&nbsp;Enright, Dr.&nbsp;Katabi, Ph.D., and Dr.&nbsp;Cheng, M.D., Ph.D. The chair of our
compensation committee is Mr.&nbsp;Enright. Our board of directors has determined that each member of the compensation committee is independent under the Nasdaq Listing Rules and as a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT>
director&#148; as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The primary purpose of our compensation
committee is to discharge the responsibilities of our board of directors in overseeing our compensation policies, plans and programs and to review and determine the compensation to be paid to our executive officers, directors and other senior
management, as appropriate. Specific responsibilities of our compensation committee include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving the compensation of our chief executive officer, other executive officers and senior management,
and overseeing the development and performance of our officers and our succession planning; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and recommending to our board of directors the compensation paid to our directors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing employee diversity and inclusion initiatives; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and approving the compensation arrangements with our executive officers and other senior management;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">administering our equity incentive plans and other benefit programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing, adopting, amending and terminating, incentive compensation and equity plans, severance agreements, profit
sharing plans, bonus plans and any other compensatory arrangements for our executive officers and other senior management; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing, evaluating and recommending to our board of directors succession plans for our executive officers; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">reviewing and establishing general policies relating to compensation and benefits of our employees. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Nominating and Corporate Governance Committee </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our nominating and
corporate governance committee consists of Mr. von Emster, Dr. Katabi, Ph.D., and Dr.&nbsp;Cheng,&nbsp;M.D., Ph.D. The chair of our nominating and corporate governance committee is Mr. von Emster. Our board of directors has determined that each
member of the nominating and corporate governance committee is independent under the Nasdaq Listing Rules, a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, and free from any relationship that would interfere with the exercise of his
or her independent judgment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Specific responsibilities of our nominating and corporate governance committee include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">identifying and evaluating candidates, including the nomination of incumbent directors for reelection and nominees
recommended by stockholders, to serve on our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">considering and making recommendations to our board of directors regarding the composition and chairmanship of the
committees of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">instituting plans or programs for the continuing education of our board of directors and orientation of new directors;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developing and making recommendations to our board of directors regarding corporate governance guidelines and matters; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">overseeing periodic evaluations of the board of directors&#146; performance, including committees of the board of
directors and management. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have adopted a written Code of Business Conduct and Ethics that applies to all our employees, officers and directors. This includes our principal executive officer,
principal financial officer and principal accounting officer or controller, or persons performing similar functions. The full text of our Code of Business Conduct and Ethics will be posted on our website at www.veratx.com. We intend to disclose on
our website any future amendments of our Code of Business Conduct and Ethics or waivers that exempt any principal executive officer, principal financial officer, principal accounting officer or controller, persons performing similar functions or our
directors from provisions in the Code of Business Conduct and Ethics. Information contained on, or accessible through, our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is only an inactive
textual reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">None of the members of the compensation committee is currently, or has been at any time, one of our executive officers or employees. None of our executive officers
currently serves, or has served during the last calendar year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation
committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth in summary form information concerning the compensation that we paid or awarded during the year ended December&nbsp;31, 2020 to each of
our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors who served on our board of directors during 2020: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FEES&nbsp;EARNED&nbsp;OR<BR>PAID IN CASH</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION&nbsp;AWARDS<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Beth Seidenberg, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Andrew Cheng, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Scott Morrison</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Brian Kotzin, M.D.<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kurt von Emster</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Maha Katabi, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Patrick Enright</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Joseph Walton<SUP STYLE="font-size:85%; vertical-align:top"> (4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Krishna Yeshwant, M.D.<SUP STYLE="font-size:85%; vertical-align:top"> (5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts disclosed represent the aggregate grant date fair value of the stock options granted to our named executive officers during fiscal year 2020 under our 2017 Equity Incentive Plan, as amended (2017 Plan),
computed in accordance with FASB ASC Topic 718. The assumptions used in calculating the grant date fair value of the stock options are set forth in Note 7 to our audited financial statements included elsewhere in this prospectus. This amount does
not reflect the actual economic value that may be realized by the named executive officer. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The aggregate number of shares underlying outstanding options to purchase our Class A common stock held by our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors was: Dr.&nbsp;Seidenberg, 69,043;
Dr.&nbsp;Cheng, 69,043, Mr.&nbsp;Morrison, 69,043; and Dr.&nbsp;Kotzin, 38,405. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">During fiscal year 2020, Dr.&nbsp;Kotzin received consulting fees equal to $95,100, unrelated to his service as a member of our board of directors. Dr.&nbsp;Kotzin resigned from our board of directors in October 2020.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Walton resigned from our board of directors in October 2020. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Yeshwant resigned from our board of directors in October 2020. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have reimbursed and will continue to
reimburse all of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in attending board of directors
and committee meetings. Marshall Fordyce, M.D., our Chief Executive Officer, was also a director as of December&nbsp;31, 2020, but did not receive any additional compensation for his service as a director. See the section titled &#147;Executive
Compensation&#148; for more information regarding the compensation earned by Dr.&nbsp;Fordyce. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the year ended December&nbsp;31, 2020, each of the following
individuals served on our board of directors as <FONT STYLE="white-space:nowrap">non-employee</FONT> directors: Kurt von Emster, Maha Katabi, Ph.D., Patrick Enright, Andrew Cheng, M.D., Ph.D., Beth Seidenberg, M.D., Scott Morrison, Joseph Walton,
Krishna Yeshwant, M.D. and Brian Kotzin, M.D. Other than as set forth above, none of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors earned any compensation in the year ended December&nbsp;31, 2020 or held any equity awards as of
December&nbsp;31, 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2020, we granted a stock option to Dr.&nbsp;Cheng covering 4,315 shares of our Class A common stock at an exercise price of
$2.32 per share, which vests monthly over three years following January&nbsp;10, 2020, subject to Dr.&nbsp;Cheng&#146;s continuous service to us. The vesting of this option will accelerate in full upon the closing of a change in control (as defined
in our 2017 Plan). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2020, we granted a stock option to Dr.&nbsp;Kotzin covering 3,452 shares of our Class A common stock at an exercise price of $6.37 per
share, which vests monthly over three years following April&nbsp;16, 2020, subject to Dr.&nbsp;Kotzin&#146;s continuous service to us. The vesting of this option will accelerate in full upon the closing of a change in control (as defined in our 2017
Plan). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2020, we also granted a stock option to Mr.&nbsp;Morrison covering 3,452 shares of our Class A common stock at an exercise price of $6.37 per
share, which vests monthly over three years following April&nbsp;16, 2020, subject to Mr.&nbsp;Morrison&#146;s continuous service to us. The vesting of this option will accelerate in full upon the closing of a change in control (as defined in our
2017 Plan). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2020, we granted a stock option to each of Dr.&nbsp;Seidenberg, Mr.&nbsp;Morrison, Dr.&nbsp;Cheng and
Dr.&nbsp;Kotzin covering 69,043, 69,043, 61,276 and 38,405 shares of our Class A common stock, respectively, at an exercise price of $2.90 per share, each vesting monthly over three years following December&nbsp;16, 2020, and each subject to such
individual&#146;s continuous service to us. The vesting of these options will accelerate in full upon the closing of a change in control (as defined in our 2017 Plan). The options issued to both Mr.&nbsp;Morrison and Dr.&nbsp;Kotzin were conditioned
on the cancellation of an option covering 3,452 shares held by such individual, granted in April 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors adopted a <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation policy in May 2021 that will become effective in connection with this offering and will be applicable to all of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors.
This compensation policy provides that each such <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive the following compensation for service on our board of directors: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an annual cash retainer of $35,000; and an additional annual cash retainer of $30,000 for services as non-executive
chairperson of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an additional annual cash retainer of $7,500, $5,000 and $4,000 for service as a member of the audit committee,
compensation committee and the nominating and corporate governance committee, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an additional annual cash retainer of $7,500, $5,000 and $4,000 for service as chair of the audit committee, compensation
committee and the nominating and corporate governance committee, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an initial option grant to purchase 19,850 shares of our Class A common stock on the date of each such <FONT
STYLE="white-space:nowrap">non-employee</FONT> director&#146;s appointment to our board of directors; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an annual option grant to purchase 9,925 shares of our Class A common stock on the date of each of our annual stockholder
meetings. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Consistent with our non-employee director compensation policy, we have granted to each of our non-employee directors an option to
purchase 9,925 shares of our Class A common stock under our 2021 Plan, which will become effective in connection with this offering, at an exercise price per share equal to the initial public offering price in this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each of the option grants described above will be granted under our 2021 Equity Incentive Plan (2021 Plan), the terms of which are described in more detail below under
the section titled &#147;Executive Compensation&#151;Equity Benefit Plans&#151;2021 Equity Incentive Plan.&#148; Each such option grant will vest and become exercisable subject to the director&#146;s continuous service to us through the earlier of
the first anniversary of the date of grant or the next annual stockholder meeting. The term of each option will be 10 years, subject to earlier termination as provided in the 2021 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_12"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our named executive officers for the year ended December&nbsp;31, 2020, consisting of our principal executive officer and the next two most highly compensated
executive officers, were: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Marshall Fordyce, M.D., our President, Chief Executive Officer and Director; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Joanne Curley, Ph.D., our Chief Development Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Jonathan Wolter, our Chief Financial Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Allen Ebens, Ph.D., our former Chief Scientific Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2020 Summary Compensation Table </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table presents all of the
compensation awarded to, earned by, or paid to our named executive officers during the fiscal year ended December&nbsp;31, 2020. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>NAME AND</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>PRINCIPAL</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>POSITION</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FISCAL<BR>YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SALARY<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCK</B><br><B>AWARDS</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>AWARDS</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">NON-EQUITY</FONT><BR>INCENTIVE<BR>PLAN&nbsp;
COMPENSATION<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ALL OTHER<BR>COMPENSATION<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.41em; text-indent:-1.41em; font-size:8.5pt; font-family:ARIAL">Marshall Fordyce, M.D.<BR><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,441,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,226,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.41em; text-indent:-1.41em; font-size:8.5pt; font-family:ARIAL">Joanne Curley, Ph.D.<BR><I>Chief Development
Officer</I><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">709,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.41em; text-indent:-1.41em; font-size:8.5pt; font-family:ARIAL">Jonathan Wolter<BR><I>Chief Financial
Officer</I>&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,300</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.41em; text-indent:-1.41em; font-size:8.5pt; font-family:ARIAL">Allen Ebens, Ph.D.<BR><I>Former Chief Scientific
Officer</I><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,333</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">397,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In October 2020, in connection with the closing of our Series C redeemable convertible preferred stock financing, 49,636 outstanding shares of our Class A common stock held by Dr.&nbsp;Fordyce were amended to be subject
to a 12 month vesting period. The amounts disclosed represent the value of such amendment, computed in accordance with FASB ASC Topic 718. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts disclosed represent the aggregate grant date fair value of the awards granted to our named executive officers during fiscal year 2020 under our 2017 Plan, computed in accordance with FASB ASC Topic 718. The
assumptions used in calculating the grant date fair value of the stock options are set forth in Note 7 to our audited financial statements included elsewhere in this prospectus. This amount does not reflect the actual economic value that may be
realized by the named executive officer. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts disclosed represent performance bonuses earned in 2020, but paid in the beginning of 2021. Dr.&nbsp;Curley&#146;s bonus was <FONT STYLE="white-space:nowrap">pro-rated</FONT> to reflect her partial year of
service. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Curley has served as our Chief Development Officer since March 2020. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Wolter has served as our Chief Financial Officer since March 2020, whereby we contracted with FLG Partners, LLC for his services. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts disclosed represent consulting fees paid by the Company in consideration for Mr.&nbsp;Wolter&#146;s services as our Chief Financial Officer. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Ebens&#146; employment was terminated as our Chief Scientific Officer effective October 2020 following a shift in our operations from preclinical to clinical development. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">This amount represents severance payable to Dr.&nbsp;Ebens. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Narrative to the Summary Compensation Table </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors reviews compensation annually for all employees, including our named executive officers. In making compensation determinations, we consider
compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and objectives, our desire to motivate our employees to achieve short- and long-term
results that are in the best interests of our stockholders and a long-term commitment to our company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors has historically determined our named
executive officers&#146; compensation and has typically reviewed and discussed management&#146;s proposed compensation with our chief executive officer for all executives other than our chief executive officer. Based on those discussions and its
discretion, our board of directors then </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
approved the compensation of each named executive officer. Upon the closing of this offering, the compensation committee will determine our executive officers&#146; compensation and follow this
process, but generally the compensation committee itself, rather than our board of directors, will approve the compensation of each named executive officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Annual Base Salary </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Base salaries for our named executive officers are
initially established through <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations at the time of the named executive officer&#146;s hiring, taking into account such named executive officer&#146;s qualifications, experience, the
scope of his or her responsibilities and competitive market compensation paid by other companies for similar positions within the industry and geography. Base salaries are reviewed periodically, typically in connection with our annual performance
review process, and adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance and experience. In making decisions regarding salary increases, we may also draw upon the
experience of members of our board of directors with executives at other companies. The 2020 annual base salaries for our named executive officers are set forth in the table below, except for Mr.&nbsp;Wolter. We pay FLG Partners a rate of $400 per
hour for Mr.&nbsp;Wolter&#146;s services as our Chief Financial Officer, to a maximum of $25,000 per month. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020 BASE<BR>SALARY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Marshall Fordyce, M.D. <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Joanne Curley, Ph.D. <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Allen Ebens, Ph.D. <SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">320,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Fordyce&#146;s base salary increased from $300,000 to $400,000 in December 2020. Dr. Fordyce&#146;s base salary will increase to $525,000 once the registration statement of which this prospectus forms a part is
declared effective. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Curley began her employment with us in March 2020 with an annualized base salary of $375,000, which was decreased to $350,000 in September 2020. Dr. Curley&#146;s base salary will increase to $385,000 once the
registration statement of which this prospectus forms a part is declared effective. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Ebens&#146; employment was terminated as our Chief Scientific Officer effective October 2020 following a shift in our operations from preclinical to clinical development. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Outstanding Equity Awards as of December&nbsp;31, 2020 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table
presents the outstanding equity incentive plan awards held by each named executive officer as of December&nbsp;31, 2020. Mr.&nbsp;Wolter and Dr.&nbsp;Ebens did not have any outstanding equity incentive plan awards as of December&nbsp;31, 2020. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION AWARDS<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>GRANT<BR>DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SECURITIES<BR>UNDERLYING<BR>UNEXERCISED<BR>OPTIONS<BR>EXERCISABLE<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SECURITIES<BR>UNDERLYING<BR>UNEXERCISED<BR>OPTIONS<BR>UNEXERCISABLE<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>EXERCISE<BR>PRICE&nbsp;PER<BR>SHARE<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>EXPIRATION<BR>DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Marshall Fordyce, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">01-16-2020</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">2.32<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">01-15-2030</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">12-16-2020</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,107,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">2.90<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">12-15-2030</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">12-16-2020</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">2.90<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">12-15-2030</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Joanne Curley, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">04-01-2020</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">03-31-2030</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">12-16-2020</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,022 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">12-15-2030</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">12-16-2020</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">12-15-2030</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All of the option and stock awards were granted under the 2017 Plan, the terms of which plan is described below under &#147;&#151;Equity Benefit Plans&#151;2017 Equity Incentive Plan.&#148; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All of the option awards were granted with a per share exercise price equal to the fair market value of one share of our Class A common stock on the date of grant, as determined in good faith by our board of directors
or compensation committee. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">One-third</FONT> of the shares subject to the option award vest on January&nbsp;10, 2021, and thereafter <FONT STYLE="white-space:nowrap">one-thirty-sixth</FONT> of the shares subject to
the option award vest on each monthly anniversary, subject to continuous service to us. Dr. Fordyce exercised this option with respect to 3,607 shares of Class A common stock in April 2021. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the shares subject to the option award vest on December&nbsp;16, 2021, and thereafter <FONT STYLE="white-space:nowrap">one-forty-eighth</FONT> of the shares subject
to the option award vest on each monthly anniversary, subject to continuous service to us. This option was conditioned on the cancellation of an option covering 12,945 shares granted to Dr.&nbsp;Fordyce on March&nbsp;26, 2019 and an option covering
17,260 shares granted to Dr.&nbsp;Fordyce on February&nbsp;7, 2018. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the shares subject to the option award vest on December&nbsp;16, 2021, and thereafter <FONT STYLE="white-space:nowrap">one-forty-eighth</FONT> of the shares subject
to the option award vest on each monthly anniversary, subject to continuous service to us. The option award includes an early exercise feature. Dr.&nbsp;Fordyce exercised this option in full in February 2021. This option was conditioned on the
cancellation of an option covering 12,945 shares granted to Dr.&nbsp;Fordyce on March&nbsp;26, 2019 and an option covering 17,260 shares granted to Dr.&nbsp;Fordyce on February&nbsp;7, 2018. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the shares subject to the option award vest on March&nbsp;12, 2021, and thereafter <FONT STYLE="white-space:nowrap">one-forty-eighth</FONT> of the shares subject to
the option award vest on each monthly anniversary, subject to continuous service to us. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the shares subject to the option award vest on December&nbsp;16, 2021, and thereafter <FONT STYLE="white-space:nowrap">one-forty-eighth</FONT> of the shares subject
to the option award vest on each monthly anniversary, subject to continuous service to us. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the shares subject to the option award vest on December&nbsp;16, 2021, and thereafter <FONT STYLE="white-space:nowrap">one-forty-eighth</FONT> of the shares subject
to the option award vest on each monthly anniversary, subject to continuous service to us. The option award includes an early exercise feature. Dr.&nbsp;Curley exercised this option in full in February 2021. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Options held by certain of our named executive officers are eligible for accelerated vesting under specified circumstances. Please see the subsection titled
&#147;&#151;Employment Agreements&#148; below for a description of such potential acceleration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Emerging Growth Company Status </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act. As an emerging growth company we will be exempt from certain requirements related to
executive compensation, including the requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our chief executive officer to the median of the annual total
compensation of all of our employees, each as required by the Investor Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Wall Street Reform and Consumer Protection Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Pension Benefits </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our named executive officers did not participate in, or
otherwise receive any benefits under, any pension or retirement plan sponsored by us during the fiscal year ended December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Nonqualified Deferred
Compensation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our named executive officers did not participate in, or earn any benefits under, a <FONT STYLE="white-space:nowrap">non-qualified</FONT> deferred
compensation plan sponsored by us during the fiscal year ended December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employment, Severance and Change in Control Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Offer Letters </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Below are descriptions of our offer letters with our
named executive officers. For a discussion of the severance pay and other benefits to be provided in connection with a termination of employment and/or a change in control under the arrangements with our named executive officers, please see the
section titled &#147;&#151;Potential Payments and Benefits Upon Termination or Change in Control&#148; below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dr.</I><I></I><I>&nbsp;Fordyce.</I> In December
2020, we and Dr.&nbsp;Fordyce entered into an offer letter that governs the current terms of Dr.&nbsp;Fordyce&#146;s employment with us. Pursuant to the agreement, Dr.&nbsp;Fordyce is entitled to an initial annual base salary of $400,000, is
eligible to receive an annual performance bonus with a target achievement of 40% of his base salary, as determined by our board of directors, and was granted an option exercisable for 1,141,733 shares of our Class A common stock (in addition to
shares of our stock that Dr.&nbsp;Fordyce held at the time we entered into his offer letter). In May 2021, we and Dr. Fordyce entered into an amended and restated offer letter, to be effective once the registration statement of which this prospectus
forms a part is declared effective, pursuant to which Dr. Fordyce&#146;s annual base salary will increase to $525,000 and his annual performance bonus target achievement will increase to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
50% of his base salary, as determined by our board of directors. In addition, Dr. Fordyce will be entitled to a stock option covering 110,038 shares of our Class A common stock, at a price per
share equal to the initial public offering price, which will vest as follows: one-fourth of the shares subject to the option vest on the effective date of the registration statement of which this prospectus forms a part, and thereafter
one-forty-eighth of the shares subject to the option award vest on each monthly anniversary, subject to continuous service to us. Dr.&nbsp;Fordyce is also entitled to certain severance benefits, the terms of which are described below under the
section titled &#147;&#151;Potential Payments and Benefits Upon Termination or Change of Control.&#148; Dr.&nbsp;Fordyce&#146;s employment is at will. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dr.</I><I></I><I>&nbsp;Curley.</I> In February 2020, we and Dr.&nbsp;Curley entered into an offer letter, which was amended in September 2020, and that governs the
current terms of Dr.&nbsp;Curley&#146;s employment with us. Pursuant to the agreement, Dr.&nbsp;Curley is entitled to an annual base salary of $375,000 (which was decreased to $350,000 in September 2020), is eligible to receive an annual performance
bonus with a target achievement of 30% of her base salary, as determined by our board of directors, and was granted an option exercisable for 25,891 shares of our Class A common stock. In May 2021, we and Dr. Curley entered into an amended and
restated offer letter, to be effective once the registration statement of which this prospectus forms a part is declared effective, pursuant to which Dr. Curley&#146;s annual base salary will increase to $385,000 and her annual performance bonus
target achievement will increase to 40% of her base salary, as determined by our board of directors. In addition, Dr. Curley will be entitled to a stock option covering 108,217 shares of our Class A common stock, at a price per share equal to the
initial public offering price, which will vest as follows: one-fourth of the shares subject to the option vest on the effective date of the registration statement of which this prospectus forms a part, and thereafter one-forty-eighth of the shares
subject to the option award vest on each monthly anniversary, subject to continuous service to us. Dr.&nbsp;Curley is also entitled to certain severance benefits, the terms of which are described below under the section titled &#147;&#151;Potential
Payments and Benefits Upon Termination or Change of Control.&#148; Dr.&nbsp;Curley&#146;s employment is at will. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Mr.</I><I></I><I>&nbsp;Wolter. </I>In March
2020, we entered into a consulting agreement with FLG Partners, LLC setting forth the terms and conditions of Mr.&nbsp;Wolter&#146;s service to the Company as our Chief Financial Officer. Pursuant to the consulting agreement, Mr.&nbsp;Wolter
receives $400 per hour for his services up to $25,000 a month and no additional compensation. The term of the agreement is indefinite and either party may terminate upon thirty (30)&nbsp;days advance written notice. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dr.</I><I></I><I>&nbsp;Ebens.</I> In July&nbsp;26, 2018, we and Dr.&nbsp;Ebens entered into an offer letter that governed the terms of Dr.&nbsp;Ebens&#146;
employment with us. Pursuant to the agreement, Dr.&nbsp;Ebens was entitled to an annual base salary of $320,000, was eligible to receive an annual performance bonus with a target achievement of 25% of his base salary, as determined by our board of
directors, and was granted an option exercisable for 32,364 shares of our Class A common stock. Dr.&nbsp;Ebens was also entitled to certain severance benefits, and his employment was at will. Dr.&nbsp;Ebens&#146; employment was terminated as our
Chief Scientific Officer effective October 2020 following a shift in our operations from preclinical to clinical development. In August 2020, we entered into a transition and separation agreement with Dr.&nbsp;Ebens. Pursuant to the agreement, we
made a lump cash severance payment equal to five months of his base salary and the payment of COBRA premiums through a date no later than February&nbsp;28, 2021. Dr.&nbsp;Ebens ceased vesting in his outstanding equity awards as of the date of his
separation and did not receive any vesting acceleration in connection with his termination. The receipt of severance benefits was conditioned upon the execution of a release of claims in our favor and subject to his compliance with his obligations
under the agreement, including those relating to confidentiality, <FONT STYLE="white-space:nowrap">non-disparagement,</FONT> and return of company property. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Potential Payments and Benefits Upon Termination or Change of Control </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dr.</I><I></I><I>&nbsp;Fordyce.</I> Pursuant to Dr.&nbsp;Fordyce&#146;s amended and restated offer letter effective once the registration statement of which this
prospectus forms a part is declared effective, if (a)&nbsp;his employment is terminated without cause (as defined below), and other than as a result of his death or disability, or (b)&nbsp;he resigns for good reason (as defined below), then in
addition to any amounts accrued and payable under the terms of our benefit plans through the date of termination, Dr.&nbsp;Fordyce will be entitled to receive severance in the form of 12 months of his then base salary, such amount to be paid in
equal installments over a <FONT STYLE="white-space:nowrap">12-month</FONT> period after the date of termination, subject to applicable taxes and withholding, as well as up to 12 months of COBRA coverage. These severance benefits are conditioned upon
Dr.&nbsp;Fordyce continuing to comply with his obligations under his proprietary information agreement and his delivery of a general release of claims in favor of the company that becomes effective and irrevocable within 21 days of the date of
termination. Further, if within the three-month period immediately prior to or <FONT STYLE="white-space:nowrap">12-month</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
period that immediately follows a change of control (as defined below) Dr.&nbsp;Fordyce&#146;s employment is terminated without cause or for good reason, then (a) 100% of his then-unvested equity
grants shall accelerate and become fully vested as of the termination date, (b)&nbsp;the amount of his cash severance and COBRA severance described above shall be increased from 12 months to 18 months and (c)&nbsp;he shall receive additional cash
severance in an amount equal to his target annual bonus for the year of such termination, to be paid in a single lump sum within 10 business days after the effective date of his release. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dr. Curley.</I> Pursuant to Dr. Curley&#146;s amended and restated offer letter effective once the registration statement of which this prospectus forms a part is
declared effective, if (a) her employment is terminated without cause (as defined below), and other than as a result of her death or disability, or (b) she resigns for good reason (as defined below), then in addition to any amounts accrued and
payable under the terms of our benefit plans through the date of termination, Dr. Curley will be entitled to receive severance in the form of nine months of her then base salary, such amount to be paid in equal installments over a nine-month period
after the date of termination, subject to applicable taxes and withholding, as well as up to nine months of COBRA coverage. These severance benefits are conditioned upon Dr. Curley continuing to comply with her obligations under her proprietary
information agreement and her delivery of a general release of claims in favor of the company that becomes effective and irrevocable within 21 days of the date of termination. Further, if within the three-month period immediately prior to or
12-month period that immediately follows a change of control (as defined below) Dr. Curley&#146;s employment is terminated without cause or for good reason, then (a) 100% of her then-unvested equity grants shall accelerate and become fully vested as
of the termination date, (b) the amount of her cash severance and COBRA severance described above shall be increased from nine months to 12 months and (c) she shall receive additional cash severance in an amount equal to her target annual bonus for
the year of such termination, to be paid in a single lump sum within 10 business days after the effective date of her release. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the purposes of
Dr.&nbsp;Fordyce&#146;s and Dr. Curley&#146;s severance benefits, the following definitions apply: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;cause&#148; means (a)&nbsp;the officer&#146;s commission or conviction (including a guilty plea or plea of nolo
contendere) of any felony or any other crime involving fraud, dishonesty or moral turpitude; (b)&nbsp;officer&#146;s commission or attempted commission of or participation in a fraud or act of dishonesty or misrepresentation against us;
(c)&nbsp;willful and material breach of officer&#146;s duties to us; (d)&nbsp;willful damage to any of our property; (e)&nbsp;willful misconduct, or other willful violation of our policy that causes harm; or (f)&nbsp;officer&#146;s material
violation of any written and fully executed contract or agreement between us and the officer, including without limitation, material breach of agreements relating to <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> nondisclosure and/or
assignment of inventions, or material breach of any company policy, or of any statutory duty officer owes to us; provided, however, that in the event of subparagraph (f)&nbsp;above, we are required to provide written notice of such alleged violation
and breach, and officer will have 30 days from receipt of such notice to cure. For purposes of this definition of Cause, no act, or failure to act, on officer&#146;s part shall be considered &#147;willful&#148; unless it is done, or omitted to be
done, by officer intentionally and without reasonable belief that officer&#146;s action or omission was in the best interests of the company. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;change of control&#148; means (a)&nbsp;any consolidation or merger of the company with or into any other corporation
or other entity or person, or any other corporate reorganization, other than any such consolidation, merger or reorganization in which the stockholders of the company immediately prior to such consolidation, merger or reorganization, continue to
hold a majority of the voting power of the surviving entity (or, if the surviving entity is a wholly owned subsidiary, its parent) immediately after such consolidation, merger or reorganization; (b)&nbsp;any transaction or series of related
transactions to which the company is a party in which in excess of 50% of our voting power is transferred; provided that the foregoing shall not include any transaction or series of transactions principally for bona fide equity financing purposes in
which cash is received by us or our indebtedness is cancelled or converted or a combination thereof; or (c)&nbsp;a sale, lease, exclusive license or other disposition of all or substantially all of our assets. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;good reason&#148; means any of the following actions, if taken by us without officer&#146;s prior written consent:
(a)&nbsp;a material reduction in officer&#146;s base salary, which we and officer agree is a reduction of at least 10% of officer&#146;s base salary (unless pursuant to a salary reduction program applicable generally to our similarly situated
employees); (b) a material reduction in officer&#146;s duties (including responsibilities and/or authorities) (with respect to Dr. Fordyce, as our Chief Executive Officer), provided, however, that a change in job
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
position (including a change in title) shall not be deemed a &#147;material reduction&#148; in and of itself unless officer&#146;s new duties are materially reduced from the prior duties;
(c)&nbsp;relocation of officer&#146;s principal place of employment to a place that increases officer&#146;s <FONT STYLE="white-space:nowrap">one-way</FONT> commute by more than 50 miles as compared to officer&#146;s then-current principal place of
employment immediately prior to such relocation, provided that if officer works remotely during any period in which officer&#146;s regular principal place of business at a company office is closed, then neither officer&#146;s relocation to remote
work or back to the office from remote work will be considered a relocation from officer&#146;s principal place of employment for the purposes of this definition; or, with respect to Dr.&nbsp;Fordyce, (d)&nbsp;prior to a change of control, no longer
being a member of our board of directors or reporting to our board of directors as Chief Executive Officer. In order to resign for good reason, officer must provide written notice to our board of directors, or with respect to Dr. Curley, our Chief
Executive Officer, within 30 days after each occurrence of the event giving rise to good reason setting forth the basis for officer&#146;s resignation, allow us at least 30 days from receipt of such written notice to cure such event, and if such
event is not reasonably cured within such period, officer must resign from all positions officer then holds with the company not later than 30 days after the expiration of the cure period. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Compensation and Benefits </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our current named executive officers
are eligible to participate in our employee benefit plans, including our medical, dental and vision, in each case on the same basis as all of our other employees. We pay the premiums for the medical, disability, accidental death and dismemberment
insurance for all of our employees, including our named executive officers. We generally do not provide perquisites or personal benefits to our named executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Equity Benefit Plans </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that our ability to grant equity-based
awards is a valuable and necessary compensation tool that aligns the long-term financial interests of our employees, consultants and directors with the financial interests of our stockholders. In addition, we believe that our ability to grant
options and other equity-based awards helps us to attract, retain and motivate employees, consultants and directors, and encourages them to devote their best efforts to our business and financial success. The principal features of our equity
incentive plans and our 401(k) plan are summarized below. These summaries are qualified in their entirety by reference to the actual text of the plans, which, other than the 401(k) plan, are filed as exhibits to the registration statement of which
this prospectus is a part. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2021 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board
of directors has adopted, and our stockholders have approved, our 2021 Plan. We expect our 2021 Plan will become effective on the date of the underwriting agreement related to this offering. Once our 2021 Plan becomes effective, no further grants
will be made under our 2017 Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Awards</I>. Our 2021 Plan will provide for the grant of incentive stock options (ISOs) within the meaning of Section&nbsp;422
of the Internal Revenue Code of 1986, as amended (Code), to our employees and our parent and subsidiary corporations&#146; employees, and for the grant of nonstatutory stock options (NSOs), stock appreciation rights, restricted stock awards,
restricted stock unit awards, performance awards and other forms of awards to our employees, directors and consultants and any of our affiliates&#146; employees and consultants. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Authorized Shares</I>. Initially, the maximum number of shares of our Class A common stock that may be issued under our 2021 Plan after it becomes effective will not
exceed 4,405,336 shares of our Class A common stock, which is the sum of (i) 2,212,335 new shares, plus (ii)&nbsp;an additional number of shares up to a maximum of 2,193,001 shares, which number consists of shares of our Class A common stock subject
to outstanding stock options or other stock awards granted under our 2017 Plan that, on or after our 2021 Plan becomes effective, terminate or expire prior to exercise or settlement; are not issued because the award is settled in cash; are forfeited
because of the failure to vest; or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares of our Class A common stock reserved for issuance under our
2021 Plan will automatically increase on&nbsp;January 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of each year for a period of 10 years, beginning on January&nbsp;1, 2022 and continuing through January&nbsp;1, 2031, in an amount equal
to (1) 5% of the total number of shares of our Class A common stock outstanding on&nbsp;December 31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of the immediately preceding year, or (2)&nbsp;a lesser number of shares
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
determined by our board of directors no later than the date of any such increase. The maximum number of shares of our Class A common stock that may be issued on the exercise of ISOs under our
2021 Plan will be 13,216,008 shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shares subject to stock awards granted under our 2021 Plan that expire or terminate without being exercised in full or that
are paid out in cash rather than in shares will not reduce the number of shares available for issuance under our 2021 Plan. Shares withheld under a stock award to satisfy the exercise, strike or purchase price of a stock award or to satisfy a tax
withholding obligation will not reduce the number of shares available for issuance under our 2021 Plan. If any shares of our Class A common stock issued pursuant to a stock award are forfeited back to or repurchased or reacquired by us
(i)&nbsp;because of a failure to meet a contingency or condition required for the vesting of such shares; (ii)&nbsp;to satisfy the exercise, strike or purchase price of a stock award; or (iii)&nbsp;to satisfy a tax withholding obligation in
connection with a stock award, the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under our 2021 Plan. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan Administration</I>. Our board of directors, or a duly authorized committee of our board of directors, will administer our 2021 Plan. Our board of directors may
delegate to one or more of our officers the authority to (i)&nbsp;designate employees (other than officers) to receive specified stock awards; and (ii)&nbsp;determine the number of shares subject to such stock awards. Under our 2021 Plan, our board
of directors will have the authority to determine stock award recipients, the types of stock awards to be granted, grant dates, the number of shares subject to each stock award, the fair market value of our Class A common stock, and the provisions
of each stock award, including the period of exercisability and the vesting schedule applicable to a stock award. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under our 2021 Plan, our board of directors also
generally will have the authority to effect, with the consent of any materially adversely affected participant, (i)&nbsp;the reduction of the exercise, purchase, or strike price of any outstanding option or stock appreciation right; (ii)&nbsp;the
cancellation of any outstanding option or stock appreciation right and the grant in substitution therefore of other awards, cash, or other consideration; or (iii)&nbsp;any other action that is treated as a repricing under generally accepted
accounting principles. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock Options</I>. ISOs and NSOs are granted under stock option agreements adopted by the administrator. The administrator will determine
the exercise price for stock options, within the terms and conditions of our 2021 Plan, except the exercise price of a stock option generally will not be less than 100% of the fair market value of our Class&nbsp;A common stock on the date of grant.
Options granted under our 2021 Plan will vest at the rate specified in the stock option agreement as will be determined by the administrator. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The administrator
will determine the term of stock options granted under our 2021 Plan, up to a maximum of 10 years. Unless the terms of an optionholder&#146;s stock option agreement, or other written agreement between us and the recipient, provide otherwise, if an
optionholder&#146;s service relationship with us or any of our affiliates ceases for any reason other than disability, death, or cause, the optionholder may generally exercise any vested options for a period of three months following the cessation
of service. This period may be extended in the event that exercise of the option is prohibited by applicable securities laws. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to death, or an optionholder
dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 18 months following the date of death. If an optionholder&#146;s service relationship with us or
any of our affiliates ceases due to disability, the optionholder may generally exercise any vested options for a period of 12 months following the cessation of service. In the event of a termination for cause, options generally terminate upon the
termination date. In no event may an option be exercised beyond the expiration of its term. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Acceptable consideration for the purchase of Class A common stock
issued upon the exercise of a stock option will be determined by the administrator and may include (i)&nbsp;cash, check, bank draft or money order; (ii)&nbsp;a broker-assisted cashless exercise; (iii)&nbsp;the tender of shares of our Class A common
stock previously owned by the optionholder; (iv)&nbsp;a net exercise of the option if it is an NSO; or (v)&nbsp;other legal consideration approved by the administrator. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless the administrator provides otherwise, options or stock appreciation rights generally are not transferable except by will or the laws of descent and distribution.
Subject to approval of the administrator or a duly authorized officer, an option may be transferred pursuant to a domestic relations order, official marital settlement agreement, or other divorce or separation instrument. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Tax Limitations on ISOs</I>. The aggregate fair market value, determined at the time of grant, of our Class A
common stock with respect to ISOs that are exercisable for the first time by an award holder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated
as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our parent or subsidiary corporations unless (i)&nbsp;the option
exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant; and (ii)&nbsp;the term of the ISO does not exceed five years from the date of grant. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted Stock Unit Awards</I>. Restricted stock unit awards are granted under restricted stock unit award agreements adopted by the administrator. Restricted
stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock, a
combination of cash and stock as deemed appropriate by the administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered
by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, or other written agreement between us and the recipient, restricted stock unit awards that have not vested will be forfeited once the
participant&#146;s continuous service ends for any reason. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted Stock Awards</I>. Restricted stock awards are granted under restricted stock award
agreements adopted by the administrator. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past or future services to us, or any other form of legal consideration that may be acceptable to our board
of directors and permissible under applicable law. The administrator will determine the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a participant&#146;s service relationship with us ends for any
reason, we may receive any or all of the shares of Class A common stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock Appreciation Rights</I>. Stock appreciation rights are granted under stock appreciation right agreements adopted by the administrator. The administrator will
determine the purchase price or strike price for a stock appreciation right, which generally will not be less than 100% of the fair market value of our Class A common stock on the date of grant. A stock appreciation right granted under our 2021 Plan
will vest at the rate specified in the stock appreciation right agreement as will be determined by the administrator. Stock appreciation rights may be settled in cash or shares of our Class A common stock or in any other form of payment as
determined by our board of directors and specified in the stock appreciation right agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The administrator will determine the term of stock appreciation
rights granted under our 2021 Plan, up to a maximum of 10 years. If a participant&#146;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death, the participant may generally exercise any
vested stock appreciation right for a period of three months following the cessation of service. This period may be further extended in the event that exercise of the stock appreciation right following such a termination of service is prohibited by
applicable securities laws. If a participant&#146;s service relationship with us, or any of our affiliates, ceases due to disability or death, or a participant dies within a certain period following cessation of service, the participant or a
beneficiary may generally exercise any vested stock appreciation right for a period of 12 months in the event of disability and 18 months in the event of death. In the event of a termination for cause, stock appreciation rights generally terminate
upon the termination date. In no event may a stock appreciation right be exercised beyond the expiration of its term. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Performance Awards</I>. Our 2021 Plan will
permit the grant of performance awards that may be settled in stock, cash or other property. Performance awards may be structured so that the stock or cash will be issued or paid only following the achievement of certain <FONT
STYLE="white-space:nowrap">pre-established</FONT> performance goals during a designated performance period. Performance awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise
based on, our Class A common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The performance goals may be based on any measure of performance selected by our board of directors. The performance goals may
be based on company-wide performance or performance of one or more business units, divisions, affiliates, or business segments, and may be either absolute or relative to the performance of one or more comparable companies or the performance of one
or more relevant indices. Unless specified otherwise by our board </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
of directors at the time the performance award is granted, our board will appropriately make adjustments in the method of calculating the attainment of performance goals as follows: (i)&nbsp;to
exclude restructuring or other nonrecurring charges; (ii)&nbsp;to exclude exchange rate effects; (iii)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (iv)&nbsp;to exclude the effects of any statutory adjustments
to corporate tax rates; (v)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting principles; (vi)&nbsp;to exclude the dilutive effects of
acquisitions or joint ventures; (vii)&nbsp;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (viii)&nbsp;to exclude the effect of any
change in the outstanding shares of our Class A common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or
exchange of shares or other similar corporate change, or any distributions to Class A common stockholders other than regular cash dividends; (ix)&nbsp;to exclude the effects of stock based compensation and the award of bonuses under our bonus plans;
(x)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and (xi)&nbsp;to exclude the goodwill and intangible asset impairment
charges that are required to be recorded under generally accepted accounting principles. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Other Stock Awards</I>. The administrator will be permitted to grant
other awards based in whole or in part by reference to our Class A common stock. The administrator will set the number of shares under the stock award (or cash equivalent) and all other terms and conditions of such awards. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit</I>. The aggregate value of all compensation granted or paid to any <FONT
STYLE="white-space:nowrap">non-employee</FONT> director with respect to any calendar year, including awards granted and cash fees paid by us to such <FONT STYLE="white-space:nowrap">non-employee</FONT> director, will not exceed $750,000 in total
value, except such amount will increase to $1,000,000 for the first year for newly appointed or elected <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Changes to Capital Structure</I>. In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or
recapitalization, appropriate adjustments will be made to (i)&nbsp;the class and maximum number of shares reserved for issuance under our 2021 Plan, (ii)&nbsp;the class and maximum number of shares by which the share reserve may increase
automatically each year, (iii)&nbsp;the class and maximum number of shares that may be issued on the exercise of ISOs, and (iv)&nbsp;the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all
outstanding stock awards. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Corporate Transactions</I>. In the event of a corporate transaction (as defined below), unless otherwise provided in a
participant&#146;s stock award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by the administrator at the time of grant, any stock awards outstanding under our 2021 Plan may be assumed,
continued or substituted for by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to the stock award may be assigned to the successor (or its parent company). If the
surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then (i)&nbsp;with respect to any such stock awards that are held by participants whose continuous service has not terminated
prior to the effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full (or, in the case of performance awards with multiple vesting levels
depending on the level of performance, vesting will accelerate at 100% of the target level if the award is not assumed) to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate
transaction), and such stock awards will terminate if not exercised (if applicable) at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such stock awards will lapse
(contingent upon the effectiveness of the corporate transaction); and (ii)&nbsp;any such stock awards that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the effective time of the
corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such stock awards will not terminate and may continue to be exercised notwithstanding the corporate transaction. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event a stock award will terminate if not exercised prior to the effective time of a corporate transaction, the administrator may provide, in its sole
discretion, that the holder of such stock award may not exercise such stock award but instead will receive a payment equal in value to the excess (if any) of (i)&nbsp;the value of the property the participant would have received upon the exercise of
the stock award, over (ii)&nbsp;any per share exercise price payable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
by such holder, if applicable. In addition, any escrow, holdback, earn out or similar provisions in the definitive agreement for the corporate transaction may apply to such payment to the same
extent and in the same manner as such provisions apply to the holders of our Class A common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under our 2021 Plan, a &#147;corporate transaction&#148; is
generally the consummation of (i)&nbsp;a sale or other disposition of all or substantially all of our consolidated assets; (ii)&nbsp;a sale or other disposition of at least 50% of our outstanding securities; (iii)&nbsp;a merger, consolidation or
similar transaction following which we are not the surviving corporation; or (iv)&nbsp;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our Class A common stock outstanding immediately
prior to such transaction are converted or exchanged into other property by virtue of the transaction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Change in Control</I>. Stock awards granted under our
2021 Plan may be subject to acceleration of vesting and exercisability upon or after a change in control (as defined below) as may be provided in the applicable stock award agreement or in any other written agreement between us or any affiliate and
the participant, but in the absence of such provision, no such acceleration will automatically occur. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under our 2021 Plan, a &#147;change in control&#148; is
generally (i)&nbsp;the acquisition by any person or company of more than 50% of the combined voting power of our then outstanding stock; (ii)&nbsp;a merger, consolidation or similar transaction in which our stockholders immediately before the
transaction do not own, directly or indirectly, more than 50% of the combined voting power of the surviving entity (or the parent of the surviving entity) in substantially the same proportions as their ownership immediately prior to such
transaction; ; (iii) a sale, lease, exclusive license or other disposition of all or substantially all of our assets other than to an entity more than 50% of the combined voting power of which is owned by our stockholders in substantially the same
proportions as their ownership of our outstanding voting securities immediately prior to such transaction; or (iv)&nbsp;when a majority of our board of directors becomes comprised of individuals who were not serving on our board of directors on the
date of the underwriting agreement related to this offering, or the incumbent board, or whose nomination, appointment, or election was not approved by a majority of the incumbent board still in office. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan Amendment or Termination</I>. Our board of directors has the authority to amend, suspend, or terminate our 2021 Plan at any time, provided that such action does
not materially impair the existing rights of any participant without such participant&#146;s written consent. Certain material amendments also require the approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date
our board of directors adopts our 2021 Plan. No stock awards may be granted under our 2021 Plan while it is suspended or after it is terminated. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2017 Equity
Incentive Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors adopted the 2017 Plan and our stockholders approved the 2017 Plan in February 2017. The 2017 Plan is the successor to
and continuation of the PNA Innovations, Inc. 2011 Stock Plan. The 2017 Plan provides for the grant of ISOs, NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards and other awards to our employees, directors and
consultants or our affiliates. ISOs may be granted only to our employees or employees of our affiliates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2017 Plan will be terminated on the date the 2021 Plan
becomes effective. However, any outstanding awards granted under the 2017 Plan will remain outstanding, subject to the terms of our 2017 Plan and award agreements, until such outstanding options are exercised or until any awards terminate or expire
by their terms. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Authorized Shares</I>. Upon the effective date of the 2021 Plan, we will no longer grant awards under our 2017 Plan. As of December 31, 2020,
options to purchase 1,855,507 shares were outstanding, and 1,150,088 shares of Class A common stock remained available for future issuance under our 2017 Plan. The options outstanding as of December 31, 2020 had a weighted-average exercise price of
$2.99. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan</I><I>&nbsp;Administration</I>. Our board or a duly authorized committee of our board administers our 2017 Plan and the awards granted under it. The
administrator has the power to modify outstanding awards under our 2017 Plan. The administrator has the authority to reprice any outstanding option with the consent of any adversely affected participant. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Corporate</I><I>&nbsp;Transactions</I>. Our 2017 Plan provides that in the event of certain specified significant corporate transactions, as defined under our 2017
Plan, our board may (1)&nbsp;arrange for the assumption, continuation or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
substitution of an award by a successor corporation, or the acquiring corporation&#146;s parent company; (2)&nbsp;arrange for the assignment of any reacquisition or repurchase rights held by us
to a successor corporation, or the acquiring corporation&#146;s parent company; (3)&nbsp;accelerate the vesting, in whole or in part, of the award and provide for its termination prior to the transaction if not exercised prior to the effective time
of the corporate transaction; (4)&nbsp;arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by us; (5)&nbsp;cancel or arrange for the cancellation of the award prior to the transaction in exchange for a cash
payment, if any, determined by the board; or (6)&nbsp;make a payment in such form as determined by the board of directors equal to the excess, if any, of the per share amount (or value of property per share) payable to holders of Class A common
stock over the per share exercise price under the applicable award. The administrator is not obligated to treat all awards or portions of awards, even those that are of the same type, in the same manner. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of a change in control, as defined under our 2017 Plan, awards granted under our 2017 Plan will not receive automatic acceleration of vesting and
exercisability, although this treatment may be provided for in an award agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Transferability</I>. Our board may impose limitations on the transferability
of ISOs, NSOs and stock appreciation rights as the board will determine. Absent such limitations, a participant may not transfer awards under our 2017 Plan other than by will, the laws of descent and distribution or as otherwise provided under our
2017 Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan Amendment or Termination</I>. Our board has the authority to suspend or terminate our 2017 Plan at any time, provided that such action will not
impair a participant&#146;s rights under such participant&#146;s outstanding award without his or her written consent. As described above, our 2017 Plan will be terminated upon the effective date of the 2021 Plan and no future awards will be granted
under the 2017 Plan following such termination. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2021 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors has adopted, and our stockholders have approved, our 2021 Employee Stock Purchase Plan (ESPP). Our ESPP will become effective immediately prior
to and contingent upon the date of the underwriting agreement related to this offering. The purpose of our ESPP will be to secure the services of new employees, to retain the services of existing employees, and to provide incentives for such
individuals to exert maximum efforts toward our success and that of our affiliates. Our ESPP will include two components. One component will be designed to allow eligible U.S. employees to purchase our Class A common stock in a manner that may
qualify for favorable tax treatment under Section&nbsp;423 of the Code. The other component will permit the grant of purchase rights that do not qualify for such favorable tax treatment in order to allow deviations necessary to permit participation
by eligible employees who are foreign nationals or employed outside of the U.S. while complying with applicable foreign laws. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Share Reserve</I>. Following this
offering, our ESPP will authorize the issuance of 220,251&nbsp;shares of our Class A common stock under purchase rights granted to our employees or to employees of any of our designated affiliates. The number of shares of our Class A common stock
reserved for issuance will automatically increase on&nbsp;January 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of each year for a period of 10 years, beginning on&nbsp;January 1, 2022 and continuing through&nbsp;January 1&nbsp;, 2031, by
the lesser of (i)&nbsp;1% of the total number of shares of our Class A common stock outstanding on December&nbsp;31 of the immediately preceding year; and (ii)&nbsp;440,502&nbsp;shares, except before the date of any such increase, our board of
directors may determine that such increase will be less than the amount set forth in clauses&nbsp;(i) and (ii). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Administration</I>. Our board of directors will
administer our ESPP and may delegate its authority to administer our ESPP to our compensation committee. Our ESPP will be implemented through a series of offerings under which eligible employees are granted purchase rights to purchase shares of our
Class A common stock on specified dates during such offerings. Under our ESPP, our board of directors will be permitted to specify offerings with durations of not more than 27 months and to specify shorter purchase periods within each offering. Each
offering will have one or more purchase dates on which shares of our Class A common stock will be purchased for employees participating in the offering. Our ESPP will provide that an offering may be terminated under certain circumstances. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Payroll Deductions</I>. Generally, all regular employees, including executive officers, employed by us or by any of our designated affiliates, will be eligible to
participate in our ESPP and to contribute, normally through payroll deductions, up to a maximum percentage of their earnings (as defined in our ESPP) for the purchase of our Class A common stock under our ESPP. Unless otherwise determined by our
board of directors, Class A common stock will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
be purchased for the accounts of employees participating in our ESPP at a price per share equal to the lesser of (i) 85% of the fair market value of a share of our Class A common stock on the
first day of an offering; or (ii) 85% of the fair market value of a share of our Class A common stock on the date of purchase. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Limitations</I>. Employees may
have to satisfy one or more of the following service requirements before participating in our ESPP, as determined by our board of directors: (i)&nbsp;being customarily employed for more than 20 hours per week; (ii)&nbsp;being customarily employed
for more than five months per calendar year; or (iii)&nbsp;continuous employment with us or one of our affiliates for a period of time (not to exceed two years). No employee will be permitted to purchase shares under our ESPP at a rate in excess of
$25,000 worth of our Class A common stock (based on the fair market value per share of our Class A common stock at the beginning of an offering) for each calendar year such a purchase right is outstanding. Finally, no employee will be eligible for
the grant of any purchase rights under our ESPP if immediately after such rights are granted, such employee has voting power over 5% or more of our outstanding capital stock measured by vote or value under Section&nbsp;424(d) of the Code. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Changes to Capital Structure</I>. Our ESPP will provide that in the event there occurs a change in our capital structure through such actions as a stock split,
merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of shares, change in corporate
structure, or similar transaction, our board of directors will make appropriate adjustments to: (i)&nbsp;the class(es) and maximum number of shares reserved under our ESPP; (ii)&nbsp;the class(es) and maximum number of shares by which the share
reserve may increase automatically each year; (iii)&nbsp;the class(es) and number of shares subject to, and purchase price applicable to, outstanding offerings and purchase rights; and (iv)&nbsp;the class(es) and number of shares that are subject to
purchase limits under ongoing offerings. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Corporate Transactions</I>. Our ESPP will provide that in the event of a corporate transaction (as defined below), any
then-outstanding rights to purchase our stock under our ESPP may be assumed, continued, or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to
assume, continue, or substitute for such purchase rights, then the participants&#146; accumulated payroll contributions will be used to purchase shares of our Class A common stock within 10 business days before such corporate transaction, and such
purchase rights will terminate immediately after such purchase. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under our ESPP, a &#147;corporate transaction&#148; is generally the consummation of (i)&nbsp;a
sale or other disposition of all or substantially all of our consolidated assets; (ii)&nbsp;a sale or other disposition of at least 50% of our outstanding securities; (iii)&nbsp;a merger, consolidation or similar transaction following which we are
not the surviving corporation; or (iv)&nbsp;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our Class A common stock outstanding immediately prior to such transaction are converted or
exchanged into other property by virtue of the transaction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Amendment or Termination</I>. Our board of directors will have the authority to amend or terminate
our ESPP, except in certain circumstances such amendment or termination may not materially impair any outstanding purchase rights without the holder&#146;s consent. We will obtain stockholder approval of any amendment to our ESPP as required by
applicable law or listing requirements. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>401(k) Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We maintain
a 401(k) plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. Eligible employees are able to defer eligible compensation up to certain Code limits, which are updated annually. We have the
ability to make matching and discretionary contributions to the 401(k) plan. Currently, we do not make matching contributions or discretionary contributions to the 401(k) plan. The 401(k) plan is intended to be qualified under Section&nbsp;401(a) of
the Code, with the related trust intended to be tax exempt under Section&nbsp;501(a) of the Code. As <FONT STYLE="white-space:nowrap">a&nbsp;tax-qualified&nbsp;retirement</FONT> plan, contributions to the 401(k) plan are deductible by us when made,
and contributions and earnings on those amounts are not generally taxable to the employees until withdrawn or distributed from the 401(k) plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitations on
Liability and Indemnification </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation, which will become effective immediately after the closing of this
offering, will contain provisions that limit the liability of our current and former directors for monetary damages </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for any breach of fiduciary duties as
directors, except liability for: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any breach of the director&#146;s duty of loyalty to the corporation or its stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">unlawful payments of dividends or unlawful stock repurchases or redemptions; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Such limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of equitable remedies such as
injunctive relief or rescission. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation will authorize us to indemnify our directors, officers, employees and other
agents to the fullest extent permitted by Delaware law. Our amended and restated bylaws will provide that we are required to indemnify our directors and officers to the fullest extent permitted by Delaware law and may indemnify our other employees
and agents. Our amended and restated bylaws will also provide that, on satisfaction of certain conditions, we will advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to
secure insurance on behalf of any officer, director, employee, or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of
Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by the board of directors. With certain exceptions, these agreements provide for
indemnification for related expenses including attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that these amended and restated certificate of incorporation and amended and restated bylaw provisions and indemnification agreements are necessary to
attract and retain qualified persons as directors and officers. We also maintain customary directors&#146; and officers&#146; liability insurance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The limitation
of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. They
may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder&#146;s investment may be adversely affected to the
extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Insofar as
indemnification for liabilities arising under the Securities Act of 1933, as amended (Securities Act) may be permitted for directors, executive officers, or persons controlling us, we have been informed that, in the opinion of the SEC, such
indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT>
Plans </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our directors, officers and key consultant may adopt written plans, known as Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans, in which they
will contract with a broker to buy or sell shares of our Class A common stock on a periodic basis. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a broker executes trades under parameters established by the director or officer
when entering into the plan, without further direction from them. The director or officer may amend a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan in some circumstances and may terminate a plan at any time. Our directors and executive
officers may also buy or sell additional shares outside of a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan when they do not possess of material nonpublic information, subject to compliance with the terms of our insider trading policy.
During the first 180 days from this offering, the sale of any shares under such plan would be subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement that the director or officer has entered into with the underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_13"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other than compensation arrangements for our directors and executive officers, which are described elsewhere in this prospectus, below we describe transactions since
January&nbsp;1, 2018 and each currently proposed transaction in which: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the amounts involved exceeded or will exceed $120,000; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">any of our directors, executive officers or holders of more than 5% of our outstanding capital stock, or any immediate
family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2020 Convertible Promissory Note Financing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From March 2020 to May 2020, we
issued and sold convertible promissory notes (2020 Notes) in the aggregate principal amount of approximately $5.6&nbsp;million. The 2020 Notes accrued interest at a rate of 4% per annum. The aggregate principal amount and interest on the
then-outstanding 2020 Notes converted into shares of our Series C convertible preferred stock (Series C preferred stock) in October 2020 in connection with our Series C convertible preferred stock financing (Series C preferred stock financing). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the principal amount and accrued interest of 2020 Notes purchased by holders of more than 5% of our capital stock and entities affiliated
with our executive officers and members of our board of directors. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>PARTICIPANTS<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRINCIPAL&nbsp;AMOUNT&nbsp;AND&nbsp;INTEREST&nbsp;OF</B><br><B>2020 NOTES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">KPCB Holdings, Inc.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,073,314.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">GV 2019, L.P.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,048,876.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Andrew K. Cheng, as Trustee of the Andrew Cheng 2010 Trust UA <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">10-26-2010</FONT></FONT><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">101,928.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">James W. Fordyce, as Trustee of the James W. Fordyce 2005 Revocable Trust<SUP
STYLE="font-size:85%; vertical-align:top">&nbsp;(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102,081.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Walton, Mitchell&nbsp;&amp; Co.,
Inc.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102,060.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">BNY Mellon N.A., as Trustee of the Trust U/D/T William L. Mellon DTD 6/29/35 for James M. Walton<SUP
STYLE="font-size:85%; vertical-align:top">&nbsp;(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,182.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Additional details regarding these stockholders and their equity holdings are included in this prospectus under the caption &#147;Principal Stockholders.&#148; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Beth Seidenberg, M.D., a member of our board of directors, is a partner of KPCB Holdings, Inc. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Krishna Yeshwant, M.D., a member of our board of directors until October 2020, is a managing partner of GV 2019, L.P. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Cheng is a member of our board of directors. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Fordyce is an immediate family member of Dr.&nbsp;Fordyce, our Chief Executive Officer and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Walton, a member of our board of directors until October 2020, is affiliated with Walton, Mitchell&nbsp;&amp; Co., Inc. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Walton, a member of our board of directors until October 2020, is affiliated with BNY Mellon N.A., as Trustee of the Trust U/D/T William L. Mellon DTD 6/29/35 for James M. Walton. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Series C Preferred Stock Financing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2020, we (1)&nbsp;issued and
sold an aggregate of 168,756,599 shares of our Series C preferred stock at a purchase price of $0.5918 per share, and (2)&nbsp;issued an aggregate of 11,404,246 shares of our Series C preferred stock upon conversion of the aggregate principal amount
and interest on the then-outstanding 2020 Notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes the shares of our Series C preferred stock held by holders of more than 5% of our
capital stock and entities affiliated with our executive officers and members of our board of directors. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP>
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>PARTICIPANTS<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES&nbsp;OF&nbsp;SERIES&nbsp;C</B><br><B>PREFERRED STOCK</B><br><B>PURCHASED&nbsp;FOR&nbsp;CASH&nbsp;(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE CASH</B><br><B>PURCHASE PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES&nbsp;OF&nbsp;SERIES&nbsp;C</B><br><B>PREFERRED STOCK</B><br><B>ISSUED UPON</B><br><B>CONVERSION OF</B><br><B>2020 NOTES (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Abingworth Bioventures 8 LP<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,346,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with Fidelity<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,346,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Longitude Venture Partners IV, L.P.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,346,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Sofinnova Venture Partners X, L.P.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,346,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ares Trading S.A.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,171,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(14)</SUP></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Citadel Multi-Strategy Equities Master Fund
Ltd.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,897,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,999,999.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">GV 2019, L.P.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,379,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,999,999.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,073,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">KPCB Holdings, Inc., as nominee<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,379,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,999,999.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,109,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Andrew K. Cheng, as Trustee of the Andrew Cheng 2010 Trust UA <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">10-26-2010</FONT></FONT><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">James W. Fordyce, as Trustee of the James W. Fordyce 2005 Revocable Trust<SUP
STYLE="font-size:85%; vertical-align:top">&nbsp;(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">253,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Walton, Mitchell&nbsp;&amp; Co.,
Inc.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">BNY Mellon N.A., as Trustee of the Trust U/D/T William L. Mellon DTD 6/29/35 for James M. Walton<SUP
STYLE="font-size:85%; vertical-align:top">&nbsp;(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Additional details regarding these stockholders and their equity holdings are included in this prospectus under the caption &#147;Principal Stockholders.&#148; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Abingworth Bioventures 8 LP beneficially owns more than 5% of our outstanding capital stock. Kurt von Emster, C.F.A., is a managing partner at Abingworth Bioventures 8 LP and a member of our board of directors.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 631,285 shares of Series C preferred stock purchased by Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund, (ii) 3,591,850 shares of Series C preferred stock purchased by Fidelity Mt.
Vernon Street Trust: Fidelity Growth Company Fund, (iii) 3,612,515 shares of Series C preferred stock purchased by Fidelity Growth Company Commingled Pool, (iv) 613,150 shares of Series C preferred stock purchased by Fidelity Mt. Vernon Street
Trust: Fidelity Growth Company K6 Fund, (v) 8,448,800 shares of Series C preferred stock purchased by Fidelity Select Portfolios: Biotechnology Portfolio, and (vi) 8,448,800 shares of Series C preferred stock purchased by Fidelity Advisor Series
VII: Fidelity Advisor Biotechnology Fund. These entities beneficially own more than 5% of our outstanding capital stock. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Longitude Venture Partners IV, L.P. beneficially owns more than 5% of our outstanding capital stock. Patrick Enright is a managing member of Longitude Capital Partners IV, LLC, the general partner of Longitude Venture
Partners IV, L.P. and a member of our board of directors. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Sofinnova Venture Partners X, L.P. beneficially owns more than 5% of our outstanding capital stock. Maha Katabi, Ph.D., is a general partner at Sofinnova Venture Partners X, L.P. and a member of our board of directors.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ares Trading S.A. beneficially owns more than 5% of our outstanding capital stock. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Citadel Multi-Strategy Equities Master Fund Ltd. beneficially owns more than 5% of our outstanding capital stock. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Krishna Yeshwant, M.D., a member of our board of directors until October 2020, is a managing partner of GV 2019, L.P. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Beth Seidenberg, M.D., a member of our board of directors, is a partner of KPCB Holdings, Inc. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Cheng is a member of our board of directors. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Fordyce is an immediate family member of Dr.&nbsp;Fordyce, our Chief Executive Officer and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Walton, a member of our board of directors until October 2020, is affiliated with Walton, Mitchell&nbsp;&amp; Co., Inc. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Walton, a member of our board of directors until October 2020, is affiliated with BNY Mellon N.A., as Trustee of the Trust U/D/T William L. Mellon DTD 6/29/35 for James M. Walton. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares of Series C preferred stock issued to Ares Trading S.A. were partial consideration for the license agreement entered into simultaneously with the sale and issuance of the Series&nbsp;C convertible preferred
stock </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employment Agreements and Stock Option Grants to Directors and Executive Officers </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into employment agreements with certain of our named executive officers, and granted stock options to our named executive officers and certain of our
directors, as more fully described in the sections titled &#147;Executive Compensation&#148; and <FONT STYLE="white-space:nowrap">&#147;Management&#151;Non-Employee</FONT> Director Compensation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>License Agreement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October&nbsp;29, 2020, we entered into an exclusive
worldwide license agreement with Ares, an affiliate of Merck KGaA, Darmstadt, Germany. Under this license agreement (Ares Agreement), Ares granted us an exclusive license to certain patents and certain related
<FONT STYLE="white-space:nowrap">know-how</FONT> to research, develop, manufacture, use and commercialize throughout the world therapeutic products containing atacicept or any other compound that is covered by a claim of such patents. In
consideration for the rights granted under the Ares Agreement, we issued to Ares an aggregate of 22,171,553 shares of Series C redeemable convertible preferred stock, we paid Ares $25&nbsp;million upon delivery and initiation of the transfer of
specified information and materials and we are obligated to pay Ares certain clinical, regulatory and commercial milestone payments, sublicensing revenue payments and royalty payments on future sales of licensed products. For more information
regarding the license agreement see &#147;Business&#151;Exclusive License Agreement with Ares Trading S.A.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Consulting Services Agreement with
Dr.&nbsp;Kotzin </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In February 2021, we entered into a consulting services agreement with BLKotzin, Inc., an entity affiliated with our former director, Brian
Kotzin, M.D., pursuant to which Dr.&nbsp;Kotzin provides certain consulting services to us. We pay Dr.&nbsp;Kotzin for his services at a rate of $400 per hour up to a maximum of $40,000 per year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Consulting Services Agreement with Dr.&nbsp;Ebens </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2021, we entered
into a consulting services agreement with Allen Ebens, Ph.D., our former Chief Scientific Officer, pursuant to which Dr.&nbsp;Ebens provides certain consulting services to us. We pay Dr.&nbsp;Ebens for his services at a rate of $350 per hour up to a
maximum of $300,000 per year. In addition, pursuant to the agreement, we granted Dr.&nbsp;Ebens an option covering 38,405 shares of our Class A common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investors&#146; Rights Agreement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2020, we entered into a Second
Amended and Restated Investors&#146; Rights Agreement (Rights Agreement) with certain holders of more than 5% of our outstanding capital stock, including Abingworth Bioventures 8 LP, Ares Trading S.A., entities affiliated with Fidelity, Citadel
Multi-Strategy Equities Master Fund Ltd., GV 2019, L.P., KPCB Holdings, Inc., Longitude Venture Partners IV, L.P. and Sofinnova Venture Partners X, L.P., and including certain affiliates of our directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Rights Agreement grants to the holders of our outstanding redeemable convertible preferred stock certain rights, including certain registration rights with respect
to the registrable securities held by them. See the section titled &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. In addition, the Rights Agreement imposes certain affirmative obligations on us,
including our obligation to, among other things, (i)&nbsp;grant each holder who holds shares of our redeemable convertible preferred stock with an aggregate original issue price of at least $4.6&nbsp;million (Major Investors), a right of first offer
with respect to future sales of our equity, excluding the shares to be offered and sold in this offering, and grant certain information and inspection rights to such Major Investors. Each of these obligations will terminate in connection with the
closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Voting Agreement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2020, we entered
into the Voting Agreement with certain holders of more than 5% of our outstanding capital stock, including Abingworth Bioventures 8 LP, Ares Trading S.A., entities affiliated with Fidelity, Citadel Multi-Strategy Equities Master Fund Ltd., GV 2019,
L.P., KPCB Holdings, Inc., Longitude Venture Partners IV, L.P. and Sofinnova Venture Partners X, L.P., and including certain affiliates of our directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant
to the Voting Agreement, each of Abingworth Bioventures 8 LP, Longitude Venture Partners IV, L.P. and Sofinnova Venture Partners X, L.P. has the right to designate one member to be elected to our board of directors.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
See the section titled &#147;Management&#151;Composition of Our Board of Directors.&#148; The Voting Agreement will terminate by its terms in connection with the closing of this offering and none
of our stockholders will have any continuing rights regarding the election or designation of members of our board of directors following this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Right of
First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2020, we entered into a Second Amended and Restated Right of First
Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement <FONT STYLE="white-space:nowrap">(Co-Sale</FONT> Agreement) with certain holders of more than 5% of our outstanding capital stock, including Abingworth Bioventures 8 LP, Ares
Trading S.A., entities affiliated with Fidelity, Citadel Multi-Strategy Equities Master Fund Ltd., GV 2019, L.P., KPCB Holdings, Inc., Longitude Venture Partners IV, L.P. and Sofinnova Venture Partners X, L.P., and including certain affiliates of
our directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement, we have a right of first refusal in respect of certain sales of
securities by certain holders of our common stock and redeemable convertible preferred stock. To the extent we do not exercise such right in full, the investors party to the <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement are granted
certain rights of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> in respect of such sale. The <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement will terminate in connection with the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of
incorporation will contain provisions limiting the liability of directors, and our amended and restated bylaws will provide that we will indemnify each of our directors and officers to the fullest extent permitted under Delaware law. Our amended and
restated certificate of incorporation and amended and restated bylaws will also provide our board of directors with discretion to indemnify our employees and other agents when determined appropriate by the board. In addition, we have entered into or
intend to enter into an indemnification agreement with each of our directors and executive officers, which will require us to indemnify them. For more information regarding these agreements, see the section titled &#147;Executive
Compensation&#151;Limitations on Liability and Indemnification.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Policies and Procedures for Transactions with Related Persons </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have adopted a written policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of our
common stock and any members of the immediate family of any of the foregoing persons are not permitted to enter into a related person transaction with us without the approval or ratification of our board of directors or our audit committee. Any
request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of any class of our common stock, or any member of the immediate family of any of the foregoing
persons, in which the amount involved exceeds $120,000 (or, if less, 1% of the average of our total assets in a fiscal year) and such person would have a direct or indirect interest, must be presented to our board of directors or our audit committee
for review, consideration and approval. In approving or rejecting any such proposal, our board of directors or our audit committee is to consider the material facts of the transaction, including whether the transaction is on terms no less favorable
than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person&#146;s interest in the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Directed Share Program </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At our request, the underwriters have reserved for
sale, at the initial public offering price, up to 3% of the shares of Class A common stock offered hereby to our directors, officers, employees, business associates and related persons through a directed share program. See the section titled
&#147;Underwriting&#151;Directed Share Program.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_14"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth information regarding beneficial ownership of our capital stock as of <B></B>March<B></B>&nbsp;31, 2021 by: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our Class&nbsp;A common
stock; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">each our of named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">all of our current executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have determined beneficial ownership in accordance with the rules and regulations of the SEC, and the information is not necessarily indicative of beneficial
ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect to all
shares that they beneficially own, subject to applicable community property laws. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Applicable percentage ownership before the offering is based on 16,242,992 shares
of our Class&nbsp;A common stock outstanding and no shares of our Class B common stock deemed to be outstanding as of March&nbsp;31, 2021, after giving effect to the automatic conversion of all outstanding shares of our redeemable convertible
preferred stock into 15,774,013 shares of our Class&nbsp;A common stock in connection with the closing of this offering and including<B> </B>138,989<B></B> shares of our unvested restricted Class&nbsp;A common stock subject to repurchase as of such
date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Applicable percentage ownership after the offering is based on 20,592,992&nbsp;shares of Class&nbsp;A common stock and Class B common stock assumed to be
outstanding immediately after the closing of this offering, after giving effect to the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into 15,774,013 shares of our Class&nbsp;A common stock in connection
with the closing of this offering and including 138,989 shares of our unvested restricted Class&nbsp;A common stock subject to repurchase as of such date, and assuming no exercise by the underwriters of their option to purchase additional shares and
no purchase of any shares of Class A common stock in this offering by the beneficial owners identified in the table below, including pursuant to our directed share program described in the section titled &#147;Underwriting&#151;Directed Share
Program.&#148; In computing the number of shares beneficially owned by a person and the percentage ownership of such person, we deemed to be outstanding all shares subject to options held by the person that are currently exercisable, or exercisable
within 60 days of March&nbsp;31, 2021. However, except as described above, we did not deem such shares outstanding for the purpose of computing the percentage ownership of any other person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise indicated, the address for each beneficial owner listed in the table below is c/o Vera Therapeutics,
Inc., 170 Harbor Way, 3rd Floor, South San Francisco, California 94080. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL"><B>NAME OF BENEFICIAL OWNER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SHARES<BR>BENEFICIALLY<BR>OWNED BEFORE</B><br><B>THE OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE&nbsp;OF</B><br><B>SHARES<BR>BENEFICIALLY<BR>OWNED BEFORE</B><br><B>THE OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE OF<BR>SHARES<BR>BENEFICIALLY<BR>OWNED AFTER</B><br><B>THE OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CLASS A<BR>COMMON<BR>STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CLASS B<BR>COMMON<BR>STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CLASS A<BR>COMMON<BR>STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CLASS B<BR>COMMON<BR>STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CLASS A<BR>COMMON<BR>STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CLASS&nbsp;B<BR>COMMON<BR>STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B></B><B><I>5% Stockholders</I></B><B>:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Abingworth Bioventures 8 LP<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,187,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with Fidelity<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,187,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Longitude Venture Partners IV, L.P.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,187,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Sofinnova Venture Partners X, L.P.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,187,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ares Trading S.A.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,913,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Citadel Multi-Strategy Equities Master Fund
Ltd.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,458,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">KPCB Holdings, Inc., as nominee<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,343,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Entities affiliated with GV<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">944,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Marshall Fordyce, M.D.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jonathan Wolter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Joanne Curley, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Allen Ebens, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Kurt von Emster, C.F.A.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,187,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Andrew Cheng, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Beth Seidenberg, M.D.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(7)(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,352,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Maha Katabi, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,187,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Patrick Enright<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,187,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Scott Morrison<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">All directors and executive officers as a group (10&nbsp;persons)<SUP
STYLE="font-size:85%; vertical-align:top">&nbsp;(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,125,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than 1%. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2,187,504 shares of Class A common stock issuable upon conversion of Series C preferred stock held by Abingworth Bioventures 8, LP (ABV 8). Abingworth Bioventures 8 GP LP (Abingworth GP) serves as the
general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to
Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. Mr.&nbsp;Von Emster is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a super majority vote, and no
individual member has the sole control or voting power over the shares held by ABV 8. Each of ABV 8, Abingworth GP, Abingworth GP 8, and each member of the investment committee disclaims beneficial ownership of the shares held by ABV 8. The address
for ABV&nbsp;8 is Abingworth Bioventures&nbsp;8 LP c/o Abingworth LLP, 38&nbsp;Jermyn Street, London, SW1Y 6DN, UK. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Consists of (i) 54,482 shares of Class A common stock issuable upon conversion of Series C preferred stock held by Fidelity
Mt. Vernon Street Trust: Fidelity Series Growth Company Fund, (ii) 309,992 shares of Class A common stock issuable upon conversion of Series C preferred stock held by Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund, (iii) 311,775
shares of Class A common stock issuable upon conversion of Series C preferred stock held by Fidelity Growth Company Commingled Pool, (iv) 52,917 shares of Class A common stock issuable upon conversion of Series C preferred stock held by Fidelity Mt.
Vernon Street Trust: Fidelity Growth Company K6 Fund, (v) 729,168 shares of Class A common stock issuable upon conversion of Series C preferred stock held by Fidelity Select Portfolios: Biotechnology Portfolio, and (vi) 729,168 shares of Class A
common stock issuable upon conversion of Series C preferred stock held by Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund. These funds are managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the
Chairman, the Chief Executive Officer and the President of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of
the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#146; voting agreement under which all Series B voting common shares will
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#146; voting
agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the
shares owned directly by the various investment companies registered under the Investment Company Act (Fidelity Funds) advised by Fidelity Management &amp; Research Company (FMR Co), a wholly owned subsidiary of FMR LLC, which power resides with the
Fidelity Funds&#146; Boards of Trustees. Fidelity Management &amp; Research Company carries out the voting of the shares under written guidelines established by the Fidelity Funds&#146; Boards of Trustees. The address of FMR LLC is 245 Summer
Street, V13H, Boston, Massachusetts 02110. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2,187,504 shares of Class A common stock issuable upon conversion of Series C preferred stock held by Longitude Venture Partners IV, L.P. (LVP IV). Longitude Capital Partners IV, LLC (LCP IV), is the general
partner of LVP IV and may be deemed to have voting and investment power over the shares held by LVP IV. Patrick Enright and Juliet Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and investment power over the shares
held by LVP IV. Each of LCP IV, Ms.&nbsp;Bakker and Mr. Enright disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. The address for this entity is 2740 Sand Hill Road, 2<SUP
STYLE="font-size:85%; vertical-align:top">nd</SUP> Floor, Menlo Park, CA 94025. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2,187,504 shares of Class A common stock issuable upon conversion of Series C preferred stock held by Sofinnova Venture Partners X, L.P. (SVP X). Sofinnova Management X, L.L.C. (SM X), is the general partner
of SVP X. As such, each of James Healy, Maha Katabi and Michael Powell, the managing members of SM X, may be deemed to have shared voting and dispositive power over the shares owned by SVP X. The address for this entity is c/o Sofinnova Investments,
3000 Sand Hill Road, Building <FONT STYLE="white-space:nowrap">4-Suite</FONT> 250, Menlo Park, CA 94025. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,913,501 shares of Class A common stock issuable upon conversion of Series C preferred stock held by Ares Trading S.A. The address for this entity is c/o Merck KGaA, Frankfurter Stra&szlig;e 250, 64293
Darmstadt, Germany, Attn: Alliance Management. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,458,336 shares of Class A common stock issuable upon conversion of Series C preferred stock held by Citadel Multi-Strategy Equities Master Fund Ltd. (Citadel). In accordance with the preferred stock
purchase agreement between Citadel and the Company and our Fourth Amended and Restated Certificate of Incorporation, the shares of Series C preferred stock owned by Citadel are convertible upon the our initial public offering into a combination of
Class A common stock and Class B common stock. The Class A common stock component issued upon the conversion of the Series C preferred stock in connection with our initial public offering cannot exceed 8.49% of the total Class A common stock
outstanding (after taking into account any initial public offering allocation to Citadel) with any excess shares issued being issued to Citadel as Class B common stock. The Class B common stock is convertible into Class A common stock in
Citadel&#146;s discretion but subject to the limitations described below under &#147;Description of Capital Stock.&#148; Citadel Advisors LLC (Citadel Advisors) is the portfolio manager of Citadel. Citadel Advisors Holdings LP (CAH) is the sole
member of Citadel Advisors. Citadel GP LLC (CGP) is the general partner of CAH. Kenneth Griffin owns a controlling interest in CGP. Mr.&nbsp;Griffin, as the owner of a controlling interest in CGP, may be deemed to have shared power to vote or direct
the vote of, and/or shared power to dispose or to direct the disposition over, the shares held by Citadel. The foregoing should not be construed as an admission that Mr. Griffin or any of the Citadel related entities is the beneficial owner of any
of our securities other than the securities actually owned by such person (if any). The address for this entity is 131 S Dearborn St, 32nd Floor, Chicago, IL 60603. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 409,620 shares of our Series A preferred stock held by Kleiner Perkins Caufield&nbsp;&amp; Byers XVI, LLC (KPCB XVI) and 14,022 shares held by KPCB XVI Founders Fund, LLC (XVI Founders), (ii) 97,199
shares of our Series B preferred stock held by KPCB XVI and 3,327 shares held by XVI Founders and (iii) 791,876 shares of our Series C Preferred Stock held by KPCB XVI and 27,108 shares held by XVI Founders. All shares are held for convenience in
the name of &#147;KPCB Holdings, Inc., as nominee&#148; for the accounts of such individuals and entities. The managing member of KPCB XVI is KPCB XVI Associates, LLC (KPCB XVI Associates). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E.
Schlein and Wen Hsieh, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI. The principal business address for all entities and individuals affiliated with Kleiner Perkins
Caufield&nbsp;&amp; Byers is c/o Kleiner Perkins Caufield&nbsp;&amp; Byers, LLC, 2750 Sand Hill Road, Menlo Park, CA 94025. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 301,580 shares of Class A common stock issuable upon conversion of Series B convertible preferred stock held by GV 2017, L.P. and (ii) 643,211 shares of Class A common stock issuable upon conversion of
Series C preferred stock held by GV 2019, L.P. GV 2017, L.P. is an indirect controlled subsidiary of Alphabet Inc. Alphabet Inc. and certain of its subsidiaries may be deemed to beneficially own the securities held directly by GV 2017, L.P. as a
result of this ownership structure. This ownership is described as follows: GV 2017 GP, L.P. (the General Partner of GV 2017, L.P.), GV 2017 GP, L.L.C. (the General Partner of GV 2017 GP, L.P.), Alphabet Holdings LLC (the managing member of GV 2017
GP, L.L.C.), XXVI Holdings Inc. (the managing member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have investment power or sole power to vote or dispose of the shares held
directly by GV 2017, L.P. GV 2019, L.P. is an indirect controlled subsidiary of Alphabet Inc. Alphabet Inc. and certain of its subsidiaries may be deemed to beneficially own the securities held directly by GV 2019, L.P. as a result of this ownership
structure. This ownership is described as follows: GV 2019 GP, L.P. (the General Partner of GV 2019, L.P.), GV 2019 GP, L.L.C. (the General Partner of GV 2019 GP, L.P.), Alphabet Holdings LLC (the managing member of GV 2019 GP, L.L.C.), XXVI
Holdings Inc. (the managing member of Alphabet Holdings LLC), and Alphabet Inc. (the controlling stockholder of XXVI Holdings Inc.) may each be deemed to have investment power or sole power to vote or dispose of the shares held directly by GV 2019,
L.P. The principal business address of GV 2017, L.P., GV 2017 GP, L.P., GV 2017 GP, L.L.C., GV 2019, L.P., GV 2019 GP, L.P., GV 2019 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc. and Alphabet Inc. is 1600 Amphitheatre Parkway, Mountain View,
CA 94043. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 99,272 shares of Class A common stock held directly by Dr.&nbsp;Fordyce, (ii) 34,521 shares of unvested restricted Class A common stock subject to repurchase as of March 31, 2021 held by Dr. Fordyce, and
(iii) 4,123 shares of Class A common stock subject to options exercisable within 60 days of March 31, 2021 held by Dr.&nbsp;Fordyce (3,607 of which were exercised in April 2021). </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 23,733 shares of unvested restricted Class A common stock subject to repurchase as of March 31, 2021 held by Dr.&nbsp;Curley, (ii) 7,551 shares of Class A common stock subject to options exercisable
within 60 days of March 31, 2021 held by Dr.&nbsp;Curley. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 23,687 shares of Class A common stock held directly by Dr. Ebens, (ii) 2,133 shares of Class A common stock subject to options exercisable within 60 days of March 31, 2021 held by Dr.&nbsp;Ebens.
Dr.&nbsp;Ebens&#146; employment was terminated as our Chief Scientific Officer effective October 2020. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 17,488 shares of Class A common stock issuable upon conversion of Series C preferred stock held by Dr.&nbsp;Cheng, as trustee of the Andrew Cheng 2010 Trust UA <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">10-26-2010</FONT></FONT> and (ii) 13,807 shares of Class A common stock subject to options exercisable within 60 days of March 31, 2021 held by Dr.&nbsp;Cheng. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 9,589 shares of Class A common stock subject to options exercisable within 60 days of March 31, 2021 held by Dr.&nbsp;Seidenberg. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 9,589 shares of common stock subject to options exercisable within 60 days of March 31, 2021 held by Mr.&nbsp;Morrison. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 8,080,678 shares of Class A common stock beneficially owned by our current executive officers and directors, and (ii)&nbsp;44,659 shares of Class A common stock subject to options exercisable within 60
days of March&nbsp;31, 2021. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_15"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following description of our capital stock and certain
provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to the amended and restated certificate of incorporation, which will become effective immediately after
the closing of this offering, and the amended and restated bylaws, which will become effective upon the closing of this offering. Copies of these documents have been filed with the SEC as exhibits to our registration statement, of which this
prospectus forms a part. The descriptions of the common stock and preferred stock reflect changes to our capital structure that will be in effect upon the closing of this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon filing of our amended and restated certificate of incorporation and the closing of this offering, our authorized capital stock will consist of 500,000,000 shares
of Class A common stock, par value $0.001 per share, 14,600,000 shares of Class B common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. All of our authorized shares of preferred stock will be
undesignated. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2020, after giving effect to the automatic conversion of all outstanding shares of our redeemable convertible preferred stock
into 15,774,014 shares of our Class A common stock in connection with the closing of this offering and including 41,363 shares of our unvested restricted Class A common stock subject to repurchase as of such date, there were 16,129,310 shares of
Class A common stock outstanding (which includes no shares of Class B common stock convertible into Class A common stock as described below) and held of record by 63 stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Voting Rights and Conversion Rights </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The holders of our Class A common stock are entitled to one vote per share of Class A common stock on any matter that is submitted to a vote of our stockholders and
holders of our Class B common stock are not entitled to any votes per share of Class B common stock, including for the election of directors. Additionally, holders of our Class A common stock have no conversion rights, while holders of our Class B
common stock shall have the right to convert each share of our Class B common stock into one share of Class A common stock at such holder&#146;s election, provided that as a result of such conversion, such holder would not beneficially own in excess
of 9.9% of any class of our securities registered under the Exchange Act, unless otherwise as expressly provided for in our amended and restated certificate of incorporation. However, this ownership limitation may be increased to any other
percentage designated by such holder of Class B common stock upon 61 days&#146; notice to us or decreased at any time. Holders of our Class B common stock are also permitted to make certain transfers of Class B common stock to non-affiliates upon
which, such transferred shares could be immediately converted into shares of our Class A common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation does
not provide for cumulative voting for the election of directors for our Class A common stock. Our amended and restated certificate of incorporation establishes a classified board of directors that is divided into three classes with staggered
three-year terms. Only the directors in one class will be subject to election by a plurality of the votes cast at each annual meeting of our stockholders holding shares of Class A common stock, with the directors in the other classes continuing for
the remainder of their respective three-year terms. The affirmative vote of holders of at least 66<SUP STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the voting power of all of the then-outstanding shares of
capital stock, voting as a single class, will be required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws, the classified structure of
our board of directors, the size of our board of directors, removal of directors, director liability, vacancies on our board of directors, special meetings, stockholder notices, actions by written consent and exclusive jurisdiction. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Economic Rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as otherwise expressly provided in our
amended and restated certificate of incorporation or required by applicable law, and other than the voting rights and conversion rights stated above, all shares of Class A common stock and Class B common stock will have the same rights and
privileges and rank equally, share ratably, and be identical in all respects for all matters, including those described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dividends</I>. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the
holders of our Class A common stock and Class B common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts
that our board of directors may determine. See the section titled &#147;Dividend Policy&#148; for further information. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Liquidation Rights</I>. On our
liquidation, dissolution, or <FONT STYLE="white-space:nowrap">winding-up,</FONT> the holders of Class A common stock and Class B common stock will be entitled to share equally, identically, and ratably in all assets remaining after the payment of
any liabilities, liquidation preferences and accrued or declared but unpaid dividends, if any, with respect to any outstanding preferred stock, unless a different treatment is approved by the affirmative vote of the holders of a majority of the
outstanding shares of such affected class, voting separately as a class. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>No Preemptive or Similar Rights </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The holders of our shares of Class A common stock and Class B common stock are not entitled to preemptive rights, and are not subject to redemption or sinking fund
provisions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fully Paid and <FONT STYLE="white-space:nowrap">Non-Assessable</FONT> </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with this offering, our legal counsel will opine that the shares of our Class A common stock to be issued under this offering will be fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preferred Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon
the closing of this offering, all of our currently outstanding shares of redeemable convertible preferred stock will convert into Class A common stock and we will not have any redeemable convertible preferred stock outstanding. Immediately after the
closing of this offering, our certificate of incorporation will be amended and restated to delete all references to such shares of redeemable convertible preferred stock. Under the amended and restated certificate of incorporation, our board of
directors will have the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix
the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares
of such series then outstanding. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect
the voting power or other rights of the holders of the Class A common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the
effect of delaying, deferring or preventing a change in our control that may otherwise benefit holders of our Class A common stock and may adversely affect the market price of the Class A common stock and the voting and other rights of the holders
of Class A common stock. We have no current plans to issue any shares of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stock Options </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2020, 1,855,507 shares of Class A common stock were issuable upon the exercise of outstanding stock options, at a weighted-average exercise
price of $2.99 per share. For additional information regarding terms of our equity incentive plans, see the section titled &#147;Executive Compensation&#151;Equity Benefit Plans.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the closing of this offering and subject to <FONT
STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreements</FONT> entered into in connection with this offering and federal securities laws, certain holders of shares of our Class A common stock and Class B common stock, including those shares of
our Class A common stock and Class B common stock that will be issued upon the conversion of our redeemable convertible preferred stock in connection with this offering, will initially be entitled to certain rights with respect to registration of
such shares under the Securities Act. These shares are referred to as registrable securities. The holders of these registrable securities possess registration rights pursuant to the terms of our amended and restated investors&#146; rights agreement
and are described in additional detail below. The registration of shares of our Class A common stock and Class B common stock pursuant to the exercise of the registration rights </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
described below would enable the holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. We will pay the
registration expenses, other than underwriting discounts, selling commissions and stock transfer taxes, of the shares registered pursuant to the demand, piggyback and <FONT STYLE="white-space:nowrap">Form&nbsp;S-3&nbsp;registrations</FONT> described
below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Generally, in an underwritten offering, the managing underwriter, if any, has the right, subject to specified conditions and limitations, to limit the
number of shares the holders may include. The demand, piggyback and <FONT STYLE="white-space:nowrap">Form&nbsp;S-3&nbsp;registration</FONT> rights described below will expire no later than three years after the closing of this offering. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Demand Registration Rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the closing of this offering,
holders of an aggregate of 15,774,014 shares of our Class A common stock and Class B common stock will be entitled to certain demand registration rights. At any time beginning 180 days after the closing of this offering, the holders of (i) 40% of
these shares issued upon conversion of our Series C redeemable convertible preferred stock, or (ii) a majority of these shares, may request that we register all or a portion of their shares. We are not required to effect more than two registration
statements which are declared or ordered effective. With respect to (ii), such request for registration must cover a majority of such shares then outstanding with an anticipated aggregate offering price that would exceed $10 million. With certain
exceptions, we are not required to effect the filing of a registration statement during the period starting with the date of the filing of, and ending on a date 180 days following the effective date of the registration statement for this offering.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Piggyback Registration Rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In connection with this offering,
the holders of an aggregate of 15,774,014 shares of our Class A common stock and Class B common stock were entitled to, and the necessary percentage of holders waived, their rights to notice of this offering and to include their shares of
registrable securities in this offering. After this offering, in the event that we propose to register any of our securities under the Securities Act, either for our own account or for the account of other security holders, the holders of these
shares will be entitled to certain piggyback registration rights allowing the holder to include their shares in such registration, subject to certain marketing and other limitations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the closing of this offering, holders of an aggregate of 15,774,014 shares of Class A common stock and Class B common stock will be entitled to certain Form <FONT
STYLE="white-space:nowrap">S-3</FONT> registration rights. Holders of (i) shares issued upon conversion of our Series C redeemable convertible preferred stock with an aggregate original issue price of $500,000, or (ii) 20% of these shares, can make
a request that we register their shares on Form <FONT STYLE="white-space:nowrap">S-3</FONT> if we are qualified to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and, with respect to (ii), if the reasonably
anticipated aggregate net proceeds of the shares offered would equal or exceed $3 million. With respect to (ii), we will not be required to effect more than two registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> within any <FONT
STYLE="white-space:nowrap">12-month</FONT> period. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Anti-Takeover Provisions </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws, which are summarized below, may have the
effect of delaying, deferring or discouraging another person from acquiring control of our company. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe
that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an
improvement of their terms. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Certificate of Incorporation and Bylaws to be in Effect in connection with this Offering </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because our stockholders do not have cumulative voting rights, stockholders holding a majority of the voting power of our shares of Class A common stock will be able to
elect all of our directors. Our amended and restated certificate of incorporation, to be effective immediately after the closing of this offering, and our amended and restated bylaws, to be effective upon the closing of this offering, will provide
for stockholder actions at a duly called meeting of stockholders or, before the date on which all shares of Class A common stock convert into a single class, by written consent. A special meeting of stockholders may be called by a majority of our
board of directors, the chair of our board of directors, or our chief executive officer or president. Our amended and restated bylaws will establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our
stockholders, including proposed nominations of persons for election to our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As described above in &#147;Management&#151;Composition of Our Board of Directors,&#148; in accordance with our
amended and restated certificate of incorporation to be filed in connection with this offering, immediately after this offering, our board of directors will be divided into three classes with staggered three-year terms. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The foregoing provisions will make it more difficult for another party to obtain control of us by replacing our board of directors. Since our board of directors has the
power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it
possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy fights.
However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in our control or management. As a consequence, these
provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Section&nbsp;203 of the
Delaware General Corporation Law </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When we have a class of voting stock that is either listed on a national securities exchange or held of record by more
than 2,000 stockholders, we will be subject to Section&nbsp;203 of the Delaware General Corporation Law (DGCL), which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three
years after the date that such stockholder became an interested stockholder, subject to certain exceptions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Choice of Forum </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation to be effective immediately after the closing of this offering will provide that the Court of Chancery of the
State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction,
the federal district court for the District of Delaware) and any appellate court therefrom is the sole and exclusive forum for the following claims or causes of action under the Delaware statutory or common law: (i)&nbsp;any derivative claim or
cause of action brought on our behalf; (ii)&nbsp;any claim or cause of action for a breach of fiduciary duty owed by any of our current or former directors, officers, or other employees to us or our stockholders; (iii)&nbsp;any claim or cause of
action against us or any of our current or former directors, officers or other employees arising out of or pursuant to any provision of the DGCL, our amended and restated certificate of incorporation, or our bylaws (as each may be amended from time
to time); (iv) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws (as each may be amended from time to time,
including any right, obligation, or remedy thereunder); (v) any claim or cause of action as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi)&nbsp;any claim or cause of action against us or any of our
current or former directors, officers, or other employees governed by the internal-affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#146;s having personal jurisdiction over the indispensable parties
named as defendants. This choice of forum provision would not apply to claims or causes of action brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which the federal courts have exclusive
jurisdiction. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation to be effective upon the closing of this offering will further provide that the federal
district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such
complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession
gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. Additionally, our amended and restated certificate of incorporation to be effective immediately after
the closing of this offering will provide that any person or entity holding, owning or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitations on Liability and Indemnification </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See the section titled &#147;Executive Compensation&#151;Limitations on Liability and Indemnification.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Exchange Listing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our Class A common stock is currently not listed on any
securities exchange. We have applied to list our Class A common stock on The Nasdaq Global Market under the symbol &#147;VERA.&#148; We do not intend to list the Class B common stock on any securities exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the closing of this offering, the
transfer agent and registrar for our Class A common stock will be American Stock Transfer &amp; Trust Company, LLC. The transfer agent&#146;s address is 6201 15th Avenue, Brooklyn, New York 11219. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_16"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before the closing of this offering, there has been no public market for our Class A common stock. Future sales of substantial amounts of our Class A common stock or
Class B common stock, including shares issued on the exercise of outstanding options, in the public market after this offering, or the possibility of these sales or issuances occurring, could adversely affect the prevailing market price for our
Class A common stock or impair our ability to raise equity capital. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on our shares outstanding as of December&nbsp;31, 2020, upon the closing of this
offering, a total of 20,479,310 shares and no&nbsp;shares of Class A common stock or Class B common stock, respectively, will be outstanding, assuming the automatic conversion of all outstanding shares of our redeemable convertible preferred stock
into 15,774,014 shares of our Class A common stock in connection with the closing of this offering and 41,363 shares of unvested restricted Class A common stock subject to repurchase. Of these shares, all of the Class A common stock sold in this
offering by us, plus any shares sold by us on exercise of the underwriters&#146; option to purchase additional Class A common stock, will be freely tradable in the public market without restriction or further registration under the Securities Act,
unless these shares are held by &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act (Rule 144). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The remaining shares of Class A
common stock or Class B common stock will be, and shares of Class A common stock subject to stock options will be on issuance, &#147;restricted securities,&#148; as that term is defined in Rule 144. These restricted securities are eligible for
public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rules 144 or 701 under the Securities Act, which are summarized below. Restricted securities may also be sold outside of the
United States to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> persons in accordance with Rule 904 of Regulation S. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described below and the provisions of Rule 144 or Regulation S under the Securities Act, as well as our insider trading policy, these restricted securities will be available for sale in the public
market after the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, under
Rule 144 as currently in effect, once we have been subject to public company reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act for at least 90 days, an eligible stockholder is entitled to sell such shares without
complying with the manner of sale, volume limitation, or notice provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. To be an eligible stockholder under Rule 144, such stockholder must not be deemed to
have been one of our affiliates for purposes of the Securities Act at any time during the 90 days preceding a sale and must have beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior
owner other than our affiliates. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then such person is entitled to sell such
shares without complying with any of the requirements of Rule 144, subject to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, under Rule 144, as currently in effect, our affiliates or persons selling shares on behalf of our
affiliates are entitled to sell shares on expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. Beginning 90 days after the date of this prospectus, within any three-month period, such stockholders may sell a
number of shares that does not exceed the greater of: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1% of the number of shares of Class A common stock then outstanding, which will equal approximately 204,793 shares
immediately after this offering, assuming no exercise of the underwriters&#146; option to purchase additional shares of Class A common stock from us; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the average weekly trading volume of our Class A common stock on The Nasdaq Global Market during the four calendar weeks
preceding the filing of a notice on Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Sales under Rule 144 by our affiliates or persons selling shares on
behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 701 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rule 701 of the Securities Act (Rule 701) generally allows a
stockholder who was issued shares under a written compensatory plan or contract and who is not deemed to have been an affiliate of our company during the immediately preceding 90 days, to sell these shares in reliance on Rule 144, but without being
required to comply with the public information, holding period, volume limitation, or notice provisions of Rule 144. Rule 701 also permits affiliates of our company to sell their Rule 701 shares under Rule 144 without complying with the holding
period requirements of Rule 144. All holders of Rule 701 shares, however, are required by that rule to wait until 90 days after the date of this prospectus before selling those shares under Rule 701, subject to the expiration of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Form <FONT STYLE="white-space:nowrap">S-8</FONT> Registration Statements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act with the SEC to register the offer
and sale of shares of our common stock that are issuable under the 2017 Plan, 2021 Plan and ESPP. These registration statements will become effective immediately on filing. Shares covered by these registration statements will then be eligible for
sale in the public markets, subject to vesting restrictions, any applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below, and Rule 144 limitations applicable to affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Arrangements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, and all of
our directors, executive officers and the holders of substantially all of our Class A common stock and Class B common stock and securities exercisable for or convertible into our Class A common stock outstanding immediately upon the closing of this
offering, have agreed with the underwriters that, until 180 days after the date of the underwriting agreement related to this offering, we and they will not, without the prior written consent of the representatives of the underwriters, subject to
certain exceptions, directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or
dispose of any of our shares of Class A common stock and Class B common stock, or any securities convertible into or exercisable or exchangeable for shares of our Class A common stock, or enter into any hedging, swap or any other agreement or any
transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the securities, whether any such swap or transaction is to be settled by delivery of our Class A common stock and Class B common stock
or other securities, in cash or otherwise. These agreements are described in the section titled &#147;Underwriting.&#148; The representatives of the underwriters may, in their sole discretion, release any of the securities subject to these <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements at any time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the restrictions contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements described above, we have entered into agreements with certain security holders, including the amended and restated investors&#146; rights agreement, our standard form of option agreement and our standard form of restricted stock
agreement, that contain market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions or incorporate market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions from our equity incentive plan imposing restrictions on the ability of
such security holders to offer, sell or transfer our equity securities for a period of 180 days following the date of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon
the closing of this offering, pursuant to our amended and restated investors&#146; rights agreement, the holders of 15,774,014 shares of our Class A common stock and no shares of our Class B common stock, or their transferees, will be entitled to
certain rights with respect to the registration of the offer and sale of their shares under the Securities Act, subject to the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described under the section titled <FONT
STYLE="white-space:nowrap">&#147;&#151;Lock-Up</FONT> Arrangements&#148; above. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act immediately on the
effectiveness of the registration. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our Class A common stock. See the section titled &#147;Description of Capital Stock&#151;Registration
Rights&#148; for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_17"></A>CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a summary of certain material U.S. federal income tax consequences to <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) of the purchase, ownership and disposition of our Class A common stock issued pursuant to this offering. This discussion is not a complete analysis of all potential U.S. federal
income tax consequences relating thereto, does not address the potential application of the Medicare contribution tax on net investment income, and does not address any estate or gift tax consequences or any tax consequences arising under any state,
local or foreign tax laws, or any other U.S. federal tax laws. This discussion is based on the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the Internal Revenue
Service (IRS), all as in effect on the date of this prospectus. These authorities are subject to differing interpretations and may change, possibly retroactively, resulting in U.S. federal income tax consequences different from those discussed
below. We have not requested a ruling from the IRS with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This discussion is limited to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders who purchase our Class A common stock pursuant to this offering and who hold our
Class A common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all of the U.S. federal income tax consequences that may be relevant
to an individual <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s particular circumstances. This discussion also does not consider any specific facts or
circumstances that may be relevant to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to special rules under the U.S. federal income tax laws, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">partnerships or other pass-through entities (and investors therein); </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;controlled foreign corporations&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;passive foreign investment companies&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">banks, financial institutions, investment funds, insurance companies, brokers, dealers or traders in securities;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations and governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who acquire our Class A common stock through the exercise of an option or otherwise as compensation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">qualified foreign pension funds as defined in Section&nbsp;897(l)(2) of the Code and entities all of the interests of
which are held by qualified foreign pension funds; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons subject to the alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons subject to special tax accounting rules under Section&nbsp;451(b) of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons that own or have owned, actually or constructively, more than 5% of our Class A common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who have elected to mark securities to market; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons holding our Class A common stock as part of a hedging or conversion transaction or straddle, or a constructive
sale, or other risk reduction strategy or integrated investment. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If an entity or arrangement that is classified as a partnership for U.S. federal
income tax purposes holds our Class A common stock, the U.S. federal income tax treatment of a partner in the partnership will generally depend on the status of the partner, the activities of the partnership and certain determinations made at the
partner level. Partnerships holding our Class A common stock and the partners in such partnerships are urged to consult their tax advisors about the particular U.S. federal income tax consequences to them of holding and disposing of our Class A
common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE
PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, OWNING AND DISPOSING OF OUR CLASS A COMMON STOCK,</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
<B>AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL OR FOREIGN TAX LAWS AND ANY OTHER U.S. FEDERAL TAX LAWS.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Definition of <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:ARIAL">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is any beneficial owner of our Class A common stock that is
not a &#147;U.S. holder&#148; or a partnership (including any entity or arrangement treated as a partnership) for U.S. federal income tax purposes. A U.S. holder is any person that, for U.S. federal income tax purposes, is or is treated as any of
the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a trust (1)&nbsp;whose administration is subject to the primary supervision of a U.S. court and which has one or more U.S.
persons who have the authority to control all substantial decisions of the trust or (2)&nbsp;that has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Distributions on Our Class A Common Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As described under the section
titled &#147;Dividend Policy,&#148; we do not anticipate declaring or paying, in the foreseeable future, any cash distributions on our capital stock. However, if we distribute cash or other property on our Class A common stock, such distributions
will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income
tax purposes will constitute a return of capital and will first be applied against and reduce a holder&#146;s tax basis in our Class A common stock, but not below zero. Any excess will be treated as gain realized on the sale or other disposition of
our Class A common stock and will be treated as described under the section titled &#147; &#151;Gain on Disposition of Our Class A Common Stock&#148; below. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussions below regarding effectively connected income, backup withholding and FATCA (as defined below), dividends paid to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder of our Class A common stock generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends or such lower rate specified by an applicable income tax
treaty. To receive the benefit of a reduced treaty rate, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must furnish us or our withholding agent with a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> (in the case of
individuals) or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (in the case of entities), or other appropriate form, certifying such holder&#146;s qualification for the reduced rate. This
certification must be provided to us or our withholding agent before the payment of dividends and must be updated periodically. In the case of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder that is an entity, Treasury Regulations and the
relevant tax treaty provide rules to determine whether, for purposes of determining the applicability of the tax treaty, dividends will be treated as paid to the entity or to those holding an interest in the entity. If the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our Class A common stock through a financial institution or other agent acting on the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s behalf, the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be required to provide appropriate documentation to the agent, which then will be required to provide certification to us or our withholding agent, either directly or through other
intermediaries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our Class A common stock in connection with the conduct of a trade or business
in the United States, and dividends paid on our Class A common stock are effectively connected with such holder&#146;s U.S. trade or business (and are attributable to such holder&#146;s permanent establishment or fixed base in the United States if
required by an applicable tax treaty), the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be exempt from U.S. federal withholding tax. To claim the exemption, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must generally
furnish a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or applicable successor form) to the applicable withholding agent. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">However, any such
effectively connected dividends paid on our Class A common stock generally will be subject to U.S. federal income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the
United States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its
effectively connected earnings and profits for the taxable year, as adjusted for certain items. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders that do not provide the required certification on a timely
basis, but that qualify for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax
advisors regarding any applicable income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Gain on Disposition of Class A Our Common Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussions below regarding backup withholding and FATCA (as defined below), a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not
be subject to U.S. federal income tax on any gain realized on the sale or other disposition of our Class A common stock, unless: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a
trade or business in the United States and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual present in the United States
for 183 days or more during the taxable year of the disposition, and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our Class A common stock constitutes a &#147;United States real property interest&#148; by reason of our status as a
United States real property holding corporation (USRPHC) for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding the disposition or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s
holding period for our Class A common stock, and our Class A common stock is not regularly traded on an established securities market during the calendar year in which the sale or other disposition occurs. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Determining whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our other trade or
business assets and our foreign real property interests. We believe that we are not currently and we do not anticipate becoming a USRPHC for U.S. federal income tax purposes, although there can be no assurance we will not in the future become a
USRPHC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular U.S. federal
income tax rates in the same manner as if such holder were a resident of the United States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation also may be subject to an additional branch profits tax equal to 30%
(or such lower rate specified by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. Gain described in the second bullet point above will be subject to U.S. federal
income tax at a flat 30% rate (or such lower rate specified by an applicable income tax treaty), but may be offset by certain U.S.-source capital losses (even though the individual is not considered a resident of the United States), provided that
the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S. federal income tax returns with respect to such losses. Gain described in the third bullet point above will generally be subject to U.S. federal income tax in the same
manner as gain that is effectively connected with the conduct of a U.S. trade or business, except that the branch profits tax generally will not apply. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Information Reporting and Backup Withholding </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Annual reports are required to
be filed with the IRS and provided to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder indicating the distributions on our Class A common stock paid to such holder and any tax withheld with respect to those distributions . These
information reporting requirements apply even if no withholding was required because the distributions were effectively connected with the holder&#146;s conduct of a U.S. trade or business, or withholding was reduced or eliminated by an applicable
income tax treaty. This information also may be made available under a specific treaty or agreement with the tax authorities in the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is established. Backup
withholding, currently at a 24% rate, generally will not apply to payments to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of dividends on or the gross proceeds of a disposition of our Class A common stock provided the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder furnishes the required certification for its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by providing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS Form <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or certain other requirements are met, and if the payor does not have actual knowledge, or reason to know,
that the holder is a U.S. person who is not an exempt recipient. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Backup withholding is not an additional tax. If any amount is withheld under the backup withholding rules, the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder should consult with a U.S. tax advisor regarding the possibility of and procedure for obtaining a refund or a credit against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S.
federal income tax liability, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Withholding on Foreign Entities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Sections 1471 through 1474 of the Code, which are commonly referred to as FATCA, impose a U.S. federal withholding tax of 30% on certain payments made to a
&#147;foreign financial institution&#148; (as specially defined under these rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities
substantial information regarding certain U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or an exemption
applies. FATCA also generally will impose a U.S. federal withholding tax of 30% on certain payments made to a <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity unless such entity provides the withholding agent a certification
identifying certain direct and indirect U.S. owners of the entity or an exemption applies. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. Under certain circumstances, a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder might be eligible for refunds or credits of such taxes. FATCA currently applies to dividends paid on our Class A common stock and would have applied also to payments of gross proceeds from the sale
or other disposition of our Class A common stock. The U.S. Treasury Department has released proposed regulations under FATCA providing for the elimination of the federal withholding tax of 30% applicable to gross proceeds of a sale or other
disposition of our Class A common stock. Under these proposed Treasury Regulations (which may be relied upon by taxpayers prior to finalization), FATCA will not apply to gross proceeds from sales or other dispositions of our Class A common stock.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prospective investors are encouraged to consult with their own tax advisors regarding the possible implications of FATCA on their investment in our Class A common
stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_18"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the terms and conditions set forth in the underwriting agreement,
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021, among us, Jefferies LLC, Cowen and Company, LLC and Evercore Group L.L.C, as the representatives of the underwriters named below and the
joint book-running managers of this offering, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us the respective number of shares of Class&nbsp;A common stock shown
opposite its name below: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>UNDERWRITER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters
of officers&#146; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of Class A common stock if any of them are purchased.
If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated. We have agreed to indemnify the underwriters and
certain of their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the Class A common stock as permitted by
applicable laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can be given as
to the liquidity of the trading market for the Class&nbsp;A common stock, that you will be able to sell any of the Class A common stock held by you at a particular time or that the prices that you receive when you sell will be favorable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters are offering the shares of Class A common stock subject to their acceptance of the shares of Class&nbsp;A common stock from us and subject to prior
sale. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which
they exercise discretionary authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commission and Expenses </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
underwriters have advised us that they propose to offer the shares of Class A common stock to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers, which may include the underwriters,
at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of Class A common stock. The underwriters may allow, and certain dealers may reallow, a
discount from the concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of Class A common stock to certain brokers and dealers. After the offering, the initial public
offering price, concession and reallowance to dealers may be reduced by the representatives. No such reduction will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table shows the public offering price, the underwriting discounts and commissions that we are to pay
the underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Underwriting discounts and commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately $3.1
million. We have also agreed to reimburse the underwriters for expenses of up to $40,000 relating to the clearance of this offering with the Financial Industry Regulatory Authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Determination of Offering Price </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, there has not been
a public market for our Class A common stock. Consequently, the initial public offering price for our Class A common stock will be determined by negotiations between us and the representatives. Among the factors to be considered in these
negotiations will be prevailing market conditions, our financial information, market valuations of other companies that we and the underwriters believe to be comparable to us, estimates of our business potential, the present state of our development
and other factors deemed relevant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We offer no assurances that the initial public offering price will correspond to the price at which the Class A common stock
will trade in the public market subsequent to the offering or that an active trading market for the Class A common stock will develop and continue after the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have applied to list our Class A common stock on The Nasdaq
Global Market under the trading symbol &#147;VERA&#148;. We do not intend to list the Class B common stock on any securities exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stamp Taxes </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you purchase shares of Class A common stock offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and practices of the
country of purchase, in addition to the offering price listed on the cover page of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to an
aggregate of 652,500 shares from us at the public offering price set forth on the cover page of this prospectus, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to
specified conditions, to purchase a number of additional shares proportionate to that underwriter&#146;s initial purchase commitment as indicated in the table above. This option may be exercised only if the underwriters sell more shares than the
total number set forth on the cover page of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>No Sales of Similar Securities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, our officers, directors and holders of all or substantially all our outstanding capital stock and other securities have agreed, subject to specified exceptions, not
to directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open
&#147;put equivalent position&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16a-l(h)</FONT> under the Exchange Act, or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">otherwise dispose of any shares of Class A common stock or Class B common stock, options or warrants to acquire shares of
Class A common stock, or securities exchangeable or exercisable for or convertible into shares of Class A common stock currently or hereafter owned either of record or beneficially, or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">publicly announce an intention to do any of the foregoing for a period of 180 days after the date of this prospectus
without the prior written consent of Jefferies LLC, Cowen and Company, LLC and Evercore Group L.L.C. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This restriction terminates after the close
of trading of the Class A common stock on and including the 180th day after the date of this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Jefferies LLC, Cowen and Company, LLC and Evercore Group
L.L.C. may, in their sole discretion and at any time or from time to time before the termination of the <FONT STYLE="white-space:nowrap">180-day</FONT> period release all or any portion of the securities subject to
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. There are no existing agreements between the underwriters and any of our shareholders who will execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, providing consent to the
sale of shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stabilization </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, pursuant to Regulation M under the Exchange Act, certain persons participating in the offering may engage in short sale
transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the Class A common
stock at a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either &#147;covered&#148; short sales or &#147;naked&#148; short sales. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares of our Class A common stock in
this offering. The underwriters may close out any covered short position by either exercising their option to purchase additional shares of our Class A common stock or purchasing shares of our Class A common stock in the open market. In determining
the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the
option to purchase additional shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Naked&#148; short sales are sales in excess of the option to purchase additional shares of our Class A common stock.
The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares of
our Class A common stock in the open market after pricing that could adversely affect investors who purchase in this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A stabilizing bid is a bid for the
purchase of shares of Class A common stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the Class A common stock. A syndicate covering transaction is the bid for or the purchase of shares of Class A common
stock on behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to other purchase transactions, the underwriter&#146;s purchases to cover the syndicate short sales may have the
effect of raising or maintaining the market price of our Class A common stock or preventing or retarding a decline in the market price of our Class A common stock. As a result, the price of our Class A common stock may be higher than the price that
might otherwise exist in the open market. A penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the Class A common stock originally
sold by such syndicate member are purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we
nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our Class A common stock. The underwriters are not obligated to engage in
these activities and, if commenced, any of the activities may be discontinued at any time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters may also engage in passive market making transactions
in our Class A common stock on The Nasdaq Global Market in accordance with Rule&nbsp;103 of Regulation&nbsp;M during a period before the commencement of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
offers or sales of shares of our Class A common stock in this offering and extending through the completion of distribution. A passive market maker must display its bid at a price not in excess
of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits are exceeded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Electronic Distribution </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A prospectus in electronic format may be made
available by <FONT STYLE="white-space:nowrap">e-mail</FONT> or on the web sites or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may view offering terms online and
may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of shares of Class A common stock for sale to online brokerage account holders. Any such allocation for online distributions will be made by the
underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#146; web sites and any information contained in any other web site maintained by any of the underwriters is not
part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Activities and
Relationships </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters and certain of their respective affiliates are full service financial institutions engaged in various activities, which may
include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriters and certain of their respective
affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the ordinary course of their various business activities, the underwriters and certain of their respective affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities
activities may involve securities and/or instruments issued by us and our affiliates. If the underwriters or their respective affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their
customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our
securities or the securities of our affiliates, including potentially the Class A common stock offered hereby. Any such short positions could adversely affect future trading prices of the Class A common stock offered hereby. The underwriters and
certain of their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time
hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Directed Share Program </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At our request, the underwriters have reserved for sale, at the initial public offering price, up to 3% of the shares of Class A common stock offered hereby to our
directors, officers, employees, business associates and related persons through a directed share program. Shares purchased through the directed share program will not be subject to a lock-up restriction, except in the case of shares purchased by any
of our directors or officers and certain of our employees and existing equity holders. The number of shares of Class A common stock available for sale to the general public will be reduced to the extent these individuals purchase such reserved
shares. The underwriters will receive the same discount from such reserved shares as they will from other shares of our Class A common stock sold to the public in this offering. We have agreed to indemnify the underwriters against certain
liabilities and expenses, including liabilities under the Securities Act, in connection with sales of the reserved shares. Jefferies LLC will administer our directed share program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Disclaimers About <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Jurisdictions </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Canada </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(A) Resale Restrictions </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The distribution of the securities in Canada is being made only in the provinces of Ontario, Quebec, Alberta, British Columbia, Manitoba, New Brunswick and Nova Scotia
on a private placement basis exempt from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades of these securities are made. Any resale of the securities in Canada must be made
under applicable securities laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable Canadian securities
regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the securities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(B) Representations of Canadian Purchasers </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">By purchasing the securities in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the purchase
confirmation is received that: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser is entitled under applicable provincial securities laws to purchase the securities without the benefit of a
prospectus qualified under those securities laws as it is an &#147;accredited investor&#148; as defined under National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> &#150; <I>Prospectus Exemptions</I> or Section&nbsp;73.3(1) of the
<I>Securities Act</I> (Ontario), as applicable, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser is a &#147;permitted client&#148; as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103&#151;</FONT><I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">where required by law, the purchaser is purchasing as principal and not as agent, and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser has reviewed the text above under Resale Restrictions. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(C) Conflicts of Interest </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers are hereby notified that
certain of the underwriters are relying on the exemption set out in section 3A.3 or 3A.4, if applicable, of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> &#150; <I>Underwriting Conflicts </I>from having to provide certain
conflict of interest disclosure in this document. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(D) Statutory Rights of Action </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the prospectus (including any
amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s
province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(E) Enforcement of Legal Rights </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our directors and officers as
well as the experts named herein may be located outside of Canada and, as a result, it may not be possible for Canadian purchasers to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and
the assets of those persons may be located outside of Canada and, as a result, it may not be possible to satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons
outside of Canada. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(F) Taxation and Eligibility for Investment </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers of the securities should consult their own legal and tax advisors with respect to the tax consequences of an investment in the securities in their
particular circumstances and about the eligibility of the securities for investment by the purchaser under relevant Canadian legislation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Australia </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This
prospectus is not a disclosure document for the purposes of Australia&#146;s Corporations Act 2001 (Cth) of Australia (Corporations Act), has not been lodged with the Australian Securities&nbsp;&amp; Investments Commission and is only directed to
the categories of exempt persons set out below. Accordingly, if you receive this prospectus in Australia: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">You confirm and warrant that you are either: </P></TD></TR></TABLE>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL">a &#147;sophisticated investor&#148; under section 708(8)(a) or (b)&nbsp;of the Corporations Act; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL">a &#147;sophisticated investor&#148; under section 708(8)(c) or (d)&nbsp;of the Corporations Act and that you have provided an accountant&#146;s
certificate to the Company which complies with the requirements of section 708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL">a person associated with the Company under Section&nbsp;708(12) of the Corporations Act; or </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:8%; font-size:9.5pt; font-family:ARIAL">a &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b)&nbsp;of the Corporations Act. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the Corporations
Act any offer made to you under this prospectus is void and incapable of acceptance. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">You warrant and agree that you will not offer any of the securities issued to you pursuant to this prospectus for resale
in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708 of the Corporations Act. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>European Economic Area </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In relation to each Member State of the
European Economic Area (each, a &#147;Relevant State&#148;), no shares have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which have
been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that
the shares may be offered to the public in that Relevant State at any time: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to any legal entity which is a &#147;qualified investor&#148; as defined under Article 2 of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus
Regulation), subject to obtaining the prior consent of representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided that no such offer of the shares shall require us or any of the representatives to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or
supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the purposes of this provision, the expression &#147;offer to the public&#148; in
relation to the shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any
shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No securities have been offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business
is to buy or sell shares or debentures, whether as principal or agent; or to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong (SFO) and any rules made under that Ordinance; or in other
circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong (CO) or which do not constitute an offer or invitation to the public for the purpose of the CO or the SFO.
No document, invitation or advertisement relating to the securities has been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the
contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside
Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made under that Ordinance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus
may not be issued, circulated or distributed in Hong Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the securities will be required, and is deemed by the acquisition of the
securities, to confirm that he is aware of the restriction on offers of the securities described in this prospectus and the relevant offering documents and that he is not acquiring, and has not been offered any securities in circumstances that
contravene any such restrictions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Israel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This document does not
constitute a prospectus under the Israeli Securities Law, 5728-1968 (Securities Law) and has not been filed with or approved by the Israel Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, and
any offer of the shares is directed only at, (i)&nbsp;a limited number of persons in accordance with the Israeli Securities Law and (ii)&nbsp;investors listed in the first addendum (Addendum) to the Israeli Securities Law, consisting primarily of
joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million
and &#147;qualified individuals,&#148; each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum,
for the accounts of their clients who are investors listed in the Addendum). Qualified investors are required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Japan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offering has not been and will not be registered under the
Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948 of Japan, as amended) (FIEL), and the underwriters will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan
(which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in
Japan or to, or for the benefit of, any resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and ministerial guidelines of
Japan. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Singapore </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been and will not be
lodged or registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the securities may
not be circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional
investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (SFA), (ii) to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions
specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Where the securities are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of
which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary
of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the
beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the notes pursuant to an offer made under Section&nbsp;275 of the SFA except:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising
from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">where the transfer is by operation of law; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations
2005 of Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Switzerland </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The securities
may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (SIX) or on any other stock exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure
standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or
regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither this prospectus nor any other offering or marketing material relating to the offering, the company or the securities have been or will be filed with or approved
by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of securities has not been and
will not be authorized under the Swiss Federal Act on Collective Investment Schemes (CISA). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>United Kingdom </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No shares have been offered or will be offered
pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the shares which has been approved by the Financial Conduct Authority, except that the shares may be offered to the public in the
United Kingdom at any time: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(a) to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(b) to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation), subject to obtaining the
prior consent of the representatives for any such offer; or </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(c) in any other circumstances falling within Section&nbsp;86 of the FSMA, </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided that no such offer of the shares shall require the Issuer or any Manager to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or supplement a
prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the shares in the United Kingdom means the communication in any form and by any
means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares and the expression &#147;UK Prospectus Regulation&#148; means Regulation (EU)
2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_19"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The validity of the shares of our Class A common stock being offered in this prospectus will be passed upon for us by Cooley LLP. Certain legal matters in connection
with this offering will be passed upon for the underwriters by Goodwin Procter LLP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_20"></A>EXPERTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The financial statements of Vera Therapeutics, Inc. as of December&nbsp;31, 2019 and 2020, and for each of the years in the
<FONT STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31, 2020, have been included herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing
elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="tx96328_21"></A>WHERE YOU CAN FIND
ADDITIONAL INFORMATION </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with
respect to the shares of Class A common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all the information set forth in the registration statement, some of which is
contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our Class A common stock, we refer you to the registration statement, including the exhibits
filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the
registration statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC also
maintains an internet website that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also maintain a website at www.veratx.com, at which, following the completion of this offering, you may access these materials free of charge as soon as reasonably
practicable after they are electronically filed with, or furnished to, the SEC. Information contained in, or accessible through, our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is only as an
inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>VERA THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="index"></A><A NAME="tx96328_22"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin96328_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin96328_2">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin96328_3">Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin96328_4">Statements of Redeemable Convertible Preferred Stock and Stockholders&#146;
Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin96328_5">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin96328_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin96328_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the Stockholders and Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Vera Therapeutics, Inc.: </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Opinion on the Financial Statements </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have audited the accompanying
balance sheets of Vera Therapeutics, Inc. (the Company) as of December&nbsp;31, 2019 and 2020, the related statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders&#146; deficit, and cash flows for
each of the years in the two-year period ended December&nbsp;31, 2020, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the
Company as of December&nbsp;31, 2019 and 2020, and the results of its operations and its cash flows for each of the years in the two-year period ended December&nbsp;31, 2020, in conformity with U.S. generally accepted accounting principles. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Basis for Opinion </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These financial statements are the responsibility of the
Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">/s/ KPMG LLP </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have served as the Company&#146;s auditor since 2018. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">San Francisco, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">March 19, 2021, except as to note 15B, which is as of
May 10, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin96328_2"></A>Balance Sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(In
thousands, except share amounts) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,195</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,654</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted cash, current</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">557</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,565</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,261</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted cash, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,394</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,381</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54,554</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities, redeemable convertible preferred stock, and stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">342</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">909</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Capital lease payable, current</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restructuring liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">962</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,060</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,406</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Capital lease payable, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restructuring liability, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,634</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued and other noncurrent liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">764</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,834</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,326</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Commitments and contingencies (Note 11)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred stock, $0.001 par value; 15,907,207 and 182,772,372 shares authorized as
of December&nbsp;31, 2019 and 2020, respectively; 14,015,773 and 182,772,372 shares issued and outstanding as of December&nbsp;31, 2019 and 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,095</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,576</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Class&nbsp;A common stock, $0.001 par value; 23,000,000 and 273,986,920 shares authorized as of
December&nbsp;31, 2019 and 2020, respectively; 322,007 and 355,296 shares issued and outstanding as of December&nbsp;31, 2019 and 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Class&nbsp;B <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock, $0.001 par value; no shares
and 21,593,607 shares authorized as of December&nbsp;31, 2019 and 2020, respectively; no shares issued and outstanding as of December&nbsp;31, 2019 and 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,486</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,099</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities, redeemable convertible preferred stock, and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,381</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54,554</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin96328_3"></A>Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,290</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,206</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,410</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,039</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,996</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,961</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,241</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gain on issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,076</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53,412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(40.14</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(166.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295,328</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin96328_4"></A>Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(In thousands, except share amounts) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>REDEEMABLE<BR>CONVERTIBLE<BR>PREFERRED STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADDITIONAL<BR><FONT STYLE="white-space:nowrap">PAID-IN</FONT><BR>CAPITAL</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED<BR>DEFICIT</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>STOCKHOLDERS&#146;<BR>DEFICIT</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>Balance as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,015,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,095</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312,082</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,172</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,008</TD>
<TD NOWRAP VALIGN="bottom">)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Issuance of Class&nbsp;A common stock upon exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,925</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>Balance as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,015,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,095</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322,007</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,486</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Issuance of Class&nbsp;A common stock upon exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">282</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">282</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Issuance of Series C redeemable convertible preferred stock, net of issuance costs of $389</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,180,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,611</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Issuance of Series C redeemable convertible preferred stock upon extinguishment of convertible notes</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,404,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,749</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Issuance of Series C redeemable convertible preferred stock for license</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,171,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,121</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>Balance as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,772,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">139,576</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355,296</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(91,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(89,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin96328_5"></A>Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">509</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Impairment loss on property and equipment and intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,185</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Issuance of Series C redeemable convertible preferred stock for license</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,121</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Restructuring costs, net of cash paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,423</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> interest expense on convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Issuance costs for convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Gain on issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,076</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.67em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Prepaid expense and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.67em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.67em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Grants receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.67em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.67em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Accrued and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.67em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.78em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Proceeds from the sale of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.78em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Proceeds from issuance of Series C redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Payment of issuance costs related to issuance of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Proceeds from issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,602</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Payment of issuance costs related to convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.11em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Payment on capital lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.78em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,290</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Net (decrease) increase in cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,439</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,109</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,558</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,558</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,997</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Reconciliation of cash and cash equivalents and restricted cash to the balance sheets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,195</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,654</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">343</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Total cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,558</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,997</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>Supplemental disclosure of cash flow information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Purchases of property and equipment through capital leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Issuance of Series C redeemable convertible preferred stock for license</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,121</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Issuance of Series C redeemable convertible preferred stock upon extinguishment of convertible notes</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,736</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Receivables on exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin96328_6"></A>Notes to Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar amounts in thousands, except per share data) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1.
Organization and Description of the Business </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Description of business </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:ARIAL">Vera Therapeutics, Inc., (the&nbsp;&#147;Company&#148;) is a clinical stage biotechnology company focused on developing and commercializing
transformative treatments for patients with serious immunological diseases. The Company is headquartered in South San Francisco, California and was incorporated in May 2016 in Delaware. In 2017, the Company acquired all of the outstanding shares of
PNA Innovations, Inc. (&#147;PNAi&#148;), which was based in Woburn, Massachusetts. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidity </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the
satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result
from the outcome of this uncertainty. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has incurred recurring net operating losses since its inception and had an accumulated deficit of $91,447 as of
December&nbsp;31, 2020. The Company had cash and cash equivalents of $53,654 as of December&nbsp;31, 2020 and has not generated positive cash flow from operations. To date, the Company has been able to fund its operation primarily through the
issuance of redeemable convertible preferred stock and convertible notes. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company expects to continue to generate operating losses for the foreseeable future.
There can be no assurance that the Company will ever earn revenues or achieve profitability or, if achieved, that they will be sustained on a continuing basis. If the Company is unable to obtain funding, the Company will be forced to delay or reduce
some or all of its product development programs, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although the Company continues to pursue these plans, there is no assurance that the Company
will be successful in obtaining sufficient future funding on terms acceptable to the Company to fund continuing operations, if at all. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company believes that it
has sufficient resources to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance date of these financial statements. While the Company believes that its current cash and cash equivalents are
adequate to meet its needs for the next 12 months, the Company may need to raise additional equity or borrow funds in order to achieve its longer-term business objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. Basis of Presentation and Significant Accounting Policies </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Basis of
Presentation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of
America (&#147;GAAP&#148;). The U.S.&nbsp;dollar is the Company&#146;s functional and reporting currency. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Reclassification </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain reclassification of prior period amounts related to restructuring activities has been made to conform to the current year presentation. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Emerging Growth Company Status </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is an emerging growth
company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#147;JOBS Act&#148;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act
until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private
companies until the earlier of the date that it (1)&nbsp;is no longer an emerging growth company or (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may
not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The preparation of the Company&#146;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management estimates that affect the reported amounts of assets and liabilities
include useful lives of fixed and intangible assets, the accrual of research and development expenses, restructuring liabilities, fair value of common stock and <FONT STYLE="white-space:nowrap">stock-based</FONT> compensation expense, and the
valuation allowance for deferred tax assets. The Company evaluates and adjusts its estimates and assumptions on an ongoing basis using historical experience and other factors. Actual results could differ materially from those estimates. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Segment Information </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company operates as a single operating
segment. The Company&#146;s chief operating decisionmaker, its Chief Executive Officer, manages the Company&#146;s entire operations as a whole for the purposes of allocating resources, making operating decisions and evaluating financial
performance. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Concentrations of Credit Risk and Other Risks and Uncertainties </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company
maintains bank deposits in a federally insured financial institution and these deposits may exceed federally insured limits. The Company is exposed to credit risk in the event of default by the financial institution holding its cash and cash
equivalents to the extent recorded in the balance sheet. The Company has not experienced any losses on its deposits of cash and cash equivalents. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company&#146;s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company&#146;s future operating results and cause actual results to vary materially from expectations include, but are not
limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#146;s current and potential future product candidates, uncertainty of market acceptance of the Company&#146;s product
candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s product candidates require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory agencies prior to commercial sales
in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed, or the Company was unable to maintain approval for any product
candidate, it could have a materially adverse impact on the Company. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> Coronavirus </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to rapidly evolve. The extent of the impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s business, operations and development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak
and its impact on the Company&#146;s development activities, planned clinical trial enrollment, future trial sites, contract research organizations, third-party manufacturers, and other third parties with whom the Company does business, as well as
its impact on regulatory authorities and the Company&#146;s key scientific and management personnel. The ultimate impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or a similar health epidemic is highly uncertain and subject to
change. To the extent possible, the Company is conducting business as usual, with necessary or advisable modifications to employee travel and with the Company&#146;s employees working remotely. The Company will continue to actively monitor the
rapidly evolving situation related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and may take further actions that alter the Company&#146;s operations, including those that may be required by federal, state or local authorities,
or that the Company determines are in the best interests of its employees and other third parties with whom the Company does business. At this point, the extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may affect the
Company&#146;s business, operations and development timelines and plans, including the resulting impact on expenditures and capital needs, remains uncertain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash equivalents consist of
money market funds and are stated at fair value. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Restricted cash represents cash held by a financial institution as collateral for a letter of credit securing its operating lease for office and laboratory space and as
collateral for a credit card, which are classified within current and <FONT STYLE="white-space:nowrap">non-current</FONT> assets on the balance sheets. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comprehensive Loss </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Comprehensive loss consists of net loss and other
gains and losses affecting redeemable convertible preferred stock and stockholders&#146; deficit that, under U.S. GAAP, are excluded from net loss. The Company has no items of other comprehensive loss for the years ended December&nbsp;31, 2019 and
2020. As such, net loss equals comprehensive loss. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Property and Equipment, Net </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property and equipment are recorded at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of
the asset category, for which each category the useful life is estimated at five years. Leasehold improvements are capitalized and amortized over the shorter of the lease term or the estimated useful life of the related asset. Expenditures for
repairs and maintenance of assets are charged to expense as incurred, whereas major improvements are capitalized as additions to property and equipment. Amortization of assets under capital leases is included in depreciation expense. Upon retirement
or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is reflected in the statement of operations and comprehensive loss. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Impairment of <FONT STYLE="white-space:nowrap">Long-Lived</FONT> Assets </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company reviews its <FONT STYLE="white-space:nowrap">long-lived</FONT> assets, including property and equipment and intangible assets, for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its
eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. During the years ended December&nbsp;31, 2019 and
2020, the Company recorded asset impairments totaling $10 and $1,185, respectively, on certain intangible assets and certain laboratory and office equipment (see Note 3). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and Development Costs </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development costs are
expensed as incurred and consist primarily of employees&#146; salaries and related benefits, including stock-based compensation and termination expenses for employees engaged in research and development efforts, allocated overhead including rent,
depreciation, information technology and utilities, contracted services, license fees, and external expenses to conduct and support the Company&#146;s operations that are directly attributable to the Company&#146;s research and development efforts.
Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Costs incurred in obtaining technology licenses including upfront and milestone payments incurred under the Company&#146;s licensing agreements are recorded as expense
in the period in which they are incurred, provided that the licensed technology, method or process has no alternative future uses other than for the Company&#146;s research and development activities. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research Contract Costs and Accruals </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company enters into various
research and development and other agreements with commercial firms, researchers, and others for provisions of goods and services from time to time. These agreements are generally cancellable, and the related costs are recorded as research and
development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments
and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ materially from the Company&#146;s estimates. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Redeemable Convertible Preferred Stock </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company records all
shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The carrying value of the Company&#146;s redeemable convertible preferred stock is adjusted to reflect dividends if and
when declared by the Company&#146;s board of directors. No dividends have been declared by the board of directors since inception. The Company classifies its redeemable convertible preferred stock separate from total stockholders&#146; deficit, as
the redemption of such stock is not solely under the control of the Company. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Stock-Based</FONT> Compensation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company recognizes compensation expense based on estimated fair values for all stock-based payment awards made to the Company&#146;s employees, nonemployee
directors and consultants that are expected to vest. The valuation of stock option awards is determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the Company to make
assumptions and judgements about the inputs used in the calculations, such as the fair value of the common stock, expected term, expected volatility of the Company&#146;s common stock, risk-free interest rate and expected dividend yield. The
valuation of restricted stock awards is measured by the fair value of the Company&#146;s common stock on the date of the grant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For all stock options granted, the
Company calculated the expected term using the simplified method (derived from the average midpoint between the weighted average vesting period and the contractual term of the award) for &#147;plain vanilla&#148; stock option awards, as the Company
has limited historical information to develop expectations about future exercise patterns and post vesting employment termination behavior.&nbsp;The estimate of expected volatility is based on comparative companies&#146; volatility. The risk-free
rate is based on the yield available on United States Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> issues corresponding to the expected term of the award. The Company records forfeitures when they occur. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of the shares of common stock underlying the stock options has historically been determined by the board of directors with the assistance of management
and input from an independent third-party valuation firm, as there was no public market for the common stock. The board of directors determines the fair value of the Company&#146;s common stock by considering a number of objective and subjective
factors, including the valuation of comparable companies, sales of redeemable convertible preferred stock, the Company&#146;s operating and financial performance, the lack of liquidity of common stock, and general and industry specific economic
outlook, amongst other factors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which
is generally the vesting period of the award. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounts for income taxes using the asset
and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#146;s tax returns. Deferred tax
assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in
deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight
of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets
is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a <FONT
STYLE="white-space:nowrap">two-step</FONT> process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing
authorities. If the tax position is deemed <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the
benefit that may be recognized is the largest amount that is more likely than not of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax allowance, or unrecognized tax benefits, that are
considered appropriate as well as the related net interest and penalties. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Net Loss Per Share Attributable to Common Stockholders </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net loss per share of common stock is computed using the <FONT STYLE="white-space:nowrap">two-class</FONT> method required for multiple classes of common stock and
participating securities based upon their respective rights to receive dividends as if all income for the period has been distributed. The rights, including the liquidation and dividend rights and sharing of losses, of the Class&nbsp;A and
Class&nbsp;B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share
attributed to common stockholders is therefore the same for Class&nbsp;A and Class&nbsp;B common stock on an individual or combined basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s
participating securities include the Company&#146;s redeemable convertible preferred stock, as the holders are entitled to receive noncumulative dividends on a pari passu basis in the event that a dividend is paid on common stock. The Company also
considers any shares issued on the early exercise of stock options subject to repurchase to be participating securities because holders of such shares have <FONT STYLE="white-space:nowrap">non-forfeitable</FONT> dividend rights in the event a
dividend is paid on common stock. The holders of redeemable convertible preferred stock, as well as the holders of early exercised shares subject to repurchase, do not have a contractual obligation to share in losses of the Company, and therefore
during periods of loss there is no allocation required under the <FONT STYLE="white-space:nowrap">two-class</FONT> method. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic net loss per share attributable to
common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Diluted net loss per share is computed by giving effect to all potentially dilutive securities outstanding for the period using the treasury stock method or the <FONT
STYLE="white-space:nowrap">if-converted</FONT> method based on the nature of such securities. For periods in which the Company reports net losses, diluted net loss per common share attributable to common stockholders is the same as basic net loss
per common share attributable to common stockholders, because potentially dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Leases </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company leases office and laboratory space under
operating leases and laboratory equipment under capital leases. Leases for which the Company assumes substantially all risks and rewards incidental to ownership of the leased assets are classified as capital leases. The leased assets and the
corresponding lease liabilities (net of interest charges) are recognized on the balance sheet as property and equipment, based on the cost of the equipment, and borrowings, respectively, at the inception of the related lease. Each lease payment is
apportioned between the reduction of the outstanding lease liability and the related interest expense. The interest expense is recorded on a basis that reflects a constant periodic rate of interest on the outstanding finance lease liability. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Leases for which substantially all risks and rewards incidental to ownership are retained by the lessors are classified as operating leases. Payments made under
operating leases (net of any incentive received from the&nbsp;lessors) are recorded on a <FONT STYLE="white-space:nowrap">straight-line</FONT> basis over the period of the lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Restructuring Costs </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Restructuring costs primarily consist of contract termination costs related to leases and employee termination costs. The Company recognizes restructuring charges when
the liability has been incurred. Key assumptions in determining the restructuring costs include the terms and payments that may be negotiated to terminate certain contractual obligations, cease use date of leased property and equipment, and the
timing of employees leaving the Company. Accretion expenses related to restructuring costs are included in general and administrative expenses. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fair Value
Option </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The convertible notes issued in 2020, for which the Company elected the fair value option, are accounted for at fair value on a recurring basis with
changes in fair value recognized in the statement of operations and comprehensive loss. Interest accrued on the convertible notes is recorded to interest expense. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fair Value Measurements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Fair value is defined as the exchange price
to sell an asset or transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Fair value should be based on the
assumptions market participants would use when pricing the asset or liability. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Fair value measurements are classified and disclosed in one of the following three categories: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Level&nbsp;1 &#150; Quoted unadjusted prices for identical instruments in active markets. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Level&nbsp;2 &#150; Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not
active, and <FONT STYLE="white-space:nowrap">model-derived</FONT> valuations in which all observable inputs and significant value drivers are observable in active markets. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Level&nbsp;3 &#150; Model derived valuations in which one or more significant inputs or significant value drivers are unobservable, including
assumptions developed by the Company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The carrying amounts of the Company&#146;s cash and cash equivalents, prepaid expenses and other current assets, accounts
payable and accrued expenses approximate their fair value due to their <FONT STYLE="white-space:nowrap">short-term</FONT> nature. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Money market funds are highly
liquid investments that are actively traded. The pricing information for the Company&#146;s money market funds are readily available and can be independently validated as of the measurement date. This approach results in the classification of these
securities as Level&nbsp;1 of the fair value hierarchy. There were no transfers between Levels 1, 2, or 3 for any of the periods presented. As of December&nbsp;31, 2019, and 2020, the Company held $2,470 and $52,301, respectively, in money market
funds with no unrealized gains or losses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The estimated fair value of the convertible notes, which is classified as Level&nbsp;3 of the fair value hierarchy, is
determined by using a scenario-based analysis that estimates the fair value of the convertible notes based on the probability-weighted present value of expected future investment returns, considering possible outcomes available to the noteholder,
including conversions in subsequent equity financings, change of control transactions, settlement and dissolution. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Recently Adopted Accounting Pronouncements
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November&nbsp;2016, the FASB&nbsp;issued Accounting Standards Update <FONT STYLE="white-space:nowrap">(&#147;ASU&#148;)&nbsp;2016-18,</FONT>
<I>Statement of Cash Flows &#150; Restricted Cash</I> <I>(Topic</I><I></I><I>&nbsp;230)</I>. This standard requires companies to include amounts generally described as restricted cash and restricted cash equivalents in cash and cash equivalents when
reconciling <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">beginning-of-period</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-period</FONT></FONT> total amounts shown on the statement of
cash flows. The Company adopted this standard as of January&nbsp;1, 2019 on a retrospective basis. The adoption of this standard did not have a material impact on its financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June&nbsp;20, 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT>
<I>Compensation&#151;Stock Compensation (Topic</I><I></I><I>&nbsp;718): Improvements to Nonemployee Share-Based Payment Accounting</I>, to reduce cost and complexity and to improve financial reporting for share-based payments issued to nonemployees
(for example, service providers, external legal counsel, suppliers, etc.). This includes allowing for the measurement of awards at the grant date and recognition of awards with performance conditions when those conditions are probable, both of which
are earlier than under current guidance for nonemployee awards. The Company adopted this standard as of January&nbsp;1, 2020 on a retrospective basis. The adoption of this standard did not have a material impact on its financial statements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT> <I>Disclosure Framework &#150; Changes to the Disclosure Requirements for
Fair Value Measurement</I>, which amends ASC 820, Fair Value Measurement. This standard modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. The Company adopted this standard as of
January&nbsp;1, 2020 on a retrospective basis. The adoption of this standard did not have a material impact on its financial statements. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Recently Issued
Accounting Pronouncements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In February 2016, the FASB issued ASU No.&nbsp;2016-02<I>, Leases (Topic 842)</I>, subsequently amended by ASU <FONT
STYLE="white-space:nowrap">2018-10,</FONT> ASU <FONT STYLE="white-space:nowrap">2018-11,</FONT> ASU <FONT STYLE="white-space:nowrap">2018-20,</FONT> ASU <FONT STYLE="white-space:nowrap">2019-01</FONT> and ASU
<FONT STYLE="white-space:nowrap">2019-10,</FONT> which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessors and lessees of a contract. The new standard requires lessees to apply a dual
approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on
an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability for
all leases with a term of greater than 12 months regardless of their classification on the balance sheets. Leases with a term of 12 months or less may be accounted for similar to existing guidance for operating leases today. The Company intends to
utilize the modified retrospective approach to adopt this standard effective January&nbsp;1, 2022. Additionally, the Company intends to utilize the package of available practical expedients, which allows it to (i)&nbsp;not reassess whether any
expired or existing contracts are or contain leases; (ii)&nbsp;not reassess the lease classification for expired or existing leases; and (iii)&nbsp;not reassess the treatment of initial direct costs for any existing leases. The Company is currently
evaluating the impact this standard will have on its financial statements and related disclosures. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2019, the FASB issued ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> <I>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</I>, which is intended to simplify the accounting for income taxes. This standard removes certain exceptions to the general
principles in Topic 740 and also clarifies and amends existing standards to improve consistent application. The new standard will be effective beginning January&nbsp;1, 2022. The Company is currently evaluating the impact this standard will have on
its financial statements and related disclosures. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2020, the FASB issued ASU No. <FONT STYLE="white-space:nowrap">2020-06,</FONT><I>&nbsp;Debt&#151;Debt
with Conversion and Other Options (Subtopic <FONT STYLE="white-space:nowrap">470-20)</FONT></I><I></I>&nbsp;and<I>&nbsp;Derivatives and Hedging&#151;Contracts in Entity&#146;s Own Equity (Subtopic
<FONT STYLE="white-space:nowrap">815-40)</FONT></I>.<I></I>&nbsp;This standard simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC
<FONT STYLE="white-space:nowrap">470-20</FONT> that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock.&nbsp;ASU <FONT
STYLE="white-space:nowrap">2020-06</FONT> is effective for the Company for annual reporting periods, and interim reporting periods within those annual periods, beginning after December&nbsp;15, 2023, and early adoption is permitted. The Company is
currently evaluating the impact this standard will have on its financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. OTHER FINANCIAL STATEMENT INFORMATION </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Prepaid Expense and Other Current Assets </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current
assets consist of the following. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Receivables on exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">557</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Property and Equipment, net </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property and equipment, net consists of the
following as of December&nbsp;31, 2019. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Equipment under capital lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">734</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">421</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,414</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,020</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depreciation and amortization expense for the years ended December&nbsp;31, 2019 and 2020 was $432 and $251, respectively, including amortization expense related to
capital leases of $184 and $108 for the years ended December&nbsp;31, 2019 and 2020, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the year ended December&nbsp;31,&nbsp;2019, the Company
disposed of certain laboratory equipment, incurring a loss on disposal of $94, which is included in research and development expense in the Company&#146;s statement of operations and comprehensive loss. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the year ended December&nbsp;31, 2020, the Company determined that its property and equipment had no future alternative use and recorded an impairment charge of
$1,185. The Company recorded an impairment charge of $1,039 for laboratory equipment and furniture and $146 for office equipment to research and development and general and administrative expense, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Accrued and Other Current Liabilities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accrued and other current liabilities consist of the following. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued payroll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. CONVERTIBLE NOTES </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March, April, and May 2020, the Company issued
convertible notes to certain existing investors of the Company for cash. The principal amount of the convertible notes was $5,602 in the aggregate with a fixed accrued interest rate of 4% per annum. The convertible notes were either due on or after
December&nbsp;31, 2020 or upon a change of control of the Company, unless earlier converted. No principal or interest was payable prior to maturity as the convertible notes and any accrued interest would automatically convert upon a qualified
financing event at a conversion price equal to 85% of the price per share of the qualified financing. Holders also had the option to convert their notes to shares of Series B redeemable convertible stock at a conversion price equal to $4.2926 per
share on the maturity date or upon a change of control of the Company, if no qualified financing occurred prior to such date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Due to certain embedded features
within the convertible notes, the Company elected to account for the convertible notes under the fair value option. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table provides the changes in the
fair value of the convertible notes for the year ended December&nbsp;31, 2020. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,210</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Conversion into Series C redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,749</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2020, the outstanding principal, and accrued interest of $134, were automatically converted into 11,404,246 shares of the Company&#146;s Series C redeemable
convertible preferred stock in connection with the closing of the Company&#146;s Series C redeemable convertible preferred stock financing (see Note 5) at a conversion price of $0.5030 per share, which was 85% of the $0.5918 original issuance price
of the Series C redeemable convertible preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. REDEEMABLE CONVERTIBLE PREFERRED STOCK </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2020, the Company&#146;s redeemable convertible preferred stock consisted of the following balances (in thousands, except share amounts). </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ISSUE<BR>PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES<BR>AUTHORIZED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES&nbsp;ISSUED&nbsp;AND<BR>OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CARRYING<BR>VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE<BR>LIQUIDATION<BR>PREFERENCE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series Seed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,010,456</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,010,456</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,789</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,020</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">Seed-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.92</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,787,640</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,787,640</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,718</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,430</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.15</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,120,111</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,120,111</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,851</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,136</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.29</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,097,566</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,097,566</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,737</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,882</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.59</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,756,599</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,756,599</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,481</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,870</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,772,372</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,772,372</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">139,576</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">139,338</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2020, the Company issued 135,180,800 shares of Series C redeemable convertible preferred stock for a purchase price of $0.5918 per share, payable in cash.
Gross proceeds to the Company were $80,000. The Series C redeemable convertible preferred stock financing triggered the automatic conversion of the Company&#146;s outstanding convertible notes into 11,404,246 shares of Series C redeemable
convertible preferred stock based on price of $0.5030 per share (85% of the $0.5918 original issuance price of the Series C redeemable convertible preferred stock). In addition, the Company issued 22,171,553 shares of Series C redeemable convertible
preferred stock to Ares Trading S.A. (&#147;Ares&#148;), an affiliate of Merck KGaA, Darmstadt, Germany, as the initial payment for the Company&#146;s license of atacicept from Ares (see Note 9). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The holders of the Series&nbsp;Seed, <FONT STYLE="white-space:nowrap">Seed-1,</FONT> A, B, and C redeemable convertible preferred stock (together the &#147;redeemable
convertible preferred stock&#148;) have various rights, preferences, privileges, and restrictions, with respect to voting, dividends, liquidation, and conversion as follows: </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Voting </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On any matter presented to the stockholders of the Company
for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of redeemable convertible preferred stock is entitled to cast the number of
votes equal to the number of whole shares of common stock into which the shares of redeemable convertible preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Holders
of redeemable convertible preferred stock may vote, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, together with the holders of Class&nbsp;A common stock as a single class. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Dividends </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Through December&nbsp;31, 2020, no dividends have been
authorized, declared, or paid. The Company may not declare, pay or set aside any dividends on any other class or series of capital stock (other than dividends on shares of common stock payable in shares of common stock) unless the holders of
redeemable convertible preferred stock then outstanding first or simultaneously receive a dividend on each outstanding share of redeemable convertible preferred stock in an amount at least equal to (a)&nbsp;in the case of a dividend on common stock
or any class or series that is convertible into common stock, that dividend per share to equal the product of (i)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had
been converted into common stock and (ii)&nbsp;the number of shares of common stock issuable upon conversion of such share of redeemable convertible preferred stock, in each case calculated on the record date for determination of holders entitled to
receive such dividend or (b)&nbsp;in the case of a dividend on any class or series that is not convertible into common stock, at a rate per share determined by (i)&nbsp;dividing the amount of the dividend payable on each share of such class or
series of capital stock by the Original Issuance Price of such class or series of capital stock (subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (ii)&nbsp;multiplying this fraction
by an amount equal to the applicable original issue price; provided that, if the Company declares, pays or sets aside, on the same date, a dividend payable to the holders of redeemable convertible preferred stock is calculated based on the dividend
on the class or series of capital stock that would result in the highest preferred stock dividend. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each share of redeemable convertible preferred stock is convertible, at the option of the holder, at any time and from time to time, and without the payment of
additional consideration by the holder, into such number of fully paid and nonassessable shares of common stock as is determined by dividing the applicable original issue price by the applicable preferred stock conversion price in effect at the time
of conversion. The preferred stock conversion price for each share of redeemable convertible preferred stock is initially equal to the original issue price applicable to such share. Each such initial preferred stock conversion price, and the rate at
which shares of redeemable convertible preferred stock may be converted into shares of common stock, is subject to adjustment. No fractional shares of common stock will be issued upon conversion of redeemable convertible preferred stock. In lieu of
any fractional shares, the Company will pay cash equal to the fraction multiplied by the fair market value of a share of common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidation Preference
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series C redeemable
convertible preferred stock then outstanding are entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made to the holders of Series Seed, Series <FONT
STYLE="white-space:nowrap">Seed-1,</FONT> Series A, and Series B redeemable convertible preferred stock, equal to one times the original issue price of the Series C redeemable convertible preferred stock. If upon any such liquidation, dissolution or
winding up of the Company the assets of the Company available for distribution to its stockholders are insufficient to pay the holders of shares of Series C redeemable convertible preferred stock the full amount to which they shall be entitled, such
holders will share ratably in any distribution of the assets available for distribution in proportion to the respective amounts that would otherwise be payable in respect of the shares of Series C redeemable convertible preferred stock held by them
upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Thereafter, the holders of Series Seed, Series <FONT
STYLE="white-space:nowrap">Seed-1,</FONT> Series A and Series B redeemable convertible preferred stock then outstanding are entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall
be made to the holders of common stock, an amount per share equal to the greater of (i)&nbsp;one times the applicable original issue price, plus any dividends declared but unpaid thereon, or (ii)&nbsp;such amount per share as would have been payable
had all shares of such series of redeemable convertible preferred stock been converted into common stock immediately prior to such liquidation, dissolution, or winding up. If upon any such liquidation, dissolution or winding up of the Company the
assets of the Company available for distribution to its stockholders are insufficient to pay the holders of shares of redeemable convertible preferred stock the full amount to which they shall be entitled, the holders of shares of Series Seed,
Series <FONT STYLE="white-space:nowrap">Seed-1,</FONT> Series A, and Series B redeemable convertible preferred stock will share ratably in any distribution of the assets available for distribution in proportion to the respective amounts that would
otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After
the payment of all preferential amounts required to be paid to the holders of shares of redeemable convertible preferred stock, the remaining assets of the Company available for distribution to its stockholders will be distributed among the holders
of shares of Series C redeemable convertible preferred stock and common stock, pro rata based on the number of shares held by each such holder on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Redemption </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The holders of the Company&#146;s redeemable convertible
preferred stock have no rights to cause the redemption of their shares outside of a liquidation or winding up of the Company, a change in control, or a sale of substantially all of the Company&#146;s assets (a &#147;deemed liquidation event&#148;).
A deemed liquidation event would constitute a redemption event </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
that may be outside of the Company&#146;s control as a result of the preferred stockholders&#146; control of the Company&#146;s board of directors. Accordingly, the redeemable convertible
preferred shares are considered contingently redeemable and are classified as temporary equity on the balance sheets. The carrying value of the redeemable convertible preferred stock has not been adjusted to its redemption value as redemption was
not probable as of the balance sheet dates presented. The carrying value of the redeemable convertible preferred stock will be adjusted to its redemption value in the future, if redemption becomes probable. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Classification </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has classified its redeemable convertible
preferred stock separate from total stockholders&#146; deficit in the balance sheets as the redeemable convertible preferred shares are contingently redeemable upon a deemed liquidation event and in that event there is no guarantee that all
stockholders would be entitled to receive the same form of consideration. No accretion to redemption value was recorded during the years ended December&nbsp;31, 2019 and 2020 as a deemed liquidation event was not considered probable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. COMMON STOCK </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2020, the Company&#146;s
certificate of incorporation, as amended and restated, authorized the Company to issue 273,986,920 shares of Class&nbsp;A common stock and 21,593,607 shares of Class&nbsp;B common stock, each with a par value of $0.001 per share. Each share of
Class&nbsp;A common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#146;s stockholders. Class&nbsp;B common stock is <FONT STYLE="white-space:nowrap">non-voting.</FONT> The holders of Class&nbsp;A common
stock, voting exclusively and as a separate class, have the exclusive right to vote for the election of one director of the Company. Class&nbsp;A common stockholders and holders of Class&nbsp;B common stock are entitled to receive dividends, as may
be declared by the board of directors. Through December&nbsp;31, 2020, no cash dividends had been declared or paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. STOCK COMPENSATION </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2017 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2017, the Company&#146;s Board of
Directors adopted the Vera Therapeutics, Inc. 2017 Equity Incentive Plan, which provides for the grant of qualified stock options, nonqualified stock options and other awards, including restricted stock awards, to the Company&#146;s employees,
directors, and consultants to purchase up to 286,578&nbsp;shares of the Company&#146;s Class&nbsp;A common stock. The grants of stock options and restricted stock awards generally vest either (i)&nbsp;over a four-year period, with 25% vesting on the
first anniversary of the grant date and on a ratable monthly basis thereafter for the following three years, or (ii)&nbsp;on a ratable monthly basis over a three-year period and expire ten years from the date of grant. Certain awards provide for
accelerated vesting upon a change of control, as defined in the 2017 Equity Incentive Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2020, the Company&#146;s Board of Directors voted to amend the 2017
Equity Incentive Plan to increase the aggregate authorized number of Class&nbsp;A common stock to be 3,052,169 shares. No other changes were made to the 2017 Equity Incentive Plan. As of December&nbsp;31, 2020, there were 1,150,088 shares available
for future grant under the 2017 Equity Incentive Plan. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Stock-Based</FONT> Compensation Expense </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following tables summarize the <FONT STYLE="white-space:nowrap">stock-based</FONT> compensation expense for stock options and restricted stock awards granted to
employees and nonemployees that was recorded in the Company&#146;s statements of operations and comprehensive loss for the years ended December&nbsp;31, 2019 and 2020. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Employees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Nonemployees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2020, the Company had $4,219 of unrecognized stock-based compensation expense related to unvested stock options and restricted stock awards,
which is expected to be recognized over a weighted-average period of approximately two years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of stock options granted during the&nbsp;years ended
December&nbsp;31, 2019 and 2020, was estimated using the Black-Scholes option pricing model based on the following weighted average assumptions. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.5&nbsp;&#150;&nbsp;6.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.5&nbsp;&#150;&nbsp;6.1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">74.0%&nbsp;&#150;&nbsp;74.3%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">86.1%&nbsp;&#150;&nbsp;92.5%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.19%&nbsp;&#150;&nbsp;2.22%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.41%&nbsp;&#150;&nbsp;1.67%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes the Company&#146;s option activity for the year ended December&nbsp;31, 2020. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>OPTIONS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED-<BR>AVERAGE<BR>EXERCISE<BR>PRICE PER<BR>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED-<BR>AVERAGE<BR>REMAINING<BR>CONTRACTUAL<BR>LIFE (YEARS)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE<BR>INTRINSIC<BR>VALUE<BR>(000S)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance&#151;December 31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,599</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.88</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,865,091</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.45</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cancelled and forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(134,892</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.75</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance&#151;December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,855,507</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.99</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Options exercisable &#150; December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.84</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unvested and expected to vest &#150; December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,818,708</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.96</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The aggregate intrinsic value of stock options exercised during the year ended December&nbsp;31, 2019 and 2020 was $6 and $1, respectively. The weighted average grant
date fair value of options granted during the years ended December&nbsp;31, 2019 and 2020 was $4.06 per share and $2.24 per share, respectively.<B><I> </I></B> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Restricted Stock Awards </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2020, in conjunction with the
Series C redeemable convertible preferred stock issuance, the Company restricted 49,636 shares of fully issued and outstanding Class&nbsp;A common stock held by the Company&#146;s Chief Executive Officer and founder. The restriction allows the
Company to repurchase shares that have not vested. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
vesting term of restricted stock is one year. The grant date fair value of the restricted shares was $6.37. The following table summarizes the activity for the Company&#146;s restricted stock for
the year ended December&nbsp;31, 2020. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF&nbsp;SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unvested as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,613</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unvested as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,363</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For each of the years ended December&nbsp;31, 2019 and 2020, the Company recognized $1 and $55, respectively, of stock-based compensation expense related to restricted
stock awards that vested during the periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. EMPLOYEE BENEFIT PLANS </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company sponsors a qualified 401(k)&nbsp;defined contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation
limited to a maximum annual amount set by the Internal Revenue Service. There were no employer contributions under this plan for fiscal 2019 and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9.
LICENSES AND COLLABORATIONS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Carnegie Mellon University </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
2012, PNAi entered into a license agreement with Carnegie Mellon University (as amended, the &#147;CMU License Agreement&#148;), which was assigned to the Company upon the closing of the Company&#146;s acquisition of PNA in 2017. The CMU License
Agreement provided exclusive, worldwide rights to certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to synthetic oligomers. Under the CMU License Agreement, the Company is obligated to pay Carnegie Mellon University up to
$9,000 in aggregate milestone payments upon the achievement of specific <FONT STYLE="white-space:nowrap">sales-based</FONT> milestones, which have not yet been met. The Company is also responsible for reimbursement for future patent expenses and
payment of future royalties based on any sales of a licensed product at a percentage in the low single digits. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the Company were to sublicense the technology
licensed pursuant to the CMU License Agreement, the Company would be obligated to pay CMU a percentage ranging in the low double-digits of specified sublicensing income received, subject to reduction for a specified percentage of sublicensing income
payments above a specified threshold that the Company may be obligated to pay other third parties. The Company did not achieve any of the development or sales milestones. Accordingly, no royalty or development milestone payments were made nor
required to be made under this agreement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Yale University </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
2017, PNAi entered into a collaborative research agreement (the &#147;Yale CRA&#148;) and license agreement (the &#147;Yale License Agreement&#148;) with Yale University, which were assigned to the Company upon the closing of the acquisition of PNAi
by the Company in 2017. The purpose of the agreements was to fund the Yale University research program in the field of <FONT STYLE="white-space:nowrap">nanoparticle-sized</FONT> nucleic acid mimics and peptide nucleic acids as gene editing
therapeutics in return for an exclusive license to certain related patent rights owned by Yale University and the option to license any patents discovered or generated under the terms of the collaborative research agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Yale CRA required funding the labs of collaborators with $1,500 per year for a minimum of two&nbsp;years. The Yale CRA expired in 2019. No payments were made to
Yale University pursuant to the Yale CRA during the year ended December&nbsp;31, 2019, with no future obligation under this commitment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As consideration for the
Yale License Agreement, PNAi paid an initial fee of $37 and had the option to issue 5% of the company&#146;s common stock on a fully diluted, as converted basis. If the shares were not issued, the agreement
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
could be terminated at Yale University&#146;s option. After the completion of the merger with PNAi, the Company exercised the option and issued 264,301&nbsp;shares of common stock to Yale
University with a fair value of $100. Under the Yale License Agreement, the Company reimbursed Yale University for patent related expenses. The Company reimbursed Yale University $45 for patent related expenses for the year ended December&nbsp;31,
2019. The Company and Yale agreed to terminate the Yale License Agreement in 2020 and there are no future payment obligations under the Yale License Agreement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Ares Trading S.A. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2020, the Company entered into a
license agreement with Ares (the &#147;Ares Agreement&#148;), pursuant to which the Company obtained an exclusive worldwide license to certain patents and related <FONT STYLE="white-space:nowrap">know-how</FONT> to research, develop, manufacture,
use and commercialize therapeutic products containing atacicept, a recombinant fusion protein used to inhibit B cell growth and differentiation, which could potentially treat some autoimmune diseases. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As consideration for the Ares Agreement, the Company issued to Ares a <FONT STYLE="white-space:nowrap">non-refundable</FONT> license issue fee of 22,171,553 shares of
Series C redeemable convertible preferred stock resulting in Ares becoming a related party to the Company. The Series C redeemable convertible preferred stock had a deemed issuance price of $0.5918 per share, or $13,121 in the aggregate. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2020, the Company has paid Ares $25,000 in milestone payments upon delivery and initiation of the transfer of specified information and
materials. The Company is obligated to pay Ares aggregate milestone payments of up to $176,500 upon the achievement of specified BLA filing or regulatory approval milestones and up to $515,000 upon the achievement of specified commercial milestones.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">non-refundable</FONT> license issue fee of $13,121 and milestone payments of $25,000 are recorded to research and development
expense. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Commencing on the first commercial sale of licensed products, the Company is obligated to pay Ares tiered royalties of low double-digit to <FONT
STYLE="white-space:nowrap">mid-teen</FONT> percentages on annual net sales of the licensed products covered by the license. The Company is obligated to pay royalties on a licensed <FONT STYLE="white-space:nowrap">product-by-</FONT> licensed product
and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis from the first commercial sale of a product<B> </B>in a country until the latest of (i)&nbsp;15&nbsp;years after the first commercial sale
of such licensed product in such country; (ii)&nbsp;the expiration of the last valid claim of a licensed patent that covers such licensed product in, or its use, importation or manufacture with respect to, such country; and (iii)&nbsp;expiration of
all applicable regulatory exclusivity periods, including data exclusivity, in such country with respect to such product. If the Company were to sublicense its rights under the Ares Agreement, the Company is obligated to pay Ares a percentage ranging
from the mid single-digit to the low double-digits of specified sublicensing income received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. INCOME TAXES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The provision for income taxes for the years ended December&nbsp;31, 2019 and 2020 consisted of the following. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">State</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current provision</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total deferred provision</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A reconciliation of the provision for income taxes computed using the U.S.&nbsp;statutory federal income tax rate
compared to the income tax provision included in the statement of operations and comprehensive loss is as follows. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tax at U.S. statutory rate on income before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,409</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,999</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">State taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Deferred tax assets and liabilities are determined based on the differences between financial reporting and income tax bases of assets and liabilities, as well as net
operating loss carryforwards and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. The significant components of the Company&#146;s deferred tax assets and liabilities are as follows. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,267</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,681</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and other tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,603</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,652</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,019</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Reserves and accruals</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">554</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,068</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,050</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,002</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,050</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total deferred tax assets, net of valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2020, the Company has federal and state net operating loss carryforwards of $44,007 and $3,531, respectively, of
which $10,246 of federal net operating loss carryforwards and $3,531 of state net operating carryforwards will begin expiring in the year 2032 and 2036, respectively, if not utilized. The&nbsp;Company also has $33,761 of federal net operating loss
carryforwards as of December&nbsp;31, 2020 that does not expire as a result of recent tax law changes. The Company has $2,159 and $1,156 of federal and state research and development tax credit carryforwards, which will begin to expire in the year
of 2037 and 2033, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Utilization of the federal and state net operating loss and tax credit carryforwards may be subject to a substantial annual
limitation due to the &#147;change in ownership&#148; provisions of the Internal Revenue Code of 1986. The annual limitation may result in the expiration of net operating losses and credits before utilization. The Company has not performed an
analysis to determine if such ownership changes have occurred. An analysis will be performed prior to recognizing the benefits of any losses or credits in the financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will
be generated to use the existing deferred tax assets. Based on the weight of all evidence including a history of operating losses, management has determined that it is not more likely than not that the net deferred tax assets will be realized. A
valuation allowance of $10,002 and $21,050 for the year ended December&nbsp;31, 2019 and 2020 has been established to offset the deferred tax assets as realization of such assets is uncertain. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounts for income taxes in accordance with authoritative accounting guidance which states the impact of an uncertain income tax position is recognized at
the largest amount that is &#147;more likely than not&#148; to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained. As of
December&nbsp;31, 2019 and 2020, the Company had no material unrecognized tax benefits. No significant interest or penalties were recorded during the years ended December&nbsp;31, 2019 and 2020. We are currently unaware of any uncertain tax
positions that could result in significant additional payments, accruals, or other material deviation in this estimate over the next 12&nbsp;months. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company
files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by the United States and state jurisdictions where applicable. There are currently no
pending income tax examinations. The Company&#146;s tax years from inception to 2020 are subject to examination by the federal and various state tax authorities due to the carryforward of unutilized net operating losses. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Coronavirus Aid, Relief, and Economic Security Act (the &#147;CARES Act&#148;) was enacted March&nbsp;27, 2020. The CARES Act provided for various payroll tax
incentives, changes to net operating loss carryback and carryforward rules, business interest expense limitation increases, and bonus depreciation on qualified improvement property. Additionally, the Consolidated Appropriations Act of 2021, which
was signed on December&nbsp;27, 2020, provided additional COVID relief provisions for businesses. The Company has evaluated the impact of the both statutes and has determined that any impact is not material to its financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. COMMITMENTS AND CONTINGENCIES </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The aggregate future minimum lease
payments for operating leases as of December&nbsp;31, 2020, are as follows. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>Year ending December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPERATING</B><br><B>LEASES <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SUBLEASE</B><br><B>INCOME</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,926</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,483</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,823</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Future minimum lease payments include repayment of outstanding restructuring liabilities </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Facilities Leases
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2015, PNAi entered a lease for approximately 3,800&nbsp;square feet of office and laboratory space for a term of 39 months in Woburn,
Massachusetts. In January 2018, the Company elected to renew this lease for three years, beginning in August&nbsp;2018. In connection with the lease, the Company maintains a letter of credit issued to the lessor in the amount of $50, which is
secured by restricted cash that is classified as noncurrent based on the term of the underlying lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In April 2018, the Company entered into a lease for approximately 24,606 square feet of office and life science
research space, which commenced on October&nbsp;1, 2018, when the Company obtained control of the rented space for a term of 84 months in South San Francisco, California (the South San Francisco Lease). In connection with the lease, the Company
maintains a letter of credit issued to the lessor in the amount of $293, which is secured by restricted cash that is classified as noncurrent based on the term of the underlying lease. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s total future minimum commitment due pursuant to the South San Francisco Lease is $11,128 as of December&nbsp;31, 2020. In November 2020, the Company
entered into a <FONT STYLE="white-space:nowrap">non-cancellable</FONT> sublease agreement for the facility, under the terms of which the Company is entitled to receive $8,823 in sublease payments over the term of the sublease, which ends
concurrently with the original lease in September 2025. As tenant, the Company remains responsible for the $11,128 minimum lease commitment on the facilities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company recorded rent expense totaling $1,726 and $2,089 for the years ended December&nbsp;31, 2019 and 2020, respectively. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Equipment Lease </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has certain leases on research and laboratory equipment with total future minimum commitments of $581 as of December&nbsp;31, 2020.<I> </I>The Company
recorded rent expense totaling $416 and $298 for the years ended December&nbsp;31, 2019 and 2020, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>12. RESTRUCTURING AND RELATED ACTIVITIES
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the year ended December&nbsp;31, 2019, the Company completely vacated its leased facilities in Woburn, Massachusetts. In connection with vacating the
leased spaces, the Company recorded a discounted lease-related restructuring liability, which was calculated as the present value of the estimated future facility costs for which the Company would obtain no future economic benefit over the term of
the lease, reduced for actual or estimated sublease rentals. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2020, the Company initiated a restructuring plan to reduce operating expense as a result of
the disposal of PNAi technology. The restructuring plan included reducing the number of employees, vacating leased facilities, and ceasing use of leased equipment. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of this restructuring plan, the Company completely vacated its leased facilities in South San Francisco, California, which was subleased to a third party in
November 2020, and returned certain leased equipment to the lessor. The Company recorded a discounted lease-related restructuring liability of $2,228 and $768 for the abandonment of the leased facilities and equipment, which was calculated as the
present value of the estimated future lease costs for which the Company would obtain with no future economic benefit over the term of the leases. In addition, the Company recognized restructuring liability of $321 related to severance and other
employee termination costs related to the reduction in the number of employees. The Company expects this restructuring plan to be completed in 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The activity related to the restructuring liabilities for the years ended December&nbsp;31, 2019 and 2020 are as
follows. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">LEASE-RELATED</FONT></B><br><B>EXIT&nbsp;COSTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EMPLOYEE</B><br><B>TERMINATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,996</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,317</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(609</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(309</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(918</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,584</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,596</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>13. NET LOSS PER COMMON SHARE </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following outstanding potentially
dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have been anti-dilutive (on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> basis). </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,209,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,774,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Class&nbsp;A common stock options issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,855,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unvested restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,378,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,670,884</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>14. RELATED PARTY TRANSACTIONS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2018, the Company entered into a
sublease agreement for a portion of its South San Francisco office space, the term for which commenced on December&nbsp;7, 2018. The Chief Executive Officer of the sublessor is a member of the Company&#146;s board of directors. The initial sublease
was established for approximately 400 square feet of space. Prior to the initial expiration of the sublease in April 2019, the space was expanded to approximately 3,700 square feet with the term of the lease extended for an additional two years. The
monthly rent charged by the Company to the subtenant is subject to escalating rent payments according to the terms of the Company&#146;s lease agreement, and the subtenant is required to reimburse the Company for monthly facility operating expenses
based on its proportionate share of total square footage pursuant to the lease. The Company&#146;s lease agreement provides that 50% of any profit resulting from the excess of the amount collected from the subtenant less the sum of monthly rent,
operating expenses and reimbursement of direct expenditures made by the Company in order to arrange and maintain the sublease is to be shared with the lessor. To date, no profit has been realized on the sublease arrangement as the monthly
collections from the subtenant are equivalent to the Company&#146;s cost of rent, operating expense and recovery of professional fees to arrange the sublease. In June 2020, the sublease agreement was terminated. During the years ended
December&nbsp;31, 2019 and 2020, the Company recognized $279 and $160, respectively, of sublease income under this agreement, which was recorded as a reduction to the Company&#146;s rent expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2020, the Company entered into the Ares Agreement with Ares, pursuant to which the Company obtained an
exclusive worldwide license to certain patents and related <FONT STYLE="white-space:nowrap">know-how</FONT> to research, develop, manufacture, use and commercialize therapeutic products containing atacicept, a recombinant fusion protein used to
inhibit B cell growth and differentiation, which could potentially treat some autoimmune diseases. (See Note&nbsp;9.) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>15A. SUBSEQUENT EVENTS </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January&nbsp;27, 2021, the Company entered into an asset purchase agreement with Neubase Therapeutics, Inc. (&#147;Neubase&#148;), whereby the Company agreed to sell
all assets relating to its investment in PNAi, including all inventory, machinery, intellectual property, goodwill and licenses, including the CMU License Agreement, and Neubase agreed to assume certain related liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>15B. SUBSEQUENT EVENTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On May 7, 2021, the Company filed a certificate of
amendment to its fourth amended and restated certificate of incorporation to effect a 11.5869-for-one reverse stock split of its issued and outstanding Class A common stock. Adjustments corresponding to the reverse stock split were made to the ratio
at which the Company&#146;s redeemable convertible preferred stock will convert into Class A common stock. Accordingly, all share and per share amounts related to Class A common stock, stock options and restricted stock awards for all periods
presented in the accompanying financial statements and notes thereto have been retroactively adjusted, where applicable, to reflect the reverse stock split. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>16.
EVENTS (UNAUDITED) SUBSEQUENT TO THE DATE OF THE REPORT OF THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The sale relating to the Company&#146;s investment
in PNAi closed on April 26, 2021. The Company received $796 in cash and 308,635 shares of Neubase common stock, with a fair market value of $1,759 based on the closing price reported on Nasdaq on the date the sale closed. Of the total Neubase shares
issued to the Company, 162,260 were placed in escrow to secure certain obligations under the agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:90pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>4,350,000 Shares </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96328g52t94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:90pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Class A Common Stock </B></P> <P STYLE="font-size:90pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>Preliminary Prospectus
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="font-size:90pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="bottom"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Evercore ISI</B></TD></TR>
</TABLE> <P STYLE="margin-top:90pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2021 </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise
indicated, all references to &#147;Vera,&#148; the &#147;company,&#148; &#147;we,&#148; &#147;our,&#148; &#147;us&#148; or similar terms refer to Vera Therapeutics, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;13. Other Expenses of Issuance and Distribution. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following
table sets forth all expenses to be paid by us, other than underwriting discounts and commissions, in connection with this offering. All amounts shown are estimates except for the Securities and Exchange Commission (SEC) registration fee, the
Financial Industry Regulatory Authority, Inc. (FINRA) filing fee and The Nasdaq Global Market (Nasdaq) listing fee. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Nasdaq listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">885,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Custodian transfer agent and registrar fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P> <P STYLE="margin-top:0pt;margin-bottom:1pt;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> $<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" ALIGN="right"> 3,087,671<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD NOWRAP VALIGN="bottom"> &nbsp;<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;145 of the Delaware General Corporation Law (DGCL) authorizes a court to award, or a corporation&#146;s board of directors to grant, indemnity to directors
and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities Act of 1933, as amended (Securities Act). Our amended
and restated certificate of incorporation that will be in effect immediately after the closing of this offering permits indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the DGCL, and our
amended and restated bylaws that will be in effect upon the closing of this offering provide that we will indemnify our directors and officers and permit us to indemnify our employees and other agents, in each case to the maximum extent permitted by
the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into indemnification agreements with our directors and officers, whereby we have agreed to indemnify our directors and officers to the
fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer
is or was a director, officer, employee, or agent of Vera Therapeutics, Inc., provided that such director or officer acted in good faith and in a manner that the director or officer reasonably believed to be in, or not opposed to, the best interest
of Vera Therapeutics, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At present, there is no pending litigation or proceeding involving a director or officer of Vera Therapeutics, Inc. regarding which
indemnification is sought, nor is the registrant aware of any threatened litigation that may result in claims for indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We maintain insurance policies
that indemnify our directors and officers against various liabilities arising under the Securities Act and the Securities Exchange Act of 1934, as amended, that might be incurred by any director or officer in his capacity as such. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters are obligated, under certain circumstances, under the underwriting agreement to be filed as Exhibit
1.1 to this Registration Statement, to indemnify us and our officers and directors against liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;15. Recent Sales of
Unregistered Securities. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Set forth below is information regarding unregistered securities issued by us since January&nbsp;1, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Equity Plan-Related Issuances </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Since January 1, 2018, we have granted to certain of our directors, employees and consultants options to purchase
2,514,361 shares of our Class A common stock with per share exercise prices ranging from $2.32 to $10.55 under the 2017 Plan. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Since January 1, 2018, we have issued to certain of our directors, employees and consultants an aggregate of 206,535
shares of our Class A common stock at per share purchase prices ranging from $0.02 to $10.55 pursuant to exercises of options under the PNA Stock Plan and 2017 Plan for an aggregate purchase price of $908,667.05. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Issuances of Capital Stock and Convertible Notes </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Between March 2020 to May 2020, we issued to 12 accredited investors convertible promissory notes for an aggregate
principal amount of approximately $5.6&nbsp;million. In October 2020, these notes converted into 11,404,246 shares of our Series C preferred stock. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">In October 2020, we issued an aggregate of (i) 157,352,353 shares of Series C preferred stock to 14 accredited investors
at a purchase price of $0.5918 per share for aggregate cash proceeds of approximately $93.1&nbsp;million and (ii) 11,404,246 shares of Series C preferred stock to 12 accredited investors upon the conversion of outstanding convertible promissory
notes. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offers, sales and issuances of the securities described in paragraphs (1)&nbsp;and (2) were deemed to be exempt from registration
under Rule 701 promulgated under the Securities Act as transactions under compensatory benefit plans and contracts relating to compensation, or under Section&nbsp;4(a)(2) of the Securities Act as a transaction by an issuer not involving a public
offering. The recipients of such securities were our directors, employees or bona fide consultants and received the securities under our equity incentive plans. Appropriate legends were affixed to the securities issued in these transactions. Each of
the recipients of securities in these transactions had adequate access, through employment, business or other relationships, to information about us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offers,
sales and issuances of the securities described in paragraphs (3)&nbsp;and (4)&nbsp;were deemed to be exempt under Section&nbsp;4(a)(2) of the Securities Act or Rule 506 of Regulation D under the Securities Act as a transaction by an issuer not
involving a public offering. The recipients of securities in each of these transactions acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed
to the securities issued in these transactions. Each of the recipients of securities in these transactions was an accredited investor within the meaning of Rule 501 of Regulation D under the Securities Act and had adequate access, through
employment, business or other relationships, to information about us. No underwriters were involved in these transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(a) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>EXHIBIT<BR>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>DESCRIPTION</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">1.1&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521155556/d96328dex11.htm">Form of Underwriting Agreement. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">3.1&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521155556/d96328dex31.htm">Fourth Amended and Restated Certificate of Incorporation, as amended, as currently in effect. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">3.2&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521155556/d96328dex32.htm">Form of Fifth Amended and Restated Certificate of Incorporation, to be in effect immediately after the closing of the offering.
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">3.3&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521129272/d96328dex33.htm">Second Amended and Restated Bylaws, as currently in effect. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">3.4&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521155556/d96328dex34.htm">Form of Third Amended and Restated Bylaws, to be in effect upon the closing of the offering. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">4.1&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521155556/d96328dex41.htm">Form of Class A Common Stock Certificate. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">4.2&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521129272/d96328dex42.htm">Second Amended and Restated Investors&#146; Rights Agreement, by and among the Registrant and certain of its stockholders, dated October&nbsp;29,
 2020. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">5.1&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521155556/d96328dex51.htm">Opinion of Cooley LLP. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.1&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521129272/d96328dex101.htm">Vera Therapeutics, Inc. 2017 Equity Incentive Plan. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.2&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521129272/d96328dex102.htm">Forms of Grant Notice, Stock Option Agreement and Notice of Exercise under the Vera Therapeutics, Inc. 2017 Equity Incentive Plan.
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.3&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521155556/d96328dex103.htm">Vera Therapeutics, Inc. 2021 Equity Incentive Plan. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.4&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521155556/d96328dex104.htm">Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Vera Therapeutics, Inc. 2021 Equity Incentive Plan.
 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.5&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521155556/d96328dex105.htm">Forms of Restricted Stock Unit Grant Notice and Award Agreement under the Vera Therapeutics, Inc. 2021 Equity Incentive Plan.
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.6&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521155556/d96328dex106.htm">Vera Therapeutics, Inc. 2021 Employee Stock Purchase Plan. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.7&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521155556/d96328dex107.htm">Vera Therapeutics, Inc. 2021 <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.8&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521155556/d96328dex108.htm">Form of Indemnification Agreement by and between the Registrant and its directors and executive officers. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.9&#134;&yen;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521155556/d96328dex109.htm">Amended and Restated Offer Letter by and between the Registrant
 and Marshall Fordyce, M.D., dated May&nbsp;7, 2021. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.10&#134;&yen;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521155556/d96328dex1010.htm">Amended and Restated Offer Letter by and between the Registrant
 and Joanne Curley, Ph.D., dated May&nbsp;7, 2021. </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.11&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521129272/d96328dex1012.htm">Confidential Consulting Agreement by and between the Registrant and FLG Partners, LLC, dated March&nbsp;15, 2020. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.12&#134;&yen;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521129272/d96328dex1013.htm">Offer Letter by and between the Registrant and Allen Ebens, Ph.D., dated July&nbsp;26, 2018. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.13&#134;&yen;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521129272/d96328dex1014.htm">Separation Agreement by and between the Registrant and Allen Ebens, Ph.D., dated September&nbsp;24, 2020. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.14&#134;&yen;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521155556/d96328dex1014.htm">Amended and Restated Offer Letter by and between the Registrant and Celia Lin, M.D., dated May&nbsp;7, 2021. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.15&#134;*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521129272/d96328dex1015.htm">License Agreement by and between the Registrant and Ares Trading S.A., dated as of October&nbsp;29, 2020. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">23.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d96328dex231.htm">Consent of independent registered public accounting firm. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">23.2&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001831828/000119312521155556/d96328dex51.htm">Consent of Cooley LLP (included in Exhibit&nbsp;5.1). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">24.1&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1831828/000119312521129272/d96328ds1.htm#ii96328_sig">Power of Attorney. </A></TD></TR>
</TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Previously filed. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Pursuant to Item 601(b)(10) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> certain portions of this exhibit
(indicated by asterisks) have been omitted. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&yen;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant undertakes to furnish
supplemental copies of any of the omitted schedules upon request by the SEC. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(b) Financial Statement Schedules. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All financial statement schedules are omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or the
notes thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;17. Undertakings. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(a) The undersigned
registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each
purchaser. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(b) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the
registrant under the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the U.S. Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or controlling person of the registrant in the successful
defense of any action, suit, or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(c) The undersigned registrant hereby undertakes that: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(1) For purposes of
determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance on Rule 430A and contained in a form of prospectus filed by the registrant under Rule
424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act will be deemed to be part of this registration statement as of the time it was declared effective. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(2) For
the purpose of determining any liability under the Securities Act of 1933, as amended, each post-effective amendment that contains a form of prospectus will be deemed to be a new registration statement relating to the securities offered therein, and
the offering of such securities at that time will be deemed to be the initial bona fide offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of South San Francisco, State of California on May 12, 2021. </P>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="3"><B>VERA THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marshall Fordyce, M.D.</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marshall Fordyce, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the
following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>DATE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">/s/ Marshall Fordyce, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Marshall Fordyce, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">President, Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">(Principal Executive Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 12, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">/s/ Jonathan Wolter</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Jonathan
Wolter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">(Principal Financial Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 12, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">/s/ Joseph Young</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Joseph
Young</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Senior Vice President, Finance and Chief Accounting Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">(Principal Accounting Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 12, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Kurt von Emster,
C.F.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Chairperson of the Board</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 12, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Andrew Cheng, M.D.,
Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 12, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Beth Seidenberg, M.D.</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 12, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Maha Katabi, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 12, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Patrick Enright</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 12, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Scott Morrison</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">May 12, 2021</TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="99%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL">*By: /s/ Marshall Fordyce, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Marshall Fordyce, M.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Attorney-in-Fact</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d96328dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vera Therapeutics, Inc.: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use of our report included herein and to the reference to our firm under the heading &#147;Experts&#148; in the prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ KPMG LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, California</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">May&nbsp;12,
2021</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g96328g00c36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g00c36.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2&P4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (92^A98X0DE-! 0      $L< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M 5H  QLE1QP"   "   < @4 'U9%4D%?,C%?,# R-%]B=7-I;F5S<W-E8W1I
M;VY?=C$ .$))300E       0<5ZQ"1K$\*/ST3UDI/-EVSA"24T$.@
MY0   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _@
M.$))30/R       *  #_______\  #A"24T$#0      !    !XX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              ,=   '9          !
M      $             !V0   ,=                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     %ML    !    H
M $,   '@  !]H   %K\ &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@               0  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
MQ@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%%
M 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!
M\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+!
M LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#
MQP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-
M^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_ D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #_ ET# 1$  A$! Q$!_\0
M'P !   ' 0$! 0            $%!@<("0H$ PL"_\0 9!    4# @$$"@L)
M"PD%" ,  0,$!08  @<($2$2%C%!"105455AE9;2UA,85%9QD9.4T]35%R)2
M4UAS@;+P(S,T-C<X5W27H;$9)B="=GBSM=$D*#)'MPHU0T9RIL'Q=[;A_\0
M'0$!  $$ P$               (! P0'!08)"/_$ &(1  $# @,"!@P&# H)
M @0'  $  @,$$042(1,Q!A1!46'1!R)24U1QD9*3E-+3%3)R@;'4"!8C-D)6
M=I6AM<'P%R0F,S0U-U5SM!@E='6RL[;5\2=$1666X4-78F2"I*7_V@ , P$
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M]KZX?E!ZBO/2,>H]./CP'#_0/]ZF0]V_RCJ3VOKA^4'J*\](QZCTX^/ </\
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M;1'C76(Y&L!#H8I;G0R&8$= V4L8MXP3TJXYI.Y[F_)##?QYF._19>'N*O\
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MM,D("\\\LN['IJ6IK)F4U)3S551)FV<%/&^:5^5I>[+'&'/=E8USC8&S02=
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M$O8 ;N;>EQIJ-=VHU\7.OZR)F+$6($[0KRSE/'&+TLA7"UL"G(DXC,)3OCF
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MAG0PBEK6<8CAA=AT=.Z3*#&U\[H6&\C@6M?(][6Y@TBR(3$YK&O?>.ED[9H
MN0]I&IN0 =S1H0-;JS>KOL@.=S,%X.EC1F/-D#U%L>@;2SG=._F:@77%,,R/
M,9.8+A,'K'FGJ(XFD*'4,^G)$KBIRW=-Y6P0J*,:<Z],B:R&U;<OR\'X/T''
MZZ)]'0U&&OQ_%: QB@95STL$0RPMJ,0FJXW8?'F+11["*2:60ZEY+<M'S/V;
M2"\2[&.2]RUKB3KE;E.<FQS FP!%K+,V6ZI,_P +UYZE8O!,KS+4KDF18PU*
M2'!6/L5Y3EES%IY?\::?5SU&<:Y[TEN4.&,&M[C/4J6W'>5VIY,<)U*G1C27
M+G!(['("^&@PO#Y\"PR:HI8<,IHZK#8Z^HJJ6+/B$=3B 9+58?BS9]KF93EP
MJ:-S,M/$Q[LK7-!5TOD$KV@EY(>8\IT86LN&O98#5VY^8DDY= "KB]A=S%FG
M*N3E;E)M5L9S!%7G3#&9!E'$CGJ"R9G;*L1U !)V.QTF+ZQS3#&/FC !*M(Y
MR*-/N'6&2N[4W.C>W&L9;RW(;WHG'X9T=%24H9'A,M'*S%)8Z6L;04U#2S8?
MLGY(&205M0[$""V.6.L?&U[F.=M"US@PRIW.=8F3,#&,S27%P??4]LUN7>06
M[@18 $&]L-0N8M%6=^RNX:Q*H58HT_->C_4*WY*R#D-1$K(]E34IJM=EZ-LB
MF,XJJ8X]W66Q5DD)3<KR#,I4Y BE#@"1F;4YB9$B?3<K#J/&L/X)UM6!58@[
M&<.=34].V4RTN&X4P%\U5,'RY&2OC+Q301-)B:72/L7.C$'F-]0QNC-B\/<<
MI!?(00UH(L2!>[B;@FPY"LK^RY*Y7GO,&DW0[!<+/VHQO<W&4:I\_P"(X[,H
MGCX]YQ1C%,9#H$B>)9.G%JBZ-D><J2M,X'HUBN\Y>?#"DR=*<::5MQ7! 18?
M28MCD]<S#7,9%A6'UDD,U1DJZH[:H='% UTID92PEH<T -$Y.8 %2J;O='"&
M;0$F1[20!D;H+D@_A$$7TT6G?'LE5&*^Q3L6J3)^:-/[YHEU$:E="^:'F/3D
MUG28^>H1B]:NPH:A=8XWR%L2/>2F)\CF+U3\U*W-MGD585S>UJ+VPDQRL[E4
M1- X6R85346(1XYAN&8Y11R0!YJ&3U;17 LD=&XLI9(Y:H1N#74\KVN< \AI
MQFWO2B0O:899(G]MIVL;MF21W7:"^XW()5_,::W,[2;7]&"\(SK,ZTR:2+7[
M#I;@7+>?7S*4B"3XJQ5DR78?9YCIY#%L3@.F_P!FFL,1?<[:(Q+G^3R&,)W!
M$[J#R"5Z]TXRIP.ABX/RFNAHQL(\ FAKZ.@CI8Q%555-%6/BQ#C<L^)6AG<*
MATL,<4<H#F6.4,O[5YE&4NL3,TM<ZYNQKBR[ T9+D7 O<CD.A7@C.HRV0Z)H
M'-HCK3U*9@U/R#-NA@[51 9^^2):QX;R#(=0K>W3*+L;0NB#.V8U.5.%KK&#
MX"QNMB%3'&)L<>X19%Y2]5<DPX1X[44\V"X91X7'18Z,+GIV1A];31T#C#,]
M[9GNJ0&EDHJ'LNV61S<]PYHBV1VP:X2/=*70[1KM['%[0]N6W:[R,O(+'F*N
M[&]4&73[]?TD3ZD=1"_LCT!DFLUFQIHP*L?G;%T>Q?!6ER,Q1)&;$ET+71J\
MEDC13?,(3.[7%.LR+*[V^/G*I->_W-;EARX71@\'XCAV'-X-U$6#/J<:^YLJ
MY*F=S>-1R5>W;(TOD+HIZ<M+::(&2T6SSMD'OM,<[C,TRY(OP0&_$(;;46L0
MZ^I-A?<L4TVJK4O']#^K++./-<)$N0,^,-&[]8DA^HW*>HO-F*\OR/4CCABF
MLB<G><X6QN..2)[%')Z8Y'@M*J?$*!Q0*D"9H%H<%-E_*C"L,EQW":2IP,Q.
M?4XRR\V'TV'4-511X;524\;605M1Q@T\K6/CKB&.<US7.?G:U6W2/;%(]LMP
M&Q;LSG-=M&AYU8-X-BT7U!  !LI'J&E#YF+3OK^+@VJG5/J#T98)S=H0G$$S
M--Y%)5SC9,'^7-2742Q+7]=#VEQ=HWCCNDS3:^-$M2!LQC,&Z/."9O2C:;8O
MGA\,='B/!_;85A6'8U74./4]10P1Q-;L60O.&R",3/8R6I+7P"0O<ZIA,C2X
MW!;24N>V>SY'1-? YKKD$=L-H 0 2&BQW&VHTRKL*P8NB3GAG%KC I^_95A*
MZ!195$\F2AZ/D<CGT>/9TAC1+GR0*4B ][=) BN)<UCH:B2WKCU-ZD2"_9.2
M&GZYLK*RJ;/3LI9VU$HFIHF"..GD#W!\+(P7!C8W7:U@<0T"U]%R+;918DBP
ML2;DCD-^7Q\JNK6*JI1%)W(=C;.G][Z@$?\ 6N[U%:?O'B_:5.**ZE$2B)1$
MHBP[[(;'7^7:"]9\6BC$\2>3R/2WG=DCT;CS6M>WY^>G3&4E1MC.RL[:0J<7
M1T<5AQ*1 WH4QZM8J-*(3DF&F66#S'!Z2.''L%EED9%%'BE ^261[61QL;51
M%[WO<0UC&M!+G.(  )) 5N4$Q2 "Y+'@#>22TVMTWW+EOSCI#U8NNG_,NCD<
M)90<-/6FG'LVUA8-L:X))'%--<AZAH-!FR)X1C+$C9S3%+QA.<9"U,R$YB0
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M'N+91[(Y)(3J04PA-KJ@X2C$FFJ0L3;+$NH:>3W'V9+]:&.H[DQGCTCRMA:
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MKKCAOL .3<)MU]]QHW (F777#=N-PB.%<WO<W%K'E%MWDY%)?0 "T MM  M
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M6L1PXX;,ZG?64E1/'))%-%3&I)@DC(:YLCIZ:!A.:[08GR"[77(%B33F%[$
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M9:I]/'FPTSQ2&F8T&9S"0\=L.<,3K?&N2'AU[?A@WL0+FSK$ G<.31,DZ/\
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ML^8)?HJEMY^_2^D?UJFSC[VSS6]2]Y111!=I1)99)5@;6%%66EEV!N([6V6
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M=&GB-D0?A$./CZ^H?[^/#D\-J#Q Z=')RC]%QKFUNB!\ @ ='#Q"(^/IZ?&
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M)X;4M#S&3 2VTH$@+"8\UGC+OT76+C74:;]1II?7FTUUY%70"%P!=:(76W
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M_6C_ ->BBW\+Y1_8M0'9,?X]8PZ?XIO7P?\ O@C]A[P<>%>>GV:/WR<"1_\
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M'9 LIRG".A_5AEB#GFHYE!,!Y.?HJX$<KV5ID*>*N);0\E\GB-S*N-(=0#@
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MAP6'FGJ3##+[KAQ9JB>H>U\\TLSV1QQ,?*]SW-BA:&11M<XDAD; &L:#9H
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MC&N;')$ 9GQ-?)*R-CB<V6#GAIL0= "3R $V%[D<HY+GE655<4II1$HB41<
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MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(O*EZ#_ZT?\
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MW5>$3>D?UJ.RB[U'YC>I.:<9\ -/S%/]'3C=5X1-Z1_6FRB[U'YC>I.:<9\
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M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%SRZS_P"<[E;^OQK?CL/\28P
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M $-N]PXCMT\-_P!([[#MT]'?K1X)O>_3H+[N3Q<XONW[K+9JCQ'O</\ 'O=
M^(=^O8!VVJF[G%_G^?>.D6Y+GE10VW$-^/>$!V_;;CU] \-Q&JWL#;3G!%_W
MOIR;QK8!$'XND>GK#AQV'@' -^D.H=AZ0\NX;N0ZZ7&IU/,>47&XKI8/XYGQ
M*/7]TF$?_P!E;OT\>/\ T#C7>^Q;_:5P!YOMQX._/_K:DZ;<W[V75^&_WF\*
M_P G<9_5]0NFBO:->:ZY).ST?SOL=?[N$1^#^4S+O[?%7USV _O/Q+\I:O\
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MW#QCL'P[AP\73XN ;U73?<V\0YMVAUTW[NG4V1.]T=8<.'3P#Q\=A'O;<=^
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M;](47_$??=E=]!7Z.\2_BK&?]GV;_ER:O-VK_I=5_M$W_,<OJZ'^:B_PV?\
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MB+X*OX,H_,&_\.ZI,^.WY3?I"B_XCODN^@K]'>)?Q5C/^S[-_P N35YNU?\
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M3?\ .+*<3JO!Y?,*;6+NV^5.=<;\--_SBRG$ZKP>7S"FUB[MOE3G7&_#3?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g96328g01a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g01a11.jpg
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MQ  7  $! 0$                )" 0&_\0 (Q   @(" @(" P$
M P0"!0$&!Q,2% @5  D1(__$ !H!  (# 0$               <(! 8) P7_
MQ  B$0 " @(#  ,! 0$        " P$$!1(&$1, !Q0A""+_V@ , P$  A$#
M$0 _ '[^2GR;W'F?D&SURKVL^K\7I7<Z2H4 W8)U3:87,I$VC9_J1,O6<6<8
ME885BJ]BN0\%T$#NX8,ZT_#N&8_CN*3;?1&[FFUXLV&$M+'K82_2*5+W):DZ
M=PJ3EBO9O9M:*]!5FY]J_;.<YUR:UBJ>99A^)5[Y8^DE;[**;T _P/+Y::8,
ML6Q;U-F$PFQ^6MJJO78_U-_(/[#R'\3>5RTVB\A-6D:I'4[=F01/*ZOL@-BU
MFFV4B;VOMM$BTAB%K),++,%;+(QQ?!"I=E$:T]53$\ZP0V,GB@3^AE] 01+.
M[3.I=LTX8JVL(D&S->&$ 2:>YE1S85$R?B6<IR;Z9YD=#CW)G7!I5\-=;(!8
M5B,HO*8FCE32_&.:4-KP-V4 U@JMZC%E<4[!0*EXUWYG<,6NOT5I9W)*FRLJ
M>L?L*KI]CZQYQ(##=?[&)#P?TCD(MW8'#!>OS\(^7C@"V_KOD2+5E*:XO2FP
MY2G[0'LI;"!;=/\ K3T&(/7N==NNYZ[^.QC/O3@UW&X^Y:O32M6Z-2S9IS'I
M-1[ZZVNK2R-89*&&2I.!'?3;6.^O@<\Q<97O$7(FR:/>J'!*LL&)5+982B&W
MHC')*IMU"YQB!@.*8A*>89ED#46$S>#*QQP9/ 9FMG\33R=9@%#U![@,QM7M
M",?HKL&/Z)K9,Q$3$002#![ Q*<^N<\3R/">3Y7C^12Q<U;+2I.,9A=[',8<
MTKJ#G^,4],#)2,S*W"U#-7)8 [^6MN!RSR3F[UBJM\YMJC0]>0JC+#-:M65%
MI^O:J00%4#.8-)VQK"R0$*<SF"8&)"&>4@PYX*@6"P\5KKT=5WY2VUXG(H!-
MG(6[T$1M%>L*2\8:11 B0G,%(Q!3(YGFE\TY5.0Q%.[,W:7'<96IL4)W&VL=
M@\9AS!:JQOADV+50YKB!$PP8N" 63(0A&N?KE.WKU$U=[..LNF::K8MZW_<W
MU]H9(!+!'M#Y!+ZC<C [!2D.?7Y0EF.<9_!3;^W07;M+K49?7"PX*[O^!]DB
MPA4W4H@A]%P)]%&T=]3_ 'XS.+_R^;L9CG9#*?DOMHU&7JL29Q6N'765FON$
MR!^+I->P3(%KV,S$Q/RIOFMKU!:<+V]I9T=/8V=24>*JQ>K$FWZW#$2=^*]M
M@!&$^_K'W>L0?;UP\_+QC_*1]<V[2>1UT)LV%(>)>Z5.8M3M)'3U6!0#-=BU
MW@M>YZZ[GX8/OC&8VYP2[;MX^C:MTF!^.U9J5WV*GKMZ_F<U9,1Z:!Z>1!OJ
M.W>L=2E^N#7=?=8VF[<HZ=NZJQX^LMV:Q(]I7=Q8!+Z-@4$VU.T,YB)ZYA^8
MYRA+^QEG&;W]P6K2AIUEV;"ZSCGVK@Y@(;K!$/JH2A;-2B"C89ZF(F/['P.?
MY=QF-<S*Y!V.HNOU(C\MYM2NRY6W*0/\]DURY.X3('YF.PS(SW$S'Q:OP#?'
$-^?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g96328g01x89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g01x89.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2-\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (V"^D%8X0DE-! 0      "\< 5H  QLE1QP"   " /\< @4 &U9E<F$@
M+2!38VD@1W)F>" M(%8W8E]04DE.5  X0DE-!"4      !#,D8G!^G])%_KS
M(:=Q[==M.$))300Z      #E    $     $       MP<FEN=$]U='!U=
M  4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0
M  ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E
M '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I
M;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
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M8VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;
M   .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L
M;VYG       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F
M   .             #^    X0DE-! T       0    >.$))3009       $
M    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M   ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!!X       0     .$))300:      ,U
M!@             #LP  !V0          0                         !
M              =D   #LP                     !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   #LP    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M [,     4F=H=&QO;F<   =D     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M      EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A
M=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E
M9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO
M;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T
M;&]N9P      .$))300H       ,     C_P        .$))3001       !
M 0 X0DE-!!0       0    $.$))300,     !C9     0   *    !0   !
MX   E@   !B] !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$
M;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M              $  /;6  $     TRU(4" @
M                                       18W!R=    5     S9&5S
M8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    4
M9UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0
M  "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P
M! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E12
M0P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U0
M86-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M               2<U)'0B!)14,V,3DV-BTR+C$
M                                             %A96B        #S
M40 !     1;,6%E:(                     !865H@        ;Z(  #CU
M   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D
M97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@
M                            9&5S8P         N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                             &1E<V,         +%)E9F5R96YC92!6
M:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2
M969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                              !V:65W       3I/X %%\N !#/%  #
M[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M 0                        */     G-I9R      0U)4(&-U<G8
M   $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X
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M2-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $O ET# 1$  A$! Q$!_\0
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M3*'S*_<E^]PA?'+S/]L/3+?YI?N2_>X0O]/,_P!L/3"'S2_<G^\PA?'+S/\
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MK;+$L\E+"E/KE4K9"W4K83.*2&5N.+83+J2+R=\&7G7&2M(6@8QE[_+54*K
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MG_W1&\%:W3_S9_\ 3KK$??9)]!G#_P"\0MU6\RL'9;#<?Z_^G_W1.]'])/\
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M/.T>(]P='3Z]F$13F/7KP[, =HZ:FO\ U>FW9NTZ-1$-<(F@T(IXZ#IUQYX
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MPARKU.F&5*#AKSAH([->KVZ=P=0\,(8@9X=?ECYGJ.,3A$1 =/CMXV'6VFT
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MW81C%,YG3]ZNBU:I*KJ$3-BAMQTE+:%N*"5+*4)4LA" 5+60D$A*4@J4HX)
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M-TA'^;-T891)Y))I2*A6S.R-7'7OOCKP$;AHV@*-R^8*QM'0#&":N#D4=>;
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M;PJNI6#D"GX;P&.[O&M !'-M-9M_=!:$I2@Z4/1,]F56\3!F8.4:IR<J3_\
M>4DSRHK&?&OJIS>85;!T+EM,RN<,="4".7CZ'])MH5=M.MS!"SS>;@>2<D]G
M)AYYP/HE)=:@N\U.MUEE*FF$"7:DUL+>F6TRBW'C,I7<W@*%)*D;M=0<G&P$
MELNK&!O-*(6 E9O%P*^!2E )*%BH3=(42H1MYSFMRUGL$QE*'@&=0-XNC\W:
MCD7=8\G6L\MIRLI*G)'*UA0\'$T-/9M^E:;?KHU/F/+)LY]\QE*_1H!.)@8R
M!;S#:L@TQ*V(ERZ^LMWWY-H(8M)F:0RAU$TI]U;Z9,)=2%-2Z"6P42QF:NJ<
M*%(3F5S)35*2JB'"+[!;4HI4BZD)WINU!6H542H(NA*;P,:^?\ISE@(57!4E
M&4B:1D'E-U]4='-77)WS!CY;-M&!KBCJ=HDE8PB]>-Y#DT1%4MIJI&$G4^82
M#MC$$A&-8OV,,E),Z(?[ LNQE,NO*>N(#K#3Y3:4NM,GO)=UU\R[@EU)M1UI
M26U(:EU)*KZF 57%/IQW\P%A(1\0"EHJRN\Y1RB"L7_P:IO5*B<@J@_(:BD<
MQ.710-+TO3U3PLA.P[Z-H68F,Q_O)U_7M;Y=L9IQGHWF:>EJ*C:\4G\V*A0E
M:-R;C9*0ASPCNFHS,V1JB2@OD[&).HH]+V!,OON-+#2DN/H1+>_,,,310)%2
M76WU2V[E&BAZ<4A*@M#RY5+2'=ZI5\E4TE"$J2550E2G-TI2VR2X+I25A3JL
M&[RJINA=X@  C5 <N'EC)5+E=EP-&4"ZS^J7+DL]-Y *4P5E-#($Y'-99N^F
MJ@ET\UG4[ERNIR@XF,RU5HB;HYR5*"-%*_+(J]5Q,NIMFPK%+4U,^\3*;/;?
M"$6@';R<;99DRTTD2FYF0+/6J9$PV^#?"SN2AE8%0F9F\VC=H+RA\3021A[N
MIV^HW[S?XH2BXI P*05@D5^EG);K'.BN<K2SN>E/Q$!5PU).LXWT3 5G27IF
MEFJJ)8B9DJ2S AX*JZ:DUUA?-%X^3BVGG+=DVF6S=LVE$FK?K-JLR3$WNY!U
M;K.[;4J^XR[<=-;[:76%+:=2!=4%)4:%2D$DIJ=QE3BD NHN*JH4 (JD4HHI
M(2H'$C$"M <CCT9;LZA'J#U>- QQL6U\>H'4^O>)C+V/]$;_ -F79LPBX9#H
M,\_&*K")AA"+!,_E4./,/_Q%^K"*UY#AW^L:ZG]"'#<(@'#>6PZ6V#PZ=F)_
ME\3_ /RY0 J:Y'X2-=,<]#QX\XW)B(LAA"&$(@P\TIC#<0* CH%QT"^@!<1'
MH#"$<+N>5M6=9'ED,L<C:]IRE8Z,GG,SGCGO&CE;EE1[:*C7CD:E<Q\NJ6I*
MGB&3AN0'C-FC#N0+Y3R[AD@DX=-^OFV9A\N)E+.F664)<+EH6DD2<HP$(4=\
M4.$/.MH4FBT@-* J24@$CT]&P-FV<F6<MO:FR9R=?>E$2VS&RK_\>MRT%OOM
M(]R0[*I5)2,RZVM19<<7,ME03=0XIQM"YR%RK=5LZCLV*F<S(0SB6;53%/7#
MN/9S.>LHVB6;&G<W\Q&T$DFV8PB30JZ^6.6C5ZO3T%#+Q=02+,:@,@E&96=*
ME\IG'"X&RL/(45)2Y:*PA*&YZ:2VE(2BZ"9.4"E--ME#JD[VZ&\=JK;:LUMZ
MP))N6WZ9=<C,,AMYV6V68<F7'YS9VQUSBE..S1=N)MRW'&T3LW,I?DV7!)A:
MICNC'/1YE#"$,(0PA#"$,(0PA    L   < T#"$,(0PA#"$,(1J-I_?&0_[2
M??\ ,J>/7B?Y1U/R$8_S_P#A^O?RC(]^S9T<=MA[O7?=B(JTSSY\,JCS]*:P
MT#VC\1OU;1'KPAB?D/L*=<@.D+Z!O]O=NUVWL ;QPA3$Z?+SUPRI4G00OWZ>
M+Z;-1XVW:X0IY8]TQSP'"NN$.CC[[]>O'M'<.$.?#Z>6'#P&HAVV'A\0X7X<
M-HWPAX5''['C3CQR%(=NG'HV]UM.R^$#TQX<\O.N/C2&T0TZ=>/=NW6'7=<,
M(9 X\O#SUUJ,-:&'"VRVWV:[PV]_7A#C7.N7SPT.7ETB#?S3:_X)M@#P'IT]
M^FN$!B1AJ,R/7#'Z8X1;J=O\H@_V!U;2W^,;=]]OU8D]US\>_ 18DU*O4USS
MRX>N$;+Q$9PPA'S'K'EY5Y2F8E44N.4E/NX6F9+,(LPU0J.M'.8-)4MEQG#E
MMEVYKBNJ92RY"(AJ;K2B:QJ+..B7#.HY$TG0U-I/6_GR*TTZI_LK%A,/2[3I
MG5(4Z)>Z2TUN7G)F4F)@,,+]X+BGF'F42CZ5-)H\X1@;@<T%SBTK4D-!5"L7
M:J"PEMQ*"M0NTNJ"BM)!-$C&I)IB"7+QS5<5M6<\PI2B7.4Z]/@VRP;2SFL(
M9>H','RLLX,A*LS/6J-"CY,RU!4U0%-T-G'7AF$5($IFA9:/F&B[B.FTY@+C
M8$JEEE"GW1-!P&:NAE0;2[9,I:#<LEM3Z:3"YAQZ28O+2'7TJ20E22W& G%E
M9HE)04D(!O K*7U-*<J$GX$H"75@ E*3KF+^TY?F8SN:HF,4R=I6.3J*L*3I
M,47=85N:7K6'J',^L\OW6;64#0,K4F%594-8REX>K6<[.2E.+.(JLXM1^G%I
MC2RE?8&P)8(?6)UU6[:6[4,L%MA:)=A_W2<4)LJ:FBIY;10VEVBV%E(4G>;G
M+WMPJ0-VD7B :E8*@2H;QL%L51\(.)&"P#B,;/"\LSE(U#)<FM:H\N,N\JH3
M,2I<MW^83E6=JZIXME1F<^0&8]=T5 >G)"A:<+3U<1V85(ITF\(Z:+QC^HI"
MBH1N],>IWK5G*K&LYM-I;N:?FURS<TB7&[9:4I^2GY=A]VXB8=#K"I=[? I5
M>0TEY9'P J@33Y+!4A"$K4@J(*E"ZZRI:!6Z/B"A=R(4JZ,!4QJ?*#[H-R@6
M<%4"]599.LW),S&B9:$HUDXDH[."%BW_ "%<IL^)6HYZGZ8R?CH%]ER.:[ZI
MJ+FZTC$32#6LJM0I^"I0SJ+A:'<[DYL]9]]L-3:9--YU+CR[JY-Q0MN9D4--
M..SBG43/N@;?0RY\!994XIVBU.C%J;=N$J2730$!(-\#W=+A4H(1=*+]4D@%
M55"B: ).79D\OW.<U/3T52-"T53LJRG*;BZ<S19S]53]'9RMY/,*D:?E7/)S
M(]RL6;5^K2T%+RJU?)S 1C2!<L'/HN3DX%!Y6L31+6!);U"G9AUQ!:<6Y+%#
M+;TD1+NN(%H$30W =<0D,7+Y54!Q*'"EA4KG'+AHE*55 "Q?*%B^D'=7D *H
M#\0)%#6[445&0-N7IG;"U+*T6GR>Y6LBPL3FU+$J*HJZIREIR?+28YN2\-)Q
M5/M*78.'=!,U:(IJ@Y*J64 NG&2E1@I+.EW\8Q"M,%6#)+;2]_$4-7W)1O=M
M2[KZ6R][FE:5K+RKKR@^X^AM;@OH; 0 %T:E,V\"4;A2B$K-]2DI*KH</Y;J
M:A-U*"I(I56>!,?0#D\YJ2.=645+YD2T"A34C.N*F:.HAH^/*,4CTY5DY3!7
MD?+ @DSEHZ73AB3$?*PCF:IF19/T'E+515M.+1=3RW 6A*IDIQZ62YO4M[LI
M64A"B'&FW;JT7BIM:"NXMM80ZA22EUMIP+;3ML.EYI+A3=*KV&)&"BFH) J#
M2H(JDU^$J%"=U8TXNC"\PI>J8.DY62HV+@I6H&Z9!:DJB;&GJ;8H\\!>R\[*
MIMW;E&-BV@+/%TF;59RY%(C8@MB*J/6W(66Q)3,ZPS/OS+$JM1"U2<M[W-N*
MH0VQ+,%;:5O/.%+:2MQ*$7BLWRD-KXVUGY^6D'WK-8E7YM"06Q.S/NDFTFOX
MDQ-/A#BTLL-WG5);;4MRZ$"X%%Q'#=.1-9YTRD%6]+OT:YJB%=&;HYV5S!R\
M3E!2G.,X5&7R$RJ5=$"L)1N58T7\M)QRW05,U;.VTX_2669-?1)E^0V>9FK-
MG6EV=)S* M>SUFS4N_;TY0("9;:BVPV3(,**?>/X=+H6M.\6A<JRI*7%>8R;
M%H[2O2MIR+R;4GI59;3M-:DK,,;.R)JM1F=DK!+@3:,PB]N!:4TI"%EI#B)I
M]"E-HSVH>21753S<M+2'*UY0#)"3D'+Y.*I^?3@&#!-RL94&3)M''39MVK<#
M"DW3;LT2$2*0HD$P"8W'2FW-FR4JQ+M;#;*NK9:0V7YN4,TZZ4)"=XZMX*<6
MM= 5E:U?$5*&<<I.>S^U9Z;?F7MO]K6D//+=3+R<V)-IH+).[0EDI;2VFMU"
M4MI"4@"AT[&@HPT)"0\,>1D9<T3%L(PTM,. >2\F+%JDU&0E'8$3!U(O!2\X
M>N 33\NY455YA>=S0Z%,/>\3#[^Z:8W[SKVY81<89WBU+W3*"24--WKK:+QN
MH 34TJ?199DRTM+RY>>F#+L-,E^87O)AXM-I1OGW*"^\Y=ONKH+RU*505I%U
MQ3%\,(0PA&IWO_2>8_VAM_R;7$CZ'Y'KWPSC$_R_][[GEWQUO_'34 #MVZ?7
MLV\!Q$5<,<"3X98_IGEQ$.OKWCKT80Z=-!ASAL'3>/3ZM!#</#UX0SST'+UQ
M!U''TA?Z_</JV?8*%/T^H]<_W#A\+=.R^W?OV#LPAQ^]>6=,M-,QG&'RLJ^D
MWZU-TTN"+Q#R03TZ"1%T*<172(NDW;D525;/:G>(*)+,HY8%&\4R<(STVD=J
MM"Q-27H;2E(==!NFN[;J4J=(44DU%%)92H$+6DA2U)++2@L.N2[++.F)SNG'
M#4%5,;JA@""0<$JR"*BF,(Q0CHY$46R ''\-19PX7654,LX=O';A15T^?O'"
MBKI\_>++O7SM55T[76<*J*'K<<4XHK6:DTR 2D   )2E("4)2D!*4("4(2 E
M*0D ",,AQPJ:YYU)Q))Q))SJ3B28N%M=W=KW]>N,(FN&OGAY=,(#N'K'9<.@
M;]&W=UV#" U'09T/,4YY:]*F%MG$.[7OW;,(5SX'SP\M<X7 .SQNV!UVV80H
M3X]ZYGI7.&\-^W7HW==^CAA#CIEASUZ4Y\8;N@=E]X6^W;PPAKS&=-#7]LN,
M UV>V^WMX_ ,('#/Y4R\.'W,-MNW9KKL]6H:AMMA#*OAGAAGZX' \8:W#72U
MND>G39LT'KZ,(84.&-:\ARQSSQ'3G$[/;A$9_*(N'> ;MOCX\!PB:'&F%#QR
MIEWTXPZ-G;NO;V>VU^"'//PUI7Y_*M./AY)+R@K"F3RO,\GY7F%\H*?.Y_DQ
M/83"F!Q$W,$>:!OPK7UPJ:4KA6M-*Y5IQIA6%3@:XTI7(T!K2N'UKZ1Y[?%A
M\=V$,NZCOSB;]F$13QC+F7]$;_V8>_"+QD.@BJPB880BP3/Y1#^H;UF+A%:]
M/'TC7\XF8Y#6UN(?_P"HAKV6MLX#LQ.AZ4KP->F>!]8D871CKKAG2E/$:8>=
M-OXB,X80AA"&$(YZY4N5U8YTY)U5E;1,Q%P#^LW%/Q,Q*2JSM%)O27R@C'55
MIM19-'JBC]W!MGC)J@HB1NX,X,@LX:D4\X3XVUY-^?D'Y.7<0TJ8+;:UKK0,
MEU!? HE55*:"DI!%"30E(-X=MV&MRSMFMII"W;2EGYMFS$SDS+R\NELJ7:/N
M4PBSE.;UQI(9;G%LN.K2HN(2B^A*U)"%;UB(IA!149"139-G%P\>SBXYHD%D
MFK!@W3:LVR8;DT&Z2:1 W%* 8Y!"$MH0V@!*$)2A"1DE*0$I Y   1U=]YV9
M>>F'UEQ^8=<>><5BIQUU9<<6HZE:U%1YF+AC**H80AA"&$(80AA"&$(80AA"
M&$(80AA"-4-4S!(2&FV0>B&S4!<'->][=G"VW$XTRYUZX?,1A4!521@/+AIC
M@>>N6$7[??QN[[:VV<-]\1%>E.]?*N%<^.E(;_5L[>OB&HVZ.*&GKGX=.!P%
M>? /CB(=&SCA =\ >>?" WUW;  >OAMONX:@-\("F&N9(Z<<J:\<"*0Z!#U:
M=V[9[,(<P?7'SUS^< WB%AOMUO8= Z-..\<('0&HIEA2HQ//'AH(7U'HW]>W
MJU#7UX0I@.>G3+K@</2'7;ZK:[^/C?A#I7]:X:<.](>T/?\ '=ML.FNN$/D?
MI]M<JC'#"(-_-, 7$1*-M!'C;H\:Z80&8RSXC]XHX A@J+G#H'F#D Z1%1OZ
M].[MQ)KAPIAGXY_3"+$T!(UKERIAX<S0\<8V-B(SAA"%@X!A"(L' .[AL[L(
M1-@X!A"%@X!A"%@M:P6X;L(0PH#F(1%@X!W80B<(0PA'@JDDNFHBLFFLBJ0R
M:J2I"J)J)G 2G(H0X"4Y#%$0,4P"4P"(" @.)!((()!!!!!H01B"",00<01E
M$$!0*5 %)!!! (((H00<"","#@1$D(1,A4TRE(0A2D(0A0*0A"@!2E*4H !2
ME   I0      "P8$DDDDDDU).)).9)U)@         !0 #( #(#0:1Y8B)AA
M"&$(80AA"-6/$Q&I9<UAL99  X:,VQ1UZ=;CI8;WP[\>ZQB:5 -..-:YFE.F
M IKPB]:\=@ZZ;?7Z\(JPX9C#'+T](>J_M]_U=&$/6GR^GZ\X;.ZVV^\+ %^/
M$>&N$,_.N(IH:DTX<!QPAH&_=?;?3P&$,3IK3*F/9C#I25?23Y:FZ:6!%XAY
M,)Z=\DFNWIQ%=(JZ3=!-5-1J]J9XW.DNSC5@.WBV3A"<FT5&J\-$U'>A"4)#
MSH^''=MU(+RDFAJ4D+0RDA04X*%:TEEHA0>=EQS/'"IS*:C(5S70@@&MT?$K
M^4*R"*B6,(Q0CHY'R+9#GC<ZRR[A9950RSAV\=N3K.GSYXX.HZ?/GBRSQ\[5
M5=.UUG"JBIJUK4XHJ4:DZ !*0   E*0 E"$@!*4) 2E("4@)  5TQUYU.)))
M.))J22:FI)UBX@'?KQV[]!'0+\-N,($^6'#+3$#$TXY1ZE54FZ2BRZB:**29
MU%55#D33333*)SJ*',)2D(0@"<YC&*4A0$PB !?"A.0KTSX #B2< ,R2 ,3$
MXGYU() &).9(IAF<]2(Q5M53J01*[BJ3J*3C5Q,9G(HK4PR0?(%,)".VJ$Q4
MD;(>:+\T5&JZ[%$CMN9-TW\HV6164O+ 22E;["%"EY"M\I232I2HMLN(O#)0
M2M5#4$@@B,"K@A:P<4J^ !0-?BQ6#0Z<1B#0B*CT]-;Z%J;_ 'C0O_SEB-TC
M_P"9E_*:_P#M8B\?^$O7"K>77>?2'IZ:_P#J+4W1_=&A?_G/#=(_^9E_*:_^
MUB+RO^&OGBW_ 'Q STUJ'R%J;4-/[HT+IMU_Z9]75VX;I'_S,OY37_VL2%G
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M]X<:Q<FY.4N%"<%!(?6Y7,J"4D70:UNES>,A"RD.$H(N)5^5"U5!/$) (J*
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M0I_J'#4<N'>/. O$0N/X5@T_P?9SKZZ=FS;A$4TJ/7YTIWCE 7B6X#".ZX
M=]QM[=V$30?U"F1I4^E,1Z1:UEN8J5PW5.V7((\Q4@ASB\X! V@C8Q3 (@)3
M (" V$+:8RNX5)&669QRKPK&5ZAH*G0\Z#,'.O,4RUS%&>9GKCS99R ?V;7W
MH@/?T<,01S^G#(''7ASC('C77B>.&HR&ASJ*"/#TW/\ TNY_0M=__J.[U;,1
M$X<?4Z>/GZYP]-SWTNYV?--=E[7MY#7X[\(=YG/.G+P\H>FY[Z8<_HFO5\SZ
M^/3A##GZ]>QPY0]-SPZ>F'-Q'<DU]OD=.S;A#+'&@&I/RU\<H>FIZW]^'.S7
M\6UX_P!CH.G2(X0KCX\#PSYC'D!KI#TW/?3#C7@DUO\ _ OXMT80PYX<2:?.
MG=><!FY[9Z8<Z?ZIK??_ *BX^JW1IA <>/,TTYT'K7GC#TW/?3#CA^2:CO\
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MB>6*!B.Y$! 2-[7YZ;83?@"J4+@HN-RI#<I.<H'/3O::!^)= FE14@#C4FH
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MS99--9NT@IR:A:D?*O44DXYE#+RZHIIL/*EI)#S"E-&\'6PILBH*@%)6;J2
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M51JR?-7*CAVX34*!W:9'<F^Y*RU6>FTI$VJAQRS1-,^_(964.F6*P'BA205
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MIBU=QM89Z5=',ACF$7E@N^4>&ICDUTN]<+C3[1D\%:HG#!U%W>1BCVI)[&Q
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MKG-:R<,V<#$+/43PRK!9JZ,\1O3M5,(F5/HED;LJ=6)5;SBY<..6DS:(<+9
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MQ52R9EV:1,/+152%- A+I":')$$'=E";R[RDEL%!!?:=Q36BKB6[B4G @D8
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MD>R-HE;,DKI6AF4DI92ENN$(2VRP@K=><4<!4!;CBR,,5X $#7F5><67>=<
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MHJ8^W:ML6C;3Z)BT7TO.--[IL(98EVVVRM3B@AF6:::25.+4M:@B\I1JHF@
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M]>$1U[Z\O+TB._;VA8+[=_ =;:[<(GRR/0U-,M..5<,H#X\;.T=G;A =]Y^
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M<&S,H\[3FBZ72YP?FW'CCRC:^UW;"V9MJU9=&\FI61<]S10$*GIA2)61"@K
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M1-1_1Y/UML.\?]?T[=M[[,*\AV>QAIXQ%#Q)Z$:=1U)\L<X!$U']'E#I!XV
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MKW.SYQ-NVDY=&)0B1LIY"CD%.MU.(![87TR<G:D\H@"2LN=<!/\ QIAI4E+
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M;3_Z/]&..L=Q!=?/N[- A/\ ,_B2HZ;_ $IWKR^VJ2)61&_<)4^Z:%+.%UL
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M(GT&.0UIEY@89#2D/9XV^+;;[L(?/O+NN5-8=6S2W5ZO:/NPAUSQKU]?D/K
M>(:[]HA?AO\ J'V(#@<-,@:<=/U'S6[?&OV;- T"V$*^'>'[YXG$UATAOVB&
MVUM+<<(<CID#E6N->$/6 WW[+<-/A:W&XBAZ$<LZ\<?O6O"@%(^_(#_6#V&Q
M(Z5P/RS\,XD?S8T^'ZC#QRBXT1_>^0_[56_Y5F'NQ!-2>OE%HR'01Q[FE6O+
M?+EAGBM3^7M#4?7T1RALJZ8Y.CJG95YF$A7>3LIFYE?$S52YE1)H<5*13D*5
MDZP0K)1F4RU'4\23GFKAF,"VJ!YSDJS8GO4B'9A]V779\V[:(<0)?<3B).:6
MVU+K"SO:.I9+5ZF]<N-D*WA0-9U4S<<NH 6'6TM7?BO-J=0%*6,: )*KV5$W
MC04!CG$W*]Y:T?4\S4I.3/F"YH>OI:%D\N*/GLKJP<3-!TZSC&<8VHRMG-&L
MWLC!57F7($F:SD:UE$9^G<J62#"E)NF7THZ14<<D+(L1324&U6 _+H6F9=;F
M6+C[BE*67F ^XVEQJ63<82R@H=FU%3K:P@8:YF9H*)$NHH6H7 I*ZI2!^55Q
M*J*6:F^JJ4 4-301DE7\L_E6PT9F6K&<G&HQ>4@_S54I=\;(7E"U+#UDYI%$
MQ\O,NX6/IB,5J][(9AD3=N3YQ/:?I_+R$5C1B@@Y!2<IR1DJV[%LI:I>MI-W
M742V]3[]9S:V0[4/S"U..;H)E_A/NB5NS"PH$+%QU*),U,"_^"?A4L).Z>(-
MVEU &!*EBOQFZ@4QS!C,,P>5CRB<MTI"=JO+2F:>H*4J:OH"(JYW1V9TJO0$
M=1V>E"94T]/U=3$<JE*YAO<T(.MU:HH.BJ$/$S\VVIQX_A%IV+=/E*>IE;)L
M^:4AIF9==F$H86ME+TLW[PIZ2?FG&V75C=RXEEL;E]Z8*T(+B4JNKH%Y.3+S
M8)4A*4DN45<<-P(=2BJT@U7?2J^E***(2HT(PC3D+RXN5#-92NLW::R:DYYO
M5-)S-9T@HPRISDS%I6:DX.B(B0I6@:0A,N*><5E&(9K2*THZ:YA5(YF*7I1Y
M"/HR5Y\A4-.Q1-ERQ+,:FS*.SR$%IY#+H,S)R[B$K?6EU]UR8<#*_=4A(+#0
M2Z\E:5H^!"G#6F:?4F^&C\8J"&W5I)" 0A(2 H%1*OB55(H036@CHBH<[.4/
M1>3$7.DHVHI.K*@SLY15/R$I(Y4YE5VZHZB8"N,XWN57-R]RM@EJT?,*D@:=
MHJE:8JM5CZ#:LI>,J67=3[E]&QM0Z")*SGIQ;?O#:&6Y*SUI")N68#SZV91,
MU_O,TX&4%I2WW76@K>%2%-H#82I2+BZ^EH**57BX\"5-K5=0E3A0+C8O?$ E
M*58@ @F]@#SU37+;Y6-/9=+KYBY%3U.RM/1.05..:GK;*7-E55U4V8&;N2.4
M<C-F8TC%$;YERM2Q&8M39BMZ&R\;4_4-(R5.)T*^C9>1<R;BG^2>L2R7)@"7
MM!*T.*M!T-,3,E1+<M*3TVAN^^[672VN6:E2_,7FW@Z9A"@E*4.T)FYD()6S
M=N[E-5-O%55N--E12$@+)"U.76S>3=ND&M1LYWRN^52@S1<M^3C*+OS4W43N
M/A%\JL_D0JI&.IO,:6A\QRSD=1\TCE_$24C2-,LE,BZMB7>=Y0K)!DBV-.D@
M8JJ-063994H?Q)%S>-@N":L_\(J<ED+EE(4\DS"TAYT^_,K$D-P5$W-XINPS
M,P!4,&H23=W;WQT#AOA5/@%4)_"6-X;Z0**(!L <H+E=5%+Y5U&UHRNJ%I*8
MK6FH?,R/EN3[74L\+!/Z,Y4T89_#TS&N)BHZ+CY&NJ&R==.)9Y+58C3:E=45
M+3[YK1PS4?4N9L^R6A--&89?=0PM<NM%H2R$)<3,6:HI<>7<:?*99Z;NH2EE
M2RR\A 4[NRUCOYE02K=J2DJ"5@M.&H+;U"E-+R07$MBM54*D%12F\#<(/E4\
MKSY/-69.3Y-O*H2HJD;QE39<YL-'4=+/8W*DJM8516S6 BZ'J9M.R%:5,D^H
M.A4$:QH=2EGSR>;*)QU5QM)EV59 65&TFPV7GA>;F)0A2 J;(:;8+JWVE-I9
M9(>?5N9C?)2V:J:4YD)F8_X!_*F@*' :W6S>*B @A5Y0"4_$DH)4<%!.U\P^
M4/RB*,RF@*A0RG%Y7 UMG3251KQ>5><M=0ZZ>5TI7<=1$E%9?4 SFLP8R,SP
M3I6'?4W4;]S)TK2C2H&QW,Q5*KZFT:AU)>S[/?FW&_>[K'N\D\V')F3EUUFD
ML*?;5,3"FY=2Y$NK#C:0EQW=$!+5%E%BWWTMA0:JN^ZE5$.*%&RL)(0@*6 Z
M4 ()) O#\U0#A!.4]RMD8XDS+9$(1\3.A/H,%F>6F<E13- )4WF1DY1R]2U?
M2<(@XGZQ:S5/YD5=5T'25)H1,RZC<LI1ZC+.XMU.O:,N%F60I6[1:-]: V25
M3$FRW,EV6G'@TRZXH-LJ0Y+,M+=>4I"532$E 6$)=P]XF:5+-$DJ'^6Z2BZM
ML7E)352@0M1 2 3<)K2M,(K_ ):&<61?)<H3-&O8N/8UE4[WE&S#]>O\N\QV
MBW,H:IJWFLN*+0RQC6--9CTRQJVCV4>1I7=61:$50=/Q+>3K])R_G&:J]\O8
MTG/VH_*RSBE,M)LY*1+3$LL'?MRZ)I[WI9<EW"RZI:E,M**GW%%$N:((C%<R
MXS+H<70*472;Z%U%%*N)N I< -4IO$&Z,5YQE-*\I7E2QTDG#RF3]33X/:NK
MUU'ED<L,S#.)VFI3.O..(BE(ZMX6#0R]H>&RMRYIFBIUJPKEPK46:\%-QJ%,
M.4YF3@G=3U.V;993O$3K: &9<*I,RWX;R9*36Y>8<<,P\J:F''D5ETAN4<0K
M>)N)<2T1,3 -"VI7Q+I5MRJTEQVEU8%Q(;0E- ;RG 01B03;I'E3\MREZ:>S
M\UR;XZK%RR4)3J,+0E#9KGEV*\]DY0N;C^N%(]^HZ<3M+T&^J>H\KY2G(T&<
MW6-;48[:1,Q3T\_&C(_--EV&ZXEM%IJ9!2XX7'WI0(4&YV8DTL!7P!#KZ6FI
MI#BBI#4N^E2T+0DO0,S-I2I18"L0E(2ARM2TAV_FJ\A)46U 4)6@@$'",YIW
ME-\IERSC:LJC(MU#T-&P>4#VJTF66V<4GF#(+U]G)7U!51(4_0;6)<5 Q0HV
M@:4IS,6;I=./J^HH!*MVK>26<0L42HYK7<LVS*J:9M +?4N<2U?F))# $O*,
M/-)=F"X&JO3#CK#;Q6RRYN"4@+7<;S3,/T"U-40 V5T0Z5T4M22I**%1 2D*
M((O@*%105.E9'E?<L&'IRH*Y:Y"UFJI.T2I6M,4G-Y&YW5"9M4T3E]03Z,RB
M9P-%4\%7TM*5S.3]3OG=85SY:$I)_1TE34DU(^EFHQ.ZW9%CN.(8-I,@-S&X
M=>3.R3565NO!4Z7'W0RXB72VV PS^(\'DJ0JZ@UJ,U,I"E;E6+:5!);=-%T'
MX8"4E25*))O+H!<H156'7Z^8>?C^@YNJ)"D!B)!#E.Q% TI3-+PM1'J)WE)#
M<IMMEG)5I5)9=@]$T;4F7#9Q7B[J'BVL6TI)<TXUGRL':3^-X?W>0$PAM,Q>
M0;,5,..N*0&Q-KLWWH,-;M8-]N85[N M147DW2@$%"MDN/%!5<(/O 0E(!O;
ML/[LJ54&H*!?JF@NFM0*QRXMRMN53&Q^7:E791HMLP9_*PF;K/+^EJ<K1H:<
M)(Y2N:LGLM7%,3K.2K&?K++&>:+1\RVIEPPE'4G*4W&JT^TD')8N3Y3^$V8K
MWC<SH4RW-"44^ZMDALB;4RW,AU"FV4,S+8O(WP*0B^YO+H"DT>\3%6[S5%EM
M3@2 KXANPJX4&J[R"JBKN)4D)I4@#.7'*TY1#EMG57T?DRC3^462](268@O,
MQJ'S0H"K\PJ7I[-7-6"G(VEV59MJ90BYT<J,N&M<,SS3/G$?532A74.6$JAI
M(L*19-G),E+JGM[.3KR9>[+/2K[,JZN6EE(+RF%.E;?O4P624*H4M.E+BEME
M)S,P^=ZM+0#;22L7TK2IQ(4H$)"KM#=258BM2D$4-1V]DW5575UEA1M:US3)
M:,J.KHDM2K4B8%P?4S%SCA>3IR"G"KG4,6IXJG'42RJLJ)@9EJ5"5*Q(FR!N
MF7A9QIIB:?89=W[;+A:#PI==4V AQQ%/^S6X%J:.)+1022:F-II2EMI6M-Q2
MA>N_T@FJ0?\ 4$TO?ZJTC9N-:+(80AA"&$(80AA"&$(80AA"+=+G*E$RBAQL
M1..>G.-A&Q2-E3&&P7$;  Z!J.[ 8D#C$$T!)T%?*-#Q-<TVT2*19XJ4P$M8
M&;H0O8 M<J([P$;[PXXN+2Z 4&',?;C7SB@N(-<3C30\>'2FHQ B\??%I3<^
M6OTL7F[_ -3XVXC<KY><8A:=2:<J_:'WQ*4_TY;6]_Y$\[/\3T= !TX;E?+S
MB;Z>.5*8'Q^?,GE#[XE*?Z<MQ_H3P/\ ]'KZ]F_#<KY><+Z>/+(GO3IGI%P@
MZNAY\ZR#17R;A,Z@%;N+)JKHE,)2.$"F !4(=, .<E@51 1*JF4.:)X4VI!R
M) QJ :>F(ZX1*5)5@%8\.(Q.&/+ <:<Z<\5G!#&2LC'E()4A4\Z8"-["W5$5
M$0*-_P ("?AMC&OJ=,_#"9:$U*K12JJ7DTT<1B*=<4X4P416E8W['GOX9:;$
MPHD,WBT^!D6'1=57_P#;)2X, :HIA4QR9G;D\RS<IQLU2=IP]5P"KAY2LXJB
MHN@V7<D2(_BY-)(R:KB#FDD$$GZ*9A40<M8Z5;D.\BVR9K]A]LI[8JV!/RZ"
M_*/I#%I2)5<$S+A5X%*B"$3#"JK8<(U6VK\-U=>1]KOLJL#VO[(S&S=LD,/H
M5[Y8EKLH0X_95H!!#<PT"079=Y)W4U+E24/,JK4.):6CY>U; 5!E](#%5Y#N
M:5>BN#5LO(6]"2ZHV$IJ>J#FIQ<X11,2*@@T6"3:IJ)IRL9&/?*LTOL_9W;#
M9[:F70]9%HL/.E 4[).*#,_+DC%+THL[P &HWB XRNE6W5C&/QX]H_L+]H_L
MRM!^7M[9^<F;-0XL2UOV6R]/6--LU-QP3;3:A++6!>5+S:6'T$T4@BBC9Q?J
MPQAET)R5IE5%!5$\Q#5'*TLY*T<F1,LU6EHB0C'!F2ZJ+<ZS59T9HLLBW542
M,=)(2<K:5F65:K*6;6D)"T&&%EY#<_+,3+32T@WG E]"TH-VH6H4^&M32.H[
M';7;<[)S[O\ L-;5NV1:%IH;DW46([,(?GDI<):94PP%*?4E:CN1NU.(4HAL
MA1-=ST35BF73"35S3-6QH+,-@T<0D3+*OI=RQ8PSITC+YBS\-4,D$G%P4D23
M3B69V[)>>JY@PG))&*DF,'!*O_GC;_9>SMOW'9/8*S[)O;,2SZK2GI)IF5E9
MV8F2GW>R))<JR6)R8:;8F'5J4M#+>];9#M7%!/Z4^PKVA;3^Q"S[,M/V^;5;
M0)G?:3;DK+[-V3;,P_:$_8LI+,DS-KVH9AXO65+3,Q,R:"T I;3C:'766RIP
MM^Q5"0R/DDH"HCR:&7B4J+RB:XCE5S2F7,BZ5%5"+D':'EE0B5%%Q]&RWXYL
MX07!!T+ENN8K7XFMRP96::;DK1$U+(E9CWJR;6DG%,6E84\FMUV7F +S8!);
M5?O,/-*4S,-.M.*2/U<;=8VJEC.R/NK]K.RR6K3LQY+:I6WY=* />9=M5$*?
M"4I4ZQ5"TK&]:4E24ESM:D>4).,&+0M6PX5G&JH)J,ZQH@S$[I\W.0HH.'M/
M*.6[505BCSSO(.06;J!8R4>B41 +93:G;#9]"&+>L9S:ZST ):M_9=$NFTW4
M$ (5:&SDP]+IWA.+C]D3DPTHU4))A)*4>66IL-(S+KBK+FOX5,!1#MF6OODM
M-*!-]#,]<6XFZ:I#4ZPA:: *?4<]D(\HO+02@+Q6JXLXA^2?4+5QC@-KV$[&
M'>H= ""P@([!UQR0]J>SB/\ XRS]K[.7_P .;V*VK*L:9&5LB:;5U0M0UK3&
M.O+V"M\5#7\,?&84U:]FA)IK^+--JR-<4C/&D>IURC,O$R":.;5G.'V G&T9
M/-Q$=;?C9QK#MB@-KW47( !K?3!7M1L58'\/L3;:UE$"B9/8ZW6$UR%Y^UI.
MRY9%:@DK>"4BI-*&,V]@;;41OWK(DTG^>8M646!_X91R;<4,*"Z@XG$X1K"I
M\ZJZJ9%=G3\<GE[$F*<%Y=ZZ:2U5JMN:83BS;H>4AH)04P,"CA5U+.&X@)T
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MGXC09XD5IJKC2/-MR<^3^T.V.WR0RE1.SHY/+QJ),O:3NA0:,&%,)4<G>(_
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M/7"O>6=! ./1T;^_AQMUX0/#GSTKTX\*](@0OS@-J4P6$+"("&P0ZAWA;6_
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M'%#GQK@.^^/";6V:>/&SXX1%:YX]]Y_:,M8_T-O_ &1<(V(J\(0PA&/S.BB
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MV@ _S1L(6$ '#+*%>-""<:X]>.>I QTC2M39;+(>4=0)1=-QN8\<?\-=,/\
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M\S77&'FR/S8;MX_'OV:;-<*GB?.%X\AGA3C3L9XYX0\V0N \P.@+W 0[QO\
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MK]F[L^&$*<L:T\=?'[Q([[>/KZ\(CA7O].D0(\-=0WZ<-NX+AWZ;[81(''#
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g96328g02a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g02a11.jpg
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;6?U[)KER=PF0/K,=@F1GW$S'QM?X!OCF?/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g96328g02w97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g02w97.jpg
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M6>:;&BF)$N)'>(2H[;\J,RI;R*G"Q+,[+QL.DJMF5=70C6$BM#8P7G80&(1
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M#X^'6ZGV+=<NQ&NPZ=8IU%N#K=2,011V3(18=J'LH>4A:DRDT/477&<5U?\
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M<1<X_;.3%XQ6QS[H*[*'.=C.0J2_VQ</NW0KWT^_MPKK$IL**/CR;=T:T38
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M.1=&[33JC5N?7&DTQP!UGCG5"4VY4\[;T3Y'%>MT3K]?$08X2Y4]4)DN9H[
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MV?T;\W8TCO,1F01B(Q$H]YJ_X+Y]_G]B_P!W$9]?/^27_A_TW?<?H7\MZHG
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MO>][WO>_7O*8X6&Q+-B8S,Q)9C14223N224W))[DGN3)PR<@  7W    "UP
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MT# &%R-A/*N_89W7^T=/Y9>"C8A%>Z9PZXV?JRB-*L%%?&K+UFNQ7X=>A6%
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M>#R]GEM^Z>'R\M_9Y>7>7FSY(?C#C>-\>?D8^.-OJGB>O?&'X[>"?']6Y?\
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M2TNJ3$>(1)#D9*G$I<WIE2-;6E*]Z]K6MZFUWWU!EJNMJ5O="NQT#=MO:"D
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M; I5CJ8T2VS(9B0DQ"IN,3R'3NH'PK%-V#@Y-?.IV5*/4GWHJR*JN^ ^+6Y
MR;"[7UW.Y(+-R1"M/9CAP0KNIV(!+<_,JQ_?.1'=1ML0!\&VX/L<X\3+E3.E
M5(B9Z.$L/+.7]D\@^^<]%)JLF!T.7T/R/D=!G6MNZ6%@PFL20=?G=AZP^*:
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M+X7JTLK+NP*(]EBC8\BUI8GD=]MAS?;;SW'EMWNH=!0K% V.GOF(\=3K;VW
M5BL%7G^VUZ]I3HI6B8DFEK?M;]XPF9IA[ZFGFUZ2GU6-'*'D I/<>VB6#O\
M_*ZLO\^VX]Z3B-^W?^8D?]X(,P?BC*(_)>>QV]NJ;8JHEE"GWWI+RD-1TH3M
MZ3)<=D2'=Z3K;C\AUUYU?K<=<6M2E;FY1WR+C\+L>P 'WAV'UAVGB>Y'_KWS
M)0R1(HQ$8B,1&(C$1B(Q$8B,1.<3S0]#?Y!^27D[UGMU/Z/QL+6[\7#D!8NR
M$;LR;B-#JL"!.H(-"Z23@(<7)%ONMZCSY"=L.-;4I+FUMHZ3Z)],_3W3/2VD
M:%F:9K-^3I]-]=MN-7@FAS;EY&0#6;<VJP@+:JGDBGD#L"-B=4=0=!:IJ^L9
MVHT9>GUTY+ULB7/DBQ0E%51YA,9U!)0D;,>Q'O\ :5>_Z/\ ^4_VW/'_ /TM
MT7_EUF4_MA>E?H-U!_1:=_F$LW[&.M?Q[2_Z3+_5(_Z/_P"4_P!MSQ__ -+=
M%_Y=8_;"]*_0;J#^BT[_ #"/V,=:_CVE_P!)E_JD?]'_ /*?[;GC_P#Z6Z+_
M ,NL?MA>E?H-U!_1:=_F$?L8ZU_'M+_I,O\ 5)??T<7HK.W^''D,_P!>Z#?>
M560 [S^RU)(ZFS[=),:GFIP*5&D;;-U$)"^"-(%OI?5J;M[2W&O=LN:VO:-?
M^DGTL:'UITZNCZ?I^JXN0NHXN9XF8F&M/AT5Y",N]&7<_,FY2OL<=@=R.V^3
M=)]%ZCH.JG.RLG"MJ.+=1PQWO:SE8U9!VLHK7B AW]K?N-@?>WRYH.;*C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1-
M:WI??L=?D3_DN5_VV\VS9GH=^>/TW_*U7\R:E,1Z[^935?\ L/YRPYPX9W9.
M=8Q$8B,1.[/T5GV/[QL^:UB_+ZVYP5Z5_GA=3?;>/^;\2=(=%_,QI/V&[\JO
MFP7->3*(Q$8B5L#^1#);RMN'B_JI.L/U/CH/K:KKLVAQF>V:L;=?T!T ^*FU
MQEQE+^%[);,/I=UKW/P%O>_>Y1+F<M0LP/#V->,N3XO/SY6<.'#CVV\^7([^
M6WOS-LGHUL?T?Z;UW\<5=-0ZDRNGAIGJI5JCC839GK9S/6"'#\?#\#U92N_+
MQ6]S+)Y6S"8Q$8B,1&(C$1B(Q$YQOV0U_!'Q:^<?5_Q90\Z2^)T^7>JOM72?
MQV=-4>E+]XT;[+G?X,6<P&=333T8B,1,AJ/\*ZQ\X0OXRC939ORGE_:U_P"*
M>3:/W^G[+7_C6?I+Y\T)UG*Y!O(>$7\IKCXPIJ\I@A4.1@NKNV]11ER'.C&S
MZ 2 J ^H27V'XZU_"5353W6W$Z]WJ.C?[O*)<P-GVX/AD&O'3(-G(;$._'CQ
MVW&WGOR^IM[\S3)Z.MQ^@M-ZZ.?6].H]1973ZZ<*&%M3XN&<LY1R?%*NC@<!
M4*5*GVN9':6-RMF%R(.F=IK7,2M4K,D+<;C=+K'L1*MTB@5YVQ66< I_Q*FW
MV=YE4B".&UVM.V6M0R1(F2AH=*V.O@QJ)YLT,'2JS%PK<I+K0]--%!K6V_(L
M%52V7<_!J!V9FLM%5K*J*Q"566-QKK=A SA2!LS,=R%4;G9=MSY@ #< DGS(
M'F0)BM>\H>76;JF^3C?HJ23DG[S3@-KF5<E%Y_;+SS%O;O1J/6+6XGX*2LM,
M2R306C*9CPWY%=MD,1.)S:E98XJ=9I655B>MMX/$5X]UE*VJ<BFC*^5K[:1[
M2U7[H4.Y(%M+.JK=47\%J%^ WWW8 ['B67W2AO(E>^X^H=M]CM8G+;)DC3C?
MUJZ%\VAO^QUD_)^6+?Y9D*>Y'\_]YDEY(D48B,1&(C$1B(Q$8B,1&(C$2)^J
M=MY[QE%5^CF3:MS+P;EUZIAJ3S?I/4[*=+#P9.R3X\&K<MJ5RL:F8((.3)S9
MS@MN!$C1%JD2FU*;2NLQ,')SC;ZN*=J*Q9<^1E8N'56C6+4I:[+NHJW:QT15
M#EB6&P/>0.ZIMRW]H[ *K.20"3L$#'L 23MM,7M7E%Q&BVQZF7:TEZ@59!&[
M!LC9N?\ 1P=->B5NBSNG6$=#Z(3J4:@3[2$YX*+7,K2H5FD7&!7 Y@I)!-Q1
M1!R--ITK.R*1=14ER&RNOC5D8UEX:W(7%K8XRW'(6JS)=*$O-0I:UT06$NH/
MAMK4\6)4[$[E6"]E+D<B.)(4%BH/( $[=C,EI?<^7]"F 1M3L,H@5L<&\$80
MB56;8$,08W-[8BBW1-F$'@8PE3I82X+575C[=%"3YQ2-.C#8TQ0Z?N/)NP<K
M'6Q[:PJ5-0K.+:71CDTG(H\)Z[&6X64_NO*DV*J%2Q7DN_JNK; 'N0Q V(/L
MGBVX(!79NVQV.^^WD9+>4DCC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(FM;TOOV.OR)_R7*_[;>;9LST._/'Z;_E
M:K^9-2F(]=_,IJO_ &'\Y8<X<,[LG.L8B,1&(G=GZ*S[']XV?-:Q?E];<X*]
M*_SPNIOMO'_-^).D.B_F8TG[#=^57S8+FO)E$8B,1*K _'HN)\Q[OY..6,<\
M$M?#J_R9BK(AR4E(D\-:&S[A=Z<I>XCD-]I&XZ(Z&]/)<W[:E;3]3*!<-EU*
MW.YJ4LQ$QQ7L>09;.?(GRV([;><S_*ZQQLCT:Z5T*N%>N5I_5.9U ^>;*SCV
M4Y."V(N.M0'B"Q6;F7)XD#8#>6IROF 1B(Q$8B,1&(C$1B)SC?LAK^"/BU\X
M^K_BRAYTE\3I\N]5?:ND_CLZ:H]*7[QHWV7._P &+.8#.IIIZ,1&(F0U'^%=
M8^<(7\91LILWY3R_M:_\4\FT?O\ 3]EK_P :S])?/FA.LY5 #X^'Q'F;??)E
MT\'=K=MX;6^51*XVU-T<BE EF;.O$Y#JF=0%0'F$;8:0V\J1IW>MK;TCZN6]
M,-UU*[.+J:[,6N@)WYAD?D6/;;B1Y;'??WIL#+ZPQ,CT9Z3T.N)DKFZ?U5F]
M069K-5ZK9CY. V(M"*&\87*Y#,60(5\COVEK\N$U_-;/DMX#)ZY/!%JB<"%B
M42@]XYTM_P @)]^Z[(I;_<G^638W4^9E#-FE&ZW<^5D>60Y=+ B25?&*78"K
MP\]4R++1%[)M,Z@]36Q;JW16R-/R0-/7'PQ>, 9:G$RD2I4MHRURV6^QUL8B
MM0]=RDJ*:S'#D$$'9+$WLY6$<^!#J2W9E*;C;;S.Q'G,MY7XD7JA]!HOQWT
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M.KX2([-D.2YCL<6*CQ8;+DJ4\[(D+0RE3SSBW'-J6K>\@OR+\JPW9-UN1:P
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M-X./=DVDLJJE-"%[&+,0-SL$1=^5EC)6@+NH,+,%VW_TF"CWR2QV';ZG<GX
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M+V%L52%78!*[T8^R-SN-V+$D]AY "0/+3Y@'NQ]GLG$N?]CY;?CG$O2!UQH
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MM)D:;DZ-T;I[-AY%!IU&O4AC58N-4N%E-CV^LXF3>F8]+^&R)BV%R@!,X_\
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MMQ*/6W%+TM'A<R!7827"\0K,5<,Q"@E0P('OR6BSO;C'G/S@U0^;]FH0ZO\
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+C$1B(Q$8B,1/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g96328g03a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g03a11.jpg
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M_\0 &    @,                 " D$!@K_Q  D$  " @(" @(# 0$
M   $!0(# 08'$Q(4"!4 "1$C)/_$ !H!  (" P                <(! 8#
M!0G_Q  C$0 " @(" P$  P$        #! $"!1(&$0 '$Q0(%2$B_]H # ,!
M  (1 Q$ /P#0CSM\B]CY[Y7OTZ/($N/.(!WI"80B-K""J2L*VVJ_:-@'5?\
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C51<CBV]II?\ .S<<F#O29I?YWKM69K/<3,>-J_ -XYOG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g96328g03c36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g03c36.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1\H4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'PR^>4@X0DE-! 0      "D< 5H  QLE1QP"   "NY < @4 %59E<F$@
M+2!38VD@1W)F>" M(%8W8@ X0DE-!"4      !!EZ!=09%,Z_H"AX%[10_7A
M.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
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M;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6)
M;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M        0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M            4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O
M;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2
M;'0               !4;W @56YT1B-2;'0               !38VP@56YT
M1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O
M<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M  UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M   X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M         #^    X0DE-! T       0    >.$))3009       $    'CA"
M24T#\P      "0           0 X0DE-)Q        H  0         ".$))
M30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       !
M #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M  !P  #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!!X       0     .$))300:      ,U    !@
M       #7P  !V,          0                         !
M      =C   #7P                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   #7P    !29VAT;&]N9P  !V,    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   U\
M4F=H=&QO;F<   =C     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    #.$))300,     !2,     0   *    !)   !X   B.
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MES'7OK#TCJUV)C]/R#D6 V2[90
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                            _^%>V&AT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED
M/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN
M<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@
M-2XS+6,P,3$@-C8N,30U-C8Q+" R,#$R+S R+S V+3$T.C4V.C(W(" @(" @
M(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G
M+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T
M<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z
M9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @(" @/&1C.G1I
M=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D
M9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY697)A("T@4V-I($=R9G@@+2!6
M-V(\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \
M+V1C.G1I=&QE/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @
M/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B R-2XR("A-86-I
M;G1O<V@I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z0W)E871E
M1&%T93XR,#(Q+3 S+3$V5# Y.C,P.C0S+3 T.C P/"]X;7 Z0W)E871E1&%T
M93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C$M,#,M,3A4,3<Z-#8Z
M,C@K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D
M871A1&%T93XR,#(Q+3 S+3$X5#$W.C0V.C(X*S U.C,P/"]X;7 Z365T861A
M=&%$871E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP
M34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @
M(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E
M;G0C(@H@(" @(" @(" @("!X;6QN<SIS=$UF<STB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+W-4>7!E+TUA;FEF97-T271E;2,B/@H@(" @(" @(" \
M>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET:6]N
M0VQA<W,^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I
M9#HV-44V,SDP-C@V0T8Q,41"039%,D0X.#=#14%#0C0P-SPO>&UP34TZ3W)I
M9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX
M;7 N9&ED.CDY,S@W1$5"0D4X-T5",3$Y,D,T048X04(T,3A!-S Y/"]X;7!-
M33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N
M:6ED.CE#,S@W1$5"0D4X-T5",3$Y,D,T048X04(T,3A!-S Y/"]X;7!-33I)
M;G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N
M8V5)1#YX;7 N:6ED.CE",S@W1$5"0D4X-T5",3$Y,D,T048X04(T,3A!-S Y
M/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE
M;G1)1#YX;7 N9&ED.CDY,S@W1$5"0D4X-T5",3$Y,D,T048X04(T,3A!-S Y
M/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN
M86Q$;V-U;65N=$E$/G5U:60Z-C5%-C,Y,#8X-D-&,3%$0D$V13)$.#@W0T5!
M0T(T,#<\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @
M/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO
M;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @
M(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z9#-A9&$U.#8M8C,Y,2TT.#,Q+3EB-&4M8V4Q9&$S8S,P,69A/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(P+3 T+3(Q5#$Y.C,V.C(Y+3 T.C P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU
M<W1R871O<B R-"XQ("A-86-I;G1O<V@I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HY
M.#,X-T1%0D)%.#=%0C$Q.3)#-$%&.$%"-#$X03<P.3PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP,RTQ
M.%0Q-SHT-CHQ-BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!I;6%G92]J<&5G('1O(&%P
M<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F
M<F]M(&EM86=E+VIP96<@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O
M<VAO<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z.3DS.#=$14)"13@W14(Q,3DR0S1!1CA!0C0Q.$$W
M,#D\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C$M,#,M,3A4,3<Z-#8Z,38K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HY
M0C,X-T1%0D)%.#=%0C$Q.3)#-$%&.$%"-#$X03<P.3PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP,RTQ
M.%0Q-SHT-CHR."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F
M<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O
M97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z.4,S.#=$14)"13@W14(Q,3DR0S1!1CA!0C0Q.$$W
M,#D\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C$M,#,M,3A4,3<Z-#8Z,C@K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @
M(#QX;7!-33I-86YI9F5S=#X*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1-9G,Z;&EN:T9O<FT^16UB961">5)E9F5R
M96YC93PO<W1-9G,Z;&EN:T9O<FT^"B @(" @(" @(" @(" @(" @(#QS=$UF
M<SIR969E<F5N8V4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" \<W12968Z9FEL95!A=&@^+U5S97)S+VIO:&YS=&5W
M87)T+T1E<VMT;W O4V-R965N(%-H;W0@,C R,2TP,RTQ-2!A=" R+C$R+C4V
M(%!-+G!N9SPO<W12968Z9FEL95!A=&@^"B @(" @(" @(" @(" @(" @(" @
M(#QS=%)E9CID;V-U;65N=$E$/C \+W-T4F5F.F1O8W5M96YT240^"B @(" @
M(" @(" @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/C \+W-T4F5F.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#PO<W1-9G,Z<F5F97)E;F-E
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$UF<SIL:6YK1F]R;3Y%;6)E9$)Y4F5F97)E;F-E/"]S=$UF<SIL
M:6YK1F]R;3X*(" @(" @(" @(" @(" @(" @/'-T369S.G)E9F5R96YC92!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @
M(#QS=%)E9CIF:6QE4&%T:#XO57-E<G,O:F]H;G-T97=A<G0O1&5S:W1O<"]3
M8W)E96X@4VAO=" R,#(Q+3 S+3$U(&%T(#(N,3(N-38@4$TN<&YG/"]S=%)E
M9CIF:6QE4&%T:#X*(" @(" @(" @(" @(" @(" @(" @/'-T4F5F.F1O8W5M
M96YT240^,#PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @(" @(" @
M(" @/'-T4F5F.FEN<W1A;F-E240^,#PO<W12968Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @(" @(" @/"]S=$UF<SIR969E<F5N8V4^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T369S.FQI
M;FM&;W)M/D5M8F5D0GE2969E<F5N8V4\+W-T369S.FQI;FM&;W)M/@H@(" @
M(" @(" @(" @(" @(" \<W1-9G,Z<F5F97)E;F-E(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @/'-T4F5F.F9I;&50
M871H/B]5<V5R<R]J;VAN<W1E=V%R="]$97-K=&]P+U-C<F5E;B!3:&]T(#(P
M,C$M,#,M,34@870@,BXQ,BXR-R!032YP;F<\+W-T4F5F.F9I;&50871H/@H@
M(" @(" @(" @(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#XP/"]S=%)E
M9CID;V-U;65N=$E$/@H@(" @(" @(" @(" @(" @(" @(" \<W12968Z:6YS
M=&%N8V5)1#XP/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \+W-T369S.G)E9F5R96YC93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1-9G,Z;&EN:T9O<FT^16UB961"
M>5)E9F5R96YC93PO<W1-9G,Z;&EN:T9O<FT^"B @(" @(" @(" @(" @(" @
M(#QS=$UF<SIR969E<F5N8V4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" \<W12968Z9FEL95!A=&@^+W9A<B]F;VQD
M97)S+W-G+WHP<S!M,F=N,&,Y,VQV:&-V>GIG=W8V.# P,#!G;B]4+U1E;7!O
M<F%R>4ET96US+RA!($1O8W5M96YT($)E:6YG(%-A=F5D($)Y($EL;'5S=')A
M=&]R*2]!25\R-5\R+S-H4&$S92YT:68\+W-T4F5F.F9I;&50871H/@H@(" @
M(" @(" @(" @(" @(" \+W-T369S.G)E9F5R96YC93X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1-9G,Z;&EN
M:T9O<FT^16UB961">5)E9F5R96YC93PO<W1-9G,Z;&EN:T9O<FT^"B @(" @
M(" @(" @(" @(" @(#QS=$UF<SIR969E<F5N8V4@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" \<W12968Z9FEL95!A
M=&@^+U5S97)S+VIO:&YS=&5W87)T+T1E<VMT;W O4V-R965N(%-H;W0@,C R
M,2TP,RTP,R!A=" Q,2XU."XP-R!!32YP;F<\+W-T4F5F.F9I;&50871H/@H@
M(" @(" @(" @(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#XP/"]S=%)E
M9CID;V-U;65N=$E$/@H@(" @(" @(" @(" @(" @(" @(" \<W12968Z:6YS
M=&%N8V5)1#XP/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \+W-T369S.G)E9F5R96YC93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1-9G,Z;&EN:T9O<FT^16UB961"
M>5)E9F5R96YC93PO<W1-9G,Z;&EN:T9O<FT^"B @(" @(" @(" @(" @(" @
M(#QS=$UF<SIR969E<F5N8V4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" \<W12968Z9FEL95!A=&@^+U5S97)S+VIO
M:&YS=&5W87)T+T1E<VMT;W O4V-R965N(%-H;W0@,C R,2TP,RTP,R!A=" Q
M,2XU-RXR-"!!32YP;F<\+W-T4F5F.F9I;&50871H/@H@(" @(" @(" @(" @
M(" @(" @(" \<W12968Z9&]C=6UE;G1)1#XP/"]S=%)E9CID;V-U;65N=$E$
M/@H@(" @(" @(" @(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#XP/"]S
M=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \+W-T369S.G)E
M9F5R96YC93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1-9G,Z;&EN:T9O<FT^16UB961">5)E9F5R96YC93PO
M<W1-9G,Z;&EN:T9O<FT^"B @(" @(" @(" @(" @(" @(#QS=$UF<SIR969E
M<F5N8V4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" \<W12968Z9FEL95!A=&@^+U5S97)S+VIO:&YS=&5W87)T+T1E
M<VMT;W O4V-R965N(%-H;W0@,C R,2TP,RTP,R!A=" Q,2XU-RXP-2!!32YP
M;F<\+W-T4F5F.F9I;&50871H/@H@(" @(" @(" @(" @(" @(" @(" \<W12
M968Z9&]C=6UE;G1)1#XP/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @
M(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#XP/"]S=%)E9CII;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \+W-T369S.G)E9F5R96YC93X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1-9G,Z;&EN:T9O<FT^16UB961">5)E9F5R96YC93PO<W1-9G,Z;&EN:T9O
M<FT^"B @(" @(" @(" @(" @(" @(#QS=$UF<SIR969E<F5N8V4@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" \<W12
M968Z9FEL95!A=&@^+U5S97)S+VIO:&YS=&5W87)T+T1E<VMT;W O4V-R965N
M(%-H;W0@,C R,2TP,RTP,R!A=" Q,2XU,BXP."!!32YP;F<\+W-T4F5F.F9I
M;&50871H/@H@(" @(" @(" @(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)
M1#XP/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" @(" @(" @(" \
M<W12968Z:6YS=&%N8V5)1#XP/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \+W-T369S.G)E9F5R96YC93X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1-9G,Z;&EN:T9O
M<FT^16UB961">5)E9F5R96YC93PO<W1-9G,Z;&EN:T9O<FT^"B @(" @(" @
M(" @(" @(" @(#QS=$UF<SIR969E<F5N8V4@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" \<W12968Z9FEL95!A=&@^
M+U5S97)S+VIO:&YS=&5W87)T+T1E<VMT;W O4V-R965N(%-H;W0@,C R,2TP
M,RTP,R!A=" Q,2XU,2XT,B!!32YP;F<\+W-T4F5F.F9I;&50871H/@H@(" @
M(" @(" @(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#XP/"]S=%)E9CID
M;V-U;65N=$E$/@H@(" @(" @(" @(" @(" @(" @(" \<W12968Z:6YS=&%N
M8V5)1#XP/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \
M+W-T369S.G)E9F5R96YC93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1-9G,Z;&EN:T9O<FT^16UB961">5)E
M9F5R96YC93PO<W1-9G,Z;&EN:T9O<FT^"B @(" @(" @(" @(" @(" @(#QS
M=$UF<SIR969E<F5N8V4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" \<W12968Z9FEL95!A=&@^+W9A<B]F;VQD97)S
M+W-G+WHP<S!M,F=N,&,Y,VQV:&-V>GIG=W8V.# P,#!G;B]4+U1E;7!O<F%R
M>4ET96US+RA!($1O8W5M96YT($)E:6YG(%-A=F5D($)Y($EL;'5S=')A=&]R
M*2\R4#(R1&0N=&EF/"]S=%)E9CIF:6QE4&%T:#X*(" @(" @(" @(" @(" @
M(" @/"]S=$UF<SIR969E<F5N8V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T369S.FQI;FM&;W)M/D5M8F5D
M0GE2969E<F5N8V4\+W-T369S.FQI;FM&;W)M/@H@(" @(" @(" @(" @(" @
M(" \<W1-9G,Z<F5F97)E;F-E(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @(" @/'-T4F5F.F9I;&50871H/B]V87(O9F]L
M9&5R<R]S9R]Z,',P;3)G;C!C.3-L=FAC=GIZ9W=V-C@P,# P9VXO5"]496UP
M;W)A<GE)=&5M<R\H02!$;V-U;65N="!"96EN9R!3879E9"!">2!);&QU<W1R
M871O<B R*2]E:TDR=D8N=&EF/"]S=%)E9CIF:6QE4&%T:#X*(" @(" @(" @
M(" @(" @(" @/"]S=$UF<SIR969E<F5N8V4^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP
M34TZ36%N:69E<W0^"B @(" @(" @(#QX;7!-33I);F=R961I96YT<SX*(" @
M(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W12
M968Z9FEL95!A=&@^+W9A<B]F;VQD97)S+W-G+WHP<S!M,F=N,&,Y,VQV:&-V
M>GIG=W8V.# P,#!G;B]4+U1E;7!O<F%R>4ET96US+RA!($1O8W5M96YT($)E
M:6YG(%-A=F5D($)Y($EL;'5S=')A=&]R*2]!25\R-5\R+S-H4&$S92YT:68\
M+W-T4F5F.F9I;&50871H/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=%)E9CIF:6QE4&%T:#XO=F%R+V9O;&1E
M<G,O<V<O>C!S,&TR9VXP8SDS;'9H8W9Z>F=W=C8X,# P,&=N+U0O5&5M<&]R
M87)Y271E;7,O*$$@1&]C=6UE;G0@0F5I;F<@4V%V960@0GD@26QL=7-T<F%T
M;W(I+S)0,C)$9"YT:68\+W-T4F5F.F9I;&50871H/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=%)E9CIF:6QE
M4&%T:#XO=F%R+V9O;&1E<G,O<V<O>C!S,&TR9VXP8SDS;'9H8W9Z>F=W=C8X
M,# P,&=N+U0O5&5M<&]R87)Y271E;7,O*$$@1&]C=6UE;G0@0F5I;F<@4V%V
M960@0GD@26QL=7-T<F%T;W(@,BDO96M),G9&+G1I9CPO<W12968Z9FEL95!A
M=&@^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI"86<^"B @(" @(" @(#PO>&UP34TZ26YG<F5D:65N=',^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SII;&QU<W1R871O<CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O(CX*(" @(" @(" @/&EL
M;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E=E8CPO:6QL=7-T<F%T;W(Z4W1A
M<G1U<%!R;V9I;&4^"B @(" @(" @(#QI;&QU<W1R871O<CI#<F5A=&]R4W5B
M5&]O;#Y!9&]B92!);&QU<W1R871O<CPO:6QL=7-T<F%T;W(Z0W)E871O<E-U
M8E1O;VP^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F
M.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$U+C P/"]P9&8Z4')O9'5C
M97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&9X/2)H
M='1P.B\O;G,N861O8F4N8V]M+W!D9G@O,2XS+R(^"B @(" @(" @(#QP9&9X
M.D-R96%T;W)697)S:6]N/C(Q+C N,#PO<&1F>#I#<F5A=&]R5F5R<VEO;CX*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @
M(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX
M;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP
M86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!% )= P$1  (1 0,1 ?_$ !X   ("
M @,! 0             !" D&!P0%"@,"_\0 8Q    4" P4%!@0#!0('"P41
M 0(#! 4&!P 1(0@Q05'P$F%Q@9$)$Z&QP=$4%>'Q%A@B%R-6F-<D,@HG,S="
M=Y<E)B@U-CA76&BVV$-&1U)FJ+@9-$1(4V)G<G.(E+?#Q];_Q  > 0 " 04!
M 0$              0<"! 4&" ,)"O_$ %\1  $# @0$ P8$! ,#!@H %P$"
M Q$$(0 %,4$&$E%A<8'P!Q.1H;'!%"+1X0@5,O$C0E(D,Y06)31#4],U1$54
M56)R=).5U!=D<W56A)*DLL35&"8V8V66L[2"@Z/_V@ , P$  A$#$0 _ /=O
MX??4=V?'QSY[\>VH_621.DWF1KVD0;8\/']+#6-O".FF(H[5FV+:?9)IJ(D*
MX&8J6M*P7=L+=6KHULC)5S7<BR3(H\_+VBZ[5C$P4611)6>JJ>>1T!#(JIE<
MO#O'+-DZVGA;A#..+ZQ=+EC2$LL\BJRN?44TE(A1A)=4 I2W%P2TPTE3CG*3
M ;2M:<#Q'Q-D?"655.=<09A3Y;E](CG<??6$S/\ 2AM,%;CBU$);0A*W'%J2
MAI"W%)0:K'OM6MK20?#)0FSI8BG8(#]M*F*HNK6TW5*J :@DYJ2GZ+94\P>*
M!H8&\/,-D#Z%<.B!VC34S[",O]R!4<15RZ@I(YV*"G;IPHVLTZ^XXM(/5U"B
M!,)!@<OUO\9' -/7FGI<DX@KJ-+G*:]MFE:0I(49=;8J*IFH*.6%)#C;2R#!
M0")$A+;>V%M&L"+#:/M=<79WD!$"JU,1HM=RU Z 'O35M04<M-0R)CYC[RJZ
M*IYN@G_6LZ*4!-C3<[]B_$U!S.Y2]2YZPD$A#2DT-;&LFFJ7"RH@;,U;BB20
ME$XE[@_VZ>S3C3W;>6<1TM-6N0/Y=F1-!6!9C_#0U4AHU"A-U4OOT @_GWQ9
M];FZ]L+PT^E5=J;A47<FFEP3[$Y0]30]3QI3G*!RHK.H9X\3;.2@/]XV<"DY
M2$!*HD0Q3 $55V75^6OJILSH:O+WQ(+593NT[A FX2ZA)*1,A292;$&,2ZVX
MAQ/,VXA:>J%)4/,@G6-#\+WS_/,>O+Q =1S#EBSF8 CO:W@!N-=#MY8KB/7Q
M\"+"#UP:_77OSTY9\-^G?Q)TZR;'74Z?3H!>2-2WV^$7ZQOI?ML]!_?[8)$$
M ]=X,ZF_K?PPKC^WZX7+OX=#]_' 8B\" =;]+WU^=[3U?7MOZ'Z>&#KSU^G#
MEOT'!:;F]HMO/7O:1.E],'KRM]]^NEQ@X[\N/#/EGUW8?80/A/0'U]H)Y3MO
M'6/7?!GP#?EF'[;_ (84F8&I3/8:]OJ+]H@@&YT! /[?WP?KOTSRR[OB 9?#
M!.QU@S-@3 TW^'<],'[:7B9[_(F?G@\!T[M=WKG\\,::STB^GZ^9UOT-[B_>
MVOPCZ88^O7'N]?# 8@^<B0+QN?E_:0A\/KKMW^'CA9[^7IX_N'AH(80.NP$
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M2!I?8=-=B;6'<3IM +WGSZ^NOSP=?8=^[3A]\/K?T0(C[:W/B,'K]1IK??\
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MRR #()C3SVB;GON1H</KW_?3^P.W63+YYAGX>?,?MH&%%NL&T^$7^)/;8$
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MBY)0M=.O\74-D_Y*JK>382FPC.  "@!0  *4 *4    I0   H &X     #0
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M([=,<A-F':QL,H-RE2.Z"2)OH+#KH8OM?&G*XG]F/$Z@.)^#'^%<P=!]YG/
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M*YQE;[CO+9?N33,*,D,#7';6_<7/LDY2>[/E\+K6=%N('3IJ.J9S6ELG*A=
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MM(CY$7WGJ,1^]D69TU*Y6/,<M,TQEM0IP.)*2UF[)>H2F/ZRM E24RIDCE<
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M,@::"UI)L8\-K V^)^D^0/PXZ>O'KY$; B.@ T,_7T#? /GM?X;>OKAUQ/\
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M*GL7X6S#BKVD\+4=$PXZW09I1YQ7.I22BGH\MJ&ZI7O5@?D#[J&:5!L?>U"
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MMOV^I-AY0<\A^H>/#>'(<N7'!KHKYR)Z]Y&PL(.^ [2/L?#?0]1/7; .8Y@
M]V?'K=Z]V#46[7W$[C;3H=Y&T@@$$CO&WK7X=\'?KKPY>6_ANYCNP]),F.AV
MCY_OJ#L=K6WZ^>F^O0:X/#+Q\.?/+QP1K!N8\HF/&^LF_P L'C/AX_2?#%>T
M5[0ZWTOM0H[.3&A*K6C'E>3MJ&-U4GT(K .[ETS%3$C.0I( C@9T(-B]IV=I
ME2I  XA4D8X04B4X8 G Q[>=\..<35O!#6=)7QEEW#;'%E=DB:*J+5/E%2NB
M+*7,T"/PB<R529E09C^"5"#0U31%4:LFE&<7PYG*.'6>*W*5*<CJ<Q7E=/4J
M>;#SM2V7T*4BEGWAIO?4]13^]$GWS*X;]U#AL)ZX@/KF'Z_/(:]18P!8VCUL
M+B<8/UL1\(/[?0_;>/CKKGGR'7+,,*^QWC7;<$R3/>Y';8_OH.I%K1'46F#@
MR^._=KW#IY<!RWX([Q.NF@L1<"PZ_';!/RTUMWU\]Q.F*];T^T1MY9*_B=EY
M^B*J?PL,YHIC<6YK9[#-(*@G5?%9KPBZT,\6)+SL-&Q\I%2U63$?[EO"1CU1
M5JG+N8R5:,;"ISSARAX@X8X2S'.12<4<:4]?4\,96JAJG6,P10.5#'NGLS0C
M\)1UE?54=72992J+BZFI:;;=_"_BJ-=1G:+AG.LQR/-^(J.D0[E.1N-MYB][
M]"7VBXEM:EMTQ/O76J=MYIVH<  0VHK3[P-N\EA60Y[\Q =WD.G'+?Z<]1&_
M[S/TF- +_*\"+R2<%/:!\]?*=/C.E@#++[Z9]?+AEI@C6]^L"VVN^\_ 1@F?
MTOZ_7>;X-_EUYAA^<7T/SB==1&VD=":>?KR.'@O-SX:7W-H\M9@>96%KW>/K
MD.666>[NWXI(4=])CYP=!X'4&3$##MW\/A(F9C7OIAXJ\#VB) T^%O+?"PO'
MANTY[^>GRPMY,:B-1J .YU-A8:D]</PWUOTTZ7^N&/GY!G]!PS:3>/CY[QV&
MG77"'EYF/N,+Q'(.\<@#AF(Z#ZCO]<4G2Q.L $GK:X@Z7&MNMCA^ $]8\_ #
MR%NTX\QVST<VT+MR6^JE$AG457VTE=+:#?JB453!0=N!J>9M=(''4,FK^+LJ
MP34')-,RB D$3 F!X5R$?\H/XG?:CG+I]Y3>R_@"AX)RM28(8SRM9RKA_-:<
M'_*735\=O%(_,3[Q,D3$U9P?Y'[$>%<O2"V_Q7G:\WJAH7J-+M5F+"U0#/*A
MG)$21$<EP8&/3CX^>GZ]!IWXFSL=S?R\3.HMK:VE\0KX>5_V]&_;!EIZ#N'(
M,M= T'RSTW81%M3V&UKV&LVL";:7%L$W^(U$F;7-QYQ?7#RZ\>OGSP1&GD(L
M)[_&=XT[J?7AZ]1@\^8Z];L'QO.LZ=@(WCN!:<'ET'KOA9#S^ =?IWZX#-KG
MIIX]I^>@)G?#D=/F?7[]K8Z^7C&TW$R<,\%0&<M'O8QV*)P36_#/VRK1Q[I0
M0.!% 25-V#B0P%-D(E'++%2%EM:' ?S-K2L3$<R3(F(M(O,2#&NB(!!!W!'2
MQ$3\#:-[^.,TS(45 _@[90]30SB7HJF8=!6G%)R,<U/'4^Q:-H^-DI>,15(_
M;MUT4D0_'K,V[5=4^:60'*4*G2MQ2GUB ZM:BI*2$%:U%2@G7J;28MO?  (
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MUA3\[2#)\WIRIWE3R$%63&:=3D4]D@9OH9JF=L:'BOPNQ<$\+9+GG!/%C;U
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MZND>$\KU,^@H<:< )3S(4 I"E-N!;2EMJ\Z^TM2.TAL\W4:V)CIS9^NW</\
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MA;'3?72^D^O#!N/+3UKA>>@_7( RU_<1S#+!;J+R?C:WQ\R>^'Y7'VDF;?V
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M9HWJEU0/0Q;V7EVHYR34,4Z<=;&T+*HINVLJLJ?04HTT5:5J"X=@I1]TJ0I
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M5B("H,G7D#:BFJ$D$9^T;JH;(U<S$%&%76@J"4H29;JE,!_]J3AW"45.-%#
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MZWEB,H9?_G],Z[S'+ZFE:#M0@K"$^\;4VI#S2T(EUIQ'*V'BIA%>=PZ]O_M
MRCBI=H"\]>/U7Z@K(6NME655VSL]23<QA4;Q$9 4C+Q$E5"K #"D>I*TDYJ7
MD# "P_A$RHMTIMR+@7A;A^G0S1Y52U#R4PY7Y@PS65SZHA2U.OH6&4JG_=4Z
M6F@)_*3/-Q1QY_%7QYGF8U".$7T\-9*AQ2:4HIZ>IS*I:!_*\^NK0_3L*6$A
M8999]XU_0:AT$JQK29H*<?TQ*T7$WIV@*:I.:/'+25*L[Q5I4%)O',1*L9R+
M<N*6KF1JN!%5C,1D?(MU$&""Q'+1)0JH& 1&[S+A'A;-Z>JI<RX=R>J9K:*L
MR^J!H&&G'J+,*1ZBK:9;].EI_P!U44E0\PX Z#R.*@@P1@N'?XJ?;!D%135"
MLYH\V72U#-2R<RR]E*VWZ=Y%0RXES+_P2N=MU"5H4X' "D!22D#&Z]FR_P#M
M5;)"56LZ G+/78AJXJT*QJ9I="C:@IFJ7K].$B*=;M6-7T-40Q,<S9Q$&P;L
MVW\"KM$5OQ+P6QW#QT=:,Z/^'[V>9+D.5<-<*TU?PUE.2L5%/EM'1UKM>TC\
M96U&85+U2YFIJZZL??JZIY;CS]>7>7W;*5(989;1/#'\<^8Y]F;^:<=\,/U6
M85JFC5YAE553*"DLL-T[:6: T] RPTVVTGD:0\H"ZE%:EK6;#*.]L*_:&22O
M1LE7'IY H 5S/V=K2DKOQI3 .7OPA)/^SFKBH#D)O=-863<%+ED50P]G&L9E
M["\V:"E95G=!7"90W6L/Y>X1.@6V:QI1'=2 ;R1O+60_Q0^R7.BVV]G;V3/N
M0 UFU&_3)22/\]3R*H4"^IJ['28G$KJ"]J-L,5XY0C5KZP]N)Q8 *:#O9"5-
M9=XBJ;( 0_'7)AZ<@G2PB.0!&S#TILA$IS%#/&@YC[->-<M!+^05=2V)AW+2
MUF22-U<E&X^^D;RXT@F]B<3)D_&'"^?-^^R7B#*<R;@*YZ.NIGT@'25-.+1.
MEN8ZC$XJ;JREJRC49JD*FI^JH=P "A+4W,QTY&+@( ("B^C'+IJH @("'86,
M&0@(;\QTU^GJ*5PM5+#U.\G5M]I;2TG?\C@2H38$1V%Y(V)*DK 4@I4DR0I)
M"@1XBQCKCO\ E]=-^N[NW:Y#OQXGK>\@: WO M:(W%I)FV*NOD>NEK[;]QIB
MBWVZUO32-GK$7;:-?>N*!NP_HJ8<%3 19TO=&F'PG754 ,RI'K2BZ&8$*80*
M*\BGE_6( :6O8QF?X'C)NE4H):S6BJ:17-NM 34M #3F4XR$B?\ 61 ))QI7
M']'^+X;J' )70O4]6G?11IW-1HEI]Q<?^IO%Z7;OH,ZXV,=B>Y&0K/K9S%]-
MBZLSG',"HP,H%U+-1B@YB/NFEKQEQ;E, %(5Z=,HB)@#$C<%I3D?M/XPX?6G
MDILS0[64K1NE0YT52 9U IGGAX#2#C6.)E*S7@C(LX09>HU4P><!NDE"J-X@
MB.6:IMHVM.MP,=#M6(R5<VUV0;MIN5@D[D;)3:UDQ.$-_M2UU-E2L9NU<[..
M%RB!@EG#-_1KXJ@@"HIM$%R&,F5/LKV=4@:J_:%P/41R)?JE-).S3_O:1:T@
MDRF%TZ@8@'EUYABKC&IEKA+BEG5*J=2R!(E26JQ#:HT,HJ$D7L2!_21C/-NF
MKUD-H>W>UE1"1VSF^]D]F3;.I\J0 D1"O8"+BX^6B4A(&1'D=,6M@5)-, $Z
M3V6.8X9+$ <?[.VCFO _&G"+PEZB=K$MMJF>9UM2FA!!(":JD!&X*@H"9)NN
M+5IR_BGAC/4&&72VPZM,"4)=A9.T*IJP@7NE)22(QE>TQ4+'9U]I.XO=!J %
M%FO'9?:JIQ\C_220MI=5G3<_<)XB)-Z4L9[=>/4,0Q@5(JN43?UFQ1PZE7$'
ML>SO*E?GJLF75^Z0/ZVA3N(KT&+&Z34I!@6F-,/-?^:O:%E%:/RM9JPBG=,P
M%N+2Y0P3 _I4FE7?2!S6Q[(W+DC9JX>&_O$F[=9P/NQ*;MII)F4'L"&>?:*7
M,N0ZCNS#+'.B4E1 $ J4$[1*B$W,;'72X.T8D_3Y'<>IT!Z':^/$3#;2=N$X
MU[=B[-Q(1E<*^]4S=TZL!==Q)3!I"L)%P[BF:\;&HOY&,AZ>I\(BG(DKENWC
MH^-BF[9(Z9"B ]_Y9EC659=1972-\E/EU,S2M\L $-("5+.DK=<YWEK)YE+6
MM:I42<?++VN9#[1/:E[3.**O*\@S3,LOR6H7E5"YR(I:%JGH0 ZBFJ:URFI7
MWGJA3[RF6'''CSI3R%*$Q)1@^92C)G)1KMN_CY!L@]8OFBR;AH\9NDRKMG+9
M=(QDED%T3D4153,8ATS%,4P@.8W=P2#W!\1^G?Y&^.;:FE?I*A^DJF'J:KIG
M7*>IIWVU-O,/M++;K+[:PE;;K:PI+C:@"A0(4)%^7@$1?KZ_>\Z1$DX\!K'6
MUS8][6BT "8N#(@$P3'PZ==9F9G[C33# GR/<:"T]+0-21'<G"T .66_@'>.
MO#O^.%VB_P _#"Z7)DB3KX=9\")UD7$8*>XU..I\M'TJG.W)KE01*C0EJZ=F
MKDUB<Y1[(E6@Z/92SF.* _[SB7_+VB89F4<$*&>/"LK*3+V55685=+0TZ9*G
MZQ]JF9! D@K>4A).P2)),@#K)7"?LA]H?&BFSD?#.8*IEP17US9RZAY"?ZVW
MJH-JJ4"W-^$0^L3S<O\ 5$P+:[ ^VM>E1L,W3=/;+%$/1(9Q4M?R<57=UQC5
M0 14@K9TH\=T[#2ATQ$$AK.LTE8Y3^MW3[A0OX88LSWVR<+Y:AUO*149[5B0
MCW*%TE E8G_>5=0A+CB ;S3T[B5Q"743S#J[@7^#E##]+7\=YXBJ2T0XYDN5
M(6TPXH%)#3]>I2:AUI4E+B&F:-?^EZ 0;Z=G79XMMLOVNA[46OCW;>$CW#V6
MEYF8<EDJIK.J990'$]6-8S0)(J352S;D"G>O5$DDD6Z+2,CVS**8,&3?F?/L
M^S+B7,W\VS1T.5+_ "I2A(*6*=E AJGIFRI7NF6Y/(D**E*4MQPK=6XXKN#+
M<NH<HH*7+,MIF:2AHF44]+3L-I::9::2E#:$(0E*4I2A*4I2D )2 D0D!(WC
MY;O,=/4?KKC$6U@^.NA([G<WC0ZXOO/7R%_@/M;#^?AUURP&#/7K'WZ6Z^8.
M%]/'UZZX0Y<1\0YAKPURU]= PO&.XC47&DG6T=8 W@,3L/ ]#;>TV^%S@^&_
M?UN\![M-V#2\@&XO8'<:R8\#^@/GIIZU\1WOK@#@'RT#,. >@^6_3> V B+3
M $7Z;=[=-;8#N?K<P=S\1YZ7T8]?3=PP=".DB)ZVL!TTZ2;$3A#]?WUWP@#G
MPX9YAX\\]<L$;D=-P=#8SK;OMUPR>F^\0? [1:</#']MH]>KR2L+P\^&_P"O
MH.N>$HV,?<:W^._;4X?CY;Z?;XBT8-^?Q#Z<O+[X=B#;74>(T[&(MM\\&D?(
M_?KY_I@S^_'X_8<$B1?:0+SOYDQMKKKL1^FWKS& =<PW]V[3K/NX<\(F0=^N
MH(!'K6!UT. 6@Z=];^H[[],&GR'P^(APX:?/!U.H_J[]>L$=(MYB<%_J/'Y
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M7AX4[M<'7D.JS%%(P&G%Y>U3>_<4>4//)15)I77%.! ;D8MLA#%!G6<9K4U
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M[:/XH7>%\VJN%N!J>EJ\QHE>YS+-JOWCE)2U"20Y2L,-*:6_4M6#RO?(;IW
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M" ;R!)^L0?E(,Z=\&"1%M9F?7?M@4(G2#-X.OD29[&!K;!@F-.Q\Q^\Q.V
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M-=2TU<S?_"K*=FJ:@V_H?0M-YO83IVQ)61>V;VG<.J0<OXRSA24A(]UF#_\
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MAJ'#+7>.8CYB(8XV$=;[$ZZ6UUU/Q(C;'T,]$=;R;#30?"</+].[KOTPX'U
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M^^[GGH.8>(Z[^_ 8/D9TF=C8;R?OU@_37I%Q!\!;3MA\NNNX-^'T[6F^OGY
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MZ?LC+[8=SMBV+NTVN[&R]1/+B4165=T?!5.6V(4:Q63HFI)"B#QS]XK5Q)F
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M&T<BLNFA4-(?;I5U#;;[J''&Z53R$U#K;?\ O%MLD^\+:)'.X$%"24R9*<=
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M]],>SV._\7L>YFUY?_H$]-./PUTQRPJZSO\ F-_B;WG6]^HWOC<E:GQ/U]?
MXYGEUEW:_MX9TR 3WZ?>\S,BV\#I@\_4][?W\8>';6]O'T=;:QMA80#\_AGY
M=^F\..NF$#.YL0/G?7]20(F^&1]/G'GVOH=K7P#]_+P#+7KG@,_ &2=B+6B#
M/>/#<$'Z>?B9MZZ8>'T]?/U/EA8!Z[NOUP?,:6F;[B-=M/M8'KOZ_;"W>8\<
M^@Z#+7!I'?4F=?M/[1?#U\AV]'T9M@#3R#@(CUIEP]<\(>.G0S$"([Q8W%CU
MG ;^9W 'J\[_  C#ZSZZY\,/KX'L+3&MO/S-HPO4>O73?"#PRR'P#?\ ;7E]
M$-(C2=H&NWEIUZZPSXS(\3IOYVZ_<] \?$,LO4?/+3!OI&^MS>=)%ITG<Z:X
M/B?#P,S\!Y3?!U\.?EKGSW[L$=(FTF)/ZP8W/G:,'KY]//;IIKA\>LNO+#W]
M1X1/U!&%MZGUYX ]?TP"( F8^WRM\1;>#@/P_?"TWY: &GAER'( Y>&% U(M
M&FWC!L#K]\.^DW)OXSU$D]?'#P];CM^N_8^,>6%A?'+GS\<O7+=A6.ER)[7[
MZ"3O:U\/Y3]/"?A.N#AKUWZ;N8<L.)$&3U-A]#V^8[X-[>NU]>AZX.67=N'<
M'VTRW:]V#4#RMV_0QTOI V-S/?4:G];SK;O@U[M!#=GH&F@@'=GW;M,L(SVL
M1I.EMATUZ6%NA;O<'6+F]P3WCOK><++/B(<=!WZ!OT[M,+E!\)V([;1 T\>N
M',; [7&ESI?O?#[\OOW?/R]<GOOMMX0+B]YWL3?J%VG]._T\_A)\^&>F>77
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MLFGO3@&2:0*BJJ;(B9#G$"C<45#6Y@^BFR^CJZZI7_2Q2,.U+JAL>1E"UD3
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M5Q*%:A7*9Q'N?>USV<<-)<_F_%^24[C?]=,BL9J*P$:Q1LJ75JC_ /=LKDV
M)%JD-KG:8OEM87NV5[Q4=9VE+)*;*M;S=>4VG<VN_P"/W55RLF[I-VS2FJ<H
M*-C6D<R9*4LB+AJTKE==X5XJF5\S% BBTR\)^S-&091Q%E>89LJM3Q'1LT50
M:*G_  QI6VTU2%EEZH6_[Q:A4GE6NG0$E )0OF(3 W%'\6GLZIWJ5W)J;.L\
M=HGENM>YHS1TKZCR )4[7JI7VQ*)E-,Y8P)@C&I4OY@W%Y+Y7[6VA9.D+A[1
M4+%4]<\MKJ"HZ#IV2@X6 8TXQAV;&NFER'C-F2.CVY%5VCYJ_<*BJJJZ R@
MGM;7!?#B,JR?)7J%=;19$ZX_E_XJI?\ ?-/N/KJ%NK53+IDN*]XM1 6@H2
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M=-/AO<Z8/[:X6[X]P:ZZ_+/!'GKT&\B?#K<ZF+X>OR[FUK?6, [OGQSSX</
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M4N)S7B*KI*)TJ!R[*%+RVC*%:MN%EPU52V1JBJJ7D'_*!$XS4  - #(- TY
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M>F_QV8'<D6D&01Y: 1)GM ,P< "//T'C^X?##M>1?Q[=H$3N)Z=#A"2?"(D
M6%Q>#'JYT.$&H"%95$6MJ0>5#;.OTQ$4K@6KJ*6MY60")P4,5W-4PYCU)= Y
MP 564XG)L5MRS50,PQ:UE%1YBPJES"CI:^F5_4Q64[52T29_-RNI4$J&RDPH
M:@B,25PC[7_:%P.ML9%Q'6_A&PE/\MKG%5^7\@C_  FV*A2S2H_* ?P;M.J"
M4\T2,3-MA[0O;.LT+=K5ZM)[5=$LRD34:U$VC[8WG19I=E,OX*LH%H%!5.\1
M0 1 D_2,$ZDEP 750)**'5-$^?>QCAO,?>/9*]49'5KDI;E5;EY49@%EY?XA
MH*,"6JDH;!_*PH#EQUMP/_&-1U"Z:BXZR15 5%#;F;Y6IRHHP20%.O4:@:NG
M: !4?=&O<D7W(N2H';?V=*_V=)_:A0K0*;MI1+23&XJ=5-%8JJ;=3T*""<K1
MM6TT07,@TJ]%TZ9,X^&:$?*U M)1"E-GEFTQ%KN^?,PX/S_+N(&^&GJ%3F:5
M+B44:&3SL5K;G-[NI8>/*E5,4A16ZOD#'NW0^&E-.)1VEE^=97FF5,YU05M/
M59744R*IJL9=;<86PM(6E274*6@@@@I*%*"I!3,C%1%QO:8[6MV7[ES9B+H_
M9MMRL8XT^[K.E$[D7FF&!C&%K+S$8^E&5"T0H];"DN6FUHRKW\<<PI2$B*P'
M;)3QD/L3R.G8:<XAJZG,JT@*=IZ-TT="T3!4TA:4_BJ@A4_XP=8"A_2TDB5<
MB<??Q>9-DF8U.5\'Y0.(33+<9<S1ZI%-EY=;44J-*I#-0NK;"AREU#;3*X*F
M'WFR%F)%7SUZ[GJ+'NWM,[0EP$7?:%[!IW%?6ZHYSV]3)FHZTR-"P)FXB(@5
MNX:N2%)D0PF+OD?+N#>$\I"?P'#V5M*1'*\]3)K:@'J*BM-0\%6G_>7O)QSO
MGO\ %/[5\X+C=+7Y=D;2Y"4Y90I<="53(+E>NL1)%N=#+<3S)2F;8/3UJ[;4
MHN+NGJ%I:,?F.*IY1&&9*2ZRHCF*SB8<)+2CE8QOZCJKNU%#F$3&,(B(CLH)
M"0D62D !*?RI"=( $ "\:=NQAK.N..,N(><YUQ1GF8H63SLU.9U2J8D_Y12)
M<32I Z(9"8/*!%\9]GGKSP;Z:[0;].]])&O74XU8$R;FP.IL#?6;=[$Z3&P,
M!\O">MY]$W%]AA1MIKKK\8B ;VU!ZZF"=? B?43,Q>2-=HP#8VF!:Y)TC2>Q
MVDV-C.*>]I"M-JR-NS6;.-5N-'TBD\6;TZA3,5)J4T[ILZ>31858]FLRD%G*
M!S&DS/%5UTW1EVBI4DT$VZ5VVADH23$P)E0%_!1'6W41!QW9[*,A]C%5P5D#
M]2CA:ISQ;#;N:.9K5T:<W9S9*O\ '0$5+Z*FE0RX *44Z&FRT&GFRM;BG5]I
M:;VE_M'+ T/35(6]O57$';VDF 4]34-.4)1]3P<5&0RJC/\ )F+FKJ-F%4FT
M4=)1B#9-X!H\J'X,GN"H%2)IF9^S_@/.:VHJ*_**5ROJ'"]4N-UE53/K==A1
M<<33534K<D+E2(63S7)QUG39OF":=E=-4ERE+2%,+"&GF5,D H6VZ4+"T$$<
MJ@LI((@P<2PI3_A GM$J23C7=3I6HKAA()'79.:QM8YADI9NB<I%E63NC)FC
MFZQ2&.4#';D.0H*$/V1(H0QM*/LF]GF9N*IZ$YU2+4EQUE33[R67VFEI:<=I
M'<PI'VZIM#CC8*F5N"'&W 2VXVM5\GB+,$E8*Z)Y3*T-OM@MJ<86XDJ2AY#+
MH4TM24J("T@\R%(,*0I*9I6U_P"$SS!?P[>[>RQ$OPT*]F+;7&=1O8,&ASMJ
M<J:GY<#;A$$%:J((9@!E]/ZM>J?8135(6O)>* L)64<E52-/I2I,<R'*BEJ$
M +3(Y@*>;_TC3%\GB1:.45-"4D@&4.*02#>0AQ!D'8\Y'<XLCM'[?/V?5R/P
M;6JJJKVRTHY["9D+BT+).XPCD^69"SE!'K1BB@ B/^UR@1: %#M*BD&0#I&9
M>QGC?+^<L4U%FK29(.7UC:7.429]S6_A5E41^1OWID@)!OC(,\09<Z0%K6PH
MQ9U!BVW,WSIM:Y*?B8Q:M:^^=E[V1GYQ9ZZ]N[G1H)%55<T)6,!5'X0#  ]A
M^C#OW;B.7+F *-GR39PD;^A1(A@$ CG,,IS7*7/=9GEM?ERY@"LI'J8&/]!<
M0D.),6*"H$$D&,9=IUI\!33K;H.[;B5:]8)B9_7&U?#RY>F+"QT,;#X=)@VN
M.V*_'SZ_'"\.>ORU^G/3AGA3I8[&]IO!GPMIVM&'X]+?6WWZ7WC'S]ZB*ON/
M>IBN!>T*('+[T"Y_[WN\^V!1'B(9#EXX>P)TZZ#K8][6G3!X>M?I>\6Q].(?
M#=\/+?IQWX0M &WAUO'SD; VZ$V/SU^?GI?;3#ZZW=>63O?U]^_C8]H7KUKZ
M\Y.N/U^FF 09\;^(]3^^#UM]OO?!@^/0ZD]>_7X;VP87T\-?'ESW8.W3PV\M
MK'0;>&']_&WAUZ:]<&>_NZ[^ X#UZ:_"_P C/6T;X(^?Z^6XP_/]PZ^^#7K<
M^!MX^'3"\O['U^F%N^7?W>/'P]<*T:$6MUTT$2;7UTOMH]?KV[^&WC\,'K\1
M^'E]M1P^]Q\_*+@:=/"YP?#Y#Y^?ZV& .[+R[^/KGUN0/AK8=B=?&Q,;:' >
M\^?;;X1ZU.'?ES^_S$,.;6^9TZWUV-R-=1&#?M/3]/H#AX!)@Z6T-_COTWOO
M&%C\_3/7+=IEWCO\- WY!F-,C72=_@#N=X%B+;[FK[Q:;F\]AIXW.DF \P#?
MIXX9(WD?'[??KA03I?PP<-=.X-_AUY#QP&8ON#I!.YC:;6M?OO@M-H-][#S[
M8,ATU^?W^>?+/!&VH[@ZZ]=!;6=P3."1>WT_3Z1UC!J ?O\ KIGY 'AA$:#4
MB"-@#.L=S,]!,1N6)_M^UX\R?'#]/GQZ\!YX<$Z@1]>\3;:)F+X7Q^FWKQ'3
M"],PWB.F>7TUU'QTP:6U.\VD :SK:=;W)\0_C!T O$GZVL/"^#7=YZ;M=_'/
MGD/#!!@#0=08C6=Y-]+1XQ@,:^5];:;1TD;X ^6[P'@'<&7C\, M;X>';K%I
MO.YVD/UU\1N>YGP^>#?SR\P'/?W#X?I@U!!$_$2?,#]M,&G2?(B-.X\?WP<-
M1\PW_OWZ!W8(.A,]3<1TCSN3^EC>P\CI_;M<]\&6[R]-=,]_KW;]<R(([ 7^
M/JYM:YDC!.OG\;7C3X=]+1@EPKI6UM) +55=.X-%6XIIN ^]GJYJ>%I6) Q0
M[0I%?3;UDW47,&0)-TE#KJG$J:29U#%*:\H\OS#,GTTV74577U!*88HZ=VH=
MU@GW;*%K O))L!)) %Z%N-M)*W5H;0 25.*2A( '^I1 V];5A7)]L)9IL#B/
MV<[;7&VC90ACII5$WCE[4VG*8@F(<XU_<%@S?S"*9P 2K4=2%4-W2?\ 6V<&
M()3C*>2^QCBC,.1W-7*3(F%08?4FLKBD@$ 4E*LH22!</U3*TF 4 V$2\7^W
M+V9\%AQO-.)*-^M;YDG+<N4<PKN=/^1QBE2ZJG*M$JJ0RT3'^+?%?MR=LG;=
MO6+IM-W:A["4B\[1?X-V>HLS:I?PPF[22$C>*L4I.IA<E#^AP\H^#H@ZN0^Y
M]R4<L2]DOLDX0RD(754[V>52()=S)8_#<W5%"Q[M@HZ(J#56-U&,<K<8_P 8
M^9U(>I>">'FJ)!*DMYEG2RZ]R&1SIH*5:4MKM^4JKEI_ULW(Q$9[9JW\H[5E
MZB8S54U"L<R[JKZMK&L*CK%=SH8[U6K)B==3R;H3![SWR$@C[LX 9($P ,I&
M9HZ1AH4]/24K%.!RIIV*9EI@)_T^Y0A+?+!-N4BU]L<]5?MU]K5;6FM7QGF;
M;Q6%AFE%,Q3)(4"$"E0P&5B820XAQ3@_*LKOCL+2^V.E-BRIG-&MJYJ?:QM,
MI'R: 4-5%52$G45NZA;H":(-2%YYQG-O)>E'2R24=)TS*#4Z<0D89"#DFRR+
MB)?1UQ9[(\GXD"*K+4,</YD'$%U^GID_A*EDJ =]]0M*:0FH2DE;;S1:+BI0
M]SA0<:[X]B_'7M.S#)UGVDY"*<!M#F79BM35'F-<E0B*S*DDKI%)CF#CB*7G
M0H!%(CEYW(U;07MVMNZ_KUW3=L)")L)3<LM^#CH.U$8K*5VZ15$2I-EJ[F$7
MTX,D83=D'=(,*344R I&Y<S ;UR7V.<&Y*E-3F:7,Z?:25K=S)U+5$D@76*-
MHML\@ _IJG*D;DV$2S4<05SYY*<)ITJD -@K>-[?G.^G]"$XKVI^RVU'M52-
M=UFN\G;C3](V7K&_M23]>UZ$U4;JW%#(,'=02#56=EWLW,R2!9>+,W@6?OY!
M<)!$Q44DR.3M\M7<89)PKE=,XC+#E=/F2$C(DM4C#=%6..I!84ZFB4H4:.1;
M3SB7PTOW"P$DNI6AK'TC:LWJZQANK-4]ESA:KT*4X'6EH4I"@T7D0[*VW&@M
M$H#B"2.125KW1:[8=@:UM7M'7-<W$>/)'9XA+/5U_!"-.D;I5I0]:U^-)UK)
MJSR4X#B,2HUDW4EG"+2/7.X:/&I%7K0W]ZKCN)N+,PR7.\@X<KPBHH\^J:?W
MF;TZG:!UAG\0A#U*&V5.'\ZDW?:J6W$T[W)R*<1[URRREP9SDF;9G2-FFK<O
M:JTMTJE(J$%U%.7F'I=0G\Q25)"%H4CWK979*N1&V::V:K2H[,54WD@J5.I<
M>UVU53%'U:[=2DG)1S>RUW[52!**<_DKYVXC6RS6[L-(P*$F1L+U9-^FT4<'
M3(4J=@_FE=EWM+RSANM>]_D-31NU65L520^MJJ>8=;4?Q#P74.\KB*AEE+KJ
M_=-.%* $!,VQ6<TX"J\R;4I&94[B&ZQYH^Y+J*:J:404M\J4S3NLNKY$I"W$
M!1'-S'&XZQMU;@=C/99NC1U&4Q3<[3USK_[,=WG]/0$5#NJIFUG"%W+6/ZF=
M,&J"TS)M;9).VB;Z2.X<'27%-,Y$P[ V'"]759;[3^).':RI>>HJBB6<IIGG
MG'&J6F2I%6U2TJ%J*66&Z9UU(:;"$ )M_3&'Q"D9EP/DV<-I_P!HIG:9=4ZD
M)"EN%*Z.H><(_K6NK;;65*_-*C)N2/3#L5Q=,[6WLM[<6RK8PKQ-561J#9^K
MA9J"97Y)"A1FK124Z40R LVHO3:53M'*H"J+Q9J\.)C&[0P#FAJ^%.,ZIVG5
M_M.29VIYA3DJ"TT]0'6DDR99<;A) ,*;5 L9,G4CK>;932O*@M9A0M+6E)L"
M^R.=(&@4A1*3/]*DWN(Q1O*Q=;6/K-S82_R!:9NM3)?P4?)O2G94[=ZGVIOP
M\9<2W4JZ]TTGH^=;$3<2D6T6/+TS,"_AYEBT<-![78O#_$&6<3Y8SFF5O)6V
MXE(J*?G!?HGR 5TU4V+MK09Y5'_#>0$NM%3:TJ/RG]M/L3XA]GV?9A64&6U-
M;PG5U+U50UU*PMYO+VW5ES\'6\B5J813%0;8J' &GFN1)<_$!UIO)0UW9#GR
MX\OIKQQFKZ?'Z7\/6N("((M$$"(UZS-B+WM([V$X.NOV]<';<^O.;$8#>"=S
MVF#:^P-C/7P&#H>NO'F :>?]M-?CJ,&EI$CM8=?@3:VL0+D8,%MN^OG^W:9F
MV$.:8F([C?I>#U^\X,/>U^Q@:GL=;]H$$0-')W,'K,BW@"+>,WB\X,(V\3K(
MOH.OUUMMN)FPO'8@:S?J8Z38B_3$:TV4NKM NZ#--.C6P:1K/:(_@,5 _)/[
M:'R;BUR=:G9#F0S].E8Y8I%.Q_=R2WYF!BO!!0;<Y?1_C/YK^'1_,32_RW\5
M$N?@DO&I%.%#_*7B%FTF(F+'HA7M"SUK^'AGAQ-4\EE_C*IX?+@4H.?R9K+F
M<W72<X_,$E^H13!//!H@:8 M%21)3%QMXG[0?CO<>$1'.\V !$1O;55KVF.N
M@OA#UUW[N&_?@U@>7[^??XQ8$$1K&_21'36(F;]Q8X>#X>O7Z[86AC4F08N>
M\3UUF/ ZX6N?=I]<^/AAC43>\]9O\;_'L;84 BWGV_O!Z1OI)PR?N%2-.2+2
M#>ROXVIY)0J,31U/,I"J*UF%SA_=HQ-'TXUE*CD3J&_I*9K&J)E$0]X<@#VL
M>;KS-.TM^H>;IV$"77WW&V&&TC4K=<4EM('52A&M\;IPK[/>->-7T,\-</9C
MF:5*Y35I9+.7H5_F"\P?+5(DI'_5^_+BB(2A1,8Z*D)&[5T;N4Y:"/HY2Q",
M_<./M=*5_>^)>?CZ2JZ:8LW,)&R-JHE^QJ%)W-O96%A(D9F9AT23DS',Y9)B
M4ZYT(;SSV]^SK)N+QP SFIS;C-[AMWBJARBB:J$TU?E5.JJ+YILY4PK+G*EJ
MDH:[,5TS3CKWX&C??0E1"4*[+X'_ (%N)JOAU/&O&V9"GR%G,$Y=5TV1K96\
MU4++(2*BIJ?\5#2G'V:9:V\OY/?NI2FID\Z?25LA;!UMME!28J\9Z:NM>RK(
MU.(JN[M7-F3.0&$3<)O I.BJ=CP-%T+18/DDGZD''*/'DB^31=STS,+M61VL
M)\8\>9QQD\A%4&Z/+*=9<I<LIE*4TASEY??ON+ 54U 2I2 ZI*$(25):::YW
M.?KC@O@3AG@#*491PSEK=#3 \SRQ*WZIP@ O53ZRMU]U82D%;KBU (2A)#:$
M(1.;Y>'+OS^F-(UZ1<$$;_*8/WQN.G6=O ]K_7!XCUQ\N/URPNYB(/87V,]=
M>H-I,X/ >MO/;[3A]?/]/3 )DC3306TTGX"X%H@"1A>OI^_QQ$':TV+K6;7$
M#"EJES-47<:BS.W%NKNT6HU:UG1[AZ0"NX\X/$',=4E)2IR(C.TA/-W43)%2
M(LF#&22;23?;>$^,LXX/JU/Y<M#U,^4BMR^HYE4M4E)A*B$$+:?;!(:?;4%I
M!*5^\;*D*U[BCA3(.,\JJ,EXBRYC,<OJ$GF9>3)0L72XTX"E;+R#^9MYE2'6
MU?F:4A4$>::\T==G9TO-5%F9%M'[1S.D)^BJ0?5S:R)-2=1#5U>?DHP-'K6Y
MG)>32EZG]W4]+FD!I>I%XU%Q/M6:) >-9-FQF[+?X@?9^]Q/PSP-G%:[D/&/
M%>59EG>590\S4UE.K*\J;S%U^L?S1BE32T*'6\GS=RF;K33NNHR]U12D/49J
M>2.+?X%LVJ\ASGC#V?9FI.2Y35,T=139VMI2!5U*Z="6:6J:6*Q3:%5=(VM2
MJ*L*34(YGU<CQ:(VX=,OIQQ2<@M(TC7#(WNY"W]?0LO0=>QZH?[Z;JD*L91$
MX)2#F4SANS79B8!!-RIF XFJFJ::L9344=33UE,L2W44KS=0PL1,H=96MM5A
M<!1.T3IQCQ;[+N/.!G'!Q%PW7TM.@D',&6OQ>6D<Q"2JLI@XTR3$AJH+#T:M
MIC&;CGP^./;ZD@WC[C0SX?;0+BVHN!?3;SC2W6-21@P?,;3/JWPF=<(2#XP3
ML"#Y:7Z6O(P#IKRZZW=^F'H/D8^A(B0=KZ=8P1>.\21&^P^$P+#Y@==?3AA>
M>FAO'CU^'33#\]HV-NDD0(,;B;$$6Q&JN&$TC>BA*283SMA;FZKLM:7+HE%3
ML1%8U=8V-D'-OI>5:_\ )NUXUQ5Z2ZY5"F([_AZ#,Z*H:(8';VZJ"C=JZ?,G
M:9I=?1,OTU)5*2/>,LUI;_$)2=N8,@!5RD*="8#BYZ+X,]HF>9=[#O:+PZQ5
M5'NZ6MR:GH7 XH&DH^(:EUFO8:(5+;1335)0E"A#M:M8_, #)7%R!/P.O7H.
MI/RGL)YS,SK\]-0"=?$^/?!T'7[=VX<('YVWWM\MO[8>YFQ!'UU$[7F--S%A
M@ZW=<>/+UP?+7]=YD"UO@)O@.X\#YW!!N -YC4R=+8.NMV77A@ZG7K?J1K][
MZQH< L)DS\K#;69! %M)\0M>N'(<M>[YCENP>O#70Z^NV VWL+@7!MKL!/ST
MP\&_7?[_ -\.\)O&OPVW'8#QUF)Q0\I4-655&VDLW"#<F]M5&%I3-$1"@+EC
M14$B:M45R^1[;:CZ)@P4![,SLVJR;F01,T8F<OE4D1Q^;9OE^1T#^:9K5(I:
M.G22I:C^=Q<?D9IVP>9]]Q0"6FFPI2B)(2D$B7O95['.)_:5G=&TUE]71\/-
MO(7F6=/,J:IDTR%<SC-&XXE*:JK=2"A :YTLE0=?*4<H5?\ /:4B/9]>S<JZ
M#;OTJD>V3L77,T\F7+8A"5G=69:S$Z^E3-%_>@0:NN;/**,VBQEE&Z4@U9G5
M5%(#FXKS7,JGC#BUZOY%-O9OF+**=I*I6PQS-4]*S[P0"MIA+:%*  4H*6("
MHQ]=:*DI,DRFGHJ=*&:+*Z)++:$B$-L4K4 (1LA*$0E)FUA.WECV?[94<AL_
M[:MR*TH^F*OC;4;-E%V7MV-70494+:+NSM%U_#T53]5P2,LU=IMJMH]O3#:6
M:2K0"2$<VEG#CWJ2"RHJ3]Q]45:.(>!.$LHK*JB/*AMY=&^[3N*HW%-4I:=6
MTI"U,J:I5*6VHE*K%0) (C?@Y2$97Q1Q)6-H<4Z\Z\ ZE*P5T[;M6>5)$ J=
MJ4("@!<!(N ,:M+LWV<F=EZ[%YJIIDYJK4OI9'9WL\XBI)_"M(R08P%17>NV
MX=QL8Y:LIDKRVJ<;"HK/VZYXATHW78K(+]LI\KFF:5O_ -,C+>%<G<119>_E
M+)SMJF0AE;C-/^(J6T-O-I2]2K%.4-)=IUMN<CO*%2&^6WR=2Z7@C,<ZJU+?
MJ35OKH7'R7@AUQ3%(E?*X%)<FIYW%H6%(4I *DF%XU/6&P["L+ V\V@&M:/8
M ]WK[7'M[2=OQ@@?-RT!:ZFT$:IKQI/NIDKHYT;CIK4G^4*QJR"8/V[PL@ (
M?@UK[*^*ZU_C+..#,M;_ -EH2:HYH^\[6.42$LL!^C0P]=:5UBE>Y<=J5)8#
MRDI:4VEML7+JS0\)T&?5Q]_6/I0A+'Y*=%27GGBPXHMI!"DTB?>+"$!3ONQ)
M2I2W,:0FMG;:-L4SM-=*&6=P)+I4Q55>VNJFCZS;054.*5I.I%*:<3:B+"6:
M3M-J23LK9S#IJJ$+*-7(+1[IR5J]%MEZ'BS+<_.99/\ @SG=9E+U33YM3HI6
M4T2D4[[C2:AO\<[^&=%2E*5-TZ7G5I65)6I+:0Z?>I/\L8H,PJ:@Y<SF"*<T
MX*G7'D.OM(=4TLL-<T,!1#CJD)20 0CG4$";NS[[;O;]V>U8R'JRLDKVTJV(
MT6/3=[HIS)5 :.=)).$SM:Y;'BZW!9RU4359.IN3GV29%"+$8+I& IL+F7LJ
MX&XEIT5^7,?RI=4TEUFJRIQ+3*N=/,E2J%8<I0!S0I#;3#DRE2TD8R[6=YE1
MN%JIA[W:BE:'DPN4DI,.I_,1:4J)6(N)!Q,^[?MQ)_:Q7IZWS*=J'8XH!2'0
M/6SFDZD=R-95S4Z[EP0\(SNM&0T0]M]1#1L1HNLXCHV(G9999TU>5%'QJ8HN
ML?PO[&\HR&I?K,V6SQ%4!S_84/TWNZ-AD)'YWJ-;CR*BI4KF$.J<90D H;+A
M"D:![5^-?:#0\/<WLXR%K,,S7S?C'77V5OT+*0"7:.B6II68/*_I;:;67$J'
M,6*A)]V<9:6=MBX,WJ",8OC2KDJ4BSKB,K.K?XL7.N4%T95M7+:H!J)9=8#@
MNF^)+G%4#@<JAR&UD]5)2EG\.JDIC3\O*6%4[)8Y8 Y?<EOW03I;DCQQ\\5^
MV_VO4N9N/O\ &.<LUK#ZTO4C[-,AIIU"REQAW+G*5+#9;7S)<:+*5(4#*4K!
MB55M=JC;4L?^';T1?;^UFEFHERH3:3C5Z[,9$! #-X^Z4*XA+D,<D@!-NI.R
M%8HMS9&%HJ4!3&/\[]E7!N<EQQ%"O)ZE8_W^4*33HYIF5T*TN493-U!IIA2M
M"X)!$Y\'?QC<0T/N:7C'(J;.&DD)77Y6O\)5A,76NF>4XP\Y)G_#J*5N=$#3
M%@=M?;"T"4$F&TS9FX5C'("4BU:THBZO=:L<@[)W3F6HF)3KNGT#G$#$+.6^
M0;H)FS6DA[ G&(\[]B?$-%S.9+54N=LB2&21EM; N2&WW#2N6DGEJPI5H;&F
M.JN#_P"('V8<8^[:I.(:?+:YSE'\OSG_ )NJ2HD0AK\1RM52YF4T;E1 !DQK
M9[:N]UG;XP1:EL[="A+FP@E(95_1-3Q%0E9'4+F#>30CG2[F*>DS[*S"31:O
M6YP%-=!-0!*$3YCE.9Y0\:?-<OK,O?!,(K*=RG*XD<S9<2$NIM^5QLK21$*(
M)F9FWFGTA;+K;J" 0IM:5B#H3RDQ)O<"^PQM'PX9:!EI^G'K+&/D7O:UA&D?
M2))%Y&AVQZ^.\W,W_?;U.#4-?7PR'F.7+=EN\L%Q>1\21'F=K:1'RP6-OAXR
M.@GKK.OG@R#EW^>[ZX<1M.IZ7_4B9^V"3U[>6OVP;OTY]<\$1?0G6 8GO\?U
MTL:_OT]=,&>_KTRUW_'"G6X/;KUZVUM>XB=L$:>OC-M/E@#777X#RY"/+CKO
MU# )UOIXZ1I=4[[$]],!M:WS'7J!UVMV.#C]_#AS[_'!I(UWZ?#:]IBTR3J!
M@V]==^G[8?776>'T-Y/?3[6Z_KA>O7J,+7[9AGN\]=<A_7"O.@Z FY@:7F=;
M^1WC#M^L&-?*UI'[8/'/@.H9_+B'ZZY8+VF8L;@'<:0+':_EU!X1N+&/KL?V
MM.'^_KGQZ^. =B.MQ,S.\CI]Y).%_;X=O7RPA\<@[NNN\-,&QVL-)F!XQ>/.
MUYTPQX2>_KUV-\'/N[MP=P>'Q\,L.VHZ; Z:B!X:6U^&#IWZG4]SX_+QG#PQ
M_?UZ\L+"R[Q\.M?CA1W/2-MM-#YS;#GL/'U;Y8.>?7WTR\\\$R+W\B?#K.VD
MQUP=(]?I>?*,/KKK/"/<=8V%H,DB=P-;]L+UZ]1A;N'/3+K?ZCZX?E%C87_3
M7R)\L/7?I>?6GP'PPA$"@(F$   [0B.@  !J(CN#++/41R#7/DM)L)L>VV\:
MSH+G!K$>&M[SW[ZP!BL*\_M7MG>WTQ-49:B+K':6KR"=*QDBSM0S9DM]$2Z
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M0$AR^Z/[E(Y"Y 00EG/B>(_8WE.9)/O*K(U4WO5_YFA2+51+'4_X:Z=:N62
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M$XL;P4BG6#T(.N,ELP[9USL:[;]N"E!RYM^G9+;.HL0$3^[1HN=+0EXI1$H
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M16;FGYS& !S#(,H<SCB'.\_=][G.:5E>>;F0T\Z13-J!)EFE;Y:5@0;!II
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M!:@=%J!5'^;0B?12%3(4A"E(0A"D(0@ 4A"$ "D(0H9%*4I0 I2@     !D
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M;S3>[&SK2+AD]+3L3;BX-2T^8&ZQD:LKBIZ@@84T%#=@IOS.H8F-IID1.+:
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MFQ/*N:ZH!@1<@T=+!F1#FQ*1@'_.WM(4?ZV<DI%7U3S-LP3K$IJJPD#<MP9
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M.NS!F9=XNH8QQEW)N%.'.'TI_E.3T5*ZD"*M2#45QWO65)=J+Q/*AQ*+V2+
M<I<7_P 3?M-XJ+S%+7L\-T#A*4T^4(_VDMFT.5[X4X%B?][2-4:CT G#B(:'
M@&*,9!14;"QK<,D(^*8MH]DB&67]VU:)I(DS#01*0,^.>-AN;F3J9,^?EX1K
MB!*[,*[,JA=9F-;5U]6Y!<J:VH>JJAS7^MQ]:W%$'_4HP0( &G9<<\]?/[]>
M>%O\KZ_?333;2<6@CR@3&YB(U'0DC<C4R,1$K5G$V>OO;*M0?FB*'N XJVBY
M:)4='1IV"KBJ4(212J=BR.H#&,=5>K2D1&U"Y;I-TG*D6SD'YS*%67PTMME3
MKJ6D!]:&DN.!*0XXTR5EMM:XE8;+KBFPK^D+7RSS$'H+(LYS[VA>R;B3@AYV
MIS.OX+<H>*LC"BX]4.Y33K<H\RH$W*W$T+53[^F *UE!%,V.5MA EWXZ:Y:]
M?KA;>O@!/S\--^?=;6%@=.L1)MUO$:^6#!_:;[>/;;P\S0@& ))(L=3I;: (
MD:W\,<J6L*4HQ@,I5M20=-QX .3N;E&<:BH(!G[M$SM9(5U1W$11!14X_P!)
M"&,(!A@$D!(DG8"3?M<6[]?AELHR'.^(*G\)D>49CFU28!9RZC?JE)']/,L,
MH6&D"22MQ26P >90 )QH0VTE_%:AFEE+:UI=90PF(2H!9J450A#%T,*E55.W
M;%5.F/\ 5[ELP4,N0,T%#YE$:_=\I_Q%!/;^I6^R3;S/CT,F)]DO\E1[_P!H
M/%W#_!:  HY9^(3G_$:TD" G)LJ=>*$J_P!3M2/=J,.(3?"_@':#N!_7<"Z$
M?;:&7,(JTK:%D8)<4!',J3BNYL%7K=R4H]A<\5'E04$!]V(%'#"D)_I256-U
M=M/RB;Q,R=#/3%)XE]E_#/Y>&.$*KBW,&X#><\<5 _ !P !3C7#>7EMAUDD2
MVFLJ2ZD0% JN,VH[9[M+13H95C2C>9J(Z@++555RZ]5U(NX   7 RDV=VHV6
M-D B+ C,F>8@0,QQ25K5-X$&R?RIB09BVA^VP,Z[GOM/XUX@:%%4YT[E^5)2
M4(R;)$-9-E+;=S[H4>7I82\W<@?B2^3_ *C8#=/++AD =P!RY9< Q3WCJ">M
MOWG8'RQH&^O?J"=3IH.NNF^.KI2Z4YLEW(CMINWIW,>C!.H_^W&DXTQD(JZE
MIP=IDJA&:CB9-%ZJI2,6=5+2%1J(*23![&FC3JK1<BZ:&U?B_A>CXMR:HRZH
M;;_%H;6YE=60/>TE8E!+1"['W+R@&:AN0E;2B3"T-K3U'_#;[7,YX7XLRSA/
M,:U^KX:SVH3E[-,^ZIU.75[Y I#2%9*D,5#T4ZZ=!#:7GFZA'*4N^^LG]M/8
MFK[K6ZL1>JUM$5/<=Y;V?J2!J1K05.RM7SQ+=7)A(^23J!O3]/M)">F(V.JB
MCZ706"*CGRS%K4#B3<(I1S9^Z;\V^R?B2BX9XDJ#FM0**BK:)ZE?<=2HH:?:
M6AUOF"$J5)4@MR$F.<R0)CZ+<;9+49WDON:%L/U=-5,U+#84A"G$PMEU*5.*
M0D?D=*R"L!7NP "KEF,=0>R_VB=IK9/V+)EI_"UN+JT#9:5LK6]%7E+4M./4
M;4-JOF75IGCQ.(@:@E&524O1KA(LC0TU&1;H#5"Y8/I2"DHIRS6NLDX]H.$<
M^XM%%1G-<FS>HJ?P82Y^'! <=+#I2M"C[I;;JDJ0.593<$7FG-.&WL^R_(Q6
M51H<PR]-.\^M*4U!]Z66A4-)4%H!6'6TJ2[*D@ICE(,XLFN1[*6PUY*OL]<&
MY=77)DJLMQ;^U]"5G^1R<'#P-YDK6-DBQ$I6S-U 2TRR>/W!5R2JU+5!!.GD
M2JE%JNS%:-'*.E9;QAG64Y9FN44#Z&<OS<N&I96VEQ20ZDH6&'%R4%;<(619
M20"=!&=J\FRZNK:+,*FG#E7EZN:F<"UI*(5S)"TI(2X$K(4CG!Y5R=R#+ NR
M!LV$OV?:>+:6G@OD<ICFKCW\P)P?GB1@3SQ*>&2&E254>#$84]6$@BU*>*,9
M@:5%J8R0X<YIF9R[^4_CJK^6>^]_^!]\LTWOO^T#1(25#6=Y.H$&\%-3BH-6
M&&?Q1;]S^)]TW[\M3/NB['/[N;\G,4R!;?&W*GFZ9M^V_B=[%E25J.K+?TB\
M=Q,>S"2?R]<5C 6]II:26$S11RT92E1L/Q2ZRRRK*,(Y.U1<'33:JVS+2WU*
M;01*&:AZ%S ;IF7*AP ;**&E% A(*R)@2K'JM00 3,%:$"+_ )G%I;&YMS*3
M.IB\3;&;9YYAIGEIKXAPUTX_ICQ)V&L6N)W'Q&_G>UZHB#>)O;P.]K[?OA\O
MA@T(F(\8ZQ:PO]>L677Y_'"Y9<O4/'S#77 8L-;'4DS;ZWV!M,8?6>OP/AY&
MUL/[>OH'R],/3?R$=1)L)WO&QTPOU^'Q/U^./.I[5*X+IUM$RK>+,+X;*[/;
M9K&,$3B<ZE>70G)>?>1)4@$2E?/(ND+:>Y)V?>'+*MA',JJ8# OMZI!Q56^P
M_P!E#:BE7'?M(3F>:#1+654*Z#AZCK5I$*]TRC..*G%J,0FD=Y),C$X^Q]0R
M7+/:!QHX/_ N0&EI%$#\U0IM[,'64F?ZE+I<L1 O_BI!%TXO@LQ;IC:"T-K;
M4QN0LK;V]HZAFYPU]^6EJ?CX4SDYMYU72C([E90V9E553J&$3&$1Z&S&L_'Y
MA75Q2$&LJZFJ2@"$MA]Y;B&P (2EM*DMH $!*>5(@1B#4I*$I23)0E*229*B
M  5$FY*B"2=9)F^-E>?R]=V_X8L_.^FVDZVGKX=ABKR^OPUT^>#Y\=1R],],
M*!UO>;G6VTZ=ND7C!]-K"?C%\ ;O7/XY_'X\ X TZW,SWO\ L;"\V& Z_"/E
M'R^6YW ]<N/?NXY]_/+CAQMXR>^FLS.HW(ZBTAWVG;MKM';I.V'UT/6>$;Z^
M-I^1MWL+D:87KT/48/'O_3X8+[Q<=.DR/$@]3OMJ>';Q[_/"W!H'@&#30=3I
M&UM=(T':T'4/4W/B<(Q2G*8ARE,0P"4Q3 !B&*;,!*8! 0$!#00$,ASRUSPP
M8[09!TB\CP(MTBV#P[^/?RO\)Q1'9#8LVA;([:E#*TE0Z\=9*W%P+@OX6YHU
M/2AJ>=V*J^EZG1B;<+P2<X:M%YR$?RM,4ZC&+TRC&@ZHJ*JTTN+5%!-;2\GX
M&=R/VJ>T'VA4>=Y6.'/:)PS2G-N&BU7_ ,X1QVC,,JJ:G,D(%&G*TTCK]+FV
M;?S 9BMX-YY698*+G6JH1O\ FO%]'F_L^X<X8JZ2J5GG#F9*11U\M?A#DB6:
MEIIDK+JJ@NI9=I:,L>X"2:%JH+Q "#>[UKIY=;PYXW.1\S,V.Q\P!K?0#7&@
M>NOGZT/3#[_,>'7G@WW\2(&FIT\+CI&^%V\AOZ\L'SZ\<,1J.F^N^NNIWWUO
M@^GKPQ1SML[)6TW?;:IEG--4HX>V\KVCK=6\A;JLZBI-E%VIHEDYDU+@C+P\
MG/LZJ/4S.0GZEJ6#- 4[,MJA5?4O&*NVPQ#]2/T/C/V?GCCBCV59GF6;Y4G@
MK@/,<US_ (AX7JD9@K,\]SS\12U% BF0Q0O9=54&9,9;E655?XROHG,NIVLV
M?0A\U;3;LB\(\9T?"O#?%])3TM7_ ,I,^98H<NS%OW'X>DHRTZTXI;BWD/-/
M4JZBJJF_=L.A]U5,DJ1[M2DW74] 0]*0$'2]/,$(J IN'C("#BVB8)-8V'AV
M2,?&,&R90 $V[-DV0;HD   B:92@ 98D!UYVH>>J'UJ<>J'7'GG% E;CKJU.
M..*-R5+6HJ).I/?$= !("4@)2D0 - !  &T 6$;=L=ON[_F/TY\N/#/+R-B/
MTN2([:Q(V@$G08>O;Z#[].OQB7SZ^8_;@'##B)C?XV\>GW T PNGKZ#]=SOA
M>6?+@.GCE^N?+45^IB^IC>1.VVUM,/SCKN+^$_M'6P![_EOZSRRWCPP&-]#V
MG:T$>)UF9(%C@\/KIZB9T&^'UZ_M\L,]; CK.F_B8&F%Z^']_KA?#K=Z_;OP
MKR)M/?3M&]SJ.UM#A_/7^_P_7MA_?KKCYX)!O-I'QVV\.UAWE?IZ];>6.!*1
MK*9C)&'DD".XZ58NXU^V5 !3<LGR"C9V@H70!360543.'$IA 0'C4A:VG$.-
MJ*7&U(<018A:%\Z5#02" 0=;'H<! 5((L001J((B+S/A\QMYJ_9]2LA9?:WM
M+1,\HH+YPWO;LEU(NN< !2=H-5]-,))R;4JBKN6L0Y9L% T4/4_]R<2.LE(1
M]G2$9![;?XBN!FA[BAS1W*O:GDU)HVBFK*RFJDLTP(T1EGM"9*P/S!K+#S_F
M:@39QU.=>S#V:<3*/O*BB0[PW6O6YE+;IW*=Q;I$_P!55D"R)@<U2( YC/IC
MQ-H /8G6"9&G6X,1-O'$)X0_+=W^F?/+++?STPB=]A)\[B-^L;7'?#'UU[?&
M.DS.G2^ <M?MQ^8\N_=SP'J-HB>OCJ=AWTP";?KM]!U[:],&OZ_/3/Z_J]>Q
MM>)OOX6,:[V[EOV^EX^W[<%Y&1DBHR4D(]B^5CG1'\>H\:-W2C!ZF4Q$WC(Z
MZ9S-71"G.4CA 4U2E,8I3@!C8)N0#$@SW -YC:=9M;37!>-]?G\=1'3Q.F(]
MUIL?[-=Q+STMM"5G:6GIZ[]'#$J0=7.5YA(0<T^L9Q3DA+P323;TU4DI3;@P
M+TW*U'#RLC3ZR+56(=,E&;0R%^SFN9,4-3EC%?5,T%6H*J*-MY2:=]:2"%.-
MA7*JX22"-I(G'@NFIUOM5*V&%U+"5)9J%M(4\RE4\R6W5)*T!0)"@E0!!(,@
MXT'1_LS[ 43M73&UU%R]PG%;OZEK2N8JCY&9A%Z!IFO;A1\U&U75T0R2IQ"H
MEWSU&I*B<,V$S4DK#13Z;>NV$<D=O$EC,K4\6YW5<.TO"[M2A64T;OO66O=)
M2Z2A2U(;6[92T(6XLA)M*N@3%FSD^7LYH_G+=/RYA4,AEYX+604!*$R&RHMI
M40TV%*2D$A$3^94UI6+]E9M(;*T1M+W,+4M#7+KV#V9[V6WV<8VC5YM2I:IK
M2M(= C&N:@2J&-AF-,52=G$C%-(!A-5(@ZD*FERJU,@W314=[3Q#QZQQ)EG"
MV1JH%9;0Y.Y2BN6'??![W*&Z<.-M@)4$);2MP)42I2UJ$V!QB\IX=&4YCG>:
M)J35U&:N.+:0ML-AE*G5O^Z4H*6%\SBD(Y@E("6TGE%\=Y[$+9IN!1%57EO3
M<"V]<VZ9$HZE;/6\97"HVHJ$GGR*<LZJ.X+EI 57&Q$W^4)N(F@(Y.3,Q+'O
MI"-D&S-PX4C'()9/VN\4Y3G]7D])DM6BKR_+J):E+;"TMH?=4$A"0M*%2AAM
ML$\L7*=+G'<#Y)79329@[F;(9KJZMYU(YVW%%EM,I4I32UC\[KCJDI*IB#O:
M,>T)=^1VO[]5C<ZIG9I:U-NJTJ:A-GJC55#KTS'Q-&2SVF9FZRL6H86CRL:Y
MGH^6=,)ERW%Y$4F2'C&)TBF<J+S;[.N%:7ACA^D660,WS.F:K,RJ5)!>2:A"
M76J%*B.9#%,V4(4A)"5/AQT@D@#A_P#BE]K><5?$=1[/\CKWZ+*LK;9&=+I7
M%-.5]74-!X4CCC:@32M4SS2W6P0'W'5-/!2:=(.-Y]?+KAC?>VGB/VGI:_SQ
MQB8M$P;D W([W.A[>=B<:DK>Q5J;@J_C:BHZ-_.2G!5&I(<%("I$%RCFFN2<
MACLI$ZB9A$Q <+KI9[TQQ6EQ8F%$C<$ @Z@2#ITM;;H#NW#WM%XRX9;%/E>>
MU0H"GD7E-<49EE+C=@IM675Z*FE2E:1RGW3;:X'Y5#4:\&UU[Z# 5+87@-5<
M6E_4E1]YF1YT!*&@HH5O%?AI]$H%#L()+MG"2?\ 2*ASCVQ,PI)_K3!.Z;6
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M=M1"TF04@@@3T3.FJF11(Y%$E2%.FHF8#IJ)G* E.0Y1$IB&*("4Q1$H@("
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M\% 0M+U4ZE4G\LSC?1"$2(1)(A$TTB%(FF0H$33(4.R0A"% "D(4 R*4H
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M6?H.9>N5W<RM!6KI]TBW57*_GH:A)R=[;L^?::MUX>B9EP+A7,/Q -T#9'7
M0X$="Z^HKZM" A(4]7.)) Y4NU*$0 #<I74('*(M/2,?9B4-!IM1)*BEI%C<
MI;4N3:TH;,$VVC3&T!UZZ\0RX\<6D?"UM/'X:[&=^E8MZ]>!G;;"[^.0\]W@
M.6N[/T[\+N!?3?3Y7TG<&Q(U#[;2.FOB)MK'Q[8,@]-W7P[N&"!.]M!L)M,=
MK^ &D1@D_'7U\^^^-&[0O_D-3'=?G9>_^^5M/W?;QYW^71[]Z/\ S#-O ?\
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M 0$ $! 0$!U 0$,A 0X@(:"'$,*3!$B/KZ[]/+%0!!!',DBX(D0=;&T$'2"
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MIQU:S "4I2"5*438)!,V$$XT#46TS:Z)D%(&G'LM<ZJ2 /8IJV$2YK)Z)O\
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M]1L.FO7#PNWD-M-8.NVG4&Y%\+!AQV$>ATZ?I;!A9<- Y9<.L_C@\+;B-AO
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MD@SCLY&1CXABZDY5\SC8UDB9P\?OW*+-FT03 1.LY=.#IHHI%#4QU#E*'$<
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MQ29() .HDW&N-\#W:>6>,=)CO?;H=(TTM_5\P<>H[W\XPA$.@'X9!KX<L^_
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M$(FDD0I"%*4H $:*4I9*W%%:E**UK45*4I1!4I2E&25%4DJ-S-[G$A0-!H+
M=+V BWPB_P ^1N$1UZ .N/'+4<AIW.LZ6O&ATMMX[P9-S4 6]$^MMIL)#'YZ
M<?IN\<,^?EZM-_#J)&%]KWC[Z^&#H>LM<+OYFYWVOW M;[$]#U-L++3+Q#R]
M.N_?@M$:B_@ )U.VGCXP3AS>? ^?Q]=M, ?N&_GN]?33(. )UGR^?W'EJ)L
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M/8O+%-^&Y0$%XOA1!YBH(#9 )_*I,&3'YIMKAZVMKUZQK>VGEYC&?".0")A
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M4[XAZ,J5(Y@,""].U'*).2AVT3'((#B6,LS?*LY:]]E.9468M\H4325#;JT
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MPAT>]Y#CQ14++U(CWJ%>^6H.-^[*5-\K+J^62200I L;P" #<XU?9#:>VAK
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MZ?KUZ8/ ]?TWM;<;6\"OO^WKXX/UZUZ'!KVU^L#4>?PV.#]O5O0P==?'!?\
MMMWO8_;H9.#UZ^6#!U\[[WZ'U\L&%W_+CP\_/=@TOY]SUD6[7.G:,/M]=M_+
MRUP_/+K?Y8.\Q:.VMCI^PPO*?6GGA>8C\.N_SRRTPMHF1J? [S;4S,3VB1#W
MT ^?KM\YO@W[NM/CO#!,FQ'?7I8Q;MKKM$8--?5_EH< =PZ9:!X<0[OTRP"=
MB-+"YTF^UHWW^H>XO-SX['O^\X-^NN6_3B&F_3/TP7L9.DV%B+=="=NPP:6M
M.E]C?O'QPQ#/KKCET.'KX:ZZ[['PUG>V^%,>O6T^A@Y?#KA@M$?"VD^.FL '
MP[8.OS];X7=G\N&689?OOWAIA;Z]#;M&VH!'>+^$OO'UWF#/]M-#?!RZX;^[
MB'UX8>^VO?:8\(N#U^6#KZWT[['[;X!SY9_#=J&6_P !SR],(S&DZG>2=1U@
M>,1X6P".L?/6QG3Q$3\</KK3P^/+#U,^K^5]MX\P,+UZOX_+K@P;3;2W][VP
M87#Q^OI\=<(7FVO6#Y$6.Y-^LF]L/?P^-OC\K8!Y^O', ST#7?@(WG400!J+
MF!TM.^ =/AM!,7-M,'?T'B.O+?NP7F9MJ-(B-"1<7WN( U.#MZ-]A;KIK@^?
M/+KY_+#O;KU VF^I^\[@6P?3I/KZ?7#'KK[98(^/7U>/ C"'KU^LX7'?NWAX
M[NMV_P D;[Z3-XL1]1:YMKOH_+70^&OK73S?U^WZ=_IA_?U]A_;1?;]?W[?'
M!U]< \-[P=_WMXS<:X/7VP<N_K[X#XZZ>(N#IVZQ;3!U[>OTP>(= .GW[L'B
M.H$W\+W-XF^_E@\#Z(O^G?"^0>8[MW6?D.61$=@"(N?"/VO/CA_4^0UU]1YB
M9./'CIP^P=V>6 Q(,$FXZQOX ]-#?X&VVU]_U/>)P^NOA@W\;=#UMOZVBZ]>
MOGA9ZY:!KYCIQ#A^GJI$Q87ZB3;?<"P'>VV'%IN;>0OL=_W^#Z^G0\N[#\)U
M@VUTF;=!K\.F%Z^_H=>^#H-/GT&#76(U$C3N08_M@]&_T]'!@V\- 1IL.O>>
MWS,++H0S\^&$0?&X()VB=A'H]L.?0,>6^#SR\,OKGAF;1Y[?8X/*?&?M&#N_
M;PW#UNP'3:(\MH[0?B=L'?\ OXZCUK@W=:\-_/OUUR -<+?Z'X"][SN";QI@
MU^?AOIT[6L23;!XCGUUX!OYX=QKVOXVT[&/(W,S)X"/7KQ.G3 (=:[]X<=W<
M.F[!'3KWB9)VM8S(ZP+6P ^K::';7N+ZX>%/3XWO(!L+QX&TP-398.N6*O']
M/7G@]=<'7[8IZC;<@Q BT7,1%]/#7!Z_OA#KUQ >?</</P'#U];@VZP?*\=H
MPQ;UL1T[CN/F,/K?UUGYJPT @"02?,QJ3]^HMA>M/7J/):_IEQRZXY9Y!GOS
M#>)F^T;QXSN=[$:B#AV_>=I];3$F-(.L^'S^F')DVWUV\-? 6WVP>HW^GWP:
M]!E\QXCN],(DCP&MHCP),:^IB2WHS\8&PU^.#GW]V7Z[LN7=W O/>=B)UB_2
M#T[Z@@!^G>?VUGKW[@9?+OSW?IEGJ/EA"YB >I^$;3'229N9,# 9^O:-?WF+
M#SP>>F_[:_/UTPSUD1'0W$S;;0>!_P PB,'E?3];?3X7P^77SSPXTOI8][>C
M.OQPNOKZ1@X[_+EUEQ\L*!S;=_K8;WB2?+L;:>?7U.WGA#UOX:\/TSW89GKJ
M;:G23$".D]].F&/6F]M_WC7&BJC_ /.8L]_U'[1O_OULN]<<7[4_RNN_]_RO
MX?A\WG8>.XG?;'F?]XC_ -AS_P#&;_;I]\;V]>L^O3,,6&I%M)[>>NG;N)MB
MOX>H]?&#A!N^6@AIX?M@T ^ @$?+R_3NSK];@W\?[X.6FX?IPZW9\<'EI-O+
M8_2- 3:; ZWU'WW]:QMA[^LOU#!%NT#7;J=1%CV/CIA:>I_8X0\/'KK(?++,
M$=OT(.UCM>\B/(1(8W\/7J1YS!!#]=XZ:_?=EW<LF?,];G2\[Z_$Z"VH ?VT
M%[?IK/?K+P7O(\!U'?7H8D@'>,+!U\O/Y?7! TO:XUVCQ)UB.\0<'KZ^7U^V
M$.OW[P[OAOSUR[\*T#<6(/>^W6=8N9C#%OG;L>_STBT]L/KK+!J!MM]@-_"Q
M'EA>O4X0<.N'F !\// +1-I.FP,'0:7Z==S;#._K?R)/S\L/#\@3H9^=XT\!
MKMKA86OKX9AW\AX?KA7_ %(V/A)F^WE?3#M\/&#VZC?]L/UZ_;ASX8?83W/Z
M3;M %IVC"^'K^^_3?"RTR#3EQRY>/@/VPHL0.D>%C GYQ>)\,.;R;]=IZ^'B
M/UP!GRTU[M-0T] ]=, D^ Z&+21M?:WG?2 QUO\ &]C?XGX7PQZX_#K+NPSZ
MU/A;QWPAZV^?J>^$'E\]WG]]>>6H)[=-2=">_CWV.EV?/Z:^7Z6Z38S#/P[M
MV>7[CG],*;Q]=1/]@2-;R8@X(,>/?6)_L(^^&/#QTZ\,\!U'<QOXR(^!(ZW-
MHPNOA?UXQ@Y^G6[GPP3KW&M]N@U.I,CM?!T^/K7IO@#[]>//OP_G>+3I,7O<
MC<[7P']/7AT[8.MW+K[8/EY'2;7^VD=KX/6O7U\=< ]=:?# ?/0W)MY^O"TP
M#UZO\\&#Q^>]S%[:]--HP86O=^O/OX:?'!!UMWL>^T^'C'A#MW_;IVWO\L''
MAEX:AUX!IQP7W UTZ;3/[#6YP;;SXV/KQ-]L&6F0[M<^'KW]_GIA1:#<7)-A
M;7XSO WT.";R-;1OZ';RO@'F/#7B&@>&_(.''#TOTWDZ"?&8G?7X8!T&]MC<
M^.DG?;!OS[O+H/GKPWG7:#WOY6U[:F;'<TCOY^C]+;Z&6>_[:];M?EA$38])
M-C\O#87O>)$DF-/UMZUM]</AIU\OI@U!&_<?"Q@;>6\:86]_7U^^%IT/+ZY>
MH;], CYWU)F-!U/4WM(-M'?Z[=?M/P.E\&7=N#3GZC@\+Q8:2+=3L1'?[$]]
M3?I\!AZ];^/Z?' 38FQ WG772)B\85O7E^^#KTP1N3X^77PBYMI<1H>OC@^?
M'OP[[7,:]0!KH0+F8_M@^FW;"W!J/ZCX?0,(Q;F/0]-(U UOIKO&F'J;#]AX
M_<X/ERRY\^M-<^XTG>=HZQK/:)GN3K8^O6>G3U>T=WUKADV\M-#\=KD7V^BP
M85^HF1IY=]+&1;?S,+ZZ<]==^O/3+R\ [7!N=?&_B+\L1-]1A_:_2UM+=+SY
M^+PR">GGU\-.]Y\-\+!A7F.TZ_2T6D:P/.<&%].[Y?7Y8/MU!O8Q!F^L&3UT
MP_OW^OKSP!KEO'/CGE]M^? .7(,  .DP=Q((CS[V $=HC ;3H(VB?UTC<]>I
MP^X/O^_?QP[Z>$&-NFMS:_CA=S^G]NVV%W!U\<]/+NPK:1!B1X:7B#;8>$01
M9]SZ^47\^^#PX\_++3]OC@UT\;@Q;2UNL^770\=NGG-_[_+!GUD/+/7H. 8<
M@[]- =#X;F\>7F1ZD=8MZ.YP==9^0:<?/"(\=;'I/0SH=!:)UG!Z]1YF^WE@
MW="//T^/++=A[&.F\GKY^8DG;;!KZ Z?'Y=9UP^O']?70/0B^NMM[_,0?C86
MC3"]>'[?"Y^)SX^/7WP==^QB_P O6^V#IMX>OTPM>M?'Q].(:;\*\2-IVM'0
M#?2Q$6/B,.WJWAX=[[&^F#TR\<]0^W/?G@O:8UZG6=YU[;@V$:X/C/A%C^O3
M3#Q5A80\>'#K=\!WX1/>/$'?II\C;#'QW]:_,:8?IW?3!H(\8D_ 3Z\XPOCW
M^^%Q >OGX<_K@-R+?V_O&QVTD'#V(]?3QZ?;#^/A\_#UP$V[^0[2;FWQC"^7
MC]/'X87P^(<1[O73/,-_!::=;R9 W)Z_29$]G\_D=AW^%X@Z;GT^G=H 9_+C
MR (MKJ!X @1!TFP,"-R<'W^_>Y,?7;JP^/'?O[L^'6_/#%A?S)ZP!-]N_P"^
M$?EMI,3O&_K2,&0=>F"-=M;?  ZC8;1\1@D^O&< =V[+3!T@6^&L_'P([X#W
MUDS@ZW?3?@[SZ$VCKUW^$8/6OWTP8-/E\.T#:\#J>XP87CN[PY=?+S-IM$]#
ML;29.AU-QY8?AKX]?7U\C=EZ?;NW9B/IKI@TCX"Y/U[3/PO;!K/QO\^^L ?&
MU\&?Z#OY_3YY8)WCH;;Z_:-;#K:<$?N#;I]_I.'A'N(G6_8#8W T.D:]\+!A
MF>F]OAWT&WGWP80^OCURS[\N>$=K3KK'P@:VG0$CH<,?#P]=8[3TP9>@;NO7
MRT\33I:\ 1'AY@S.QN8U)^)U]?#SOX:*J/\ \Y>SO#_B/VC?+_OZV7?+&0:M
ME5=;_P >RO6+?[/F^@D 1I\?''F?]ZG?\B_/\S?GC>N?EUZ_;CENQCP=+=]C
M>8.F]^@UON,>D:[^OA^NTZX/'P'EUUKIAQUOJ.VQW_>-)L(/#Q'7UZM?!NY<
M_OR[M>''3")@';P.\P;FT7 Z#R&#7KN/TZ][;[7P^AZ\,,&P^<_4ZQ:]_.,+
MT/7CA#UUSY<O@*-]-;B9TZ]]1:VW3#'K]^W7K\P^NNM,/U?O.A^0'V.%Z]>K
MX7=H(CJ/ANW:\-._"&\Q)GQC0VOI [38]2^]P!8>.NMM[]L&NOB&6O ,N.6?
M//H< DSXB+["-?G,B=L%K>!FVYG:8Z1Z&#AGW /6[RW8!/;KXF-/\MR((D6O
MVP;QW(]:^>N'AGX]-OGKU)['?"P!^GIH. ?*X[VMY^CO #^_QN,(?GW[O#?@
M(VZZW.G;43\//#'T[:^.F'H/(>OU^.#7IOW^.DBXMW'CA7'4>OV^6#[_ *]=
M^N#M&EYC7>P^/<&-<'Z?MZ[6PAW9@/?T/UUTP;=(OVC47T\8G<8>\$=O0^UK
MX-X?/A^WTP:[ZVZ:3IN#U^!P:'Z;_P!_OA\OK@'2_23KOV(V]6E=?MA!Y^?7
M7#3+"$]"(/3:]M3,:6C:+:L^7EZ];WG!KF.NF7IO\OMRP7!N;1T-CUW$>-A;
MS+0+7GXZ>?Z]</K/[]9?##/Q$:_KMIU$$ZQA=?IZ_O\ /  9>F7I@ C3^\"T
M]-I/[8"9^)/QP=W=UD.#MI;63OIYVOTM@[]_4CUOA9CI]M-=W?X[MV8Y;L($
MV^L6C8> )$:&)F-W O\ K>VO;ZZP)UP9!\\M1W=P>>6G#TPXB?. -8[#J)@1
MM P2?UL->Y\IOO\ '#Z^N"U^WUUT&IGIOA>OJ, X+CO.EQTGH/O]8!Z^.#/K
MK7[\,\%N]NLZWT^.VLP,$>O5OTWC!R_;KUPNG8[:6M/;I$C>9 .#K_?U\,+Y
M^68[^N&'IZN=8'UZ ;6F']/.!IZWP\!UC373^WQ-B+=<+"Y_;=W#D(YCX;\
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M@02-=SO&\ZZ2;=C@/UT]0/"T7P^NOGX8=A;R@=^WS/:^%Z]?3QPLLMW77PR
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M-_K'@_FU2-6LM'CDV4"__ ^/HX/PC1_S5-K_ /3:S_O\+^5RVF7_ )1[0?\
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M4%),&4WL9&ABQ.P[/TW-TTA<@DVQ,Q--W?N!4D6!UFZWXN$F)%%>-?%_#JK
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MT3=9PO6YIF?#]+P[F5'5T[5%[BF-%^-0ZXVAQM5*L)6H)0MQ86L$RWS(("7
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M\P;MG2;YRP[=*KRT(FRBYY)J7%\84%*UEF29FK+&<DS2N-0FLRYA/NT%MO\
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M!LC3*-5[P+ IU*0ZMN"5*>;"DH4(A($<BC<DJ3,8[N9]G;1=U]J#:CO'>_\
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M9W BJ119LNW4624,101*<Q1Q]5G>;UK:V:G,\PJ*=:B2R[5OJ:4)LE39<*%
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M9LJ&G5XT]KZ?94S,04]"4FT.^;7LE'U>LY5PR:2BA7EVPVE5)D>6T=7F-/\
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>>.^_K3;I@P86@,;3Y_EW^/QOK@P8<=R/A]P<&/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g96328g03p94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g03p94.jpg
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MZ[_IEK_B)?\ G<8'L/L%,GW/VFGOUW_3+7_$2_\ .XP/8?8*9/N?M-/?KO\
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M]RW!PPP,CD56IGG8]!N-&<6#55@U[K&Q^-6U-V9H-@OM.H+JUD0; \;ZY0G
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ME?C:Y\:K]AZ<4K;/Q$T/6-]6;::ZU8VLD37VGV.QP55.L%0JK1TR$V!KJG8
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M*S6[B266 L%4-JYS2KW=.*5^K#]'5_\ (OHC_P"H;:_[3[%SZ?X8_P"*(?\
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M'-UK-WJ]M)IQ\,V\"Z;<6<*,DWAZTD<RBYL;MF8,H"E60 9R">:MW_3GOO\
M9EIS_![Q_P!_^?$_UZ7Y4OX"\!_U7K__ +FKD_K;? W\)^*?Z=I7]RT_TY[[
M_9EIS_![Q_W_ ./UZ7Y4OX"\!_U7K_\ [FI^MM\#?PGXI_IVE?W+3_3GOO\
M9EIS_![Q_P!_^/UZ7Y4OX"\!_P!5Z_\ ^YJ?K;? W\*>*?Z=I7]RT_TY[[_9
MEIS_  >\?]_^/UZ7Y4OX"\!_U7K_ /[FI^MM\#?PGXI_IVE?W+3_ $Y[[_9E
MIS_![Q_W_P"/UZ7Y4OX"\!_U7K__ +FI^MM\#?PGXI_IVE?W+3_3GOO]F6G/
M\'O'_?\ X_7I?E2_@+P'_5>O_P#N:GZVWP-_"?BG^G:5_<M/].>^_P!F6G/\
M'O'_ '_X_7I?E2_@+P'_ %7K_P#[FI^MM\#?PGXI_IVE?W+3_3GOO]F6G/\
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M:/-'_H]>%G^HF]/_ #$<?XI_#_[_ -:_G[#^[J?*,_[B#^1+_;4_XS1YH_\
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MXJJAO%'P[(9!6A ^H6&I*&#M;O8%'CL:&RT^QO-R4Y=K>P.=G6U^U=N\AH*
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M+-+E75AG=TLDD[G((JS-K^.WEVJ_7]-J'9.\FXBT#QWKFEP7V[#6Y%GID+Y
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M#!"-H8,P8#.3G-13FW5-.*55_P"ER_\ YOX8_P#X"Z:_[1MT\^&6G_&_B_\
MZUZA_P"$T^OO&C_\2:+_ -&P?_G)7DOSIUT*<4KU6UELVQT_3O@S9EMTTHUO
M6G?(GR'L"2F-MM:]HQ=<IE[UKX["4*6PS)G:EI3LVUKH&T");$XR!8I++D(]
MM3%=E8UC$_R5W:Q3WVO1/!?I;WNFZ9').EG<SK+/;W6I-<"/>CI-LAN+11&F
MY7BS'"K=)U795RJ0$%2R22$+N484K'M)P01DJW)Y!Y;&0:V4K>Y=3UJ[>^%7
MD5V8'AMK6E\\S!]A;F(V&[V_JCO0B!5==+(KZP&!+\D:K4K0-LG6Z6N PO\
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MI\LJ-.*55_Z7+_\ F_AC_P#@+IK_ +1MT\^&6G_&_B__ *UZA_X33Z^\:/\
M\2:+_P!&P?\ YR5Y+\Z=="G%*O'5'CAN+=RA\\UI6%SQ;77*6MFR,+K1*H2;
M:;*JLKNMU*M+[A9D#&XV^PK*=9B$-3J(KNQ.,DY0ZY825W%#)H7>IV5B\<=U
M*T;R1O*H6"XF"PQ/%'+-*T,4BPPQ/-$))IBD<>\%V"Y(FJ.X)49P0/I*.2&(
M #$%B0K85<L<<"K!U-X?[,V';->*K&*52*KL85R8CM<(JRVFG]+-=6?9(*Q'
M4UE@#:-[!9E57)6UQ/+.LR/=FKU\A(\Q&./>O>:S:VT-R\16>:V**\+,\"KN
MN8K5FDF>-D2.)Y@TK@/M168 @5)(F8KG@,"0>#V4MP <DD#@>]26M^+%+;6_
M<]"LFR-EZVMFHJO?;L0JV'X_F5J?"LT6C?%>4UY&-V/BTU\XL;G(2EUU-(ML
M4C)Z]JL0Q,T]@@"@IDU:X2&QN([6UN8;V:W@#VVHB4=6XN.CBW*VI2Y2*,-/
M*^^()''-D 1ECD1 EU+,K*&.&0CA5W>KU94D^D#!R2OQ.*KZ^ZWPH>D:%L.B
M[>;6>F;8M%SHUFK&:)Y1X\+CK!)KBR.,X%\[E@'=ZC!'LQ.$HLQ8Z=C@Y7-Q
MS*RJCP7%,=FWNO,7]Q;3V:13V<4$\4O4CGS#=2742 L$5H)CY5V>(%UV.A65
MSN"P9=J*P8D.6!&".4"$_$Y&7 !X.0>!QG6GG4J%.*5^B'_]-%_\\.Z__P -
MMD_]KFB.?,?RL?\ )RS_ .FK7_P=_71TS]OD_P#X'_\ SCK]G_/Y]KKTXI5:
M;+V]0M1!I3;TR;AXV-D:H0A(*A<KPZ;L5R%M:& P%?HR"R/">P:\A<N2Y(UW
M<(Z]:61-)AA%EWS;M+&YOFD6V2-NDBR2-+/;VT:(TB0J6EN98HANEDCC4%\E
MG  .:BS*@!;/)P, L2<$\!03V!/;X5T%V\=9/6HJ"M6.*S6!DEA?I$Z<8G*1
M\O+KF%K79JVAT0-?S]YHY8# IBG @F74\6,Y,'?>?>$GT^[B1I9HC#$DABD>
M0C$;K*87#HI:3T2 JP5&;@X!H'4\ Y.,@#X@C(^KD?75#$^79\E04.4NH7!]
MM*!\EK$[HAUN1+BTE4\5MC]:RV01$^%';IVUF.L)]?&JB$:2%2T(<9]&VI6M
M6DM\NE\AJ)Y(Y+Z-8%;28H[E8)662;6;3SEH#&Q22.%8EE::5@701^F&1V"5
M7U>!Z#D]4E2PX6)MK<\@G)&!VYY8 9J,'^>5>P<[77):&6^CUGK"Y;.Z"&LH
MX]P)3U6JT^UJF5FJ,R;*6FU'8HEQ&@UO:\VCS*RRJGF7N4/I49C#<GAN8QV+
MR7"Q>=O8+/<T1,"R33SP.L4XDQ//:M;DW<.R/HB2+YQNHI..NN7 &=B,^,^K
M"J&&1CTAMV%))S@X'%;9ZGV!!L^CK+B.322L&!#0;*77M\#V55\95C(I=+")
M;@%24<XJ&0;*)D+TN@D6'XD+IOOS#9YY<2]MC9W#P%;A=H0@75LUI-AT5P6@
M9Y"H(;*'>0ZX<8# 5:K;E!XYS]%MPX)'# #/;GC@\?"K'YJU*G%*EUW_ /?N
M'_T.L?\ 5M5R*_G?Z1_\JDWYO^B/_.HCR51IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*JS>?_P2W%_]K-@_
M]4F_-2__ . WO^J7/_<O7J? W_+;P?\ ]:?#_P#M:TK\;7/C5?L/3BE.*4XI
M3BE.*4XI3BE.*5[H:<K-D?>&?BQ*BKSQU$/%NR,B12I/8X09Y[:=Y8839ACS
M8Q9YX]=Y8XY]X]Y===]]==]==\_DG_"FT76=5O/ 4FF:3J>I)%I&M)*]A875
MXD3MJB,JR-;Q2!&8<A6()'(&*_GZ34M.L/RB_E%6^U"RLVDG\*M&MW=06[.J
M^&[4%D$TB%@"0"5! )P:R7ZNM@_U$N7^K#O^!Y_)_P"I#Q9_FOXB_J34O]VK
ML_JAT#^'-'_K.R_MZ?JZV#_42Y?ZL._X'C]2'BS_ #7\1?U)J7^[4_5#H'\.
M:/\ UG9?V]2FO*-JUH<P9?0+-)&<QK[.;LJI6"3+HBMGY,@,8^XX(>L8LR,^
M\2L<NLLI(OLQCSAR^W/ON:3I_CK1HKB&T\*:TRW-YI-](9]!U9V$VC737=H$
M*11@(TKD3*0Q=,!&C/JKEZA=^%M2DADN->TU6AM[^V3I:K8*#'J, MYRP9W)
M98U!B(("MRP<<5VCA]QM.I1F5+M9JF=GFS(225)Y"OGSD8Y,Y1<I1!!VF LA
M&>>.7X#*(K&++OJ,J.3K&3&ZYA_*'>AX;SPWKMS82WAO)M-?0-3CM)2UV;QX
M&D@@BOE@>5F4].\CG5#A)U<!Q7!)X0MBLEMK.E0W:6PMH[U=6L7N$"VXMEE"
MRRR6K2K&JD;[=XBP&Z)ERIF,C[9$Q]D83:&&DEM*9,A8X8UK:\'<2U/![+^
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M;?\ ='/]*_R_H7\-:3_6-G_;5^/?R;J/[PO?Z+/_ &=/U&;M_L=VG_L^MO\
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M?4IM/MH(4VE=[M%&Y=MP1999&0I;,"DG*"4C;E6V1@\ D1B1F8Y[#)&!C)
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M81LDDA>.27EI'=R6.3$C$$AN"3C>X!);=R P##=R P('8 #BI/K?72[6ZRQ
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MQ Y6!EWPB-BQ(Q(5*X(4J$(#,HVC/'I(QG<<XY8'#9 %9BGZ>K]+O#>\ ,K
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M%9B Y@>TCP0'A^%UVPZB)9V1IHB+<+9R0#7?D-9/,FXZ@WN5NES;;1%E&8,
MQ>8()W1[5!"GU$N&,'6QMVXXP5/J[X.,5DZ/YH;9N<FJU^?CRJKI^TKS&H6M
M[-L*\5FF84*#4ANVW5Q6,K3HM!:GIZH12VK$*R*EA5QNSZ4-0[IBI8,,D<+C
M1;.#S;?*3RI:VY=EBMH)9S<><6SCA=(K^2*-7+I,7,[2HF]#!O5=^1.YV#I
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M?.TKN;=(6P2<(LI0!2J88@ G+;.PR06R+I1>8VPS3]>M+'IBL5;5^PMU[%U
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M#8Y-Q:6L'B2]+IU]]VZB\=%_GUN&\72H.'\P.2O2I _B4?54=UI%^-J=AN%
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MWL?LX%@&&F2M$RI*-:TP2.TT-N546VHM!BXG!B@5G$Q,L@,22+"\GT4K8?\
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M:UM8MPAMK>SAN%NGNNA(V+-;J=[;H,2O3BBO4<D,34PF9$<H5*1AV;NS.RE
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M'E:$3/"EI=&6%&>9%ZJ&%2I802.I&Y"@.'W*ZHZL?)WH!G )=<$X4G!W?#<
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M*T+M9NK4K%-:K!C4ZPW V/3BU=CM698 &%:0GCN9!'%@R.:JP\4R^4ACD6R
M'Z&[F,'PD-INHH\D;V%ZLD,1FEC:UG5XH0K,99$,89(@J.QD8!=JL<X4X"2,
M@$2(0QP"&7!.0, YP3D@8'Q(%0Q3Y:>/+IQL $+;% [0:T34%M:=B9WJD=ZW
M&(V*ZOB%+7<;=%8Y0H;,&?KYIBW4,, )!\&B'H60Z8TB$*]]%U.-+9FLKGJW
M<ERD-KY>X\T1:QV\DDO0,08Q,MRFQUW E)-P4*"T1-$2V'7"A26W+L]990-V
M<;LJ<@X[C&<\3-OOW12 @H5]NK4J0H%*!9#1F^QZ<M(#KK65' L?%0F.89!T
MK&>SUJ$!I-C@"9+84<8\\F;8#HBA--U&4 QV%[(&D:)2EK.X:5!(7C!6,@R*
M(92R#U*(I"0 C8D9(QW=!QGEE'!Q@\GL=PY^L>XJU!R!RQX"Q)X2A2H8B!B1
MY<)AR!YL,9(9X)H\LHY89H\L9(I8\LL),,L<\,N\>^N^],@J2K A@2"""""#
M@@@\@@\$'D&I]^U<W,4IQ2G%*<4JA+_Y&T'7-["H+P2T%G_@:W+LSE.EP-KM
M" W%>VNLM6,;@=(8,5 %=KXB=U\&5( ][3^Z3W-JP05R#MQWT;;2[FZMVN8V
MA5<W2Q1O)MEN6L;=+N\6!0I!:WMY(Y6$C1A]ZI"9)3LJMI55@IR3Z22!PH=B
MB%C[,P(&,XP2<#FNSK_>RN^[%MVKI*'L>E6NF5E!<&<-S55\8&>O6EW94%=/
M#-KUHL>&/OD^GV7W>.PQ7E$CISIXX<L1Y?N8N=.>VM8+P7-K<0SRR0(8'E+"
M6&.*25666&+Z"S1;BNY074$\BLK(&8IM92 &.X#&"2!V)[E3C..QJ++O*FDG
MKM3V'NJ;%'I>YBZZ+4+]E7@R*?'\>/SD.L)6S 1O.:/ALG(=:Q0>PK6/ND"R
M5V6Y=UG-K!AW<VCW"M>Q=:U,]BLK3VW583_L:-9+O8K1A3Y7++)N=-[12B#K
M;":CU5]!VMM?&&P"OJ.$R03]/@C@X!&[;FL]I[R/H&[6!2^IB6D#O*H5G9%8
M+LJ3%2%?M870QT#5-BTR? PS(ZMNYT!^4,#.-18PA)E#!L@7@6!"2RKOM+N;
M!5:9H6^?FM95BDWM;7=NL;36LXVC;+&)%R4+Q,P=4D9HY N4E60D+N'I5AD8
MW(Q(5E]P=I[X(X) !&>DJ\G->NALF :VZBK ]Y*M .S+#56%4FK]SL*A0PK!
MK5/9NE3^!!96=HIE:3E^ZO;9W-O2Y2+H5F1;$7+Z3<QG:S0,[:>^I1K%,LPE
M@C=UE5'BWQF2%(IY9%W[1'!)ARX56"53SA@!((R2I&&(&,@X(#%E4'&<L.,<
MUL5SF593BE.*4XI6,=,\4B9LYS!9L\%*TYGDM2@RLW+#$ 64KL%2N@_YX]D7
MU%^ "%%_SA14D4&'?66?7)QIU)$CW(F]U3?(P1%W$#<['A47.68\  GX5@G
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M<9C*XY3GSP"S%9BPTW-L]J\:.RN);>WN4="2K1W$*2J.0#NC+&*08PLJ.H)
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M"< ?KJ&2;7FT^2*^33UFMYYWE2#,#R&-)GE,/3=I(HR&5P"Q567:00QY R)
M4,A#*H4MR!DJ!NR "?A_']5=&N[^3NX]43LZ/?J7%N2RM:I3>K>%6QB)6@%
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MK!IW6FG;?L#3K^#7V9\ NPNO'1A#L^OA&V)18,6.HK4RW<Z[U1=H9%OV=6Z
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MC006LT-M:F"!5=<H\<[22HMQ.\TV&&L;;=&49R6P_K4%<EP-S,I=MS'!Y!4
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MT!/R^^*4]S-?0$_+[XI3W,U] 3\OOBE/<S7T!/R^^*4]S-?0$_+[XI3W,U]
M3\OOBE/<S7T!/R^^*4]S-?0$_+[XI3W,U] 3\OOBE/<S7T!/R^^*4]S-?0$_
M+[XI3W,U] 3\OOBE/<S7T!/R^^*4]S-?0$_+[XI3W,U] 3\OOBE/<S7T!/R^
M^*4]RM?0$_+[XI3W,U] 3\OOBE/<S7T!/R^^*4]S-?0$_+[XI3W,U] 3\OOB
ME/<S7T!/R^^*4]S-?0$_+[XI3W,U] 3\OOBE/<S7T!/R^^*4]S-?0$_+[XI3
MW,U] 3\OOBE/<S7T!/R^^*4]S-?0$_+[XI3W,U] 3\OOBE/<S7T!/R^^*4]S
M-?0$_+[XI3W,U] 3\OOBE/<S7T!/R^^*4]S-?0$_+[XI3W*U] 3\OOBE/<S7
MT!/R^^*4]S-?0$_+[XI3W,U] 3\OOBE/<S7T!/R^^*4]S-?0$_+[XI3W,U]
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MHFPE^HJ<]HU&]B9>'5E8M[+9#$UUOX&Z_*W+63BHZK#BQZ&/*K*"BM9;U!/
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M7&E6SS(%E9Y ;6YNI9ECD9FA:$1N6,;9M#L8T.XG=.4W]B465@IX&/4J@%@
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M<9X,[(59YHD2(SNTB*D #L9F9@%B"Q,LI,A(3$;*YSA&#8-8) !).T $D\<
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M++(F79R#6 CO[2'D&>0W>4+B?O\ EF9Q]XFR]_RYSY=\K$TH! ED 9!$P#L
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M\[9;NYG>6229RT\KS2A3L1I)',CMTX]L:[G);"HJ@]@ !6 BJ% 4>D #/)
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MUG<PCI-..M#)%NA1D5Y$$BJ75#(FXINVAMS84$@)$/T75N=OI(."02 <9P2
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MMR,4;-?&20VK@ITKA? +(W41DREAQ8#YM5F,W<>3 3J8]G=Q01W4EK<1VTI
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MZ?0HN[2HZ8RJNZW)<L2<!_:OO9994Z*6WX"]?^EYU6*6QXP=IH\S<=3Y-O\
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MHBDCAB2 K(W52A(YHT8*,DK&@)924V[]W3SQL4-\TK<@DEL@;3MTWU^55"?
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M!@$@MEB!A02.YP 36"0"!\3G'\0S_P!E=L_W$J!-:-/=*U8M$)/8L3_8PP0
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MVG3M$G-V\1,SPO!=6MGCHPL\ACEGO(NC))TF>-)V,:R1=)BW&X#$;Y8J$!P
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MJRZ?+>VENHE#&./48[#JO*%,:DRI<+TF!]"B3=N9$.7F8.%4<"14=CCN8R^
MN03QM.0>_&,9(P%4\]P"JROD=4!]G9#Z7XYGT\%@0LI[C;E@\@Y-+UU&ZIZ!
MI.0NCUJNON[:Y4[5=5=GLXE.?K+(D<!X&#5O&U63>'G65@EQ%TUFU)9F4-,E
MG'IPOI)(YY$ ?S36]A+-# \41GC>)T;:9.D$_'*G=MC(!(4N9-@!4$_0W.%+
M D*0P/(&>RS\_P %/!:,C]*W3LK6=-W+;=M0!V6G315673%L/HIZ% 40R#QN
M+&Z66-1W2RL(TBKI$UE8W,ZG,EA*+/">'F<P[;Z#%U-90VA:*<&47L2SK)(
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MM%;Y99I9'E>1)+=Y9XKUUB6*3ILL5VF8V<$O$H#JI8JL5B($0+'YH8  !#
MH"V1G+(>0.QS@_&LOJ;P[6ZB@5AI]M[%:AUJ@ZZTM48&8E'CDKNAM:ENIU6L
M(35U4"/)D<B.(5-BODA,=W*"KU<G5MU#<-BT:PO-9:\+E[.V5I;BYO9BIG(E
MU"Z$8>[*M,5&PH7CM\& -+*'1T*(F4A"8P[<*J+]'B-<X3@9YS@MG=PN",',
M*@\":-2,9U>IV]K55FT;;\6KK9TEUV9L>] 56H^*=DJ]YI=<UT#<'5I]FS9O
M]?5&NEC&' C+ZD8QA7F8#(T=?FO/B"XGPUXD+RQ6>K01/!:VUNTTVKQ2V\\E
MRT"0Y"QW$TJE58M,J[E)DDD&.@J\(6 +Q,P9V; B(90H8G&2J@\]B2.P%;_<
M\]5].*4XI3BE.*566R-7*-H$:ZZL#%G&FU_LA#L[.O"=B]*K:[J(;6:G!V7$
M@:>>975[D4AV,KB F")QN-*JQ<I,@(A@!VU;73VHN>FJE[BVDM>H=V^%)B@F
M:+! #2P"2V?<&!@GF4 ,RLL64/MR3A6#8'Q*\J#]0;#?I4<\<P6[:@M3O<ZO
M9]2M\51P(TM=-6V$Z$0%D]%8DW*DVZ@/$BQTG<5T\15[OOJNQ -HX)"Q[*MG
M7D0D+LL^[X+R&.R>UFA,Q%[!=QJ69(RH@GAN(W:-TE5GW6[QLA(4Q,&4AJBR
M,7#*VWT,IX!()964@$$?!@0>X(Q@BH@B\0ZB)36]"M%SN]OJUQM=LV1L1;@8
M!0I;;M.P[$I6R4E\!=ZQ!IMHHQE"<TS 2KK*0_1KCA&QQ]UPMUDQB?=72:Q,
M9TN(H8(98(8;6V8JUP(;2*VGM7MVCNFGAG6XCGW2M/'(RLBK;]"+,=1$*X*L
MS,&8NPR%RY=7# J R[2O ! P?5N/-8;57B*NT[=]63UBR/V^O]9B^3#^".\7
M&U76ZG[#\B-CUNX=D]MK'.RDCKE52CW%1AA*UG/<G6$9PRCF=1N'#JR[UAKV
M"[$L4:7%T=+C)@AB@@6VTVVE@V[(PHZDSF!SA%6-8BB8C*1QX2$(RD$E5ZI]
M3,S;I6#=SG@#<.Y)SD\Y)W/YQ*OIQ2G%*<4IQ2M6;WXAZMO&X*5O/IGL>K[!
MIVPA=DR%5?9U]7UVQ/UFG[MIA-DZHDEA(H6?2RMW227N<:KP$N,5G2*P2MJL
M_MB-]UK?6+NWLY[#9:RV\]L;;$MK;M+'&U[!>OLN!&+CU2P 8,I";^I&$ECA
MDCJ:%&=7RP96W9#L 2$9!E<[> WMSCG()!XE/BNHZ0>0@5RO5BO-D\E*=%0K
M_:#$]3K?X-87T]Y2TH2A%4$J17&2"NL;@LMLPQ8-V1QO0\A\")8@2)CZL_4T
MYH+>*"/3)C<6\0>:7,K31SNTCS22,0S1HH1-B*JYVF1I)) B&),L6,HVL2%'
M !4 !0!P">3DD_5@#BJV@;]G=]&;<NNU2AKSJ_13K4CVHU5-73:"T.OP^KF6
MQ60+9Y7![A- 7;]2U-H@FGF7RB@AD"3@XX,RHHTVH6_0O[."T!@NK]+R.:5Y
M%N$6W-VMLK(DIA!$-Y,L@ 8%BI#'8"0C;=&[.=R1E" %VDMM+'E=W)08Y''P
MYJ0Z8T-8=/+<E,>Y[A:P"]J;,VH[&;5G7P.#TW:C:Y6NQ5\R135Q20THUYN,
MML52)R%K<>52M2DLBT,C%>=7>ZA'>MO-E#$RVEK:1E);AC&MHD$,4B[Y2&<P
M0B%PX9"'9PJR!67*1E!@.Q];.<A>2Y8D'"\#<VX8P> ,XR#&5_C)C7 /&:JH
M7N3"MZ6VK;=RWI]8Y>L[CLF]6:E[7 9O#XEBP51[VMNRMMM]FV<Z'-8*,P6X
M+%BJ0%GE@MN;5.JVJ2R1[9;ZTALK>.(?,6L$5Q9ND:EW9^G#:V:6L*G>2K;F
M<,F6CTL=( \(S.Q/TF8JXSVQEF<LQX]@.>-M><>KJ<4IQ2G%*JS<^J%.ZM?'
M4)PU9H<<[#0KBF?)HEA#%%<-7WZL;/HKN$-V T3L<%%UIZ!B2J:KRUS44:=<
M;#D.5)]FU97;V5PMPB+)\W<0/&Y<+)#=6\MK<1EHV1UWP32*'1E9"0RG(%1=
M Z[22.58$8R&1@ZGD$<,H.""#6J77Z/FC?CY$Y;*OO<]I-S.W)GBMH,?6V,_
MU\O_ "/&'GQQJ'?P*.#L6UV<87.B]ICOA9X4-.=/:A5=Q7]<^(KC&!;6^(5V
MV66N#Y/_ .GQZ82#UAY@M;0Q$^8WKUHU(40EX'I\NI[LW/T^%]?SAD [94!F
M(&T@[3C.<,+FM>C+(\VAN"W);AA5T^YM%Z[U6V/!%$/LE;<ZVMNTFHC=.L<J
MF-?8BV>N;==J&LC&2.93/7$DH )F3$LE?I17\4=I90O#U7LK^YNT5BRQ2I=0
MVB,CO&Z2J8I+*-T"\.)7#,-H#3:,EW(; >-4.,9&UG.1D$'(<@Y[8&!R<1T'
MQ8: ">+ &&[+G()XKF"%U^*2L:_^]=,A*+;=6QQVF3&N8Y#X9:ZN;:O9=H/=
M6?M6 CWK+IE%GG)8VK*QU9O(P ZLI60B6X^8S<0W9,0,IS^R8$D^<W\;H_H$
M .EQ$-[?-'(X7G"LG/I_<L1QCWQFI%;O'9IL)EKK*^[BN=GK= M](V'E7)JQ
MK)7G8;QKBW27.G-S+ FI8#M2$&VB3]-%5>)5X.0T0RXHK!6WM0%@KAU);9;G
MR]E!%+<0SVW4$MT_3@N8>A.BQO.T;LR%]CRA]AD+!=Z1-&:,MMW.2%97QM09
M93N4Y"Y'.,XP2!C."P,Q\?=:MM3ZN756PF+C[0QM.S-C7"=-(5,DQNNX]G7'
M;MS$13G" &D(@+3>&X"4DP  LA6,).2 %-)F-%3J-TEW=M+$K+$L-K;0AP!)
MT+*UALX&D"LZB1HH$:0*S .6 9A@F4:E%P<9)9CCMN=V=L?5EC@X&>^!VJZ>
M:-3IQ2G%*ZQD4\XA4 I68),PT\0YL<4,\@<\D66$16$!&$@\V8\F6,V,4\><
M,F6'6$N&6'>6/>5(# D;@""5)(# 'D$C!&1QD'(^%*TI[\.&W>G?U/\ Z_KY
MT)WY 3>1&=E^$M:^^,[3-OO'R8Z2^S?"_NG%#'M[J1QCCB%TP[32=U_(WL/'
M"3KN?+2"\\Y\GV^?DX::(NM<[.B-.^2]^>KOZAL\)G=MZ@Z@&>*HZ)V;.HV.
MIU,X3.[J=7'T<8W\]LXXS4AHWA_6:5O(G>GQO97;^1OL)_$,:GI@3 AGLX9,
M-90;#<U5<"NEJJ"W!$NZI5+=NR$=4B!2BP0F#5.F15VJ?699[ 6'0BCC"6T9
M*O.RA;0R&)HX'E:"*9NJ_7GCC$DI:0Y4S3F7*PA9.IN)/J/(7/JQD%@ Q P-
MJDX'UX7$?.\3K*ZHUDUIEM(ZDUF+RJ9^2-/85)4A=.2Y3=UI/*(%79X;?7SP
M@<U&]<[)C[,FS+B:TR!1@2P&+8&KUEJZO%'<1W0M%GE.DKIDRS/(B+ML9-*9
MXC#(K-OL!$<N 4G+X4JJLXQ$J5WE1U3("H!/[8)0#N! P^>V<C'(S@9I%XAB
MUFW'VI#M[8*_ )ONNTZY2^Z]>F+]:7+R(NN&P=L6=5FPIQ9-@*:64BPR5\&U
M2MEM;6W&RK8!2XLD.:&N36#+"L,EG;,2EC#<R;KA7NH--@-O9Q.%F58PD0C$
MK1!'E:&)B5/4Z@0X8L'8<N5&%(5I&W.1D9.3G )(&3P>,0;:?@PCNDOD-:U#
M5'CLG?&JMEZ.C>RTVDTV"IZ^W:R0Q[&8&LZ/3Q;-L.X!I$:;X;9WQHXR_$J:
M53&0BZ>W&P-]BTUZ2 :="Z/Y:PN[6_V":>8S7-BLAME"SSF*VA+R/U4MTCSU
M7<B3IP1QQ> -U&!&Z1&CSM485R-W*KEFP!@L3V XRQ._4<>$6&$4>/6$<>&,
M>&/7_JQPPZZQQQZ__IUCUUUU_P#TZYYXG))/<\FMBOOBE.*4XI5#[!TJ?>]L
MZCVAAL9_7A]2$.B@Z8 CJAJ6Q2V18:BL'OE@U4&/(L&"$WW=A@L8!]!Y0X&#
M_=)RDRRZ%O?+;V=Y:FVCE-X$#3M),KQ")EDCV*CK&2LB[O6K;LE3QBJV0LZ-
MN(V$G "X.1@YR">1QP16JR_]&W0U:BJ+H=GW-GEKQ+JBDT$:S5?6%AK .L=*
M5S;]6U[0KC3RZ7@EV,*K!W7:6<SVT1SO,[2EI=F"+7L41>3CK-XFN&>9O*P(
M+E[N>X,4MU%*UU?2V<MS<03K.9+8NUC$@CB^;$,D\3*ZR+LJ%LH &]CM"*N0
MI4)&'"J5VX;&\G)_."D8QS>XGC=W3UGB$EHC\@T#Q=;Q+<R;H;E,YM5 (TW=
M-5,!)3%*J,")_&8]K=I&B%4JTO?PY(A"A1KC8<@N>=3$SZR\\85M50N! N$A
MN!>P7:D!W+&,K'+"2SO)\Z)&,C*0UG3QT0I.(CCD\LNPIS@8SDANP'&!@'B#
MKO#-FL^ZV%\@=APWI?N2W;KKEVBJNK\2D;_852L5+O2;))+3YT3:O/%-BR-'
M$8A2%*GJ5"P&,S&%-7,=AM;5O0VG6QMVLH;&6W,UUMDCMIHYX'Z@F$B2H\>T
MLK /')(I4$JR1Z..>HVX.7#83(+ JPQMP00?;@@'MD&?C^*]9'U)4]#]W*X%
M:CI1&DAD52+QK>>?=1TA%49EE(<.1T(S:P([JZIH#;8&;HDTY_ Q>5[ @.N,
MY%F&L=6E-Y-J'0@%Y.+]I)AU<=:_,P>=(S(4CD@2=DM]@"QE8Y,&5 ]2$0"+
M'N;8O3 !P?3'MPI.,D-M]6<YR1V.*G5)UJV1[CWAM5V8NGDV)#K&J581=(5)
M(#0M:UYH6'B[Z($&CA?$W^_[*G[A!E/"^'NZY+V9B?,>"%1/=))96%I&K 6Q
MNII6;&&N+J1%;9@G,8M[>U&6"MU.H,;0K-)5(>1SCU; ,?!5!QGZ]S-[C&/C
MFKIYHU.G%*QGOE5Z\;YG7%*>^57KQOF=<4I[Y5>O&^9UQ2N*=FE)AF'G+#F@
M(BDAFBDSQRPEBEP[PDCSQ[_DRPSPRRQRZ[_D[Z[[ZYD$@@C@@Y!]B*56@&K=
M(*XU<2ZF4T.)(/0!5&$"\?#%<-JN P;7,(O777V11TP=B="@QQ_D C*FPB^S
MK/OKFRU]>/N+7,S;S<,^7/J-V5-R3[F<JID_=%03VJ(1!V4?F_#]Q]'^3\/:
MH;CXV^+^-9CIG6L*+W5!G2Y^NK^0F>:M(Q4KFB99U7!<I^XZTN!1/'M?&2(.
MEJ6*O/GJ#%?TG<LPBK_E?4NJ9_.S]8QO&\FX;Y%=D=^J<?.LTD<<ADDW.98X
MY-V]$81Z4>,;!C.0/@" 0,#X  D8&!@D8P:XF?C+XJN:XOJ#'4>M2*PK7J%
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M174<<%P-CE#+;3HSR0HYC5@:UY&9)4.[T'8I0,NXL[[02K*2R\C.UE( 8C)
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M50*#V P*PJ*H "@;0 #W( &!R<D\<9)S4@#JE77 #JE];0 JQ)#)15H:=<,
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MRI)=7$<0A25DC65IT"G:R2M&(G9' #IU(PJR*K!7")N!*+C!5222 21M.>Q
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M-6AIK1H?.2P9&%&DSD29GGEN9I)YFWRRL6=MJJ,GL%1 J(J@!41%5$4!54*
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C*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g96328g03t13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g03t13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2)@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (D2^AW(X0DE-! 0      "L< @   @  ' (% !]615)!7S(Q7S P,C1?
M8G5S:6YE<W-S96-T:6]N7W8Q #A"24T$)0      $,-1.K3R1] /6FL?S3J&
M!)\X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0
M  !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R
M:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M            /X   #A"24T$#0      !    !XX0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M          /8   '9     8 9P P #, =  Q #,    !
M          $             !V0   /8                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   /8     %)G:'1L;VYG   '9     9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   #V     !29VAT;&]N9P  !V0    #=7)L5$585     $
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M!!$       $! #A"24T$%       !     ,X0DE-! P     %[,    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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ML;76<&L!ESLLL>&GTGDVO^U'<7;-SG6;$;
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MGKTXXZ!P(<J5KW>[D>[GX\\\"'''/P#GGIW<:4K3O .[Q'D>O/\ X<\]W<
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MBC&TQ#.@>QSL5RH. 270\H[5RLS<D,BY21<)*(.FZR"J:R1#D43.4Q0$-*5
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M.OPYYXYXYYZ<!U'G@>>>=*4 >/=UZB'>/'40'GGGG_1W]-*5S=9'^$E?X_\
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MED,Z6[<1E#J\27B@+G3[8EYZK6NM65'CGSL!.Q<REQP \^<CG3DG' @///'
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MCXJOI:\DZ=.7;]=95VZ<+.%E%#*56K>+L9VZ[[*17*)N&JTE/1E0L/RFJ\G
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M(L5%_%R2#EB\2*LDFJ5-P@H0JJ9%  #D*(521QS(T<L:2QN,/'(JNC#.<,K
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MU5[]F'X"_.U>7S(@?P_O ]>?EC9N[GGCUT][^!'PYZ //' ].[7K-K_-K?\
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MMX(COC1+C!D<EFEM+8HT=8TVK7T$BQMI9F" -/-#<*JA#XPPRQK+)( &+1'
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M:$!;N( H^V*0@/&KC57\+++%=P2M!, T,CHJ,)8R"4CD5U96V/Z<9QN4[@I
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M@6F()) P#X$YQ^/EFL$\?#J'7GGD>@\<  AR'P[^? .G&145KT\>@^'(\]>
M_.(<] 'GGP'CN4KFZS_C) =W^'(GD/'_ .GM^.1Y$>\>G@/'3@!U1)]C?\!O
MF-*_K!9B3CE<1Y32F)1O!Q*F.;NG*3;MD22:P\<>LR97LHYCE6$JF_;Q[857
M:S)2+DB.DT3('8/"J"W4^0K/=WNUVH9&[Q!MC!VEVXJX0-E=I8^B#N7!.<CK
M6^?W+<P/1/,C('(\R/$#RJMVR9U.MZ;9*M;6EFB;57'%9,]A;?<,U6^9)$25
M>0]23A%LT7G(4A&QD^5B]6:1\#8#-6KAH^9S+5M/LY!,NTUT1M/%+#PVBD$N
M'BBL8D,BRGB)BQMK52T9*@F6,L0048H5-6X2=I!SD8Y$N3@@8/ILQY^HCGGE
MFK"VO&1; Y8/8RS3T(Y1O-<N\@#E_)69B\4K:*B*$/&Q-ADGD758YX IJ/4Z
MNTBR+N$S.U4E'BZS@VCJ]7XQABICC)*22:SDK.@[:Q$.P-*)1R)HJM5TTH>!
MA$O5S1H5V+%2:E%%I-V51\].Y %CE3013(I4J  !T#GJ(CU$3=1$1'J81$ Y
M'H ="AP!0   -*5KI2FE*:4J@.[KLS=IN]BY5#).;*9)N<C42#6KU9N5?G7<
M4]0C2.GTK#M9B*5*]KMF95V?D7<]%1UAAY&..\<NV<FUD89^_BW70:/VGU?0
MX9;>QG5;>:02R1.@8;P%5F1P5DB9T549HW5@ K*5=586);>.8Y<'.-N1CF/(
M@@@]3U'C7RQ#8LI8NF97%#N/:3-HI,:$M)XD:+%BHRXT$B[:-8Y8VP24Y)N$
M8JMF='3C+9@JV3:S?&UG71K\-9H*IN:/*9!V-VVG:NBW-TYMI9V"1ZSM+@7)
M!9K3M!#"NZ24C+1ZQ:P\:Y0&6YM[J8SFUUZ1W%B=MN.-"O-K(MAE3H7L7<A5
M4>-I(Q12=L4D2@*U@JCNHP!=[^ABFOY+@U<GKL7+TV/Y%*2A;:T,Q356D8Q_
M#3#%BY8S\:@W<.9"O.03FVC1!9ZLP*S(+C6OO.RG:"QT]M6N-,F&EK(J#4(F
MBGM'$A"QRQS0R.KV\K,JQW"Y@=V5!)O(6KT.K:=/<"TCND-T5)[NP=)05!+(
MRNJE9% ):,X< $E<<ZL#KGJV--*4TI32E-*4TI32E-*4TI32E<!80LHM6@U@
MT,5R62:&DBS*3U4%84HG&11C!9NFGF9A0GD%CUW:AV*2G)G*1R=RE4SA:=GE
M=U57R;')5<;&N\Q**P,[EE2P(4]LXF<7*-O6\DI=)M_?JLM4X3(J'JF7<2B4
M;;K6Y+$UIA#-Z^^A5/X^'X>57KTI32E-*5Y<M\5J[03;;VHS;(&WZA7FI[3[
MN^PS<\PV>KPR\CB&Y(Q+>-JV2+GE27>G3J5.LC"% M<=JS,K6&QH6O5VS/72
M0J.ILGL79B7L[J795=-U>6QN+V(WT%JMV +ZS-P6>!;!XU:\,0=4G"0I,O$,
MT8B<,T;:&^@F2X>[MVN(Y J-B%R(I^%T2:)BL+ELNA,FUPK AQM0KZ7Z5>JO
MD*&"=JLD#]HFY6CW[99NYCY:%EFP$%Y"V"%D$6TK!33+SB8NXJ5:-7J)%453
M(^97144\IOK"ZTZ?@7<7#<JLD;JRR0SPOG9/;3QEHKB"3!V2Q.Z,01G<K ;B
M"XBN8^)"VX E64@J\;K[J.1& >.1?Z2. PY'&""<NUAU>II2FE*:4II2FE*:
M4II2FE*:4II2FE*^2YEB(+'02*NX(BH9% 5 1*LL4@BFD*PE4!(JAP @J"0X
M)@;RA*;C@5*J%D&RYK2M2@5YO>8V.4I46XML9#5YO9(^J.%KE3D)5[29A>DH
MM[78&U+<7%XU81\E9))24:)IJTX2)QJ;Q2K%XV=65[1:RZMY'9+$M&)G?C(-
M$8^36+YQ0&3J6CVR2#>/F'<>#5U+L$&S5%E)+.FJ31J1(K=)2LWTI32E! !#
M@0 0]P]0TI5'\T;6'A;8YSAMZ<%I>6//N)&R0$=))UB&R*JY,U/)OT)((^4C
MZOD*038LDW,[)P5AIE\(PC8G*U3L01=2L]&Z72M?>WA.G:@J7FFR;08KA&G2
M/:"$W1AXW:./<W#>"2&[M=[FSN(A)-%/@75BDS">,M#<H"$FB(209() 8J58
M-@;HY%>%S@R(2JLO&5O>_3JI2IZ?S\9U2$:6]) 6NQ%K4P12#M0H^?)3+]1(
MM2SS^/[NX;F3<Q::+RU8YO$>NQGL;Y&M$9+-$$<\=DIM7NHH>S0[W+< R)IT
MUQ LRP@@&XM;R4VUO?V:DX=PMO>VQ#)>6,.SBOB-JHL8V;5/K2)Z(NXXY#%(
MW/"21*'DMYF Y*2\+]8IF]RMLL6Y4H.::-!Y)QE8VEJIEB265BYAHDZ; H9J
MY59O&SED_0:OV#UF[06;.V3YJW=(+)F*HD "41YS5=*U#1+^?3=4MGM+VV*B
M6%RC8#J'1T>-GCDC=&5D>-F5@>1ZUL;2[M[Z".YM9!+#(#M< CFI*LI5@&5E
M8$$, 0?5@U(.M=6332E-*4TI32E-*4TI32E-*4TI32E>,[M[! -_<+X\[6<2
M=P\?YS,^>[_;W>.O9^P(SH+_ /ZG=?T=W_+V7Y*U5[]F'X"_.U>7S(@?P_O/
M''^.%FY'IW!-/@_('P .H (#UZ#ZU:_S:W_L(?\ +6L5NI^$_/5[]C.S:A;E
ML;[ELEWL^X"80P(.%$8VA;;,?PF1LD7!;+=NG:LLHQKTT^CR.$:[ZJ;RSPJ+
ME(P1P2"YU !N0I]#K^M3Z5/IMO -/4W_ 'W=/J5Q);6T(M(8Y1F1$?!DWE0"
MO7'KJ[%&'#DY]';R R3N)'F*Y;)/9B94A=PN<L/8LNV.KQ2</Y4I^'H_+=UO
M%(Q)7;EDC(4&VG:?BZ'&UV<&;[*"I3OX:7JT3(R9(F7@Y,9%\R9@W55M6W:N
MS;3M/O+R"YM[B]M9KMK."">[EAMK>0QS73B*/<+485TD95+HZ[%9L@2;=MS*
MI!"D#<3C)/0>H^8Z#Q/C6>;&NRHRIN!S)C:,S=%_<VQ#/9@O^([0@ODC'5'R
M_+3F+F,BCD=IC2G6YQ(R]L6H-A091MN<PU9GD(X0DDTTE31T@JPL:_VNM--L
MKE[%^\WD=E!>PD6US/9JET5-L;J:$*D0N$W-$&EC)&TDC<@9' S$;QA<D>Z4
M,=ONL9ST^ ]1R(JG->V7[@+2GC56&K$8Y)ES#&3,^T<5+17VXR.-,1FN!;O+
MN06D$_5SV/&C6 &L0]!&1D1;MQ9(*>E)\[N76].A-X'E<=QOK73[CZU(=ES>
MF 6ZC"G>K=XBW.N0N3NQM-6Q&YVX'NPS+S',+NW?DVGE^FI JW9[9RERX$>6
MB6Q1CQCN%D\=FJ4?;LO8RB[ZQI&3WKII4<ERN.9*VQUF:T^>*R=J0;YVBS"5
M7&.:%%L:7C5%\67M)8(=16)+RY;34N>.T-G<O;F>U ,MJEPL31M,A90ZKNVC
M<>?#<+4(6RH) WX(!(R V<$@D8& 3\ ^#,\YM[+RZX7JV2HMBX#-61XC=M5-
MM&-Y;$&3,,66N2;VQ.+K&,8+(6,H:U6+*%"R;:Y&N,E8.N2JS5K7TRS$99%O
M3VZ2@X%AVK@OIK9V!L;9]&FU2Y2\M;V.15C$#M);W3Q1VMQ:Q)*V^1 3(2C1
M J:K: @,!Z3"0(-I!',D<P#N!)'B!T(Z\JB"6[,;=C'VW&]-C:_CRYR.3\DV
M'#,"_P ?9?QK>("+S!5(9Q8;'BZW3E;LCZ/J=UBH=HX?*Q<TJV(Y205%@Y>"
MDKY&8G:K1WAN9FDN8%M;6.^D6YL[F"1K*5Q''=1))&IEA=R &3)4GTU6J3!(
M"!Z)))488'T@,D$],C_4>=0EN%VD9HVP,L=RN48^I'@\I1UA>TZPT;(%,R37
M7[NG2Y*_=*\I/T:;G(A&Q4^;52B[#%"[.9D]4!$BJYDU?-Y^FZQ8ZJ;E;1IM
M]H\:S1W%O-;2J)DXD,@CG1',<R>E&VT;@,X'+-#QLF"V,-T(((_*/X_%5BY#
ML\,DW@V/C8:K;N&CU=HN%MR^3Y[-F5\-U2N143DZ<D*\ZO$/8#S4+$P.-3/D
M$%8^(MCH;Q$LV[Y2;15558H*ZP=I;6W$_?I0[>R][IEK'8VEY+(SVL:2B!X]
MCO)<;2=SQ#@L2H0\F(K,+'!1<#8&)9E'4XSG/\>55QLFV*_8NW10^US,K(E3
MN)LAX_I=B-$R438F[6/OSFNN(N>A)6-=.X>99/JY9(Z<B7*#I1%=!RW*N"*O
MGT4MG%JMO=Z3)JUBW&A%M<3Q!U>,EK=9 T<B, \;+)&R.",@@XSR)IX9$@C;
MD2R@X(/NB.?+D>M6JL'9:9NF\WYJQQAUY3Y6I8]W!YCP+0Y_)V2<>8VG,ES6
M&V[BPVQ&O0U@FHQ27?UJC>@VFU+1S<(J,:.B@5R98/12:B/M;81V-A<WJSI-
M=:=9:A/%:VUQ=):QWI$<)D>-&VK+/NABW>D[*>0'.JS;ON<*1M5F4%F"Y*\S
M@$^ YGR_)G*\?["<10V/<-26:W^ZK(>6MP&/Y',-3Q3LVPY!Y=?X[PJA;'M(
MA,F9#>RDXT]<,[3-L5E8N)K"**+5AZ)ZQL2#V5CVI[-QVAO)+F]2Q32;:ST^
MX6REO-:OGM%N;XPK.]M;*B-L,2, [R$DMNVQD(QJ1"N%W%RS*6"HH.%!VY.2
M,Y/K Z<^==5M@C48B?G(ELL]<MHN8DXU!:2C%H21718/5VJ2S^&<JKKQ#U5-
M,JCN+7756CUSJ-%%5%$1.;KHG+QQN0H+HCD*P=064$A7  =03@,  PYX&:L$
M8) SR)'/K7TK7^,E>[_\.17Y_3D YZ#W!X^'7CX D^QO^ WS&HK^J]N'M,M4
M,.WN5AZS=+0[5KDW&^CX^KK.XVJ*"2AY!JE.QM0>*IA:#QCL[8XPB*;DSL5"
M^DHA')O7"'R/I\237<"/+#"!(C;IY##$Q5U;8TH!$6X @.< ?#@'>N2%) ).
M", 9//Q \?@J)=F%0+2\?SD46G4>G&5FV+IPWHVV6U[86DH["!C&2LC(U>UW
M2[.)YX"+)LQ0E&#]K'QL<S90+9L"$<B(9FMS">Y1N---A"H,VI1:F57>Q"I+
M#! $7)+%6#,S$NS$L<TQ+M!]$+DYP%*YSYY)R?6.7J%2KD9;**3^IKP,7+2$
M<VRG5E'#>C2,"D[<48S!^C8E;RG<'D&CZJ;.UDG -*H^>S"ZB$>8B#A$'K4^
MFJ[6RP5%Y&BB7Q"_ELBZ1[8Z5K<I:I-%S*246H==4QDHIC<[M&148V%1%"..
MR=P(OT@,+BJ0YVQ5'RE3V'/'[[@1Y'N 0#CD?)[Q'J!> $>X1Y$  !X!2M=*
M4TI32E-*5$>7\3,\I0T6=G,.J=D"F28V7&.1HIL@YF:/:B-E68NDVZXD1EZ_
M-QZ[F N=6>*$CK56)"0B'1VRJK5^RR[2[:U=P4$UO,O#N;9R0D\6<X)'-)(V
MQ)!*!NBE"N,C*M0Z;P.95E.58=5/^H/1E/(CUX(Z1J[+[-7?:%^JYO*K[$?:
M4EF7)W.'9!I*V_!+W)IJL5<TA$V=&L-4WD'DNCN_E)7H)Y?(.VQ19Y%J\BHR
MX,0K0>L^S_:(=BTTJ6PAO^QW"$+7\1[MK"V GW(F&F>)9;*Y4(TALY(9DBP2
MT+F:N8?1+0ZJVI12RPZAOXBQN%DM>/MP2PVB39(F>2R*49@PYKL/>10\DH6M
MW(5>>BE:=D>OMTW%CI+]T1VJFR56.V;6.M2A$FZ%JIDFL0P1EB8H(F34$8J>
MCX&QM9&#9>7ZAIC6B1W4$HO--N6*VU]&I4%P S6US$2S6E[$I'%MI&.1]=MY
M+BV:.=]_;W0F+12(8+J, RP,<D G DB? $T+'W,BCD?1D5) 4$FZU=9=-*4T
MI32E-*4TI32E-*4TI6@B!0$P\\  B/ "(\ '(\  "(C\  1'N .=*5"S;<%B
MYT\:1X2TVV?NK&]JIV;^F7*.<QLNP4JZ"X3B3V!0- QYG%VJ35O+S'H44Z=6
M"-;-WBJZQDR*5-6E*:4II2O@Y;-GK9PS>-T';1V@JV=-7*2:[9RV73,DNW<(
M*E.DL@LD<R:J2A3)J)F,0Y3%$0&02I#*2&!!!!(((.001S!!Y@CF#3KUKKIE
ML=.-L]TB"P=@5IN,YU>-K&,,EJHFDHO%\FY=J-:U@+-44*S(EHP7(/Y L=A6
MRO9%E/8QE'RF-6%F@HV6J8/NMM=3%_:O;W< OE3?-=6.X12R<E,NIZ3/M<VF
MI!4#7T0CDMKU$6>>VG:-]FLFM-DG'@D,$YPJS ;D8#.V"Z3($L.21&V5EB)(
MCD3/.4[CO>PYA><K]%W&2@X@R+.N46[2)59SEFK,JQ7<G9-K;"6Z&AE&(4]Z
M]26;$>6-"NS$8NBNE.0L:1$%U+MGV'UC6H+B_P"S<7LQIL"EFF#P6MU%(JAV
MM)[.:8/WQ$*L5MFN8)596@GD+;1CRZ[9V<D=OJ3&SNG. A626)U)VB:.9$(X
M+$8!D$<BG(=!C-7) 0$ $! 0$ $! >0$!Z@("'00$.H"'?KC.G6MW6NE*:4I
MI2FE*:4II2FE*:4II2FE*^2ZQ6Z"S@Y53D0146,1NBJY7.5(ACF*@W0(HNNJ
M8"B":**9U53B4B9#',!14JHMYW//(6SJ5R"JKV-;JU=C(-;!D*N7>JL&LK+6
MO', 1[)I2,#&-V]<KL=?O6L\*\LRDSO(I[#G)$&;G?'4JQ&-[4XN]&K-K=-V
MC=Q-1I'2H1RYW,6X.515 9"'<J "CF%D_,^L89R</+<1;IHL83"<3"I6;Z4I
MI2FE*:4KJ3[8/:'DC<MM<M+O;?4FDGN3AG-33@W3"::5:P6>CL+$1].U \G(
M2$57YM)H1V[G8&,M[E5E%R))!Y7%(^??D6<]MV%[1#L_K44UQ=R6UFT<Z,P3
MBK%)+'L$@39(Z;@-CO$H8^@7RJ#&NU&PAOH.'+"LP#HQ5B1G825Z%<X)!P<@
MC((P341]E9,YIVI[=(#!F[%@W@KA3G,Q8;["+-XHMMQ5 W"Q2;RJ7:Q2$ \?
MP>0\73S<Z$;,9"K#J4/CBV-).%NS@8QI)O*=NNUYMNUNI/J6G3//>R)'!;N[
M'@:OW:-4:W@#A6M=4@ )CM) B:E!L>V'>R$O<*S5='0P\,)8ES(P4'=9M)U=
M^9,EJ[<S(-S6[DA_K&##WBIJ)K)D52.15)4A5$U$S%.FHF<H&(<ARB)3D.40
M,4Q1$IBB @(@.O,""I*L"&!((((((.""#S!!Y$'F#6]!! ((((R".8(/0@^(
M-?O45--*4TI32E-*4TI32E-*4TI32E>,WM[?Y?4+TY_BLXD[^?YS,]^X0U[1
MV &=!DZ?\3NNN/>]EY@_Z5JKW[,/P%^=J\O^0P_A_>?_ +XV;@0X#_CM[W\]
M!ZCTZ>'(=1#7K-K_ #:W_L(?\M:Q6ZGX3\]69VY;R[MMFPSN,QMCM&<@[EG*
M2P/+P64ZW<'=8FL;OL'Y ?WE-=HQ91JRTX%D%[ZI62&8ATF2)55'"<JBNHSU
MK-3T6WU2\TZXN>')#8K?H]K+")4N%OK=8#EF8",Q;=X.QR2>6P@-5:2% P'5
MMO/.,;<G\?,]*O5$]KW',I[<"++"^1\64[/65JEN =Q^W3<..(;A6<R1]&0J
MF0'3.VJ8HM<?)4+)<DFM:7]3?5;UA S2A'3&Q/5DDSDY]^QC&/3LWUM=S:?:
M3:<&U+3N^0RV3SM+;@PB[A9;BV7;$LHEV2*"&C .*N]XSORI 8AAM;!##UD'
MD>?AD<O*N$P?VKU8QX_PK;\H;<9C-.3MN&:LZ93P[>)3/$W"/$HK<397%KR%
M$9)!2D3CO(EK1F)"7D8:[.G\1YZ4D2/IN DTF:S&3N7_ &1FNEOH;74TL;34
MK&QM+RV2PCD7=IT0AMFMCQHQ;0\-41H0KX1=L;HQ#*6< #<I9E+%26Q[HY.>
M622>><XSU!K#,2]I;2L=8@Q14I[;26XY8P_@;<#MMJN4D\N2M=B$L;9V1OKI
M5ZK04:C(-5[A6Y>\NT$Y-W.N8N0KI9%D:%:S3Z,G8"_>=F+BYOKR>/5#!9WV
MH:=J<UIW1)'-S8-;87O!E5A!(ENI*! RRA6#E T;PLX54&P%D5U!SRPX;)QY
MY8_".77G44Y3WNT/*,9MXNS[ *['<U@BLX)HQLKAE&07H=IJFWX6Z56<*8G1
MJK12,M4_%QT-$624&\/X@&[!R[B8!@\D2*QV5::%<VCZG -1#:7J$NH7 M.Z
MJ+B&?423+_*S*P>*-FD:). KY90\C*I#4-(&V'9AD"+G<<$(,#EX$\L\ST]9
MJ<+#VJ49&7G(&0<,8!5H<W?=Z6)M[SI*X91/D&/0R%0QR$]M5;4;M*)3UUJS
M<Y:_.!:E;.V+VN1;#T9):0=NRO66!%V2=K>VMK[4!<);Z%=Z"##:]W8V]P;<
M0R F>8"2!+=0<@K*QR0H&#7WC!8JN-TBR$$Y](9R.@.&)]6.G/J=_5NU*Q]B
M>\8BD<&[7I*FXYHVZ2T[O+S3+/FU:Z3UTRC9J'+X\;0L'< QO!(5"CU> G)!
M**CW%:L\P^65*O*3"JJ8'-$O9.YNX+Q;_54GN9]*BT>":*QX$<%I%.EP7>'O
M,AFGED0;VXL: 8"H!RJ1.JE=J$ ,7(+9.X]!D # Y@>CG'B:H7DW<<.1=MVV
M[;V-/+$!M\G<YS06L)T7WRL#-%I@;+Z-ZE]4-/4OR=]2"R!4)66]:@Y!?S4=
MYD45.@M=-[MJ6HZAQM_LA%8Q\+A[>%W*)X\[]YW\3?G&U=N,9/6K)?**F/<D
MG/B<_P"@_P!?QFQ]K[0\;/B&SXJ'$I67RBV-;=]F/KOY;BX]$^X)E!GD<,B#
M'?)-$%QM -30_P E?3D?4PG!\%AE #T0VLB[-\*\@N^^9X.N:CK7#X&-W?[0
MVO=]W%Y<+._B[3O]SL7K5PSG:5VXR@3.>F&W9Z>=0[G'=L;,^[2N;H_D$%=&
M 7P&O\B?E*,H#P<(4R@U("_*$8*.\R%E-1QD.?4BHQ 28-^)+T/S[G-L-'[E
MH\VE=XXG%&H#C\+9M[]-/+]CXC9X7'V^[&_;GT<X%)DS(LF,8V\LYSMQGG@=
M?@Y5W4X0WY;6\E8QRA)97RPVP ZS9NPW79KRS!UVRW2.S-C>DYKI]7A(5KAN
MP1^WO)\/D2Q23*.EJX^=QLQA9VC'O'<7,$7BI-R\#A;_ +/ZM:W5HEG9MJ*V
M.D:18VDDL4#6-S/8S2NYO8FO[:2WC0LDJ@I>*7 9/34*<A94899MA,CLP&=P
M#@#T3M(/0CP/JYU0C;]VG%&QDVVXR64]O%@RADO:"B$!@S)U+S?*X<D9K&\=
M;G%UK6-<RUY"FWR'NU:K\^Y7<,0CE810K$R<8Y3>F(N^=]%J'9:YNFU-;34H
M[2UUH\34+2>Q2]6.Y:!8);FRD,T#02R1J Q829(W*4Y 6EF4;-R;C&1L8-@X
M!R PP<^/EZ_52W.]MP/:\>8MEZ3$.%,^W"T9ER7N"LB3JSI5^,^6=X4/CO&$
M1&SAD8Y\ZJ4#'.Y^5LL&Q19OQN+*)5>R3R%=^B;S3X;^&YNHYV T^"&QM=/C
M/#,C\"$]YNG*#<@F=TC6)R2I@9P L@JVY4A2/=$L6Y8P"<!3ZQC.<^/JJN-9
M'^$E?X[_ %W$AQW  >GMN@<=>@CX@'3GGGC6TD^QO^ WS&K=?UD\F3;BLXXR
M!9&<Q'5YW7Z1:YMK/R[)W)Q,&XB8%^_0F).-CTEW\A'1BK<KUZR9(+.W;9!5
M!LDHLH0@_(-K&);FWB*-())X8S&C!7D#R*I16;T59@=JL>0)!/(5OV.%8YQ@
M$Y\L#K5-]E.>+1D7U]4<DWM&S7!LTE)6OQYV3IQ,C6Z];Y2%EY"SS['%6+:L
MTMC(9JH0]@HB,.TLE=4293LQ"P;>VL(QINM<L(;;ARVT!CA)19'# )Q9(4=$
MBC:ZN93$=DS1S[VBE])$DD,3,;,+ELAFRPS@>. <')  )YC(P",Y( (JQV2,
MO#45HYC!-XE]-*V^*K*L'9EIJL.9\\@@D\71I;YS#*1<TX81JBTI(2)71H2+
M;L5T9)XV5.)F_/5?IA?+;S*B$ZL\B8J,&/)$2+,(B85F2HQT\,H#2(G3JL&/
MJZW17JE0T[%) X0;(OHQ9-P8'0D34J;P'D.0Y#J(=0$!_>B)1Z" #P(AR ]Q
M@X, B @.E*UTI32E-*4TI32E=8F8>RWP-<-S1]\V/F"]6W90SF#LM=E):0<R
M.*YJYU=BUBH^1NE,!!1<YI>O,DJO)2D"_8/(Q(Z-IBVAK7'H2"W3V?:G4(=,
M]@[AA+I+AXI$50MTD,K%F6&;(7*NQD59%8,?K3,(C@8[VZE^*I(DY$9.5R/,
M=1GH<'QS@\P;4UV4JFY2ID?NF4[CC*6.9UU"S;%%TQ1R1A')*#!HM*Q)) B+
MN.D8^2C7C!\U7,WDJ5DNCRD3*BTEZ[,-RFPHI[G19V5>#>6-[$I>&57:QU.T
MW-L,D>Y'22-PVQU:.ZLKE6,<D<J[C1+#'=H"2T4T3$QRH0LUO)@9*,1@JPP'
M5@T<J<G5ATHGMT[0;,MIW%Y7PUGO%C>KTW&R$PQ<Y KE(OC=2'DH.9;1#.3N
MK<CNVQT3"7! SB59/2.&L7$$%$HRTI'&-)E]'[1_4\T:U[.:5K6@:JUU>:DT
M+II]S?6#">*>%I7BL6*6DLT]FVV*1"KRS>E]:BDQ$>7TWM'>R:C=66HVHBAM
M@ZM/%!.#$Z,%5[@!IE1)N9!&%4D>DR9:NV6 L5?M<6VG*O.P]CA7@"9I+P,F
MREXQT =#"W?L%G#5;R1Z&\VJ;R1Z#P.O);BVN+25H+JWFMIT]W#<1/#*OX4<
MBJX_&*Z^.6*9!)#(DL;>Y>-U=#\#*2#^6N9U8JY32E-*4TI32E-*4TI7!SU9
MK]H09-K##QTPC&R;.:C22+1!V$?,1YCFCY5EY\AP;R#$ZASM':8%60.83)F*
M.E*A=EMKH;1\A)*R=N?/_E1(6R77<RS)(ED?2+VF2BK2<:1\4Q8JL"RN/JE*
M<,&L>^=2,:X=R#YXK,SAI)2K":4II2FE*:4KB9^ @[5!S%9LT1&S]=L,8^A9
MV#F&;>1B9B(DVRC.1C))@Z35;/&+YHLJV=-7":B*Z*ATU"&*80&N.1XG26)V
MCDC971T)5D=2"K*PP0RD @CF#4$ @@@$$8(/0BO,%VB&:=KFW7=A@/;-NJQC
ME#/3$L74I;'>3:_>).&N-6PS=;E/UV,QODD'[=V]S"K2K-7YE>'LT=8J];Y&
MI2+-A8)&3N+*6L-Q]G[%WW:2/1-6O>SU_9Z<)Y)1<VD]I'/"VH0P1EKVS.Y5
MLFGA>-9(I(IX!+'N6)8C&D?.:II6GWUQ U]')*81A725HV,)8L(I0 2ZJQ8@
MJR/AL;LUZ%R!E+%)2)@63S/CUN5),HE!DEE^KM2B8IC*%#U?"Y,BF:/D<>:+
M!7E%JV$ 3R#-.N=>:GV*U<DDQ:)J+98YWMHUTYP< _7)]+E<Y]T;BP+-UT^%
M:V0[Y98'IW]L, <E%["H\P-D=TBCR$=QCPN'-9S"Y:QG8&$3(QMXK?F9N35@
MHUO(2;>&E5K @!!=5M:$F#,)AG960J)E?5UZP;S;%0Y4W;!%00+K GTC5+:2
M:*6PN=T$0N)6CB::);=L[;D3PB2%[5\$QW*2-!( 2DC#G63'>6DJHR7$6)&V
M(&<(YD&,QF-]KK*,C=&RAUR 5%2'K75DTTI32E-*4TI32E-*4TI32E?-55)N
MDHLLHFB@BF=5554Y4TDDDRB=1110XE(FFF0HF.<P@4I0$PB  (Z4JN]BW#4U
MA8Y:L)0;NS^9@(!_%O(R0JCAI<!N4W"UR)BZVB^FVR\HT=2T[%M).8!(M>C?
M.^5)2")2E\I2IGIUD8V^LP]BC6KI@UDFHF]7/DVZ;V,<-E5&;V,>$:+NF8.H
MUZW<,5S,G3ID=5N<[-TY;&26.I62Z4II2FE*:4II2H@R[AZ)RHPB'B,H]IN0
MJ<X=26.LE02#56PTZ3>)I)2#?S#PAV<]4[&W;HQMTI<L56#M420B+I-O(LHB
M6B\NTO'M68;5F@E 6XMW)"2JI)4AEPT<T1)>&9"'B?F,J71J'0./(C.UNN,]
M00>14CDRGD1D>NJ-L=RR>T:.L</FR+3JT!2V#9].4. \X\:Q$>^D6T#$7S;J
M,D[24M6#[)87D;".\;.'9;C@*QR[&%DBK4-_7WZ';V^BR=LYX(K!@^KW!81W
MLV4COA$AEFAUAD1^[ZO;PK)-W\*8-7AC+L%O@YGT<UTNB1/+,#W!<9A3!>V9
MCM7NH9E#VKL500;MUNQROUGT8[N8"SYCG<IC6)RIB^0?/JS*.7K Z,JQ/&2\
M5*QRA4G\3*L3*+$1>M3'3,86SEVT7161<-'3ANJFJ;E^T&@:CV:U.;2M4CC2
MYB5) T,G%AFBD!,<T+X4LCX(&]$=65E=%8$5L=/U"VU.V2[M68QL64AUVNCK
MC<C@$@,,@^BS*0003FIGUI:SJ:4II2FE*:4II2FE*:4II2O&?V]8B&_N%X_H
MLXDZ\E#_ #F9\]X#W?Z]>S]@1G07YG_B=UX$_P#+V7E6JO?LP_ 7YVKR^9"'
MF_WGO_QQLPB/0./[LO>.>OA\>.[Q'G7K5K_-K?\ L(?\M:Q6ZGX3\]8?]//=
MP'A\!Y[ORAUX#J'3NOU%/#KX" ?1U[@#GN\>HATZ\  !I2K^U;8M9<F;?=L>
M2,5/G=ER?N(R[GS'84J3=5ZN5BOPV$:O6K=(6AS:IN1CF4<R;0$A/S-D?3+M
MI'QL7#'6(H)@."O/3:_%::CJ=M=J(K73K+3[GCJ))99'OIIH%B$,:LS,9$C2
M,("SO)C'2KPB+*A7F6+#'3 55;.<],'_  SG'3DJ%V=^1U]S&!,%Y7LM,KE9
MS+4ULQ.<A8^O5)R?%1. (.(L-LM.3$7=4FY./;MRU.HV-Y IS*K$)%XV11 @
M@<Y HG[26HTO4+^SBGEELIELA;7$$]H[ZC+)'##:D31JQ/&FB60QAPJDG-!"
MV]5; # MD$-Z(&2PP>?+P\<'X:AS>CMQ8[6\]S^,Z[9'EWQY(URCY&Q+D%XR
M1CSWS%V2:E$W"H68K9NHHW*<[:26BGHMS>9"5BI B0 4@E#-T/4VU;3X[J2(
M6]RLMQ;7=L&+=WNK69X9HB2 >3)N7(!VLN:ID38V <@@%6\P0"#^0^9KFW>P
M_<&2E5N^1;;&=LA;!=L9X[?-J-F;%EWFZ1<<Q 8<;0^1(>K6N6>TE6SF3401
M6G$VS=@]06CI=6.D"&:A0FOZ<UQ+:L;F*2*"YN 9[.Z@2>&S.+E[=Y8D$PB.
M"0F2ZD/&'3TJ&)@-W(C(')@2,Y(R,^0_%T.""!FUX[,;>509?'E?D\<P,W8,
MEY><X$A(>EY,QM='L1F%NT+)#C^ZEK5ID4:/8!@Q"QJ-K2M%D90!59*358I(
MK@ECV_:K1;A+J1;B6..TLQJ$DD]K<PJ]D6*=X@,D2FXCX@X8,0;=)A5#$C-1
M@D&.0.6V#!!PPZ@XZ$>O%<SNMV,&VL;9]NV2;1.Q\ODW+&3<^52Q?([(] R7
MBXU>Q@7'B->=U2=HAI1 )09&R6.-M"+VQ/5V\A&)LAC(E9JOZ53H^O>R^I:G
M;Q1LEK9VVFRQ<>VN+6ZXEYWLR":.?:=FV&)HBL8!5RV]@1A)%PT0GJQ<'!!'
MH[?$$CJ3_A6EG[/NUO(;;H^Q7.Q\P;*FT,FZW)\UD.QU''5'Q37TLFV;'+Y6
M1MMDEHR*2@TG[&M-&AWBYI5_,SZ3-JT7 2^:E.T4*-J/>XV3NFLG2+6.VCEN
M9[N3ND%TNR&-6<N5ED+!1M5(BQ89J.$3LVD'='O.2   S*>9Y>'^./AL?ACL
M?[1<*_NBJF5+XE2-QF''U3K&,L;U)_3\B5>^9 MF(LE9FAZ?/6ZN6%\RAWU@
MKN.EHJ*!DJLX:3$S'%=M5Q71:J:N^[90PR:5-:0=XTV]6:6YN9EGMI8+>&\M
M+)YHX98E9UCDNA(^X*#'&Y5AC-7%MR0X8X=<!0I# L59@"<^.W'(DY/3D:@Z
M5V!0M>[.I7>38<AS#')SJ5H<_%XD)!L_51,1Y&OMTQM4;3+32KPLBWEK!/8X
MNDK&M4F8LE(!G&*B)U'XJ(9R=HGE[2>PL5O&UJJ7$;W?$;?WRVMX+F:)$"[&
MCCCNH48[MPD+@@;/2I,0$6\D[N1VXY;26 ]>?1.?(8/2NLON'Z.. 'PY_P#[
M@[N\!XX$..[W=35BOUX\=0\>0'OX#QZCQW].?#@![N-*5S=9#^$E?XZ?W;BO
MR@#] >0X$.G7KSTYX#W<T2?8W_ ;YC2OZR.2_2ON<9 ]!:P#Y[\B;7Z&RM:;
M-:K/'7J)_P"CM;*C(O8R/5@'"OD(S";Z1CV9XX[DKIZT0$ZZ?R#;8[S;Y,BC
MCQ9:'=Q0.(N3%M#-Q .:;5+;L8!/*M^WN3T/(]>G3QSX>=4%[.RMX>?P]VR#
M1HMB:V(R:M9GI9K9<"61%FO+M(&;LD='GV^6NS5AH64EHR+?RKBQ>AVZ86CX
MYU)&=-F[-0O0=I);P/!;3M((0@DBC>.]C)5#(D;8O8HI"%5W""/,2[G"XR:Q
M[<(07 ]+H3E3Z\>BS#R]=7KR+-8]@FL,\R)'-'<>:6;H1[U_5G=C8P\@NHDD
M@_>.F\5)(5YN"QT$C3#\[%HDH=(%'1.\.8K)K[T"UTJVM)E_1T#%8$G'Y)%Z
M6MR4 UE)DJQV\@_;KOXV/3G#'7;&27EFAGB2QTB@9R?@NE*S[2E-*4TI32E-
M*4TI32E5RR]CFT,["TSIAIJV4RW6XE"%GZLN\1BH;-^/&3IW(&QU8WRQ1;,9
M^(</Y27Q5<'7 U"SR$BP>+EIUON;&0V-I<Q&-K&\+=TD<O'*!O>RN& 7O$:]
M6C<*B74*XXT2JR_7882+3J<\1/=@8(\'7KM/K'/:? DCH>7PPIN]VX[@[#/4
MG%F5*Q/9'J$>F_O6+U7A8[)%#.5R2.DHZX4Y[YF8AI2OS!P@;&S50.,'-^3&
M2!T7*J!%:KW1]1T^..>ZM9$MIFVP70&^VG&"RM%*N599$'$C/+>GI*" <(Y8
MY"0I]+&64@AA@X((('0\C^\5R.7=O\!>J]>W5'6/BW+-FK<O'1>4J4\EJE/)
M3B\<NVA9"S.JH^B'%NCXUV=);U=832C=,A3G:HI. 24+GZ/VAN+"XL$O@-5T
MBVN89)=*OHX;RW,"R*TT=JEVDRVDDB CB6_"8G =BN0<*]TV*XCG:#^27DL;
MJEW SPR;R#M,IA9#,H/59-X )*@-@U4#9%M4W>;;L>6>NV_.U EW\S:U9F/@
MIJ NV5(2,: U(DX783+JX8TE(EW..O*=2#-)G(L4S(HO \X^=/0#L.V_:SL?
MVEU"UN+70=1B2"T$,EQ!<V.E3R/O)59(%LM3BFC@3T8W+Q2'<R<HU0G3:)I&
MLZ9;RQR7]L2\N]8I(I[N, #!*R<:U>-I#S8!74  XW$XD+=IE7>;AW!=DMF-
ML>8ZOML8.XEN$K4 N,Q*Q<:[>%2D)M#%KJ%>'DR-$P*D?S-U?C'>EEDG,:^8
M,7GDZ_LEI78K6==MK34M1U*PM725C#>]SAAFE1,QP'54GCX18DD V4?%V&-9
M8Y)$!R-6N]<L[&66"WM9Y0R@/!QF>-&."_=71@^.0)XQ"[MQ1E5B,DVZ[E[Q
M+X1H5JW.XXNN+;U+1BKB:?$Q_9%JDY0]/=IQDPY&#3L;FD@_B",GDBQNZ=<%
MD]4= @GZ +-13&[1=F+&+6[^U[+ZG8ZK8Q2A88CJ-LMXK"-#-"O>#;)?<.;B
M)&]B;G?&%W$R!\7=.U69K*"35;:XM9V4EY.[2&!AD[')CXI@W)@LL_"PV2 %
M*U-UDW*[?*C Q-HL>:,:1==G98L'$3*UQ@U8]_+"4#J,4'+=XLF*S9,04>^4
M)2,$Q!1Z9N00-K16W9GM%>7$UK;:)J<MS!$9YH19SK)'%G =E=%.&/*/&3(0
M0@8BL^75=-AC262^M5CD<1HXF1@S_:C:3T_I$X"Y&XC-34DJDNDFN@HFLBLF
M15%9(Y5$E4E"@=-1-0@B0Z9R"!B'*(E,40,41 0'6D(*DJP*LI(92"""#@@@
M\P0>1!Y@UG @@$$$$ @@Y!!Y@@CD01T-5KR[O!V[X*OM-QIE#(C*MW&] V5A
M(TT=,2"2#1[(*Q+*0FW\:P=L8&/>2:"[)!W*N&J0J-W2IQ(U:N5TNFTCL=VC
MUVPO-3TO3GN;.QW":3B0QEW2,2O' DLB/<2)$RNR1*QPRJ,NRJ=9>:SIMC<0
MVUU<K'-/@HNUF"@L55I&4%8U+ @%B.A)P!FK,:YBMI7!3\G*135NO$UQ]9EU
M7S=LLRCWL2Q6:M50.*TB=28?,&RB+7R2@=!)8[I05"^91/P<2J52^)S'N)?2
MT&C8,?V.E+O<AS442OR%-8S24A'!*8M!A".;'4;%;8B,C(RK63(,B:XO)"*0
MG)>J)G138H(KP;Q2KVZ4II2FE*:4II2HAR3M]P/F24KTYES"V*<HS-23?HU>
M6R%CZJ7*1KJ,HF"<DC"O;#$R+B,1?D*7TM%FHBFX,1,ZI3'3(8N9;:A?V:R)
M:7MU:I+@RI;W$L*R%?<EUC=0Q'@2#RR.A-4,B/[I5;ECF >7\=/(\Q42>I\D
M;:!\]5$+/F+;\B(&<T@RSVR9APZR\H 46H#QTJO*97QU&( 54,?RBSG)=;:)
M/$J1,WEF-=QU$9>^WU/E*8K/4#TGP([2\;RN% "VMRY/.X7%M(<&9(6WW#T8
M:+IEXN7H]7C_  ?%D _H\V'/!(P!5K=%L4QUV@%JQ'N H&:F\!#-(AO%R<O6
M(9K.EL\#'S3A\BO%224C%N(.VQ+M22A79I=&15C'"+=H[CF3N$<,7?>]D/JA
M7?8C3]4T6YTGOIFF>>W6>X:%;:>2%8G26,QRK-:R!$E"Q&+=F0AV$P=.;UGL
MY%K5S;WD=UW<H@24I&&,B*Q=65@RE91N*Y?=@!>0VX-\#4G,\(DFG5\T,I\B
M8% R>6,=0\^Z6*0./-IRF.)/%!&IC<!RY<Q,L<.HF15,/(<1W[1)R3=:&]L3
MT;2-2FMT4YYDPZG%JQ<?U4FA]3 <JW7=[^, 0WZR@#&+RU21CR^Z6K6FTYQS
M,;\LC:<@BC.^3=;O'VU5['3JC86H%L7L]B>QLI9((U]R!')^@HL3L8=S6FD-
M47M;D;*J[<#&*#.V9-1*->M4C [\RJ;N>PW9/L;VFN-16]UK4;5;6W22*VN!
MI^GR_7#('F6Y:>\2ZCM@B\0=WM2#(CL"A*C1:YJVM:9';&*SMI#+(RM+$9[A
M,J%*HT1CB:)I"6V_7)<JK $,,U<^!W!QJ=;@9+)E%R7C"<?P\6\FHR6Q_;9^
M'A9)VR07?LE;;4(BP5PC=DY.J@5U(2,>H8B8'<-FRIC(DXRX[.RFYN(]+O\
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M-0H&(HF<HB4Y#E$#$.41*8H@("(" Z@@J2K A@2"""""#@@@\P0>1!Y@T!!
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M@2R=MKC@S*%/TO:'M7J':74IKS3+Z65'5$.BZC#;SQ2&)2O'M;"Z%UI\C.@
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M'"ZRPUC3]2DFBLYQ*\'NQL=,J3M#H74;TSRR.AQD#(S937,ULZ\9_;U\??\
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M7GGCO@V^6^9KVY@9H^$[VMQ<,\D3-& ,99%*AT19,L<:X[.:/<S03/:)&8,
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MD(UX<J:\>":Z"AE*GPHB(#R42]3!P(E$1 #" &_>B(<&  , "(& ! # 4W(
MI6NE*:4II2FE*:4II2FE*:4II2FE*" " @(<@/00'N$/<.E*=W=I2FE*:4K@
M):J5:>DH*9G*U 3,O5G:[^LRLM#1TC)5Q\Y1!NY>03YXV6=1#MP@ (KN(]5N
MLJB )J',0 +JXDTL:R)'+(B3 +*B.RK*H.0LBJ0' )) 8$ G(J"JD@D E>8)
M )!\P?#\5<_JW4UP%CLL;5V;=])HRZR3I\WC4"0T!.6!<7;L%/,>D(0<?(*1
M[+E,P.):2!I$,>2&?OVI#E,*E5!K.[UU9"U91.FQ#,9N:\W),'%J4-(,X*0D
M<5,8 (46\*NPL5E=M<LPLU(Q*+QFA&1[)TBX=E?J$;D4J[NE*:4II2FE*:4I
MI2FE*:4II2FE*:4K$+WCV@Y1K+^EY,I%1R)3I0S8\G5+S6X>V5N0.S<)NV9W
ML'/,W\8Z.T=(I.6QEVIS(.$DUDA(H0I@O07%Q:RK-:SS6TRY"RP2O#*H8$,%
MDC97&02#@C()!Y5#*K##*&'DP!'Y#60QD9&PL;'P\-'L8F(B636-BXJ,:(,(
MV-CF*!&S)A'L6J:35FR9MDDV[5JW230;H)D223(F0I0MNS.S.[,[NQ9W<EF9
MF)+,S$DLS$DDDDDDDG-       , #D !T '@!6^$ $.! ! >\!Z@/Y-4U--*
M4TI32E?%<5P;K&:%2.Y\RH+8C@ZB*!U_(,*)5U$TU54DC*>2"IR(J*$()C%3
M.8 **E4<M\'N;?9!L<B1.R(UMU6JXV=15)MK1&']$2EZ(YM3:F2DG-P;M.QO
M8Q&]1\0NO3*M/,UEO6)[^JW>0,+ J5;#&C>S-:'5F]Q%Z-C2BDB2)9-TU?2R
M0>6H+-O,OF*SAD^FVS 6K>9>LW+IJ[E$G;ANZ<HJ$744K.=*4TI32E-*4TI3
M2E-*4TI32E-*4TI32E-*4TI32E-*4TI7C/[>L>-_<+UX_BL8D_ZS,^?^Z.O9
M^P./8%\X_P")W77_ -WLOZR_ZUJKW[,/P%^=J\OF0NF0+SP/?<;/W> C-/>_
MKQT'P'OYY#GNUZU:_P VM_["'_+6L5NI^$_/6'#T#W\#R'TB \<![N>O3D/=
MR B 7ZBM>O?U$?I#IUXX]WT]!#H'0![E*T#CO'CGX=?=QY(<=X=W'/ =_</5
M2M>.! !Z\]P]0'N !Z>'3\_''NTI3IU'IQQTZ]P#W]  >....@!X\B(\Z4I[
MO?T 0YZ" =WPZ_'\+@>.0$%* '0/?TY 0#Q#QZ<AP ]W/=T\=*5IX\<AP !\
M.X0\0Z\<#R'7OXYZ@.E*!TX'D.>G/<'0?Z^@"''AT[N@<J4^(=>HF\. Z<CR
M/'//NYX\!\.-*4ZB/< ] #GOX#D0Y[N.1YY[N.-*4ZB/=X"' CW]1Y#NY$..
M[N ._KI2G3GCP'@0Z^ =>H=W'>/N]W7N4KFZR ?*6O\ A_=N*'CH/3T]N(?1
M^01_,.J)/L;^/H-R_$:5_6$RV_,PQI=A12:+O7]=E(2*1DJO.7.'6FIYJK#0
MR4]6JY%S,M*5Y24?-"3R*$<X2+$&>*._-M2+*D^0[1=US!DL%65'8K*D#A(V
M#N8Y9&14D"J3&2P._&,G%;]O<GUC R,C)Y#( /+/7E5..SXI9*16\M14;#1$
M/5_E^4:R+#!S#!+Y_%ILC@P=2-:BL!X!8O3)09H2/4=!!6!9&893B:4V2)/$
ML&VZ[1SF>6T9W=YN[_7<WYU!%;<,A)3?Z@1EP[8XD8*&/T-X<U9@  ;:H4;O
MM-F[EU(*)\QYYKL,USE7Z:4J,LI94KN+*^XE)59NZEU63]U UDCD4Y>Q'C4T
MEGY(QFW;OI%X2.;*@^D/5T=(NT6::BB#)TMYINJI7.T&VDO51A+22/6BQE69
M%EF*J@N$V[HG]B>),W_F&Z4JP2=$6293#5$K&6;D3D&!E&;A!4ZE<3D._GQT
MVCIZ2@'SZF)*.1N5E8+HJJ4U@4B1&<LX@RE/*3+!1VJ"4AZH2<.HUL4[\[9=
M!-0"*5(*"Q'"*+A+R_-KI)K)^<2504\A4@')YQ%8B:R)_),'E)*ID53-R10A
M3@)04J(;;D]_2;U586P0S!I3KC)C58&<2E'#VQR%O/"OI]!JVJ[*,<'5B5&D
M6_8G<%?#))/DRNCQI88KB114J8]*5#<5E20=Y>LN+7U+FD6<8V9O(FZQZ+I_
M7E2+0K"34C["X,S;)0<JY5</@A4T5Y-G(-HQV#IW&OP:,GRE3"H8Q$SF(053
ME(8Q$RB4IE#%*(E(!CB!2B<0 H"80* CR(@'(Z4J <*9M?Y0D+;7Y^FO*=9:
MBY3"09&D8^4:I).'#IH5B[.V<"_C9MBZ8ND73.3CV2,BS!G.P+B2AI%NY*I4
MJVNS!!HMHZ--#/;A.$>IU&MRLVUA#V!ZP2(X?$;K+E674;Q3(YI.4%BS>ND8
M]!91)JJIY!#*5P&+,AHY%@'CTZ#9M-0$[/U.T-8U5V^AVECK,W)04HWC)9RR
M8ED$!7C1=%*"17;)%T@UDD6SXBR!%*XS*V5F6/(:4<QZ3:P3T"2L3,Y66CIN
MI-1U-F[&$(YLZT<+ENHC%H@VDREE'BK2(9J,G#R3?-H]@]534K,:+;6]ZJD1
M:FK!W&(RR;@Q63U1FNJD9J\<,53)NXYR\CWS-95L=>/D&+I=I(,5&[UNH9%<
MFE*A?)>XJ(IT@HQK1(.T'@5) +F5>8<Q@12S0%/0H%L\)&/8\L]85(^Q,():
M5<Q]>7L5<=U-[,,9UXU;@I5C4'22[1%[^_116;)NO[9(9NHDDHD"O]L)J^29
M Z9!_LI%/),D8#%/P)1TI5=UMQ$8\O-2@Z;!O,A4^QE782-IIY'DDYK,P21C
M6Y7<I'"R3;C56K"4CY"4F"2 /$6LS7I",C)B)DU'[-2K(:4II2N#2K%;0%H*
M%?A$182+N78BE%,$Q9RK_P [Z=)M1(@ MY!YY];TIXCY#EQYY7SJA_+-RI7.
M:4J+)#,%1C<DQN+W"CGUY(Q"4J#TIF 1;7TN0=1D:P7,H^3D#O9-ZP?MV@-(
M]RV\^S<(+.4EDE4TU*E/2E1H\R6TB[TE3IJ$DX6/>M5?5%PDW$4U@IB807KR
M!X1@B=_ZU.X64LT<W8.CL2M'\@A(QZ*GI#9$'2E27I2HBM^9ZM1;_4J'949!
MD:Z-TB0\^1)-Q$EF74F2,CH1ZD@H>2:J2!Q54)+&9&@V0I$0EI&.7?1I'JE2
M[I2H3R%G*NXUN5:JEAB+"+6?8.Y-S9&,1(R,3#,6B,DHL\=A',WBZC)@>-(G
M/NR%*E7TY>">2 E8R"CEJI4V:4J-[OD5&D.(15W!2+^OO9)K'SUH;.XI"(JG
MI\M&P3%23],>H.7!E9.5;BX19HJ>A1K:1D'2A/146[M3/\?Q\U2 T=MG[5L^
M9+I.F;QNBZ:N43@HBX;.$RJH+I'*(E.FJD<JA#@(@8I@$.@Z4J-\BY3A\<*U
M1.1CY*4^55C7K2!(= [UTC()5^4GTFR;-NFJLZD'B$8*;1@4$3*)G5=J+I-V
MJAC*5G<%-QEEA(>Q0CHKZ&GXN/FHAZ1-5(KR,E&B3Y@Z*DNFDNF5PU725*19
M)-4@' JA"' 2@I6 Y#RK$T,\;'HL3V>QR<BQ8(UJ,EH)C)(A(MI1S'KO#3,B
MP;,2S*L0ZAZZ+Y9LWFK&LQAD7*2C@ZR"E9Q6K%%6ZO0MH@USN8>?C&<M&KJH
M+-E5&;Y BZ(K-G!$UVZP$.!5D%B$514 R:A0,40TI6(9,R? XSKDS./O,RSZ
M%8,I=>LLY:%8SJ\.YFF$*O*((S$@P;D9-%WQ14=NW#9D*B?HYW:2JA=*5DU/
MML%>ZS#6^LNEGD%/LROHUPX9/8UT9$QSIF3=QLDW:2,<[05340=L)!JV?,W"
M:K9VW1<)*)E4K)-*4TI6@B  (B(  =1$1X  ]XB/=I2JP94S=+(N&]2Q"U4L
M-M4DZVFZD4HM.4A6S.;CEYY%LU65D(YB[E5X-%*;09NWT8SEH4K]I$3:<\5)
M-LI5D(MP^<Q<>ZE6)8F178MG$A&@[2>ECG:B!%'3+TU$I$70-%1.B+E(H)*^
M0*B?)# (J5%.2+%8W%6?V'%UC:OUZH4DK)14##M;?(V/EG%R["!:I)KG!-&4
MAG_IPBP3-*.T'<:K&.FY3F,NI4J0SQ[(Q4>_D8IQ!O7C1%RYAW;AJZ=QBJQ
M4,R=KL55V2CIOY0)N!:.'#8%BG*@X<) 58ZE1QD>PV9Y3IC[C\A&R]WCW59=
M-FC48>63.Q=S[=-RF[0?24>S]!?,&<L@NL$DR<D;(/E(YTE(-T3%4K.ZNZL3
MRNPKFW14?"6A6.;&L$3$R1YF)8RX)@5^C$RJK1@O(Q?I)5#QSQU'QSQ=D9!1
M[','1EFB*E8!E"?M+JFVAMB"4AI'($.Q3DTXM-XP6>F:)OI)FLV:@NSEV3>3
M>.X66C&'K*/5:'D6#QBN9JJFHY:J5E&/9:T3E1BI*Y0R4%8%_3"NF*/I!$U$
M$'SE"/D/17B:3R./*QZ;:14BWA/2XQ1T9BX,95 QA4KA,AW-K!JQ-8//NJ5(
M6HP)1EU=0(R%<CE6KYB9W$N)9X7Y/Q=DF8LS]*KISIS-%WZ)E 9R:B!(I\I6
MXQ1/6ZQ4R.>W:#>PD\AY4<Y/((-F#B;/'E(V7L!8ELJL$0UE72:Z[-DL<BPM
MO-N0;MD'""15*VV5+P:HPIV3-<\5/62.FHZJV.08KFJ$/:?1$T*\E:IWT5W'
M5]*6F'K)C%KRR1VKU\;T0B3I8Q&JRE;;#=CR#:*NO)9$@&\!(C(D")31*@F=
MY#K1$4\!5T5I+S3-PX8R;J3AAEV+M".L2<8G8(Z,B6,FWCVZE;C*U^>42"*M
M'0<U)OY3RV#6591[=Y"59P\79Q+"?M)G4C&&/#M)B6B_2HZ)._L#QF+UQ&Q;
MI!@_6:J5Q6%[!?9^&DUKJS<@@FY8J5^7>_)\'DDU=QZ2\@V.K5G3F!F&<7(^
M>3BK1%I1C.>BW#0WJMNZ9NW#Q2LKR%?$L>P8SJ]<LMD;("X<2"5::,5U8J'C
MVBTA+SD@M)R,4Q28QC%NJN9LF[5EI)7S;&%CI)\J1N*E8?AN:RK+IVS[HK.#
M4B&]CF$Z-8(Q]'*R4Q"(SLTS\S.1T0LZC&*T>FT9DC5VSHSE]&+(&G&,5/H2
M3$BG^/KJ;-*5XSNWL 1W]PO!>>-K.).\??DS/GQ#W:]H[ $#09,DC_>=UX?_
M (>R]1K57OV8?@+\[5Y?,A<?=!O/0!'Y86;OZ_\ '3WD![O#ITYXZ]1ZZ]9M
M?YM;_P!A#_EK6*W4_"?GK$..> Y\ XY[NX/#GJ/B'(<=>!^%^HK3GD>..?\
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M>Y+V]O;6[CY:'/$$O+_<(M;PA%XIBLT):8K/,I9VT+9$UCN23".+;K;*"^<
M60;/63YPYC6N;V@6);F'A<''!]/NZZ<(>(&(/":P6-GCQC8;J&.=1Z.&4!C1
M"25.<YSXA@<>'(Y _P#\3CX.E6VRA*76$HEAE<>0J5AMC%LBO'1)P157<H%=
MM_6@QS1U(1#.2F$(KTU>&BGLS"LI.43:,7<O'MUU'*>@J]54L8XQL&:+"7*^
M5S$<P#J*+'H53SEI&)EIAL1HBXL,%'VEK%RM3KSA,9&'5BVL=$OIQHK+QDPO
M-5>6=A.OX_C_ !I5S[(PEI.#D&$%+(P<LX0 C*3<1WK5JW4*<AQ([CBNX]9R
MS<$*9JZ3:R,<]!NLH9C(,794722E5TPOMY/4"K2V27#2X6)*107B4Y)V2X-(
M9Q"+*QT5:(NP3\"QM@6&<K3&IMK$67D)<J;VK1 L7@HQS'S"E2SEVH6F\4B5
MKU1LA*U*/D%4O25#2;4'!#)'!--&8@GL?.P#UNY\P]83,6X6,S=-DQ=QDLR.
MXCUU*Q;#F&&%!BXZ4L3=A,WXY'+QQ,N$8J3>5I2=+ZQG:M7K(A7J])2-::V!
M_8'<2ZDV"$D+:9=H*@D@IZ,12OAGO'%[R+"1K*FV!@S39R#5U(0,D\E8-"71
M!0[9Z0+!#)OS%1=PCV6C'T'8*Y:JW+D=-Q=QB)FIE'"E9MCC&%=QO%-VK A)
M2?-',(Z<NLA'Q2-JM01J0(-'ECD(QBQ+(OP1*F#AT9(IW:Y3NW '<JJJF4J)
M\SX8OV2[57'$9>E8:I)'7;R:4>]>PU@KQ?,MY-C-0R0M9RIVM_&6N#K<M$-K
M/7FSV$/ZZ786$3.V"$8I_'\?QXU,1(BOXNJDH>FTM-)NBIZQ7A*;",4'+]XN
M+9JX?EBV7H)7BK=L1-99NT [T[!D#**:.%DV;$ZE4QHM=N^YY\WM5^7/$UF!
M?.DTXX6K&P5B5,[.YA;C3FL5*A 3,5+5N7B))$LC;ZF_:O(&R1S;U?*RE<B+
M6"E6IR//JX<QH[=4.E^GEA6;@(R)C(YV>'CO-$6?'6ED(1!Y,MV3U4JJ"TG'
MQ4J9K(O4I*832C2R,@W4JON+,5268'<9E;*+H9N(=-&Z,7!3C" L,=;H-&.,
M:K7&)EV3A%M'14]#R,7(2D:K4X2>3M4;-.(XU9K]GL-8F%*E?<-DJ>QE5&:5
M:BEV"4BLTB%;7Z(L6$K#60!:);KHO&<9.,XJ4C'[B*D6H6:):55Y&H/F*DNV
MD#M$CJ5P.)<'K*R8Y.R>Q2=6F<<C9T:E/Q4/)/Z%8I!6/>2;(EG;2<PWF6D5
M)QB(UA>,2ABI1R<<I-IS4M%P[Z)4K;9\RSD&M6.MTFDU:47>3R[I-BN*I8D]
ML?LVC:7"NUJ?=M75827E(-O:&*I9N:JTU$S3**E&))-D)&<HI6:X<P+"8R2)
M)2:["V6Y/SR3.UNJXRBYIG'+@N<6JJQ'LJLJ_44>R!WKI!\C'E,_>,X.*@X=
M7U9I2K :4II2FE*J#G7-5XK5L-BZN5F2C75J@4$JI<FSN-(^=3LC*1,6DXAF
MLHV<QK^/B7LF@TLC-D$K<XI@JZM"%6-!QZ,B]4K-\&87-C]JM9[2=.0R'8&X
MA.NR"V4;H&"7GI1-<@-FS9H%@D GEEK4_BT&,.]ESNQ@(F%A#-HQ-2LHS:RR
M<_HTDVQ6=L6?%,RIDP>1["77*U,D\0:PSF<C9:N**/EF_JV183S1NS?1;UVB
ME+P[H$7Q%*P["6#(NDM8ZTV*/0<7PR1?-/2C)L#1T2FP7C*W'2L$2RSM:6M=
M2JCP:,>TQ_G7;J$:BS0?>@N5TE5*DC*[+(,C29=EC1XT865TV=().U72+&0;
M)JLG)$W,$[>QTO$I3+5Z+1RV2FXU>)?)I+L':\:#HLHR4J(,%8." ;1MWOL6
M4M[,)'<4S!9RP5JD4[9J.4*O/1T)8'U+L<O5).9LL;$65G'HIMX%PPC8AM%1
MK!DP:*5.M^;6]Y5)=I1EV+:Q.FJS9JX>NSQQT$W"*J"KB-D?5LTW83#4%"NH
MMR_A9>.*\12(_CUFQU!*I5>,&X-D6Q&E[RTQ,M>Q=B_CV2BZD<\@%%GQ9:9C
M)UO5K*]I%K9+WE*0OU=7]6)HQ#Z=.NT81KQ%-)LI6=YSS,.+V<3&Q+'TZUV9
MXA'PB;OS+5@1P\!R@P5*I)N8AA/"I,IQT5(P,-,#9FC.73FD(U=HW,)E*CS%
M^(I&YV N7\EJ/Y$TT(V&HQ<NM<86Q0<1+2J-CAJG::Y(.VK*.2IP)LF1X!1O
M(L'$ZWD9UHE!IR\E$NU*E/..7V>):ZV7!$5)F;7)&PPK$108-EG+ANP&06>2
MCF)@G9HE5\VDG-?7L$3)R40VDW,<<Y8]T=)2H=Q]BJP93L"65<M%D3,GI7CR
MO5*3=W2 FZDJY41:R=6<0RKF-9(0J*S5_&OU4TE8V_0;:LR3B&BG7K]S:5/X
M_C^/RU.F9,K16'ZBI8'[99RH<Z;=DW3,@R;B .&J;U0963,TKS5VPCUW$HQB
MY:5BU)[U>O&1:JCPY2 I5?*;C*W9KGD,@Y:7?$@R*KH-:DJM=ZH]@Y&,CAJ\
MXPAHU"2:,S5BS23>0LJ$^E(R+>QUZ2A(]W'NGT.PLB*@^?SJR65LDQ6(Z6^M
M+Y@X?D9IF281K809I/'*:*BY&)Y=PEZFAE'"*"J,>M-NH]B]D1:123H'K]JD
MHI58ZE3KEN#FHV[7]T[0IL8X1;H0HJVZJKA(1;0QV-GI(0TT,,Z865NZB9YA
M<(J<D 9HR5HJ1G-I:H5^;@5*N^Q8M(QDTCH]NDT8L&R+-FU1+Y*3=LW3*D@B
MF7KP1-,A2EY$1X#J(CR.E*W6E*:4J$,^5K)5DIB!<86*0A9F+EFLF_CXET2,
MEK%$HIK$<1T/,J/(]!A-LE5$9J%;2CLE8GI*-;UVW%&M2LF=-2N)PIA"/Q^I
M(7.;2(ZR';4&2T^J"425E$';C('18Q:<5&1K;TA-*3<H2$@":OG#&48Q0L*Z
MA&Q+12IVE(UO,1KZ*=G>)M9!JLT74CI!_$OTTER&3.=G*1;EG)1[DH&$R+QB
MZ;NFZ@%50634*4P*5#>*<#5G%4O8Y]F^=SL[//)(2SD@V8Q\H2&E7#&3<1$J
M6!0BXB>6).MWDHWG'T.281)(K,"N1:E,"JE36[:I/6KEDOYX$';=9JL+=PX9
MK@DX3,DIYAVT50=M5O(.;S;AJNBX0/Y*J*J:A2G!2H-QQM^JN.;?8+HWD).?
MFY9S(*1\I,BD6:C6<VA$$G8V0E8T&/RK0D7<%%R0/K.TDIM-^BN[6E7;IVNX
M,I4\'(50ATS<^2<IB&\DQB&\DP"4?).02G*/ ]#%,4Q1ZE$! !TI4 TO;M4J
M;D.5R&20EIZ37,BM!JSBOI$U KJ1KV%E4G%G;F;3%PCY&(4BVJ;>[J6%XS<0
MZ$GZR<22OI**E2G>0M9JM+DI2356Q*M5$60.7R<:HD"Q#)*N8]VXCI5B26:$
M.+F+2DV*L4Y?)(MI)1NS66<HJ56C".%+ Z6;9#S @Y"Y$<D6C& KK1<A'HIR
M R[^)LK6&G9>N2\<2\)R-TK8QJZ+-OZ^<(ECHR.%"OQZE6ILAI\D)(&J[:.=
MSH)$%@VE7R\8R7-YU/SZ:DBWCY91DJ9MY[T5P,:^22=^8,NV50!0HJ54'#N$
M+;//C7#-Q)%68CI!4T,U>+)PUC"23<G865W-C4+#)5"2KMS)"5JSM6<(C$)H
M/GEG9.&"4=8YR/D%*N/,&EB1;X\"C'.)DC90T:WEG+EE&KNBARDB]=LVKYTU
M04$/(.X09.U$0'SA6R_D^;,I5,L<85O%UL,U8,X)R::,;*R+>&9+/T8NP.'9
MO-Q[^4&5I,N%?EZK<*F2 B99L6*KKI:1JK9ZI#M)!1](R*E74?"]*Q>#&%:G
MD0:.!CR/CJIL3/01/Z(5XHW(JNFU,OYL'!T$E%2(B<R9#G I14JE-5PWD7(=
M[LTQFE-\RA8Z9?>J&:<FFVDSN4W!7M=E:I9:B_8-GM>:PDY.TQ^,W6:]9GI(
M.IS[E%M889@_8/X_C_TI5VV[=%J@@U;IE2;MD4T$$B\^2FBB0J:9"\B(\$(4
MI0Y$1X#J(CI2OMI2FE*\9O;V_P ON%_YK.)/^LS/G^W_ )Z]H[  '09,C_VG
M=?\ [>RK57OV8?@+\[5Y?LA_Y0+SR/\ ZX6;\WKIYSR'/</<//3Q^GUFU_FU
MO_80_P"6M8K=3\)^>L-Y\.GT< '7@?#CW]W(\CW"''75^HK]=X<CP/CSUX#I
MUXX[PZ=0Z (^//0%*#W<_#CX\]W7IX!R CSP'7II2M.>>G <]1]P=P@//C[^
M\0'N[@'HI0.[H'41Z]_'@(AQU'N[^0X#KQ[A4IW]>0#CN#KQW]_@/4>@CQQ[
M]*5KWAR(B/00#@>@\] #KUY^(@/O$=*5^0Z<"(!QW]X].OO[N0X\>H\<<]P:
M4K7H(!QP'O#NZ"'4._J/3D!'CP'WZ4K7J'/NZB/?T[^?=SU[N!#J(CQQI2M!
M]_NY#@0 1 .GOZ#W@/=W=!-W:4K7KQQP'=WB'Y X ?ZP /H[^!4K3XCT 0'D
M.@B/'?UX^@?SCTXTI7.5CD;)7^[_  W$\^'3TYOQQTY_/T'C@.FJ)/L<GX#?
M_*:5_7(U\=5T%-*4TI32E-*4TI32E-*4TI32E-*4TI3@ [@X\?R^_2E-*4
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MC^7$>_D>>4^H=X^(@/ @(]P/;7V:_P"MZ;^<Q_IIP)ON;_%-:^RS[1C^AEN
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M5CI(F(BH8MZTL[N_F%O96TUU,5+"*"-I'VKC<Q"@X49&6. "0,Y(J&94&6(
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M215DDE2D5*"B9#@8H3-#);S2P3(8YH)'AEC.,I)&Q1T."1E64@X)&1R)H"&
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MJS,^<;&+7=(@25A=2R/:77:*>" 6LJIJ*Z[8QP1!V8XA-K)N$O%'I(NZ+<6
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M"J@MO&Y<IR7T0""-P.3S(//R\ZJ[MAV7[L<*9%V2NW]=$\+BNKY#K&7R3F8
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MM]S#MDJM%F9Z/M,O;SV03U_.",]=I>NK3PVB3;FE2Q(.&UED&[NU%VFMNZW
M$Z6U[<Z':P32KIT!BDU"RU*2=(VB2$QX>R*0QR"/A*0N_:8U*R8#N7EE5D8A
M=W]%EYG)/+GUZDG\M0]4^SYWNQ5KP)8'T(X#(4)B'812IS-Z.XJ48.\86' 6
M3;Q:\[.K!4XV04#,C:Z8\L+O'\=ZR"4(9:QO6J14866L4@VSI^TFA/#J,2/B
MUDO=?G2Q.G*RW<6H6\$5@J2L!W)H)XUN&V[?L:D^FJ*8$+Y4E<L!& V[W!7(
M.>9)Y<CCK62K['NT!<5[-32)D9BMWN8QAE*M7R^'W)V1VAN]M=DW'4?(-2D:
M_%)/U@P<G%X,K]\Q8SDUVM9>5X<AH5N.;C5XM:72M>S_ &=XEB719;:.[MI;
M:V]C8U.BPQZ=-;RJ\A7-_F^>"[9095E[N9&^N,$+A2X? PQ!RV[/%.\'ID;?
M1!7/+&:UA-A.]R(JEP98D1^]V>6FU[\[36HHF<Y&UN*4AG/"N$*M@Z/EK:U=
MOY62F82>IMFAAFF@S"V/5T$Y2O/GC)&)?/$G:'0I)(#>GV2$4/9^&63N A$Q
ML;W4IK]EB(551DN8'V'8+D K(H.Y1 AD&<#8,RD#<#C<L849R>NUN?AZLYKG
MHK9AO!AZ/A4]7KF1"66I[E)/(08WR?FVH2F(:75Y6&Q!"2:LW$TJY$L*T&S/
M7KW:Z YI5QF+55[K)S<B]J;N.O\ (L(:R^N:,]Q?"62 Q3Z6EL;JVLIEO9Y4
M>\=0CSQ&,.>)!#.LT"PS0)&O%5H 7D12 (-O-9"V"PV@<N9 .?#(P<@D\N?*
M[.\7!]<QOA?'[W%%!7)6:SOLVX[B,I5NL,Y*8?S#-SN%JLO?;2$8D+UX_"OO
M9)M=G+%JF9O'Q=8-Z&V;M(]%-+2:+?RW-[<K=W ,LO9_4]-M))2JB-AI\JP1
M!O14%U5H0S'+-+U+$5=D144%1@"59&Z\_2&3T)\OR<^6:KMB_8EN@@K-8)9:
M]SM4E,F8WW3P>0+)-9JS38HE*T3&[^E9#VW+LH7'69<;6V"1A,&HWJ':JXVN
ME'-"#-/(:;6=IR<C&R6SO>T.E2QQHMO')':WFF2VT:6-DC<!=(N+?4@6N+.X
MA<R7W=G*W,,X?AJZ!2BLM"1.N>>&9&#,6;KN!7HP/3=@CSY]2*YG(NU#<S5S
M;/0AJ/7-Q5MPKNB3SE<,I#DF[Q$RQH;&C76GI8WC93<YF;/6479'TG=$K.=J
MSR$%/;G@C@WK;*3= Y<VK76-+D&N!YY=.AU#2/8^"U%K R&X-S;7!NGCTRTL
M;4%4MC""T'&/$!,A52 :.3,9PK,DF\G)SC:5V@L2>9(/ER Q6-4+9KO:V_[D
MMS&X*N2V&LUSF2]O.2$*])C79&B3=QS;9<HSMLH$';5K'DVR,&450XI6L0AY
MYM&M80V.JS7JC"P3*8B%I22NW&MZ%J&F:7I\B7UDEIJ-L9$XBSQPV,=I%#<O
M#P[=&9[AUE<(6,G>)9)I)&1@BECE21W]%LH0,<B26R,DGPY<^F!CJ,F2\/[:
M)3"&XGL^\55XLI,K8 VQ[H;5GC)IH]\2.NETS//X?;RB\C.J-R(2%@R+E5G=
M,@DBW#E=^@QK2SMT0A4V:BV+>ZHM]IO:.[D*H-1U72XK"VW M#!8QWI55CSE
M8[>U:W@+@!2[J .?HUJI#Q#[5&+G YEMH'/X0>7E723V]@\;^X7H _Q6<2=X
M=W]\S/GC\?\ 5KMNP SH,G,C_>=UT./^7LJP;W[,/P%^=J\OF1 $;_>?_OC9
MN!Y'D!]=/>[X=_/'=U'KP&O6;7^;6_\ 80_Y:UBMU/PGYZQ >.X./CQX![Q*
M \"'CU'N'J \#J_44#W]>!'O[^.O/?SR =_/(CUZB =PJ5H/<'0!ZCX"'<'7
MJ(C[N.ON[N TI6O'QZ^/P_>\ (CR/''40\.?'N'2E?GW" =P /''Y.G <<].
M>?HZ=.-*5^N@ /0..H"/^D!\>_N[Q_JTI7Y .@_UCQTZ#P'CT'W\AW>'O4K4
M1[P$/HZ#UYZ\=WASP \=/R\:4H(@/N\!-QU^'^GD.@\@'4.=*5J "//(>\>@
M<<\\AQUZ^'_?X:4K3O$! >>G=W<=_3D.1#@!_P!?/3C2E Y^CNYX#GH(#_WA
MT'D0[PX#2E: (\]>1X#CD!$/=[_'I\.1\!\%*YRL]++7^_\ PW$ASUZ?V^WX
M#P\/#@>O'(CSJB3W#^/H-R\^1I7]6?/BTV3%%N:P54<75678>HY2NMV$5)"^
MK4R<L?:"JMYG(V*61$0KZ\B4SL;M&JLC&([30?BB+-;Y&T]4-W"7F6#8PD25
MRRA9$]*/W%O<DDN% 7@L#T.!SK>R$A#A2Q/+ QT/7JRCIXYJONQ*1GI+'5@7
MF9F1G&IY>/4K[U_<9BZIK081235NM'RLQNIW7*'8G<-'*15&]LKJ"[ANX,:%
M<KD5D5MCKZQI<QA%13L;>$@C@Q)NR0ZQZ7I8W88'!BD(4KZ8!"U1"6*DMY\O
M@Q_:2^OQ'P5P&\G=[?MLUFH,=5*3C>]1%R]+C),DWD&1K5EI\LK4<EV6OST[
M#-*W,^10)=YC\8'U^W46<)2"DF0S,IF30DAHJR%&3_'JZ>O!J1JINUKY<2X3
MOV2(&:BYK,=IA:(R9X[KESR)3HZU3N2XO%K!20O+&M-86N5MW/S<8Y8S5U7K
M/K)DJNG%-Y&2;C'G5&#DCRSUP.0Y^?EY9]56]TJ*:4H/4!#W^[OTI6PBV'JN
M/:1_ILA(^BI EZ=*. =R#G@1'SCMR":0*JCSP)@3('   %#C5<C[W9]J)N).
MR,;47U*N3@>K)J , #).!C).2?A/B:W^J*FFE*:4II2FE*:4K9IL_-OW3_TI
MZ?TILS;>AJ+B9@W]$4=J>D-6WD@"+ESZ7Y#Q4##Y]-LT*)2^8 35%LHJ;5&T
ML=P&';<%Y,WB%VY4>!9O/E&.9.3S &,\AC/,#P)SS\\"MYJFIII2M!#D!#D0
MY 0Y#H(<^(#X"'AI2MI'L_5[%HQ]*>/?1&Z3?TN07%R^<^:(!//.W E(*SA3
MCRE5/)+Y9Q$> YXU4[;W9]JIN).U!M1<G.%&3@#P&>0J , #).!C).2?A/B:
MWFJ:FFE*J;GG<5.8@L4O!-:_3$X]IA>=RBSN%YN;RNP!9."O]+IKV DFL37)
M^8*DFTN;&19GBVDE+3\FLTKL+$+OU_+TJ0,_#GICP\_X_+44[:-Y=TRU)Y0;
M91QM7J,ECJBMKBZB<?V*Q98N#-TQOV4L=VJNRM;KU1]*?2K27Q@]?5Y"G_*5
M>QQTFT%DW%P9)-=3'3U^K _$3^ZKB8JR?6<QT>.R#4$IU" E).TQ35&S0$I5
M9U-U4+7-TV6)(UR<;LYN&6"8@'X$83+)A+((^:+(Q[!YYYFBJ",5(FE*:4K@
MI6%<2<C77Z-AG8=*!D7+]S&12D62.LR3B,>QQ8RQ%?13]XI'-5G:<LV+$/(=
MX$FP9&6>+,BN6+FM7"K(I1'XBA0SABT>&#;HR& #'&TE@PVD@ '!$$9(.2,$
MG Z'((P>709R,8Y@>'*N=U14TTI32E-*4TI32E<+.Q"\RU:MV\Y-5\[66B90
MSN"4CTW3M*+D$'RT.Z&3CI1N>)F4D3QLLFDW1>GCW*X,'T>\\P\1K1PA)*(^
M59<."0-RD;AM92&7.Y3G 8#((Y5!&?$CF#D>KPZ'D?&N:U14TTI7"SL0O--F
MC="<FH S66B911S!*QZ3EZC&/D7JL,[-(QTDF,3,$1%A+$;)-GZC%98C)^Q<
M&(Y)6C["3L1\HRX<$@;E(W@ CTUSE2<@, 2#TJ",XYD8(/(XSCP/J/CC!]=<
MUJBIII2FE*:4KJ_LV^S)4#F-GCY#'V(9.JKY5;452T,LL2[E\HP^[#@7#\S&
M1L>C2?1)#(-7DLYLI2P0B3\*^U&!E8)*QK3<;--8I56.0ZYQG&/43GKTY?#X
M^JKPPN;Z5/9>L.$6#6Y(W2L5H]KDUYBB6RO59Q%DD(R,$:[:[!$QD)<C$<RS
M4KA>GNYV/8&\XWDGS-[YMJHJG'C_ !^ZI?TI32E-*4TI32E-*4TI32E-*4TI
M32E-*5\'*'I+9PV\ZNAZ0@JAY]LH*+E'SJ9D_.MU0 1273\KRTE  1(H4IN!
MXXU*G:P; ."#AAE3@YP1X@]"/$5!&01S&1C(ZCX/77Z;I>8010\XJMYE)-+S
MS@_G%U?-D*3SBRG ><54\GRE#\!Y1Q,;@.>-"<DG &23@<@,^ '@!X5-?744
MII2MFNS\^[8N_2GB/H)G!O1D%Q3://2$#(>2^1\D?2"H<^=;@)B^:7 %.O'&
MJ@V%9=JG< ,D99<'/HGP)Z'KD9%01S!R>6>7@>6.?G^FO&WV]G([^X7@.?XK
M.)/=_.9GSW@/]7Y?#7LG8( Z"^3C_>=UX9_Y>RK5WOV8?@+\[5Y>\AB'R_O7
MPN%F]_(_W:?!U[NX1#XAX:];M?YM;_V$/^6M8K=3\)^>L/'W< /0> XZ^[N#
MK[^O''0../"_44  $ $.?=\/$>!X#NZ]>X!Z>/32E!$1^GGP#H(!QX\>4'AU
MZ_#X*4$/ 1Y'C@??QR @(CW=/'H \<CUTI3GD/ 0'Z>_D./>;O\ #X]_ \ I
M3OY[QXXY#O\ I']]U]X=.OY]*4\D! /R>\>/$ Z"' ?3[^_QTI6O<'CSTZ<<
M]![@#H  /CQP \AU 0TI6G'>/'B/ AQ^<1 >.@AU\ Y'\BE..G''0!\? .1'
MG@>H].G=[^.>NE*!TZ^X/#KP =/=W]3=>[D._CD-*4'X^\ XYZ@(=.@<?'GC
MQ#KP&E*U#IT'P'I\>>>[ISSUXX#GKP'OTI7-UD.+)7P\/7<3X<]1?M^G/T]>
MOPU1)[A_P&^8^?+\M*_K'909I2.,\B1Z\3&3R+ZBVYFM!34N,!#S23F D$5(
MF6G@42&$C)$AQ9OY<%4QC6JRKP%">9\H/D&U)6YMV#M&5GA(D1.(\9$BG>D>
M#O9?=*F#N("XYUOV]RWCR/(G Z>)Y8^&J0]G>M%/JYEJ6B9Z+MC:4O1W[:=2
MRS2\KV6,82;N=G6U'N<ACZ9F:E&6&$7F'MID6\$MZL+(7M_&MGMA-#JVF<WO
M:,2++9K(CQE8-IC-G+:1,R+'&9H%G1)7CDV"-3( V(0=D881K8M\8;'3.1Z0
M9@#DX8CER.<8\^9)R3>ZQ42D6\QCVRFU6T'/#R=>.:Q5Z(FS'@)I5BXF(,QI
M)FY$T/++QD:M)Q@B+)^K'L5'2"IVC<R?-UD5 >Y""A*QA:G5^MPT57H&(S]L
M]914)!Q[2)B(QFENTPF"32/C6"+=FR;) (@F@V122('0I TJ1G/XC\QS5IM*
MBFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*Q6TT6DWEDO&W6G56
MX1SEJ#)RPM->B+ R<,@?L90&B[669NT%6H2<9&R(-U$S) _CF+SR/2&C=1-2
MMK5\;X[H[V5DJ50J73Y&=38)3C^KU:#K[V92BTU$HQ*5=1+%HO(IQR2RR; C
MM18K1-50C<$RG, J5$^U?_)1(_\ +=NB[_\ G.9>_P!@^&E2>OXE^858S2HI
MI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2HM2P;A1"2;S2&'\6HS
M#2QKW%K+)8_J:<DVMSE5!=S:6[\D05TC8W"[5JLO.)JEDU56R"BCHQT4Q*I4
M=O/Y8E<_YM-T_P"M&A:5/@?A'S-5EM*BFE*:4II2FE*:4II2FE*:4II2FE*K
M/NSW+U_:IAZ9RC,1);/(MG4=&UZGI3+6$>6&3D7S=IY";QPW?*HLX]!920DG
M+:-D%6[1 W#8YE":UNK:E'I5F]TZ\5@56.$.$:1V8# )#8"@EV(5B%!Y5VW8
M#L5>=O>T=MH5M<=QB>.:>\U%K:2YCLX(8GDW-&CQ*TDSJ(8$>:%7D<#B  U@
M>WS>"_W!8DKF3JU@#*JZLRI),WL9$O*$>):2$3(.(YT6.LUSMU"0FF(JH"8C
MQM'I'(?SK9=LFX04)JQI^KG4+2*ZBL+L[]P**8-H9&*D+)-- '7(Y,%'B" 0
M:VO:_P"IU%V0[07NAWO:W0%%L()(YYX]6%Q)#<0I,AFL=-T_5GM9MKX,3S,"
M-KK(4<&N1SK>MUJN'+\_PGAMM!9 0A#'K066YU:6LJ"WI;8'KB(JT,UL=8F9
MAO%"^6C&,C;$6JDB1MY3>5X"+>S?3ZKW.=K*S"7 C/#$LT3R@Y&2D2"2)W"[
MBJM,!N Y/[EK'972^P0[1Z1#VG[1R7.D/= 7QLM-OK>R9>&_"2XO[B2SOK:V
M>XX2SS0Z>TBPER'M_L\7ZV.3>Y:?P0P?[JHUQ'9)"PS"#(TE&1<)/OZFDFQ&
M*?V.(AD6L?'RAWIY5N1)-C'K*1K:/<NV@.5E5UYT-]2DL%;55*W7$D W*B.T
M0V[&D1 %5MV\8"KE0I(R22^JA:]BK3M5-#V"G6;1.YVSR\&>>YM(M08R]XBL
M[BY9YIK<1"W<L9956=YDCDX:JB7!UMZ\[II2O&=V]@<[^X7I_P#59Q)W<_SF
M9\]Q1U[1V .-!DZ?\3NNN/>]EYD?ZUJKW[,/P%^=J\ON0@_A_>>?"X6;NXZ_
MW:?=1Y[Q$.>_X]/$?6;7^;6_]A#_ ):UBMU/PGYZY;#E+8Y(R_BG'4H[=,(V
M_P"3*%1Y%_'^8]/8Q]LM<37WCQGZ2FLW%VU;2"BS8'*2J(KD3!9-0GE%U%W,
MUO:W,Z@,T%O-,H;.TM'&S@-@@X)4 X(..AHH!(!KL6D.R;SA;\MYFJN%)G'S
MJ@4G=AF_:GCJ6RME&G4:UW^^XF>IN8NHQT2^]7^N[E:JT]9/8U*&8IQCAZUE
MP=GAFC9$RO,KVPT^&SLIKY;A;F?2+#5KF.UM9[B*WM[Q/2F9U#!(8I596+MN
M *8#$U>-NY9@N"!(Z DA<E3R',YR1_'A49.>R]W5DN>'J+%,\7VB:S@RRX:F
MN:CERDV.N-K/@J#?S^5<?66U1DDO7(*[5!JP%M(,EY-6%.^<MTD9Q1$CQ9IE
M+VKT@P7ER[74,=BUGQA-9W$<ABOW$=I/'$R"1X9B3M8*&PK93IF. ^5'++;L
M892,J,D9!QD?#S',>5?9IV7FYR7O%;IE=>88M#&W86M&?:YDBOYBI[W$<GC6
MB6:/J-_ED\C*.6\ @XHDY($0M*#Q9LE'(-W3PCAPT(FLM![5Z4D$LT@O8F@O
M8M/EMI+.9;Q;J>(S6Z=V"F0B= #$P!#%E'(Y <"3(&!S!8$,N,+G)SG'+!SS
M\#Z@=E3^S,W)7R,)(U62PQ+O+!,99B,0UQ#+]3+9]Q"&$WTM'9 L& XE5<BE
M]K+%>%E#Q4T*L4A8T6BAX('YBF3+5/VITNW<I*MZHC2S>[D[G,8M/-\B/;QW
M\@!%O*RR)O0[C%D<3;D4$#MC&.>[;S'I;3@[?/IRQG/AFH_7V'[ATF;N3)"5
MYW#M]LE*W:(33.Q-G,9*XHR%.1-5J",2N1$3O;M,VV71JS:F%23E!G6L@Q,7
M^U15-D#M!IF0IED#G4Y](*&)PZW=M&\TVX$#;"D*&4S'ZWL*L"014&%QX<MB
MOG(QM8X'CUSRP.?J\*DN7[+O=/$VBC4PB&,9JRW'-$3MVE8ZN9*@)P^-,X34
M([L4?C?)JK'SJ%?G%8B-E7)G4:K.0)5X>5C_ %OZS9+,PQH^U>D213S;KF.*
M&Q?4U>6UE07-A&XC>YM@1ND0.R##!'.]&";6!IP),XP,[@A 93ACT!P<"LQ9
M=D'NWE&]<7AY/;[-GN,==$Z8R@]PF-9=_<KUCE"5=7[$%4;,)AP:PY.J#6$D
MW$]%Q9G5<CTFY?/6?RUT$UK#=L]'0R!UU%."T!F9].ND6*"Y*K!>2LR 1VLQ
M<"-WP['(X8VMBKN\AQ[GF#@!E))7.5&#S/3D/,5!$3L.S],X6'-S9O1THQ3%
M%CSW'4!Y=HEMEB:P;49AQ!6/+D71SCZ0I38I^PD3'4=/&DT^CXR0EXJ%?1"
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MPAE*P3Q7,A(-&$2WEY9PQK[ [WS"ZR\F]BVRM_LUH.AZEJ!M[_6HFC$#R)'
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MN2*(6]N4")<73O,K<(3)MA265F] (_*XKROD/<WCVIY#H3$F',>V^,!^C.6
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M=.!@DF"CP<?7^SUQ<6M_)8N\US>1Z#;")1$AC32[YI6G1Y7V,Q29WV.,#A@
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MV;=XPQ29C"%HRNOE)C*6&6DXVT-*DQKE7B)5K$NE(<[J!G26NS@LNHN-?.I
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M7]Q.QF<MB^),PBG"UN#S"\J+E::EL-S<*VF&K7+*[:8MSZ%K\[*TT64@*\9
M,;DHY:&3FF*NK[=FXK?L_?:K<:#VE@L8[VS1[BX[G',AC%Y#(RA[198X%ED2
M*=FBV-,T*APT;+5"ZI;R7L5I'>V<ERT;LL<;.Z,"$< LK%"Y0%D4-N"@G!#
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M-UN%WVA7:\(G,_CI&[T',DR6DKO$!(M'TV)B\DQ53KAFJ*JL8K-P4&UGYAF
M%FYJ6 2GUTMK;=G D,U[%K=Q?!$:21KG3S%#,4'%%I'W,)#&&+*C!3,T>!++
M(1NKRK5=>NF-[INAK:Z7H#RR1);VL<T-QJ-I',QMY=9NGEEO+Z5U$<SV\]PU
MA;S[C96ELOHULMP5;[2R7Q@]8PUGVO/WYK?BQP1MCZAYOC+09LPRI2W\@J@[
M6RHLF6';1[9TYM2'FQ.\JJ,TS3,FHN10F[L).S"72,\6K*HCN 3<7%@T63;R
MJ P%J"6)($9\)"IY@8KEI!<E#@Q9Y8V!PV=PZ$G ]?JS4T^K>T8_'+93^C3.
MG[6=8>[LU]QUS\YL/V2J_P"4^<'Y)/TU&^9(#M)9+$.58Z,M6TUW)/\ &]Y9
M1[2FX^SBQM[I\ZK$H@T;U5\KE95-G9%G"B:<&Z434(WE#-5CD.4@E')LY.S*
MW=JS1:PJK<P%FFN+!H0HE4DRJ+4;HP.;@$97(R*I<7)1QF'FK>Y$@;.#C:2>
M1\CX'G69P,3VCB4'#)+7#9HFJE%1R:I'^-\YJ/B*$9HE.1ZH&6 !1V4P"#@X
M  &6 Y@  '5J5^S1ED(AUK!D<C;<V 7!8XVCNG)?(>6*D"Y  S!R ZB0GIXD
M'F:^%GB.T=7K5A00M^S=1=:#EDD4XS'&<D9)151@X(F2.5-E@Q4GQSB4K10Q
M3 1P*9A 0#C2)^S0EB)AUK D0G?<V!3 8$[P+3)7[8#F1FC"Y*L,P]#T$F>G
MAZ0Y^7/K6)8:@.TFC<08ICI2U;36DDPQM1F4BTN6/LX/[>U?-:Q%H.V]K?)9
M523>V1%PFHG.NTTDR.)0KI8A"%.!0NWDG9EKNZ9(M8*M<SE3#<6*PE3*Q!B4
MVA*Q$8,:DDA< DU"BY"KSA]R/="3=T'7TNOG4D^K>T8_'+93^C3.G[6=8V[L
MU]QUS\YL/V2JOY3YP?DD_34D;38O*,-@NMQ^9Q V2D[-E1>QG33ED6BI7V6K
MP^A5HM&<D)660A%Z^YBEH)N]D'2C>&.Q1*J*:9 #%U9[5[^5K+/=3';"($H6
M&+6%7#%%1"XD#!RJJ-V>55Q!@BA_=#=GXQ_PQT]56.UK:N4TI7C/[>P1#?W"
M\ (_Q6<2<\<?SF9\XYZ#\>/RZ]G[ C.@O[G_ (G==21_R]ETQ6JO?LP_ 7YV
MKR^9#Y^Z!>>O_KC9O</7UT]XZ<]_N'GIP("  &O6K7^;6_\ 80_Y:UBMU/PG
MYZF[:]FG$F$+8O:\G80L.6Y.-DZS8*%,TW.5LP3;:+8:T\>/1786*N0-H2?1
M<Z#ILE,-E8=M-MABV"]>LD&J9^5_@ZM8WE_"(;6^CLU998[A)K&*_AGBE4+A
MHI)(BKI@[&#E,.W$CD&T"I&53EE+=,88J0<]<@'/GC',@#(ZUV%0O;.9)>)Y
MC3OM,R P#*&X&R;B8ISMLW(7?;%*5ZQ6BMP55D*=8)&!K=T4O-$]65:ONDFK
MHD)8T)EM(RB-D(K++$1YQNQ-LALC;S6S]UTZ+3775-+MM526**6259HUE>$6
M]QOEERZ\1-A5#$0HJ]WECNR"-S%AL=DP2,'IG(P.0/Y1XU-8[]+;$RFP^Q1E
M(CSV+8U/V2RQDG/6.1G$LH25CSE)9L7-8$A8,G\,GZ1)'KKM1&6F7SU,%9GT
MYJZ6*U2V[=GX737XFG81Z]&D3K'$L9M52P2Q'#])E? 3B*"J*N=FTCF:.,?K
M9 YQ\QSZD,S>7CNY\AT_)9QAVK=,I5SPQ-8DVCQN/ZGAW-.XK-;:J.,X62VR
M%JGMQF*EL;S[68L\Q2$_0PKRS@TC$+Q<(V:+0K*'KSF)"3;2=OFM6>R,TT-X
MEYK#W,UY9:98F464<*Q1Z9=BZC*1).<\3&UP[LP=GD#E2L25<< \DP-SMUR<
MN #D\LXQRP!RP.9YU!F+>T.D<91&V.)2Q.RF0VVX!W18+;KJ71=@-P0W+JY"
M5<6==,M7=A J4PU\$$8@AY<D^$4'E2</Z=RSS[GLVEP^IMWQD]DM1TJ_(X(;
MA'2^ZXB!X@WB;NW-_0X>_P!R^WTJ1-C;Z/N4=>O7>&!/3UCSZ5#^TO=<CMM-
ME^IV_%L-F_"FX&A(8\S#BN7LDO2G$Y&Q<VULU8G:U=81M(/JM;*I/LR2$)+'
MB)IDGYYX1>+464:NV>9K&D>R?<IH;N2QOM.N#<V=VD:3!&>-HI8Y87*B6&6-
MBKH'C8X&'',&F.39N! 97 # ^60<CU\JEO$6[W:WAW-#++M<V33+ U'L%'M>
M(XJ W89'@Y:NSU+.9Z=7(%F5I\LGD-C9)D&LE,,8:OXZ\RBV+$1RK:+<.D%<
M2\T;5KRQ:SEUQ'$\<\5X\ND6TB2I-@ 6\0F3NYC7*HTCW0R=[*[ 8J62-6W<
M,\B"N&QC'F<'/K VD_; \ZCW'6]*7K&^%_O:NF,JC>IR>R/D?)%AQ^U4&M0!
M93)#.S-G:U5D'4?9U*[,55U91G*7/O8RQ.HFP1$3,/6\J[05.MD7.AI+H*Z%
M!=S6Z1VUM;1W)^N2;;9HB.*H:(2)*(MDT:M&'C=T!0$8@2_73(R@Y+$KX>D#
MTZX(SR//'6K)Y<[5.8RH>WD<8IGU0L^R.=V6$FKWFR6R3=CQ,KFA+++7)EHM
MTG1XIS:K,W;H(UR1B@8PL>^7\N8CW$%'E;5EIK;/LFEHL %W&.#KR:[LM[%+
M:#>MB+-K6*%)W$,)(,BMND900C<1LRM49MQ)()^M&+).XG+%LDD<SSQ^+/+H
M-F;M-*]:("X8\RYMGCLC8GNFWS:CAR5IC7+<W3I5*V;18GU;2,BM+A$U%P\;
M,+)Z3+IVJDIQ@+'C)%-C&W%FZ:>LG,MV6D26.ZL]4:VO(M2UB^68VD<R&+67
M+SVIA>8#,>$X4^[DR[GA93L 3#&W9D;(TZG(X8P#XYSX].1(SXBNN7-[=ZR!
MO>7WSU"N16-\@(Y Q[DB K3=\YL\#"SN/H6JQ;-FHX=-HIU*0TDI6"*O&*Z:
M*OJ]^O&*.U_(%\OLK/0K>WT(:#-*]S;FWN+:24J(Y'2X>5V;"E@KKQ?189&Y
M0P Z"@R'B<4  Y!QX @>'J\AS]=29D#?K36V4VVX3:[MG@=L.X21M]LN5RR$
M%^<9KK<FYO\ 5+;5K[6ZGBG(],-0ZK3[:G=9J0D(B8CKL_8J@QCX"8B(UH=L
MYQ;;L_,;4Z=JVIR:MIR110P6Q@[C(HMY8I;>2:[M9UN)IH3#'L='@4D%G1R>
M532^EOC41L222#GJ/2 4@K@\^1!_%4<[P=\=[WD0>WN(NE3IE94P/BW[GXNZ
MG5Z'72VV8=6&4F9*S@RI=%I:%9B7+1S%1[#'[$SZJP#J.DYN$29R%HG!<96C
MZ%;Z-)J4D$L\HU"[[SMFFN9C"@BCC6+=<7$YE8,KLUPV)I%9(Y&9(8@M+R%P
M@./17')57)R3GT0!@9P!T',@#)S3^M<_*.O!W?W<BAY'@.Y\W'J =WOX'\_N
MW,GV-_P&^8U;K^K3GFEXUO6)KO%9;A'D[1&-?F)Z<:Q:\RTG$&<-%O7;MU /
M:Z[83[67!@5XW;C$/$';M-PM'"*K=XNW5^1K":Y@NX&M'$<[2)&A;:4)D8*%
MD#@H8R2-V\%0!GD0"-\ZJRL&&5QSQG/+GRQSSY8J)=HV0L0WNKV(N)8ZZ12$
M3(-D[+&W'(2V3',5,E=3,(,2G8T\BY-AR.6Q:ZHZ68PEA.P4CG\--MP<LIID
M]<9>KV][!+'WQXI"ZDQO% +?<A6.3<8^!;M@\0 %TW;E=3@J15N$H00@*XQN
M!.<'F,9R>F/#EY9JW.M15ZJW;J_\EM>_YP^T'_YM,):5(Y?D/^((JR.E132E
M-*4TI32E-*4TI429JL$M$4D\+6'A65VR!*,,>TI?GE9G-V85DG<Z@EWK_(VM
MMY^\ND0X%2/K+P Y'@!W&AV\,U\)[I"]CIT4FHWR^#P6NTI;L3T[[<M;V"MX
M272$\LD85_*\=N4B.)[EUM8#XK)-D&0?V,0DG/\ 5B/4\JH9VE^^IIV6VV/'
M=RIF(29%"1N-:PY3ZZO.K5JLUUHTJLU+(N9F6;QDN[,5*&JB[&-CV[4BKUVI
MY]1VBBS6*MM>SVC2=KM8O.]WIA=UGO[F;:'FFDEF7?L5B%&9)=SN<A1A0I+
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M1GQ1]RGQ%3)##,4,L44IC;?&9(U<H_VR;@=K?UEP?77/F*4Q1*8 ,4P"4Q3
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MHI(I(V!3E(F74*7B.0ZJ3T8J64$BU.N4K;TTI32E-*57+:M_DGD?^6_='_\
M,YE__;_1I4GK^)?F%6-TJ*:4II2FE*@K+FY/#&$UD86\7VMM[]*QH/Z=BAG.
M0Z^5<AKN'Q(B*BJ'1%'Z,]9)";FU486.]#:BS%\H<7;QJU:O7+;/M--O;T%X
M+>4VZ-MFNS&XM;< ;G>>?:8XUC3TVR<[<8!)4&V\B)R+#=CDH]T?( =>=;3"
MN-K%$NY_+652L7.:\DH,23Z+%R21B,;TZ/47<U?#E.D1;MCNX"J&>O'T]/&0
M07O%ZD[%:U&T9$NZ]6JVO;F-Q':6NX65L6X98;7N9FP)+R9>>))0 L<>2((5
M2(%F$DDA%(R[\W;KXA0.B+ZAXGQ;)\JL (@ "(CP =1$>X ]XZP*N57 0'<)
M*_A8$@9 P"'[TR6;9^-7XX$!*8JV)(%\D(@8IO(R3.-2B C08W^'O2__ -.Q
M?_W!<1#'GH=O*N?/*ZQ<1G&",Z; YZ7\O\@U?_$G_P#RZ-OQ7TB'\8-G&P\\
M7,B_<%^O6(;M6S0ADVK=!L0ZJBQR-TDT2'66,)U5C%3*4#*JG$3**" G.81,
M81'KKG&=W(+LSD *"S%B%4850220 .0'0#D*V:JJ@A5"@DDA0 "3S)./$GJ>
MIK[ZIJ::4J!MPNVO$>Z&EM:)E^ <34/'3#>?B7$?)O(>6B)9NBNU]*82#%0A
MR@NR=.6;INN1PU716$QT//HMED-_V=[2ZOV6O7O]'N%AFEA:WF22))H9HF97
MV21N"/1=5=&4JZLN VUG5M?J.EV>JPK!>1EU1PZ,K%'1NA*L/!AE6!!!!SC(
M!$G46CU;&E.K5 I$0C U*H0[*!K\0W4<+)L8Q@B5%ND+AVJN[=+"!14<.W:Z
M[MVX.JY=+K+JJ*&U=_?76IWMSJ%],T]W>3//<3,%4O+(<L=J!41?!4151% 5
M5"@ 95O!%:PQ6\"".&%%CC0$G:JC YDDDGJ6))8DDDDDUE>L2KU-*4TI32E-
M*56EY_+$KG_-ING_ %HT+2I\#\(^9JY+(F &%@LJ^4,9V-YA[-1FS5LO?:\P
M1D(>ZLXU)5.,K^8:,LX91&3JRT!4Z+07KF)NM<:+/$Z'>*:X?.W2V=!?,D8M
MKB,7=GDD02,5>$M[I[68 O;R'J0 T,A"F>&4* *"N3D'!\_ X\",X(_Q'@17
MF>MFZ;'%,[8J!I5DVSWE;/U8MT42_NL;79Y;,<6FX)X_4E75FH.-%,:1=_*@
M]IKEA:F*KFV+M&5G:+1LC&2<%Z9=%_<;*\U*?ZG<FF2:I:KH]S;M;VL\UJRW
MUK#+=+P8;NX2YF@:%;C^33LMLLD=G(TRNKPB&N5ET6W.LKJ5O&6N8Y..\#SQ
M0P2&*-C*T9EX02;A@RPH92)KA4B56:88].D/N%Q_8(F,GH*-RI+PLTP:2L1*
MQV#\R.X^2C7[=-TQ?LG2-%.BY:.VRJ:[==(QDU4CE.0PE$!U\\SS]UGFMKBV
MOX9[>62&:)]/O5>*6)BDD;CN_)D=2I'@0:]*B[.WDT<<T5]V=>*5%DC=>U?9
MK#HX#*PSJP.""#S /F :IKN<[32I[=;U0Z2AA[(MO4MC(DI(NY>,L&,W<>P6
ME%8ENG PEQJ2,C:I$Z[=<QT4RQ4<03-$"2RSE9=%IH-3[2PZ?/;P"SN9C, S
M%TDMBJEBHV)-"&E.0<@;%'(!R20OJ78?ZB6H=L=*U75&[1:-IPT^4P0QV\]G
MK<<LJP+<.;NZTW4&AL(0C+M9C/,<2.UND:HTEQ2XPGL@J%?YOD8^7C!.*K3$
M=<5=CC9F4#E40"VN'J#*3RG(MQ ?*-8&412Q,#9PVQ^VEF",RKM^ZR7'I7S*
MZYR+.//=E\N,6"O=L/\ [Q4@/(BV#J'/G!URTTE3%V8AFMY\!9.T%XL8UJ0[
M2K^QZ1/)!H4+@\A:2W&I8WH^KO!*ULLZ)ID2(1)(A$TTR%3333*!")D( %(0
MA"@!2D*4 *4I0 "@     :S^G2N7)+$LQ)8DDDDDDDY))/,DGF2>9-?K2HII
M2FE*:4II2FE*:4II2FE*:4II2O&=V]@"._N%X#G^*QB/OX_G,SY[_P#;NU[/
MV!V^P+[O^IW6.OO>R\JU5[]F'X"_.U>7W(8<Y O/'>%PLO=T'_#;T??QW>\.
M!'KSQKUJU_FUO_80_P"6M8K=3\)^>L.\.>O@/?QX=_7GGW#X]W3WWZBM>!Y'
MZ>.O<("'C]/ !TYZ\].!TI4FX3HK+*69\18RDGKJ,CLC92Q]0I"28E14?1S*
MY6V'KCM\S(N4Z"CIFWDE'#<BY3H'63(54HDY+K%OIVM;.[N44,UO;3SJK9VL
MT4;.%;&#@E<''/'2JE&Y@/,XJP]DV86^2W4[H=OF*Y&,>UK;3>,T,;1D;(]A
M@J56ZWC;$V0GM%&[WF>?*-8N/,]<C!M191J+AV_F9=NQB(UR8X)DUL>MP)I.
MDZC=JZR:K;V#16UM')/))<WMJMQP((U#.P4<0[FP B%F8548R7D5>B;B<G'H
MJ<9R?Q?"3CK6XM/9Y[HZF*Q'=.AI90F9,38/9%K%OKUE+,VS.]4;W7#DO"+1
M#URWDZ-D6ON4%ZY;T%ABE7AQBW1FDFBJS2B'M)I,V-LTB V5Y?'C0RQ;(M/F
M,%ZCAU4K/;2 B2$C<!Z0RO.JC!)Y ^DJC!!/I#*GD3R(\<US(]FYN>*RLJX,
M,='E(23S5'5VHAD^G$N654MNSV589FF<0UI20)(7R#I#B"G"N9",33+,&AI1
M*N)S+A@Z13M^V?2MT0+W 1UL6EE-K-PK0ZB$-DEY(%*V[S"1/1<_6]Z\38&!
MH8)!X GGC!',+G)'F.7(CD>?.I1R9V=<FX+BZ6PW+PT/33[(-KVYC-MZS1D*
MKU*H4^V9^%]%(QK::=LXDC.)F;*@C'5J/60DEV12.5IB;!J0SHF):=IHQWI;
MY6:;V;U33;&"RMY9I9HK##;BBE]SK'EG8%0Q(")GE4M"?Z.<!4+%B!@MR]6!
MGSJA.,\43.4+BZIL=9L<5)6.8RDG*V;(^1*I0Z5&QT2LDW=.5;//2+>/?JJN
M'""$='PHRLK*G6 \9'NTB*J)=#=7D=I L[QW,H9D18[:WEGF9I.GUJ-2R@ $
MLS[54#TB#@&TJEB0,9'F0/GQ5L8[LS]S[^Y93J*Z.*8%OAMAB2P7J]V?,5!K
M^,6=/SE'.Y7%]VCKY*2[>!F*O:FC=+T%W&N'+X[Q_&QH1HRCH&9=0W:C2EAM
M)@;N0WS7D=O!%97$ERTU@ZI=0M;HAE26(L2RLH&U7;.T9-8A?+# &W:2=PQA
M@""#G!R"/'KRZUF&).RZW%6C,,]0LCQ%3Q]7\8[@J+@/)CZTY5Q]2UY>Z6=X
MSD5J+BR2L,F:-NMX?T<75I@6$4F_([8*1ZH).'#YHP=V;SM7ID5E'<6TDMQ)
M=:=/J%JL5I<S!88@5$]TL:;H(%F*QR-(4P0PR "1(@?<01@!@K'(ZGG@9/,_
M!GU9P:J'NCQM7\,;F-P^(*HO*.JOBG..5\;UIQ..6SN9<0%(O<]6H=:6=,VD
M>T<R:L?&-COW+6/9-UW)E3HM&R1@2)N=*N9+W3-.O)@@EN["SN91&"J"2>WC
ME<(&9B$#.0H+,0, L3SJVX"NRCHK$#/7 )'.H(ZB ]WAR/3CW!UZ_ 1#@!#K
MW<@&L^J:U'KR///AX!W\<]>X.G(<\?E'II2N;K7^,E>YY_PY$AX#U!^W[A_,
M \!X=XCJB3W#_@-\QI7]8O*QBDQ=DDY[))4XA:#<3'MT,U?/IBJE+79$362*
M91ATY)Y)08 ,FQ:QYR/G#IJDDT.5P=,0^0K3^=6V(UF/>(?K+D!)?KB_6W+>
MB%D]RQ;D 3GE6^;W+<\>B>8ZCEU_%5#-BF.\YPT]-V^^3\LA03P4[%UVL2+J
M5:DE/E'.UZU5J9"O%M%F@U7=7CBV.&6OLBX^Z%=F\^U2M:IF]>BDT^@U^YL7
MCCA@C7O(D1I91M8KPTEBECXABBD"R,8F$"@V\)C8Q!3(^;,"N.9;EC '/Q((
M.,D9Z\\ D$ DXY3QN8QGEV]2,2]QC:;Q"-&V*\PUJ685"\Q5-5=SMC6H#JK/
M&1YB)F(_Y4IMX*R1<!-/F*C&%"7?$6=0XR19EER]9'PC/^/^&1G]U1;DZDY$
MA-M6WAA9;-(UZ4J.9]HC:Z5=-TVN7RF4<;J,)HQS.QV^T*V:Q'EX8/-.I.0@
MK(9L_FQ>IH/WT&5B72I'4X\FQGX#787I44TI32E-*4TI32E-*55>[9"JL-D.
MU9'NDB1M0-O<(TK;;T=F[E9&3S!DQ.)45BH2&9(N9"8M;6J25/K%0CH5NZE)
MN2RK-5YJW6>F(@/2Q6\L6CV]I"I[YK\YN7R0BII&G/)'$TCL0$AN+];J:?B8
M1!IEO-NVFM;N$M^\C$&'3X^$N 23>7"J\F!]M%;&)5(]\RJ<8K\T7$#_ "1+
M.<P;C*M$2-IFHQ>*I&)9Q&,LU:PK17R[9X>#70,>3K\[E"R*-&#W)5P8^DL4
MUV<;2ZH[<UNNC.6C7SW:VRBSTV9UB1@T]W&7BEO9U!&\$;7CM8PS+;0G!(+3
M2CB2;(LQ4+>G* 2?<H<,$7RZ8+'^DWP <ADVG33323(DD0B221"IIIIE*1--
M,A0*0A"% "D(0H 4I2@!2E     -:HDDDDY)YDGJ3YFKU?O2E-*4TI32E51Q
M[LJV]XOSI<-Q-0J3EEDJYJ3*[YTXEWKN'BWMD<>E65_ 1"QA0C'D^X,J=\J!
ME@13<NVL:1@S=N6ZO6:CVV[0ZIH5GV<O+M'TVR$*HJPHDTJ6R[;:.XF'I2I;
MJ $&%W%4:0R.BL-1;Z)I]K?S:C#$PN9BY)+ED1I3F1HT/N2Y)SS( )"A5.*M
M=KDZV]-*57+=A3LD7W!MIK.*9*QQUM>25/='"GST=6+9*UJ+N$%)W&NUNPR[
MZ*C(B9L=5:2\*P?/IB&;(KOBBI+QP#Z6DH/X_@YJK^TO#FYBG7;.)LJ*7"HE
MGZC'PT!<398<Y6I[^U_="RS+H6#&5/NUSN[^KQ%9HL_0*X5&W5V D)T\$CZZ
M:SBS5>275)P>GY/'\?+'/KRJR&S]H]882*QDI5Q.R#/+^Y=J^FG;9BS=2[QO
MN4RVDYDW#2,;M(YJN^6(=RJW8-6S-$ZIDVR"2)2$*H>OXE^859W2HII2FE*:
M4KHHR]V9-#W;=J2&[=7)]NKL3MI<X&1L]:BD$'@6W,--;KY!:5>,FU'C5>EP
M=?ILAB.9L:;>/GC612Y2C-BO77J#MXKW=GVGGTCLL=([I#*^IB^,4KDKP;.5
MA 970*>/)),MVD1+QB(0H2) 0HPVA$MP7#$"/9N'4ENN <X4!=N>1R2>0ZGO
M7UPE9E=/E$WBY%W1;O\ )VT"8QVO3\44Z<NL?9IR#-+&M<M T1^ZB315JF0>
M-V$!7;_)HMT7:D.T]8J1CD:PV>*A*.9QG[%?=CM-[+=C],[8PZB+S5KN"QEM
M8)Q"+2&XOT242VD&QI+BYT^)F:,3/PQ(G>F0<)8'XR#6;G5=8N=': PV<4DZ
MRO%O,S1VY9=DLF=L<=PP"OL4,5;A*WI%Z[?&K5JQ:MF3)L@S9,T$6K1HU13;
MMFK5NF5%NV;H)%(D@@@D0B2**9"IIIE*0A2E* !X^[O([.[,[NS.[NQ9W=B2
MS,Q)+,Q)+,22222<UV2JJJ%50JJ %50 J@<@ !@  <@!R%??5-332E-*4TI3
M2E-*4TI32E1_DECE.0KZ2&(+10*E:0DVRB\ID>BV'(4 I#E1<@\9I059R'C*
M12DEES,U&TB>Q+-6R*+E)6+='<)+-5.7C\^/]#77CES"&YY]G*!GZTIE"TTE
M3<4WN+-]&YM)58BD4Y>:V32LBO-U=.Z5<+'24(#&^Y.J1M%"&MBR2UK4<K0B
MPV5>:4?Q\'\?CJ>6,<NG4C/,9Z=<>'/EC%649P\Y'[VS/Y.VR$]&S&W2T+P<
M&[BX)DUJ3=ODBAHNF,>]C(]I)RB3]<0=K+3KN1<(*%!)JJB@)DS*?T3\(_\
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M.0>&*5D:2*.1HFW1LZ*[1MR])"P)1N0YK@\ASY5T5KJ6HV45U!97][:07T7
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M^J/8Z[8:;:]G].N=&GMT>.YN<6T,R6SQA&TZTGMF,W<W8!IO2MQ*(XU>$J6
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MXJ>I_*4T/0\=S-QM2-1Q=E5"!%5Q96,'(.92FUAV_;O4"8UE:JWM#]IZ+8+
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M7DQ@ :6944L[*BCJS$*H\.9) '.KL,$]S(L-O#+<3/G;%#&\LC;06.U(PS'
M!)P#@ D\A6]*8IRE.0Q3D.4#$.40,4Q3!R4Q3 (@8I@$! 0$0$!Y >-5=>E6
MR""0000<$'D01U!'@17ZTJ*:4II2G(!WCQI2J?.]\^ (_(A\5R+S(C"\(7*.
MH[Z(>8BR8@6*E)BQT:IPLE+OCU<&,55IJ>R51641:W[A" D LL:Y;/U&JWG@
M5./@_**RMY_+$KG_ #:KH'YLHT'_ +^[P_+I3P/PCYFJRVE132E-*53?.'9^
M;/-R.6:=G'-F#ZY?,H46.;Q-?LLA)69C_<YBY>/HQK,Q$/-QT'921#Y^\>PY
MK%&RBD4Z7,JP.@8I/)W-CVAUC3;2:QLKZ2"UG8O)$JQ-Z1 #%&=&>/>% <1L
MH8#F#DYM/#$[!F4%@,9R1D>L @'\?A61?<\SCB,PKX@NPY8I:2BJJF)<YV&4
M=62.:^1^\9X_SQZ+-6DA&_[]8D5EZ(R6YEW1TF"5^I<4F"B-OO%A><KR#N<Y
M  O+&-1$Q\6N;#*1Y/B]F]L$ SW:9CSC;(GN#O7[1SS \E?KRQ_3W$Y.6%=5
MO:07SL^<@*XF>;QLC9-VAY/CI-Y"(5V:QQ)O[7+Q,H=@>3(Z?U6OWNH6>M0K
MAHCZ)D&I6BQU&$<OW3)V]<.WGH*/I/8+6>U?9Y-1BT*RLM>L;E$E):Z*PP31
M;PCQAYK>6&217/%MIHHY952-EV!-S<_K>C6.KM!)<22VLT)92R1J6D1\$J^0
M0<%?0<,0N6!!R .W/#%S0BHVJ8HL1XI&7CJG&!CZQ0JZR]/RQ18B*8HQUIIC
MYR[D% ?)18LU['574I)2L*94D@@_G*\\C[ \X+6;3O#W6LV9DDMY[J1[^"4+
MWK2KVXE=GMKQ45%,3R;Q:WB1QPW '#:."X22W3:64IA$5A. LL42K!(,\.[A
MB4*)(MQ8AU4*9869G0G<"\9#FPNN>K95\7#ANT;KNW:Z+5JU15<.7+A4B+=N
MW1(919==90Q4TD44RF4554,4B9"F.<P% 1"I59V5$5G=F"JJ@LS,QPJJHR2Q
M)   )).!SJ"0H+,0% )))   &223R  YDGD!76_NIV^O>T1HL35(2S+8UQE5
M["E:ZOD)[".9YQD2=38/(@CN%J@S%?(6@(Q<I)#'6F0?$?V.04;OZZQ)5DDI
M>S^D]E>T$?U.KZ:ZGM1J>JW5N;2ZTY)D@738"Z3%)[O@W!.H-+%'Q+2).';1
MADN)#=$PVW-:K8/VC@2*.0VUI%)Q8[AD9S<N 4W1Q;X_K 5FVRN<R,0T:\/#
MO8#;%$)X9IM:VPSKAP:QXMK16M;F'9U!;9'HK1YYAK<8,53*%;*LEWC>*M%4
M!RY=4V0.Q0\ZZK\M69B6Y_M1,=:O+GM1;JO=M5N=US"@&_3;]DW-93X WB14
M::UN]JK>QB1B$N(KJ&+8:4G<H8]*E),MK&1'(<XNH W*>/.<;2P26+<S0MM&
M61XW:TVN4K;4TI76=O\ MQJ6/\&YGM+"N,[W2,118)6BH.))-@CFS)KM5JG7
ML#1QR"J]E(-B9TA9\OLXMF]<2M>:?(-JWD@?W5E$=QV:TXP7-A*\K6^IZD2V
MG2!26TJR ?BZVX("I<2%&M](+,ICE+Z@2ABLGFT]W(+MI( %:S@8"[)/*YFR
M"MDOG&N1)=\B&7;!S#3!,+[&G=1*;MMH[F_2.WVD[>D8#)=FI\;!XQ@G%;QS
M;6K6.@9E6VU6)=%.X;D,\FG,#+F%]+)K3$(\6+)"H=:/C[/;JRELM;V3ZM=Z
MQ-+:Q2/<7\YN+N+TI(UAEE).0JH'1<)M1P-N,,V58)#'!L@@AMXPQ(2!!'&2
M0,L% QD]">><=:[9=<;6=32E>,_MZ^?O^X7@ '^*QB3OXZ?WS,^=WYNOY->S
M]@?^ OZ17_>=UY\_Y/9>5:J]^S#\!?G:O+YD/_'^\\CW7&S_ /\ VGHAR/'3
MCISX=W.O6K7^;6_]A#_EK6*W4_"?GKL>PCV:=SGL(9DSOFP6U4JT)LHR'NBQ
M%!0.3,<DR',+Q3Z$2QQ9;AC1=2;NK;%%T:?*I1K+I1$/Z>M',0)/10O&*<IS
M5]VH@COK.PL,S2OK,.F7DDEK<]V0&*5[B.&Y'#A-U"PAW+O<*&;T'PQ2^L!(
M);EZ&Y0"-WNE R.9P<GIXX\.O'8-[-"\V/=9M[VX9[LU;QRMFAR]]?1%-O%!
MNF5<=M1Q-(Y9@RVVA,9QR_K3N?@$XE=D,R@FS!"051,L22:+LB3?]J;>+2=1
MU+3XI;GN( 1IX+BWM;AA="TDX5PT8601R;PP3TLKR&TAC @;<JL0N['0AB >
M?,9\N=9OC[L_,#;@R[<LB[=\T90>X;RONTH>TG*,1E*@5BLY:Q;;+TP/886Q
M1Q*Q<+53;;7)NNM)4S%PF]C7,7+L2-'[1T5T<6MBX[1ZAIWLE;ZE8VJWMIH]
MQK%H]K<2RVEW#;MPY(G,L,,T,L<C)N7:X9'W*1@BI$*MM*N2"XC;*X()\0 2
M"/QC.#TKC=Q?9L1F"*YNXO#+)$G<*#B"H;:,G[?;BUB&;:*S+C/</?GU,3E)
M@HKG6A)>H.HV5AI6/0 BY;'#/BN6K5FLU ;FF=IFU"728&M5@N+N;4[748"Y
M9[*ZTZ%9=B'&)$F5DD1^AB=2"3FDD(0,VXE1M*'&-P;Q]6#X=?/%8WNJ[/:*
MV[[6L2YNB<A2=HR&I,42I[F<;/(EJT#"URR_B:+S;BZ%2<MU3N78/*2]<LIU
M=Z446UD:&CVZGG/+0)7I':1]2U:\L'MDAM@EQ-I=RKEC>PV=XUC=.00%4K.H
M:,*?2B8-S',Q)"$C5PQ)RH<8 VEEW#UG(]7+!S6+]G5LII.\2ZWM#+.4)##F
M,::TQ[6PO$;%,Y95YEO-.2*]C/$--,VD%FS8K6=EI.8E)1X1456,17WKDP)(
M JY0O=I==GT6"W-I:K>W4QN9> SL@6SL;:2ZO)\J&)**B1H,8:25!G/(Q#$)
M"VYBJC:,@ ^DS!0.9'GD^H5B&+>SHW0Y<D,BQ];K]*A0Q/F)+ E_D,@9,HV.
M8V!RD[=2L='5@RUTG(55\^EIF)6@XI&,0>.GTLZ9M$&XBJ<Z-Z[[3:39K;-)
M)/)WRR.H6ZVUK/<M): (S2X@1PH57#L6( 4$D],P(78M@ !6VG<0O/G@<R*G
M3'791Y8LF,XS)%MNN-:G,,-VLOM?NV&I_*N(:+=V$C4#G1M:,59[K?&E<'(2
M\HSD8>KX^=1JLA,,S15W9+OZI)M5E\"Z[7645RUM%#=3(VD)JD%Y%9W<\#)-
MSB9DAA:3@!2KRS#T4(>%MLJ,!4(&(R=O)]F"RC..OB/6.OXO&I,E.R>EK[CB
MR/\ !!)9EE6#WU;@=K3>C9LS#A2K+NXC&4!5GU,J<:J5Q#1%QS/,R\C.L7R5
M)GY>O2A8X7$9'L(] 9%;&7M?';7$2Z@5:TDT'3=6[Q8V=[+A[N2=9YG&':&R
MC1(F4S1)*NXAF9B$%1@+ E,Y$CIAF4>Y"X'7FQ)/CT'@.9IWC?LZ=UF5*>RM
MU9IE;:*V!WD-E0:1:<BT2I9.RD[Q*+LF3&V,<=V.>C[3<U*4M'2#:8"*CSE%
M_'OHU@9[(,W#9/<77:;2+28PRSR$1BW:>>*VN)K:U%WCNIN;B.-HH>.&4IN;
M.UE=@J,&-L0R$ X'/. 2 3MZX!.3BILVT=FA=<CXRO.:LPBWJ>/$]I&?=Q>,
MHN$R7CEAD^?^YI6YA:EVV3QK)*3-S4Q-.6V&=PCR:0@F)WHIHE:R\8B_82#G
M"U/M1!;WEO8669KDZQI^FW3R6MRUK'WJ5!/"ERNR$7B0N'5&D8+DY1RK**EA
M)4NW(<-G4!ADX'(D')VD^0Y\^8Q6!W#8'>)"QP[?&L*ZI--C=MVWC-F1;ON%
MRIA^JU.ON<[0S$U>>)6]E)QT!'0=XL3WT+'U4DU%[XFU2<_*)L0S&0=-[\7:
M&WBCD-W()ISJFIV%O!I]I=RRO['RN)%X11G9X(UW7$RX@+$<,X908X+-@J,#
M8C$LP RXR/'^D?<CKY@8.(PLFQ#<71:IE:XY%@J=C:,P]?;9BVQ-KYDNA5N6
MG<B4>LH7.STZ@1SZP M>YEC5'C*<9)UH7S>PMI"/0K3F8?O&[-7*B[0:9/-9
MP6TDUR][;PW<1@MIY4CMIY##%-<,J8@1I04/$P8RK&0(JEA!A< LP"@$CTB
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MH%XR/-V5I6']HBWA8)Q66\!Z'79>6-+/99)6$<OT&S@Y>F[-]F+KM&;[@2K
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M+,S$EF8G)))YDDG))YYZUK$C2%$AB18XXE6..-%"HB( J(B@ *JJ JJ
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M%V-=GK#89.0G9YTG89)$[%K,SK]1)!%J@T.Y;LVS9,BF"?#KG])_]*L):*G
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MFO6;7^;6_P#80_Y:UBMU/PGYZP[CO#Q[Q'H ^X._D>>OP\!YZ\C?J*#W]P\
M/4>O@'/4>GP[^[P'@>BE. _KX#O*'/(\>'/3\H@/>/'<I6@#X]>OATX#IT[Q
M#CKU#KU  #O#HI7Z >1Z?0'7CX]>O(\"/7@1 >H\>]2M.[@ YZAST[N>@]W3
MN[^!Z!SS\-*5J(<@(<]W ] ]_(]W'Q]_Q$?>I6@ /<'7KW_3SU^(@/ \AUX\
M>-*4Z\AS^82].>.._P 0 1X#KW\> \Z4K0>.._GJ(=.HCSQWC[^/ ._\^E*U
MY ?R]>>[@>@=_(AP(ASU]WB/&E*U 0\>1 !'W@/(CW"'</?_ .'?I2@!SSR
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M_M:/_0!\J'_RZG<#]V']T?I*U_<K,/\ TXI/NX_DZM?S_P"6[O\ CI_M:/\
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MAJ.#<^^Q_<#Z2GWF/:A?/(3?U#-MWZUT]F^RWWFK\OW_ -#3@W/OH?W(]?\
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M(S?U#-MP?]JCI[-]EOO,7Y?O_H:<&Y\+H?W(/_U!3[S'M0_'MD9OZAFVX/\
MM4=/9OLM]YB_+]_]#0PW/A=#\<(/_P!05I]YCVH?SR,U]0S;=^M=/9OLM]YB
M_+]_]#4\&Y]]?]D?KT^\Q[4/Q[9&:^H9MN#_ +5'3V;[+?>8OR_?_0TX-SX7
M7_9!_P#J"GWF/:A^/;(S7U#-MP?]JCI[-]EOO,7Y?O\ Z&G!N?"Z_P"R#_\
M4%/O,>U#^>1FOJ&;;OUKI[-]EOO,7Y?O_H:<&Y]]?]D?KT^\Q[4/YY&:^H9M
MN_6OT_[!U>S?9;[S%^7[_P"AIP;GWU_V1])\'\'EK]YCVH?SR,W]0S;=^M=/
M9OLM]YB_+]_]#4<&Y]]#^Y'TE:?>8]J'X=LC-?4,VW?K4-/9OLM]YB_+]_\
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MTI7Q<.&[1!5RZ71;-D2"HLX<*D102('>=550Q4TR!XF,8 #Q'4JK,0J@LQY
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M:VX2)K)K0QYSCG&R,AWF0DELF0L2=U>)M<7G>C.TLPN^+N+[FXHEW>'B"&Y
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M@(L]574*!C !@Y'F'FED5$DED=(AB-'=F6,'&0BDD(.0Y* .0\J  9P ,]<
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M+[!A-YW9;8.2YSM'3%-J\O1'+IR'+X/*N0<4BEO)"6EG=0J[J4GVK-C.R3B
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:7::4II2FE*:4II2FE*:4II2FE*:4II2O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g96328g04a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g04a11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5!5:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/C T/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @
M/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @
M(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@3F%M
M93H@(" @(" @(" @(" @(" P-"YA:28C>$$[57-E<FYA;64Z(" @(" @(" @
M(" @("!R<C(Y,S<T."8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,3@M
M36%R8V@M,C R,2 Q-SHU,#HU,28C>$$[15-4(%1I;64Z(" @(" @(" @(" @
M(" Q."U-87)C:"TR,#(Q(# X.C(P.C4Q)B-X03M38W)I<'0@5F5R<VEO;CH@
M(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N
M,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!
M.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E
M;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S
M+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT
M(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!4<F%D94=O=&AI8RU"
M;VQD)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT
M(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @
M(" @(" @($--64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'
M26UG/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @
M(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,2TP,RTQ.%0Q-SHU,#HU,BLP
M-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$
M871E/C(P,C$M,#,M,3A4,3<Z-3 Z-3(K,#4Z,S \+WAM<#I-;V1I9GE$871E
M/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,2TP,RTQ.%0Q-SHU,#HU
M,BLP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O
M<E1O;VP^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R
M96%T;W)4;V]L/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @
M(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M=VED=&@^,C4V/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \
M>&UP1TEM9SIH96EG:'0^,C4V/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @
M(" @(" @(" @/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T
M/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K
M6DI29T%"06=%0DQ!17-!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML
M3D$K,$%!04%!04)!0DQ!04%!045!)B-X03M!445S04%!04%104(O*S1!1&M&
M:V(R2FQ!1U1!04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='
M0F=G3$1!;TM#=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%4
M17AW8D=X<V-(>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(
M>#AF)B-X03M(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G0D%!14%!=T52)B-X03M!
M04E205%-4D%F+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%1
M04A#06M+0W=%04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G
M8TE#46],14%!0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%
M1T4R16EC645537!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I2
M5&MQ2WE9,U!#3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P
M5G1.5DM"<GDT+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7
M-799,U(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E
M66U:)B-X03MQ8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"
M455%0E%914-!341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO
M8DAW1DU(4C133D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X
M9%5K=V=*0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-
M5%4U4%)L9%E75G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F
M2#$K9C-/16A984AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K
M<4]K<&%A;G%+;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'$W1EA9
M<3=&6%EQ-T9867$W)B-X03M&6%EQ-T954&4V:EE72V,W=3130F4S3F=#9FM/
M<"MJ2G=X>6QY1G176$Y$1TQK44=.,R\U:C901%9B4TM3-EED1R]U,% P=%9V
M*T9Z)B-X03M-:#)F33@Y;E8U=3(X569P0FPY;C0K4U$S9C5J-C-+4TQE3TLS
M6'-10S=F97AP*T=:8T]Z-$1N6F1B:S=B>6XV44DO86Q.>#5Q.'A4)B-X03LQ
M-3,X;W(O=G,K;B]!35$T-69(4S1X+T-(0VXR:FYL>FUF=2LU05-8,3=+87E8
M16IN+TMD:BMS-6%)4DA)3U!,3DTX>69M;UI*<F1I)B-X03MQ=DAF6'-2<DAC
M4TEF.&PR2#9J:U1#2C5H<VIM;4]24'I2.78U<3AX454T6#AP<"]V=RMP+W=!
M5#5:5DQ3-'HO04%H>4ED;S4T.'!N)B-X03LW+W9483 O3697-&E"8U)X6$,Y
M>5%58C<Q3E!W>6EF6CA$>7-/8FHW8GEJ-F=*9EEN,6@K62MJ>E57-VEK=%=0
M5G8W>$(Y2S!B+VAC)B-X03MX2CEN>DA,9#)72'1V1DPV9UDO8BM0:WE3>3%'
M=W9K-3)L=VLV.2M$06MF3612.4]98SAC;SAX5'1-5V%'45A%9V]J24YR<U9D
M:7)S)B-X03M69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U93
M=E=0375K-E-P*W-Y,6TO6G0T+VEK4#!D=G!Y+T1P-35/43)C5%4V)B-X03LW
M1FA(<4\O9#%94G$S-6AA=&1%<%I!5V-0:5!I:TDO,6IS4&](,#5S.%=G:$@V
M='DX+W%E,G-K.6]E:V9A>&5A86%A47E44TY*23,R)B-X03MN8VQM4'I*>DY!
M03)$<4I436I:3FQ::%EU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5F9$3DY$24I)
M6D=J:U@W3&]3<D0U15E#061I>6I-)B-X03MX3F<P5U5A5"M95W)7<$-8;T8U
M1#1N-%I!4#A!5T=X*VMF5&U&;#!%2F94<UAB-F)T<DI$869Q2#)S,S!F>DQP
M3W)+4'$P=$IV,G)E)B-X03M4-%I".4AF-DTQ;6)4>G@X>',Y0G!T9&EZ1#!N
M9G4V<'!L1&QU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%93=3=U
M,G1))B-X03M'=4QM4EEO54979&I16DM-1$DP3V)$2FMJ06-5:E%90G(O-6<S
M3G=79S!O1T-(;V)G+S-J9C9O+UHO6#AS,G5$44%B>C-,>F5S-UIL)B-X03M,
M,#0Y:#,Y9C)-4&0S9&DW<U=D:E9M2G%39F-N3FE"5&]Y4U1:5S1O9&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&EQ-4AD)B-X03M'1&]X5C%.5EE'
M:$(Y:4U33%-#46)$34Y!+TU'-71Y<T=Q9WIW.4)C1"LX6"]72#=8-B]N;75Z
M-D%(94=X9#5O*S):4CE/5&-D+U@Y)B-X03MR4#=3-W1R=4)B:3)K5U=&>%98
M53%'87%51$4P96(P;5!*1UDT;VUW<35&;3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867%L;74K64Q$)B-X03M2<F(Q8F<X<%=R-DU#;C1N4#A"-&Y,.$=#5U$P
M2$4Q97-H9VIC=6914$QT83$W54Y8=5!6=6XO9&<O=6]&,E)"-T1X.3@S94A"
M2$=+)B-X03M$>4=Q,6LX.')L>3=K='DU>%A9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867%M5VDV+W%':UA(<3)R,6I*)B-X03LO
M97=..6AX-VIX.3AP>EE)-4)28W)3-GEE0U9X-61Z,4A1=DU&:').=#9T=3-'
M5F%E=$%X*TI$+T%"2'9M:WHT2EEZ4F5V,&US:&YJ)B-X03MC96952FYL1&QU
M>%8R2W5X5C)+=7A6,DMU>%8R2W!.-6PX>3(R:3)W2DAQ,V-O4&]15G O<VTX
M1D@T-6LV9E1(269*=V1D<F\T23DX)B-X03MJ>41Y<2]V-W$O=6YU<G%1>513
M2&-N<U!!1'-";3EH05)&1&LX9&UZ4WE337!'>6@X:S%/>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+)B-X03MU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5D571B]D
M5T8P;#%A>4=/84TW161X-$5D=V-J3T%K2U!*='<U<%DU0U544F5Q*U=V371T
M<E9S)B-X03M304ER=4E$,31++SA-=FEP+T1.1G%.3V-:.&YS9$1R;S4T.3!H
M>D-C-6I/8S=&6%EQ-T9867$W1EA9<6QN;4188F)2<D$S179X4W16)B-X03M9
M26$W=3,Y0C-/6#1-0GE3;T]*<DY82$)$:5!0;TAK;"]F,U8O9%-85C U:VUK
M3E-E=SA!4$%$3B]#06E+2$HT=DYM;&MK6E-/-5$K)B-X03M386Y9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M:4Q#+W5R0S9J=7)6>DA.1V%G.6HT)B-X03MG*TE/4FY!4T9(:S(T8S!S8VA+
M2C-$,79Y+W)T=').9TQI3#1:5F]S.$YD,&(K:#=(3D)N=TA(2VDY<&\Y6$A0
M1&E(4'%%>GEH>3-9)B-X03MQ-T9867$W1E9+-W4T3%,R:W5B:&=K35-L;EDK
M07E526U2;V,R1U1)25)-<&-G.&<Q-U=R:E8Y464V;'%)+W-W4F1K461"."](
M3V=W)B-X03M94FIJ465),6UQ;&YN>$AL,%,S3&Y&9&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S)B-X03M6
M9&EQ6F%$<E9X<$=O2F125DUF,EHT=7IO96\K9FAL3V9#36MA3&QA4%93=U0T
M:'DV=E@W4S=G=3=A3S5T,D1W>7%'4F@T2$]F;D5X)B-X03M.2&TY=FIY0V-2
M2U!)<7526G5X5C)+=7A6-3,K64]V+T%&:35';%<W9G5B8S%U0U R<% U9CEJ
M*W8U6G0Y0F=O8UHU;#5J=&Y78U5V)B-X03M$:GE(4#,O<UEB;7AD13=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<7IV>6HU2G1,:7@K=6%R15I06&]9
M26542E)0-6IX2VXT)B-X03MU,W1M<C%7<TEL=W=02C9,<S=S<4UO8U=56&9)
M2CDO9V)Y="]Y>&8X;%IV*V$X>&9Z=5AV*W=/>"]K;E0O=T$S-U0K=#,K0G9+
M,R],)B-X03M&+WE6;2\U<G@O3S5E+S=!=CAK-F8K8CEP+U=X=GIZ-60P9E1.
M4'0U8D<S.4=2-65$3GID<7)X2G X5$XT6FUA3%54;DEI4C9/<3=7)B-X03LP
M5TQ&:D)G2TXY-5E6;7ED0S=&6%EQ-T9867$W1EA9<3=&6%EQ>DPX=G1F3G9C
M;E-P,B]C>FUT=50K>DHS6"]:9G(K96$W6#1,2$=/)B-X03M99#<R3G)/1UAH
M>35(;#<O04YR,%1.43E/-T9867%L9FU85T8P;E-:8FUV-S0O=3=D9D=2=6XS
M9&-V,"M(>$IG9$A%,3)P1TA%6F1E)B-X03MN=F50=3=/-T\U3$]X2EIJ,4I/
M-4]D0T)4=S5*2G-R8U5/>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6:W9K
M=GDR9%5V4').=W8K)B-X03MG5S5"9792,S9H4#1N*S--4%=A:F=J42MO=3$W
M3#!0:E0T<&922#=4,U!544%"46)!9$)M:F5V9&ER<U999CA!;5HO>'ER6"]!
M27HO)B-X03M!4$=J6G-/>G9R4'5D2C(W+V12+W)F;TQZ;DYW.',W1EA9<3=&
M6%EQ-T9867$W1EA9<752,E(Q9$-69%-#<D1Q0TYW8U-,4T-18D0R)B-X03M$
M>3%R0S9T<$U6>E@Y.% S9'=V:$EV6#<K=6,Y<4U0:'I)-E!C84A5:DYI175V
M6#-P<&Q$;'5X5C5N*UE/<F97=%=&:VAR1%II:#DU)B-X03M',V(W=&AM-C!'
M3&AH>&13.&XR>G%E4$IW1&Q(-S)+-6Y/;F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7%/,&93<FY63"M/>F=')B-X03LW;7)V,E)",5DO3$LX,E51:EIC
M:E,V85=A66E(<T=N869B869:4E=L<W9'2TE52&E4,UDK-4]C.6MY1V-R3#(K
M2$1(2$%2:GE#27E$)B-X03MA-T9867%W+SAZ4"M/5F$O.%HO*TY'>EED;F97
M9F,V5'0S*S9J+U<O45AN3V)H-5HR2W5X5C)+=7A6,DMU>%8R2W5X5C)+<W(O
M3#-6)B-X03MJ839S8DIZ*S5V0E%E06M89&9V1E(Y,EE/=GAC54],<4AC.6DV
M;F=Y8T(U4RLY-EAM;&5R42MO,W%73FAC6&(O04=915HV94I!,D@P)B-X03MN
M8DHT-&-59T\Y<7I:4FIG6DAO2&EK,'-K,'IZ4TAL2DEX9#(X5UDQ2GIP04M&
M0C1+8VI):VYM5FU&:3=&6%EQ-T9867$W1EA9<3=&)B-X03M867$W1EA9<752
M2&0Q4D9,3WA#<6\S2DHR04%X2G!)0DIO4%=02V9L,4Y(<T(V9T)V6G='=4<V
M,#A%2'-0,35O9%9Q4$5L=#E)97HW)B-X03M/,%%W43,K<S@O,4HU;4LW0D)A
M;'$Q=%E.87AY1W-T,TUK14U9-FMU=U5T.&Q"<FQU4$5:6%A15S0K9E52>#A)
M4$]204-.>7!Y2%EQ)B-X03MW+SA!37HO:FQ7=B]!0FXO04].1WI99&YF5V9C
M-E1T,RLV:B]!1G8P1C5Z;31E5V1I<G-69&ER<U9D:7)S5F1I<G-69&EQ*T=7
M4T=:)B-X03M*;WIX:VI93VIE1$MA9S1#3$9&;$-2:5%2>D0R=E1R,4PV=W0W
M=%!S>F]R,#A#4G50;T\R8S-K:'=Y23=N=F-/55I)0U$V:&IF-6HS)B-X03LO
M;S921F%+84YD4V9%4$9)+VE0+T%!>%A->G,K1GIV=618,C-M-&-1:B]/4#-F
M9U!.8S-,>6IS5F1I<G-69&ER<U9D:7)S5F1I<G-6)B-X03MD:7)S5EHU-4$X
M=&1.6'4P+W=#64Y$*TUN+TY0,RM'879886HK069&-E!S9E$O-5=8*V(K=CE4
M3W,Q8C!+;&0S549P8E-83G=W4T=*)B-X03M3>G-F05I+351),$]B1$IK14EM
M575195AN5W Y6#@S5TXQ2E99>&11<D)&+TEG:T9"."](3C,T27@T4U!)+V,X
M:6158RMP:DDX=4E6)B-X03LW<F5Q-6]N<UA9<7<O=T1->B]J;%=V.$%X;B\T
M,&).:#)D.5HY>G!/,V8W<5 Y8CE"96,U=4AL;EEQ-T9867$W1EA9<3=&6%EQ
M-T98)B-X03M9<3=&6'!8-6-8+W)A4$QA36%T87EF0U!"2E!I2"]$0G,P,V%%
M2VYF93E8,DIM-'-2:B].4#,O9W!$*UDY,EID8FIT=V9H=#1G0U X)B-X03MP
M>5=0-%5Z3#=0:%5,-WDV,W1V2F554B]M:C<R2C5N3VUD:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-65#=Y:C5D9E=,.$=515=-0D14)B-X03MT,#5E0T0U.2]B
M35A686IW-#=F55A9.6TV3'@U-R]13V8V;G$V26E)<4E!<4M!1E5B04%B041.
M0U1B,E%&8D)V1DQZ8GHS-6LK=3-0)B-X03LV3W17<F%7-V9V5T(R95%F=U@Y
M96)N4F%F:$A%95IE5C=8,3-I4SA/4#!J;C5N.6E1-D(O>#-D3R]W0UEQ2"]K
M-'5:5V8K-VPW:38S)B-X03M2+S,P4#8P9G9E>C5Z:C-J<U999BM:;B]!0GER
M6"]J4"]W06%.;7<W3RMS*S4P;F)V.3%(*W0K9W9/8S-$>7IS5F1I<G-69&ER
M<U9D)B-X03MI<G-69&ER<U9D:7),4'DT=7I&<F-L=50X3GA%44(O;$E1=R]#
M=5E0845,:&9C6&,Y:5I+>6U0.#1F8VQ0;7$T.69Z1F9V5W1*5$@O)B-X03M!
M36DO9R\T,7DO4WAR2$@S3T8R:E!I>GI0;CDR>54U931B<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5E)7;39F8S9H97A7;'5V2U=5,$AG)B-X03M",UDK=T=1>5I"
M0TYL='=96EI::4UE6F5W85)P5G1P9&A(6C(T*T9"5C,W<S4V<V9N;E!:8W!N
M2WDY>'!T4$A&05)I:DUR8C),*V50)B-X03M-;C9/=%!Q5G,Y3#(T6#1I3W-C
M6C)**UHV1$TW4F%F:E!%9G!$<4\Q9&0T565#4#%Y*W=036,S5'E34#!$+VIU
M-F0O>D91+SAN1GER)B-X03M0+V1Y.7AC:E(O,S!0-C!F=F5Z-7IJ,VIS5EEF
M*UIN+T%">7)8+VI0+W=!84YM=S=/*W,K-3!N8G8Y,4@K="MG=D]C,T1Y>G-6
M9&ER)B-X03MS5F1I<G-69&ER<U9D:7)S5F1I<6)E5F)J,%!-5F<Y859L168O
M27HT4"M.<V\Q56)X>3EZ;61N5#1C.$0U+V9S9TPV47DS='A)97)Y)B-X03M/
M,S-S5&QS0E512$AZ4W5:4&U61$I.8G-69&ER<U9D:7)S5F1I<G-69&ER64)*
M;TYY96=X5C9L-4TX=&I3<DPQ-VAF.5!U041*6'%I)B-X03MD46XY9C=-,&5S
M,4AI4V]F4TAS3WI.1#1-3&PY8W9S.&U2-6AU,%%'=#9X8C94<#AL,TYU4CA-
M569D,U!28W1W-&IK;%%C9E9A;4]')B-X03M":UAJ.3EE,T8W9'DS5GDS3V%6
M=51(*T$Y:#!'9$1#06E+2$HT9DQL;&MK6E,U;%%Y5%=J.4$O-#=U;F8X>%50
M+TIX8W%Z+S-C=F-8)B-X03M),&8Y.40K=$@W,W,K8S0Y-#=&5T@O;5HO=T%C
M<3$O-'HO.$%':EIS3WIV<E!U9$HR-R]D4B]R9F],>FY.=SAS-T9867$W1EA9
M<3=&)B-X03M867$W1EA9<3=&6%EQ<C)-:&EV8F519%5K4G9U64A)>D9X26)-
M37%M1#5H47E45S=&6%EQ-T9867$W1EA9<3=&6%EQ-T9786519DQ8)B-X03MR
M>6I6<G!0,TU:+S!61"LP-"]B*U,Y=F8U6G)T9'%+2$%/9E8S,UDK:#1J-'-U
M435F<F5H6G%(<&QS:VMC56)34TU%:E%&;EDW04%B)B-X03MK;D-"97E#44):
M951E879-36US-F=856M78TY6=&M0:#-C:GAB3CEP8TAH>#AZ>F5,-U$Q<'IZ
M,BMK8W8Q<$IM4S1$<U92*V=F.&0S)B-X03M4=CA!;4MH+S5/3&Q79CA!=35E
M-'52;R\W-D@Y85 S=EHX-7@W>#)+<U X07I-+S0U5G(O04U:+RM.1WI99&YF
M5V9C-E1T,RLV:B]7)B-X03LO45AN3V)H-5HR2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=F,T65EO26MH:55*
M1D=O)B-X03M614A106)!6GI"2DIS=F]566E);V-G=G=-:VXX>394<4]Q,EES
M-U<T4S-I8S%N3$%K<T(P6&)T-#5K86),1T5R271W=&1P-35O8TU4)B-X03MW
M:G%X6"]L5U8Y+WDR>&8X0S):+SAP4C=N5&9Y1% X06Y",R]!0W)+*R\U8EEV
M.$%G5W@O;$M08W8X9WHO;D(S+TMS<C<O;'1I+S1&)B-X03MS9C53:C-,+T%#
M1% K8T52<#,U95AL<'%&<F1.9'AS='9.2$M60W15:$=$52]$25I.9D=54TLU
M:'1W9&EY:$]-=4EB14@U339Z5G91)B-X03MU>%9*4$Y79U1A,5IW=U)3<D-9
M-5!53$U#45)X27!T.#AY9$QN1TUK:T]",FAO>FYG26<Q4EEX+WER2RLO=T-7
M,DPO9U=Z3R]L2U!C)B-X03LV:BM16B]Z9VA.5SAH,V5N861.979D4GE,0T%3
M:7%W2G%13R]Z>65,6$-C:$=U8E1Q3W@U66]'6FM$5$9S>FY4=7A6,DMU>%8R
M2W5X)B-X03M6,DMU>%8R2W5X5EAV;WI&93-%6C9P238O8WA'4F=B:4,R6F\Q
M36IZ2VAK;70R2W5X5C)+=7A6,DMU>%8R2W5X5C=T;DQV;VIS5F1I)B-X03MR
M<U9D:7)S5F1I<G-69&ER<U9D:7%496-V*U5:=G8X0558+VEA-6LV5"LY1&<Y
M<"\T=DPS4$ES,S=X3'-69&ER<U9D:7)S5F1I<G-6)B-X03MD:7%V67AM5SET
M-'@Q95)&*SEG36I-,45L<W=X=5E(;45F-7%T+U$X>%@V57!757EF.&I0:B\T
M,GER4WEV2$@S3U(R:D1H>GI(;CDK)B-X03LV535E-&)S5F1I<G-69&ER<U9D
M:7)S5F1I<C%N+TA0;&(O;'0O=T-353,O3D=A2#AL;#=V=$0R9CAR868K9#EH
M+U4W+T%">C57+S5B)B-X03MF*U-5,R].1U U3$PS9F%&+VQB5"]W03<W1"MP
M,RM/9DLS+TQB+WE3;2\U;W@O2EIE-S=1=CAR868K9#EH+U4W+TA0;&(O;'0O
M=T-3)B-X03M5,R].1U U3$PS9F%&+VQB5"]Z=G-0-FYF-#4X<F8X04QB+WE3
M;2\U;W@O2EIE-S=1=CA!2S)N+T%*,S)(.51V.&,K5G8K5S,O:VQ.)B-X03LO
M=T$P62]K<W9D.6]8*U9T4"]/*W<O<59,9GIL-6)U2C0T26)Z;$Q->7AX<C9C
M;W%Z1V=&4W1/=4-7:WE!5U(Y>DM(865#4D523&,K)B-X03M2+U5N3UEZ;G5X
M5D(V;G$K;F%:16MT.4PV36)T=U9U3$Y6<59P.$EB=WEZ2&EL33%%3D=F57=X
M0S5M9VPS*T]F2S,O3&(O>5-M+S5O)B-X03MY-SAL;#=V=$1I+WET<"\U,S)(
M.5-795IF3FYL*SDP3S=T8F$V.5-E5E%%5# U1G%1=U!6;$$W6F9P.4QK:DU%
M:F(T3TIR=3!C13A-)B-X03MO>&Q:4&MF,5!/8S(W>3=S5F1I<G-69&ER<U9D
M:7)S5F1I<6)E5F)F,2]-5F=L2S!L16XO04-,*U O:EA+3E9+<V-V8S5N6C!/
M3%!!)B-X03ME9C-B<'0K63EO671A:G5!4&AU25)5+S5317%F=W!M4#)F2S16
M,T9Z93--9%I23'9(,TU4>E!D33=&6%EQ-T9867$W1EA9<3=&6%EQ)B-X03LW
M1EA9<3=&6%EQ-T9867%J.4$O-#=U;F8X>%50+TIX8W%Z+S-C=F-823!F.3E$
M*W1(-S-S*V,T.30W1E=(+VU:+W=!8W$Q+S1Z+SA!)B-X03M':EIS3WIV<E!U
M9$HR-R]D4B]R9F],>FY.=SAS-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<7EZ
M.'5,47DV,4IC169$8G=M:"]Y;DE5)B-X03MF:%A-1'1#5E%R=DQU97<X9#54
M3'5(,W Y*UDY:C8R:GA84VER5W-N>$AW4U0T5"]!34YX>D8W4&Y5-C<S6F1T
M-&5,14IF>E0Y+S1$)B-X03MZ6$YY.&\W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<6HY02]W0T\W<#,O041&42]W1$IX8W%Z+W=",TPS1GE.
M2"]F)B-X03M1+W)2*SDW4&Y/4&5/>%9H+W=#6FXO2$MT9CA!:E X03AA3FUW
M-T\K<RLU,&YB=CDQ2"MT*V=V3V,S1'EZ<U9D:7)S5F1I<G-69&ER)B-X03MS
M5F1I<G-69&ER,'(X=4Q(,&1(;'5M1D=U<%!H4&EK9G=J+VAU5V%B=$-D>G)U
M97(W17<X3TEY+VY(-W9W5U-A:EI*9E=&>&%0.6UD)B-X03M'4W9G4TYJ.4(S
M>D1X>C1:03EZ=$TR25I)1THV:#1P3D1*1$Y*1$E/36MB1DA8=UI446I/:T)S
M5TAG<'A-4U%E65=95TQS5F1I<G-6)B-X03MD:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-64BMG9CAD,U1V.$%M2V@O-4],;%=F.$%U-64T=5)O+S<V2#EA4#-V
M6C@U>#=X,DMS4#A!)B-X03MZ32\T-59R+T%-6B\K3D=Z661N9E=F8S94=#,K
M-FHO5R]16&Y/8F@U6C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMR-%E:2G!O-%EX
M>6MK)B-X03M926DK3$UA05E#849L;$-*:U%">DPR=E1R2DQ'=W0W4E!S=TEQ
M5CA30G5F<$\K8S-K;GA32C<S=F-/25DT0TDV0D5:0G1E869M1G!")B-X03MT
M9%9&-T=0,TXT2W-E=VM86F@Y26]F=GID841,>%$T96]E53=:,#-":S1X>6PY
M-T9->FY43WA6,DMU>%8R2W5X5C)+=7A6,DMU>%8R)B-X03M+=7A6,DMU>%9'
M-DI*2$AR3FA*27=33DQM1FYD:E%!0G=34U0P07EV34QH3#-&=C!P07EW2C5C
M42LY-C,K;CE#+W=#<FIA+SAJ;R\K)B-X03MA<S!(9UI0-7 K5#)N-7I$+U!J
M+T%+64\O5"MH9CE81S$O-4A2+SA!3E=09UI0-7 K4R]N35 X05!J+W!G>%@X
M=W13,#8V,'DR4S%U)B-X03MO6C-787),1DER:T1G4E5H4V-Z=$)J;$=2<T5B
M3V\W6GHT-31W27E".5A1*U1!8S)R>F)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M6E@K)B-X03M8=6MM-C%5,W-I+W5B3595.6I),GDO8TMN-W-W9&9L-%EC4%5U
M-3=&,#-(:S1Z>6HY-S!V3DLY5S=&57,X>6%/=7)A5$YA,$AR1#0W)B-X03MD
M:C)K6' Y+U1,.5!L.$]94%)X3F)P:&UX;5!8<#<S:GIO>4]Y3T-R<5-'53E1
M4G-2;E%G,CA/45%A2S-&1'-69&ER<U9D:7)S5F1I)B-X03MR<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9826I/-F]G
M3$]X0592,4I/=T=*3DI!2DY"-T0U)B-X03MB,&1D2C!M1S%O4%=0-WDT23=Y
M3C$K-W!N4&%J3#1K>5AU3D9P:&AX0U!8<C<P>GEH>3-9<3=&6&YF-6<V0CE8
M=5)Q<T,O=5IZ4S1!)B-X03LO6FLO;2\R6#8O;FTS,$=E>'=(;4AM3S)D2'=Y
M.%=023@O9BLQ:'5B1C!4<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D)B-X03MI<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5EIL*U@R9V97
M3&LV<D]V-VU!,'1W9C)P4#5V.6HK=C5:<G1F;F]C035L,W99,FHT)B-X03MP
M94Q,:T]8=B]9.45Z55!4=7A6,DMU>%93=3=70S=T<&)A9&5C37%L6%4K0GE5
M2D=*<V,R1U1'2GA-6F-I.&<Q+U),:E(Y464Q:W$P)B-X03M:*TM#6',V2&]F
M;C0U,$=$34UK8D1X3W,P<W-%*T4X=6E7-6,T:G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D)B-X03MI<G-69&ER<U9D:7)S5F1I<G-6
M5$Q13D5U3EDQ0DQ73W%X:C1P-65Y24]P*V9H;$]F34UC8DQL-E!3>7IZ-%)Y
M-G98-U,Q9W1,84LR)B-X03MG6&A$16]61DAG334K8VI),F5B,C)01TE215DX
M9W$U1FTW1EA9<3=&6%EQ;&YM1%%R8E=B0G)E6#1:5G$P13%.,&(K:#<U9F=Z
M;DA+)B-X03MW-&US,&MC.$]%."MH95-8.6AD5T8S2F$S4T9*;WI1:G-2,DDX
M46,S.$II47-01C5S37-C:D=1,T-(>515-T9867$W1EA9<3=&6%EQ)B-X03LW
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&55)95T8Q9C-C
M9')A;UAM:TY!3W=(8VYW07E--6E)<W1U2$1,2DE2)B-X03MI3GDY8CAV-D9B
M84Y93&)X9D9+,4=N;7!U-V8P2&).0FYZ;DI+>3EP;SE*2$)$:$A0<55Z>6AY
M,UEQ-T9867$W1EA9<3=&56XX>2M7)B-X03MR8E=R64MX160Q1T0V13E0*T9B
M+T%#8WE.4'%$:E!K-$]U,$UC.&4V435&-51F,D8S65A4,G0Q1UDU:T\T4%%J
M>$(W9S5V;U1%:%EE)B-X03M/>EE:635'36A242M386Y9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<6E,0W=U-RLV4S%T
M67I*)B-X03M--3)!-D%E2E!91$EZ;4EI>3(T8TUS:VA'27-V5G9,9FQU,3!7
M,31R4U,V:T$Y965N6"]*6'=56F]D4G%$:U!K.6IO9$1(0D=U8VIZ)B-X03M+
M8UIJ=6,W1EA9<3=&6%EQ-T9867$W1EA9<6QM=2M8-T178F(P<FAE37$Q.4=D
M4CA32"M).7-V=UHU67I98U16-D]'94Y3-3E#.'4Q)B-X03MV44Y1,&4T.4\V
M4W-B2#DQ3W4V3U!9*U!T;3=W-30U0EEE4C%7:FYG;%5U6&5L=5A/23=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W)B-X03M&6%EQ-T9867$W1EA9<3=&57DP
M5%%.43%I-#E/,5-K86XY-T\R>4E08RM0=&Q/8E!(1TQ,;#984GIZ>7%03'9E
M;S9&-69S3D=T=E-T)B-X03LQ-5-T5#%P,DAX3V8T1#)Z4UHX.'-H<W988512
M=W=2<5!0<55Z>6AY,UEQ-T9867$W1EA9<3=&6%EQ-T9867$W1E9+-G1,83=G
M84,U)B-X03MI5U=&.6U2:%5:2TUZ13)/8D1*:FI-8TUH65E"<B\U9EA.=GEN
M,&]M94AQ8F,O,VDO=T-R+TXK=C4U=&-'=D(R;G-8;3E:,DY+4'%X)B-X03MB
M:G4V+W19939/:D9(57$V;6I+4E%G*S1/8D5',U)K14=I='A1-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T96>4DW<T52)B-X03M3>G-A2V]&4U0W
M05EK,&M!:S!'66%"*U@Q>F-C6CE62F=H-FDS2#DT,RMT+TPK=C5:<G,K=D$R
M:'5896%0<V%5=E9L,DAD,2]9>BLQ)B-X03MT3&$P9U=#,FE72T9.;%)245IQ
M<%1-:EHU=E-9.&-91&AI2T-R:U=B<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<G-69&ER<U93=E=0)B-X03M,96LV<W K<WA5;7!28FA+3$E0<#<O5&PK2%54
M>#AJ<S1M<#!/4$U054XK+W%W:E8O=T%V9%9T4UI,26DX:#=+4&AK03DQ3W@K
M9R]2)B-X03MM>GAA*T5V<3),>BMP-T=Y43-H-F@Y<D8U;UIO6D1(3D<P8VDO
M85)W5EEF34A-,$5(8T]O;$%X3D555FU&:3=&6%EQ-T9867$W1EA9)B-X03MQ
M-T9867$W1E8X34TP,&=J:&IA4U)V<V]G3$UF:T)G2D$S3$M-1$DP0EI:4G!0
M-64V<F1&6DPP:7IH-W%F:6M)+W="56)$-E0Y1UE7)B-X03M86'=J.4\U9'9P
M=7AC:SDU*VMF87IJ4B],96LV4V\K<7<Q;7!1,T5N>%-(-F4S,%IR375O;FLU
M;#9$5&%,1FA(<$<O9C%44$M(3&1I)B-X03MR<U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<4AV9$]S3#5/1C-B<$]V8FUO2DAY4%5F
M4FLT6DI2-4=M<DQH)B-X03MH:T9304Q'-R]W1$QJ4C5Q=&%3>5=R2&]V.31G
M*VAQ3B]W04YM6D1T0UDU-W5R>F1I67!F4U1(-V9X.#!H=2]Y-#%U26LR.&M6
M=W99)B-X03M!;$<K-6A4.&-Y-&1O45!/=S8S2C)*;$@P:U,K>$MB:GER-6EG
M<GIS2E14+T%(,E!5+S1H>7DK3W%X;BM)3T90<S=02&Y!+V8Y>4%K)B-X03MS
M8C)),&MT-450.$%L27<O5TUT131N:UA(;&AM3UE0>55-:S%U>%98:G-B,E4P
M:G0U2% K4VI(.5%Y2FY%8WDR4G=Z4$E(-4DK,SAQ)B-X03LK67 V8TQ#558O
M,S105"\T;GAY<5=Q>&HK24]21',W4$QL02]D.39B5VXU8V$S2U%B:5-+,UAU
M0U,W9F-O<"M/550W46=/5FQZ8V99)B-X03MM52]54D@W52MS4'DT,&5':EAC
M<VPP=S9R+V1O9F]7<F8X3FU*4'1#6C5B3WEW.6E9;R]55$PW4'@X,E-75VY7
M1FEN0S!T,&=8=G=5)B-X03M!;C5N<69P>D1N:VQ,;6)D<&EW=WAI;V="15I"
M=&1I<G-69&ER<U9D:7)S5F1I<G-69&ER+SEK/3PO>&UP1TEM9SII;6%G93X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L
M=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @
M(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]297-O=7)C945V96YT(R(^"B @(" @(" @(#QX;7!-33I)
M;G-T86YC94E$/GAM<"YI:60Z,S9%03 X-49%-#@W14(Q,4%!-CA$-#DV.3$X
M0S,S.40\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U
M;65N=$E$/GAM<"YD:60Z,S9%03 X-49%-#@W14(Q,4%!-CA$-#DV.3$X0S,S
M.40\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U
M,#A#.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP
M34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA
M<W,^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM
M<"YI:60Z,S5%03 X-49%-#@W14(Q,4%!-CA$-#DV.3$X0S,S.40\+W-T4F5F
M.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM
M<"YD:60Z,S5%03 X-49%-#@W14(Q,4%!-CA$-#DV.3$X0S,S.40\+W-T4F5F
M.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M
M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO
M<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z
M<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^
M"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX;7!-
M33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HY
M130Q1D4W1$1$.#=%0C$Q04$V.$0T.38Y,3A#,S,Y1#PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP,RTQ
M.%0Q-SHT.#HP-2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V
M("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,S9%03 X-49%-#@W14(Q
M,4%!-CA$-#DV.3$X0S,S.40\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#,M,3A4,3<Z-3 Z-3(K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ
M2&ES=&]R>3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.FEL
M;'5S=')A=&]R/2)H='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N
M,"\B/@H@(" @(" @(" \:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^4')I
M;G0\+VEL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B
M"B @(" @(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @('AM;&YS.GAM<$<]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @(" @(" @(#QX
M;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#Y&86QS93PO>&UP5%!G.DAA<U9I
M<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z2&%S5FES:6)L951R
M86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N
M8WD^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^
M"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXQ,BXP,# P,# \+W-T
M1&EM.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C$X+C P,# P,#PO<W1$:6TZ
M:#X*(" @(" @(" @(" @/'-T1&EM.G5N:70^26YC:&5S/"]S=$1I;3IU;FET
M/@H@(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM
M<%109SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^5')A9&5';W1H:6,M0F]L9#PO
M<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M1F%M:6QY/E1R861E($=O=&AI8SPO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0\+W-T1FYT.F9O;G1&
M86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q
M/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E
M<G-I;VY3=')I;F<^,# Q+C P,3PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z
M8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.
M86UE/E1'0E]?7U]?+E!&0CL@5$="7U]?7RY01DT\+W-T1FYT.F9O;G1&:6QE
M3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.D)A9SX*(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @(" @(#QX
M;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@
M(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G
M.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@
M1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP
M1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO
M>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^
M"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,3 N
M,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( !( $@,!$0 "$0$#$0'_
MQ  8   " P                 ("0(%"O_$ ",0  (" @(" @,!
M  0% @,!!@<2$Q0(%0 )$2/_Q  : 0 " @,                '"  &! 4)
M_\0 (Q$  @(" @,!  ,!         @,!! 42!A,'$10 ""$B(__:  P# 0 "
M$0,1 #\ T!?(KY&<D<]\DFZ7IC%S5IGWTM;U'5$!%]&=FMP9D 9FUB+.N30M
MQ?\ R\08J4PUHUM-%-4;HEF%-)Q+B.(XOAUY'(JKED?E^R_>M"!?$/7VFE$G
M$PA=</8L,(ACC@B(I'K6OG!Y/\H<J\C<K?@,#:OA@HR)8G"8?&M8J<L??\R[
M=R%$$VW7F1#$I=,HJ),%@,'#WNHG1/(GQ"W'1R-'Y/P]D_U)=M[$97[.=-+M
ML>/$;/7B1)GD![(NH+0E5TO:Z0+"*[HF+(AV0H*EE5PQ//L?DPR>%FM%6^['
MI-^D9%8Q6JV4VP9"A93<86ED562:(2,K?+1DE_M??;RCPEG./,X_RV,C.1PM
M7-VDU(;."<9W\AC[>,8@[+492JMV.<"\D*ZQM%D/J17(5NEK^N_,[AAKKZ)H
MS<V*63).L/8*O#['UAQ@5!!:_P!C$J\7^E?98-YL5PQ;X^_2/;K@&6_'?(T6
MK*$UHL)38<I3]Q#N4MA MNDS,AV!$'K,SKMZ]SZ]_G)QGG3@UW&X^Y:O32M6
MZ-2S9IS'9-1[ZZVNK2R-89*&&2I.!'?3;6/?K\F_85V[?%CFIX%6M!RU16.P
MTA#U9@]<VUMX,8N%<!PG*K%D3U!-D,7CW1M#)D4)9*!(Y%4&#JNQO-^.UF2Y
MG1:BLRR%5W2Y%RL:W,KLF(G656 B="&18$ P?8&!2C.3K<@\/<^R"!J5YN8\
ML@G'LR-3Z:MW%9%3ZJ;R((@VBQ2:8]BV0:&RY!R+5-"(\N<J5<R4<4(D&F@+
M6>LZB%JMXJ/710B&#Z]XW(@M04+B3+[4'1@'A4LE55?!H0SLA1GVHRG,#A)X
M\6=M6L@UR;M]EX3M6S8":H5D!+K1N!8C:]J9WNB2"4 B)+_G,1.:\P#G2^&X
M[&X*M4MXG"HP[$X_&)KLLY%E^XP:N-75:]AXV!L(^.H0 P;;;90N>Z)(X]<_
M7+>7KR(IWL]:QT2F5D-UO^]WU[2X*BQ@#Y:>U-OJ%RNH\E4I5S\?:$LQSC/X
M-K?ET%V[2ZU&7UPL."N[_ ]R180J;J400]BX$_11M'OU/]_F"Q?\7S=C,<[(
M93Y+[:-1EZK$F<5KAUUE9K[A,@?2Z37L$R!:^QF8F)_%/\U=>0-.%G#1FC3L
M6:FROZIB<L"+/6>QB?L?7F$46$!^?QU^;UK*_+TAW[=8_P I'CFW:3R.NA-F
MPI#Q+O2IS%J=I(Z=JP* 9KL6N\%K[GUZ]S^,'GC&8VYP2[;MX^C:MTF!\=JS
M4KOL5.W;M^9S5DQ'9H'9U$&^H[>]8]"C^N#7D!A&TNS$:<ITKKQ]:W)6!7M%
MWFMA3;Z+"VB98GEJG.JSU[:^]<I0E_8RSC-[\P6K2AIUEV;"ZSCGNK@Y@(;K
M!$/:H2A;-2B"C89]3$3']Q^#G\7<9C7,RN0=CJ+K]2(^6\VI79<K;E('\]DU
7RY.X3('UF.PS(S[B9C\VK\ WYS?W_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g96328g04e10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g04e10.jpg
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M.4935G*5EIBUPR,X0D1'4G1U@]&V0V2A@H2%AI'_Q  > 0$  04! 0$!
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MT"E29,AMV'U@>G+,#//(@YYGB]7&MKNW,)SS.OYJN4R.JN)I&*Q[CS)%P=9
MQV,J^P8HTRGPDPN3:SD2/4S(PFY:%-3,\WJ5/;K+1,)1\?"XZF9BHR5UC"O+
M=6B ;,R"=N0VY9[#Q;.,$<7IXLES!EQ>YWPT-ZL]^[E;]AF+N7%1DB9LY82X
MIV.B80P7Q2XEHMZL)9)&?FHR;@87$^8+)D6FPD9#)N(^KX>/&H2%O6M8+U8H
MRS^O8/\ 7[N/UG;EQFW>(SC(RA@?AJQ5EB6ID+$97NU+D[S*8MDX$T@S%_#T
M<]X>XD1GY;)V.T(:[*=F;5=JZBS9%MLK*M):0IV&[HV8R3**(!F<O]#[\_\
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M\]=CV%NE*3DN!=/$:_7\2FXA)&:E,B5^>0;1%J8MK*ME:K(/%SRW#"$U"S$
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M7D&N+X]QC:&X1CK'A#%RA&!VDDFWCU9 GFYCU9^G;L&6WB''M]:ZVY XC>9
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MK+]?\EHB=P,C[=9?K_DM$3N!D?;K+]?\EHB=P,C[=9?K_DM$3N!D?;K+]?\
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MS8H&,D0Y4"A&PLBOV9<4T>D@5$#]F52(=^"?BMVT18],O3$F_P!D!0.(;?\
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M)HB:(FB*K:#]]^;OXR(7^B#%NI/$WZOQ*@<;OK_ *TM0I7Y^O%3_ -8[-/\
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MF]";Y:/O'>&WR85[YKIXWZ4<_8GUJ3M3>E;D(^B%"WY3G+3,BD8W ]PW"(D
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MGJIU6;WB<*LY%W3'8I/KM+!GO/LL>4BG_P!2:>2"]SU4ZK-[Q.%6<B[ICNK
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M^NTL&>\^RQY2*?\ U)IY(+W/53JLWO$X59R+NF.ZHR>:S\&%,J;ZC_+ ]D4
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MTM*P'&"TS5)UH)@UQBE&;) UQ82 5U%RLG(UNP,LB5WLGGI#!VO,QZ0FZ,[
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MH',V717*4PB!3&14*H!1$.L $2["(=>P]6O#8)3!/#.T!SH98Y0TYY.,;P\
MY;<B1D<MN2]1EC$L4D1) DC?&2.,![2TD?2,\U=##-LK'] R$<J@<924>K Q
MF7;) $)>3FY)VX9H$04*SLXDGG422S])=7SB;LXL\>=$C@7/HU;PE7ZV1CJ/
MB<;UVS**N(3UHA%?NXG=L35HFQN%;&RW%;%!N-ZTK^"XJ]%U1\;93-QL^A=6
M?6#[+9&[UJPLW>G%,_7J5J5:*.9Y>TS8;G1BM.PW)C=^R36A.'NC$7R2N8'D
MBQKD>2$021KCFJN6YEWZSQ50*LI)K(-!6,@DMVFNM*N3%(X4=N6Y1Z';2VXF
MUC7M/[%NK@]1N'1,BP>? IX3+9DL/>,#=>?%7W1T3)-[2R8A.YK97SS0@ZN[
MR9DJ[5T1BKSXC.Z[(]^(QXI'((X&0L:<4;69)*&"1[!,QE6($QMBCD(SW)G$
MMGF,HSLZV<,9/LZ[6128(RYPEY@'LB5BL4R:BJAGAV"K@&R2#-%>0C9$6Z+9
MN4A3$123)@8AIMB>*0S5KNZRPW&58\0<+^(;XN-JR-<QTCG6'U9)1"R*O%);
MI7##'#$& MBC8S,JZ,4:4D<];49+7=.^HTU*AAKF=A#FL:(1.R,RNDF>R"S7
MW1\DA)!>YQRL>1$YYK9VB4.N@G9[*[L@(R$JC+-(1Y(NFSZ16A$ B&"K*0>+
MMBLUWY7(E6A.A'.&BZZ82!IQC2YF*08Y S#Y8VXWC-C&=SMWH[U?#;%N:&S;
MDPV(8?5DKV[$D(KR6]W<'X;JTY8))6[[-.'Z/.H28;*ZW&]V&8;%AVO7JOJR
MW8J\,L%=EU^^YV35X62&9D!C!9=UK$<K&.WN.DN9)4D6P4 B1G4A(.21\1'I
M[BO(2*XG["W3  $P$*!3K.% *((MTU5-C"4I#;/0FBZ]9C!>(:]>-UF[9?LC
MK58BPR2O)R&9S#(FDC7E>QF8!+@QVXRE7<\M,DTI;#6@;\N>=X(9&WC( R+Y
M'9'4C:YV1( /\R7&977M4XD\D0<B9,S]N-0=O>Q$!-(CJ6H=7EUTDDPZB)(J
M/C))E#?8A"AN/A'^A+^3;;KWO ;X.;54O-:7 WF R.+Y#"S$;T<9>\DESBUH
M+CZ\\@!D%^:GA(BEATZTGCG#1,W$Y3*&-#6"1S(WO#6C8UH<X@#T 9':NL&O
M;UQ":(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O2'@UYB4MP3T9&$QYARC6N[2'$
M+C_--JNE[7>223Z!Q1#O&= IM>AV"<<K 247+6G(,J\LSJ5FVCTMBCFHUDAH
M87+[F<;T;9CE@R6;UB&!N&V:,,%<-86R7'AUF:61VMNC'LAK,$(9&6[DYPE\
M_)N1#8=""&L:7;HU^;MNQ@\T 9;""7'6S/&-FS;<WHCG#N[<8V3E^$JROH3$
M]$XBL64*N.\N4*S5JJ4O*^>[?G3&LA&U#(7#[=J3,W3&(7.0QZY=7BM6VF3E
M?9QDXRI$'8(Z.5987BUB8%HLQB)LERQAMNQ*VG8BEEGJ8?!0M,=-7Q&"=D%K
M<&V6B"6&>.0NC=/)&YP=.[L.KG"<F-E:T:[7 -?(9&$-=$6ES-8M.L'-( .K
MF!ES/(W-LH>5,ET'+]GX=[W&7/$/%],\3>.HVHY[8PM'>PMQS5BK,=OI>3:Z
MOB"1<W.=*OC-6 K-OBI:IMF*<U%R4Q6IHU-CF$E8K:'V*E6S3BQ*NZ&[@S,+
MLOFPYSYVOAHVZ,,]6476"",BUNDT+V3%Q8]C)6;NYS:WVFO<'F-P<V8R-U9
M!DZ1CW-<#&=8^9D'#++/,@ZH"X_6.:I2H2]\/>79#A_MTCDG!]7R9B5W'HYB
MKAL1V;#V2W>?UWRJ>,K%A6T-&N7F"&?Y5)&WSDG9Z0^>5IK(3&-)).=DH]O7
M+HE/)7Q*FW$86U;\M6X';RE%R*[5;AP;G:CO1.--QP]I,,;8;#1*6LM-W-KC
M#;0#HWF,Z\;7,V/&HYCMT_JF,^>-T.TDM.J"6',A7[CGFT8;J%0DLAV"M98M
MF0J'Q1<,&1L'8C;7G'^+1;57AYP3D2E5A2[S6%>&.AXBE\4PMA?P==7Q- TJ
MEV96ORD6DSLLBVKLD_?Z^UHA=GF96BEIPUK&%8K6OW#7L6]:7$L0K6)17CO8
MK8N,N/C:^46Y)YX=U8\NB:96M;<;:8T%Q#RYLD3F,UFMR;'&]K02R)K"P$@:
M@:TY9;3D2?*WB*XFZSQ$UWA9:SE%M<+9<%8L)A^]/&5^C%ZS>:M%7B>M=>?T
MBNK40'..+"1A:9J&G'4E,WR*?]JUMQ'PT2A$.V4MUN&X5+ALN+&.Q"^*_;W[
M7#J[Q+!,^O'#*VQ(+ %F+6B8^-K&5WMUI0Z1Y>US,6202"+-I!C9J.(=L<-8
MN!:"TZAVD',O!V'(99'NBRYEN&Z]Q&8XSWC[&?&+B@^.\!X4P4>'QIQIU:IR
MEZ@<!0]!K52A[Y/0_"\Q1G:-;X#'\63)506B!:34^9&;B589DQ2KZNC.B]V3
M#+.'6;6"VQ9Q"]?#[6!RSMKR8B^Q+,^O')BIW.Q#)9?O68/SCC!8\2.<9!>W
MPT2-D:V9FK&R,!DX!<(P  XB$9M<&C6;Z3M&60"W=;FZP;M%>Y'X;$(C-2M>
MMV)6\S6,C-87$T/@6Z\92O&/)U&%QAWO7,DPML7,.W^,:[8RW@T#'TYPC(KU
M%Y,M$Q/1XFR B#A0OH[I#;<R:L9+C\0@P3@5D[[6^6M="Y@;:DBW#='S MW8
M,<4WUZ=SR?D69AV3-R=-NQ:&:NQP)+ =;(-.>J2 MBL/-CD;LC:8.Q4&UIP-
MV:<P>'E"N<HOIQ&/8\=<]!RK!X:*5KC%.6-A@L4<S9EVU'C<%E"'9O*8<@'U
M<BT0;7,4D5F+=(':./9E4;&7.P".1CFAXE.IOW7&;LG;AEYS9T-HNU@6G)V^
M ?/)_P!N0?FCY&W+YV?&U;ES@N)OAIXF;12;'P^9+?VI-/).?K1)5&+A)%C2
M8:)R'/U6>BKL[>V?A_P+<4<KWYTVDBY"KTD\SA&P[:MUL6&9[&Z<R)UZ-#,*
MQ3"XIX\1JMA)JX=$R9\C73O?6CFC? &Q8CB$)J5VEF]Y6MH/D,LFM2C#6Y+<
MD<CFF-Q/G2$@#S1K%IU@3'&[6=EYP.N!JM\\G,GQ=UW"Q$T1-$31$T1-$31$
MT1-$31$T1-$31$T1>YGF<W_"L83_ ('Y>_HZG=>?>$[^B=G^]TO_ !@L[#O]
MZ9_9?_TE?I2:^:%T2@#U2;Q"?PBFB*?1% CZ8Z\>7XLWT13Z(JNPC^!W%W\
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MN0W0-_=?7>HW1*;;U?U]1@Z]/R4O#3S!AO\ B#!_BT\O'@WYUN^R<0]PLOJ
M.)K_ #2A/]KZ[\_T_)2\-/,&&_X@P?XM/+QX-^=;OLG$/<+$G 'Q,'(4Y:G"
M"4Y2G*/=?70W*8 $!V%_N'4/@T_)2\-/,&&_X@P?XM/+QX-^=;OLG$/<+:I[
M@=XB:W%N)F6J\.BP:G:)K*)VJ 7.4SUXW8-P!))Z8Y@,Y<HE,(%'HE,)S;%*
M(A(_DH^&DG+@##?\08/\4A\//@V&TXK=]DXA[A;O]0!Q-?YI0G^U]=^?ZC\E
M+PT\P8;_ (@P?XM/+QX-^=;OLG$/<+$W 'Q,%$@#4X3<YA(7^Z^N]9@(8^WJ
M_J^Q(8=Q]C;PCI^2EX:>8,-_Q!@_Q:>7CP;\ZW?9.(>X67U '$U_FE"?[7UW
MY_I^2EX:>8,-_P 08/\ %IY>/!OSK=]DXA[A:%X ^)CIB3N3A.D4"'$.Z^N_
MM3B<"]?;^W6*9NKUMNOPAI^2EX:>8,-_Q!@_Q:@^'CP;D$<*W=H/_P IQ#W"
MK4>6)Q+2%[[L)BKPCHD8U%I ,1M]<%NQ%4P'=NP(+\0,Z=& I3J[%-V)))+<
M03*.NJ;_ "=/#55T=."4-'<-A?;F$V)6AI!A EL!@RA@UM]@B&(%Q:S:-9[W
MY!SCEHSX8O!Q/B@Q&SB]R1L$>YTX3A.(%D)=D9),MP/\X\@:SO4UC>)NWPVX
MN.1IS'^(#B8S%D;%N(*O.U%S/0$$A(NLLXSA53R5:HE2A9=+M"7LS)\4C>19
MKHIK';E37*0%43'2,4X_KC_)]QG#O!_X&?!]H;I/.:>/X!@8I8G6ABFN10V-
M^6YM5EJLR6"8;G*PZ\4CFYDC/,%?&WA"LQ:0Z:Z2XUA9,V'XCB<UBK*\&%[X
MG-8 YT4NK(PY@^:YH/T+KM];D\V/\1%/\M^(/ICKV/RE:(<X3=0N^X7&\'V^
M3'39WEB3S.9S83D*<N":>)3E*<H]^[$ ;E, " [#<-PZA\&GE*T0YPFZA=]P
MG!]ODQTV=Y#>9S.;"0 $V":> "8A/PW8@'[(YRD*'WX>N8P!OZWA'JT\I6B'
M.$W4+ON$X/M\F.FSO++ZW)YL?XB*?Y;\0?3'3RE:(<X3=0N^X3@^WR8Z;.\L
M1\SE\V$#%*."*?N;?;[MV(/^R&X_XX^QIY2M$.<)NH7?<)P?;Y,=-G>67UN3
MS8_Q$4_RWX@^F.GE*T0YPFZA=]PG!]ODQTV=Y8AYG,YL(G,3O$T_I%*4XAW[
ML0?M3B<"COW8;=8D-U>MM^4-/*5HASA-U"[[A.#[?)CIL[RR^MR>;'^(BG^6
M_$'TQT\I6B'.$W4+ON$X/M\F.FSO+$OF<SFPG 1+@FGB &.3\-V( ^R(<Q#!
M]^'K&*(;^OX0ZM/*5HASA-U"[[A.#[?)CIL[RU'S.5S8B@(C@BG[  B/W;L0
M> .L?\<=/*5HASA-U"[[A.#[?)CIL[R%\SE\V(Q2F#!%/V, &#[MV(/ (;A_
MCC[&GE*T0YPFZA=]PG!]ODQTV=Y:&\SF<V$@ )L$T\ $Q"?ANQ /V1SE(4/O
MP]<Q@#?UO"/5IY2M$.<)NH7?<)P?;Y,=-G>67UN3S8_Q$4_RWX@^F.GE*T0Y
MPFZA=]PG!]ODQTV=Y8CYG,YL('*0<$T_I&*8Q0[]V(.L""0#=?=AL&PG+^??
MJ\&GE*T0YPFZA=]PG!]ODQTV=Y9?6Y/-C_$13_+?B#Z8Z>4K1#G";J%WW"<'
MV^3'39WEB'F<SFPB8Q P13]R='I?=NQ!_P!H!$/\<>OP:>4K1#G";J%WW"<'
MV^3'39WEE];D\V/\1%/\M^(/ICIY2M$.<)NH7?<)P?;Y,=-G>6)?,YG-A. B
M7!-/$ ,<GX;L0!]D0YB&#[\/6,40W]?PAU:>4K1#G";J%WW"<'V^3'39WD/Y
MG,YL)"&.;!-/ I"F.8>_=B =BE 1$=@N&X]0>#3RE:(<X3=0N^X3@^WR8Z;.
M\LOK<GFQ_B(I_EOQ!],=/*5HASA-U"[[A.#[?)CIL[RQ-YG,YL)-A-@BG_9&
M*0/NW8@'K,.P?XX^R.GE*T0YPFZA=]PG!]ODQTV=Y9?6Y/-C_$13_+?B#Z8Z
M>4K1#G";J%WW"<'V^3'39WEB/F<SFP@<I.\33^D8IC@'?NQ!^U() ,._=AMU
M"<O5Z^_Y!T\I6B'.$W4+ON$X/M\F.FSO++ZW)YL?XB*?Y;\0?3'3RE:(<X3=
M0N^X3@^WR8Z;.\L2^9S.;"8QRA@BG[D$"F^[=B#PB4IP_P <>O[$P#_+MIY2
MM$.<)NH7?<)P?;Y,=-G>67UN3S8_Q$4_RWX@^F.GE*T0YPFZA=]PG!]ODQTV
M=Y8D\SF<V$X=(N"*?MN8O7F[$ =9#"0W^./K&*(?E\.GE*T0YPFZA=]PG!]O
MDQTV=Y#^9S.;"0ACFP33P*0ICF'OW8@'8I0$1'8+AN/4'@T\I6B'.$W4+ON$
MX/M\F.FSO++ZW)YL?XB*?Y;\0?3'3RE:(<X3=0N^X3@^WR8Z;.\L3>9S.;"4
M2 ."*?N<W0+]V[$'AZ)C?YX]7441_DVT\I6B'.$W4+ON$X/M\F.FSO++ZW)Y
ML?XB*?Y;\0?3'3RE:(<X3=0N^X3@^WR8Z;.\L?K<SFP@<"=XBG](2F.'W;L0
M;;%$H#U]V/K"8O\ _P!_)IY2M$.<)NH7?<)P?;Y,=-G>67UN3S8_Q$4_RWX@
M^F.GE*T0YPFZA=]PG!]ODQTV=Y8E\SF<V$PG ,$T_<A@(;[MV(.HPD*?;[\.
MO[$Y1W#V=O"&GE*T0YPFZA=]PG!]ODQTV=Y9?6Y/-C_$13_+?B#Z8Z>4K1#G
M";J%WW"<'V^3'39WEB3S.9S83E*<N"*?T3!N&^;L0!U?F[L=/*5HASA-U"[[
MA.#[?)CIL[R'\SF<V$A#'-@BG]$H"8=LW8@'J -QZN['KZM/*5HASA-U"[[A
M.#[?)CIL[RR^MR>;'^(BG^6_$'TQT\I6B'.$W4+ON$X/M\F.FSO+TUY/O*#X
M[N"?F X5S7Q$8OK]2QX5GD:I#+QN2L?VIR$Y/8WM:D8V\ZJW89.2[&L2.="=
MR#;L"(D*"JA!.3?D-.-,]'\;T?GH8=;DFLOL59&L=5LQ LCE#GG7EB:P9#T$
MYGT+*IU)X9VOD8&M <,]9IVEIRV DK^V_7B2W*@#U2;Q"?PBFB*?1% CZ8Z\
M>7XLWT13Z(JNPC^!W%W\ JK_ ,&9ZEW&?K/WJEGR1^W[RK1U"J31$T1-$31$
MT1-$31$T1-$31$T15;0?OOS=_&1"_P!$&+=2>)OU?B5 XW?7^ 5I:A2JNPK^
M"ZG?^W+?'WFI=QGZS]ZI9\D?M^\JRG7J9QXA;X,VH52GT10+>F-?'F^+.-$4
M^B* /5)O$)_"*:(I]$4"/[=SX_\ Y".B*?1% U]3-_$(_!ET15KF?\'$[_ZN
MM_\ Y3":J9\H?M^XJE_R3^S[PK1U2JE MZ8U\>;XLXT13Z(H"^J5O$-_A'6B
M*?1%5V,! 3Y&V$!^ZE:0ZO9!&*W#\X>OJIW]7^R/Q5+?ZW]H_@K1U2JE U]3
M-_$(_!ET1''I9?'M?C*.B*?1%"?TY#_Y/YH:(IM$4!?5*WB&_P (ZT13Z(H&
M_I9O'NOC*VB*13TM3_0-_-'1%HCZ4EXLG\T-$6#CTLOCVOQE'1%/HB^<_JI#
MQ+G^>VT1?1HB@3]/7_,C_--HBGT10-_2S>/=?&5M$1UZF<>(6^#-HBGT10./
MVJ?CT/A"Z(I]$4!O5*/B''PC71%/HB@2]-<^-)\ CHBGT10-O2A\:X^'5T1'
M7J9QXA;X,VB*?1% M^W;>/\ ^0MHBGT10&]4I^(6^$0T13Z(H$?3'7CR_%F^
MB*?1% V]3I?Z :(CKU,OXH_\T=$4^B*K<B??%AC^-);^B[)NI'$[ZOQ"@\;?
MK_ JTM0I4 >J3>(3^$4T13Z(H$?3'7CR_%F^B*?1%5V$?P.XN_@%5?\ @S/4
MNXS]9^]4L^2/V_>5:.H52:(FB)HB:(FB)HB:(FB)HB:(FB*K:#]]^;OXR(7^
MB#%NI/$WZOQ*@<;OK_ *TM0I7\)'$CQ4\3].SUENKU'B/SS5JU"7N?8PM=KF
M7L@PD'$,4GJ@ILXR)C+"U8,&J8F,)&[5NDB03#T2!N.ON'0#1/1:[H9HY;N:
M-X#;M3X;#)/9LX1A\\\SRYV;Y9I:[I)'G(9N>XD^DKYYTEQG&(,>Q2&#%<2A
MACMO;'%%>M1QL: W)K&,E:UK1ZF@!4D/&;Q@F 2FXK>)(Q1 0$!SEDX0$!\(
M" VC80'UP'78>).AOZ)Z->PL,^%6CX?QWGK%O:-SWRU^K/XPO?7<2?ESR?\
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MQ8-[+H^X6UW>?EI?M']JT#F!<>8  !QM\70     '$EF4   Z@  "Y[  !U
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M[_WD\R_333Q<T>YBP;V71]PF[S\M+]H_M6GH@7'GN _5M\76X ( /U269=P
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MNC[A-WGY:7[1_:M Y@7'F&XAQM\70"([B(<2690W'8 W'^[/K'8 #<?6  \
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M.>2Z/5:QVO=HQ#+%B,L4MJN*[[3JN^F5VLDBJV8:\@>UL[YVAKI2=W<QC/-
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MRU8'N< YSX@UQ< 22=JJW_>UI7[\MZT[0R=V^)M:9@! ;*[7SD: 2 UY( )
M"Y!?N(++N2'U7>V*[3J9*5%4:,JD;$2DE%0]?4QW48.E5N:AXML\!I&V-*$K
MT85W.LDT)%V\34=G6*=38,?#M',&PR.U'6HUR;LMZ6W+/%%--8&(VY[MF":5
M[->6L9[$NI \NC8PA@;D%=M8I>MNA=-8ERKLK,@8Q[V1Q&K!'7ADC8UVJR81
MQ,UI6@/<X%V:KH]NM:DA8)92SV$\K;$'[6U29YJ2-(69M*N4GLHWL#TSD7,R
MA)/$$7;]&15<IO'**2[@JBJ9#ALA3J".O"*M80U'1OJ1""(1U7Q-+(G5V!NK
M"Z)CG-C=&&EC26M(!(6*9YR^5YFE+YPX3/,C]>8/(<\2NSSD#W .<'DAQ )S
M(6X%R+D$D#$58EZN1*Q7Y%.8@:X6SS98&$ETESNDI2(B ?!'QLBFZ54<IOF;
M=%R1=0ZQ504.8PVSAF&FQ-;.'TC:L1F&Q9-2 V)X7-#'133;GNDL98 TQO<Y
MI: TC(9*O?=H11PBS8W&)XDBBW:3<HW@ZP?''K:K'AQ)#F@',YYYK-AD:^QC
MYG(-+A8^V6*TFN@#F6>O6PC..TG\^BY9/5G#)XTL+M%->PLGC==G/&+M+H/"
MF,48DPS#Y8WQOI5M61L37:L+(WC<&&.NYLC&M>Q]9CBVM(QS7UP?YES#DC;=
MECFN;/+FTO(S>YP_G'!TH+7$M<V5PSE:X%LO]<.5KYYXI<M\1Q()#)$A#JLJ
M]-6ZS,&$)#-XIL:S7U>+<6^><& [ATJ\FU(2) [4KE.(CR,B)Q$;'D5<@OJ-
M']$\'T:,[\,CF$EB"G5DDGG=,X5:#96TZ[1DU@9")Y<GZIFD+R9I9"&Y9N)X
MS>Q81BVZ/5BDGF:R.,,;NUHQF>0[2XNDW*/9GJ,#<F,;F[/KIKI5JDT1-$31
M$T15M84W$M))P++I%,N K2#D-P*V9CN'8RG\ .'(@)2]>Z:0&/U"=,VN<QFY
M8FE9@F'ES;%I@=<L-SSJU#F"UCAEE/.,VM(VQ1ZTGFN=$Y;2C#%%&[$+(!BA
M=E!$?_?3C(@D9'../Y1SV.=D-H#PNA_$^P;Q>:;$P:$!-NWK^-BD(4-@W/C&
MFJ'-M[)U#G./LB81UY^RNRH^S6C&4<%_$8F >IE^RT?<O8L'F?8PJA,\YODJ
MQ.<?I+>Q4!JM;)-$31$T1-$31$T1-$31$T1-$31$T1-$6]IV6QHQ3""1L$VE
M!Q4TXLD9#)RK\D5'6)XWCV;N?81Q5P:,YITTB8IJXE6Z*;Y=O&1Z"JYDF;8J
M=!BC+W2&-AD>P1/>6-UW1M+G-C<[+6<QKGO(826@O<0,W'.<SLVG8<QMXCZQ
M].P;?H5AM>(+/;%TV?,<W9>9OF4G:)IF\:Y*N;=TTF+N)C726;.$9HBR$G;C
M'.:T/TCD=3XF,,JJ[$P[XQP[#W M=0IN:YL3'--6 AS(/]@P@LR+8<AN33LC
M_J *==_'KNSS)SUCQN^4>/C=Z3Z?2O@0S=FAJVE&;;+V4&[2<M$;>)IJA?[6
MBVE[I#.6;R'M\H@G+%2D+1%.X]@ZC9]V5:68N6+-=J[25;(F))H426.-*H71
MPNKL)KPDL@>"U\#"69MA>USFNC&3'!Q!:02@>\9Y/<,R'')QVN&63CMVD9#(
M\8R'J4#7,F7F,7#PC'*N2&<+7K2>\0$0UO-G;Q<'=5%5EU+A#L$90C2,M*BS
MAPL>P,DD)8ZJZRAG8G5.)JG4J;GOD=4JN?)#O>1[J\1>^#(#<'N+,W0Y #<W
M$LR \W8$UG9 :SL@<P,SD#ZP,]A^GC5K)\9?$PGCV[XY',-\589'OD)D*\6=
M:UV-6_V:7@J18\>-8R:NQY89Z4K#BJVB1CY&NR#IS&OBI1XKI&(Q1(&&<$PL
MV:]G>5<.JUY*U>(0Q"O$R2>*RY\<&IN;)1-$US96@.;F[(^<2JMUDU7-UW9.
M<'..9UB0TMR)SS(R<0051CJ^7A]%U*#>W*UO(6@JOUZ)#NK%+N(NE+RKY"3D
MUJE'K/#M*XK)239M(/U(=%F=X^;H.W J+I)J%V#:\#7S2-@A:^P&BP]L; ^<
M,:6L$S@W.4-:2UNN7:K20,@2%1F<@,SD,\AF<AGM.7JS/'DK#'B9XD!F L(\
M06;AGPAWE>"<'*]\&8" D%D7+^#"3\_^W0AWSAN@N\C 7[2<K((JK('.F0Q<
M7@O#-3<^#J&YZ[9-SWG7U-T:"&R:FYZNNT$AK\M8 D C-5;K)GGNC\\LL]=V
M>7JSSSR7"VN4<F,:PE2&61;VSIB%A1MR-1:VZP-ZPC:VYR*M[.E )2!(I.PH
M*)IJ(S1&@221R$.1R4Q2B&0:M5TIG=6@=,8S"9C#&93"<\XC(6ZYC.9SCSU3
MF=BIUG :H<[5SSRS.6?KRXL_IXU,WRODYL[3?$R#<E7":UC7'MNQRS]!<]R<
MHN[D1XT>NG#1^A<7#=!6W-7J+AM:!2*$ZC(%#HZI-.H6EN]H "(AYL3&D" %
ML&1:T%I@!(A+2#%G_-EJG6=\YWI])/ROE<>PY^G/C].:[ \4G'-G_C ;5UAF
M.7KKB-K5KO=^9QM:K;* :.;WDT8#NZMCWL1EUS/I\E7@4AC&B[2M1"4>"=?@
MHDKIZ#G783@&'8*974F2ATL->NYTLKI"*]7=-[PMSR&K'NLAUW!TKR[^<D?D
MW*N6>2;+7(V%SM@RS<_+6<?I.0]0'H S*Z?:W2M)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB]S/,YO^%8PG_ _+W]'4[KS[PG?T3L_WNE_XP6=AW^],_LO_P"D
MK]*37S0NB4 >J3>(3^$4T13Z(H$?3'7CR_%F^B*?1%5V$?P.XN_@%5?^#,]2
M[C/UG[U2SY(_;]Y5HZA5)HB:(FB)HB:(FB)HB:(FB)HB:(JMH/WWYN_C(A?Z
M(,6ZD\3?J_$J!QN^O\ K2U"E>4$'RL.";,,:ED^_XNEIBYW9=].V.31R)D*+
M2>R;I^Y!9=./C+*TCVA3 0NR+1LBB7;[$@;COZ/AGA7TXP:A5PO#\5AAI48A
M7K1.PW#I2R)I.JTR2U7R/(S/G/<YQ])7*6M#-'K]B:Y:IODL6'F25XM6F!SS
ML)#&3-:WB&QH ^A;BOR:>7P1!8Y<.S8&(DH<H]]/* [&*0P@.PVWKZP\&L[R
MU>$3GF#V3A7P:L>(.B_YA)UVY[]2^@S\O?\ $Y-^5/*'TMT\M7A$YY@]DX5\
M&GB#HO\ F$G7;GOU$IR:>7P4Z !AV; #JF*;[J>4.LH(+' /OMZOLB%'<.OJ
MV\ CIY:O")SS![)PKX-/$'1?\PDZ[<]^I?09^7O^)R;\J>4/I;IY:O")SS![
M)PKX-/$'1?\ ,).NW/?J(.33R^.SF)WG9OH@D0X!WT\H?MA.<!'?NM]@ ZOR
M:>6KPB<\P>R<*^#3Q!T7_,).NW/?J7T&?E[_ (G)ORIY0^ENGEJ\(G/,'LG"
MO@T\0=%_S"3KMSWZB3Y-/+X,98!P[-[$5Z!?NIY0ZB]B2-M]]O7]D81W'V=O
M  :>6KPB<\P>R<*^#3Q!T7_,).NW/?J7T&?E[_B<F_*GE#Z6Z>6KPB<\P>R<
M*^#3Q!T7_,).NW/?J)#DT\O@Z")S8=FQ,=),YA[Z>4 W,8@"([!;>KK'P:>6
MKPB<\P>R<*^#3Q!T7_,).NW/?KA.2^4%P$5RF2LQ$8CF6S]JXA$T5C9.R6N4
MI'D]&,7 "DO:E$C=-LY63 3$$2";ID$IRE,$M\-/A$) .,P;<_\ Y5A7J_N:
MI=H#HN 2*$G7;GK_ /OKG?H,_+W_ !.3?E3RA]+=1Y:O")SS![)PKX-5>(.B
M_P"82==N>_42G)IY?!3H &'9O8ZIB&^ZGE#K*""Q]OOMZOLB%'</8V]?3RU>
M$3GF#V3A7P:>(.B_YA)UVY[]2^@S\O?\3DWY4\H?2W3RU>$3GF#V3A7P:>(.
MB_YA)UVY[]1!R:>7P*RJ?>>FP*5%$Q=LIY/W QS+E,/7;1WZB%V 0$.KP=8Z
M>6KPB<\P>R<*^#3Q!T7_ #"3KMSWZ^5/DK\O1)95<F)+$"JVW3-WT<C;[  ;
M!N%D 1#\XC[ =6K3/#%IZR5\S<4JB63Y;^"L,+G9999DU3Q9#+++)2[0/1I[
M&QNIS%C/DM-VWD/J_GLUUS;<A/EH98L>0;1><.VN3F6UU=UILNUR_D^-23A*
MQ"04+"-1;LK.@D=1M'-$$5'!RF7<'**JZBBAC&'7/\)>E[GOD.(0E\TDMB0[
MPI>=+/*^:5V6X9 .D>XAH :T'(   +=U<'H58(ZT$3F0P-$43=UD<6L:,@"Y
MSBXG+TDDE;K];C\I[\1ES\MV6_I;JCRE:7\X0]0I>X61P=5^8[IN[5$AYG)Y
M3YT$3FP;<Q,=),QA[]N6PW,8A1$=@MNP;B(]0=6GE*TOYPAZA2]PG!U7YCNF
M[M1;S.3RGR$*)<&W,!%5 H_=MRV/V)UTR&#KMOKE,(;^$-]PZ]/*5I?SA#U"
ME[A.#JOS'=-W:I?K<?E/?B,N?ENRW]+=/*5I?SA#U"E[A.#JOS'=-W:HS^9R
M>4^"B10P;<]C=/I!W[<M]>Q0$/\ &W<-A]C3RE:7\X0]0I>Y3@ZK\QW3=VJ3
MZW'Y3WXC+GY;LM_2W3RE:7\X0]0I>X3@ZK\QW3=VJ(OF<GE/BNH0<&W/HE21
M, =^W+?48YUP,._=;OU@0O5X VZO".GE*TOYPAZA2]PG!U7YCNF[M4OUN/RG
MOQ&7/RW9;^ENGE*TOYPAZA2]PG!U7YCNF[M42/F<GE/G(838-N8B"JY0^[;E
ML/L2+J$*'5;?6*4 W\([;CUZ>4K2_G"'J%+W"<'5?F.Z;NU9G\SD<I\"'$,&
MW,! IA >_=EOP@ B'^-NGE*TOYPAZA2]PG!U7YCNF[M6B?F<CE/F3(8<&W/<
MQ"B/W;LM^$2@(_XV^SIY2M+^<(>H4O<)P=5^8[IN[5BMYG)Y3Y"%$N#;F BJ
M@4?NVY;'[$ZZ9#!UVWURF$-_"&^X=>GE*TOYPAZA2]PG!U7YCNF[M4OUN/RG
MOQ&7/RW9;^ENGE*TOYPAZA2]PG!U7YCNF[M4)O,Y7*@!=(@8-N?1,FL8P=^W
M+?6)#(@7K[K=PV YOS[]?@T\I6E_.$/4*7N4X.J_,=TW=JF^MQ^4]^(RY^6[
M+?TMT\I6E_.$/4*7N$X.J_,=TW=JB)YG)Y3XJJE'!MSZ)03Z(=^W+?5T@$1Z
M^ZW<>L/7T\I6E_.$/4*7N4X.J_,=TW=JE^MQ^4]^(RY^6[+?TMT\I6E_.$/4
M*7N$X.J_,=TW=JB1\SD\I\Y#";!MS$057*'W;<MA]B1=0A0ZK;ZQ2@&_A';<
M>O3RE:7\X0]0I>X3@ZK\QW3=VHOYG)Y3Y$%CEP;<P,1)0Y1[]N6QV,4AA =A
MMO7UAX-/*5I?SA#U"E[A.#JOS'=-W:I?K<?E/?B,N?ENRW]+=/*5I?SA#U"E
M[A.#JOS'=-W:HEO,Y/*?(!!+@VYANJD4?NVY;'[$QP 0Z[;ZX#X?#IY2M+^<
M(>H4O<IP=5^8[IN[5+];C\I[\1ES\MV6_I;IY2M+^<(>H4O<)P=5^8[IN[5$
M;S.3RGP73(&#;GT3)+&$._;EOK,0Z %'?NMWZ@.;J\ []?@#3RE:7\X0]0I>
MX3@ZK\QW3=VJ7ZW'Y3WXC+GY;LM_2W3RE:7\X0]0I>X3@ZK\QW3=VJ)/S.3R
MGS'7*.#;GL10I2_=MRWU *29Q_QMZ_LC"/7^;P:>4K2_G"'J%+W*<'5?F.Z;
MNU2_6X_*>_$9<_+=EOZ6Z>4K2_G"'J%+W"<'5?F.Z;NU1(^9R>4^<G2-@VYB
M/9%B_AMRV'414Y"^"V^L4H!^7PCUZ>4K2_G"'J%+W"<'5?F.Z;NU%_,Y/*?(
M@L<N#;F!B)*&*/?MRV.QBD,(#L-MV'80#J'JT\I6E_.$/4*7N$X.J_,=TW=J
ME^MQ^4]^(RY^6[+?TMT\I6E_.$/4*7N$X.J_,=TW=JB4\SD\I\ID0#!MS #J
M]$WW;<M]9>Q*FV^^WJZR@.X=?5MIY2M+^<(>H4O<IP=5^8[IN[5+];C\I[\1
MES\MV6_I;IY2M+^<(>H4O<)P=5^8[IN[5$/F<GE/@N0G>-N?1%)0PAW[<M_M
MBG2 !W[K=^H#&ZO!U_DT\I6E_.$/4*7N4X.J_,=TW=JE^MQ^4]^(RY^6[+?T
MMT\I6E_.$/4*7N$X.J_,=TW=JB3\SD\I\QUP'!MS$"*E*7[MN6^HHH(G$/OM
MZ_LCF'<>OKV\ !IY2M+^<(>H4O<)P=5^8[IN[5+];C\I[\1ES\MV6_I;IY2M
M+^<(>H4O<)P=5^8[IN[5$AYG)Y3YT4SFP;<Q,8H"(]^W+8=8_D"V[:>4K2_G
M"'J%+W*<'5?F.Z;NU%_,Y/*?(BJ<N#;F!BIF,4>_;EL=A !$.H;;L/\ +IY2
MM+^<(>H4O<IP=5^8[IN[5+];C\I[\1ES\MV6_I;IY2M+^<(>H4O<)P=5^8[I
MN[58V$N4%P)<$V><+YKX>,96*IY#+;I^I!+2F2K[:FOG'/8QOZDFV\ZK'/2,
M=V18\>U$CGM;LZ/0,"2A0.??78KIGI!C=*2AB-N.:L]T<CF-JUHB7QO#F'7B
MB:\9'T Y'TJN.G!"]KXVD.VC,N)V%ISV$KV)URBRU 'JDWB$_A%-$4^B*!'T
MQUX\OQ9OHBGT15=A'\#N+OX!57_@S/4NXS]9^]4L^2/V_>5:.H52:(FB)HB:
M(FB)HB:(FB)HB:(FB*K:#]]^;OXR(7^B#%NI/$WZOQ*@<;OK_ *TM0I7@D]Y
M]G+NX<7\E@S)]RR4PR!C"3DJI;&<5BZPS$<WF&+YP9PFSDVH]KO4 !4G172^
MP-N.W@UV]'P?Z28E4@OU8*SJ]J,30N?;B8XL=GD7,<<VGZ"L$WJ\9,;B[6:2
M#DTD9Y^M?"OYI4Y6IT%B%OF6A,=)0A?N.6@.LQ1*&XB/4&X]>LKR8Z6?FU3K
ML/:HX2J^M_0*E^N5^5G_ )^Y:\CEH_\ O3R8Z6?FU3KL/:G"57UOZ![5$IYI
M4Y6ACH"%\RULFJ)S?<<M'@%%8G5U]?V1R_R;CZVGDQTL_-JG78>U.$JOK?T#
MVJ7ZY7Y6?^?N6O(Y:/\ [T\F.EGYM4Z[#VIPE5];^@>U1!YI4Y6G9S'[O,M=
M$4B$#[CEHWW YQ'JW]@P:>3'2S\VJ==A[4X2J^M_0/:I?KE?E9_Y^Y:\CEH_
M^]/)CI9^;5.NP]J<)5?6_H'M42?FE3E:E,L(WS+6QU>F7[CEHZR]B3+OX>KK
M*/5IY,=+/S:IUV'M3A*KZW] J7ZY7Y6?^?N6O(Y:/_O3R8Z6?FU3KL/:G"57
MUOZ![5$AYI4Y6B:*)#7S+72(DF0VV'+0(;E( #U[]?6&GDQTL_-JG78>U.$J
MOK?T#VKAF2/-'/+#LM.E(6*O65E'SIQ#*(D6Q#9D4Q*RG8U^OTE#CT2B#=JJ
M8H#^V, $#K,&JF^#+2P$$UJG78?5]:AV(UB",W] ^M<X^N5^5G_G[EKR.6C_
M .]4^3'2S\VJ==A[5/"57UOZ![5$IYI4Y6ICH"%\RULFJ8YON.6CJ 45B!Z_
M6/2.7^3<?6T\F.EGYM4Z[#VIPE5];^@5+]<K\K/_ #]RUY'+1_\ >GDQTL_-
MJG78>U.$JOK?T#VJ(/-*O*U*LJIW>9:$HHI%#;#MGW$Q#+F,'68 #J.781$
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MC(A?Z(,6ZD\3?J_$J!QN^O\  *TM0I7Y,O,=_P"O9Q4_QR6SXV77UGH=_1?
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M3V?SNKFP0BO'!$8;#'/D:Z68"/9F[*KSL@!)8YSC(TG(@#48.+CVZQ<X.:0
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M?.UZ7C5(N;=BFT2?),7K3Z.8QD;&QQM:QC&M8QC&AK&,: UK6M: &M:  UH
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MHB@6_;MO'_\ (6T13Z(H#>J4_$+?"(:(I]$4"/ICKQY?BS?1%/HB@;>ITO\
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M;G9G  '/?+E^Q,4X;8(S[X2& P?^*W@W#K_)IOC0?F[23VCA_P &FK<Y2O\
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M#_@TU;G*5_LY.^L24;G9ID*0N>^7+L4  -\$9]$=@]G[JVF[Z#\W:2>T</\
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MNGRA<TB5KF.DUHBU[<\P%EL?KQM?E\INMJ@YGBSU=H;YPXB"!D<P>)=8\/\
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..B:(FB)HB:(FB)HB__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g96328g05a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g05a11.jpg
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#Z__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g96328g05v45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g05v45.jpg
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M5UB8UB0X05%UMM<989*6U24R,S0UD28G0E*7*&)V@8;_Q  = 0$  04! 0$
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MT:PP1K%$GYJ(. .?)/XDD^23R2?<Y$[C=;7J#83[7=7[.RV-DJ9K=J0R2,$
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MM*>75))MI:$R<!\$7(:)$:::1D?<;62 5I-C=>N&[A"UF4Q]WJB<,5[^"5F
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M8X3,46.%"066&")(X(>\@&0QQJ9& 9RQ .8]=JM=J8GAUU2*JDC!Y.SN9Y&
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M'0)%\6,%>%C8J)C!'92RVZRRCNA8*GT^!%THZP6BP'*;"BHH)M2W'%+))6,
M,66/+:32W]_L(M=KHU>5P\DLTKK%5IU8AWV+EVP_$=>I7C!DEE<@  (@>1T1
MM#9;*KJJKV[;E8U*I'&BF2>Q-(>V*O7B7[TL\K<*B*/Q9BJ*S+H+K?V1G?\
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M+'2\UM]M"7%L:<1MY#:][TAQ;>M_&E"]I5I*MITE6];UK>]ZWE>U@ Q4]I)
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M<<:L[NQ"JJEB0 <RPPRV)HJ\$;S3SR)###$I>2665@D<<:*"SN[L%15!+,0
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M A@&4AE(!!!!!!]B"/!!^A&>7RQ2P220S1R0S1.T<L4J-')'(A*NDB. R.K
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MF7<8*/=3ZN$H^=]M<ZIV;6[ES80WKTZ.SV)3:EMR/VD#MFGG?A@/NQ]W*IX
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MUU,>&>+J#=6(M.7Y!)3IW3?9>C$9('Y*:C.I'ABWOG@1^(>TI\ITWK-%TK&
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MRL:NZUWXKQ6]]"O<?Y0^4,>,ST=D<I/&>--EZE*QXXU>41M+B-.)^$*P=AL
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M/M*2XR^PXMIUM25H6I.];WPTD<D,CQ31O%+&S))%(C))&ZDAD=& 9&4@AE8
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MHFRUY@L"0%4K0I(OJ?PWMHG4]/57+$,>FW_?J]Q6M\&I=KRQR-!#(&91'/\
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M_P!/H/\ [:WG^KQ]I[W_ *-2_P!+:[_WX_I]\N/[A5E_Q%</_P#5<?8'1_\
MT^@_^VMY_J\?:>]_Z-2_TMKO_?C^GWRX_N%67_$5P_\ ]5RGV!TA_P!/:_'_
M /#>\_S>G_YX^T][_P!&I?Z6UW_ORK_F1YC>:W)O'J]7BN^)4KRD^+1%M.=)
ME.D<PZ@#2PC9,44R;?J%<)/)+VTRYL9DZ0%>A(I\EJ1EV2 QW!GNJZ,Z-Z(V
M_45&C8ZNCVT<OJE=9'K-IJGO.D3.D"W+ 14Y([S'&ZSS*ACA978,L-O]]U#1
MU=FS%I6H,G8#<DMT[JUU9U#2&"$L3X^Z'<&*,L'D#*O:T0?90VKIWF+(VKR4
M\GRIGI%FY(7'T;B%GF(V$AZ7"NRPDH7?9*KU:NPL+7]WE"%0D9-7'0Q$FB(*
M!@Q70D,&I)F?BS4UG1D53IGI=(=95W"27]Y5ADFFNSK"\2:^.U;LS36?D"1/
M+!2[EB,R23L'+)V1O14MKJ":?<;AI+LVO*5M;/(L:5H6E$C6V@@BCCB^: ])
M);':9!&T<0*A6YW67"]TSG\9N8NMFAJS'>JDM/RQS(JRW4ZUO8X RE;*D2]_
M$G2 P62"G-J2EME2E:UOYIW_ %-T]TM3.PZBW.OTU3DJDM^S' 9W''Y*K$Q]
M:W.>1VP5HY9G) 6,D@9[#J-'N-_9%/3:VYLK'@LE2!Y1$I_^9/(!Z5>(<'NF
MG>.)0"6< 9#_ /2AT[H']5R/G3\3#.[^%/1.MLGUB*4TK>MZ+@:.A";A/MK9
M5IT9V215PGE?"GW2D;6I/ _NTZSZI_)]!](RT-?)X'5O7D=K2T>T^1/K.FE5
M>H-HC(0\+W%TM9R5'KLO=QUO[F>FM#]_JSJ&.W<7R>G^DW@V=H,.08KV[8G4
M4&5QVRI6;9SHO)](-P,Y(GC_ !TZ6Q,=CM,UV&68=00Q&3J6XCGT<\WO>V]Q
MW.XIQ,"]\OU^%+]A_: U7PH6LK;B=*UG@^%M/9SQ7_B!NMCU_>B=98J>S"4>
ME*DBGE34Z2I,NKD*>PEVWVK9/:K-.7'=F.;KRQ1BDJ=(:RGTC4D4QO9HEK>_
ML(WAA8ZAM*;R=WUCU_R$ Y*B+M/&3V((* ,P&",.&&,TAD801EL<8=EM.DML
ML,,I0TTTA.M)0VVA*$IUK2=:UKTST^"""M#'7K0Q5Z\*+'#!!&D4,4:CA8XX
MHPJ1HH\*JJ% \  9PLLLL\CS32232R,7DEE=I))'8\L[NY+.Q/DLQ))\DYR,
MRYCQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8SI-VYQ1^C1Z(VZ5N.
MG&6%?,")?;4Q*1;^MZ4DJ'F!%CRL.8A24J27&&"D:WK6OF>GKK?.]1])=-]6
MU5I]0ZBILXXF[ZTLJ-'=I2@AEGU^P@:*]K["L 5GIV()01X?CD9,Z7J'==/6
M&L:?8V*3R#MGC1@]:U'P08KE.59*MR$@D&*S#+&>?S><AF3Y_P!:ID<;&5J7
MCNX4 L9X(_F?7'1]SSD6^VI!$=&WQT,H::8>;6IC4=>(HU#C&],O3:$:]=\3
M'I_B3T.\=CI'>'K755F5X>G^JKK4NHZBH0RC3]9PQNUB5&_>H]_5F< *#M(^
M <ZA]ET5U2K1=0ZH=+["92LFXZ?K"SIK#,.TG9=,R.H@1AYDDT\\:EBQ&O?G
MC*CPG-H^DV1_7B5T25\4.B%DO2$EXM=GBC#^#W8UU]3K[=:J[TAMNI[DB][;
MW8^&6#0C;'P.$U<S6M,*]4Z>^/G2O5MN'IGXCZN]0ZD*K##6WT473_6R!?R8
M?6;)C)JNL:Z'DQ>G9V/J<=S68"WCB-Q\*M]H*\N[Z0NU;VD!:22SJ)'VW3;$
M@OVWJ:A-AT[,1XD,D%,*20(9N/,VQ/FS$4*0:J'E[29#Q?M^TOH"M%@/U8>#
M718S+CZETGL@0@T*@T@9I92*M<Q*I:6MJT&S''O:2X[W\W1$NPC:YT=>CZII
MCM+U:\?RV_I!F"@7M-([3E%8A?FJ3VZK<%S)&O@<?'U)'685]_6?2V/O!9I6
M];5V2H)YK;%%$09E!8065@G'/:$<^3+G"_+7QU\E(ZT2G%NHPER%I;B$VE&Q
M)JNG0C#R"'!Y$Z,M49"23<.4@0M0TRD144_L4IMLQ3HQ"&X+J3IC>](+')U)
M0;50RPRSI8GGK/5]*!0\[-:@FEKQF!"'G2257B0AW54(8RFHW&NWS/'J+'SL
MJ21Q&&.*=9R\K%8@L$L:2OZK K&41E=@54E@1F$D+1/]X=(C:=+&4KB8[S@L
M_P!,;=W&3?0_E+VV9"<Z?>^4Y&UM6DN,2%[UZ.F*TX+6T+;;>DL^>I-EN_BQ
M-)K^EK-W2_#V.1X=GU=5]2#:]6^G)Z=C7=(N ):FH)#PV^I@.^PX:#3@JKW<
M]=2CK.@(TM[V&MM.L'19:/3LQ6:AT_WJ'AN]0J"4L;%>5>OHR>V$%9=B062O
MDHQ=EXOS.!CZW'6OGE.@(<?0P,>Y9H&,&';3O>UJ6HN0;6Z0ZXI3Q11"W"2B
M''""777W''%>Q:'I)=+K:FFZ>T$U/6T8A#5IT:,YCC0>23V1L\DLC$R332L\
MT\K/+,[R.S'SK;;Z39W;&RW&T2Q=MR&6>S;LQAW8\  =S*J1H.V.*) L42!(
MXT5%51AS_)CQPB]?%)^0/$8Y/IZ_$?U:B!Z]/K]?4B>;UZ?3?U_[MYT,?3'4
MLOB+I[>2'VXCU-]_/X?=KG(=MQJ$_/VNM3_*O55_'\91^!_D.=*DO-_PUB/I
M(>5GCNSO^?HCL?/R%?\ A&GWM_\ ^O3U]?I_/-Z+H;K2;][Z3ZC;]>FV"_Z5
M=?/Z/?->3J3IZ']]WFH3_*V-0?\ ][S[YU5[[0_PB:<^4WY,\KD%[WZ:U#3V
MYW2M_3TTA4*.>E?KZZ]/AWOU_P!F;0^'77!')Z8VL8]_R\ K^/QXG:,YA/5?
M3@]MQ2?],4OK _J:(.#^P_4?CG'<^T,\1];UH7I4Y+?%Z_+57^0]JL3;O\__
M (+T%SN09=]=ZWK6T.*UO_?]<O\ [776'\/5P0_0BQM])7*_Y2S[&-E_:!EI
MZKT/TN2/^!CH["0']31U&4_L.?#]_P#X40K:(>M>2-A5O_X?W)XF^29*'O7^
M7RGB.8"LJUOU^BMN)3_M]?3*CX>[X>9K735<?7U^K>FE*_K5-H[#^3*#JG6,
M>(X=Q,3[>GH-T5/ZG:@J']?=Q^)YS]?OPUQ[:M1WCAYI26]?5&F_%WHT:EW7
M\];0Y8!(=I.M_P"S;KC?\_KZ?7T?N%L+QZG4O1,7X\]5:V3C]8KO,3Q]>T-_
M6.7[I(CSVZCJ)OU:6VG)\> 9%0>>?J1^G/RGS,FB][1%>&?FH<[Z[TE)7+:9
M7VU?[M_/L?38EM&M_P"]>T^G_P"KT^OI4]%0)QZO6O1"#QY3;7;!'_YM;5S-
MR/P _5@=0R/R$Z>ZB8CZ-1KP\_J::Y&G\K#]'TS[I\GNY2*?6!\"_(UY7IO>
MM62X>-U51_W>JB>VFN:]?IZZ^3\6M>O\._3TRW]RVBC/]T=?]-J/_P!EI]2V
MS_(NDC'M_P!KWX'ZJ_;.R<<Q]+[?G\)K&FA__P F_P#)FH7PP^T9\VNP>>8W
M'NC1S1--FIZZ1MOY:BEQ,6_QZ-@P)0A)RIP.*'LC3E?DQ(V(D"+5*2 LHZ<H
M1MIF1/C%,^P=:_#?HC3] ON==(R7(*]*6GM3=FE7<RSR1(8Q \S56%F-Y)XU
MJ11O$L??RT4<H;A>G^K.H+_4R4+7#P2RV4L417C0T$C21NXNL8G0PNJ1N;$C
M*Q<H0)'C*^D[/FC/7,^;KK;#3K[R]-M,MK==<5]$H;;3M:UJW_N2G6U;_P"[
M65 )( \DG@#\2<9Y?:-TFE]M^T9C.I\8\OZM;N3]PZGR^PAR#E,\QF^A/@4F
MR5"<A.3U4*1Y\SPZ+JITE5)*GD6E-IKL0Y2KI:E3L!(6#UDS/4)ZTU'IQZE[
M3RPW*-2U&4]?2FN&GBFCDMS%;!OO,JS+.L0BD<3P1!)%C^Z-4$-(&5N58J>>
MV3G@$$*#QV<'CWY\@\?ISU#9Y=FUC&,8QC&,K#X8_P"K%R/_ ('(_P#,<UDK
MN_[ZW/\ +3_PH\QQ?O:_M_TCEGLBLR8QC&,8QC&,8QC*%]?WKQU\G:!Y"L>@
M?,N[_L]P#O6T[^1'0MNV23KA/5)5>O1AK2)4HOE,Y*F+8:9 LU6V^0IN+':U
MW^G_ .4?2VPZ=;E]IH/F>H=!_"DFI]J?;^JA'YQ)B1-M!$@9FDK6^%!D8GEM
MA_Q1NZNW'"TMIZ.JVOCA4L=Q&KO2-^:.'9J$KL1PDT')(0 7TS@,ZG*J^7W4
MK/S[EP]6YFZWOMO;+%'\>XTQO2EJ#MEK;(U(W(AMO?S$1/-ZH+/WV5)4G8[;
M4 T,^K2C&DKZOH_55=CM6M;0$:/25I-SNF\#OIU"OITE[O#3;*V]?7Q(#WDV
M"R@]AX@^H+T]2B(*7G9;*5=?KAP3VSS@]]E@/(CIP++:D;V B"GRPYF+CW+:
MQQ+EU$Y-3FG&ZY0JW&UV/=?^'9AZ@V=>]F))Q.M:?EIR067,2Y/\RI,XLA7\
M3N\A]SM;6\VM_;W2#9V%F6S(%\)&';\G#$#^;#!&$AA3^!%&BCP,D-?1AUM*
MK0K@^C5A2%"WEW[1]Z1S]9)7+22-_"=F;ZY)&1F;F<=(@B"7#$##I+=;2TZ4
MEEM)+C2-^J&W'])TZMM._JE"E;2G?UUK68A! LS6%AB$[JJ/.(T$SHOYJ-*!
MWLJ_P5+$#Z#,AEE,:PF20Q(Q=8B[&-7;PS*A/:&(]V !/U.<C,N8\A?R$Y '
MW7D=NYP\>Y"2LF*+*4^SC>J3:A?*X<-/TBV .(UMULFOV>.C)%6F=H60,R0&
MI6FB7-;UKE86Z\D!/:S -&_UCE0AXI!]?N2*I/''(!'USI.D>H9.ENH-?N5B
M%FO \D&QHO\ O>PU5V)ZFTU\H)[62W1FGA'<"$=DE [D7C$>,W7R^U\CA++8
M0&X3H4$9)T+K=73Z:55>JTLI4)=X3;>E+^ 7[T85)PZOC<23 R448AQQ!"5[
MLHV3:KJ[@+,A:&Q'_P#3L1'LE7]7<.Y??E&4\GGG-CK;IV/IKJ"S2J2M:U%J
M.#;=/WCY%_0[.,6M7:YX7F3T'$%GA5[+<%B/@%",Z-Y ^.9=H37.I\)=@^=>
M1/*?O$[GMA; :#KULC)%22+'RKHX@"&=2U$N^FM-ONN)<.J\[L.V0BVI -]L
MWO.GNI$JFSJM^+&RZ<VWI1[&L9&>Q4EBY6MMM:\A8PWZ/<2J@B.W!WU)PT;J
M8_--MJ&G]&]K#%4V]#O:I,$ BG1_,U"XJ\>I5M<<$G[\$O;/$0RL'D'Q\[S
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MIP_)D9$ +,"?)\[/QX^&HZ.V.NW&ML;S9:O;12QVK.UEL;*2C>K&)4BFVCH
M4MQ2AJL-AC,&KV0KR(%";<<Z[/GS&,8QC&,8QC&,8QC&,8QC&,8QC&,92N[>
M3=CO5IFN0>),!%=.OT,4N)O'4IAXA'#.-%?#Z$-6.PQ_Q+N]V"VMO;7.*@\]
M((>^9JPRE?:%(UN,EO/+(U?7HL\RGMEG8GY6L?KZCKSZLH^D,?+<_GE #GI6
MLZ)IZNC6ZA^(%N?2:FS&+&KT5=4/5'4D?/W&ITY?&KUDO#!MSL56$J!\G!;:
M1#G:N7>)M&J14W<>G&.=\[%<HQ<5=NG=+C(Z3=,BB-.;)JM1JCK1%<H-#WMU
MQ"*G71&ARVOE[FRYDEI!";X-?%&6EL'YNS(O;+/.JMROU2.,\I#%_P#BT'!'
M'<6(YS0WG7VTV"5M=HXUZ3Z=UTZSZS1Z2>:%8ITX[+^PO@I=VVU^ZI.PN2,Z
M-S\K'61BALA7JU7*C$!UZIP$+6("/2M $'7HH&%B 4..*=<0'&QK P0R5NK6
MZM++"-*<6I:M;4K>][J1I&H2-$C0>R(H11^I5  _8,XVY=N;"Q)<OV[-ZW,0
M9;5R>6S8E*J%4R3S.\KD* H+,>%  \ 9]I:#A)\58,[#Q<T$[K:7 Y:/$D17
M$JU\*M+',9>97I2=[3O2D;UO7TW],JR(X[7577\&4,/Y"",MKVK-202U;$]:
M53RLE>62&12/8AXV5@1^(.5YM/AAXF7):WY[QSX\Z:M6U*E8RB0%>F_C5O6]
MN)G*\'%2Z'-[UK?S$&I7]/\ WLTY-9KI>>^E7Y/NRQ+&WZ^Z,*W/Z>><Z^C\
M2>O]< M7K'J(1C@""?:V[E;@ @ U;DL]<@ GP8B/T9T?]Q#CL3Z;Y]<?(?DV
MT[]4-\\\C>PA@)5Z[WK>H2PVRR0*DI7O:],KBU,;W_"MI2-:1K%]DUE_>9;E
M?_\ (W+ '\UW=>/T$$<>/;QDF?BGU%8/.WUW2&_Y\$[CHWIV24CQX^9IZ^E;
M'@<=PG#CR0P/G/TOQQ\A8)7PT+SAZNR(C6M,QW4><<=Z>RG6O324O23%3I=C
M(U\.OA4MR<V\I6]K6ZI64^1N)^\[6P!]!/#7L#VX\GLB<_S_ "?.4'6/2-KS
MM?AAH'D/YTNCW/4>C8GZE8&V&SI)R?("U>T#@!0,?<_V@%8;VD*[^+'6VV]^
MNM6.E=*Y!)OHUZ[^%1M?LW38Q#J_72-+3#H:3K7Q[;WO>T:=NXC]I:%@?_C(
MYJ[?RHTRD_\ YHY_#'S/PFO'F76==]/LW^![/2]10(3[$16Z.CG*K[\&R6//
M'(XY)/9?,:!4E%I\-H>SLM__ #!_)/(>FRRW$I]-*<%A^E5_F#ROBUI:TLN2
M.G-:^!O2EK5OTK\SLD_?-:L@'NU>[$W/X\+,D!_4.>3[?IP>G/AU:4M1^(]B
MD[?F0[_H_9UP">2%DLZ6WO%''A2RP<<\G@+QS^5>:4?#[5J^>-?EW0DL_P#S
M99/#92]Q8VM:WM:]R?(I/H@[K2-?#O;K/QZW\6M(TI6E:33[45?WZCL8?Q9J
MK2(/UO TH_:>!E?[6TM@ ZKK7X>[7N_>XTZH@U4[\^ /0Z@@T[JQ/T;CCCDD
M CG(17G[X>292 "^[U*H2*E? J,Z6Q.\KD6G?BTC;3X72(BK/M.)7OX-Z6C6
MOBTK6M[^'>]7+N-:QX-N.-OXLX>!A^/(F5"./Q]O?SF*Q\)OB)!&98^E=AL8
M>.1/I&J[Z%EXY[DDTMB^K*1YY!]B.>.1EBJET[FU_9T11.A4>ZCJUK:7ZE;(
M&R,[UOU]-Z=ACS4;UOX5>F]*]-^F_P#=O-R.Q!-^]3PR_P#Y.1'_ -%CG'[#
M2;K4-V;74;36/SQV;"A;I-S^';9BB//D?3.YD+8;8?<*6RV,VRXLEPA2$,(8
M2A2GEOJ<WIM+*6]*VXIS>D:1I6U;TG6\RL%*L' *D$,& *E2."&!\$$<\@^.
M/?(U Y=1&&+EE"!.2Y<D=H4+Y+$\=O'GGCCSD<<PLG'++$R)7%Y[F<_!#R;H
M\L1S"4JTK$L3/RT+?9D7:H^^&U)_*4VMULE22_EJ0I:?AVG>1>IU^DUT,L.B
MI:JC7>9I)HM36J587G;\^25*:(C3-_"=P7/U.3F_K]3UK,"]4P;Z"XU=367?
MQ;"*RU4,0A@&Q5937#!@IC_)]P('D'),R5R!QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&5A\,?]6+D?_ Y'_F.:R5W?]];G^6G_A1YCB_>U_;_
M *1RSV169,8QC&,8QC&,8QC&,\[WVH/EW=_#CRG<,X;'"Q-Q[%XV"Q'19B;'
M)*@C5M6BS17/+E @A%QVOZ0J$R%9 VI:2=D8U^*EHJ.-B26XUCX?HKX7=(4>
ML^E0F]D::EINIGFUT,+(LZ U:LVQI6'=)/\ B[8-)6=H8Q%*LT,TB3*9&SRK
MK'=V-#O&;6JL=C8:=8[<D@9HV/KS1U+$<:N@%NJJ3*)'+*T<D:,A$8S<)X6-
M5!OQ*\=':'!2%:JDAR"CS,7$2[R2Y=E4Y!B3$@5*GI0TB3DY.3.-E#Y9#32)
M8LUZ20TT@K3:?'NMVN'J_J07YX[-N/<WH99H5[(B()WAB2*,DF****..*.$E
MC"B"(LQ3D]WTXM==#J/E8FA@;7U9$1V[W'JQ+([._CU'D=VD>0 "1F+@<-EG
M<Y;)K&,8QC&,8QC*8_:%DP,;X<=RG)Z.E9#]G*T#/UUZ!>2+-0=XB[!$$42T
M1QRF7]@+K%NU#3I9:6E[;C03=+0XTMQM<9N2B:RW(ZLWIQB1.P\.LJ.IB=6X
M/'9)VL3_ !01[$YZ1\(DMS?$;I>K4F@A^<NRU+BVE,E:UJYZ=A-K1FB#+ZHO
M:[YFK'&2.9I8B"&"L->GAWYY>77G,Y8>5UD3DG)I^LQH<S;NTL0U@GRHRN%O
M-QHS%6YW)$&5\N[''H(?;/L%E9KS B2GFJT6L/Y"X35[C8[?U*Z+7K21@-+9
M"NY5">W\G"Q*&8D'\]^P#SV'CC/7?B)\*OA]\+EJ;Z[)U!U!4NSR5M?TT]FG
M4CGN1JT[O?W,"16X]9%"50Q4Z+7&E,:M=C$G>-IG'O%WF/()8RZ-(F^@];FF
M-,V7L_3)-=MZ1-:WI?S1AY8M"!*O";VXI#-9IX$!7F&4M-)CE;:2O?0UJ$%9
MC+]Z:PP^_9G/J3MS[@,1Q&I_B1A$XX''C/"^HNN-WU%7BUK&MJ>GZK=U+IO2
M0#7Z:MQQP[UXR7O6ON@M=V,MNX[EF,P[B,@KKU5LOBOT*P>4W(X62G^86Q]H
M[RLXW CO%DEM,)2ROR"YQ##I^'5_K@:4;Z)#CZ;:OE3#6>MO]IH@8TGT_3VZ
MO5>NK]*;B:*OM*BF/I+=3LJ*C$EAT]LYV\_9UER1KIFY:A<<1@_*S-&OD6P@
MFT5N7>:^-Y:,[!]]KH@S%@!P=M2B'@6X5X-R->!:@3N(]9 YXOECWB$K56X!
MVKF#T9;"Y*7D)^BVT1_9M6DZE,5C;,L$8H5QETX&PBR<60..T2&0T1%Z*^<T
M\"IE?Q/_ &3_ %9?^%TO0^YKZMEZMT_4NUAK&\LBU(*OV9)3W>JV<4;1RRQW
MQ8JO'%'-"PEHK:27FN%D^F/@=H*O6\?5.MGO ]/['3:]YUK,ALS3_/+9UE^E
M(ZO'&]3T;"O(\4J]EHP/$?5+)TZ<\\^A#<DJET@>-QTI:[K84T*F5U-GV1*]
M$Z!LC;3D/SZG!L+F9(((7XI:?EIR7@(6M1PTB](S#C(:""NJ^$G6GQ1^->AK
M;/I7HSIO1U8(;+;[JSJWJ&U6Z8UQHOZ=FQ6U^LH7]S;A9BD5>&62I)-<<TH)
MK!C:<P7Q Z9Z&^&FTGI;WJ3=[2>22#[*Z>T&H@EW=Q;2AH8I[MZU5UM>11WO
M++''81*ZBS)'%WB$29SKQ"L:[?:.S=8ZK;E]6Z=&Q0]T%HLBQ# 0$.#I1(7-
M*O:]A+LP5%KY3[VF!J^]5]SIJ?OV?1)3#BCE=EL^GNN>HZE;3]4_$_:GIZA+
M-)5T/0>IK=":V::7A9;ENZ+&ZZHM6;"*%::3J!)(HSZ-?Y>'\B.;H[GI?2SS
M[#1=#T/M:XD23;7JR_-U5=BCC^]'7K53#K-%!#$Y)$:ZB19'_*2F5^'%FJEP
MWDU(*W(P%'ADS*U:<<L4LV_8[,Z[K^;CECL+TI-J4K?JI7^G:3M7U^'7IKTN
MT7PVZ&Z<G-O5]-Z\; L'?;7EDV^X=Q_#;;[:2[L2Q)+-_=(!;SQ[<6[7K;JK
M=1?+W]W<-, JNOJLFNUJJ?X*Z[7I5I  >!^0YX\<YW60J%3EI>.GY6KUV3GH
MCTU$S<A"QILO%Z2O;B=1TD2,Z8%\+BE+U[9YKT6K:M?7>]YT=K0Z.]>J;2[I
MM5<V=#CY'8VM=3L7J7#%A\I;FA>Q6X8EAZ,B<,21Y)R&K[;:U*EBA5V>PK4;
M?/S=*O=LPU+7("GYBM'(L,W*@*?41O  ]AG8LE<C\8QC&,8QC&,8QF-F(:(L
M,6?!S\5&SD+*BNA2D/, BR<7)!/IVA\0^/-:?$,%>1O:71R&7&G$[VE:-ZWZ
M9:RJZE'575@0RL RL#[@J000?J".,S5[-BG/%:J3S5;,$BRP6*\KP3PRH>4D
MBFB99(Y%/E71E93Y!!R!;OXE^/-ZJ<13RN75BK@U@I^1I,GSJ/8YQ9*#,/N?
M/5,T>P4M$+)UF0V5ILI_<<^T*>\TWJ3%.9TII6I+KJ<L2Q&O'&L9[HC H@>%
MN>>Z)XNUD//D]I )'W@<ZO6=?]7ZO86-C'O;UZ6]&L&S@W$S;FEMJRCM%;:4
M]D;,%Z$1EHT]9&DA5F,$D3$,(<^]_*?QE_@L8DQY>\4#^B;+7P(X#R9I<<C6
MT(U.54)N.K/90PVDLZ=E*YJNW4CXBBGX*:?2GYFOW7Z/YX;8UA_#156[$/\
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M:][;7M*TJ3K1BH6IT$D4:LC$@-ZL*\]I*G[KR*P\@^ZCGW]LN+ >"?ZCD?\
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ML[LSN[,[N[%G=V)+,S$DLS$DLQ)))))YS?555555"JH"JJ@!54#@*H'
M ' '@9]\MRN,8QC&,8QC&8^5B8N>BY&$G(T"8AI<(J-E8F4$'/C9..-96,8
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MWYBB'.<F)7T[@\F[M>WELN<VM9RBJDDIS2&7B><66H*9'VOY8SB](VF.^S3
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MD_,9=0XGU2K6]Z,.LV%F,2UZ5F:)B0LD4+NC%25;AE4@\,"#P?!!&7EE'@L
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MBK^5\EF8 #\3@R  DJ_ \G[AS,?O,U??\N9^1O\ ATZ__E/+?LN7_"]9^/\
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M<^V^9[;YC'SO@^>U\6O+0DB[>;%%^[GCTKM:7CCC\[LD/;SSXYXYX/'L<N#
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M0\R_[AP08PA/QC1SS;7RQG/5Y;>E_ C:G$[.OLI4N0V)%9DC+]P3@L>Z-T'
M8J/!8'R1XYRCJ61E'@D$>?TY,&:679%G6*-*7R.I8D42 *Y6^J<WO)JI!9#:
M'HNG6@&;D1AMCCDJ4>0**ML)#J6AUOJ0E\AAO>W$[52=*[3EPQ$M6Q O;QX>
M:,HI/)'W03][CD\>P)\98ZENWCCPX8\_@.?Z\E/-7+\BJ6HLH?VZA=,:* 3"
MU7EG6J,>&XLC4F_*7ZV\5GXDD1M(ZA5@"B<WF6I!;Q;)#9!D8D<<EMPIP7;2
MPJT+%4AN^:W3L*P [ M>&]&P)Y[NXFTA4!2"%?D@A0;2O+JW/YH8<?CW=O\
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M#*< ?+CWG0W"1!2%CK;4\.PYM32=N_86W>NVD#*EFW9L(K !E6:9Y%# %@&
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MB;Y!U-/4"#'^>[ZTS)#\W54M6YVN.<R2N[:L:8O[F3$MN#N&(F$*B]1QZ7W
ME],P0]OI&4S_ #=7Y4 6/E"AL^KZ(E%K\@8BX?O\]O80V7^K'_&_1[-S[=WM
MQS[>>?;.J4#[3;BEJ[[TSE,G/Q*:J%3>4]*XO::W%6ZP&7KF5RX0KN=QZ)9!
M (@I%2IM1@WHEK<]+MQ86RIV%A7U;L$J!'D9K'3-V'7UK:QOZIFMUKL4KPQK
M7LP7Q0AK1LSCUII9.[\FA<\([C\FC,*"52Q7D>P8<<GE2H8DCCP "/)X'D9=
M#@_=J!Y'\XB.K\P79B*3/[2Y!25HIMGI+\U'O!A2(,U%1]KBXDZ0@Y,"0$)C
MY<5AT)_:WQ-NH/!/$%A;]&QK;+U+7I">/Q(L4T4P1@2K([1,ZJZLI#(2"/#
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MT65>^)P5*/'*@*]\<B,T<B]P[D9AR.><M=0ZE#SPPX)!X(_2"/((]P?H<IG
M?9.>(\!8"IUN,O,DR?X@L>%<C7I*SB*KY_+]58*D2%I?' A #T=5FZE'AP$M
M<Q9(=#@#.M"1(;ZEO*F9.K-O)&(R\"E=P=VDBQ'U$M>JTZQ!F=E^429C(D!4
M\,?+D #,?H1\\^3^3]/CD\=O'!/^41X+>YSI:OL=?&1R@52COVKH[YU$NB[G
M3[TY5O&A-EB%O4U=$+@3X%KQW:Y;=(<V 7OW1O0>=6VUKE4,S:+,W*CL%MY?
MW8;,3SS"*L%LP^C-!ZNR])P)_F!(LAV!M0NLGL*]B*()RGI]I(-?13@#S]T\
M@\+X\<<<<<$<?B.?TY)X'V97!(3K$7W*LVGK-2ZK$5JH4L.VU:<ID(]JEU/C
MR>+/5!<2)0DP"JY:( 6&L<_%IBDCBWBMUVP5/573&-@KUFZFV#TVH2QU9JCR
MS3F&5)G'KS7/G?6[FG[_ %(I"\:,6):"22.;U>[NQZ*=P<<A@..X< \=O;Q[
M<$<>?(\'R.,G7Q0\3N=>'M!LG/\ F\M:YP&W]!L/3K%*VW]CQ3#+79A8D*3>
M!@N>4^@4.N1ZQX4':8RK4Z$#=,V9*&-ERLB><3H[;;6=Q8BL64B1H:\=6-8O
M6($43.RAI+$UB>1N7;[TLSD#A%[455%Z($! Y\DD\\>Y_4 !^P?U\Y9_(O+L
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QGB:_?(\L?[R':__ .2+7_ZGGA?VWN/\9WO^\R_^[/U/
M_M9?#O\ Z$=+?T)K_P#48_?(\L?[R':__P"2+7_ZGC[;W'^,[W_>9?\ W8_M
M9?#O_H1TM_0FO_U&/WR/+'^\AVO_ /DBU_\ J>/MO<?XSO?]YE_]V/[67P[_
M .A'2W]":_\ U&<A/E[Y=K:2^CR'[FMA;VAT/)Z%;U-*(5K6TL)<U([0I[>M
MZWIK6]KWK>MZ3Z;ROVSNB.1LK_'/'/S$W'/X<]WO^C+#\-OAL&*'HOI,.%[R
MATVM#!![N5,/(7P?O$<?ISX*\QO+)*MI5Y']L2I.]I4E71[7I25:WZ;UO6Y/
MUUO6_IO6_KK?TWE/MO<#WV=[_O,O_NR\?#+X=$ CHCI4@CD$:37D$'V(/H>0
M<_2/,3RT<^/Y?D;VY?P(VXOX.C6Q7P-I]/B6OTD]_"A/KKU5OT3KUUZ[^N!N
MMR?;9WSP.3Q9F\#\?SO;*'X9_#E>.>B>E1R0HYTFN'+'V Y@\D\'@#SGYUYC
M^66]ZUKR/[9O>]ZUK6ND6O>][W]-:UK4GZ[WO?TUK7\\?;>X_P 9WO\ O,O_
M +LJ?AE\.@"3T1TL /))TFOX _$_D,^COF!Y<,;]'_(KN#._C<;]'>B6YO?Q
MLKVAU'HN2UOXVEZVAQ/\T+UM*M:W],J=UN1[[*^/<>;,P\CP1^=]#X/X9:OP
MU^'#CE.BNE''"MRNEUS#M8<J?$!\,/*GV(\CD9;WP2\DO):X^6/$*_=^S]<L
M50GI^58D(FQW*S2$#+,-U2P%M-$BGFN!&-H?':)0E:7$I<90ZG6E(TK4ST_M
M-I/N*$4]ZY+#)(X9)9I6C<"&1@"&8JPY /U\CG/-OBYT/T)K/AWU7=U73'3=
M+94Z=9X;-+64(+E9FV-.-F22&)98B4=D)!'*L5/@D9ZE0).-E&UO1D@#(LMK
M^4XZ 6P6VAS24KVVMP=QQ*5_"I*O@5O2OA4G?IZ;UO?K95E_.4K^L$?Y\_/O
M/J68( .X6<4,$*U\'S22WVAAV_F+2VCYCSRD-H^-Q:&T?$K7Q+4E.O52M:V
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MCG:S,!8,TWIV(8^V2=I(8U@L6+'I.BLWJ+$YA'<J(T@3O-J@CGGV^@\']?D
M<_M\YLOSGLNQC&4V\Z.(N]]XH%2T<Y-ZLS'=$I-L-I<7<J52I20#@32%NOQY
MO1J?<J1+$!*(00N L#$$/(#((<$LL9)B@ME2VFN"C<,QG6L6@FB69HIIE5G
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M .$F/W"G?[S' /\ P=C_ .DV/[9GPL_ZQ-%_W+J'_8N/[9MS_J\ZS_G]+?\
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M--_,COU^,8]T_P#AIOYD=^OQC'NG_P --_,COU^,8]T_^&F_F1WZ_&,>Z?\
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M3C'G2C'_ )A)#KCSJU[I9L2V[$]J=@TUF:2>5@ H,DKEW(50%4=S'A0  /
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M(W\N._08QCVK_P")&_EQWZ#&,>U?_$C?RX[]!C&/:O\ XD;^7'?H,8Q[5_\
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0,8QC&,8QC&,8QC&,8QG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g96328g06a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g06a11.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  2 !(# 1$  A$! Q$!_\0 %P
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-&UQKZY7O_I%PSS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g96328g06h50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g06h50.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[29N4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )E*^F! X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   ( !P X
M0DE-!"4      !#_^'[:(TV'88>P:G+N>BY<.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0&D            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              X    F0
M 0                         !              )D    X
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    X     !29VAT
M;&]N9P   F0    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M C_P        .$))3001       ! 0 X0DE-!!0       0    $.$))300,
M     !PT     0   *     [   !X   ;J   !P8 !@  ?_8_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(               $  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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MJ)(1DGH
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M.TGV!Z]&PLU$T+HI(OR@  +SN-N =^!!VC%?+2Q@F6)Y/,[<1P)XW^[#Z/\
M#H^GL-&='YN\C4^B98U.UWIH[&F$&PB\6F&:,*=^-&FE+R>^%8ZD28\6]=0$
MAYO&HN/LN.!R5.8' _B7U+^T;Q<GLJK+:63S<@%8J5@/(H922513)#1YVTD3
M3#&7RVB &=U\RR$/OJ97:(')&E3W U#9HPYM2D(2$I]D^//G]_GVY\'_ &]<
ML/RG3M$1MVV.P^FP]\2Y,[XUUW6;G]*]GVA>=:^ZP73=7B.$U4B2B&RM@W.4
M7CK:T4>(8Q$?>9%CDF13PU75<)*TA;[WQGE-1F7W6Y/*,LN<ZOJ-A:(7>JPU
MO!TTJ1(#U7(!(5 > )8D*LLP&-5:H*2%C\W"CU/IZ;QR> "<1KV_+U -<?4"
MUBF:DZN6KU=C-;+G1M+]*ZZ4XYB>FF.O.NF.S!80GX-ADDN.E'ZQ97*3\[:R
M@&(SS-8S$BL^G>G.GLOZ:M%MK>F#6J:37N& 9V<*1XFH#8C> L(LZ:?E))KM
M:M4K.#4() ()4:1!,Z1,G2"1MN6C4TM &NVANWO6W<UG<+330W2[*M4<WL.'
M&ZG%H*G4UT,N=BK;(+=XL4V-5#?)^-;7UC7004%MMYR04M.2%]?V>7V]6[S.
MK3MZ";"HSJC$]A)&[-N%4>9H.@,9&$(C.WDGDP I+&(V !D@;3VWEB )PXGT
M+_"[[C<K@1+37O7W3C2,R&F75XWA-'<:IWL,*YYCSK-^7A^/-24<)^(:Z3<Q
M@HK*):DI'=S6Z^*^44R5L;"ZNV4LLU'IVZG22 58^,S!@)DTU()^[#U;"X8@
MD(JD ^=I,'< J@.\]M?H& ,XSEE_X5*6BI=7@6\AF??I2M3$?--&TPJEU24J
M*&GIM#G,^<PVI7 4XW"D*2.%!LGN'4?2^+M,NHK]/552=Z@O*-0J-R/(+>G/
MTU))@$B2<;FRRH!*U*1$05 =#/L?. >=R.W?"'^\WTAM[NQR!(RK4W3EC,]+
M8Y6).J^D2YF8X;6M]_:V]D[:(-=DV)1'"I'?*R''HE0%?0+=2NP+OF2]9Y#G
M3+2MKLTKAY!M*U TJFGDRP9E=08!"&HIDF=MV56UKT%U.8$Z1Y@029B"?I G
M23(VYPFU1W%UC5S49)CEI/HKJCG1KJAO:.6]7V-3:0G$R(-E638CJ7XTV(X$
M.1)#3H4VXD+2020;34I"HKTG4-1J(P98&AD=&5A$D;HS#>9F#R<: Y1@5D,K
M#F-X;5!D1!(!(@#\!A^-Z'?J]R]W^/)VU;BKF&SN1PNH7+Q;*77&(_\ 39B%
M:VE$NQ=:"(S2-0*%/+^11(;(8O:LLY)#2";-MCS]\0>C/V*%SG*Z3G+691<6
MX;Q*EO4)T:D,+% D*8$E&("GPJE,+-V=X:[%*I&LQH(&GL/(PD^:9@R# @@,
MIU..&E%3:5*]R#S_ 'D?[_?\_/7-@9 (X(!&)%@ 2 9 /.+G6<8QB'6_6O3O
M;QI?F>LFKF5UV&Z=8'4OW.17E@E2PRPVI+4>'!C-!R18VME+<8@5=;$:>F6-
MA)CPHC+LAY""YLK"\S6\H6-A3+W%=RJ@B0 H)9B9 "*H9G8[*H[G8ZW=:2FI
M5WIB"0)U02 O!'<@]MN\&1'I>IYZO^M_J#9);8I33+72W;!7SU-XQI=7S5QY
MF8QH<EQR!DFJS\<(5<V3_P#52H^,I?7CM'VM!MB;/2]9/^D.ENBK#(+9+BL$
MN,PJKY[EP&1/\24T=1X=/?CYJ@^<D0JP5U=U*S%!!IZI58XV YG=AN2VT3MQ
M.$=%/?LI6CX8^EM)["ZVI1/T@! "QW$@@ <JY2"3XZN3NL@,-*@ :F =.V_:
M!W@>H$\8:%)/DEN2>)Y@_F".XD;<[[.Z?;)=XNK%8W<:9;6=P6:T[S")#-YC
M^D&;.4$MIX!3:XEM)K8M=*)00L_*RWN6UM+)[5H/49>9SD]B5IW&9V=!V$A7
MJTJ4@F/EJU:;$^4S (XW,;+T-OI4D @& 7@@[SX:M'T@$'>.3CR6JNV;<5H0
M&_Z;-!M9-*FG$H4U89]IUE6-4KRE]W"6+RPKVZAYT#PIAJ:XX"E9)/!/2[/-
M<LS $6=]0NF +$4ZB.@ (#'4CM\I901V)W)WPEE<'Y0"#$%2K=M( 8 D[&/4
M<#N,,1WYE7*AVE=.DUDZ%)8F5UC6R9$&=#F,*#D:5#GQ'67XLEEP!QA]AUMU
MIP(=0I*T(4F1J(-!#0%=2("CSRL02#PRM'.X/? *F_'',P8W]"-_Z\1ZO@_0
M(]5+6?= _;;4-?J[),[S+3[$T9#BNM\:EL+!N?B\ )BKH=6;>+%%?5Y&VZY'
M3BN13C'7E\=B?!E-JMX:'YG!?B'TI:95X>;6=2E;+6J:;BPB&=FW%6W72JHL
MZM:*%4CSHFU2):PKNY9&!(.Z. /+ WF)D'D$DE20I)E3AT(E9^$%*6GNXX*B
M.T<CW^GDD$?V3Y!!\?;KEA(W["8&\C[B.W],2@!  8@GN1Q]W.&Z/K*>MC5[
M-4S]NFVU^GRW=!:5Z$Y+<RD(G8[H=56L93D.?:,H<4W99],CK:ETF-O]S-9&
M6W<7S095$KYO1NC.AZN<U:>8YBK#+D8&E1)9/M.Y)+$;^#("D@JS[Z#HEC'W
M-[HE*9CGQ"1,1P .[1N>0L@$$\,4M0]1-0]5\VOM1-2\NOLXSK*YKEED>79-
M,=MKBSEK47%%YYYP);8;(^''AQ0Q"ALI0U&8:;9:2CO]K;4[*FEM:4DMZ"*$
M"TZ:Z0J $+I6%TDCA8"GS;D#$*Q5R6,;DL1P"2?,Q W+$3OSQP-C:PK3K/-2
M;5&/Z>X/FVH-XKA":? \4R#++;N/MW5^/5UK+Y/CW:"E?VCX'6:M:VMP6N;B
MG21099F\, #>6@,!MR2=N>,&YB%'/\1'?C3)&VVT#MC:I'IL^H$J";$[+=SP
MA)C&4IU6D>5H?^  7.4P/DE6#CI;(3\!N,MWN_R0KP89.J>FW.D9Q: S!#7%
M!2#)\I4U9F9 $<XSIJ$[(VTG^ZJG:(^;1IC@S.X&VT8U3S/3_.=.[3]7M1L(
MS/ +U*W4*I<\Q6_P^V[FB Z$5V0U]=,/PBI )+)2H$%)*2#U,4;FVNZ8:VKT
MZZ20"I4R0=P#)D#;Z\[B#@((!)4$'TW^DCD Q,\=XP:>:EY]I+F=#GNF>99'
M@>;XI+:GT>38I9/5%Q5/MGL!C28ZDEQI:%K;E0WT/0I3*E,S([S"UIZ3<4J5
MW1>UND6XMV72]!T5ETD:2 KAAPQV@CDG&((&KN=P!((;8@@S(.XW&_\ "#V+
M\+T;O6MJ]Y\:LV\[D)-'B.Z*LKG'*&WC)CU6.:VU,!*?F9U/$4MN/3YU 9Y>
MN\6B%R//CMO7-"AN,W,K:W@G6O1%;)7.99>FK+:I+/;@L]2TF);49+41!))+
M-3F'.GS"8L[T. E5@2S!:;P!,G97X&K?RD0& X!$,XD]R>%CQ]@ >/X_QZYK
MOSK '$$#8^DD_P!,2>.O*C(ELKCO(;=8>26WVW4A:'6EH4AQM2% H4A:5$+0
ML*0M)*5)(4>E>8$%&*-J!U G4-)D%3.Q!X],)*S(,%2I$0/Z@B/U'?$<1ZV/
MIZ/[%]UEA:873R6= ->';3.-+YHC+-;C=VN:N3F.F+;R!\)ES&9<J+94#"OA
MK5B]A"0U\95?/^!Z7Z%Z@&?94E*LRMF%DJT;A21JJ!9%*HB@S%1 I)(6'6J
M2JC%?NJ)HU2I$(8-,]BI !DD&2IU!N1!0F&.Z>VTK<QGNT'<-ICN%T\<=5?Z
M?7[,J?2"8["AY?BTLB-E6%V[K27!^C\CI3)A][C+R8EA^C[!MOYF&PI-BSC*
MZ&<Y?<V%R%)JTG%(M \*M'E>0)#*8*D!H<*&$$XU*VAE8'92&F2=MICN0088
M?X2T XE(=O6NN [D]%]-]<M,K1JVPC4S%JO)J-]#B%/1DSF1\Y4V#:#S%MZ2
M>F546\)P)=AV,&5'< 4WR?*.965;*;^XRZY315H52@($)4!W2HDA24J(5=20
M"58;8L5"H*U)*@!&I02K1J4B=0:"1*D$'<@\@D;XS3TUQMQP#SSX(X)'\>/N
M.DJVJ=B(,;B)^G.WZ@8,8SU@U9PC0W37.-7=2+F/C^"Z=XS:Y5D]O)4A*(M9
M4QG)+X0%J3\:5([$Q8,9)+DJ:\Q&:!<>0"YLK2OF-Y;V5K3UUKBNE$3\J!MV
M=XE@BB2Q : "3QA%2HM*FU1I.GA0)9O8=I]B1B+OWR;MLWWO[GM2-P.9/OMQ
M+^R<@X5C[DAQUG#M.*.1(:P[%X22$MI7&A//3[=:&VTR[ZSM9WE4M01ZLZ?R
M:ADF76^6T"A2B@JW52F&!K5@ 6J"?,26+'S:=*D*-@(K56H:M4ZB06.^H@P9
MV$B( B!V,3&Y)V>](;8-9;]-UN/X]<PWDZ(:7OUFH.M<]UA?RUE1QIH_0^ )
MD@]@FYS.BN0'4H6'XU"Q=S$)*D-]\9UEU$G3F55*M%O]KNPU.TI^76U1U(UF
M6$I3$U&D@D*%/]X"56]LU>KX:G2>[\J%4@M$ PQV5>1JWWT'$E;5U<&FA0ZR
MLAQ*^MKXD>!7P83#<:)!@0V6X\.'%CLH;:9C18[3;##+:4H9:0AM "0 /+[E
MZE1ZKL7>J2U5G)9G8R2Q)W)))DGF9.^+*      -@!L/P&W;'T%'M!/!/\./
MX#WX_P!?2&.A2>2-H6.3L /H(Y[#&>X'8\DGC_OAA)^(^WJVFM>Z"-M3Q>SY
MTQVW*A*OX\=UQ4:\UBOJEB;9RIB4J#+HP^BLH5+"']8N-8S+WE*'$E*O07PU
MR(9?DQS*HJ_:,R965BIU4Z%-F\))(V#$^,2)#:E)DTQB$O[E7;0JF:9>68B&
MG2L@ D\AED@$;\ @X1CV?;5=1]Y^X73W;WI@RAO(LRL5JN;Z9&>?JL/Q2L;$
MK)<RM$,J2K]'4T,*5'8+L<S[-ZNJ674/3FEB\9UF]OD667&9W"FH:&D>%Y0]
M5F947PPY41J80"9CC#&BAJN$6 7\J@\$[D D!B  "3L=I,29,EELMV0Z);&-
M(JC2C1G'(D(-LQY.7YC)90O*]0<D$5EB;D.46?;\Q(>D.(6J'7(6FMIXZFX=
M;&9:;*E^7\^SS,^H;Y[N]KOX:,WV6U#MX5%"20L  %MP'8"7.Y&P L%O;K02
M" U3;4\<]X6>%'8=O4F2=Q@. !^0'L?O^0YX\?E_JZAQ,"8F!,<3[>WIASCC
MVY4>$GV\GQQTDR)(B?<F(WVD[2?T,'W1^']"<:_[A]P&W[0+3ZTRO<1J-@FG
M^"O194.:O-K& TS=,.L.-2JJ%32 _,R%Z4PX634U\&?(D!T-.1E(6H&2R[*\
MUS&O37++2YJW*,KAZ (%$@^5ZE:0M- T&6828(!QHJU;<*5JLI5@1I^8GUA1
M);:> 1$S&(V'U$<QV;9YN6RS,-C.,97AFCUPA3]C1Y#7QZ*@_6XR'_TC::>4
M2G'[3'\/M4*;D-4ML6'8TI3ZH-=70EL1&_4W35#/;;**%+/*U"M>+L6I%BRJ
M - JNZ*7J"2*C!8<@-!:7:O5_#>H321@LB"\'8\G8GC;1N2!(,1 U2T?U;S?
M0O4O"M7=-[1ZGSW3?)JS+L:L6%<)1:U<A+R8SZ XVIVNL6OC5UG$44MS:Z7+
MAN)4W(6DR%S0H7EI>V-S1\>C<4JB.D@B6!60"05&_(AA T[X2I-.H"I*B1OZ
M09GN)'.XC^>)4':5N$QO=/MPT<U^Q@M-UNIV#4N1R(3;Z7E5%U(9$?(*)U22
M5!^EOF9]6\E?"PN-RL GSY,SC+3E&:7V6DS]DKM34]VIL!4I,9W#-2=&8'<$
MD'%DMZIK4:=0@AF'F!$0RDJ1Z1*D".T'@XV)6KMX/!//(X'Y^X_S _Z/<CJ+
M8E?-$@ R!R?2.WXGN<;N\?GV_P _RPP6_$(^H9:[A]QDW:QI_>R&=$MN]M(K
MLFC5\X_)9]K,SPW>3[1MD(;F5N H=D8Y3,+<E,HN?TW9$!TP"SZ%^'735/*\
MO3-KNG3-]?TA5HKIFK;T7\JTWU@!2],FH^@M)=%:2D"!O+BI6J,BDK37R $'
MS 'S-L=Y( 68\H,;,<(+:5:3Y]KAJ+B&D&EV-V689UJ#>1,>QG':UM3DN=.E
MJ477G' "S!K*V*V_86UG,4S"K:Z-)G2GFX[#KB>@7MQ;6-M7KW=84K2FA>H]
M0D2H!+%#O) 6!W9B%66VPS1-3JB[N3 /:20 #OL23 C?8D[3A_UZ;/H:;?=G
M5!C^>:PT^-ZZ;C5,Q9T[*+^J:L,-P2<A+:VZ[3O&[)MZ&P["6VA+F6V49W()
MSR5/Q341BF"///4_7N;9T6M[&M5RVQ64"4&T5+BG!0^,R@%5JI >FAX!#.T@
M+-V]C3I0S_O&WD;E03O.^Y@[B=@8@ R2NJPTEAI+2$-MH;2E#;;20AM"$(2A
M"$H2 $I2$@!(' '@<  "@MJ8'?S'DR>9D[\[[X?_ *_7W8^%E>*8WF]!88ME
M]#2Y/CES'7"MJ+(*N%<T]E$>0I#L:;76+,B))9<22%(>9<21]N?(72N+FT>G
M7M:]6A6IM*U*3E'!YV<$,HVY7?@<3A#TTJ*4=0RGD$2,-.-^'X;QG-]=L(RS
M9?88_IKIAJ!D/Z/U7PN\><>I=)([D=R0]G.G\1YTS[2J?6VY&_4-$UM$&U>A
M*JY,*F6ZU7=?Z=^)QM;&K;YW2JW5:E1<6U6D$)=]#"F&U:-+!M(+#8@EXE-+
MQ;Y82Y*5%\,D$ARQ:)\RS!D$'RS)'!.DRKB39/L>T0V'Z0UNDNB]"W'26XLK
M,\UL&VW<OU$R)IE3;V0Y79(0E<E\][B*VN;**RDAK3!JXT=E*U.\US[.[_J'
M,#?7U5B$E;:W5F\*A2('E"[!F, NY$L0#L(42-&BM! B ?\ J8\G?MM( &P
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MBWE@-O6,2&Q7W]<QW$A$A^M9K)K26NU4HUSS:PM26QTTS6@]15K4!^]3SU7
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M^L_=B#9W_P!:]W_V>6O\?^DF*'^[\NIN]^4?5?Y5,-*T> )G^^'O_ WN/O\
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M!5:@1HU3%E=TA3\*HJTRI 5@(1E,1J,PK20 IV:/W98;!?9L$) (XX"0/;V
M ]D^![?;QY\>.J !QL1&P&T?D?PGT_&4&_I[1Z=I]\<K4$)4HGPD$GI+.JAF
M)\JB3&Y@<F!OZ<>^,[]N?? E14$JXX!3R0>>>3QQX^PXYY^_MUD$MI98T$$F
M00T[1 _&9@C;[CZ\^VX_'%72L&#HP8.C!A)SUQ#_ .:\W3C_ .&\6_[^XM_M
MZNGP]_\ %V5?2\__ ,=?^>&=_P#[L_\ Q4_^HN(U)O\ QB/'_M7_ .]'[_O[
M_P"SKTVOST^VU7_J^_K_ *C%</(X_A]^WI&_O_7$GWZ2'CTTME0_^0N%C_\
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M$<$2P4U6:<;;6\97457E&&B(+L:C%!2,@,5W)5F8P"4W@8>K)<!"?//<5=O
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M<R'KR^R/.;[,$RVRO +*XH+0J75:[04RA='-.F*6JH 0#L!(D@XA:^8YO?\
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M V?I*CU53R*WK]&Y]E]]4:[N&SCI3-Q9>!28.RV]:U2^J"GX=PBBI</374#
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M]P$]WD<<'SY////C\AUAE.L/XE4@^7PS5<T1)Y%(MH##L0/7OOC*P"Q"H&)
MUA5#\ _,!,[[[[XK;CMH6VM(^KM"N3P2"4J!X/'*>>X\A) //'MXZP416D(H
M()JB% BHWD9]AL2I*DB)!,\XSZR2Q/=B2>9[GWQ3(:;6T2M(7]"^>\!?(')
M/<#RG[$'D<?Q/.W2HJ"J% J 0*@ #@>@8 $#Z'N?4XUM_=N" P,R' 8;&.#M
MVQ5'::2@!+:$^%H^E(![00D#D>?;QSSUKI@.!5<!JGF&L@%H!*@:N8@<3SOA
M8 4:0 %/( @?@-L4OQV?AE/8GM4KR.U)'D'D\$'R>/<\D?8CQQND[[G?G?D>
MA]1@TKL-*P)@:5(!/L01^6+L=I"$I*$A [>WM2 $^#QSQQSR>!R>?]72%55V
G554&6.D 2=A.W>.?6!Z8 29GL2 !L )G8#8?<!CL=*QG!T8,?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g96328g07a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g07a11.jpg
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M 0$! 0$! 0$! 0$! 0$! ?_  !$( !( $@,!$0 "$0$#$0'_Q  8  $  P$
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)Q>_\47ESY__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g96328g07g61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g07g61.jpg
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M 1$  A$! Q$!_\0 'P !  (" P$! 0$           <(!@D$!0H+ P(!_\0
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M&JJ\?R.\M&S;TW<=B(#YU*J/'%O(O25X]ZIUZ]V,Q^EQ<$=!PW"FEL@8.3Q
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MBC-&S(6C=9$)4X)1T)5U/J9201Q!Q5I&.'U$'O'"LERRE,4IBE88WO,4ZO\
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MMY=%TX5=(.TG!A5S8':E\T'FYF7=[@6V1!;B8VZXQ ;D1"X,6 !NS*5( !!
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M6ZJPIMI64.0]PA8?V8\R'/(Z P!_O$57NQ\<U60%1*IU:0D!_=%(]G7C:-2
M0^TH#)D,@JLF;W1 IW;13FB F IN4@;VW\C;AL&ZNDCYI C2G'+6^[ /S*XZ
MS6LFV_&,B"!G^5*P0?/I762/G93S J"Y_B^V)-B<B$JR@&Y^4/$0;1) P!_L
MY'CPSU^0P!]LR3I(!'W>: <@!O+?R7V9!@M%)<,/7.Q8?I1-W&?TH:UDVV+Z
M7($@A!]42 ']9];C]##LJ)7^UI*57%S)R[Z1<#R\J[YZL[6'E]T>51PHH?\
M_P YV;>.RAA73%$D2_!CC"+V+@=U:QVDE;5)++(WPG<L>ULFN#YPQ[<?GADG
MFXY'L/C5FGY3=M/.&/;C\\,>;CD>P^--/RF[:><,>W'YX8\W'(]A\::?E-VT
M\X8]N/SPQYN.1[#XTT_*;MIYPQ[<?GACS<<CV'QII^4W;3SACVX_/#'FXY'L
M/C33\INVGG#'MQ^>&/-QR/8?&FGY3=M/.&/;C\\,>;CD>P^--/RF[:><,>W'
MYX8\W'(]A\::?E-VT\X8]N/SPQYN.1[#XTT_*;MIYPQ[<?GACS<<CV'QII^4
MW;3SACVX_/#'FXY'L/C33\INVGG#'MQ^>&/-QR/8?&FGY3=M/.&/;C\\,>;C
MD>P^--/RF[:><,>W'YX8\W'(]A\::?E-VT\X8]N/SPQYN.1[#XTT_*;MIYPQ
M[<?GACS<<CV'QII^4W;3SACVX_/#'FXY'L/C33\INVL@JD]*7&R0E7AC&6DI
MV1;1S4H&YQ2&7. *.%>;[I6[5$%'+D_VDT$5%#" %$<@N=U:6\US+D1PQM(V
M<C.D<%&3[YSA5'K8@#B:DA@::6.)"Q:1@HX]&3TGAT 9)/J )K<E7X5G7(2+
M@F "#6+9(,TC&  .J*1 !1PKR>X*SE7GKKF#_654.;_;GD-Q.]S/+/)[^5V=
ML= R>"CY*C"KR %>@PQ)!%'"GO8T"#/2<#B3S+'))]9)-=OD-2TQ2F*4Q2F*
M4Q2F*5Q'[]E%LG4E).V["/8H*NGCUVL1NV:MT2"=5==94Q4TDDR )C'.8
M]T<N1'D=8XU9W=@J(H+,S$X 4#)))Z *M9E16=V"JH+,S'  '$DD\ !6M?=/
M%*G;G3FN5!PLTJ:"ADUGO(9%W83IF_A5"&YJC:+YQ><V:' JS@H%7>E(<2-&
MWHFQ?)X606YN@KW9&53WR6X(Z!P(>7'OG]ZOO4S@NW)[3VF]SF"#6D .&;&&
MFP?7D96/UA>D]+?!%=/.#^$&[\Z3==2]GV5I=+?*[![-/.#^$&[\;KJ7L^RF
MEOE=@]FGG!_"#=^-UU+V?932WRNP>S3S@_A!N_&ZZE[/LII;Y78/9IYP?P@W
M?C==2]GV4TM\KL'LT\X/X0;OQNNI>S[*:6^5V#V:><'\(-WXW74O9]E-+?*[
M![-/.#^$&[\;KJ7L^RFEOE=@]FGG!_"#=^-UU+V?932WRNP>S3S@_A!N_&ZZ
ME[/LII;Y78/9IYP?P@W?C==2]GV4TM\KL'LT\X/X0;OQNNI>S[*:6^5V#V:>
M<'\(-WXW74O9]E-+?*[![-/.#^$&[\;KJ7L^RFEOE=@]FGG!_"#=^-UU+V?9
M32WRNP>S3S@_A!N_&ZZE[/LII;Y78/9IYP?P@W?C==2]GV4TM\KL'LT\X/X0
M;OQNNI>S[*:6^5V#V:><'\(-WXW74O9]E-+?*[![-;OL\5KTBF*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5#=ZXA=(ZU\<G=-G5&'>-^=X
MZ*)*I2DZGS>7EY8&'"0F?M@(!_H/()OW(")O<S96NQ]J7N#;6-Q(K=$A0QQ'
M_P!Z71%Z_A]''HK&FO+6#.]GC4CI75J?]1=3]U4[NWA-]/0PK(4BM6BZN4^<
M";IX+:K0RWP3)N'02,P(<ONF*M!-QY.0 'E$>;TEKY#[0EPUU<6]J#TJNJXE
M'SA=$79,U:R7;MLN1%')*?46^]J?TX9L?.H-5)N7A)=Q6$54:XG6:,S-R@F:
M,C@EI0$S?;*L_G3/FAC\GN JUBF9R_ZQ.:< ,'16OD7LN'!G,UVWK$DACCSU
M)"$8#J:1Q^CA6MEVW=OD1F*$>K2I=OTEPR]B"JNVC?E[NJHJVVYV"P<IN>5&
M4EWKEHD(#S@!NR.MT-L4!]T"-T$B%'W0* YT%OLVSM!BVM;:#F8XE5C_ 'GT
MZF_]1-:R6XGF_"SM)QR [,P'S @A?F  KB4R6=72X5.G-'Z3-U;++!5IL[7!
M11%JXG91K%HN5DTS <Z2"CHJJA""!S$*)2B B&7W+"VMKBY90RV\$L[*OOF$
M4;2%1D8R0N!GUFK8D,LL<0909)$0'3G!=@N<:1G&<UF\G$E6A7TY1K2-X3B+
M%$UB8BVT!,1DXVD9]":7AE&;!3IJ4HT>=7I5 YFCL7C==)$%6/B7!%PQH[DB
M58KJW%J9(9)XY&EBDB9(6B60,XTF-EWT9 9=+ G#Y!%2M!E2\4@E"NL;+NBK
MAG#E"!A@P.AAZ))!QD8.1BI6NQ#%F3EI=R,2N-V[NPG+6IP2P+5VQ+*-7,R8
M&?)%MW,88LBW6?"@FLQ,5VF8S<04S(W]IF(><VF9F981OHLRLK[MEBX_?&5_
M08)DA_1/'A5FYFPYW3XC +G=-Z *Z@6]#T05](9QE?2Z.-<8#W@8 ]K"K6D:
MNFF14]D"!E_(!$E%^C)JGF.B^3BIJ.?]'(<7(%,O^]%$5/W.5WMMOA;^<6V_
M)P(=['OB0-1 CSKR%X^]Z./15-U+H,FAMV,9DW;:.)P/2T8XGAT]/#IHH>\(
MQT++K56TI1-D=(,J[**0,N2.GGCHQBM6D*],U!M*.G)B'*@W8JKJK&(8$R&$
MH\@2VQ>6,7%L9(5+31B6,O$JXU-*H.J-5R,EP ,C)XTW4H57*-H<X1MTVER>
M "G1AB3P &<GHK)AJ^RTZ5.7UU5K(Q@H"2K[!Z=[ 3S8YF]ABYN71F$E%(\K
M3R,Q:PZ 2+]5RDFW/.P E!1.13.6#SVR-S%:+<6[2S),ZA98FXPR11M&0&U;
MUFD.A I)W,V<%"#)YM.(GF,;!$* DQ..#JS!@3'C2 HRV<#6GPA73^(N#Z3L
M4?6Z];;&G6#G&768U:<Z3&-B@J8KF:8)(.5X0IB(+F$L@9/FE15$3B"9Q"0S
MVZ)"\\UK"9\;L//%ID8X]&)R5$O2/>9SD<.(JS<R,T@C1G$?%R(6RHYNH4Z>
M@])Z >1K@,E+O)0[FQ1U6M#^OLFJSYY.LH&7=0[1DW5<(KO',F@U49(-45FC
MM)9PJN1%-5JX3.<ID5 +>TMLDBPO<6R3,P58FEC61F(!"JA(8L0RD #)# @<
M15!%*REU1F1069Q&Q4 $@DL$P "#DY]1Y&NLA9^=LDBA#UV-E9Z7= H+6+A6
M+R4D7((I'76%!BQ37<K DBFHLIXM(WBTB'4-R$*80DEW4*-),\,4:XU22LL:
M+D@#4S849) &3Q) '$U:BO(P5!K8]"JA8G'$X 4G@.)Y#C4B0E8N,C7-AV:1
MC+/$LM=%3:RZ(U69=N4IM8BZODR1(8&A(5&/;MS.IQZ^4Y\.W69JJLE2ND^3
M"EO+=)K.!)+>1KW+1G?QJIB&!K0^D92Y8+$B#[X0P##2:F2VD9)W8,H@X,-R
MQ(<Y]%AI&@* 2['.D8RO&L2AI!Y,UJY69*021;TU"#7=-SE4,J[+.2Z40B5$
MY3<Q,45505.*@"!B )2\ALR)'$<]M 4!-R90K#&$W49D.K(R=0&!CU\3PJ-8
MRT<L@90(@A(T].M@H_L^HG-9-5(:8N%$NEUBY=GXVFK,RFKR@+C)S34["3EY
M=S%G+RH'/ PL2_FW[902JFB6,@[2$P,CD/#<74=O=VMJ\9Q<AOOPQNXF#QQQ
MK)_:&^ED2)& (WC(I]^"+XX&EBEE5DS$5]#3Z3@AF8KPZ41&<CX(8CB,'$[/
M*NZPK").'Z3D9NLP5F1%(%" BWG697B+<_/,/.50*/,4.7]P8P<I0 ,R(&$X
MD(0+NII83G'$Q-I+# Z#TCU\ZCD0H5RRG4B/[WU.,@>]/1_^%2<I4BJJPL'&
MWJ.=WJ=IL#<HZHN8J59>449^L-;6TA(N;#I4>YGCQKHI&S1X6-;OGI.@M79W
MJ[5NXP!?$"65[1EM8KF6V>X#QMH,-PUNTLD7HNL(=269=;(GILH0,RY!MO>H
MLJ&9HDE6,QD!@\8D"*^""^D\ P4$C .2 8B6G+ W1<.'$7+H-VC*,D72ZT>]
M21;1\T1%2&?N%3I%(BREDW"!XQTH8J#\BR)FJBI5"";8C=$@"2$EF=% 926>
M(D2* .):,@AU'%""& (-8Q1P"2, !6)*' 5\%"3HX!@05)X-D8SFN;#.KC8V
M4E)5ZN62>CH9,5IA_#0LI*,HE($E7 JR3IBW708I@@BLL)W2B102254$>8F<
MP6R26\+HDT]O$\IQ$DDB(\AR!A%8@N<D#"@G) Z2*N2*5U9D1G5.+LD3,JC&
M<L0A"\ 3QQP&:[BRL;E4JS3+=-1DDT@;U$GEH606CI1LT%/RG+1[=LJ\=M$&
M9W;YM$FFV235PY!S!OH^0(<4G'(6*"XM[B>YMXI(FEM)!'*@>-FSNXW+!59F
M"J9-TQ95Q*CIC*U=)!+&D4C#"3+J1BC >^8 $E ,D+K !.496' U@?7L_;?\
MP^O,O==2]GV5#^E?U?\ ZTZ]G[;_ )A]>-UU+V?93]*_J_\ UIU[/VW_ ##Z
M\;KJ7L^RGZ5_5_\ K3KV?MO^8?7C==2]GV4_2OZO_P!:=>S]M_S#Z\;KJ7L^
MRGZ5_5_^M;5?!T:_<S@V'<\R@86C0ZU5IHJ@/-5=G3(>QRR(&Y!$K=!1M#MG
M"8F34.YFFYN11N/)P'EKM ((=EQ,,OBXNM/J4'$$;'K8-*RG!&F)N(:NAV':
MY+W3@$+F.(XQQ(^^,. Z 0H/1Q8=(K:WGGE=+3%*8I3%*8I3%*8I716:SU^F
M0,I:+3+,H. AFIWDG*/U01;-4"<@<IAY!.HJJ<Q$6[=$BCATX42;MTE5U4TS
M2P037,L<%O&\LTK!4C099B?J &2S'"JH+,0 2+))$B1I)&"(HRS,< #_ ')Z
M !Q)X $FM&7$IQJ26X)1> JYG<'K=@YY6;$X^)D+&J@?E2E9T$SB!4P,4%6$
M24YT6@\U=P9P\*F=OZQL+R:BV6@FG*2WSKZ3CBD (XQPY7I]3R<&;B!I0D'C
M]H[3>\8QQZDMU/!>AI".AI,>KX*<0.DY."*G]?3]J;O'VLZ/<=??]E:JG7T_
M:F[Q]K&XZ^_[*4Z^G[4W>/M8W'7W_92I;@VD.]JM;LT_?F]9"V3\_7X9LM R
MTJB5Q7R0!G;J2=QJBBK1H8UB9  H,7JX$(N<J"@E*0VNEFF2XF@AM6G\WAAF
MD83QQL1,9@JQK(H5F^\-G4Z#B!FLE($,:2/,(]X[HH*,PRFC)9EX@??!T*QZ
M>%8[-LKY 2,O&O*Y.K#"V%U5W;]C%R+R)4FFTU(5X&C.21;BU='=3$5(Q[$$
MCB=XZ9N$$2&6153)/%/:S)&Z7$0WL*SJCR(L@B:))M3(?273')&[Y&%5U)."
M";'@F1F4QN=+F,L%8J7#,F P&#EE8+CI(('$&N,LCL)O-]6EZ7<D;&+5-\$
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M(M]FW,>U)KUX%$5R9H1&'0M;K&L02ZQK*$WVX F6,:U5++6NI+AA')<QM:)
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M=<A^&'YP<;CK[_LIO.KO^RG7(?AA^<'&XZ^_[*;SJ[_LIUR'X8?G!QN.OO\
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M^#^R/"OT1MZKA5)! YEUUU"(HHH\Y15950P$3223(!CJ**',!"$(43',(%*
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M'&N(5[8)6JQJTI<J16WDO8X1K"O9:%A(BR6.(F)N08-[' F7;Q+!X<JDLQ0
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M[L<*B*69CR"@$D]0%4) !)( '22< ?.36O[</A6> K2HNFT]Q!U2VS37GD"
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M<W\EV"D-RT!:V(\WL4A=(C9W,:Q))'A('E:;TJF*$&)1"&AWMINI&C@6/!9
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M-<2 8UN1T*,D1QKZ,:G RQ9FX.]NI;^7>S,<#(CC7WD:D]"@^L\-3'BQ''@
M!63K<?MO^N;G=GX([JP] YGN\*=;C]M_UQNS\$=U- YGN\*=;C]M_P!<;L_!
M'=30.9[O"G6X_;?]<;L_!'=30.9[O"IIX;;@0G$5H,[AVFBW+NG5AEUEE 22
M21+>8(55555!*1--,@&,<YQ A"@)C"  (YK]KQD[)VF F3[G7N  "2?-I<
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M@=X>UC0>8[_"F@=78?:IUM#M [P]K&@\QW^%- ZNP^U3K:':!WA[6-!YCO\
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M/(1AIIW !>1OF"J,)&J(JJ.'N;F>[E:69@S'@HRNE%SD(@).%&?G)R22Q),
M]:_E?UF;.L?C\G]BG6OY7]9BG'Y/[%.M?ROZS%./R?V*=:_E?UF*<?D_L4ZU
M_*_K,4X_)_8IUK^5_68IQ^3^Q3K7\K^LQ3C\G]BG6OY7]9BG'Y/[%3Z;C"VL
M: "#Z;3"N@HI-8]<B:UUR38XZ^3J1:"2JCL0E7"X QZBD+2SNRS 3"M1 :PK
M)'@CJ1YM9[D60EWFF?3YR;SS<W=T;3SHS^<[_P UWVXU><_\0%T;L3_?@@D
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MR=XSQ("IS/&=/YG.Y/M<[F&Y/?YH^]F)=%1N\X_MXS_Z>L?[U)&&.<#/1[T
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ME8Z[APNL<5%5UUE1.HJLJ<QCJ**&,<YS"8QA$1'.I "@*H  &     .@ #@
M.0K"TJ>D=Y\:_'I"W:&]'JRM-"\N\^-.D+=H;T>K%-"\N\^-.D+=H;T>K%-"
M\N\^-.D+=H;T>K%-"\N\^-.D+=H;T>K%-"\N\^-.D+=H;T>K%-"\N\^-.D+=
MH;T>K%-"\N\^-.D+=H;T>K%-"\N\^->B3P!/@T^&OPC3OBK1XCB7]<FGV^DE
M:?U'MI:L)37U3;))_P IB,7)=. 0IL-T, \3T80=?PGC_P!QYO\ ="\J-J>3
M2[).S#;CSPWPFW\.]_%Q9[O3Z2Z?PSYZ<\.5;+9UE!=&42AO0":=+8]]KSG(
M/(5HZXA*C%:UW[O#7-:.]+7*!M_9=*KY7[@';XL)5;I-044#QUXM+I+L&#!
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MF8:7E92/!M"5$C:Q/69U.4\K(MDM;6D^V'NIK>"=]QLBV=L[8O)HS';6Q@C
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MO9204<R#MPY4BL-F6&RXF@V?:Q6D3OO'6)2-;Z50,[$EF*HJHNIB$1510%
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MSK:.TL;>.UMHM6B&)=*@LQ9F/269V)9W8EF8DL235CN\C%Y&+LW2S')/J'Z
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M]Y'"&:6YGBCXRRQHJARS%A@'CBK%$QJ'2< !"Q)P3C"@GH!/1ZJR.L,-5W2
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M56MJK*S4JJJJK!QBBBJBCY<QU%#F:B8YSF$3'.81,8PB(B(B(Y,MQ.%4">8
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M*1V:ACIBLW034%,QB$$Q!-S3"4HB B4.2*::5U"O+(ZZ@<,[,,X/'!)&:OC
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MQB+%=.2!HX J)LD6VTS<7-L9&26SU^<[V^ABBBT3) V9Y;A(&&]D1%*2,'+
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%*8I7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g96328g08a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g08a11.jpg
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M 00" @(#          $" Q$$  42(1,Q!D$'43)QD?_:  P# 0 "$0,1 #\
MI/J;^J-N?NQV(L^M*IMH_575A'=YZ+3TX+:PIJHX2AN.4I&T]I?R0;)_:(67
M&$EBP58*7N-;0>!>@0'.^&!COT'\9^+X>R;='E38BY>ZO )YF9(WEC<IS&)B
M^9ECB*V(B_./RR6TCJG$)G<K*>>4H'X1!N*T6 (NN;U9/[JC0Z )LGCC_8_8
MSTBNVY=+T)V*:6J&I(]1W!G*&(]5:KV6!LC5U)V<2G>ZZ;LY\&B#&&W2)0V;
M&!59LAAXWX,=1>31C++D>-MWR_:!-G[<D)EDRX4LHV7BMC94V,'3(105DN+F
MR*6BLF-O*@):!:3"FXQR%@ C'V$<,H:BI)L=T#T?L4=,7USZU_2>VZ]HEJL]
MTGJ-DLU,J]@L-3R%_1RK#QTD!9-J]DPQD'Q.Y2GDD+>3,8(.">1O/Q#'QG\,
M4]D_"M[AR)XHH/-'%-+'',"5$J([*DG&CQYJ U6:NK.C*YV.RJ2W$E02M$T2
M+(NNZ]7H(O<[JY?.G78[9FB;XI/ DJ]A8R5%L5!+@'<:"8<5G4+@G*SQXB.7
MNE&$.<N<.<F0#6)DF.\+18<- ]MEW3'WC;<7.QW5A+&HF0$%H<A5 FA<>U9'
MNK_DA5UM64D!/$T,C1L*HGB?IEOHC^Q_GH]ZG>W6WP.W79G*\:LJEPSRMU.T
M#KFOU0U:.9;&MEH6F=<:F*$ 5U\QUP;(\LE6*E0#"3SG&!F@8RBCG2RAQ<MH
MPVV?;/!ERPCQ39^3)*K$1)%D9F1E L\BI7".4"0D!0P:B5HF4[B:7D@;M8T
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<.QJIM:J>;%5+"J8@%A=@T:L6/UI?/^4>C&O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g96328g09a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g09a11.jpg
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M 0$! 0$! 0$! 0$! 0$! ?_  !$( !( $@,!$0 "$0$#$0'_Q  8   " P
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4PJF(!878-&K%C_/&^?Y(_-CS_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g96328g10a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g10a11.jpg
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M 0$! 0$!_\  $0@ $@ 2 P$1  (1 0,1 ?_$ !@   (#
M  D* P4'_\0 (Q   00" 04! 0$         !@,$!0<! @@)$A,4%0H %O_$
M !D!  ,! 0$               0&!P4" __$ "<1  (" 04  @(!!0
M  $" Q$$  42$R$&,0=!(R)"46&!_]H # ,!  (1 Q$ /P"+GQU);*Z@7+=[
M3&G(93CCPWCSV0"8>1U=$2(HJ*PKMTUD+3L6-$L?9.I.?38JR(\,N<[QD4D[
MB(1GJP=JS1&_ONP?&L;X_M(S3MPW'>6@6=T(C,HE< KBX[2VD"QE@LDHIG*L
M[<@$C5>R,ELB8Q]G5"&*@^UQ'][ 46)JP#]70]LG(IX@O?I1F''BYN+/)LW*
M*^O 1DK%@QHX R.IMB"&'#24$9>&M6AIPJ)V:@Z1+1:KP2)TY?=U,1#K,Z,O
MH9ZU:R&"XX\#Y7#N.%NFV019&#,N.\L&1'E];R0K,CXN='%$PDC#@31% JN.
M$BNI*ZY)DPVC>*5BL@+!64I8#%:>,D^'TJ?^J0?=-P5SUK^$Y;7H(5$YHN(D
MA,&"Y 0B>S7Z.PQ.34(QDI8>VD-5&^K[,*_<N(W+S5!##G+;SX13QOV:R7)^
M%;W#D3Q10=T<4TL<<P)42HCLJ2<:/'FH#59JZLZUUSH&56+<25!*T3Q) )%U
M[1\O]Z29N#CQ!<%^<<S4/+"L2LWJ<.,Y?W(:#F78G+V'4\SK+-! Z"21/9%)
M9QAFNP(6:.SG5DH00SP2(%6FZ,PBVM>'N#[YL:9>TY44&7- G%W02IC9:<#-
M!/&02!8:,FKZW66.P4)PY(NB<I,I9 3]$@LINF4^?Z/W]BC^]7_,;D,$<H67
M%>G:/C;WLR2IP7(:YCK*O%M!RM]6LZ.#765$092,#94N\P]7Z*J8S7<3@CFG
MV$95ZU:M8]'+9GGSV;;I]J.ZYF<^!C+F2QY+8V"9$P,000E)IPTR1?R9!_DR
M'ZT4E%)LV==3RK,(8XQ(Y0% \@'8_)@57^DMXOTHLGW1U:W_ #6/I>NP*6.K
M20%S>4"Q:1,1G&CQY@=*GL&Q<D,%AXSRHT=XB)=5Y'X<M5%&R_K^5#?9+;3;
M*+D_DE4R<A(,3M@6>589;"]D2R,(Y.+$%>:!6H@$71 .C5VPE5+, Q4%A[X2
M/1YYX?/-%BZW]=5\5<(S$J* 0-)"@1=M,"A)/#$),3XQB1T<?0P/3$@Q<2,+
MA_ZS?W,1KAMAUX$?/W^+3M5/A&3D1;W#%%/-%%,K=L4<KI'+QKCV(K!7XV>/
M(&K-59T9G*I@)*J2"*) )%_=$BQ?[K0D/S1US7LU(6D=3 (&RQL+M$_\R8R8
MO"/RH=]UWAF\^$0NF*LO$>VS55:N?GO&_G;**(*]Z6^VF6S\DY.0B84"3S+!
M+R[85E=8I>-E>R,,$?B0".0-$ CT:$VM5/-BJEA5,0"PNP:-6+'^--\_TCUL
#:__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g96328g10g01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g10g01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1G*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &:Z^970X0DE-! 0      #<< 5H  QLE1QP!6@ #&R5'' (   +V\!P"
M!0 ;5F5R82 M(%-C:2!'<F9X("T@5C=B7U!224Y4 #A"24T$)0      $&_9
M<-H SG]D#!G%VU>9U)XX0DE-!#H      .4    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O
M &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU
M;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0
M !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O
M;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O
M;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0               !"
M;&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q >&
M  IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             $O@
M"9L          0                         !              F;   $
MO@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $
MO@    !29VAT;&]N9P  "9L    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P  !+X     4F=H=&QO;F<
M  F;     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
M   $.$))300,      \)     0   *    !/   !X   E"    [M !@  ?_8
M_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,
M$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,
M# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !/ * # 2(  A$!
M Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !
M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M"JXSWOMRRP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 2L"70,!$0 "$0$#$0'_Q  ?  $
M 00# 0$!            !08'" D! P0""@O_Q !H$   !@$! P8&# @)"04$
M" <! @,$!08'  @1\!(3%2$Q00D4451A<18B-'2!D9.AL;/!TA<S-7+1T^'Q
M(S)359*4EK+5)"4V0E)B<W6T"AA#1=0F-T2%.49D@H.CI,-68X>5PN+C_\0
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MHP4%J:4D-OS<R$EJ66A3MH-MM3G:MK:4AUM]MI"5LN)6S1/TH!)K*F6EBBD
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MT''#=S/&O<,LZ8Q/1Z\-^^L<Z8]?MNQPUPWQ$<!U;_V_MW_!W^G?H, >_?\
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M-V&F4.A#3'#?KPP/+# TK7'R0U.^$-1748CACUUE" <=6[?]''5H*#\BE<N
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MH%<J9#7"NX4K77A%$8LAVXMWDVJ0IW .#,6HF* \PF1)-191/MW'6YXJ8FW
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M?%7"+L[,MN-HO$M+/9G9]P/IX_1KM?#/Q-*9Z;L@=.!\7Z'#K[PX[O3U_#P
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M(7-)NH;MY";^%EA'?Y %5HD4?2(:U+:]%9&7<%3<FPDFM0 MIPFN[% I'O\
M_9XF>SVJMB5)I\S8*W4@_P!2I>?D@*?^1]9W81<[91D D,$TP-X"HQ//1Z@
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M3=:0 ("8OM3"("/)W#4K/K>:^=8M2105PIQPZQRR!W$B)E:^PI"CS[22!/J
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M[:R#L7KEK&Z_8]LR]M2ZWY=#C79.EIQMX)"@;J5I4DH4M*D+2HT."@I"TE
M2M7H/Q*^&L_\.)ZSY::GY>TI>TY=QZ6F6&UL$+84A#[+C+BEE)05H4E25K2M
M"P:I4%)&?.NWY9]V'XJ*'JGFD-3UZ?G]Z0CP24K%PS11_,23"*8);N=>R3QN
MQ:);P$0YQRZ421)O !$.4<-X (]PZP6XAM-YQ:6TC-2U!(!W$G#6N?E%TO+3
M$VZEF5EWIEY7Z69=IQYU60^EMM*EG$@8#41C5 XXV,9R73"L5+9RF9TMB96A
M(L%'X[DI4MECUEUX^6(2/*L["08KN5U&1P#>U.?>@5/DDY-R+><?JVU;"W26
MRR6T3Y75I6"FRD.'Z5 4*:8B.?-;.6W(M]M.V#:DFR#>[6:LN;EVP<#7M'F$
M)T!K72+J1N$<.1":249BO'K%)"PM+8W3;4^!3(VL\>]FI&.GVQ08[F\O&O;'
M/N8Y^B!'+!69DS,U$0>N /:J<FUDE4U,*);4R:O.&K1"$J:/U8H*6FPI)^E5
MQ-X&Z*=3=3HE.=[(?J_S99XFAS%30Q",=FS9\BV;2/C<)8L8,6,P\L#1FTHM
M;;MD)I_",*T\DB(I1Q2>-+UV)AX$YQ*/^9X:&C2@#.)CD6V:K1GUDJ7/32E+
M0&E%3[I*D(6IT(-5DW0XI3@%11:EJ/U+56 E(I1*1=)(H!@3F<LR,.0 R B7
MB<&87@$7J$)B?'44A(GD5'Z,?3J^U([-+.*\ZDBKE28$*HD\<5&JJ+HF 4C#
M6H  (!8>/*WP<G9QPI[2;F5E(2$WGUDBX'0BE54%T//4(Q_F.?YE7I2E*:W4
MI34U)"0*[ZT&-:"N^@K7"FOM],T_:6SA?,U9BEVB>RMLA9#>8XQ%4I,JKFO9
M%VAJOR660\M34*DBN:VJX_G79L:XFA4FLL5.T1=PL4>UZ6-&BCL4Y.,[)6$T
ME3J9:T;8DVYNTIPFCDI9<P:R5G2Y35Q+DZ@":FDM@..(<EI<!0O \:S;(M3:
MRV6K*LB2?M&8#RFI238 /:OM F8FGE+*6FV);ZD]N\M++(0Z\XM"0%19_-6=
MF&:LFQD'9YBRP.&B.U2,H6$;0KJ?78LTTP-97]9EY9LB_EI5_P",J1;APRL?
ML7B&C4B%5/./)<B_A5J6TS:UH(9??F&+(0J@2PA)=<H!_-<;6H5*U5N%2'>R
M0$T8+BED_;.P_P -;1V!V4>M&R[*L>U/B"^W?6]:<RXB2D@M2KLE*3;#*Z(9
M9N"82V])"=F7'+]H"59EP*@R/CS9^J5)B\FXBSC+>R]FV7E*O$KO$'-GF.CU
M!3D6<:PK=:B;Q4K 55/Q$57[="%:O1"'GXYD@\4>,^3.V?8LK)MVA9=K+9F4
MI4Y+ NA3CQ0?J0EMII$PTY47#>2&TJ-QY !*D]+LSM;\2;=M^:V2VXV!8M"Q
MW'D2ML*19RF9:S@^FK$PY,S<X_94[*)0KMT):<7-.M#YF1?<6VEMV<L"$_G+
M'L1M&XC=1,;MR;-+!^LS(R.VCE\RT9@8DK*XIOL2V!NM*4;+$'_ Q2BS=!G2
MLJ%&4K+R.-$2!77I^PVTK%I21LJUW$.2,ZH,6@U47Y&9-$2UM2S=0676KR%N
ME*0V\UV\L4K 2$_//Q;V!?V%VG>59LO,ILB8 F[%FG4.*9<:<!5,V.[,D%MY
MR5=2XTE*W%/I8,K-N7%/$G9EAS*E6SCBK'N7Z2NHO5<CU*$MT-SX 1XU;3+%
M)T>.D$@$00DXIP=:-E&V\1;2#1RW-UICK"?DG[.G9J0F  _*/NR[EW%)4VLI
MOH.(4A8 6@ZH4#K2-+8>0^RT^C%#J$N)KG10!H=Q&2AH01%XH3W4I[W-]8EK
M@KT[_;[^L<E&O=[Q5&JXLAI"&D(AYOW(G[X)]6KK-&9Y>XC!>0Y^QBE]64\\
M<Z;LJ>)X\XJAI]^.[/V\JXD0C&G:WB1E,&V98I.6K#/8&73#J]J"<NU9.#A^
M:S?.1'R!OW]6NAVF:[2R)@YEI;+H&'_BI03W)6HYU\H]8^"D[\G\0[(03=1/
M,6C(KXWI)Z8;!YO2[0&E::Q0FP[+^-XRL$0<X"K#W!VH0F_>)6DG&1BR(B'<
M!G2#[=NZA$!'K[N'LBY>D'FR<6IE5!N2XVV1_P#>2KSC8O[0DEV&UUFSH20B
M>L-E)53 O2DW-MK .I#3DO745&6N:.MJ&O6/']LL=8\%CJ.W0461<'12.NW!
M0$%CID,J@"P%*L"*A@$Z0*E*4JH$$O. 4H'W@4-P;^&?+VQ/YAUUX1V\<<!I
MJ>M!GT#AN$.NNC'G;JKJ@MS[4S44W"R20'515Y] @@";HO,F-S95@$1*DIR5
MB &Y0I1'3C3+2F->CGEGC2&7XZ\C%)S2SF>DE:I'JN&S%-F5>U2K92>C7+=L
M^.=!E"P<W%GBP;SC])%\[=O8F=":JC1O%NW,>C[)H%\-S8#:.U(!5>NLI(;6
M"4T*G'&UWZMH)0D(<;[-\E:4J/8N(B#]54UR&/ZA@:T"2*4.9)!JG D?4#'9
M=H)*6H-LK35NDDC(U*;A6K5%,B2*17,0Z9-T44B 4B2:?+3(D0A2E3 I0(
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M.N[GA$MX(%<ZFF5*$G'])K37OXQ;S'B::5F<,G7M%#L7K8A##N$7"2[=4Y
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M*)L/$HR(L$'['GSHW+*DS\7?K6%)N85MS)5*38E5,,>HJ/,LIEU,RM#:5DN
M!#:4_47 JZ0EM%:*J FXFI0M*VJJ4A1/I&R\TE=B6BJ;4VF39F6B77E@RX"Y
M9U4R%NNA*2WV(EUK6Y=#K2VIA02EX)&0N%<^M:W)N,QU^69SE?5*T:Y\AX!=
M&486&L,2IQ[/-$$E&J+)C<J$0S=O>$6A53V&F$.H=,TE$0R2.]V;/S-CS:C,
MMO,MJ"?GY=U"VUEN@2B;2VM(4EQE- X0/YC .:DHIY-MOL99NT=G-25F/RLT
MVXM]6QUJ2\RR^U*6DHEV8V6F9I"U-JLVU%7UV6I;E9*TB$%267IE3NXQH[92
M;)L^8N&[^/D&J+MH[;*IN&CQD[1*LW<-UDQ,DNW<(*$525(8R:J9RG*(E, C
MZ8E25I2M"@4K 4A0-0015*DG4$8@C C&/D1UIQAUQEYM;3S+BVG6G$E#C;C:
MBAQMQ"@%)6A0*5)(!2H$$ B-#>#=GF4I\9D/"N.#N83/&R'EJ;(P@S2O,NL@
M82M]A?Y!P'D6ODFG1J^U>MJ^^4I+ENFHS@)5[4+/7;,GSI&1@NV^L%=HS,AM
MC8H")NU&69M^ZJB'+4E6VV+18)<5V:)A+[8F$A12V_+S8[0E*DE/J/PO^)\O
M9<G.; ;=J,[L>_+.6:PM3%]RR99\K4PK^[-_-/2+K2[JBWVTU(S4NV_*!!2Z
MES[R)=[K,924MF6<<1#RT+-8JO,ZA:H"XQD. N(HU7KTLUK[MN23DF?LI?V"
M5C&#.<38(3,B1ZTMA'<<5<?*)V=G'+4$Q:5F(6^II,LU*S"'DLE13V3;J6UI
MJXCMEN+0E+ET+4%)?O)K'TALWLYL])[#+LK8[;9]BR6;2>MB>MVR)B2?M%,N
MAT3LQ)/S$NHMRLP)*7E6'WGI0K7*L%#MG*:>*!>M#9YA<68!R-<\V-6/LZG*
MY(0N,8"5>-)F4J]G?H/%:\Y8N4UW:!KD]L"S5TX4B7;YI6*W$%*V?(L"3QA[
M9NQ&+-L>T)RUD-?-OL.-RK)*5F6=6E78AHU4/F%/%*B6U*#338 4$APQH,W\
M3+3VU^(>R6S^P<Q:"K!LJTY28MJ?;#\NFUY*7>9_B#LZ@I;6++:DFW$-HFVV
MESDY,**V2\J42*!A:NZJN)R[0^=K Z9;/>%82QW*LP3URR7E+61U9EYYG5ZY
M%L$S +"]W \7$,E)E=Y-69N:$JT1&)Q,@QD&W.V3V8M3:&;L9A]1,H':2,NI
M0*E!;Q>6ZL)31$JFZ7G7'5%1EFKH0EHWQ3\4_B7LOLBO;"S-EY1*MK;<[.4V
MCM5#;B&9,L2") MMN.*O.V@U+E;3;4HVVPS/ONS;KSDVA3*MA.PYBVUXEV9\
M?PV0FY6N3[<O;,N93;!_'9Y'S);YS)UNBE1WB!U*_*6E6N\L@B0Y(DAB")1
M1]+VCG6)ZV)MV5452; 8D9)6BI.SY=N3EW - ZAGMJ$ U<-0#'RC9[*V)1I#
MHHZJ^ZZ-SKZU.K2?^12RC_RUC,Z$]U*>]S?6):U]=:#F=W=KUPPCL$9GEUUP
MBI]5Q;#2$-(1#S?N1/WP3ZM76:,SR]Q&"\AS]C%+ZLUY^77KW15#CCCX=/7#
M.H&7YUKCR$.NNNZ/A1,BR:B2I0.FJ0R:A#!O*8ARB4Y1 >H0,41 0[! 1#44
M"@01@H$$$;Q3><*:8^-8R0I3:DK02E2%!:5 XA234$;B"*B-3VRLHI4=HIS6
M5#&(9PVN535 P[A,I$&4D1*<!_UA/7]X!_M@ =H]?F^SI,M;A8)I>3-2QKO;
M)<\:L]81]F_&-*;;^%S%KH *6G;"ME)&-$SJ4RH*3NI:0[L8VR<<<>O7I.>_
M#GKRP/J.!CXPZZZY1YR-&Z;E=X1(A7+E)!%PL&_EJI-16%N0V\=VY(7"PEW
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ML)6FJ4"I4#=)J0J]0&I"334XF/)D':DV2K16)&"L6S?:[W"%CVUM?P\/4\1
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MFG?[1="MJ(J5^%% Z2B9(MBD(HG(<I5$FR1%$Q$@B *)J%,10H^V*H!BG #
M(:K.:JUS5OK2IIQRRIW1F*4%/\J?&@KYQ-ZBFOEQPSSQ%,XF&F6F?1. UXY\
M(0U/7?\ OIW0AIQ[^J?F$-1SIKZX>6<(:8[@<=:C+N./=Z5A#4PAJ!SZZ\#7
MA1#4]8=?;NA#Y^/T^K3\^7?]N,/+GUNYPU'G[9^XI^V*&IZY]$]9PBP "1#)
MV](2$(,R(B(" %'QE 3+#OW[O;BJIO[AY0ZMS;Y##NRTRPW15DOOXZY^O0B_
M^JM>O7P\(MAP&H\ 3Z[OS#HPXXX]&HT/>>_"F0I77 9Z$U,.L>NLX:GK77*H
M^]/*$3L1^(?_ )A>S\Q;Y]8+T[_:G7A&:,E<AGR.?"**>UZ DI!E+2,'#R$K
M'(.FT=)O8QD[D&#=[S8O&[)XN@HX:H.Q12%TD@JFFN*27.E/R"[K@XM*2A*U
MI0H@J2%J"5%'Z2I(-"4U-"<J\8PIKJ,N1SQXX8#/NBFF&+,:Q<Z-FCJ'4F,^
M%:CZ:G*-8"-0<MJI%.;"\85YF*;8I&42BYM=B5,R:$006-+O <%5*<H%L5,S
M*T=DM]Y3?:*>N%Q1275!M*G%8U4NC+5"HFET7<B8B@W# 4& P&-0-PQ.6>L2
M[.E4Z/78.6%2K+%Q%1C:%BW#.!BFRT=#LWJ4DTB6"J#4BC.,:R*"+]LP;F3:
MH/44G2215TR*!@IYY84%.NJ2M9<4E3BE!2RFZ5D$D%:DDI4HXD8$T,30#*@P
MIAA0;N7#*/<SKM?CD6;:/@H=BWCCN5(]NSC&39%B=X["0=G9I(($3;'=/P!Z
MY,@4@KNP!RJ)E@ ^H4M:BI2EJ4I0 45*)*KHN@$DU-$_2*F@& H( D"@-!N&
M7A%'2V*L8S=HKMRF*I!O[%4HY2(KSMR!C-HM@9I)QY4$8GG@AU#M6$W-,6#A
MPP6<QK.9EFK!9LA)/4U[4S4PVTZPEY26GE!;B:BJU H54KI?Q4A!4+U%E""J
MI2FD$ J"B!>&1W9Y:#,TW5PBJ$*_5&HOA;0E>;FE';J0DQ0C8U(9%^^220>O
M7XIH%\;>/$4$$73EQSBSA)%)-4YR)E M1<6;MYQ9NI 152B$H3^E*:DA*4UP
M": 5K05B<JTPKGQ^\<] 57I'I?H6O]*\R+;I3HV.Z1\7&5&=%OX[S/C/,C.;
MYD4N=Y RN^0Y/C?\-IVB[MSM%7 ;UR^J[6X4 W:TK<^D&GZ!=&&2@K6F-*5U
M_;/"/*U@*6A(O@9P=90E7[@L[(F;148F\?O#JJE"6=JIMRJO'G/ L O53*."
MG,(G4 5"\H7'% 7G%E*$A"05J*4I _2FIH$@8 "@WC 0! )I@<ZC D:>>>?=
MKHJ\)K(NHS:JC%VARIG7V=JA'*B8@* +64N>:XYV4 , @4YVSE4I% ]LF<0.
M7VP!KZH^";2'MBIM+@)"=K)QT $CZV;.V?=;-<*@+0DD9$8'"/CWX]O.,;=2
M2VR 5[(RK*J@'^6_:.T#+@QR)0M5",0:$91?_,-3E+?X'B(;0Z2RCZN87POD
M4X-^6*R45BZUT?(MB<)$2_A5%6M<K$LX123 5#JI$*F4Y^24?FKXR,K?MW;M
MML$K%L6DX*5K_)G2\:4UHV?;&D?:7]ERTI>RGOA)-32DIEUV99LDXI=+H_B5
ME+L]!43@$]I-(*B< *DX5C%#P8VTUSNT[:X3)DI$L'^9,?5&GU=XWC8R A_9
M#C [X]<K#5E%MV<:P=6*'G[0^(8K=!&2G6!6B9C2LRR:NO)]B;4^8=GI686@
M3*TL/,)2E#:7&F6RR\E"$I2F\W_)<*4"JDJ><("6U&/J[^T+L49/9^P[4LB7
M?7(65.VF+1+CS\V\T;7=:?1-///K<>6V'6C+7W%$-(^7;K2[3?UDBC1>3<?W
M3'LV)R1=TK,U6GBR0 *[1.78+LR/FPCN KM@JJF]:'ZN;<H)'_U=;U-RR)R5
MF)5W!$PRXRH@XI[1)2%# ?4DD*3E10%(^5["M>8L"VK*MN4HI^RI^5GFT*P2
MZ99Y#JF5TK_+>2E33@U0M0UC1BE9&V4ZFTR5&2#*9DXQQ[",HJ1@JG09WJN#
MT,I/HD6217+7[LV9H3<(\.ES9CN%VBZA'Z:J!?'G 57E52I;2U,3!2:I[9LE
M!6-;CM+R"0,#0_56/OG9N9;D5(L5:7&9:98%L;.%\!"YBQI_^]B5-"09RS''
M5R\RU6\&PAQM)9%^,TMJ)\ZL>#=F:R1ZIAKOL;4C'B!##S:,^C"P34A5  1(
M=1$8B;;)B.XR7,K@7\<?=L=N+4]9EBO(/\GL"A0T#H;:3C3 D=FXD;J'>8\S
M^%;#5F[=?$VS9A %H_Q),RPLCZER"IZ?=44U^I*5B<D754J%WVR3]":Z\K5)
MN82L6.;:-E72\/!R<FFDFF93V[-JHHF94"A[5 %@3!50PE(0AA,8P!K5%E24
M.*2"2A"UY5H$I))/ 4J3H(]^2IH.,I=<2VEUYID%2@FJW5A"4)K^I:B:)2*D
MG(1DI5L65%UA:M8JN59@;C J5]FTL,%8XJ.FH>:F7'*DI=VY92;.0:N7"LX\
MD)-$Q&$C+(K.#NHABU<O%Y0O3REHS<JZS.6?,S$I-MC^0_*/KEGD*4E0)0\W
M_,2HI6N\&TNOE+BRTRA3SCT>([3RTE;\[:W\6E)6T)*<F5*<E9Z7;FY=4NVM
M ED.R[I[-:&T,2Z07EL2P6TW\Q,K3+-2YMA9MF/#]4J5G]@$&PPPET')HV-W
MCB*AJ]'R\85D_5<-+E7W3"5A+&F@V7?F:O[DTD[Q&M57:T,\J;5>0>CV$YM'
M;%H53;+Z[?0@BXS:KDP\95P"J?DWDO(G)!1 )6CYF_-7&USDIV+54]'8.R5C
M61.2;FRLLC9>=+S11,6&U*L?.D.(N"?EU2RI"U %J0A"_D^RE"ZZW(3YF'PA
M=';-UFSK6ZQA6]ER)C=@KCV2K%<DG$MB>T2+E#&V;EX:H31YHS;-$06495ZT
M%J-O>$13BMSQF+\P@@DLQ5V^Q;0LF5?D7TR-I-W%(8=K:LLM 8G"AI15_P!C
MI46VW.S=*"H*!2#VOTD*['XF[+;1V@W;DB[:EA3 MF0FIZ7['9V?86;8V59?
MGY1+==I7VT3D[9IG;-1,!*FU-*4TF52I:'$;M&F!*]+2\?:,KRTEF2T0[YE*
MUY6Y-8I*J4J48.D'[5]1*+$LF=?A)%H]0Y;*TR:5@R DR45B7-T>1:AVAO53
M-K2@MRX3+-K24K#97VCR5 @AYU:E.+203>:24,D@*#04*Q\6?)MJ6EV84J9<
M0H*;+H3V;2@00IEE*4H0I)'TNJ"WP"4EXI)$7VW[OV:XF^H%#W^/ET*GEQP4
MI2@!2% I=XB %  *&_M'<&X.O<&\0[>K3C2O'#+GZ<?&)QQJ?'KUCGCC]FE>
M[3K?QI@,<<(CKK\PU/7AG^81,0GNI3WN;ZQ+5:]._P!NN46-Z]WO%4:KBR&D
M(:0B'F_<B?O@OU:NLT9GE[B,%Y#G]XI?CZ-_TZL/C73AA6NGC3=%77K3TAQ^
MC0^.NN^HW[L?2'7WAIE4G[#NJ<.L=R-3&=@Z)VL@?)^T$+/C>4*(=@'28UP3
MGWAV#SC<PCW[P](:\VM@=EM)?&']XD7.\(8J?%)C[2^'?]]^"RI=?U#^$[4R
MA'^E3]J43_Z7 !&U]PV2<BASHK!XNX3<I\TX<-]ZJ0&Y *<PHF"Z7MQY;=;G
M$%!W<XF82%W>DTKCCUCD1GQX:8B/BZM-WONTQ[CAPC2[<V+SPJ>UG,X-;.'@
M;!6R#;F2F<I!@NJC';1N?8M0KECBI&0;*)^-TJB*E,K9R-CG!1VDNJ<"JR](
MG8WT26*=BK#;M-03_P 3V]+J%FH6!VED66X"%SJD$&[,S51V)-#0@"H;F6E]
M&M)M>=5+9V=)+'S)!(3-3*2:,A0(JVV158IG4_U-J&]]BQ81+%E&1K1I&QL<
MU;1\='L6Z+-BQ9-4B-F;)DU0(F@V:MD$TV[9L@F1)%(A$DB%(4I0\V4I2U*6
MM2EK6HJ6M1*E*4HDJ4I1)*E*))))))))-8V(         "@ &   P  P &4>
MO6,3#<'7U=O6/I'=NWC\  'J#2$<&,4H"8Q@*4 $1,80    $1$1'<    (B
M(]0  B/4&D2 2: $DX  5))- *<3ASBBIN_52*9%<*3+%T14I5"ECW;5ZH#<
MR9E2O!207,J=H8"E2(LB17GG"J#9 JKA=)(_'7-,( )=00:'Z5)4;I!(50&I
M3H"*U)"14D".UE[!M6:<4TF3?:4DJ23,-.L)+@-PLWG$!(>%2LH64W&VW'7"
MAMM:AV4:PMK+#KOVS=RU!&5?L%V[KF#*I.VAR$<I\ZT6<LW!"+"8A'#-RX;+
M%*!TU1WB4MC3R7DE20I-%%!"J5"D !0JDJ217(I40=#I'&G[.=LQ],NZMMTK
M:;F$.-=H$K:>!4TJX\AIYM10 2V\VVX@FBD@YTFIG?%Z.54<*JSLDGD1=9%J
MC&FJ%S"$4D'-6E+NA$%NWL>]@_3BM2A9:P)P8V,)<\9'NG!60E2, <\2,T94
MSH;3\N 25=LS?"0ZE@K['M.WN!U:&ROL[EY0%<8X%](4$U^HX 4.=+U*TI6@
MK2N43<MEW$\"_FXJ<R?CR%DZRK#H62.EKK6XY_7U["&^ 1FV;R31<12LX'7#
MIOTVYY,.MD"X:Q1)S;B6UHE9E:70LM*0PZI+@;_Q"V0DA8;_ *RDF[_52!6@
M$@K2"*5!4*BN5<<*Z5SC%#+\=L:;5L+95\BV6-CTL.6"2JLU?)"2<XX6J$NE
M=;+C]_#C9;,VCH9^T=7*F3L0W0<!*1SIXT0>1H&"18.G6Y;+[3[7;%/UL554
M6DVVZN0<9$[+S0#+;[;I8;5VK;J&7D*[1E;3H02AQ12E2!Y7\3_@WL!\7)64
M9VQLYUR9LR^)"U[/FE2%J23;R@7F$3(2MIZ6=4@%4M-LS+"7/YK;:'3VD3^'
M2;&NS!%O*C0<@X]AU9((N6M,[(WJ'EY)1%Y%%E:W(7.P^.&85V*D8I^DO4PD
MCPD+*=)%/ HNGDJ<SOC;3;0;5[933<[;(??[!*V9.69EBQ+, K2E]$I+@7G'
M2XA/S"ZO/_0D.KN-(".7\-?A5L-\)K+F;*V-LTROSRVG[3M&;F%SMIVDME*T
MRZYV<70!IA#C@EI9AN7DV2Z^XS+I=??6Y>L^T=@,J"3XN9,:K1"B,HLK8FMQ
M@G=5CPAU:JB^3F;4U>K5V$<E5O%13;-)>39.GY[#%E8(N1=)@.M?PZ?K=,G,
MA=4 -J96EU=\.E)0T4AQP48>JI"%!/9JO$4CTCM&_P#.F@K4U%!2F9R'ZAF1
M6N$5C#Y-QM8IQ.L5_(-'G;*M!M+.C7H>V0,G.*UI^W8O&%A3B63]=^I!O6DG
M&NFDL5N+!RWD&*Z+@Z3MN92E<K,MMEUR7?;:#A:+BV7$MAU)4E396I(2'$J0
MH%%;P*5 BH-)"DDT"DDT!H"":'(TK6AT.4>VZCNK4A^<R[??[;C=W^G5$918
M:P1=O?NV:M>5>$9D9$37!M*$8D%QSRYAY21G2 G-S9D@Y8%,&[<7E;R\D+VE
M("3>I6IQNDX4&M#KIOCCN)65?36E*GZJ8U5O-,O+'?$(-5R(Z 4'"[X45 $I
M_&9TJJ(@/:!R$>+&,4>\ 3-ZM6WT#&G@DU]!%12O(G#_ )\.^A-<\J>58K&L
M8Z0BETW\LLD^>)"4Z#=(IA9MU2CO!43* 0[E4H@ IB=-)-,WMN;.<"')BI9(
MH,!O./B,*#OYT%8R2@ @G$[A@.?$]V'?%S?1W\<?OUA]C@:GRUR\^,9\=.NO
MVB9YXJ$ Y5,(;B\L0W]_MR!Y?3Z-5'!5<\CA3<#N \A6,Q^DC6OI2OEIB<#%
M%G=R(@!DXV14(8 $ATV+DY1*.X0,42)B4Q=P[P$!'>';Y=25[AYG?P]/.D @
M[QUW?MG'3XY+!_Y5*[_(,<\W^3O2XZO3NB\>.=<_Q^.&L3<K7'P%*'CU4[X"
M[ENZ+E1_^7/ _P#V=WE[^[?VZ7B3F>XT\,.N,+N&) IP!ICA7*N7ME6O'C<L
M'_E<M_\ V]YY>K?O2Z@'=]GETO'>>\@^WVIZS<RQKOPIOQP]\]3%'6JNO;(+
M-<(V30=MSD1.MT:[$3LCG$5$Q_@1Y2B1A,JWWCR1,*A#"4%1,2Q#MTFM2",!
M7(@88[CD<-QWUK6T54H17VK[;M.^*I9@^8-4&36&E$6S9,J21"QSSJ(4.T1%
M$!,8P[S*'-[8YS&.(B81'6!6HFI)UZRRW9TWQG< &%.%<L]=Y]3G6L>GQN5[
M1BY7=Y0CGFX.[O2#=V]WD[-^HO'>?'A3=AX>)H0N88$'N' \?V.[/@7<MW1<
MKV#_ .7.^[J_D1[-_;U>GNTO'?UECACS/=2)"!C7AZ\A2N5.>,<@[EAW?YJE
M>O?_ .7O W?#S/E]8!ZM+QQS[SWZ >V&$+G'R'7/?Z>I-ZY()?&VCEL!Q$"^
M,ME4!-WB!14*3>(!W!OZNT/)D%XC/=W'H9;L,Z1B4D#/GUXXG.M*5SEBF P
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MIJI*<' ,U?HK\-/C-8&U-DM;-[:ORDK:X8$DZ[:0:%F6ZS<[,*6X[_(;FW0
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ME&)NDDD #O&%O/[/;264X3V2['GYYI*S>[.9D&3.!:*S<XH*<2RM"U*>KBC
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MBJ=-,H$(558B8++;@ -YE3G.80Y1C";>.M_E;/D9$ 24G+2M$);JPPVVLH0
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MDJ%1B-?S&O\ \&<Z-@?/6VAL)+@+6M8^O3':"P2Q-RA;M\3YF22?3%=AMX$
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M<:;;>3_F&FHIC6F/<?".UWES%C&?CZL\R+2FUBE4K4M'PZMEB"/G1*.# UQ
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MT3"Z>J@V37,Y+S:Q#B*::B3<QTC"-]!YY8<.\TQH:14N8K?! 5VBL<#5%%5
M3N RI0#4 YQ HX5KK9I$,T9":%O'(,T'@.'@/BRI6+>-9?PX/2+E9E59Q:+%
M5O&@U:BS45; W AA#4DX4%#3+"AQW>M:<:UI$_-J)45) *B2," F]7*A%:%1
M(*JG.II'0&%88&J+09V=Y#4I!9F(,>@=FX0K4G6F;IL9LR1,DK'$DC24<!3
M1G))<ZD4$U5$Q@G@!R[QF,_2+!,$DD!!K^H $X%:5J&9K4@!0U&!RB_40X%!
M\D&_<1811.'</+_B=7E X%W=^X1#O'746S+B8D'C3ZV*/H(I47/UBNXME=="
M0*QW.R\XJ5M:72%?RIJLJZFM 2O_  E!.50Z&Q6@-%* I4B*\#M#NUH(K0#'
M  [ZX@U!UIPKCACKZ[&JKPD^9I%DSQWB##%IFDMH):Z)3+*$@9XL"I"Q3&NK
MSI+%(H/TVK.56%$@(U=P=V=@Q?\ 3+MM_P"TT/'"P]X^#^SK;BK3MRW9*67L
MV9 L*F)F7^9$P\N:$N95I;94XPFIK.(N!QUOY=*O[I,.]KY+\0K76I4G9EF3
M#XM9N9[;L672SV3:&"\'5!82AQ= /EU!92A1=4FDPVW<T60%!VKAR M8($F3
M$L@,[!(L'MQ96:0-*MI>'M:U2E';RVMI50ZC)K:4)".<2YI!:,75CIM4CM=M
M%RJK;Z2F)W9(V<F5F!92K-<EFUHD7)1KL%,OR8FVFT2:F0D+7**;<2QV274I
M<8!0E3K05Y U+6U\V76A."<2ZI*IA#R^U2ZW,&66I4PEPFB9A*VU.WR@J;=^
MLAIPI_03X-[,3.T8VL.*[G9I![G2FY!RB>]5V2E1F11"-L,*68GH4&;88VOU
MA[/6E-!I&%=$8N[&6TKUA$L.U581/RY\7MGW).U9:VI&39;V>G+.LAN0F660
MP%%R6F0S+/WU]K,S;<M)E3CUPK1*"33-J[=8<>]K^'=K(=E7K,F)AU=J,3<^
MN99=<+MU*7F>T=:NI[-EA3\Q1+=^ZM_YA3 [(%#7ERTJ.)O"H;#F4VXBWC\\
MXXS1LSW-9/VA%$X)DCD:A-W/\5-19];'Y4T#G$ZHI,#)%W%32 -6L0B>V)VG
ML\B\JRIVS;9E@:$U=49*;4FIJ EEL5I0 K&&)KN4Z.QMBSGP:?,LS$HX=*(
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MRRPE78A3@4HK+80I06 L*O'M%)KV;B% *'Z>4S@JBDL"J"W+(7E*MC@=N=0
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M'7./$+(-ZS)$_P#\.V/_ $BZ1D,010X9Y1?')&9W$-*FJ-+9!)V+GR,W#E1
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M9:$PM%UM-Q;X1VJD76FQ=*R*-H&20!/F,)AWB.N"2#B3W5(.&5==U!ZX1S0
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M5X;OS%'[15Z=T[&,_'5EXW#)UZCI2E8EA1.KTA.W^;CG+6%28I()+J%2C%5
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M8ND3%30=MT&SY%AHY3,61-)G6GGNW0XDLNM%2%-.I%*"\DIO!*C4 J0M)I4
M+"?J>5G+*VXLAZP7I"2;DWI90M*2G>QF&IR3=6%!U*&'PZ6ENMG_ !DL3##J
M I39*V''LLL8Y#+;6K>(D>66SH).!5*5$H)22354P"NW% QR>,IMC(*/VHD0
M.FJ955%$6Q1%/VS9;:V6M:6;EIYY+-JM-J+W:!#+,RE"RD.LJO7"Y<+:GFOH
M4%J66F^R35/PA\8?@U/[%6G-6OL_*+G-CYN;:1*?+N.SDY9+[[*5JDYUI2.V
M$O\ ,"8:D)JLPA3"66YI\32TAV]"45(+"');*%#JZU=R0 'E]ON$?@ 1ULKM
MJV<R/JFFU9X-5>)II_+O 9C%1 U)I'CC&S]LS) 3(O-I- 2_=82D$#$]J4K(
M&H2@G, '6H&$$F@8JKHP+*%$!*0OXHHAWCO#>IN[0Y0% !_U1$ '6NVA;SCZ
M5,RB2RTH%*EJ4.V6G<F[4- G.ZI2J#]8!(C<[)V49E%HF)]:)J800I#2 ?EF
MU"E%$+ 4\I)Q25)0@5Q;40E0I+(^:<28>5KB64;]7J4>UK2R,&$V\!N+LD#$
M.IN8>&  ,+:/CV37FUY!SS3/I%[%1":IY28C&;K&Q-F;<M],TJR+.FI],FEE
M4Q\NB\&_F'T2[*!6@4ZXXNJ6D N%IM]\I2RPZXWVUJV_9ECJ81/S;,LJ8+@:
M#I-5!EM3KBZ 8(0E-"M5$]HMIL$N.MI5AO1O"<[-UOR[9: ^N56KE+;]&-Z+
MD:1=WELVN,D]!!-TTD8V;QM Q=,;1BQ7A7,K-V;H]P0\<=DLX(J]48^AVE\&
M]J)*PI2TFI*<FK07VJ[1LIMNSUJD6FRHH6TZQ:LP[/K=3V=QF7E.U20[V@04
MMAW3I/XCV2_:;TJZ\RS)BXF4G5JFP)A:[H*7&G9%E$JE!"[[KKX10HN%0*RC
M.''N1*1E6IQ]WQ[8F-GK,F=PDWD6)CAS;EHL9!VR>M5R).X]^T6+R'+%Z@@Y
M2$2F.F!%$S&\QMBQ;2L*>=LZTY5<I-M!)4VX 0IMP!2'&UI4IMUI8Q2XVI:"
M, :@B-[LRTY.UI5$Y(O(?865 *235*DFBD+2H!:%I_J0M*5"H-*$16FNK%,@
M*TS& K7,\CA@*88'"D=A#4#"F!.N-#EEQH*YTKE3="-<.R4B?/OA,]K?/X$!
MW2MFF@5?9#H+\VX[5U;W4F>\97,TYLYDDY.L3R3F!?&,/.J1\VP =V\4D?0[
M32;)V*L"ROT3-M33^T,V@@U3+A EI &M*H>9N.H I132B./0,*^:M>>F<"U*
M-HD6C_\ 27NT?I_J0NJ2?\JDY1N>X'6CBA%*:4/VWX<:9QV_0AZ?)V=X\>K0
M[Z95IOQ[B1W:9[H<-^>G7?#4Z= >](1/H_D5?\X_]\GK]7&_51_7WCVC,?H/
M/[<N?5(@/G]7[]68C=GH*:BNN>9ZQP\N?[1P(@ ")A "@ B(B(    ;Q$1'J
M  #M$>K=H:8^^6OW.Z J2 *UKA3.NE.,8AV/.,/>+*6AQB3\M1L#P("I3L;(
MJHR&:K,S0/(3T'2DF#!ZZ1Q9 QP)!=\M%<M(4JRRD+"N'0BHZ6Z<6HVY-)82
MFK#B@U+O5*C-OC%SY=M -Z58;J79NJ62OZ$E13>.]O[#SLK8CMHNO 6C*-&>
MM:SBE#2+!LQ9+4FFUIQYUM+-N6I,D(L^P4-N3_RZ3,3"6KP;1D!3J<,,)9R<
M"/>6]W'HQ[M['H*(1L5&(JG7;5VNME3&%E#,!.4@G $W4LND60D>4N*23?MD
MISJ,?3#"E:Y=5I&C*57 9#SXGG$Q:+0RJS)NX<-WLB^D7B4;"PL8D1>4F9-8
MBBB;)DFJJ@@3DHI+.73MVX;,F+-!=V\<HH)&/J2:<3H.?758@"IS YQADVQ7
M?,K7RQ'M,ZI)5>8:2+6PY0@7Z,8>/@',D* 80P%XLL\DJW!+(13=#->1W!VT
MW=GFZ*A31SADQ5INN?P^;FIMX3*U%I:3VLVD]FI+*U IL^SA4K9;4A*?GYHD
M./J(2V4E*2QZTWM38-C6%(N6.PT)R7>09&Q'T&;:?GI=M27=JMKUJ0U+6C-L
MONN_\+6*V')2RD)5,30>2Z\BTLU:[6*Y48IG!U:#BJ]#Q[1FQ9QL.Q;1[1NT
MCFB+!B@1%LFF3D-63=!JAR@$4T$DTP$"D  V!IEIE"6V6D--I"4I0A(2 $ )
M2* 8@)  KB !W>83T_/6E,NS=H3<Q.S+SCKSK\RZMYQ;C[BWG5%2R35QUQ;B
MJ4!6I2J5),4O7+VI8[Y?*HUC2A%T<D"V6FP<F,+R9EFR[UTP3;BB! +'H%23
M6.583IN .4Y!*JD)<P:E0TZK@=-]/4QQ"* &N=>JBO7?2XNIZ&9U_8^.ZL1#
MCU:<:^F6)%> R$.N<-!EW<*>(&7MI6L(:D]<-(0X^S4'+&@...[OPQ'=K#KW
MAIG2OA[C(X:'[B$-*;MY/WK7?AQ[A"&GV'/&NFG5<H0TR%3WPAIYD>->6&_A
MI"+!VO?^$1H(=OCL#U;P_P!IKU?9]&KDXH[E>5:]#NBI6#G>GT$7\W=_'=^C
M5-!PK3+@<\-V&Z+:Z=:_>'S^O33'OX]#3N)UAY<H:4R)T&\^NO?SA#3/#A0C
M'EGGOQUSA$[$?B'_ .87^XMY-8+T[_;KH1FC)7+[Q!:S\M:8<-V?YY1A#04W
M:#RRPX0BQ&5_RM'_ /+!_P"I7U:V* TW^@ ]HJ<S'+W,7P;>YF^[LYA+ZLNJ
MLZZ\/+7B#%L=^E*#7/GP\*=].,(:'ENZS%.&5#OPA#2@K7SSUQY>.&[.J&E!
MJ,<#CC3K&G?2$-#XYX95T/=Y<#A"*&09I63++>.<%.HPJ%!D7[HJ:JB)BR-]
MD#0<:H1=$Z:Z"Z,16[.DFHB<BI"2!E .0P)&'K'@E^T$-G%$M*+6H D47-K+
M2#4$$$-L/@4(I?KG&Y22UV9LC,3C92E^V=H)659*DI7_ ';9^6$_-)*%A3:V
MUSEJ64LI<2I*E2UTI4+P$!0X%A&VJ\!'+OW<?5R5K&L4ZE'BC]ZLVKD8:Q2*
MYW*NX3&-+W)U'*E2(B@ET,BT001;M$$RUV:PAMZ;*2M26 Q)-*<5?44L-EY9
M*M_:310< /Y82  D".7M?:,Q-6;8")A##3]I?Q/:><:E642["'K3FA9LLV&D
M# "2L1F905E;B_G5NK6MQYQ1NQKN.NM\:%%F,OX0K67$(E\N^E*E>JL=PO2L
MB5DS9&R5I9T! >,Q*[0<L)NN2Q4TT9VKS35Y#RJ!2B=%!\@S?->KM*R9:TVT
MI<O-/-WBQ,M4[5E1I4"\"%MJ(^MI8*%4K1*PE0VW97;&TME79A#+;%H65/A"
M+4L6>OJD9Y+9);='9J0[*SLN252D_++;F&%$@*6RIUES7U?MF?)*!WK*VX=;
M9(CG0*HN+7@Z<K$1TPV5Y1>=L6),GRL2TBW2@% [MM5KC/-%E%!53*CUHET>
M;V;M%HJ'RR)Q!-.TDUMH4H$?][*S"D!)IFEIQP'.N,?16S_Q?L9;+26-H392
MTA-+-VNDYZ;$NH$$HD]HK#8F')AH5HVY:-G2SB$I (/ZHLHRV4YAPDG"Q.+]
ML9[#E)S"%/=72GT*GMT#&WF:+OIK*;OQ2,'KYYM#MG1!+O*DT/O( ]0G9>8>
M6D?PJ=5=P =,LT@"M:7G'RH"M";EXUQIE&RS'Q5L9J],+MKX>L/J-]<ZU+6S
M:\XM5*!:6).QFE+>& 2J8=12OU* !IF+BO8R=&B64-D>/JM$QLV,BM^!+&KY
M_))V7FC\\DAE;(S]K%R5JCP5,=5W4J_%PD"[<&4)*R-B8**-5-MLW96Z$FT.
MR2RG$2,NI2D+QJ!,S!"2XFN*FFTH03@I3B20?(-J_C$7W5KL%R>M&U2E;:=I
M;899EOD L75JV>L1A;TO9[R@ $VE./34XE%%-,RCZ4N#88V;MV;=!HS00:M6
MJ*39LU;)$0;MFZ! 210012*5-%%%,A4TDDR%(F0H$(4"E  W-*4I 2D ! NI
M H  !0  8  "@PP H  ,?!7%N.N+==6MQQU:G''%J*UK6LWEK6I1)4M1)4I1
M)*B:DU-8[M94SP%3WYY[L*U)W^480X]6G'AX<LCSKY0ZY\X:'K##CUIAOH4!
MW=_9Z=,*:#G3#(X]],-8"NF?"''''ITRSPQ]3X#<>=30UAUUUPAJ=>77@?;P
M1,0GNM3WN;ZQ+5:].MWGQY18WKW>\51JN+(:0AI"(>;]R)^^"?5JZS1F>7VZ
MUY1@O(<_8Q2^K.>AU]O'"F.F=8JBC,BV8M-H=OM(F JD'7I1^UY6[<H_2:*!
M'H]>\-[A\9N@7>&[E*!OZM^N+//B5DYF8P!98<6BH%+X3_+&[%=T ;S'?;+V
M2;=VCL2QZ$IM"TY.6>IFF76\CYE>&-&Y<.N&FB3&O?8:K R%TMMN73$Y(&#;
MQC90_MMS^P.C*G5(<>U1-G%.4U![1*\WB/MNO2=D)>_-S,R<F64MI)_SOJK7
MF$MJ'_F\?IK^T-:XEK!L2PVU!*K1M!R<=2D@?W:S60A*"FGZ%/SC2TTH IC+
M##9WKT ]8TP!%3GW\L#'R/&IKPH%6LN,!P+X0;&D2XE+QL87CIF^0\=_!O[C
ML\W84*_E: Y8&*552-CG'2319T)FD-'NK)+&(8Z0 ;>-C7FIS^)[+3BPB6VA
MENSEEJQ2Q:LM5V1=R) 6L7%!-%.+2RV" :QU%JI6S\O:30)<D7+SB1FY*N?2
M^GF!0@GZ4I*U'*-I!<TTZ4Q55LQU!S[,*5=8:NV*L2<2H4$)*$L[)&1BY$53
M@(-T5&:Z8G*J3G4W!R-52)K"8":2_*/RTT_)S""U,2[KC+S:ABAQI10M)WT4
M#0Y$8@TCN@\A32'D&^VXE*D*&12L7DG'>*9XXTBI:5D*MWMH9>&<F([0*!GD
M4[ B4@TWB <LR13G*L@)A "N6YU41$0(<Q%>4F6E:%(SRT(R_?A&2%I7EGJ#
MG^W&*XUA&<0%JGDZQ79B?50,Y+%LE7)6Y3<V*ZH;B(I"IR3<V518Y"G4Y!Q3
M()C@0XEY(RD7E!.532L8J5=254K33F:"*&99*/%J]'9 C#P$BL5NK'.8QK)S
M,-+H.RD$A&;AHS75(\;G/S#ILN0  Q0534,FH4"YE%15!O#&M: BG F, Y3!
M8NDXB@)!!Y5Q&L4'F+"T19XR2>)])KIO$GC=U&)."K%:A*>-G,XA&JC)VIXT
M>>>-9-PG_#N$D4WZ,"5HM).VTAT5HV:V^A:A?(4%)* ?T]H3BTFXHU+JDK4#
M>( 4&0DK4%^F[';:3=E34LT?E4*94RXU-+;*.U,KV(#<\Z'VD]DF09=E6U?0
MVI:I=<^7FY9E;&GF4H-QQ'>X]*G.NB(52=DYB4M4DH^CG E.@5)\,49991!T
M<A!<-UFY 51<$40*Y:-T'*Y6^B*9FI&:29=Q324K6OY@E:%8BBKAQ2J@)21]
M04D@*2$J-/JQJT;%VJL)]NT9%BT')AAAAZR4EN:0D!P.,+>2 AQDWTI>;<)#
MC+J%%IY:VT+5L0Q7D6)R15VTJP>MW3]HFW:S2:!>01.0Y@ICK(%WF*=B[,!U
M62Z1U$CD Z7+YY!8A/0+,M%NT)9+J%@NMA*'TT*;KM*J*:D_0L54@_4D@4'U
M)4!\?[=;(3NQUN/R+[*T2,RMZ8LEY:PX7I'M5);0XL 4FI=-UN9;4$K2JZY=
M[-UI:[EAUCQU_/\ !KL@,2<,37 DX\LLJ'?Y4THY&FZ-'_A-KG+W')N+L*Y3
M92V*\"I6:ZR2.1&[YH9#(3R'QE39N,<H).V0^(E@+399.J* X2=1;EP^%T@X
M5=QSDL?]-_!VSI61L>U;=LAUBU]HE2D@TNSE-J"K+;?M6?8=0I3;A[0S<G*L
MS@"2AY"4!*TI;=1VOAOQ FWYNU92SK0;=D;+;>FEMS04F[.J1(RSJ%IOH%T,
MOON2QK>;*ED@E3:NSU&UC$N%9!@I*V#:%AHPJ!55>@DZM+DDY%,9)_'(%CWQ
MCNBH*I)MVD@\3EHF/5YEX0K%%XS*K+(^Y3-K6TVL-2^SSSI50=N9MGLVU!IM
MP]HW1!(45+;0677$WD'M%(71E7F[,C9ZTE;UJMM@5):$NZ5K3?4@!"ZJ (H%
M*#C:"0H74J15P?H#\&%DB_VG"+*F3E9D'5 HO3D10<K/7A%"VZ,8VF3CV< F
MT3;@=,:O%HM&23ATLB8(]-BP:M3H,%%$OESXSV39<I;SD_+3K:;3M R[MHV,
MV@@R;KDFTXY-%PKQ^<=4MPH0D@.EQU:[S@!]J^&UH3S\C\FY+K5(RO;(E;06
M2>W2E]20Q0)S90$A)4JH0$(2FZBHV7:\4.-<1KKA0XU/ TI0;ZUKC'J,8M[9
MFT6QV6]G>_Y8%,CZT-6!:[C:O\V+EQ:,F643QE,A&K!,#.)$!E%"R<FT:D4<
M]!QDJNBF84! >]V9L9=OVQ)V>#1A:NVGGJW4L2+%5S+JE8)0.S!;;4H@=LXV
M#2HC@VC."1E'7Z7E@7&49E;R\&T@#$X_4H#&ZE1TBY'@\=FN0V6=E7'V/K08
M[K)]@Z1R;F:676!T]ELK7]8LW:3OWI1Y#]Q"E.PJB;\@ #UG7VKDW*45.<W/
MVIM=-M6W-33-$R+79R=FMI!0AN0E!V; 0BOT)<HI^Y_2IU2< *#CV=*F4E&F
MEU+RJNS"CBI3[OU.7CJ4X-UR(0#K&;FM=YYTT!^V)]=T<Z' :#7\Y\_>F5*"
M'1AIUSPX8GEPRA$\C^15OSC?6$X^;59_7WCVBQ/Z%=^G =5TBDI490(N2-"$
M8*30,'@Q"<HHX2C#R@-U.CR2*K1-9TDP,[!$KQ1LBJX(W%0R*:B@%*.2[X0O
MLP@N!"NS"R0@K -P+*14)*J7KHJ!6@,92XE_F&!-EY,J7FOF52Z4*F!+E:>V
M+"7%);4\&[Q:#BDH4NZ%*2DDC6UE)EM TK'%XRYM;9DKKW&,+7UT)W >"J\M
M7(JW+3CAM$1E?5R9.*H7Q%!_*O6#-VW9*(@]:*.FZSCH]=ZU=:E.)M26E9B=
MMRT&E2C;12Y9MG-*:0^7"E"&C-NTF %+4E*@FEX$I*KI4#[IL\[L9:MN63LU
M\.-F)UFWYJ=2N4VRVNG43TQ9J)1MR9F)T6#*I59"ULRS3SK2G0>R=#:TH+R&
MG&\M,$XI&G0C"UVL6TGD6<A62+A<D&R@X^@UI1!FM&XIH<*U4=IU:DU8B#9L
M$6@^=*R\PW=3\JZ=/710;]U9LEV"$//D+FW&TBH;2VF6:N@IDY= *@S+LT +
M84J^L%Q94I4><[7[1?Q.:>LZSK[%ARDVZI"#-NS;ULSZ5NIF-HK8FG VJT+5
MM!2UK^86RVF6EEM2<NVVTV;]7765RT251B,?52LJLU622ZUOM<XHG&M72BJZ
M:K$L!&$&8750232< Y!0K905RI 4134'79_4#@D:FN&O+49'$UI6-, &IICE
M[] Q;N%BGUNN=AA7]@Z2DH9A$Q.4)=NBZ:)+-Y.-*Y1H=%*GR4X."='(O(6F
M4(Z&QK.5$&B;A W,+1N(!)()QQ!-=-PX<\,N1S- *@#+ 4RQS.I)T[\\3&1C
M%BSC&;6.CFK=BP8MTFK-FU2(@V;-D" FB@@BF!4TDDR%*4A"E I2@  &K,,
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M/$DX>GC%^42"FDDF(]::9"#Z>24"[_4.[?JK/>/+]O(Q;UUU2.SZ>/T:@5\
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M'K*&G2NF3XKROO%C@:19(@U<JBB@=N];*)@<>#/R#-HM-,S"G TW,-3!0A0
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M\NM,)P+(YF=4P2S4?((XYH2XJR,BW:GFYTW,/E FZK)5-.I6MU:GI8_6U,O
MI=FW%T4IYIL&Y+R(%$2K!!<*1VCA!-5\O;MFPY68EY>1EF[/M9H%B>L>1(7(
MV#+2P+,O9LY.N(^8M?:12PY,6W:"5HE&GUB4ET*N*3+YD        !U  =@
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MFG.NAPSI@1QTQA'/*-Y?1UAN]?7NW_#W^74UK@#W@99\?3770J#='SV!O'J
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M*2&U,,I*"I2D7' VM.RDI2D*4A"E(4A0(0I0 "E*4  I2E        *&X
MW>36W4(P%,!AR%/+('QJ#01X02225$DDU).9).))WFI-=\<_-W!OW?'V_MU/
M=CEC3(UW9C@,<!7#&'GJ<_#+\1S^SC]/&]T?O[TQ-*=\?GK[=4:;_L3O\>0]
MQ"&GEKIQQ]^C"&GXZZRQ-80TQ WX8^&G0A#4_OUK6GMG"&HQ->&ZF-/&E=V8
MWF$-3]LMWA[0AIW8TZ%<_+6$-1Z:\:\?'QA'Y:,E?]G>R,%[RM5MG?:YBL3;
M*6<K,XG[EC69Q:PLUWJ$;*23.1F*E3+0+A%XO JC&QK-,C><J!I2'C(6(MZ=
MH"%(_?>J2OQ%E_EY1VT;'7.6M(-!MF:1-J:9>4A*DH>>:NE/:"\HDE+P2M3B
MV2U?*1U"[+5><0U,%N7=45*;[,*(J02E"R00DY9#  &]C'Z-<$X-HFSSA#&^
M * U=EH>,:5$T>%+*+E=23]A&LP;N9"7<IIMTW$I,N3NI.56;H-D%'[UR=LW
M;(BFBGYO/SK]I3TU:$S=[>;?6^Y<%$A2E52E -2$(31"025!*152C54=HVA+
M3:&DUN(3<2"=*4TIB<S2@KI3"*Y]A55_F5IN[>U;=V;OY7R:XQ6H?U <P(FX
MD_TX]]>'GYP]A55Z@Z%:>CK5]?\ *_1J M6AKC0'#=XG#'CG6AP!":DT%=?3
MEKK#V%57^96GQK?K=3?5O\A]H74[AX>?/ 8YC?$O&T*H+(O#*03,QDR%Y B*
MX<D1*J/5N5\H /6 ]FL%N*%**W[N'C&26T&\2G(;S]QN'A$1["JJ/_DK3X>>
M_6ZROJW[]!II2F.IPC&XG<.[NW=:1[&E8KS%0JK6'8)JD$!(H*!55""&[<)#
MJ\LQ#!N#K*(#Z=+QU)\_/\\HD)2-!X1.\;^.[CTZQ&%,]QP&.&9(W8CJL3U3
MK7KA#4]5ZZXUA#44KF.&.ZOAC@<N')#4PCCYN[]&[U;^K6(RPX"II6F&5,#G
MAQ&L3YZ_>O.F,<\<=VLOQGUG$?GK?#4;L!]L#33+,5P]H12%\O=7QI59*YW)
M\[CZ]%*QC=VXCX2=L<@H[FI9A Q#*.@*Q&S-@EY"3F9./C6,?$1;YZY=.T4T
MD#B81"UAER9=2RT$K<7?H"M#20$(+BRIQU:&T)2A"EJ4M:4I2DDG#%6F./@5
M'E0 DGD(H^ S]A:RPZ,Y'9,J+9FH[7CEFMAE4:C.QDJUFUJR[A9ZLVSH6R5R
M>96-NO /8&?B8V89S22D4Z8HOB"AJYR0G6EEM4L\2 D@MH+J%)4V'$K;=9OL
MNMEM7:A;:UME!"TDIQC$+00/J KO--2*4(!!J*4.1!KPGU<LXK0DW<(MDO'Z
M,RPFF%;?Q"MRKB<HRL4H=TG%P+M@>2!VVFI)1B\(PBUDB/GAFCDK=!04%0)6
M)6:*0X):8N*07$K[%VZIM%"MP&[0H2%)*EUH 05$"E9O#*\#2@S&!.G UJ*;
MZQU_A?Q,+1-^&4,=BQ6AW%B1>^S:M>*+5]I(&B7<ZDY"3%$\,UE2'C',H4XL
MD) AV:JY7!13"?E)NI E9B\%AN[V#E>T4F^E!%VH6I)O!)%XI^JE,87D_P"9
M.5<QD#0G,?OAG%"9">[..=<;WS'.3W^/KGC.?;R55O-<N#UHSA9!JUZ9<N.=
M"45CU!;H&J4]+0]BC%BI)GJTC.P4J!X%9ZTOEQ:4C,L3$H'V9ILI=EW605.)
M4;@3_AWJ$]JA"VE"M'4H<11P).*PA:5(<"5(4**"LB"*ZTTQ!&ZH.%8P:V:?
M!K>#&V'<@QV<,5U^GUZ\3\1-/Z!<L@Y9=6GHBL'B5%YUUC92W6)RP18I5UTH
M$A9F)'\PC7G+E%Q/%BG[PCGO;3VFVGMV75(S;KSLNVI"9AB7E$M7W NB/F@R
MV%*47 +K1NH+@!#=\ CCM2<K+*[5M 2H@@*4M2KHIB$E:C04W::TC9$KES%"
M*DJBMD['J2L%$L)^<25NE;34AH*43C5HR:E2&D@-'1,BC,PZK"2=@BS>)RL:
MHW64*^:BKK@E)LA!$M,&^I3:*,.?6XB\%H11)O+04+"DBJDE"JTNF.5>3_F&
M !.(R.1Y&HIOK$*AGG$#E)\[0OL(I&QUI)37DX!G7L<1G5,6,LV$ ;)XMT",
M.;%T@TMH68LB-:\56!CTOTL!F 3\E-@I"F%A2FB\E%!?4@32I(D-5+E\3*%-
M!JA<)JJY<%X*C>," =P)3?%3E2Z0:Y"M":X1+L<NXPDW*[>/OM6=E;U1A>1?
MHR[0T*O4)%>R-F]A86#G @I2,25J-AZ16C9!V,0E'>,2Q63=VQ5<X+E9A%+[
M#B:NJ8*%((6'D!M1;6W_ (B54=;NA2!?*J(*BE82!20:&N -:X$&M*&E#D:X
MX:YBLI%9$Q]/.W+&#O5.F7S-^UBW;.*L\)(NFLF^)(*LHYRW9OEED'[Q.)E5
M&K-4A'#@D;('23.5DX%(N7?; 4MAY"5)*DJ6TM(4E)2"H$I *4E:02#0%8K^
MH1-1B,*@T.\'=UNBL=4_CU]O#SA#KZOG_9J.7>,*\!NX<M888^7YAIYTSP[Q
MGW:YPAJ:4ZSY^O.$3$)[K4][G^M2U6O3F?;K6+$:]WO%4:KBR&D(:0B'F_<B
M?O@GU:NLT9GE[B,%Y#G[&*7U9EJ>_AUB3]HJC4SM.[[?M)HUH!$Y2'I%4)R1
M$1 )0&;PY"]NXP+3BI1 -WM@[-XB(^;;0?WFWA+UK0RDL*9_S E5,\35T[L8
M^T/A)2Q/A0[:U DJ3M!;"B<!_<^V822=URST]T;90    * %      W  !U
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M4RB3C<WBZU@>IN$I./4Y8KSC=Q,TQOO[4I8FQ #TXJ6M[:INBF9)![2RK'=
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MU7TM!PA%5]L2KYHLT?%U"@?[NBG\M0! 2$I(@HR_F+P H/IQW%5$XD@U.(T
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ME6XY=;L>Z(O)WC.F?//@*8Q4I#D4*4Y#%.0Y0,0Y# 8IBF#>4Q3 (@8H@("
M@(@(#O =8[O#O&>_=3'C4DTC*+'WC!\7?LQ8<RW,3L@ 881NJL%4RMVYXF0G
M+A&M(GIUXX,8%R.(AHV.+1$$U2BY,W<)J-3(+%=];,6<B:GY"=<<7_V>)@M,
MT3<6X^E*+ZB!4% 2: 5QH?I(HK;K)VLF+&V8VGV;E91FNU*K+3-VB5K3,,RE
MFONS/RC2*%*D3+C@#BR4D("T$.!:2W?+7988YX#CQ&F._P!1&HQP(@ "(B
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MU(5VJFG6F5]FD X$I/Z5*"4+0LNU!25)0L_RRX,$T-,D@A1Q.>6652*1\_\
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H(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g96328g11a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g11a11.jpg
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M 0$!        ! 8#!0$"!P@)$A,4%18* /_$ !H!  (# 0$
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9JG=BJEA5,0"PNP:-6+'ZZKY_[(^KCK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g96328g12a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g12a11.jpg
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%?1CK_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g96328g13v55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g13v55.jpg
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M 0$! 0$! 0'_P  1" %= ET# 1$  A$! Q$!_\0 'P !  (!!0$! 0
M      <( P($!08) 0H+_\0 :1    8" 0$#!0H&"@L+!PT  0(#! 4&  <(
M$1(3(0D4%3'5%A@B05%35)*4TB,R6&%QEQ<S-CA"='=X@;<E-5)78G*1H;.T
MV"1%8W."D[&XP=3P&296=I:RMB@T-T1'2%6$B**UT>'_Q  = 0$  04! 0$
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M3E&D]EN#L=9R;S4],H1_*#*TL!JQ-AFC;A)LH[Y)#7 RR$5'P\LFPZ:Q&[H
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MMPO%1L7D%G\;CZ+.'G8^O:<^]BZUJR)27PV9Y'EI$#F.+^\>YKFR1Q\K6,=
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MM;#9&@M'[A?0\GM;46N-C2-? 20K^ZTV LCV,1,J"YVS1U*L72R3-18 659
M?S154 441,< '*3U*MDM=8KPSN9] RQL>6]=Z!<"0-]=>&_)9L-Q7Q/P[%9@
MP/$&9PT-L@V8L9DK=*.=P;R!\C*\L;72-;ZK9==XUOJAP'12HV;-F39NS9MT
M&C1H@DV:M6R2:#9LV03*D@W;H)%(DB@BD0J:2292IIIE*0A2E  #.
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M+1K"6.S4E&3"142,\9M))2.CU)!LW631>'8,S."*&:H"2X/>&.C#W"-Y:Y[
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MK0%[\\_9H$!:>=R%/'2W8R^*6!NK,%9S)'2![>_9-()B&Q/;W,;()#)IQE)
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M'.17FI1NTB$%O-VJSTCEVT16UK5N"G'WMASFQ[T7-CDEUT+MN$3'EK0 =N<
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M7'G&3#[N)LT1T]QND?O+JKCR?7"!P A[U;1S3M=1$T9K^!B#^/R'BFK,Y?\
MDF#I\68SA\6?^3Z@_6PL;_! 6^SM;[3F?_OOBB37E/E[=@?>GDD'G[%L4_)X
M<,$.HLM#5F+,(]>W#2UMA5"C\J:D5869TQ#XN[,7IT#IZ@RGR/C/*I&W]:Z1
MGL_2O'L"RGM?[27=).*[LP]EBOC[(/ZX6*<@=_E K<I<!N+[01-&U"\0J@_B
MJP>]M]PRA/D%,8W9K8"=/BZ%Z!\08^2* ^C',S]9<N-U\.6<#ZM*QW:OQS)T
MFR.+LCS;:X5X3LAP'Z;O\(_?QWOWK&;@QJ-(PGB[[RB@C#^+Z(Y<\DD2I_)V
M$G.S'20=GX@%,P?$("'A@XJO^AFOL_6Y&Z-??G*J.U#B @-GQ/ UL>?I/9[P
M6\GWES,)&\G_ "@L(<)X%(XG9\C^:+,?X)??1;(DB$^3H2<>RI3=/^$ _P"?
MJ&/DM@\+N3'_ $^=VOPB[]_8]RN_JF6B-2<&]FT@\_\ ]#8:$GZZT4!'U$+5
M[SF02-VV?+WF>SZ!\$H[;K,F0OR=2SFNI7M]/^$$PC\8X^37;V,EDQ[O2(W#
M[SH'#[Z?U1H7#4G9[V;2>T_-^["3]=7,0:^K7N6DW%'9B!P/&\Y^6;4I?Q4W
MI^/\R3H'J XR6B%5#_G$R@B/3Q'Q'J^3YQ]'*Y ?'T-WXZF_WT''N%>")^R[
M@"3>R3$WBVJ>I\NXXK: /8 .GDLQ>.W(EL8/,>=NXE"%]1)G5?'23$0Z^I11
MIJR).<?B$0$HC^;PZ/0KH\,M9/Z^O2=\/"NW]_:M/&'![]][V6<.@G>S6SW&
M, &_THDSM@-UY#K][HLBNEN7*70([FN0Q2^KTYQNUO)','Q=LT3-5P!_.)"I
M]?BZ94U<C^ARGX=*!Q_]US!^\J-XE[/COONS0@D?VKQGFH0#[0+%:Z?ALGZU
MM5-7\YVW3S#EKII^ #_O[Q2? 8X?(<T-OR.*'YQ(F7*&#*CPR%8_K\>>OX-M
MNOO*\9SLN?OO> .(X=_W+Q[%H>W0L\)S'ZB3\5J-5?*!-"@5ONCBC,=/6>1T
M#M*).?\ 2##?C\A/T@0WZ/BQW>7'A:Q[O>ZG.W\5MRIZ=V2R';N&^/:WNAXL
MP5@#_K>$X2?O_4OAVGE#FY.B4]PRE3A_"7JN[8,#?FZ)6^>[/Z?A?H\?!K,C
MP?C'?&.TS\4C_P 2J).R!Y/-5[2(![&W^&+.OOXZKM?!DO*&LR=5*APYGCAT
M^"UOFYZZ ]/6 >=4&P '7XNIA .OB(]/%S9D?\7C7_":RSV:\87^_P#H4[GL
MAD)#<AVC5?89,5PW<'_P\M4)U\!OW+Z%]Y[,B=77&[CI-G /]YN35PC.H]?6
M!)?CZH'B'J 50\?6;I@39<>-&D[I^@O2CK_E4_O?C5/DKLJE/V/C/C"L/_Y/
M!..GU[B:_%P/0^8;X;7TNWN:J!>KSAG2'9@]983E1!+B/^+Z8U9"%Z#\7:.4
M?EZ8])R@\<9$?UE]A_A0-_&J_-[LU>?L?:1DX_\ &>!+; /W/G;)^\"A=[\L
MD2B9]P5L*G3^#"\AM*R!A_Q0DY&  ?\ E"4?S8]+R \<4_\ R+E5W\)S/R^Y
M#PKP XZB[4J@]]GA#B:(?7W$-KK]\>]?$^27(-'J:4X%[U2(4>AC1.R>-<P8
M?SD3'<;!0X?)\ HC\@8].N#J[$V_\F:B[_\ V6_T^*H>#>$7?:.U7A9Q.]"Q
MA>-*P^MWS<F:/OG_ %K<I<J[VD C+<+.6,<4OXQFT1IF=Z>'7X)(3<[U53Y/
MP:9NOQ949";6W8O(-^#:K_WFVB3]2L=P'BW?G?M)X!F]G/8XDJ[^)L\-Q@?6
M5C'F2B@(@_XN<RF %_&/^P.[EB!\H@-=GYH3 '^ !NOQ=<?*0'C0R3??Z(7?
MP'O)^H%7#LX<X;BXY[.)=^ /%<5<^&_[=J5M?Y6NOCI82\XZ 0XD?Z9Y>18%
M_'4=\3MXKI$Z>L3'C*A(%$ ^,2]K*?*L/G6R(^./MG^#$54]F&5(^P\2=GM@
M^0CX^X8:3\!/D(?=XZ\50SR>_.ZM\@>9G**M1M G:XWVTK%[%K,@^D4G:[..
MU95*AK)1A/1Q(]L>->S;5NWGRF*Y<(1KE96!6.Y6(W?NXC#99ES)WXVPO8+)
M$\;B=D-KQQ0:D :.4O #QU/*3W9V0"?5>UOLLN\)=G' ]R;+5;CN'Q8Q%V&*
M%T;9)L]?R.;$M28S/$T=61[JA!8Q\\;1;:(VE\,?N)G5+YB5:>9Z5?7X?\J$
M+76++=:PMQTW4E8:A3$XI6X6>$4UQ9"R<%52SD+9(;W1RC,5F<(>6KL]')R2
MS91Y"RC<JC%>4PAD;F<2Z&:*"49*B8YYRX01/%F(MDFY'Q/[IAT9 V2-Q8"
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M;$ K&Q\='Q+1&/BF#*,8-R@1NRCVJ#-H@0/41%LV3312*'Q%(0H!\F;H:UH
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M=!T,4C@R.25MJ(QL>]S)0QKW -<\QR<H)=R/(Y3BGY3#*'DAIC?S$#9 Y3U
MV-D>S8]Y"HSY'Y]KP^L=GQ='9:OC'[.?JKRUQ6K^-6C^.+2(E7<._CO1-F9Z
M$V)LBFW&T,EH-\5W*^F$3M6)V"D:F[@9.*D'4_QFRRVW6-AUIXY9V1.M92_D
MRYC9&GFB.0K5IH(G<XY6!A#B'<VGM<%KTG,<UY9RZ]78;%'%H]>A[MS@X^WP
MUY>*]@LXQ;J81,(JY<G?W%Z__G&\8OZ_->Y)8S[=9_:W)?R*989_HL_9H/XU
MBL;D:LRIURSU)89QA7MYZKA&LUN73"$NNTK"Z: L]R:MFD2I;+T98BKE,V?1
MUPB40?UHD@BZ:Q5YBH"0(DFF=Z<_7\+9.D/3.',V\# 9]K(9Y7CG&*R+.9N/
MS,3#O1K2/,5QK=&?'S6(G<VF 0N5@MQ25<UBG/CR^(?W]=T3W126(&N#YJG>
M,(<US^42UG@\T-J.*1A:[94$:[9634])KF].%H/]P<6+M'EM4IQA</.YL5';
M/E%5)I]Q\?RRX>@'\.^*[3GM#SRJ4,$RTEH^K/*Y*JEC3\1E<)D^%<E<Q[H7
M'T*=\5K&%P<8R.HFQTI/*Z&5A;-%%ON9HGM? Y@>T'VG'\4\-]I]&JWBNS#B
M.)9H8VXWCQL1%?)%K0R*GQM5A:7/F:1Z,>(H&^F5RU@R<5J*%\HO7JG;^MM[
M4Y*X:ZGVEC@UU7$9*LEFZS*9@)=O^"DJU;JY))-Y>N6".4$R,C!S;)H]1ZE.
M*)VZJ*JE(9JUZ NC+)HGAT<D;V^&P6OBFB>-M=XM?'(T'7B"#UXW/</9KA7)
M.QV8J24K3&LG@E8]LE:W7?ZT%W'W8'/KW*DPTZ&U5EDC=U;S![7-;1_EWQ,I
M=JM.L;)65V%#<VVYP&MIMG"UR/)'.0F#3,BC93-F2L64\PU*W7:.16%09% 6
M)3+MO,/]T_'G;]V"<-\09O@S,XB6OPO/G.(L5P?DX,9B*;:MAN1??M,R[HJ[
MJ?-D(!%)!(Z0O]*B=7:Z2+T4=[[GV3=JN9Q>+XEQN29/G8L5A[_$=&:[D9S/
M$:;:D#\<))F62*DI>R6,,Y17D$Q#)._]2S43J+;&MHN-B-5[?"5K\*P:1\;3
MMNUQG8F2#1F@FV;LV%JJPUBPQK5!NDFBU2=HSZ;4A2E31%,H)C[51X#XXX/H
M4L?P1Q[Z=BL;5@J4\!QYB:^5KQUZT3(8J];-X7Y&RU2".&-D<+)V9-D#6@,C
M+1R'S:UQ9PMQ%:LV^*.$O1;]V>6Q8R_">1FQ\SY9I'2233XO*?*>/LRO>]SY
M70OH.E<27/#B7+D/V7]AU7M%V=I*SLV20]E2T:P>H[.@C 7IVG*L0R;15X9(
M"'502^Y=Z5$H"4ZY^G;-M?/[BO";'&?9SF:]>/H_-<&6(^,L80#HS24*\5+B
M2O&1MY PMD1CHZ1WBM?YI\/Y/1X;XSQLLSM%N-XEA?PU>!(Z1MMS26L),\'U
M0?E. O)!#!O0[[3MQ:OORGFU4N\#)213=E6#5=^C+&V/TZ]AY6Y8K&>9GZ>/
M9=1R0B'B "'CG48#C_@SBA_<X3B/&7+8/*_&OG]#R\+M;Y)\1>;6R==W^#-4
M83Y;4'E^$>)<$WO,IA;U:N1S-NMB])QTC?TT.1JF>C,WWQ6'CR*CK8_+CCKJ
MR0]!6;:,"]MQA.1"@4HC_8FQ'2I#"GW2%#H;.Q6OJ*P=QWRL2DV(L($573'U
M='/D:5<EDEAADZCN8MS3DCR[F$/D\M=6@;\2M_#=G_&.=A]+HX*W'CP YV6R
M1AP^'8TC?,[*Y62G0^CZW*VPYY:"6M*C3]GGD[LL02TGQ:D*A"NR]EKL7D_9
MVNN6: &+U!XEJFK)VS9<@F'4HIL9Q.C+K=>BB[7IUS +=Z?I5H&)A\)[\@@'
MQ%>,23N_6O[D^\*:^:O!.%];B;CJ'(V8R#)A^!Z+\S(_K]K.?ONQ^$B=X\TE
M4Y5C?)KU\][)NC8Y15Y"<K-@R;!81.KK[CTQ3X^4@J:Q0*YCGMBB)"P[>FVA
MBB9$%#;&B"*)"(F8IG,81>@VINMS(3.'G#3:*<7O!>US[+AY?;V@_I57Y[\-
M8;U>$> \1!*T<K<OQ?*>+LF2T[9-'3LPU.'JL@Z.(&'L$.'20@!3/K#C=H#1
MOG,EK35-+J,J=-=62M;:'3D+K* <G:<K35VE D;A.++%)VEE929>K+"'4PF,
M/CGCJTJ+'RQP11!C'/DE#"^4M:TEQ=(0Z9YT-G;G$^0)7-YOC+BWBDQP9K/9
M+(P\S&P4)+)AQL)#M1MK8R#N<=5:TNTT05HFMWT  Z5HX225$-L/F"6MLX]D
M]N/(J<O$.HSKR\2I+TD=?ZPCT)$ZYHUH!$ M2]C.2-?*(OR/GLE(^8E(_5=+
M\1P9QUPAQ3?S5+AW*,O6Z]F2S8B90R-4Q0"*C&2]]RE6CYA+.P]R'F4=[WG)
MRESEWO:GC,]5PW9W)E!,8*/"%7%3=[>AM"#*?*V=F?"UC+,Q)] CJ-,\370F
M*&"#O286QM]"\]$7C*81,(F$3")A$PB81,(F$5#Z!#4-#F=LV78;0D9*PNJ5
M3F_HT]XB7OIQZVF-LJR-'=1Z1 <R$;KTCYQ)Q5=3'SFK+2#AV[$2. SPO 8N
MQ'VS\4QNXOXKN4L=@,#FZV&M9P3XKTKB"[Q?5MU'TNX;ST:,=&"3&UN8.IRQ
M\[I)0 &^T9R[DG]DG#L$O#=&M7^6<NQUMF&GADJP,J<+^CY6.PYQ9#9S3F""
MW>(,>19$V., L5\,]T7BZ81,(F$3")A$PB81,(F$3")A%C661;IF675202('
M4ZJRA4DR!\ICG$I2A^<1#+))(XF.DED9%&T;<^1S6,:/:YSB&@?$JYC'R.#&
M-<][CIK6-+G$^P- ))^ 71);:^KH$ICS>R*'$%)U[7I*W0#(0[(]#!V7$@F8
M1 ? 0 !'KX=.N<S>XYX*Q8)R7%_#% #Q%S/8NN?'6@V6TQQ.P1H G?36U.5>
M%N)KQ I<.YVV3K7HV)OS#KX=8Z[@ ?:3I=#7Y.Z-(82,;TC83]1*4M0@[-<@
M4,'3X*2E5AI=(XCU#L]E00-\0CG,R]LO9LTD5N)H\J1K0P.-S'$(>7'30Q^$
MQ]]CBX]!IVO?I3;.S;C4@&?"/Q[2-DY:[C</RCVN;E+E1X T=^KOH>BQ%Y"1
MC\1+7-6[RLG4/P2K?5\W -5>H")1!Y=1J[8I#=!Z'.H4OQCX"'7&WM5IVNF(
MX*[2LQOZ#XN"\EBX']= BQQ$<+"UI\0YSATZ@$*\\ V(.N0XGX)QVOILDXEI
MWY6^T&'"C)R$CS#6G\:T?LH;E?B/H7C?84$S#T36M^Q-?U\O0?Q3*H0TE;7B
M8?W10;F.7^Y$?#*?/3M!M?UN[(LM$T_1?G^+.%<4 -Z!?'CKF>G:->MKNB[7
M0@.Z"OS:X0@_/G:)CY' ;+,1P_G[YWYAK[E;$PN/L/>!I\=ZT3K](\GY4G:;
MU;2E- P^J5M=RNKE,HAX=I"+K52;'.7^$4K\"B/@4_3X0U],[9[HW%A.SKA\
M$_V]G.(.(I6MWYQ4L/@HG.#=D@6@.;0!(ZJGH_9K5=J3)\99C0\:N*P^%C<?
M8'V<EEI #Y$P$^9'DM/N.Y'270TENRCUX!'X2%0U"9<Y0$/$$WMKN\X3M!_!
M.I'& 1ZB9,0^"%/F_P!KESK<[1N&\4#XQX#@(R.;ZP/J6,YQ)DF[#?5V^HX$
MGFY1KE5?E?L]K=*_!N;OD>#\MQ8&-)UXNAQ>$HNT3XAMD=- .\UJ/I.U2?0]
MDY";HD5.@=M*"=4BDLS?W0$3K-+9/DRCX=.DB90O3J"@B(B-7=G.;N^ME^U;
MM$M..^9F,GX;X=@.R#IK<-P[7LL UII%OGT3S/<3L4;QEBZVVX[@'@ZNW]"^
M]%F\S,/82[)9F:!Q_P"CAI\.70 7PO&G6[D>W87^RKFH/@8;=MO94P@</4('
MCALZ$48I@\!(+'N^G@!0 1 0['>$)CS9:SQAQ X[!.=X[XPOQN#B"6OJG,Q4
MW-.@ UU8M:/5: .B'M'XBC&L?!PYAV^(^2N$^&ZD@(\"+'R8^T"/)W?\P/7>
M^J@7D_Q;T>TT?=YZ HT35)RHQ+RSQTQ76R#*3=NF#=0 8R[U9%RXDXQR50>_
M;.%!4*H5)=NL@LF!Q\N[:>Q'LT;V;<1Y'&\,T<)DL%3L9JGD<3%'6NRV*\;]
MP7K+V32W*DX>3-#,YSB]K)(Y(Y&AQ[KLT[3>-9>-<+1O9RUE*66M18VQ3R$D
MD]:**>1OV>I Q\4=:S&6CNY(P&\I<R1CV.+5,%2XB\>8&J0<$IK*LSRD>S*!
M[#8(MB_M$@LX.=TLYD)Q-LV=JJF56."1$A1;M$"I-6:#=LBDD3OL#V"]D^)P
M.-Q!X-PV3]$@;S9/*TJUG,7)7N,SY[F09##-+*9'GD#>[B@C#(8(XH8V,;R6
M5[6./[^4NWF\2Y*BV>8EN/H6IX,979&T1,BKTG221,:&,!>YP?)+(7RS/DE>
M]YYTW&'3!  (^O3L")0$$QK.P=B5KNA_NDB0=J8)D$.@=.A.GQ" ADH[L9[/
M "*N*R>,Z@CY&XJXLPX86ZT6LQN;JQ@#0]7D+?<M$=I7&!.Y[]&]OHX9+ </
M9'F'F'&[BYW.!\]N_?6/WNT(W  BMG;[AB% >PFVW+<I%)/KZA*E8GTVF;IT
M#H"A3AT]8#EI[)L;'OT'C+M/QP)!#8.T#B"U&S7@&196SD8@/:"P@[.U=_5
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MFRL*81,(F$3")A$PB815YU5_],W)O_UNUS_596L\MX+_ .'_ &O_ +><)_\
M8O$+O>)O^"'9O^U7$/\ VHR:L-GJ2X)5VY>S2];XG\G+"UN+O7;F"X_;DF$+
M^QKA+@]HZL;KRQ/$[>UJ:O1.S+ULR(3"< <0++F9@P$0[_J$EAHQ+E\7$Z$6
M1)D:3#7=*8!.'V8V]R9F]8A+OD,@ZLYN8>"Q3G4,I#N74;_6Y>;E]4]>4]':
M\=>:J3Y,7W-NZEN6>I-TX7OJ;8[S69*'U=P;M47=-4ZQ<H4*"B91W+SC*O5)
MX2X;"<1I+)*Q#ZML CDTFYBN9-\[DWJDQQ3WC9Z<<T&;;-'!*V2UG8WQ6K6Y
MWN:V-CGRM[BLUW=M<V1W,2=AK0P+%5 T\AT1#B"&0ZY6]""3T!VX@D[]G374
M+T_SE5M+JEOMD?4XSSAR]A$)61%TQK$?/325?93UA+'O'S&&&54;/A9 [!FJ
M*[M-@^.S:IKO 9N00%(^6&%TS] /+&Z=*YC#(8X^8-<_D!;S<N^C>9O,=#8W
MM6N<&CQ&^NMG0)UX;\OBJH:JY@/-C6F@0#_6/N=CKS.NJ6G.(7!27Z6X*1LC
M:$))0<6[J, ZF]66W6VN%;16-@/%("6?^ZBLL'%&9G7DG$;+V\,VM%8D9:[T
MP1B<,,')N'TBM4>U[A-(UEN*S8$<M=O>L;W4KFV'::'863\Y8.30<2W?-OUN
M5SP0- EA:W8<='J 6A2;R=_<7K_\_(WC%_7[KW-7&?;K/NQN2_D4ZNG^BS]F
M@_C6*QN1JS)A%0,O_P D7D,)!_W'QMY46XQR&'H6+U'R8F0$QTQZ=E**IN]$
MVPG((@+9CM) Y1,W"XE OH.OGAP[L>OQ-PI3 UXRYCAF$Z!'B9;N"+P-;YY,
M6[ISFHN8_K%E3^AQ&:GWOIR4,O)X^SDKY$#QZM9;'7E$VU(VWN,[J6MZV\-!
M6=OISD(BV01?SQ&*CR@;;CF)>C:J;NJ#15LG:8T4.VSB[6T.UNU2[:+J%E56
M[,L4OY;9HETIMTY!6N: <_6X;#1X1VHP1WC==&R#4L?BQV@&KV;A[C5E?'MX
M8XLI/XBX1<][HJAE;'EN'YI?IW^&<C(U[J,P?J6?'R!^,R'*Z.S U\IL,J'N
MCGE2*R37%<Y 4ZX:9W!K;94#L&_T%2'D;3$GI=8:R+21O5 NT:R2@;O3WR\N
MV+%*,E6]A!RF_C)"!:2$:Y2SR7M1S$,3NSAER.2M9B[4N%WRP\KI&]VROEMS
M12M 9+$?%I&G]"TL#AH^I<%]E63N_.>YPEDL=Q'P]F>%<GB<3EA9AH3C)79:
MKX<5EL9-(ZUB\C$R![IVRM?3,;HIX;<D4S'"V,USMXUME&T=2[E);JLSYFT>
MLZ=H:K6+;UC,F_0(Y:)R25,CY*,K"ZJ"A%3IVZ4@!;D$3.11 IA+ZR[+41IL
M4KK4A (BJ1OL/];1 <(FN;&=$$B5S->>EYE6[+.-'M?-D\;#PS1BEDBER/%=
MZGP]3#H7%DCH79*:&>ZQK@6AV/@M\Y&HP\Z7##L/FOM#M):_T?0^/<$N/:0N
M'(*UIWFWF:G'LE5;:CU/(#'MG@)CWI$9W:K(R1P[MTQ$W4F6]]E+'2&K#38?
M^-N2=[)KW5JYY=_K[#?>/;L?)'9I@].RW$^5XOM-&G8[A*@<7CA(.I;)Q!GX
M1,^+8Y2ZI@90[>V2ZZKC?>/,;].P]OY+;HV5OJQ0RI5F,.B>,U'K1@=,3&23
M8TO6R$7+.VY#'/VT;7<K3YR ]ET98O4H\]G. .&.*PP\6XNCQ$^(:A?=I5FN
MK:/,TU)8HVVZSFDDM?':#QL^MU*WH>UB[@:MG'\!X'$\'T[0+9IPZQG\S.'
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M"/(@]%!7.*.)<B'-O\0YRZUWTFV\M?L-=OVMFL/!^L+O@%*4 *4 * >
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MF ?T"X@&P^/K\0#Y,L'%?:F"0_LFJD#SB[0L0X'X"7%0G[^O?X]'R#P(?#M
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MITZ+TUSE5MIA$PBKER=_<7K_ /G&\8OZ_=>_Y/\ P&26,^W6?VMR7\AG^_\
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MN,X8]DC'F(#G#7L>PENG,<W;3CFWW4NF\Y[M^F'H''E/JG1'0^!ZC8\PO/\
M\D3$7ZO4WD%7KG38:O,*]MHD%5;'5QWP:H7N)AV#B/1L=1=;YW[OV4F*W(1[
M>*F8:=ITW$U%Y'S;9B1%Y/1<V#'H^,WU)+&/DK32R.DJ%\T<_P G]_ ][P>[
MF;C\=CVQR@ES7Q3,DE:YA=L,>PNU:0D#9!(UC=. :6<^G ;ZCG>_IK6B- [\
M.B]?LXM;RC/:E[GM?U68G:[KBW[)DF5?LDHRB*FG&+J+2D/%G>1$.[06D4IP
MY[&_[J+9*5^#L2S90RKAZU0;IE.IM5*[+,\<4EF&LU\L3'23.+6M:]_*]_,1
MW8$;=N=WDD8(T XG>K)'%C7.#'/(:2 T;)('0:\3L].@)]RHWQ]Y-[]V!9M*
M-;]$QT4A9Z\S1V'776J[AK^5:L4]=[&LLUNU ;1-O'E5J26Q*A7=7M*G+HR
MME;.E)N;$\5D(<@3^2Q./K1W?1Y#(Z)X->5EJ&RQTAL5HAC]PM#99?1YI+9F
M81L1=V&#3B=:*>1Q8'@-WL.!8YAY0UY[WUCZHYFAO*=^.R>H"DG>N_-%7B&U
MG6Z5NK4MOL4AR+XTG80%7V/3K!-/BM-YT)XZ,SBHF9=OG16S-!=VX%! X(MD
M55U.RDF<Y=6CCLA7=;EGH788FXW)<TDM6>.-NZ<P',]\8:-G0&R-D@#J0KY9
M8W!C6R,<[OH?5:]I/25I/0$GH.I]BO/D ME,(F$3"+\Z'/C=59X*<B=;55FW
M>6#5ENW%1N8KC7,/V&\GKZUP<G:ZU>R587H(1 5[::SI:RH0X/42Q-RA[$Z[
MMHRLA%$_I#@#"6N/.&\G;D='7RM/#7N#6Y*?UH\A4GCIVJ!M!G-*;.*:P53-
MR$S4YJ[2Y\E8@^4\39"#AK+5(6ATE*>_6SIJLTUU6>-T\%@1%VF"*X7&8,WI
MD\<ATULH7NKJ;>>J=W52M7#6]VK]ACK1!15@9,6TM''G63668HOT6DU"I.E7
M\3*-4UNYD(YXDFX9.DEFZQ0.F;/!\O@<O@[=JGDJ-FO)4L2UY)'0RBN]\+S&
M7PSN8V.6)Y'-'(PEKV%KAT*](HY.CD8(9ZEF*5LT;)&M$C#*T/:'!LD8<7,>
MW8#V.&VNV"I:R'6\F$3")A$PBQJI%6241/VNPJF=(_8.=,_94*)3=A1,Q5$S
M=!'LG(8IR#T,4P& !"U[!(Q\;N;E>US'<KG,=IP(/*]A:]CM'HYK@YIZM((!
M5S7%CFO;KF8X.&P'#;2"-M<"UPV.H<"".A!"H9PUK+".OO+A=)Y871JCR,G]
M>01)2T6*700K".M]1V)-)VWE)-VC*2X2DD\.-DE$WEB,S4)&&E!C44&B<?!V
M2\$=G;\)EN%:F9J7>)N&(K^<?D.*^*L]%?ORY.W7DO/JY[,Y*M%<=7QE&N;%
M>&*405VQ!P8Y[7;]GC[B;BYF0H9VQC;%;#YAU?&MJ8' XJ2I6CJ1R,JLGQ6-
MI3NK-ENV9NXDD?$99>\+2]K'-OODDHY,(F$3")A$PB81,(F$3"*MM6F8A;E!
MM5LC*QJJZVK-2LTD$WS4ZRCQA8=M*/FB:151.=RR3.51V@4HJMB&*98I"B C
MY%A;]&3MFXWBCNU'ROX*X%@;&RS"Z1T];*\<NL0-8UY<Z6NT\T\8!?$T@O:T
M=3Z)DZ=MG9IPQ(^K8;&WBCBJ9SW02M8V&?'\*M@E<XM#1',X%L3R0V1P(820
M59+/75YVF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%2?RB%W9TOB%N1"
M5U-NW<=?V!5974UHK/'V-92FR8FL[.BW]0G+C'I2';:-6%582:TG(R+AI(M(
M],A'4@P7C4W@DG>&JYL9FEJY1HOKRLN12Y!Q;7?+5>V6. \I!<^9S0UK0YKC
MUY7!W*L%EW+"_P!1TG,.4AFM@.!!<2=@ >\$;UL:VJ@^1BKL=&:=VC,M99]-
M.)6ZQD<1P:P<9'D-%0L-'.W,558FJ\8[W?(&E*5YY-S23^*N3^/M)!=-8Y&,
M8P$-$,6<SQQ*7WJK0P1M;#(\@Q9-CWR2/'>3.ER<4+YVR!C.1\(=%ZI)<Y[G
M.=@HLY(W [WL>+HW= #H:9U:1O1#NO0: ZKV6SB5O)A$PBKER=_<7K_^<;QB
M_K]U[_X^/_MR2QGVZS^UN2_D,_\ 3R_U'#/]%G[-!_&L5C<C5F3")A$PB\L/
M*3\8M+[QE^*DKL.I^DIF1Y&:_P!2OIEC)24/*.M>6YO:9.<K2SJ-<MS*-5G\
M4V=,US +V*65?'BW+,TB^%QZMV9\49O!0<6Q8VYW4,7#>0R[(7Q1S1-R--]2
M&"RUDC7 /;',YKP/4E#8Q*UXC9R\9Q;A\?D9,*^U!SR/RM6BZ1KW,>:LS9Y)
M(2YI&VE[ 0?I,)=R%I<[=I9;@WP^FX]A'/>-VH$BQ<>TBX^1BJ5$0-@:,F+<
MC1JDC:()".LA#HH)D*"X2OG!C%[TZIE1$X\I#QUQC!))*SB7,.,LCY9(YKLM
MBN][W%SR:MATM;1<2>7NN4>  '13$G#F!D8R-V)H@,8(V.C@;#*U@   FBY)
M? #J7[)ZD[ZKJ0<%=<PP@.M=L\HM0D*/:39T?D5L>2ADCAVNR):YLB4O];$A
M1,(E0/$';%_%!$"B8!W/GYDIA_Y3Q'"V8/0%]_AS&QS$#7C8QL6/L;('5PE#
MC[5A^;=2/\Z7LQ1'Z6ME+3F;_8[3K,?P!86CR 7T^C>7U=,8U*YKFL+9 1%I
M%;KT!KZV]X0!^"@\G=:R&H),_4/ [H4EEA\>A/$ *&=X.LC5W@CT9[OIS83B
M#(U-'],RODH\M"-?I-M;]:?)V=BUZ/Q!WK1X1W\96FV/89JSJDGQ)#R>@&E]
M-8_*!5/H:2UAQ?W(T(  =2F;+V'IZ<7$/QE$H6X4O8T,F(AXE14N  8>I3+I
MAT.(5NSRWL193BG"O/@+N-QV8@'L!FI7,=.1[2*>P/ ./1.]XH@UST\/?;YF
MO:M49"?;W=B&S&W7D._=OS+5\]]7M2M)@&T.%'(^OG[70[[6PZUWA"E+T#M'
M */>"VTP /B!1II3B4.HE*?\'CYIXFT=XKC?AJP-'U,G\I8*;IY?FZB:OD1^
M?/9K8.T^6[L.O3>'LM$3^BI^BY*,>&]FM/WH\?N.R/(>"WC'GSQC[8H6RW6G
M5+L@@5PWW-JW9^ITFI^@")'$M>:C#0!1+U 1,2643$ $Y3F( F"Q_ '%&N:I
M4J99FMM=ALKB\J7CVMAI6YK!!\ #"#OIK?17,XFPY.IYYZ3O-M^G;IAI_P *
M2>!D0^/>$:Z@ZZJ;:UR T1<VIGM0W5J>T-"-U7:B]?V)49A-)L@D*RZZIF$N
MX[I)!$IE5CJ=DJ28"=02E 1R#L\/9^F_DMX3+UGEP8&SXZY$2]QY6M;SPMYB
MYQ :!LDG0V5(193&3MYH<C1E;HN)CM0/TT#9)Y9#H =23K0ZE49\G]R0TAMK
M:',NO:\V'"V2:FN1,_LV%CFQ'[5S,T!:@ZMIQ+7$DD&;3TC$%L<$_CEUV@JF
M;&,P<.")-):+7>=WVA<-YS$8K@NQD<=/6A@X<KXR>1_(YL-\7\I<-24QO?W<
MWH\\<C6OT':D:TN=%*UG.<+Y7'W;G$$56U%-))E9;D;&\S72537J0"9@<UO.
MSO8W,+F[UZI.@]F_4//+%V281,(F$3")A$PB81,(F$7G5K9[L9?FIL&@2&GN
M+,-#4*'B]F/]A5>)L2.U'U=VN^VA"U8[9\X@T61K>JZIR@WM19VBP59RSKT:
M]?JG,F63F[,^RG%XBCQUBN'8:_%N2OY"!N1;P_P[7G&4BBI/S5F3)5XFY(QW
M(LI.V.82.L6"Y[;0:V1Y=@;QKQW=N6.&+V:L38"K5J.-%V8R\T!H\\PQT#*4
MTAI[K24X7&(QMAAY6& DL;KT5R,6=,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$5=>4F\;#QTU)-[;A=8.]I1E3*O)W",8VZ$J+F"JS./?.WMA(
MO-(.2RHMW2#)B$1'H*2"PR .$BBDU6#.DX5P5;B3,08B?*,Q4MO4=.5].>XV
MQ;=(QK*Q; YIBYF.?)WTCA&.[Y2>9[5$YK)2XFC)>CINNL@V^=C)XH#%"&N+
MI=R \^G!K>1@+SS; TTJ4M;6*V6RE05AO%&4UM:)-)TM)4M6R1%M4ABIOW:#
M$#6"" L5(#(1R324#S4 \U!Z#)?_ '0W6R*R=:I3O6*U&^,G5B<QL5YM::F)
M]QL=)JO8^RQ]W*7Q>O\ 3[OG;ZKFK=IS3SUHIK%8TYG@E]<RQSF/UG!NY8OL
M;N9@:_U?H\W*>H*[QF@ME,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A%6CEKHF[\C],2VJJ#OF^<<IB9F(%X\V+K<7J-H-"1;XKN4K"#^(L
M%5GHMC8T2E8R,A7[)"S"33O$FSXB:ZQ%)7#Y"OC+S+=G'5\FQD<C6UK)'="1
MPTR8AT<S'.B.W-;)$]A=HEIT%BFC=(SE9(Z(D@ES1LD>;?$$ ^T$'I[-KH'"
M+A\GPXH]LIA+;5+LI:;(C9'=A@=20>LYV3>ECTF+E_>)EC.V:P[)LCPR0*JV
MVYSLE/"EV6AW2B)"B&QGLT,U/#,()JXAC=&(I+LEJ-K2XN#:\;HXHJL3=G4,
M$;8]]=;5L$)A#@7AY<021&UAV!HEQ!)<3[7$G[ZNMD$LZ81,(JY<G?W%Z_\
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M]/<SB7YA\.G3H'3IX]:'CBSO8X<X*;\.$\3_ /5"57YNPZT<KQ [KOKFKO\
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M*=&;IO[!G<#,3\!'DW.)^ ._+:K\Z,, "ZQ88#]TQV19]_=3I]:Y!/GIP[,
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M/A'V8R"/D<?L7)S'GYE(TQ:;6B%T5Q9#2)!5,CH.CB&<AE:V0^IREW,T>OS
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M_P"EAL8=^?H-8'[XC!_?75G?D_>%SI)5(G'#64858AR&- 0QZVH4IP$H]TK
M.(U1$0ZB)12,02F #%Z"4!#;9VA<:L<UWSDR<A:01Z1*VR-@[&VV&2!WAUV#
MOKOQ*P.X7X?<"WY*JL!\>Z:Z(_48G,(/PTO,;R=?D_M;:)YK\@K-#[0?W$NB
M'4=4-?1:K6-9KO6>SJ!"V9Y,3#QE*.BRBU=BYYS5#%:L&C-X^ \VJ5BJ9"*;
M>H=H_:%D\]P1P]5GQ<=+Y>9)<R$H?(\,=BLA-69#$V2)IC%B6%EK;I'/8S[
M.\!=*[CN%>&*>.XBRDT=QT_R:6056%K&EPN5FRO?(YKW<YB9(8=!H!=]D/*3
MR#W\SY]7IZ81,(F$6DYR)D.HH<J::93'.<Y@*0A"@)C'.8P@4I2E 1,81
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M$C&L<^8%C98BX&-K1H2-ZEVSH#Q)Z=1XZ.E8D>7G%( $1Y+:$  #J(CMRA
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M-CH6;Z@@CW)Z37^[Q?AM_*M9N7O%$A3'/R7T(4I0$QC&V[0BE*4H=1,81GP
M   $1$1   .HY3Y&RWZF7C\*LQ/WN3JGI5?[O%^&W\JT)<P>)SA))=#DUH%9
M!9,BJ*R6WZ HDJDH4#IJI*$GS$434(8#D.01*8H@8HB @.5.&RX)!QE\$'1!
MJ3@@CQ!!9L$>8/4)Z57^[Q?AM_*BW,'B:W2477Y-Z!011(9159;;] 3223(
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M&','B:*QFX<F] BN5,JQD V_0!6*B<QR$5,GZ?[8)G.FH0IQ+V3&(<H"(E,
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M<+I+.6R:V\V>,8V2L7?9G7H9PW3OM;*\\;G<VN7HY[1HGF.]@:!6+D=WX?\
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M:].NQFA%:?+9?R,,CX'34YA%$\G;>9U7;QIO,0P<W+S!>9Y_L^&>R_$>5L6
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M]8M56XZ?$3M%:GD,[9;D;M[B+'W_ )3M4<Q:NPXVU7:+$+_0K=EMV2[8LR&
M".!OZ?\ /5%\%JB'-WC5M#D&TH:^HIJKTVYUEA?(./V3(7_<FOKGK!2[DJ@H
M7RB*ZME4H2[/JZ[J[>1=:UV/#+5JV/6\(8;/5T(R10GYK#Y"M1,XMLEFAD=
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M3'?+.-XSS%L7<;:=2K-P5/*97$5:UF /=8DR]'$7+%B0,(H0F)[6697-K/\
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M/OX1/1S/Y@/KJ??PB>CF?S ?74^_A$]',_F ^NI]_"+$DVC%A.5'N53)CV5
M27%04S"(@ ' J@B01$I@Z&Z#U*/R#C1]B++Z.9_,!]=3[^$3T<S^8#ZZGW\(
MGHYG\P'UU/OX1/1S/Y@/KJ??PB>CF?S ?74^_A$]',_F ^NI]_")Z.9_,!]=
M3[^$3T<S^8#ZZGW\(GHYG\P'UU/OX1/1S/Y@/KJ??PBTBQ8 8I13(!C]>P45
M#@8W9#J;L@)^INR'B/0!Z!XCX81:O1S/Y@/KJ??PB>CF?S ?74^_A$]',_F
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MYM^77?OZ#7O^H]//Q7H_D KE_.]E/[92/\>=_P"L*9^AD/VJ+]C9_!"\!?\
M3=^N=^,K8YD5J81,(F$3")A$PBO)Y-;]_+QU_P#7"1_^%+#G#]I/_ ?B+_$X
M_P"55U-<._UZQ_[,?XJ1?MLSXG7LR81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
I81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g96328g22p40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g22p40.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2%X4&AO=&]S:&]P(#,N,  X0DE-! 0
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M %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M#&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M  $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M  !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#
M8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M    26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @
M9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"!5
M;G1&(U)L=                %)S;'15;G1&(U!X;$!RP           "G9E
M8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M    4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O
M;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (  3A"24T$
M)@      #@             _@   .$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M-0    8              V0   =D          $
M     0             '9    V0                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   -D     %)G:'1L;VYG   '9     -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $     SA"24T$#      6T@    $   "@
M20   >   (C@   6M@ 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO
M A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S
M4D="               !  #VU@ !     -,M2% @(
M                                            $6-P<G0   %0
M,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M    %&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0
M  +$    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE
M87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (
M#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE
M='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V
M+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                                  !865H@
M    \U$  0    $6S%A96B                      6%E:(        &^B
M   X]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0
M +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M   6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                 &1E<V,         +DE%0R V,3DV
M-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M    +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@
M<U)'0@                            !D97-C         "Q2969E<F5N
M8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0                                  =FEE=P      $Z3^ !1?+@ 0
MSQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M      $                        "CP    )S:6<@     $-25"!C=7)V
M        !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M P$1  (1 0,1 ?_$ !X  0 " @(# 0             '" 4&! D! @,*_\0
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M+Q'[EU2_I=+4.&N/JK=4FLP0V&<5\-S,B?6ISW'&8'AN AKQ%V;2'$E[V@C
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MA-NS$)3&)&&0,W;-[-V-S<[Y]E%2?^ V]OT%;/\ ]7!?^%+1/Q%QY_43B?\
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MX(R\@D,#Y8VM+B&N(;G) ) Y%9\;!>% 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MW$?],W_[]>/[E.&?YOZ-_1M3^Z3[!3A7\DWCK^AV@_Z!#[O>-_YW<1_TS?\
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M@],%*7&<YSG/3&,9]61E' &MD@#CGW,B20 !J]@DD]!U[\_3R6N/&GN3C.>
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MZCV4\6M:IIWFV;#6/<UT5*-V!&P N(P3EQL./HJX1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MY\4;L*>YWJ"C9;Q9^ANP?Q:ANP;LY[)NF>F>G0$5.(/A!4ZQ#15<KF^.6$%
M04>TB8:%B=]V6/BXJ,8($;,H^/8M6Z39FS:-TTT&S9NFFBBD0J:9"E+C&"C'
MR_2?;_S[UI>Y>,QJ+J+:5U@^1O+CRU4-=W2SQ&7G(&VN&F)."KDC)L/=+?&$
M\K-_=35+QR.%$\J)]HG;+DW:P0X )Y\AXGN^?KZ5<;43][*:GUA)R;MS(2,C
MKRE/Y!^\64<O'KUY6XQPZ=NG"QCJKN7*ZBBRZRIS**JG,<YC&-G.2E2&"("*
MMVC_ .$CE+_+/#_J?UF/FG O\I?=5_[:T_\ P=PPN_XQ_B#W-_\ LE;_ /%7
M$*TAYONSH;+EF#J3A8JK0^RY'6J%51JBLS/R+J-J3*RIR4Y9#W.)4K/OF([=
MN*QEM3IMAF.BE#O7*JKHF4=)-Q]JD?$UN"6U2J:53XFL<,QZ2W27W-0LS5M(
MAU-MJ[J9UFH[3&ZFV65^F&/1KU?L*CS-*Y\H[/;Q<$Z<_A^M/'7MV=1M</U^
M('ZD[4FU*4$5G5)M.=7IZ>-)LMU'WO='$S4>TU6G/V]EHA8UD1W_ $:\L%CM
MJ@]D-;.(YM8JUKNZ2!,V^+</HRK[6N!Z=2748R)')FL4HL[34?SD2W599A66
M42E=OW:Z;;-XO=9>Z/1YK'#4M>+4M,X=UNP#J]62>MI7%FL'1M#EJP-KM.HV
MWS SWZ<3X32@V 36)I&1&)?<S:)-5A@U^.>2AJ&NZ3 1I=F.&QJ7#6E#5=7B
ML3.G(H5F1.;#3M/;,+<V\F*")CI%[)<MXY\TC3Q--]VR$K'4=PW9+VR-8(-I
M&]7BY49C&R<@LP.E'E9.ZEA^\<JI&4RTDB$19G6;X*Y-]UVM/%5-/1C/8N5M
M"EC@?JU6O'%8U[7-9T."M:L/@<ROV$VD=O/(YI=V-EH9$Y[ V2'>YA8AEL"S
MJW905I]89),S3+$SY*^C:-I.LS6*\#)@Z<S1:H8(HVN#>UKDNE#)"8\_<-WV
M!QQU9;II+6$@WKI"-?+QUIPK,((-S2_DF38L%(UY&)23DSDARQ\CA=-HJQ[4
MGAJMT3:'V.L<<WY/<Y@XVT2*E1FF94G?6U7=<9'&ZZ*=J"!U6:LRS*9 X5K/
M:-B=!FUV3\-A=XM*X.HLX\FX1U>2Y<BB=8A9/INVH]\@J>55YIVV(K+J\8C(
M[>OL=*V?%?M&>=*+0D.10A%$SE434*4Y#D-@Q#D-C!BG(8N<E,4Q<XR4V,YQ
MG&<9QG.,CZBUS7-#FN#FN +7-(+7 \P01D$$<P1R*^<D%I+7 AP)!!!!!!P0
M0>8(/(@\P5["5" B B B B B B B B B B B B B B B B B B B B B B B
M B B B B B B B B B BAH_(WCV0QB'WOIHAR&,0Y#[0I!3$.7.2F*8N9S&2
MF*;&<&+G&,XSC.,XQG ]GO=J'^8W.?,?]&FZ'H?@=ZKO9\9O^T/:I;8/V,HQ
M9R<8\:2,;(M&[^/D&#A%XQ?L7B)'#1XS=MSJ(.FCI!1-=NX04.BNB<BJ1S$,
M4V?(YKFN<US2US26N:X$.:X'!:X'!!!!!!&0>15ERA"+K7Y1<>-D[*WRQL]>
MU_'6N*G:OQN@:SL9S,55H[X_SNG^2KW;NP+6@TG'K6S$5N51<P"$2?7S25?S
M-BH\3#VHL/"X9333I=+U&M6H.BEL.A?'+J<DM<,E<W4([FF-IUX26-,?WF82
M;_*"QL<=A[XB]^YAQ/87.SC(PP#_ .$M>7.<.><D8Z=X /(G&E730F\-B<U]
M.\AE]3JUR$@\:D=2[>4G=834+$M:K#[VB;&:T33.S*;(87JMI[24]X4?JYK(
MZRLF)-7X2DY9Q[B?4G-!?HUM$N:<+?:/D\K#"R.TQ[G2OHOC[)CH_)G5Y/)!
MY0ZUMM1%H\E+!N$T%KC('8P!MY'!\<@G.01GD&^:>KO1V>6NN(6VNRU;<RMA
MA$)=KEJI*U2<D*U8F)<J$4\=$SL4JA(1CK&4\%PX:K$4\68Y.O9.;&>8BD,4
MC) V-Y8<[)6-DC=Z'L<"UP]!"S'G_P %4/26N66M.66]89C:MA6U-[QYXU21
MW^Q[S8+[+MU#['Y4-<M&4I8G;QVTCBE;%6(P0.1N5RLY<8)XUPH8VWNV#9TF
M@\Q5X=NHZHW;6@9 P_\ 1M(.7-8 "[GC<>> !W+&T8D<,D^8SKS/617=&D61
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 148XT_;3>$*_E<TG^;[&_6__?Z,
M?X!WO$_\D_<Z_,^N?^)=27*Z)_*#C'\X:3__ $=%7G'!+JEUT[EXV2^K*-R*
MVYK7D9OZD.W:.U-X+5""E]?DI^;DXB'L^X+AL]UX]F<1B[B/:-54<S67>6:6
M"%>%6ZKC17*+ZT-ZU7OW(218M]DQT/9=J6%YY&$NVDM (W9P.N>:^Q\.<:U]
M=U3@[A_6N#>$M4CC=H/"[=1M5]7.H^]K+$51A+XM8BK=NUDTCVN\F[/M'9,9
M;YBNSJN3?S6L-<3,JZ4?2DM0J?)R3U;L^.>/W]>CG3QTKV"E+XQPX5454[)2
ME[1\]"XQTP-O6<Y]>N]QRY\,3G$]2YS&DD_*22OF.NP15M;UFM P105]5U&"
M&-N=L<45N:.-C<DG#&-:T9).!S)6^C,M4@(@(H2Y+?:Z;Z_D:V;_ -2YH%!Z
M'NY+/Z3_ (&=1_R8T+_JK$@I4G B BI/6=E,]4[2Y#M;/3-JNB6;9T1/P<A6
M=6WBTQ,A%EUE0H@[AO*P<*\8*9)(1CUL<A%S&(H@;!L8SW#XAI?$L/"?%7NB
MQ:IHO%<K=4XHJ:A0L:7PKKNJU+%5O#&@4W21VZ%&>!VVS5GB<T2$AT9!P5]=
MU'A^;B7AO@233M6X:C.G<.VJ-R#4.)-&TVU!9/$6MV@Q]:Y<AG;F"S#(TE@!
M:\$9"SKW<^DI*?0M<CI?9C^T-4,M6UC>\:KTZGF[;*9TLMT)=>H'D$D,I*J)
M^*(X*GXM0Y.SV3FQG83<:\$6=0CU6QP5Q/8U2*,Q1:E-[F6ORWXXBUS#&RX_
M1G6&1[7.;L;(&[7.;C#B#XH>$^,*])^F0<6</PZ=(_M)-/B]T'18Z4D@(=VC
MZK-6; Y^YK7;G1EVYH.<@8*;GTDJYKSU72^S%7E103;51VIQJO1W-9;))E12
M;U]<U0RK#())$(FFE'&;)D(0A"EP4I<8.XUX(?+IT[^"^)W3:1&V+29G>YEK
M[I=+B8UK&1Z=(=&+J3&L:UK65C$UK6AH   1O"?%[8[\+>+.'VQ:H]TFIQ-]
MT'11'J,CG.>Y]]@U8-N/<YSG.=8$CBYSB2225J\W=N.D\W5:O-&[.0;O+#'6
M:628<;;TQ)/RD:]6D4LV$J%.*6;;.';A=5\VD<.$WF5UO'X-E0^<ZN]KON<Z
MA&Z&?@7BAD<NH5M3MLK^YIK\#=0M5IGV&'41'HH%Z-\LDCIH[(D;,7OWYW.S
ML:>D<>4I&RQ<8\/ODBHSZ=5=/[H&BS.HUK$+8'"@7ZL33?'$QC89*YC=$&,V
M8#0!M4ENG2DS",*U,:9V=*UR+]S>3("2XUWM]"QWN) [5G[ABG-058M/<C91
M1NV]SH)^(04.DEV$S&+G:V>-N";M&#3+G!?%%O3:O9>3:?9]S+7YZ-?L&&*'
ML*DNC/@A[&-SHXNSC;V;'%C,-)"UU?A+B^I<FU"KQ7P]6OV>T\HO5_=!T2&Y
M/VKQ)+VUF/5FS2]K(ULDF][M[VASLN *S[+DIKV-9M8^/U[NQ@P8MD&;)BST
M'LMJT9M&R146S5JV0K!$6[=NB0B2*"1")I)D*0A2E+C&-A#[IG#M>&*O7X>X
MX@@@C9#!!#[G_%$4,,4;0R.**-FE-9''&QH8QC&AK&@-:   O#+[G^NSRR3S
MZWPC-/-(^6::7C;AV26661Q?)))(_4G/DD>\ESWN)<YQ+G$DDKF)\GJ2HH1/
M%)WF7*ARDP8VB]H%+C)C8+C)L^]K/0N,YZYST[L=<C,WW4-#>YK1HG'8+G!H
M+N ^*@T%Q RX^]?(#.2>X<UB=[G>L-:7'5^#B "2!QGPV2<#/(>^/,^"L=C/
M7&,]_?CKWXSC/?Z\9Z9QG\&<8SCTCZ0N"0$0$0$0$0$0$0$0$0$0$0$0$0$0
M$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$7Y/O"7::H.@]R3S73O"/P?&
MNM(T>G:EGKIL38_ YWN)W(2.VGF[V*UFPXU^V8),ZO5K5K>BT6:CV$1+S[&7
MVC$V"0QY(.U0/]:X8O6+].,W=<XBLWIYK<<%6KQ *08VFVBX1;;#G%TLT5F>
M>-Q>R-S*KXV^>'$>&9@:XEL4 : TN+H-Y.[=DC;CH0T=#\+F0OTD<5WSZ4XP
M\<9.3J;.A24CH;4#Z1HT?5"4-A2WSO7M><.ZFQHR;N03IC.N.%%(=M5"/WQ*
MZBS)#E=N2L\+'^::JUK=4U)K)G6&-OW&MG=+V[IVBQ(&S.GPWMG2 !YEVCM"
MXOP,X7L9S8PXQEK>6,8Y#ECNQX=W13R/ K("("("*LE:^W)W1^31QG_6ARQ&
MSE_B:E^<]4_LNCJ@_"._(C_:D5FQK%= 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MFDU75[^EUS:>#K$?$\M6P71P5V"!NE.\H=<,4;(PU\<<;W,+8A)B,;?'.,.
MCC9(X-_!&$$'F?\ UG)L>? Y\<>/Z&].H2C;4>K&TYKZ%U+--]<4A"8U56W$
M8[KNLY1*LQ:<AKZ =PB+>&=0M,=E6KD6XB$$(Q9C&H*,$4VIDB%^=72TW+99
M8?<8;,Y9;D#Q)::97EMB02$O#YQB5X>2\.<0XYRO6W.UN0&G RT=&G',#'+
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M%FI/+6EBD=&'"K^"6V_E#<F_U]; 'K7,CI\[OK*MT"E 1 1 1 1 1 1 1 1
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M;KFLLL36F:K?;8GB;#-,V[.R66)GP(GO#PXL81ED?)C.>T#)53'&1@L80"2
M6M(!/4XQU/>>I6M5/A!QJI^Z)W?3/654D=AO<4%*GR4S5JD\+J2.UQKF*U=
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MH-?/1$I91XJL\4DTZL:*(_.Z65<G=85,NJHKDQL_/=5%H:GJ(O%INB_<%PL
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M2?$D\RO<%" B BJ+PJ_@EMOY0W)O]?6P 4#I\[OK*MT"E 1 1 1 1 1 1 1
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M'1EU;=8L"Q"=N6S-<T'.-H(*B*3M&Y\WNY-=N(R X9Y#!P>AP>2NP-$LJ B
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M=0SX#?R6_4%SAC5D!$!$!$!$!$!%47A5_!+;?RAN3?Z^M@ H'3YW?65;H%*
MB B B B B B B B BPDK_NB7]H;^D,C._P";]ZQR=WS_ +EBAD6- Y?/W?O1
M 1 1 1 14UY"7K:=>VSI>KZHV*P\N6VR5U.7U"K38.5;.M>L)AVKLG85MMSM
M8TS686/A5&,77LQODH[RS)DC6IIYU*&;Q$C&'$] #@[L8=_D@#D"<X)!SR.3
M@8S'/( YD]V,\N\YZCU=._/*Y0A2@(@(@(@?;[?;YN]$!%]F_P"Z$/[LE_3*
M*O\ @GYOK"LSX0^?ZBOH]_=2W]MC^C@0SI\_L1WPBN*+JJ BKERTNI=<\?\
M85Y6WJTXW,JNP8RTEMYQ3(/8#JO1[>58^ZF$%4+'E2(G+19R&Q5ZPP7CIUPY
MG9=@A'5^:DE&C!;8Z3#Y1J%> 4#J;I7.8VF)Y*XD<6.PY\T7GQQ1$=K*X.C
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MXX_DCQ#W?^B[/[*N/%_O;'?Q%I_DZ8XN;\++_K'_ +174,^ W\EOU!<X8U9
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M+@=QP#]'H7&\2K\4I\PWT"V1XCZ0JX/@?H*>)6^*4^8;Z R/$>K[?8X\0P?
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MI5R\>NCI-FK=(N,F4675(F0N,Y,;&.\2R(O<UC&%[W':UK07.<3T :,EQ/<
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MJLE:^W)W1^31QG_6ARQ&SE_B:E^<]4_LNCJ@_"._(C_:D5FQK%= 1 1 1 1
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MX'U>U$][LAZVWM\?5#>/ ^KVHGO=D/6V]OCZH;QX'U>U%[EK[\O7KEMW]/\
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M8ATZ<L6LJK&X5R]3C7+UF[9MWQT<-5G35RW35,J@J0EMK]N_:[9N+ _:=A>
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M^W)W1^31QG_6ARQ&SE_B:E^<]4_LNCJ@_"._(C_:D5FQK%= 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M8(K.W*B;=LDHX*=PN<B213J&*7.6&">S((J\,L\I!(CAC?+(0T$N(8P.<0T
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E("("("("("("("("("("("("("("("("("("("("("("("+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g96328g26s28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g26s28.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M81,(F$3")A$PB81:,Z+Z+JSEFJWRWK<>CVV.M9R-J:6AI1FO$NG,N>3=I(Q
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M(X,C44+3VB050.@1S=".K>O4_0C8/G\/U+X;"J+H=!179W$$8HV625'U)/\
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MWE;<5*E$99Y2>Y#61L:-R332'[,4,3=ODD>0UC023O0-$DC(F%[SIK?UDD]
M !U+B>@ ZDJ$////]J=$VK'NW>UHX9'9(P>U*^3N4W XIP9.88VZ%^@7/9Z2
M#8V^1=.2MMV4)\>-@-2UD@-^2T<V4XE+5*7>Y'(5,;4DP>#E\6*30R^6:"U^
M5E8=^[US^=%BH7?S;.CK3AXTNV\C38B8^1PGG'*1OPH3U$33^D[R,I'<]F@\
MHZ[*M%SE5E)A$PB81,(F$4*^^OZB8=^F%X>/^?WFC-WP_P#TA-_J;B/_ (=R
MBL6/YMO]O5_WF%34S2*^F$3")A$PB81,(F$3")A$PBH<LKG6Z>O.@+ZB<FA:
MIIH"NY3+'F,-DLM*P@599KH\M+W6=@Q4FP(K+5\NA15NP.439HG3+7[>?6=6
M$:>F6=TA,;+=F^6MA5 ZU\?EV[CIZ[Z]>^AHZ5ZS8XHW=M;W9N6(G!O<T*1Q
M0KVU62X-RY&M(+4I5B!>GWLA:B4D&@.2JR=[)4D#+.+WL P[PJ5]N$3")A$P
MB810MX@_HA?OZ:'77^-\JR3V;\OO*@=W?/[@II9"E,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A%IZ^KYJSFBJY5<MR2A-%(+$D@#EJPPLQ6XNC@J,"
ME:(W&VA-H;A(93(G$PAJCT>:R5#D[N:DA(E)$,>]AS<?C[>4MPT:41FL3$AK
M=AK6-:.9\LKSIL<4;07R2/(:Q@))5$DC(F.>\Z:T;/J?0 >9/8 =25!7G^AK
M3Z<M6-=M=I1=3%548./<N0^2G@PM6W<ZLJ\K9:>U;32 V-O?^G90W#"8<(>E
M"&GFQ1\GF(7RE]Y."'?9'(5,74EP>#E$S90&YC,,!:[)2-/6I4=T='B8G#IV
M==>/%D_DN1KK$<;I7B><:(ZPPG_) C\Y_D92._\ U8):.NRK2\Y19281,(F$
M3")A$PBA7WU_43#OTPO#Q_S^\T9N^'_Z0F_U-Q'_ ,.Y16+'\VW^WJ_[S"IJ
M9I%?3")A$PBT+)NH*"AM^5[R])[.8&>_;6C;M+J^K-4!RV^26.,A#XI<7-(>
M2@-:4Y99$9D)B<E>XI%2_3*YZ;R%6T9V@;"+%9";'V<K%5D?CZDK(;-H<OAQ
M2R&,,8X%P>23+&"6M(;XC.8CF&[9EC;(V(O D>"YK#W(&]D>7D?/?0^BWUFO
M5Q5GLWBI\_/=Z(::(@E])8R\] //*D>Z-75XWD<\2/HMA+<PN%4,\M#*3)8>
M];<&=T94#J;!B(NY.K<M+1/IR,C:W?3OX3R+*#KIL8]TK,<S+R8UMEYR4>-D
M+.6X^'P1"(^5[)',%@RM8YI=&">58HMQF3DY9-&0Q"7E_DS*-[8';WO8(WRZ
M)WHZ!*YBE/$RIJ[;NB5(I*MZ,K=7:1%HJJ,L&VZN)A==WNGIM0$JP3*W6"DC
MA*P^YD8MO!8)K$8<8N9] 5I0&#/2D'T7N%[M&C-?-O&6A4-5M^M3MF>SCS=&
MZXLM\)L)YW?8)@FG#9-M=K3B)CLLD>&<LC2_G,;GLTV0,_.Y3LD:[Z<&].OP
M7T]9^)13W(M@**TD=97_ &S)X_3B_H>R@4? 6>7(*AHQM?'".J[-L->_2Z)$
MHF$IR9WK8DK#\H'PM"S.+B>TE(RR#5$8CAF[F*XM16L?4BDNMQM7W^P^%UV^
M^-LC:M9L<,W-(6OCZR>'&7/:T/+B0)ELLA=R%LCW!GB/\-H/)'LCG<2YO38/
M0;.@3K2Y-G\2/G>0W%%JF84EEN[5+GF"1!ONQ+"A I!+8UFU&FO:!5FYRQ6Y
MIGI),9+52]KE28 8L='T079M:'=_;GY2%K#2_AG)1TIKDAJL?#'8G?1=/_CY
MK5;AQ]BTV$-+##%<:^$_RHD<6/>R-T8YT%F,O#!S$$M D#?Y/F<SQ&M+M[V6
M$.[:ZZ)!Z*5%+6Y'[UKMGM*(-KZBATG5O@X>X/Z9"D,ET6;7QQ:6&?LA*)P<
M=BAT^;D)$NA"Q<)$Y.D1>&9T7-38<MVB)U-VG)0LOJ3.C=-$(Q,V,N=X,KHV
MODKR%S6_RU=SC#.UO,ULS'M:]P;S&ZQXD:'MWRG?*3KJ 2 X:)^RX#F;O1+2
M"0.RK@ZACO$48Z%>T%S\$VS9CE+X5%;#=[-I_DJ[[QKVSGQV?9C&W.+6DAI:
M"2.*2>8QENA[(XN*>S4KPM51R41P 2M(2R0BQ%=!.NA^&M@>7Q/Q_8K:&]O0
M-*!"U-2%&V-;8C3-[:VMZ8E$@;T"(D"9&A0HTP"TZ1&D3EED)DQ!99)!)8"B
M@   (=%2OKPB810E?.ZJ^8Y&_ '65SN%21*V4%&R_I)O8H1NEXW:2R8ME<J8
MZI+76"AMMW;6"QG=' I7-XO5+]7T7DY;LC?)6B(CDE5,Y3KZ]]==_NU\>ZRX
M742UQMFPJK@W.E\V2354]C%;6!8\454$VP".2B35W75J;(,+GU[PF?N:5B@]
MI1!W>U3' W,'K%2MN9PO#DB.2Z)KIO8Z^77^[7EZJ5F%"A;Q!_1"_?TT.NO\
M;Y5DGLWY?>5 [N^?W!32R%*81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(JN
M_%7\3F!>&11K//'>-"L*TK'=G&-5#6X7+W.F>W)I2)UC_(Y"ZA(5'H(E$R%[
M6)V$A2*G%>XO#&S)0) .9[PU]5PEPM8XIOOKLE%:I68V6Y:+/$,;7DMCBC9M
MH=-,6OY.9S6M:R20\Q8(WXMJRVLP.(YGN)#&[UO7<D^C=C?F20//8ZQ=*_RK
M3J!!9K<HZ$HFDI-4"]T*+?&RJ&R9Q&?1]I.."6:MCKI*)]+61[5-R88E7N=Y
M;D(7H\D*0+_'RSQ*R/4[WLDQ3JKACLA>BNM83&ZXZ":O(\#8;(R&O#)&''[/
M.QSO#!YO#E(T=:S*2\P\2-A9OJ&!P<!Z@EQ!.O(ZV?,+LC<M5S*>ZI;6_B%=
M+I48( !$CG'"W-1;FA?HS543D"$"EBOZSS6X]4R2OHB9,JDI8SD%FKFBEV-:
M%H9C39B<ZN;=YGEK,6 AM<.8LN]X+C!G\IR.CEN31NU)CJH<!)#C8) 6R$\K
M[TC>=X$ 8U^PB:;!99E_-US01=PP'M(_1(=(1U'DP'0^ULJW+..68F$3")A$
MPB81,(F$4*^^OZB8=^F%X>/^?WFC-WP__2$W^IN(_P#AW**Q8_FV_P!O5_WF
M%34S2*^M'3+I>@Z_M6O*,EUL0QHN6UUQZ" 5?MV*6SJ0B3-3B]*%H(TW:5NC
M<RDMK2X'CD#NF0,7K$_LFG':PXA.;GP8O(V*EF_#3G?2J-#K%OD+:\>WMC#?
M%=RL=(7/:/#872:/-R\H)%MTL;7MC<]H>_\ -9O;CW.]#J!T/4Z&^F]K>.8"
MN)A%U4NKX1U#(>C.C^A6'C3J&5](5[V;SA*^2Y/&X=$U]6J^?>7B5$57QXZ:
MJ9VC?VIGNY!8MY29\:4L:5(U:AXB8'$PH96]LOK.(L8J/&XW&RYK%0XRSA,G
M#EXI9IFVVY'*D3-E$ K.B>^@ZM0BC>Z4$!DQ:"->)JIFRF2200RNE;-&8B .
M7PXNF@2X$!_-(XC6CL;[#6Z;)X Z4DMP3Z7MO'$==F=_LF4R1O?E'BT=EP]2
MYMKK*%SFE=SX"PM!T:BQZQ*>6L,B#,<:QLAA@F5N-&@2DCW@5>(,7%2KPNS4
MK'QU8HW1#A#!S!CV1-:6"S(X32AI'*)W@22 >(X<Q*K=7D+W'P6D%Q._>I6D
M@G>^4#E&_P#-'0=AT6T")+T3T1XBL:?NEN/.JV2BN>K6<FWDADC<6KE=1@9K
MHMTBV^M[^F*^T&B5N#@G;5:\==QF.P)Z00%D=-O!"AXDBI>8=C&+&XWAN6/%
MYK$OOY&FQV8DEFM-OF#;)OR/CX&U'PM:7-;[S+)8C=9D9R$,B:T"L&22R#+#
M*(XWD0@!I9S'8,TCN<;.M\H#7!H.]DG:QV&-O5MI^(=1'54FXNO*H)O3=4]'
M0[J-/,9E#)[1+^SF0\Q%4S'Q\Y+I$M6G2^<2UDCBN1RJ.QNO!J&4]>T2OWFD
M/4#-N3NQ-3AS(8F'-T+M>[;QD^),,$U>_&_QN:Y)F6MB $->&25L<,DMG4@8
M^$,=H*EHF?9CE,,C',9(V4.<'1D%OV!"2?SBX#9 9T)WO9W'WQ&: OCJ^SCK
MDE7(O7:MDM;P_P ZI:9B%$/]=QB85M?4AF,DD#K!>NE.IFP'O]:$JC8BXC0.
MZ^85@C2^_A)HZ>_+'15K8\-9#'XBJ*468PX?4XB%R[-D([,L-K'Q0Q1LL8<&
M"3PK1 F9S,;#:+O#W)X;6!6[,<DKO$,4VG5RQC8RP.;(XD\LOVAMOYIZ[:-G
MIO:G_8'!S;/8WRX1**,AZ3JF?UO74$Z?OV%HCV*-5]%H)3Z"+7$;&D\=4(HB
MW3N?-2A9SW5<F:& N71"!35[=XHY(F2!!;,YZOQ ^O)E?"OSG$U[-JQBL=.X
M/EL36+CI:0E=('3.KUWAN1MQ/D,$UB"-DS'26.99#JX<(MQM$KFM;+(T:#0U
M@:_EUH!SA_)L(;MK2=$!NEBG'2WQ7T":4LLXC"=*D9(Q7K8K9;ZCU/PN#QBS
M$:Z?HYY&.7@\]GB<WKGEFC26LB(:Z6CZZ2F"$IT2L.4[>DZ.[FF\)$POKREQ
MDELO;)CY;DT\M5S:SJ\N5_*0Y&9)\KK1G94 B&AMH'ADH#: (>WL&@AX8UK7
M@NYA%X?4Q <G*7]=>9.U6QXQ\B@SSV(\.]M(Y/3SO67/X6H@3O;W#2%XLJE9
M"=T+%_E=S@UW%;3!9;-/)$8^34*YGA4<E$M!-(113^JAQ,CCL)"\<*MBT'7D
M03Z.[]#UT-'R_O 7;G)T'116@"&,&BP:",P0A#$'T=>B(8A_AB&+7EL0A_A;
MWO>Q?'SPK:]F$3"*H=^O%AZ.O)XA5VHKBKVC*CO)*Q0FGDG-_0:]7?EA51.4
MHF&T[6L1MJ]QB""ET%C,*.2U?"8Z]EMTN1,+#8UD2Y9&'H%=-I5:T.FMD=>H
MZ;\@-[WKO^L:\UJWJ: 58B?>N#J@K_JYI[_L"8MDJH64!8;I.BAMO%5G7$,K
M&;UU,X6%=2;%1! X?&DEX%RUY;3E+$Q2]BMUL&R[C#08_'X]$&^F]$ 'T[;)
MU\R>H'KU]5;+<5<6#8S6RHH%?,\H=:VK3U3B[P&-5A(U3^G-3Z*+;UR>T(/.
M4*5,F-UM24:V)42P1F_0.4FDZ]7D@@=QO]>E0=^1_9O[PHV^'<RO$<J:WF&0
M2UWGCVT]>=8(729OR%A;7F2K2+KE(#GAS01=J8HZD6+!ZV:<0S,[<@+%OR3I
M"@?@X/E\C^\H//Y_<%/?(4IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+\C& L
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ML"3S>=5N=*V54S G59NZ-@GT8VJ#H.W6*/:]K>4K4\$!UO29<8V*A)]B$,H
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MZL=RC;K"41V()7OC!Y)F1RQ2-DC>Q\4C YI WT(*F*82AQY7,<QQ8]C];:X
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M0[\M;WY>6LOUZMFW((:E>>U,[\V*O%)-(?DR-KG']05+G-8-O<UH]7$-'U)
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MS?2,UH8O,6M;S(EMVIV-CFLV)HV?F1RS22,9KMRM>XM;^H!4AK6DEK6@GN0
M"?F0.JSW,=5)A$PB81,(F$3")A$PBA7WU_43#OTPO#Q_S^\T9N^'_P"D)O\
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M@@C8(/0@@]"".A![JLF2>#WP3)YL=-5%2+VK:M:)P7Q2.S.4,4,5J3#-FFZ
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M@;FHAN#I.?I>$W[9]C7"U7"<)U,E)3,68S'C3W);$)CM1P,L2Q5:K?$:V2.
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M3#RBR1K7*Z9MM&[6;6DG1&EHTDAJ-/4<E<)"L2E:B<@?4(AN+:589L D]/,
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MG29A&/?Q$+<5KQ= HMH OQ#(]S;3F \@&E&!UY8_),#_ /I%B]:^$]R4,_\
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M][WOS%YQ6*/$1B'JQ^>]#2_)_P!C%K>_-/\ B\H_)%9XU8EN6_\ O-N=S?\
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M%/[BHE39/9&@1A3K9DMB$C=VE+)'QZ6F'."W>FDA,$9:E:)M:E!:Y,TIFYN
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M]L<..4:/!JNP)3/5[NG/TL6#'PUCQ5D'0YG(B*WEG]_M5VEIJ8[8)'^+1OG
MUNR2-J/=WR];+^<=_!CVV$?UOTY"/](AO3\Q630J#PNMXNSPBO(E&H+#8\D
M@88G#V-LC<<941>][ D:V5G3(VY GT(0A>J3)B@;&(0]ZV(6][YB>>:S*^>Q
M-+//([FDFFD?++(X_I/D>7/<?BXDK*:UK0&M :T= &@  >@ Z!93EI2F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*IRP.G>E2:OZKZ_A4
MBKQ#2?*4\O-H*I!QKY<[R*TZ_P"4'MVC5^O#C909DWJ(W.7I[@]FI:N3-$9.
MCS*!EBYDI0RS;PY 0%5H; /<ZZ[Z#FT1^PC>SZ_-6AN4LB[*C0N+U(V-E0N0
M0#;U3PZH6HA9H903PZ3F+STX31>I&$S8 ;V,(-Z$(.M8T3V&U3L#N=*#/%%D
MUTDB-\A53Z%)A'=D]:*B0J)2QDB-2J;KE)J=27HQ>'9A"@H03"3@ZV6:6+0R
MQ"#O6\J(/3H>WH?4JG8!.R!U![^6AU4ROG3K'\H\#_6^/?O'(T?0_0J=CU'U
M"^%SN6I&=M<'=RLV!)FYJ0JW)>HW+&,S1")"08J5';+)7&'&:*(*,'Z!18S!
M^CZ( "%O0=TO(C:Y[_LL8USWN.P&M:"7.)\@ "3\%?JUY[UJM2J1NGM6YX:M
M:"/1DFL6)&Q0Q,!(!?)(]K&@D;<1U76:N[QTKX=IVY!HB*0:(5PWKSB6/<O8
MU<CEDA0DFB 4X/QNGA&VM>G H % 6AJ2>O;-&B3&/;D, 5&<%:XJMNE=[K'%
M'"'$,\1A?(]H/1SSS!K>8=>5HVW>N=W=?>O"_P#!5X3KXF \69#*Y'-30M=;
M_)UJ.ECZ<KV@NAIM-:2><PN)8;-B3DL<HD%2 .,:MB\/KQ+(IUQ%']LL<B-5
MK;4)"A.>VTAS$EC,G:%^S"B)%%PNZHY>D G5E"1.[*J6N1K:8<W* .:LIRT4
MCZ+"Y@91DC'L$=F$-+VLV6/8[H)& [<T!PY7-)=RDM/,>8 ?.GMI]CTGLOO4
M;-"[-DN',NZ:.E9M-C;=IVX 'R4;KH61P2N?$X35K,4<(G:R=AKQF#FEL5W9
MM=:_'.8GKS_%YO[9KS__ ).;W1]#]"O#MCU'U"\?.=7/_P!^HE^L#7__ *<:
M/H?H4V/4?4)NSZXUKSW.XCK7]^Y UZU__:QH^A^A38]1]0OQNTJUU^.?0_7^
MV1-6O_BJQH^A^A38]1]0O6*V*P!OR'8<+#O\?D*2LX=^7]_EM7K&CZ'Z%-CU
M'U"ZQOB5>)]=;I=DNISG^PG.NJVKMQ''5LE@SAIODLVDJ(  O;A\J4.].+:R
MMKAM0TM2)C6I +0)#G1P4+/;$:5LX#.9NW[W-5JRNKQ5WF-SHSRR22-Z/)>/
MM-#7;8&M(WHN<22 W[Z]AOL0X3'">*XJXIQ57/9;/5F9"M6R+!9QV/QUC;J3
M&4G[K69[-?P[4T]J.4Q^*R"!L8CEDL8)Q#XM'0-8S)/#+D?G6]81) #;FO4Y
MF#$RR*.R0_7HM2\RSIHK1HTD=4*?5I9 .8.YK>U(1[=T*A(-&I2.C!YC*27(
M*+8[&4DN2,K5:S?Y2U):F<(Z\<+CM\CII'-CY'%Q)<"S[0+7[#VO>PG@.W@;
MW$>+&/X%EP=>7)92]6J3'#G#TXWSY"2QBJ+2&2U:S)+$,M&&-\CHW0V&O8]D
MM>>]J>*6UHRS!3SL3F;F]I/T(U)'Z.9WWJZU#R_+\- .>KFEDI9H6:!Z6]*0
M,K\E*,UK85)F]^B#V6K[,?:7D8Q-8Q<'#E-PVZ?*S5J<D;3YO=E)JG*=?]74
MF([Z[@?$\G&GL)X>=X=&'B7VF9)FV[D=)@<'(\=1)#1P8RF7G9O7V9\OCRX'
M1 (!=&Q#V?PI/5Z5\6*6KI5X(.T8EF'?_<]"0*)(%(O,6ST%.)9K*6U"W;'O
M9P$9%.HE!9?I$&;(,,'LS8Q^RG$UR'Y[B9V0F!WX&)Q&<XD?T(VUA%;&X=I_
MS2V=[1W:YPVL2?V[<;F&2KP9P[C^!\?*TQO;@Z^,X8G>.S73Y5TF2XHG<&@;
M>^X"\CJUNF<LKF;NF*+FM*PE^)9X4W+\61EZ"@8*5E4,LYW;B!?_ $-.Y3J>
M0>'I1EA\M:,35VH3@,T/>R%)>P^CN8L)PUCVAM'@?CK/%O0?E!APE+I^D*N*
MHW+'*>AY3D&'6AMI[^<6[O%>7L26<GG\7!/,>:2<>\9>](3_ -;;R-B)KW ?
MIFN_J.Q!7QN5_P#AENOI&WKXO"RZM':])S8D_5<=@4'6[^/IEAB'/ (,5[,+
MX^2=2O<-A\]Z+,UK>@YE-M<4P=,%[/,5A.7I%/\ Q>DR5YGQ]\X@?D'<_P#I
M-CCWWUO:Q3AZLW](YW*Y#?Y\1O\ N=9W_P#!C656\N^NG.?KUTN3A?;7@(4^
MITKA=F\MI7DHSUOR@1PU\GLL&;K?I;-%*U,4DTE4F"%^&(P3H:,PS\,6Q#^.
M860'M3RK?#OV,\^$C7NSKK:50 ^0J1SUZS1KIH1#0Z: 655QO#=(AU:E0;(#
MOQ3 )I]CJ29Y&R3$^?5^R>O=5:^.GXPG+]J\_P!3U/RS*H_<[FYVL3*IFXK(
M584<*AT=A[$M2I2&!PEL6C23WS)U4D$B+<&DQX"W-#<[I5J (75(;KJ_91AL
MSP]Q!9S%QGNXBI.K>[MM5IA;%F5CI&3BO-,YC8O ;(WG##XWA/',&/:<7B6K
M4S>-]P+M<T@FBF#';@EB:0Q[0X-#M\[F.;O[4;GM!:2'-ZUJOKR(A;!&H8Q(
MC7G96_01JA-I#:$[T?Q#<2EBA2(G0O+\(+8$8]:WY@+WY;SZ7?Q35\/;*TYE
MUT8XL;&#\9 YSM?*/9]!Y>5,X%R!FY9+=1L&^LC/&?*6[\HG1L;S:[@RZ'^<
M5V^O#,HV!=G\1<]3[K3HT+C2JIB?4<:XD@S^GH^DV\Z+SJ3QMY<[F3MLL5V1
M>3[*I,PKIPJ*F$L;X()0]FEI8*-N-*#OY&XXXCL4N*LRZE5A9E99XY+&;L!M
MR_J6M#)##0$D;:^.@KUWLJQ^#"ZSX<32ZR7[*]CQ&/KUL;4JL<16@C+(X00Q
MI(>[GDE+3N2263FE>26L+GG3 -!=A&%/?/E;1=FA%>/-/02&1U(! P1.'N<,
MC<;941>][ D:V1G/1MJ!/H0A"]4E3% V,0A[UL0A;WY=/-8LROGLRS6)Y'%T
MDTSWRRO<>Y>]Y<YQ^))6[:&- :WE:T= !H ?J"RGYTZQ_*/ _P!;X]^\<M:/
MH?H5.QZCZA/G3K'\H\#_ %OCW[QQH^A^A38]1]0GSIUC^4>!_K?'OWCC1]#]
M"FQZCZA/G3K'\H\#_6^/?O'&CZ'Z%-CU'U"?.G6/Y1X'^M\>_>.-'T/T*;'J
M/J$^=.L?RCP/];X]^\<:/H?H4V/4?4)\Z=8_E'@?ZWQ[]XXT?0_0IL>H^H3Y
MTZQ_*/ _UOCW[QQH^A^A38]1]0GSIUC^4>!_K?'OWCC1]#]"FQZCZA/G3K'\
MH\#_ %OCW[QQH^A^A38]1]0GSIUC^4>!_K?'OWCC1]#]"FQZCZA/G3K'\H\#
M_6^/?O'&CZ'Z%-CU'U"?.G6/Y1X'^M\>_>.-'T/T*;'J/J$^=.L?RCP/];X]
M^\<:/H?H4V/4?4)\Z=8_E'@?ZWQ[]XXT?0_0IL>H^H3YTZQ_*/ _UOCW[QQH
M^A^A38]1]0GSIUC^4>!_K?'OWCC1]#]"FQZCZA/G3K'\H\#_ %OCW[QQH^A^
MA38]1]0GSIUC^4>!_K?'OWCC1]#]"FQZCZA/G3K'\H\#_6^/?O'&CZ'Z%-CU
M'U"?.G6/Y1X'^M\>_>.-'T/T*;'J/J$^=.L?RCP/];X]^\<:/H?H4V/4?4)\
MZ=8_E'@?ZWQ[]XXT?0_0IL>H^H3YTZQ_*/ _UOCW[QQH^A^A38]1]0GSIUC^
M4>!_K?'OWCC1]#]"FQZCZA/G3K'\H\#_ %OCW[QQH^A^A38]1]0GSIUC^4>!
M_K?'OWCC1]#]"FQZCZA/G3K'\H\#_6^/?O'&CZ'Z%-CU'U"?.G6/Y1X'^M\>
M_>.-'T/T*;'J/J$^=.L?RCP/];X]^\<:/H?H4V/4?4)\Z=8_E'@?ZWQ[]XXT
M?0_0IL>H^H3YTZQ_*/ _UOCW[QQH^A^A38]1]0GSIUC^4>!_K?'OWCC1]#]"
MFQZCZA/G3K'\H\#_ %OCW[QQH^A^A38]1]0N0:Y[!7M:4VLLTB;NXGZ,V0@:
MY&SN"T[118C3=E)4BPX\S190!F&; 7O0"PB&+R"'>]-'T/T38]1]5EF0I3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(JO9]Q]?;K"^DN8X=(JH3\Q=53J
MTI++Y@].<P27'6D2Z(<E+UT3 8I#&Z,KHC-EDT>9#8;A"YXY6!!AP(<Z*"OA
MTUW%"3'XI!T0?,:^73M]W377U4^Y]3M1VLW-3/:565S932Q'"4,C98$)C4S;
MV=0,@*4:AL1R-L<DZ \:8(4XSDI91@R0Z*$+8-:#A0M5ZXHXUUY^7)/,FO/>
M][\J%JO7GO>_/>]^44_'O?QWO\>]_CPB\_0IXV_-*YE_8-5G\*81898W W)L
MPKV=Q*/\V\[PY^E$-D\=9)<RTE6[<\19W>F1<VMLC:G!OC1"]"Y,BU20Y(EB
M(\E6F4IBCDQI9P #U8LP^\5K$&^7QX)8>;_-\2-S-_JYMK<\.9;\@<0X'.^%
MX_Y%S.+RW@; \;\G78+GA;/0>)X/)L]M[723M^FK*H>=O5<6I%'2)REC5G)S
M4K@F-+2N*<LT91+LR+M@TE>65>$'KF]U;S#T:LD01EF;WZ00^26*\U25T-B-
MT4C=[#AT('Z33V<P^3AT(7ZY\.<283BS$U<U@,A!D,?;C:]LD+VE\+W-#G5[
M46S)6M0D\DU>9K)8G@M<WL3=3X3OASZM!#,+DZ'ATM;*]=6=(QUJU!DLVKMT
ME"D]:2O=)66?$WJ-/A\=1)DB9O;!J5!C2]*7!8I3DG#:"5 >HX=Q#IA+:M,F
M9"Y@9 &R30.DV0YTFXW1O,8 :&DDL>7$@'D!7R[_  A_:_#B9,9PQPK<Q5W*
MUK4ES-RS8W$9VK0:R)\%:B8\G4OU&7I'2RS3^&QMFK'%'&]S6V7,-RPO#&XP
M,WH1]<3)2+7PT(^^>@1BT'S\_1UO5HAWH/GY[\M?'SWOXYT_Y(H^;;!^=Z]]
MU@+YB_PO\=>5KA]ORX(X(^O7ATKSKPP^)M>?_LGD(O/>][V9=]_&;WO?]^S+
M1%O?_OWO6/R/0_S)_P#YZ]_]RI'MAX^';(80?U>"^"6_NX='U7D7AA\0C#L!
ME.NAP-Z\MA/N"\3PBUY^?X03K*'H7EORWKTM;\MZUY>7EKR?D?']?Y.;KW_Q
MV[_]PG^&+V@>64Q3?ZO"/!S?]G !?,;X6O"!X0A44.2H"'?F$*FQ[=4:#O\
M%L6M'3XSR%O7PV+_ $O+SUY_'>1^1L?_ -5*?G;N']]A![8_:&.V8H-_J\+\
M)M_=@QT^'9?&9X4?A]GCT8?S>P*!Z!HO0U,OLI0/0-;V+0="/FA@M:\][WY:
MW^/>]_CWO'Y&QO\ U#__ )FU_P#[=_CW4_X9/:-V&=K#7^;P[PPW_9PP5(??
M_A+6A7MCN,WY7K1RFE,OY:0]+"H>)4]RBO7(I(2G7-&F96J5O[ZQK5!)CBTN
M+=[R/1A4G-;H4FTC1+7/D\OP_8AG=-1A?-6D^UX;"Z26)VAS-(<3)(UQVYKA
MS$;+7:T'.^L_8]_" X>RF"K8;CG,5L1Q%0#XO?[S(:6-RM4/<Z"9D\,45&E8
M@C+:\]:45V2>&R>LZ3Q)8J[P_/"<M2?6:T3SJ.L5<.IF-;4+%<(G:7V%^L9Q
MVG.)0L1\9,, Z-L>(4F%+GM6])T6G!.0!I;B%>EJQ6V9'#F+R53)4\H?&H/Q
M]B*W6E!,5EMJ!PDKOB (?$Z*4,D$C@""T!NSLMP_;G[;N$)>$,QPCPUD:G$6
M1XBIS8N[+2(LXNEB[;?"O^-: ->U-:K.EJQ5Z[Y0P2OFL.C$<<5B^))X8OAT
MI#=G_0<Y67'[WYB.>J,KM_-,WK^TPQ\8'$9N_P"_9@A>?Q\_Q[SUB3BSB>4E
MTG$&8+CW(R-II/ZV2MZ_'NO@!E*I&T,CK0,:.S6Q,#1\@!I9NBX*X8; >J;>
M+^3F\O\ ^S1<Z4^D!\/Q?@$0XL/P\]_V9C.S^>?^?F\N_P#K9*X[]\Q5P00#
MM#$/E&P?_2N2UQ)Q@'7D'D7F$.O[M4'5.M?^6HGF,_*9.3^<R-Y_]>W8=_M2
M%2(HAVCC'R8T?<O.N)N,M;\]<C\Q:W_?JA*JUO\ \]13,=]BQ)^?/,_^O*]W
M[W%5AK1V 'R "]GT*^-_S2^9OV#U9_"N65*@/XC7@S<U]H\]+:ZJR 5)SI;4
M?>");75C0:L8O&4HGE(C5HCXQ."XBT-;DZPR0)%AA"T)(SU;,YD-4A1)'$;6
M:SNG5<(\32\+Y,VQ$;%6Q'X%RN"&O?%S!S9(G'[(FB<.9@=]E[2^,EO.)&8M
MNL+,?+OE>T\S''J >Q!^!'IU!T>NM'JHU9_)D_$#E5TJ:[LI95M9UXQ^XE[]
M<)$D62YB=65V7/"8\%>LJ)K;W:1R5"2S&*5#'(0PPE&4YLHW-R0Z<"]:]AM>
MU7AV*J9:L=ZS9+#X=5T @T_71LTSGN8Q@/1SHO'(_1:Y:EN-L%VG%C6@C;ME
MW3U:- N/P/+\2%W7ZA\.#B6G:N@-6-/,]'RE! 8HS1<F3SFI*ZE$SDHVI$4F
M42"52%RC)JQV?WI2 YS=5@]@+,6JCM)B$R8)*<KP+)9"QE;]O(VB#8N3/FDY
M00QI<?LQL!)(CC8&QL!)(8UH))V3O8XVQ,;&P::P:&^_Q)^).R>W4]@MC?0I
MXV_-*YE_8-5G\*9@JM/H4\;?FE<R_L&JS^%,(GT*>-OS2N9?V#59_"F$3Z%/
M&WYI7,O[!JL_A3")]"GC;\TKF7]@U6?PIA%&'H+A#GIUL#DA5!^1:',9&+HH
M]VL\3'25:)4),$W1=U-@#9041'2"US#\LG&)%A2*@*B/?)C0IT1ZY.4<3(\_
MET^H4'>QZ==_3HI/?0IXV_-*YE_8-5G\*9"E/H4\;?FE<R_L&JS^%,(GT*>-
MOS2N9?V#59_"F$3Z%/&WYI7,O[!JL_A3")]"GC;\TKF7]@U6?PIA$^A3QM^:
M5S+^P:K/X4PBT_T-PUS [4#>+7!>1^>3)NY4_9C?#BV.CJP2/8Y4LA;VFCP&
M=41&B#DSJ)W,1A;U!)Y)I*O9)A9I8PZ'HG99-5W$')Z*LZ[1R3DCG(,A20:)
M)GX+E1=7GN 7DAA0%.85YQD8-,.6:6@/TJ-,,,&8?H8A#$+>Q;(LZ^A3QM^:
M5S+^P:K/X4PB?0IXV_-*YE_8-5G\*81/H4\;?FE<R_L&JS^%,(GT*>-OS2N9
M?V#59_"F$3Z%/&WYI7,O[!JL_A3")]"GC;\TKF7]@U6?PIA%%CGW@[GYJM/L
M5;..1:)+C<@Z 8G6JAOE)UHJ;3H.5S_2K4L,BI)\=/+0,FINW2THY*E+2D">
MRW95LC9R@TXV3KIKT&_GY_C[M*!\?4_OZ?L4I_H4\;?FE<R_L&JS^%,A2GT*
M>-OS2N9?V#59_"F$3Z%/&WYI7,O[!JL_A3")]"GC;\TKF7]@U6?PIA$^A3QM
M^:5S+^P:K/X4PB?0IXV_-*YE_8-5G\*811CFO"//*CK>@'UHY%H<58-=,='M
MTW.24E6A<8+ECO(^?SH$6]H01T"54[&H&J;;85!Z4\U(04]@(.("J."?/D?F
M/O\ ^2?C\?C]RDY]"GC;\TKF7]@U6?PID(GT*>-OS2N9?V#59_"F$3Z%/&WY
MI7,O[!JL_A3")]"GC;\TKF7]@U6?PIA$^A3QM^:5S+^P:K/X4PB?0IXV_-*Y
ME_8-5G\*811>[*X/Y\D//,O::GY%H@Z=*)#5YK67$Z3K1O?1(45K0E=(]I5:
M2.I#RR QI,[C<0!/ $]M"K(,"86:,H90>QUW\OGY*94,YCYLKB0HI=7G/5'0
M.5MP%);?)X94T"B\A0%K4QJ-8!$],; A<DH%:,\Y*I"0I+">F.-(-T,HP8-E
M*WCA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBJO[/2VJVW<W2N:
ME]=JN2D].MJ!J>^*Y5)4$YJ.\4\LEJR76%:E<5RO2VC;</7P<Z IX0UL,;MJ
M,1]VCDS#,:P6DR1M<RWX_'X^:J'ZM[\^Q'374]!Y[/3X%9='NN+$D#17T'YI
M8X3VU*67F2N[YL2UG"QDM!L4YC<S7RZ'0I;!FMJ@%EMAUEVO(ZJM!63"GHRO
MX7#E<=.;9%,H_P"U)TZ4FO,[&R0.F^HT='KL:!'717XL?Q 7FM)MTTG?Z#<&
MZH^1JH8+3N*SGNR6%K<QF3&L5DXBE=0B))V1U9I#/CW])J,R+;I8$;@\;:U2
M*4CFS@)<C83B@#>NO<Z'IY=3YZZ^A/P6A#O%DJ8<8L=1/&_E:0RZOU5#:BCG
M676\+MN@%+ET#-9% X^EG-_.%;1%-4;G7SG%':06GI=!GW;7!!-$BA0YVZ.H
M(PFI+6NUS-:[1V-@'1]1L=#\E?AGLU^?W>>> 2M+)/"DDB,C!W:\,<.=OVOS
M7;'4[ '5;(B'B5.-BQZ'HZPK*J+7LV3=;*N1S"JTZ6;I90HW[?,4RZB;[%C%
M[-M7G*)1"2(K&4L?EB(%:MLNC4CU+6Q''Y&Y19M;I;4K/+WZ]AOMU_.#>WKU
MWW[+9$:ZK5V"Y<ME2Z NL.G,C[3OOF64,,*MQY7PABFM,45U>]N[RI<=1"(G
MW)7;XAJ<U1'XY*XI#!MLC?HQ,U3>G?Z_0I%C\?CU36MZZ] >HZ]2/B='K\5P
M%8][SV7+Z??YOSZU0BI;TDMYPF 2)CMY5/K(W)J,CUI2YQ.?JU2U6P,R*-2V
M-T_,3XXM:K'?)(4YB86QUB2/;JH4-11KX]= _#KKSW\1Y#SZKFJ [,MNY+-H
MB,/M)U7$H'T/S]+>FH++(OT.[63*6^M8ZHK!N0MLNAZ:C8Q'VF9.KA<<*],I
MGL221 LI#-4[1+G]7'D87MY_C\?+]:D@#?4]#KJ-=>OQ^!_N5BN%2F$4(>JG
M:32:V>4N=FJ82Z!1.Z9A9[U9S[ )$YPR;/$*J:M'*0D02/S=A/12:&"DTQ=X
MHN>G^).;1*/DU'7IF:7AKV\'K22D=B?36M^I/?X]NWZ_+1\\GO,GC]F]8<]O
M,PED^C-&V/7YU92&>O[A+YLVP2TZDB<U^1$EFCT<KD4S4168CEXV>12EP=).
M9$W>.M3TZNRIIVZKB'L#OJ=['3IKY>JF[A0F$3")A$PBQV7RV,P")R:=31[;
MXU#X9'WB52J1.QX4K6PQV/MZAU>GAQ4C_!(0MK<D4K%1V_/19!(Q>6_+RP@&
MSH=ST"K)Y(L"_9MV):<BMR13!EBUM\TUM=%<<_OAHDC724/=+2LJ'PIN6L6P
M &CLV3PJ,LTQM@2P2A8T361ND(3JE#)$&<P15'0 U\=GU.AO]0/0?7S5K&%2
MF$3")A$PB81=<#K'I"R(M/\ M92@?NL5\]K6S(>P4)T+44NFB?A'FIN>X5#O
M4MW3K(P+B*\4E53+BI),.ER[!@%L.""%R-C"FDT/*=FYJAY5@#IVT>X_2/7R
MV/,:Y>NB?7178Z(.*4$$J"3BE!)Y19Q1Y PC(/*-!H99Q(P"& 91@!:&6,(Q
MA$ 6MA$+6];V5"]N$3")A$PB8102YU!)&/KCMJ%.-B6--HVVI.=I='FN>2U?
M)$,173ICLI3(&Z'MQ^B6R+L2@;.UA"TLR)(F%M$4>I]H5[-4&%)\OE]Y6AU,
M?GD/Z*I^&P?HZWKKZ:46T&<=.HRY7)M4+!.:G\F7.![%**4,?GRJ*>*&WCCD
M8HHEH2I[OFDB:TTI<I%,8JV6@]D%.QH] !K0Z;._GT._7R \NRMEPJ4PB81,
M(F$4$NEP21@ZE\/22,=B6,S-LSZ)GU4S"OVJ7+VZMI7&-<5=DV<6;)X@C]0C
MD3LFF,#ACH@6/1BXIK-C;<<UI42KVE2H*H=G=!T ._/\YH_5W\NOZE&F_KCE
M-B];W#2X8+V?/ZZYUJFK)"XQ#C^8(JA<%$OLPN8R%TFTYLQ1<%%R*5 98TRQ
MEHKRGJ[F+^ZNKD*>.\H@4H*/AWNE^/Q]/+UZIV /3KOOU[>6M'K\?VCJK/*=
MG$+LRI:RL2N9&LE\ G$!B4JADI<3%QCG(8P^L*%R9'AT$YE)W/3JO;U"=2Y@
M<TZ=R*7F*"W!.0K <4 J>RV/A$PB81,(HW=.1<,AA;2X26^G3G^G86]JII><
MA89$=7;W)*]98V^^C&07$C?V%XJ-CU)E#!(9/*HVJ1R5:RL*B-MC['BGI:OP
MI'RV?+S_ &>:KBB<FN>1)*5I;YPKSC%'=+=H64VU+-)?(I6S=&J>.ZYY@?+2
M(CZN>R$1-ML"ZQKS@\E'%9=)7!+<2?GAS;"U#TU2I4F=FPIZ=?4#KTZ;WKMT
M'0'RWU"F7R^Y22'WAU1S<OF,SGD+J4ZEYW63O8DG>)U-(]&+DBLATY5^[3R2
MJW&63))'Y97D@?V5YF3N^RDAKF*=D7/:YO:&K1)0>P/KO]>O0?C^^<>%"81,
M(F$6,S5OE+M#9:UP:1((A-G*,OR"'RQU8=2ELB\I6-:I/'Y$XQC;DS:D:!E=
MC$CDK8MN[5IW3IC&_;BBTH]I*(JT*?6IZ[Z-5IJZZ!MVU*0I^G;4*[7M"Z;3
MD-A5@AN)C70-9$ QU^E:]5%819$>;$%J.]JPFF]1JMJ]CAR%OG$48WY9!R22
MJ/8=!LGIKOK\:UOJ>J^'EZS[QLGM-TG4^E$P9:QN[E]WM"H*%=A'-K37=<LE
MKQ>,5K)'Z.'%$GI;7L6.KW2P)N)S !UC!,Q:JR5%^E Q*UI.FOB".OS!_9T]
M>O=6QX5*81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB811=MKGJ93.PD
M]IU5T39]#3!1#DL E*:.-D'G4(EL;;'5V>F!:M@EE1R2LC1-(PX/[]MEF$=T
MU*UB%X4-,P22QJ0,"-E*0>FB-^8^!_N/F/W+3S)P$T5JW0XB@+UMJE7MEJ<J
MEYK+VQ'7<QD5G1(J82VPDTCD6YG"W1F;+-:9Y8MF2M@E<>9VYE;W*QY:0KA[
MFUC8V]C)O??1Z[^[6^^B-;Z[Z=]K:KGQ_6DA:^DX_*727R)AZAAT2A$\3+WL
M>G= V1&N@5NB<F.3EEZ?29,<@++?!2-8L5N:>2E%.R4XHTL.M$WH[\][_ [+
M#G3CR53:(N[!;'4]U6%($[I6<@K&:!9JFB#E4\NJ.3?*Z)SUB9(Q7R.+R";.
MSR @F?*98SN\6ED?('%B(@QQ]P>&]R)O78>OQ[C1'[]>8]=]5E;=R^[.#I4D
MHM*\[$M:8U)?*^^V=U=VN%1UFTYJZ(LR@2(0U1>+QYN0,4)1QVT'N3;++.7R
M5?,M"<7*2*V]1MK))OOH ;&CW]0?WCZ?5?EFY A3+(J^D9$GE)JJN^L+GZX;
M"#O=/LZZ9W975W5N_1E=Z#>$SY,-+7><@7M'LXR77V]G9_;%ZE/[:2J)O]P'
MTU_<L44<<M\3K6GF.OI&\.$JYN?+SL.JM2)R"S-TDG-MU]=</*;)F\1UO*>&
MJ/H%%S.1Y+E%M(GQ#ML;E1)QYQ1Q:@F_V@#]0U_<H4^'9RO>_,LWA30V5M.X
M'!%D&.;.BG>XX)X><<',Y*QL)*:&KJGDG%[<5;TO6DRDU>I<G?IAY?W)7%%;
M@N7.BZ=+S51A5.(/IYZUS=.OGS?N'KWZ:5V^%0F$6A;UHA)<Y=>O+=-))65D
MU%,C9Y6%D11*PN+G'7I=&'^%/S:YLDG:WA@DT2E<1E#VPR2/.:+7KBE*-X9U
M[)*&2/O[44@Z^/P/_+1^/_)>:(HE%2J6?N*V922R[%MN;BL2TK(EJ=B0.\HD
MA49CD)9DJ-GC#4S1^.1>*PR(QN+QB/-2 ($C>U[<'58]29U?G]V(3O\ 4-?C
MYGK^[IT6^<*$PB81,(F$6/2R)12>QI\A<YC,>FD.D[8K99+$Y8RMLBC4A9EY
M0B%S2^,3PF6-;LV+2!")5H%Z50E4%"$6<4,&]ZV3MV42J\\/7D2I.A"^CJPH
M*F*\F:&O4,#8$D&IZL8BAC!Y#G+%3G,HZJCT5;G5HETC9I<MB+^Z(EQ(W*+)
M4K.HT-+ZTLPJBYQ&B2?F2?3^Y36PJ4PB81,(F$3"* ,LX66O"&Z()$.DK:KB
MD.A9)/I3:-5,##5KH<!PMLQ2HMM+7T_DD'=I;"6RR%SB].KX6:ID#BRNTA>E
MT$=(>,QM V%.^W0;'8_+MOR.OEZ;V.AG4QLK7&V5GCK(D @9F%K;V5H0%",&
M6B:VM(2A0)"QG#,-&!,D(*) (TP9@@@UL8Q"WL6RA<IA$PB81,(F$44ZSYMD
MM?=!V_?*Z])C,07$D86]YKYUB-=MD=:4$,,>BX*G:G9BC:"3;W&&R0.C9LY:
MZJ37H!I:IX$J5D@-T4D]N@Z?/^_XK7_/O'D^YZ$G0L/4\_DT<6SE]L*=MLDK
M2EQOEG2:5.Y[Q)G><SE!"4DM=7EX.. C$\:<BEK>THFME:1(6=I;$"0A._(=
MM>?3]JG9A0F$3")A$PBBG??-LFNNQJ*L%JO28UCJ@9LML>*QV.Q&NGYM<IFY
MUS:%1N3J\JY=&WET,3JJ\MR7,FFQ*L3(B%1B!X)+"XHP&[*0=;^(T?J#^\!>
MFR^8GV2V7(K7J>^;$H&6S^%QV 689#&&N92W2UFB"J0J(C(DC=8D1E":-V+%
MB99(6UJEC> U"O:UB)#+8W*"8[%],A-]-:!Z[\_U]CY^?[-+=]25=#Z1JVNZ
M=KY$H;H/5\+C<"B:-8L/<EQ+#%6E*S-GO!R5"&K<W(Q*C+-<7)6,:IP6F'K%
M(QGGF"V4$[)/KU6P\(F$3")A%%KIWF<[I$%4 U:4FKPNJ+$(LY$V-4=A4NC<
MID[4TKT$543",3IB?69\*A;DX;EL4(4IA$-$T;F&5DD[?8XPKFXI!UOXC7GY
M_(CRZ?(E<3*>7Y1/89$T$YZ"GKS:E96H3;E178W1&L8[**^D),2=8,>UE1ML
MB.H5(XT^Q&4SN+RAN?F-4J=X]-WE*G<6QQ1L#NSDW\ -C7G]Y6>T70Q%.GV+
M)7F<22TK/MZ3M\KLBQI4CC[4L=E#''&N)1>/,<?BS6T,,8AL3CK0F1,3$A2G
M'[6*GI_>G1YD;^\NRTA.]= ->GX[_P#(>2W]A0F$3")A%@5IPM=9%9V%7K9-
M)/7#C.H5*(@BL"$GI$LRA*F2,JUG*E<45KDRU&DD; -9IS9%:A(H+3.29,>(
MH?J]:P@Z'U^![?K4<J;Y+6U?"TE/R.U 6CS\EK]QK7=#R.F:4:*^715R;]M2
MIK=T<=A:!2\MRQN.7I7EL=CEJ&1!<UXWXIP,5'#,*2?KWWUW^_7T7&PSP[..
MZWZ C_1-<<]4E7LNBT$<(8P((/3-711N:%[B]IW4V<MA[%$T#FW30M 6JC1;
MRB6D'?)YR<&T6Q$J3 B*2YQZ$D[UW)/;R^7G\P%-S"I3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(JZ_% Z F_)O,J#J&)NCDECM%W52\LN)E:TJ
M98=+J4?IPWUQ8+&<0>D5G[3H$4X32_8F[:9P =%B1%*0E:.*.*IHV=>H.N_?
M73M\52KSMXDO>4 @5CF7*!;:]O<\+N;N1Y@QOK(A:HY*NC^F.D+7>B;%-:F8
MJ,+'4V&<X;HYO0QM%)(TA=GV4'(CG1O,.-<BWX_'XZ_!5%K>X['F/Z@!YD:)
MWOZ?$*0__+!]#3I]882VT5"(6BD'.T?D4TES9:$7D"J(678G/]Z6DT.]>R'W
M_P#)N:-4?=JI1)FR)LK-+7J1M*R22,;PVIH0N;W4HY6^I/7ITT"-M'S'<_(C
M6RK ?">Z[GO9?+:.PK+:!1V8Q!SBU=O#*\I52*P#U"&GZPEGRXL-$86E;6]W
MM8N8%VA'&QB0D-B&!2V)EFG'NPG,I*4.;RG7?IW\O0Z]=$$?,%6;85*81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A%P$HBD7G$?=(G-8VP2^+/B;V-ZC4H9VZ
M01]X2>L ;[*Z,SLF5MS@F]:469ZA6F.*]86 ?H^D .]$6+/]-U#*FF<L,HJN
MMY(QV>L0N-E,S_!XP\--AN#8D;&]M73EN<6M2CEJQO0,C,B0J7\EP/2)&AL3
M$#+)0)0%$7'"H.BAO4?DHZ6J84BB<,.KF*OXJYAXGJ-5ZH0J&P^!Q]UVS;7,
MT,/;5BMN.B[<>F9#$*I0D&A$G/-+$4[/;9T>I&^Y]5E\9@D'A0EXH;#8I$A.
MI3(0Z"C,>:&$3D3&F-#&(X2OVU(TFUA4?C36V1YD+4>L U,;<A:4&B$"1.G+
M*%E6$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$6O)*L6$.>RR52DD'J"=^@4>:6#SWZ7GOT0#UK
MSW_;OR\]X18_[R<?KZW[4?\ >81/>3C]?6_:C_O,(GO)Q^OK?M1_WF$3WDX_
M7UOVH_[S")[R<?KZW[4?]YA$]Y./U];]J/\ O,(GO)Q^OK?M1_WF$3WDX_7U
MOVH_[S")[R<?KZW[4?\ >81/>3C]?6_:C_O,(GO)Q^OK?M1_WF$7'HY24X>O
MV@D9:[29Q5-"G:-W"I]G=D6Q:6MA_J5 _5.*38!Z5(C/14I]A%HTH&P[\B+D
M/>3C]?6_:C_O,(OF2/YJ\H9Z%Z,6D%J5J(9R1Q$H* L;5A[<XI!F$G# %2@<
M$JE"M(WO1J58G/3'@+/), $B^GWDX_7UOVH_[S"+U>^5?JS#?>JCU16S=&F>
MW&^K+V3L03M&#];Z(-E""+1NA;UZO81:'Y;UOR(L1<;9AK.PMLJ=[,C+7&'@
MT!#1(W&9M2%A=3C"SSBR6UX4N13>N-,)2J30%I5!HQEISQAUL))FPDT3V&UR
MA,]:%#]N*IYFVGR<+26_BCA,B2FOVF(X[2<EZVS@6"<--)J@02"W':?V,PX6
MB@G;'O0<(N?]Y./U];]J/^\PB>\G'Z^M^U'_ 'F$3WDX_7UOVH_[S")[R<?K
MZW[4?]YA$]Y./U];]J/^\PB>\G'Z^M^U'_>81/>3C]?6_:C_ +S"+CRY24<J
M<$),C+-6M(T9;JC+=PC5-AC@6$Y !P3A4;.1C7$C":C"I 6)26()A.AA%K>R
M+D/>3C]?6_:C_O,(OF(?S51JTA,]&*#VU2!$XDD.(CC4"PQ&D<0)%I99PAI5
M(V]>A7 (/T6:)&M2*= V0H)&,B^GWDX_7UOVH_[S"+\:=UHMF!"YJMB)WK1H
M=+3=[*WL 3-:,UHWS!O98@CUH7EO8!!%K\'>MX1:]27E6K@UN[X@N&#+66/^
MP>_GA)8+ I:V3WJH$D:_>[@2[C2-OO)6 :9![:<3[8H (E/ZPP.PZ*='T/T6
M;MDF"]MR)W9I %W:7%.4L;W1L=M+VY>D.#H9*I$M2*#4RI.:#>A%'D&F%&!W
MH0!;UOSPH7W>\G'Z^M^U'_>81/>3C]?6_:C_ +S")[R<?KZW[4?]YA$]Y./U
M];]J/^\PB>\G'Z^M^U'_ 'F$3WDX_7UOVH_[S"+%AV7&BY"HB1E@,9<K2(Q.
M"N,CE2 ,A2H )@K!KE#*)?IR)1A1C K$I,3!)"F$$_8]%"T/9-'OKIZK)BG=
M8>46<2YJCB3BP&E&E+33"C2C Z&6868 W8!EC!O0@##O81!WH0=[UO6\(O6J
M?%"%*I6K7@Y&C1D'*E:M4X#3I4J5.6(X]2I4'' *(((* ,TXXT82RBPB&,00
MAWO1%[_>3C]?6_:C_O,(GO)Q^OK?M1_WF$3WDX_7UOVH_P"\PB>\G'Z^M^U'
M_>81/>3C]?6_:C_O,(GO)Q^OK?M1_P!YA$]Y./U];]J/^\PB>\G'Z^M^U'_>
M81/>3C]?6_:C_O,(GO)Q^OK?M1_WF$3WDX_7UOVH_P"\PB>\G'Z^M^U'_>81
M/>3C]?6_:C_O,(GO)Q^OK?M1_P!YA$]Y./U];]J/^\PB>\G'Z^M^U'_>81/>
M3C]?6_:C_O,(GO)Q^OK?M1_WF$3WDX_7UOVH_P"\PB>\G'Z^M^U'_>81/>3C
M]?6_:C_O,(GO)Q^OK?M1_P!YA$]Y./U];]J/^\PB>\G'Z^M^U'_>81/>3C]?
M6_:C_O,(L@C2Q8>YZ+.5*3@>H.WZ!IYI@//7H^6_1&/>O/7]F_+SUA%L/")A
M$PB81,(F$3")A%K.5?ZV%_NY/_%A%5KUKXE]8<A6^=3,S@TND\I7\[*[N@J.
M+'MREVLB6J[AB%(PFD8>P&[TXN4ZG$QFC6)O/)T8B;VI.Y.*XO25 I-+*H-)
M&^FMZ^70G?R !)_<I%CZ]Y_8;"A]'6/;%:5]T3*8RS/IU'.,[8W"8MB]U9#W
MH4?!I*866XN/J$#L-H*)*(625"V*71E0*46O3"4:.M@$CUU^_P!%FD"Z+HJT
ME[&UUU:\'F;A):U9;C84L>?4;B:Z5;(WM=&V&=)?4#$$<==W]L<F=O7"$$"E
MP;UR4K0C4AX2R:([@CJ1^L=Q\QYK<^%"81,(F$3"*O#NJ/>)*_QV4)>')GSM
M&6Q35;RDVGL%CEQEQ'V$9M\] VNI06]$5LPFGM8V1-'E,T9%J)!(@JEKJI*;
M-E#3=/P[+PK'+$>((,G*\7&$&M)"*(K#P^EJ'D-J0!_.91!(USHM-8"[8=C6
M&V7 B!T;06$?:!Y^;K^:[?*.FM;'0[).NT(/#0K_ ,;F(0Z*I>J)Y39D-#:&
MU<H8KY/D=E]'?-WLYIT])HU/*\EZB&)M+ @=C(H1,CI&Y-JPTP2_9#&)K;$^
M_P"*[/ ,\\SL17O"?W3EADQPBJXOWK3_  S+7LP-G/+]@3& 1L>T?9W)SO-B
MJV\UH\5S.7GV1(2^7EZ;TYI+='J6\Q)V>NAH"]UW5K&]I=%[<UJ'QP1-RU6A
M9$BA$D5O"Q,F-.3-:54Y*$C<F4.!X )"%"]6E1$FG!,5*"2 F&!\Y6P51]:\
ML="5\]UWJ?MXI\A,N*INCYL]5,]KZS&FN20UO:E?7D=($:FX!KY<BV]'5;)G
M)4E$6P2!O<)<!+#0[*6-KN51._H1U]/(#H>OQ_:N4KB*]HC<!JK5BUZEP=:E
M]\EQ&"VU$D,]8+7<V!C]C7 EDAZ E)$CKF*.:*4M[LU*72.P&2R)TC3ZBH%O
MAP'= C(=:Z:WU\O+RT-=">^][Z=]E;J;XETHGFCH>[H[)/*&[V2HJISCL]BB
M*$Q!S=>BN@'A.Z6]&1RY!N91)\IIZHXEC:Q1J=O,>0M#\D:$<&FVS%ZHH.M=
M/A^OH/OWOMOXJ-"!BZ\:F^/0J3G]$/<WDE?74^1YL9IE&H>J8;-98I0#1&Y.
MZR-5TM8R:10)LL!SD[F8S/+_ *9SE[X[D-=0&UN66B+)TV-=OKYGY>7D/WJ?
M'-E?/M=0^U&.51V3>\G6Z+FEQ@7F5G2UKEC;-9D]2AK71 M\F$A QL;DU.R5
M*-@6_)DM,\!<A+VP!IRER6$)W] /H%'5'5$]-H^F$SG5E[Q:5UU);;4H(C6D
MEYT3/[.HDQTO#%G1T')Y>]0E0Q^Q/*<M$4S2(Q4B<32$4H9%<042 @!!Y]NO
MF=]>N_+KU7(UI4]W(YW6_P XL$3'S)FOA?=UC7<QK8B7#G]&]\SO5;+F-A1;
M?M3[:U')'EK@3>S.443M":&Q,A\"[ VE9$:DGK\M:[^>_AKM\?V]/5-ZBZ9<
M'R;R5BD=JEN!C/TX]1-M0W"<UQWY8MT]K%3RXA+CA<L2,A+.9%OG*.6M*U&6
MP.I*@;9:1*TM/%6Y&4]/]GR\M=?+U^JX_BNR91/;ANG4O>9LI6I#)0F9VMQL
M+Y:1TUL;+;F91,G=8@VSJ0)*,E#G&G"$,+95TGAL ?=-L6>7=L;1K!3AICI0
M>PU^- >H^NB?W*S#"A,(M&W:CZ06(V$/.SW3;*N":Y_*<RWF.8/2<X@12331
MIA#$G9L$F/*.TO$O$X:5%F &DT06'8#M#Z' 2<+,DL'B>OG+$9;%[H,)8I5W
M-<'/\;W@W890]I;X8C$?(00_F/5NM9DFYAS8OR1)CHW;?XYR$5B0$:;X?A>[
MR,T0>?GY^8'[.AT.ZO\ ER"^+\QO%FFV!-:X*2K'9/M!\_*U7/FY:L">N$J7
M5ZFK-_2*HZQB)$1ZQ"X#;6P19J,MN9"5*==LCUKB[(>Q.Q!B1C:&4<]D#O%_
MBZR/'2QL+8PR/)NRM:1EFP"':DB$DH(>99W-='OB<'5]H$4ETV[-,-=("S\J
MN=:8YVW<SJC:4K70Q:UMKRR/1:&1 A^KL >GZ /6;#LST0^GL&MZ#L?EKTMA
MUO>]Z#Z7GZ.M[WO6O+SWYYX*=;.MZV=;[Z\M_'2])^:IXE7,G1[D\6U/'U@,
MD";H%Y+E$WB-?OGR"LF.%TWT1#)-0+0Y3I)<:!LD;HEH0,NC1YL0'%T:-^;F
M5$O/= G$O".%.QZ]NV^H[=>FCY_O_6LW4QGL)=;,F<'**V^GI!PEK_J4Q.,V
MHUH9D_Q%EE\@;Z^,KF8*^@AJH\M<V8^(S*5IXLS4685$$S]"7598,[(*>'8G
M37?KY=/UG?3?P'7Z!;#.B71(92-6]-%YN=?G/1ZUG:HC9M<,=D() "C^6&J%
MR28.B29QR,O; PS>/]#H9K'C%$@B[[+'5 ]*8!*HD>T.",AU^.W<_K]/CKHM
M/*&GJ>-2P@%H*[NDC)-KU&S.$;KB0MT2#(F$M+T"_MQM>2[72JEUC[/N-)X(
M8ZM:1EHM+[L8F<HMN=K $\EJ"'7EZ=?H/ATZ]/CY_&2O)%:V?!7VT7JW&V8[
MF$\;*;>7*1O4Y+DS$[.+-4<4B;ZA*:$4K<F5JEK2_,+D3*G%CB[&SOAIB1:T
M+G%K&C)1$/ZO/M_S'7X=UP;_ $<^O\=LJ<RV'3LN7SF[H<]E16J7BM$4P9:E
MI>4'-U4,"-UE3@3%%#6L+*>+AD;<G>4<F9GNT)>WQARV^-302,GI]_4;/?IH
M_+MY;67$P2\)17//\:EKE,VH\FSI@?;!T?F;7"IFGJ/4$O JMFV5R"MW5F2'
M2M.ZJJ90SH59+AMQ\S)<G1B.%%TYKB43IU^73Y]/NWK?;YJOFWW7IJFH+!8Y
M8$LM%(?.H4D<'Z0*;U9HZ[QNT"Z3A:">S1GE*RT(8B?ED.LY6Y.L;YU8I0CB
M5BK%;N9$H<=&F1:\L!5#1)[=#T\AHD]^G3Y^73X*[YG.3J&EK4(PKPI#VY"<
ME"Z@<2W0*<U,4,@+D6[_ /2P%^BA!TL Z?\ 2(5&C K?^<Z-PJ%R.$7X,]/T
M!^J]#UOH"]7ZSS]#T_+?H>GZ/X7H>EY>EZ/Q\O/R^./DI&MCFWR['-K6];ZZ
MWTWKMOIONJ8NDR_%W,E%8;@OS8%H0N1FEFJ(/5;CVE_M:79(K(^=8LER$T>S
M>MT6%O"8R>HTL]NU[P$@UOE;_P#&?Q*_@^[:V=^Y[\/FV->\>\_:Y==N7[&N
M;F^URKZIX#/\&9N.X@&7_C Z8P#P_P".+(_?O \.3F&!_BXYU<6?$Y>8S%MS
MG,7@GP!-JS6F=]&;2OWTA04H!;H]O^2_S-&3HQ+M-ZM5[U]__+<HHT)_K?8O
M=_N[TB]E[5>T>0M$^>_J>_:?[][IS;'A^Z>-K6CS<_C==[UKEZ:WM> \5?Q&
M\2G_ !)/%AAY)_RA_&IN';)XG-'[M[G^2'.:6<OB^/X^G<WA^'TYE%R5<H2"
M=SKIN:2)8]ITCM::6?U'%&\NN2T4K=6SDRJ:N;WY;)CV5;/&,C4N;)2PJ&,$
MKB:1>6R!,<TBN*/C@7(,M<J#HM_;_P"(G\?WK4AT*[43S<:9LC-AM%<-\'A,
M8>VJ/V,PDZ?V6/R/FC3\F@;DHN],FBTP>J]:+Z96U3'ZWK5Q:'M<:H5VP[+%
M\4>VL@U^-]#]K78=NV_QK\6I4W6LU!8C T MP,%D=(6+$(3$I#((4^JE#9(:
M&LJ*MT&M"3J.AD,?U-!6HYQU\!-=5E9$C,2%PU OMH30*R#6P@UO9]1Z^O7H
M!K]OZNRR]PB'5AC@O'&66\6F+"?)09330_V]&'"00&0GM=# 8I%>KD;:;XKL
M"N"I6WWD[?)/<CL?9,4=CVH$7VL4U\U1DHZ? ].O?OU_Y?K^&U9[A0F$3"+3
M=]6Z*CJT>;###7V=F-IJ1$FCT>4MJ=<K<G0S:)D3;]M4:7'A=7PUM8$Y$>:I
M(^"<'=$82Q*$!;@L0D6.6_?@:PY<L'I9+#SWD$*IM]MU)!G*2L3>>Z%M46/D
MR:/K)=%#+ C:3:P!9:0U^CYLO:2M&;6MHWE-HK9Y2!L@>ITN#IZ^YC,[8G]*
MV3!8'%)K"8-![& LJRVG"XHDKC<Y>IE'D*)Y=GFL*E>HO*B'&$N2DMF6QA6W
MNS*H3N+0^K#DCR@:B$#IHD]^XU]YVMX2"Q8)%G^,Q.02UA:Y7,U0DD2BZEQ3
M_*21F%" %48S,)8S'9P1MP1A.=G!,D,0-"70ECFI2)0#."4+45FW'8#19;54
M%.5S%K$G(Z_=+/DNYQ8[E649C\73OB:-1U"6[L]=6:Y.,EF;W[Y*9T>V!$SH
MFZ+2!Q=GQ*H+9VMZ*==-GMV]3]-C\:7QK.GXW]%^-]-,L:>G-#-HM7;G$((J
M/0MDA<)E:[M'(G!Z]=%OK%K8T.ZN>2MEB#PX:,7H&A68K6!VN3)=:.)KKKY]
MOAWTM/6!V;*:>C]K)K:KFM8G8]9*^9U?L?SX..J@=(9U!<2BE8G+W&UWFH6-
M[C1,5D\?G*B9-I]7N1J)KC;<M1*%A<E3^[R:WVWY^7F!O6MGX*2U,VR5:-;[
ML!4LK)404M?$RHVGK'<K?BZ?3$<,A<DW(5$!KYU^4"$XE0F>8X;$B5[2N)VA
M&)0IV( "A<:Z=.T4TM;<[FV A<4[U$J]G+ DC;3(I:]R6,VPH?D]:KHO'(LS
MO$ADZJ;CBTF,CK.P-CB].*2.OBXENVB:5Z@@IT>WZOIW^BX)9V+S,@$T@5V_
M&2AO-=.-MI >J=S!D5JS$2DU]FCN$IL&*/L4?/ADB:9$K?M-NH_(DB6,/(4,
MB=V9K<":/H>^OU^GS6<Q"]JMG*EA0,,B5@>)*LDS<UQV11>6PR4Z<(>A:G21
MH'6*S%B89&P+6UK?61UVD?VML/5-;NVN*(M2B6ISS"C7XV%P$<Z?HN7OT,CL
M7G0'U=/XW%99%UC;'98ICJIHG4=.ET++<9<!AW%(Z^2R+IS9!'8K(WIIE#PT
MA]N0,YY @#$37?X+[;.Z/IBFWE,P6/,OD^[*(ZKF)R8J/2I] TPIM6@;GB<2
M57'6-W1Q6#L*PTDJ13.2J&F,1T)Z<Y[=4!"@DPPIT3^/V?/X=UC(NGH0U/5P
M-TM3N#.CK&UHM5#(='VV2V'(+%>)12D!ND@49A,(C+O*5JU*SS)R*.:61OD1
MH&>*.DJ4J4C9I82V$UV^(WZ:ZD+DM]5<_;<8*V$64U+C+':(2_19>UMS^ZL
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/PB81,(F$3")A$PB81?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g96328g27a75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g27a75.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1L*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &NZ^:)0X0DE-! 0      $@< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M 5H  QLE1QP!6@ #&R5'' (   (  !P"!0 45F5R82 M(%-C:2!'<F9X("T@
M5C0X0DE-!"4      !"5WM@$PE6F@B/!Y1_4(E"9.$))300Z      #E
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M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #
MO_XU  (  @.__C4  @ ".$))300F       .             #^    X0DE-
M! T       0    >.$))3009       $    'CA"24T#\P      "0
M     0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ !
M &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M   ! #4    ! "T    &       !.$))30/X      !P  #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      ,U    !@             %0   !V0
M     0                         !              =D   %0
M               !                         !     !        ;G5L
M;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   %0     !2
M9VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L
M:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M    !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T
M960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P  !4      4F=H=&QO;F<   =D
M W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0
M   !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O
M;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M#T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
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M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !R * # 2(  A$! Q$!_]T
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M"R[;ZL:VS&I.3>UI]*@$-WNX:QSW^UC/WW_N(J<KI75,[(RZZ[WM?78Q[H#
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MVV5M8WW^U2;C9+KZKLFYE@H+G5LKKV#<YIKWO<]]OT4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( :X"70,!$0 "$0$#$0'_Q  ?   "  <! 0$
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MUMW69AP7=AD-=384)SM9\3UZ;/KQP:UK*P&]+4XF^9:M=2/-RZZZK@]=:\;
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MUEX8+/'6M+9:]"NA8.W6>6N-C>_N3S.AR8YM9RZI7K3"ZMFX!R#:&.78&AM
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M=B_^->P?^L8'N<?/LW #7NS B &%*[:F2I8X#T8.JGJT7 $'$,.F^#:]( "
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M\/=O]_++V[K//T<$Z^;V;/3$SR^7K7Y^.%Y=^?7MQV8^FZT-*5KD[FU;O:M
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M=G&WC4>TN<IB+K96K#33R>9Q--0D6VFD9IU*.!I]Z]7>%8#%-8LIG@NU3$Z
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MEE.UAVU VAV<V-M;8L#8T"?F9!29F9F$[?V+M>+^2E)I<LJ-"1 V2N#%FR3
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M(4!'DF7$@P8AA]]NH5O]T&$-*"ME[V-NE*C-P%H[Y4-(6-^(%4/=Q+$@$!R
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M$2],P7YPXCV3X'[/G(<W(3\;M=L%<]+R<3:<\J-)SBXB.XC;I@[T,Q@=TI>
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M?LX]WJ[<;/BD&WZ%\Z\&TR?#UVV,= ]+_;C3*SY#$ZY<,&NW9F/7K=D\>=.
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M)[#D!7,G4C*[XN;#SK;RRY8=AM=K=#.MO;$PAV?(->(Y;QRL-*^%JU+9_.E
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MAS,"+%CP][3O8<0E#T/<Q-,;.T#R@+N:RA&;U[4L+3<R"! E8:<D6T6HU>%
M 7!JN_4;H/FACXG;KME%#"B8@."(. 41)L8DK%A*;<6M/]%24E5#:@<@@%E!
MKV=GQWK9/;'8FTY6'&B3TK(S.XG\Q+3<>'+F'%;XPA<8H1&05 J0N&H_"0%I
M0MT)OK]YEV__ 'P*(_Y5P/?_ +/MH[J+?NHA/^K4-'_HOX&I;/'*_MW8G_/.
MRO\ Z8RGA_AL+]YEV^W]X-$=]60.7_Y_+KPM!!BW[J+XH51WU3>H?E4EB]_;
MVQ+?MG97_P!,)2O_ .&KP?#"\R[?_O@41W57 ]W^S]=]J8,6_=1"QRAJ>AI<
M<_<$8?MW8A8#;.RO_IC)W_[[/JSXNMC(,)1LF\C7S.19J8]$[8.D'C93FCGT
M;AN=1(^W W-..&RV-B**!214BQ!?0U&]5WY8Y&%&A1D"+ BPXT-3[L2$M,2&
MK5EH4I)8M8FM],3ECMQJW+*M7-?GI77@UKT^>]77JO#KS=UU[_3*@3U54O2R
M)'-3U) 4XV5Q!)Q/3$=#HJB7'G DM(N6Q%!#',I#")=N !;C-H[9V1L="8NU
M]J[-V7"6Z41=HSTK(H61<(B346"E1%'"2=TZ!B=]);-VEM)1A[/V?.S\1%5H
MDY2/-*2*,5(@0XA2*7(KQ;%H_OIN<_[[-V>S;^WE*^7]=M;[<*>WW84?_;GV
M3YCM'L>]R/[MS((.MN..3_M3[5?_  :[07M^QMI>O\EZRP?OIN<Q_OM79_\
M+REO^ENW+KX[7]OO84?_ &Y]DJ?_ '1['#"FL[E=FJ2,ZX?VI]JF_P"+/:#_
M .DVT?\ V;E7AI9_OIN<W7M79[<_]/E+?]*VO]OO87+MKV2&9/\ ;'L?_P!M
MXAKBU,/[4^U6?9GM!:G_  -M'_V;&H_*TY4-W#>[:HZ HFI8JKZGJ]D:%74@
M72<G$P\2Z,4LDZ=RK0RC!9RNS!9DT9M'*S@JK@KER1-!( 7\/_&O\8.RL/LI
MM3LUV?VK)[=VMMR7,A%7LV*B;DY&3BJ FHT><@E4JN+$@B)+P8$"+$BA4018
MJ40T#O/3OPS_  [V\O;\AMO:\A,;+V?LN*)M"9V&J7FIJ:A@F7API:(!'1#1
M%*(L6)%0A!2@PX9*UG<GOP^Z!DZ8NLG:LE6RK0]?3C=W%I*AS#+P,(U4:,7X
M$Q 2)NWSR6Z#G%#IFR2#I,3H.$3FW7]C+V;F]D]C]H[;G(2H)[1[0AQI-"TD
M*B[.D(*H,O- $NE,>8C3O=.D=Y"0B*DJAQ$'&'\;MM2^T.T4GLN7B)BC8LFN
M',J34(G9R(F+&@/8JA084MOL?AB*7"4 M"AC?;MXZX=G7;Z2^1US-:VX  $N
M]<>+<M.M>?#!:![D5\,VTNS9CA6^&#7MEK?VVOOQZ+..&>N'7SKUERPNO9LW
M>H8=>>P;32]=!7QR%R2:'3%X7OG\WX4N,&SAGW8CAWX;+44&0)RM7S.0%M,+
MZT\6#^#WP!Q#[;,@ZLMVW: V@%B*#1FT\K5U=],#H?UO4\:YVL1A]@\-=]KK
M6Q\A\GXDZT=A.8UZ\,+LZ@ -F _;,0PQX<+::<[@!J@\,PPX94R&+SXDF[C]
M: NVNN >_+/Z<!QV8?2UX\CQ-:!['EJ0S4)#PK3[ZAKO]\6->#=C=W>O C3%
MYE$4O7<!TQ72475,*PFF[1ZF401D8_XU!92.E&PCSFDFP.VD&B@ JV<I*%*8
M-Y([0G]EQTS.SIN9D8Z0W?2L:)!64N24*[M0[Q"K+0O>0M_B2H.,88\O FX2
MY>:@PIB!%24Q($>&B+!B)4&4E<-8*"D@D$$$$4MCF#RA/P_ HVG96NN3J^K*
M;6B%1DI*YFH)?]JPE8,I5!D4+O*CG!&K6]3,BF+(1T/4M1U)'3B;0]/,"0KQ
M^T?M_8NRGXK3GYN!(]IE2\24BM"&U401 C2\0L(<2;1":7B0"1NQ%PH,&)#W
MN^48B4J2?GK\0_['OLKM^0G)WLM(P=@]H$H5%EH<JKN=ES<4*"C CR;&%+]Z
MG>0F++B"(:U)6I$0)*%<XXZ192S%I)QK@CIB]1*NV7(4Y.>F;$,#I*E(JBLF
M8#)KMUTTUVZQ%$%TDUDSD+[X"" 0000X(+@@BA!%"""X(+$%QCX$GY"<V7.S
M6SMH2\64G9*/$EIJ6C)*(L&-"44K0M)T(H02E22%))203N3R+>4;(7*5C#71
M5,X4=W.7B5.VBZ9454$REUMX-52)&T>S:%44P_8.O:A>-V)XUJF)J9K671DD
M$AA)^96@O'_Q-[%PY^5F.T>S4)A[0DX)B[1A ,F>E(*77'  834K"25+46[Z
M6AE)/>PH8B?9?]CW^+T7:!E>P/:.,N+-HA+1V>VA$)6N/!@0E1#LV:625&+!
MA(4J4C*)"X2#!61$1#[Z5Y9G*+E+\:TG+J8!55A<S=Q5;^$G$0/S5;U+P*.E
MU6,DI*IE,)!H.B:ECUFD/%JE']HJLB%*C=%-%15.'?:_PT[%0=G2DMVBV@E,
M7:,[+IC2$,@%,A*3,-*D10X'\KFH2]\K#&# B"&&6N*$XO[(+\8(TFN<[ =F
MXRX,QNIA]H=I0E*0N$F*@+_9<JM)"@J)"6G\Y%!I#7W""5JB&'I_(R+*)9.9
M*1<%;,VB?2+K&*<X@ F A$TTDBG67<+JF(@V;()JN'3A1)NW257533-ZX2$@
MJ40E*05*4H@)2D!RI1+   $DD@  DEL?'6SY"=VK.RNSMG2T6<GIV,B7E9:
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M3J[?3:#L;"C4IR8Z7RY:F^N=_?CR][&&LL=X^?@&["TU(K3Q+/GGHV638/\
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M=I=I=KS\YLV8V3,3<V8L20FM_OI5:D(2(,418$M%WZ.-^7A@N  Y;&Q@;]F
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MPUY<++-X<&_7GHV9PU^?UUPOMY8X]6>6[TLKQY^#NPKFWA=V>_KZLW&E<_?
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MJ.7AKCN3=>1#,*@51>S<\\FKJ)*I*F79].BT5FIB2O;%\LBQZ5R5A'IE:QC
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MZ\?7EY/A;]WCGU;NWC8Y#BE@+L<[W(8.;\<Z7+/RIQSY:8-W <,QW=>W0;[
M3F:Y\&H6HQS+ZL#1L,]0]!GP=NCEAV!LAE8"N@>N5JG(M;$P:UKZT\<K^#'(
M\_TNZZZ^QK67T[\ LKGU3.FHX!CK3#KJOW\'.%X:PW=_=EQM"[EB'?Z<+:W(
MI4#%\^GS\/&NF#U#NQUCPPL&5=:5%<WO0%[4J +##V/BW3:OC%UZW]IH[;_;
M4O9_K-WWAQ[]NP+<UL3^ZHO^H/\ XD/]>+BK8Z=VT_O?*6_NT:O_ '/'KHV7
MAS>YJ&_N3A?][J]?^R5^'?Y!V[/:7]W3.F^G4?X)!R?QU?P/+]G?[R;._P!0
M<_\ UT7%D7L88P6_],J/:'];NWR'KPX>9]N*G99!N9NOC*M1_EK;/TGLK:?<
M6$O3.T=\NN+4R73W]H87;G$QWFS1V#YCO#MMW#9?][-GBK&2E7TK!ABG@#G1
M[''6Y_\ NV;M29C^D11J/30XK'5C\_+OV6WU,V=QS-6&E="+94QL^+?3U\+X
M,];];^OA:\"YKGY@\A;GPPIUEUT^#6.OM8UPY][\W-!K2ODZ;K]<&OOX#Z6G
M"OD#0T:CL"V@%LWPZ_3S'O@T..>M96>7BYYYZ?-\\.@U.NJX7IMQ^N.L\=MJ
M=:6<&UM:YUKE6[UOO9OLW19K8-NW=OR\>WNV]5@%&TL]Z9C]-;N^%K9Y5\N7
MCZX,._VXY\.KJRX6AU%6\6N[9^&34>V#^'STIKQXUUP!CB./5W]VAXCAA8'=
M\BWFV8R]32I8# LP;CX>/0T#O@V:V^'RWY65#9L&?G?4N6 \<[87ZMY_7*N'
M\^.'IZ>-J7]=6H_#F&J"?3$^FC^_OY8+#8T_6AISU&>IPP=75OWZWVTD9&M!
M2NM:BYXM[G#CQ\NLL%M7CQSS>GVJPT+'#"]!X=?7K;NPSE]&<GWJ]&YC6E Y
MON->'#JV;T=J0#0F_$<6I;@*/Y.)UU[X_+/_ !=.2K_U'O+_ +_[K(V*)$4+
M-50M>C=:V;I%18)W=WD*KU'#1L8F4 YK"E7Z\O1*?. #=+3"P#SL.>;V+84[
M^?V7*QBK>B)0($8FYBP0$*4I\X@"8A_T\;2,G=B&C _$,[U-<V)RQT9_T,KR
MJ N:Y;\Y<%./C-Z2Y4U%KP+%-1<4VJ-YUW2$I5M&N5 ,;H@,^I\U<TZ@4I06
M=2DS$(%,.!2&XKM?)?F-G)FD@E<E$"E-<P8Q3#B 4>BN[72R4JYXURZJJ3J'
M%'JG7P?&\?+(OJ_ZH3E17O7EM7B3^F&TZ:[F[MR@?IFRMWMW+E]"Q;]DN!C$
M7CJHJ%6JJZCE2<T#,ZL1*)><01M[Y^&>POV'V4D4Q(>Y-[0!VA-.&4%3 !A0
MU4=X4$0T$',$@!\>-]LMH_G]L1(:"\&13^6A@&A6"\97,K^!5 YA\L53D0W)
M_P#5 \JNZ2@WK 7])P$J>]>\$IB\YN6D+MG,?*MF3HIL$W#2HJZ=452L@R/B
M+J(G)0>89)!;FX?Q1VZ=B=E)M,)>[-[3(V=+L64.^!,=8:HW( B%Z,6K5L:^
MQ6S_ ,YMA$=8>#(H,=>8,0NF"DN"/XG6-"@<\?9!OZ]#KKZ[?'=M2S6&CGK(
M%F8V]I_6_AU],'R'VW[M<+73D;CYBWEX4P^H^>6?6N#=QUU^XVE@U[Z5OJ_F
M?%R6PSTZX?(87GM^7CNVAOX64<%QGIP%]::ZU88OI;Z^6=CEKBS+QP9&N[K\
MLE&O9F.-1%6%D(>,4.E)2S$T!( \BX]9,BBB3Z0;BHT9J)IG43<+)G(F<P 4
M=Q*E7YJ5*%HA+$S *8BPZ(:^]1NK6[ I22%*!(< U;&E8&XMP5#<6XS4G=+@
M"I<@$!GJWC>APQ$P&P'$38Y8@.?H/#?;;@4R.E#2H>M,\J/DPH-3U<$WU8GJ
MNK/YZ:WMU'R6Z-JJZ&XJ]B["E'%.1M.,)JZ\TE=<:KZ&H \+4U'W94['HIQ]
M,3D9=TR([JJ"AF%0RQJ>IADBHVBW$F@*[=$_,RD+:D:%.3TI,Q1$5$,.:")H
M08\QOPHTTM1WHT-4TK=@Q%JAI[V(HNH)HHG&I2 4I4+N4N' (*4Y).[_ !@.
M2!J;-;E=WR\@XTY2=[5<Q]#S]63U$TW4=+5FK<C559U@XH*\.@[WY&&?D<QE
MW\U432#D;N+O[Y59=)\1NE"4M%U"C4J46PE$$Y#7+RFW>[BRL QX<&%'B0XL
M'\]!@0$S$O,2B%I9<PB&5IF9F3"-URN*N&J'O*2Z8I4)W5NDE((.X5**5!:@
MS)*JI2LG1(+L,2<=>GR!J2IE!Q#TU25/T\PDG2;B,B.3Y7,>XIUS3L]=O6@R
M]2TTPNV2EJ3BD*@EKJ:JB:IJ:+BH62=NJ,FH:5> 6+<DU+E=O18JN]B1XL4I
M!WE[1@*$0+AS,'<A1#-%$57=HFX2X,):XB (T.(A+J!!<)( 2$I&0$-08NDU
M^!TU*""6%B#0-,O:KY$L\QO<O8B[LZ*K&I>3U1EX5?U*[5N:4@ZP"':/+VG-
M5.:/F:ZI:FTZC;U!4\7>[#GG*?EWM/NZC>U:U=RZ2DG*&7TB'MF'^4E53,>%
M"GXTO!A)_.A<'O"F4$,1D0(T4PC#A*E%]VN&F(F&(1""$I;4>[422$DH!<[E
M0$[QH2D/93,35P2#BLJ7[<E^AI8T3=[1YYV\"%D)V(I2F*1NW<TD[J%[-3B-
M-5<I1%:UU'4-=Q*0HO:%%2KJCCJV- )QM%J.G;]Q^5-$3Z!(;2C(WYB,(<!:
M41(L6-,IBB&F&@Q(0CP)=<>81$W8[082H B%<?X4#?405$2YN568)(-38%02
M"'%2^Z6#DL,7QR:TN3Q6=%1=XMRUVUW-&MDYVJVZJ%'L[KG2D'4PG:0%4)?G
MMU,O4U(O'+]E"0R)WD+44@D\@FT(D=1)%N@T;8=I&?AQE0)R9F(ZN[A5BKFA
MOPB%187P32(<4 *B+)2N&DIB&(0YJ2-T)^%(2"30)2*T!<IS8"Q.66-G_K;C
M>5A1AKH;L+6%. IC5]L&O2QJ\?EQ.CU9\J"F'7OA8>@YCU^7=AAX6A%O&IY%
MR7RX6-+#%?W%!P]?%W\\14]_=[V$#,'/)\^()X\7N<3$.U->/FP];Y@TT<88
M7>/AEW98]V(C:<W- ].;Y!QP%=*'%\!YU\:MXL!?#UV]ME_>HX"EK7#EC1B"
M 1B=<JY8/K:],U<_2]Z'6N&"T !?.IO?)_ EW H7YC#!K6''=:W!?D#3P+CC
M46Y89]?/3/"PR[-FSRW>UIYTM09-:@\,G)N!BO7G>_KG\\.VKTX4L/E]L3!:
M.W'U/5O.M*X8+*5;4YV.8X886&S?GO#M\,-WAM'&T/@3:MLSZ"MG:F>*]\J9
M'EYOGYV#8-FW -9^8ZQL>E2!G3PMXOK</H5[.>J>@Z; /7K;CEV=HYCNQLS
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M;LV+5NS:-TPP30;-4BH-T2!N(DD0A"ACD4H!;W]"4H2E" $I0E*4I% $I
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M110P%(0A YQCF,(X%*4 $3".   8C;8K6B&A2XA2A"4J4I2E )2E(<DDL D
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MKS<EQ^*/9[G]QX\^3X?VT25/Y/-:#X85]!^]P_W637^'1'^.\_S*S^TG:/\
ME4CF?XH]M?YCSTP_MIDO\GFO]F#_ +W"_=9,A_LZ(_QGO^8^5G]I.T<YJ2\%
M3!I_]#WX?3#^VB2_R>9IP@_[[KQP_P!UDS_AT1_CO/9E9_:3M'_*I'0?%'/_
M -8X'/#^VB2_R>:_V8/^]P?NLF?\.B/\=Y_F5@[$[1-?S4BW^E'\?\!UPP_M
MHDO\GFO]F%_O<+]U<SO?1&88?QO/#_67CN'+;9_:5M($?RJ1%:?''?\ \O\
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MZ]GEUCH<,PL]+FV69\R#D:6PX7]> Z#WP!LP[O#RUAU6"S&K4-*%B6X>&7/
MW?Q\_7I^.)*1CFDJS68O42JMUBB!BCASB&VE53-GS%4S?J(H&93!O 1 <$U*
M0)V77+3*!$A1$D%)8$$BBTFNZM)JE0L=<9I>8C2L5,: LIB((8BQ NE0S2H!
MBG,<0&PA3ZKBD:R/%KJ"+==P$>N(AS2K).# ,<ZPS I@,HD81Q-S"*+$YV B
M-O-ME1(NPMOF1B*)@Q8HE5DN$K3$ ,O&W:L25H.>Z%Q$@FN.Z[01#VOL<3<,
M#O8<,S"0*E*D.(T,FY9*5I -RE"FMC/O5;U!\A\P!9A:E#X-7,XZ'QP:UKLM
M3RIPU>]_:N>'777/!K7WL\  /#/2W%W<8==?.F#6M=EA\M*ZZV^NE<.NNN>%
MV^G#Q[MMGZV]J:U#N>>+R]3KY>-L \<<.([,0\M_TVVF=:4J>!=ZTJ[::YM@
M-&?078^N7WM@VX@/6';B&/TV^UCW!X^1K4Y,*7R-\+,1P/)BWWM\\/Z=>NWQ
MV6OG7F/2XY^)-,3[\.N7E?!K#?8_,G32Y^SV)#4PZ?+!95[_ &\<^3"AKEAA
M;@]QP].O<&6'5E9IPXMRL^C:7:E,7,_(/[\,S5^-<'U[]OCV6$\\V:YH?#5@
M>&>'7*WESP[#IDY\007]34TOYS"V8X]O=O\ /P#"RSU &7 9WT\ABW9N7CEZ
M>9?#V>0<.JRS!A<<!E7SL/+$N?,Z\<+7WWY=UH;"IK8ZDV=JCP:E\7K],J^.
M(J?\[N]]:"US/(?/KH8G777SQ#M?G7K7+PPP:SRM'S:V6=K<'H:UU PZI7"#
M6O3JP&P6>S/G1O2FG!CF<4]=>_%Q@XZW;\QX8[MH;[1[N6M1^%G-02W#*Q?#
M3K/*@U;.QRPQRSUKM'"U/ZOIGY\2WSEZ==<@^#M[^%CMX-P'AX>6;8<O#7!8
M?-]>5OGG1^ PP:#+UT'"SQN[4MX9\Z"VN'1K[='7"RV]@X\<=;[.-?8%VZKK
MRQ:VYAM&ZRXX?GK7"T-7#:OZ-;6AJ1Z,)Z==:X!UM\\.SVWVIK:_CG6S@BV?
M+ =6]'Y_/+!K7UL/EQOQL/&^=&+X==?;!8YZJW'B'89&YMA@UX=?MV[;#=M1
MQR;-W#T];DX=>?#Y\K8+/3B.7IPO088M:K_[5(?\,P7_ *V:>_TSP&V\DOY]
M7^HF?_+Q<<1MO^XX?_3]F_\ GY?%T^]MF!FU<\KL^NGWSQR_RQ;$4'.J.JCF
MP$Q30J0#AL3+'BJ4H8Y@'2+'/ACM$;<-(@JVKMI1=PK9Z XINB5*@&+D?&I1
M+&Y+5<XY.:+;.V6!0*$XIGKO&8""2UZ(W1PQ<P]@CAV8#EB&WKWAO"W,&M&)
M8ODUOF_-WMCC1S ?FXJQMPR.1P]>NNZUJ=.7G?/TH1G;$Z]NO'"'#9K+VW#X
M;[0U86!;*[5S?R;)C<8M;]5^>8\\L.U>I_7]+^5;6F#Y;=966J[L!K7U;QRS
MH</K;JN%U\!'RQ#SZK/ T)XV</K7A7UQ>&H'JQ]..':]=?+GB86S7?V=^S&V
MFC<'HP84KR\: XM^O#GX7;#[]?/Y989VMKGR%SZY-R;1\3PZ^GUJ],+AKY;\
M,\/6S,:YW:U6!RJ*BN6N+KU]<GH_MAV>.GO;QUN_@!,&M>-GB*>#:^AY6M?#
MKKRP6%N%78->AX/G6ERU7JPM^_7RSUA:&[YY"E7YM7@^0)?%RRZ^M.GP_?N'
M?K=O&U/)Q3-O*M3F+6=W;$^7CI?HY#"UZ^.&&/@-E'ZO7VJ^EZ8OW^7D[MYC
M!GPP\.'KCW==I6H(N3I8U\2'K0BAN<*:OYZ^S>/##T.X?+Z6N@+6/.A%F\-,
MC2V)T,QZ_?&&+T&TP7X9<S@SB#.L4Q4>A1 6+X$SI@!E2)%5.BNF8XI&44.
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M$^-@6(H]7%?=^8IQR\NF;%M1/]T-5_\ GH;_ -5IX6XB0_OKMNO^$D&#?_%
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MR)-+GV^5ABWT]L\LLW\S@#7SV;_#A8':NA<V;2WF:\BS8'KZ7R\]<'CV[O+
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M!CQU&&%LV:RX>P86,P8=>U!H&IZV]^JZ_,OBUZOQ_*4?^&(+'_\ FS3'?\^
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MW4-6U"[!A 4M!RU1SCXQ3'*RAX./<2DF[$A $YP;,FJZPD( F,!,"@(B%H2
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MZZI@UK7C9>Q%KBOSSRY&N'777E@UK7;9U\G]-;96PZZZY80ZPV[-UAMG[5-
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MA5U_=]B;+.QMC;-V9WXFA(R_Y81Q"[G?"(BU(*H6_%W%]VI&^!$6"O>4D[I
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MC:LHVMIV(>PC5%=9TP3 SAM\:+1)#F?Q([1R7;6/L23V)!CQ8DNI<.&J.A$
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MHXE2AU38"!<+</MV<_);+F8B%;L:($RT&P(BQ_@"TU_BA0RN(&+?NRPQWO\
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M*G9$:L7JRSQZ1THZ\D[,]O-I;<_$>7G8D-$&3GY68V6)(K4M,ML^"B+/H/>
M#?F1'@F-$C;@WRN)#2E$,H".\;;[+2>R^Q\: E2HLS*1X4\9G="51YJ(N'++
M!2Y*8)A1.[1#WB4E*5DK7O;W(&M.2YRA+KEI@U<7/UU%1T"U7=RE0(P#V6I5
MJR;8BJ^/54.F^I\&A2@!Q6&1 "@8@* 4P\VWMDAVL[-;7$ ;/VWLZ-%F%)1"
MEC,PX,VM:[0_R<<PYG?)H$]U6K.*X\RF]@[9V<(GYO9LY#1"251(Z8"XLNE(
M()69B$%P-UKJ[SFQQU"NOY <W2/)2OTJR\=VQAJ^K"[PDI!QA%TGR-+4]2#^
M.O!Z"5>L_B$5)*I'=.L4GB3%1TC&LD6X=,L[7=MVWE&UOQ(@3O;'L]);*0N/
MLV2VF8,Q%*##,Y-3L.+LW>@PXFZH091$U$4@Q$H,6(I7PI0E"E]YD.Q<>6[-
M[8FI]:(<]-2(BP88(6F6@2RX<]NQ%H<&),*ET!805"&D)JI:E)3R=.P?1BP-
M9%FZ8.@207%L];JM5^@=I%<-ENA7(FIT3ELLDX;J<WF+(*IK)B9,Y3#[,(D.
M*C?A1(<1#K1O(4E:=Y*MU:=Y)(WD*2I*DNZ5)((!! \PW%PSNK2I"F2=U:5)
M4RD)*2R@"RDD$&Q2010XWGY'7)XKZ]6=GJPAV#UC3U)TI6/P,ZHFHV;R=8OZ
M7EHRG86(=& I7#U&4?-9!^= 3)Q[1J!7*B*[UD1?S_MQVGV;L:7E9&8B0XDS
M.SDAWDN"%JA2$.<@Q9J8CPZ[L,P8<2%#"F,6(OX I,.(W<>RVPIW:<2-,P$*
M1!EI6;W8Q!"8DVN6BPY>##4S*6(JTKB,^X@,HA2D/J^T*=-3F' 2F*80,4P"
M!BG <#%, Y@(#D(#F @.(!;NA(()!<$."*AFOH?GCJBJE5QNI9N+5?/(8RO=
MO"S-15K1\'3R2ZTU)U%$-(PK<IA5([4?(]&N DQ%,C80^)56'FD123.L<Q2$
M,8.)VM,R\ILZ?FIDI3+P9:/$C%99/=A"BI)>^_1 2*J*@D D@8W>SX,:8GI:
M7EP3'B3$!$+==PLK3NJ?+=/Q%3T )) &,DWHUO-WB7EUE5<\X<*NY"=D"-T%
MSG,$;&M7:J$9$MR'_L2$<S32;E3+AB8AU3@*RJIS<7L79TOLK9,A)2R4!$*6
MA%2D  Q8JT)7%C+(HI4:(I2R=" #N@ ;W:L[&VAM*:FXZE*7%C1&2ISW4,*4
M(<( D[J8:62 !D22223(P,D_B'S&5BWCB/DHYV@^8/6JADG+5TV4*L@NBH7,
MBB2A2F*.S$,P$,;9IB##CP8L"/#1%A14*A18:P"A:%#=4E0-P02-?'&&!$B0
M8D.+"6J'%A*WX:TDA25I4E25 Y%) Z<#I'?%RP:D+%4K 40FRC9Q_2%,3E6S
MJC1%XJPE)^#8RQX>&;O$U6J?PJ3U,SEXLDY,!U@;($06:JJG\EV#V!DU1YZ:
MVEOQI:%/3LO(2H64"+!E9F) $Q,*00L[ZH9"(:5)#)WU%06E(]'VUVSFA!E9
M>0W(4=<E*S$Y,%"5F'&F($.*8,!*PI W!$&\LA9=6X @H43ABB^4U>K RB+N
M5G5*HC3*)F>Q4PDVYJR0F#I0:O$&Z;EBOS.=T!R&4;D.)3+-5R *8\]M+L5L
M*;EU(@2HD8[$0H\NI8W5,2DQ(2U*AQ4NV\"D+(_A6DL1PLCVMVQ+141(T<SD
M(E/>08Z4,H.'*(B$")#4UB"4BY0H4/4)I5E)O*(C+P3SC6)IN4CV[]-S,*)M
MA0,N40,R5,4Y@.^1<%5:';-RJG.Y2431!40 1\6B[,GX>THVRDRZX\Y BKA&
M' 2I>\$FD44#0E)*8@B+"0F&H%6ZY;U>'M"2B2,+:*HZ8,K%AHB=Y&*4A.^'
M[LUK$2704)WBI8(2"*XLJ(OJNOG) D9'5:S.Z54!%#XMI*1J"Z@C@4J3J38L
MVPF.; B9#*E.J<Q2)E,8P .^F>S6W96$8\;9T7NTI*E&%$@QU) J2J' BQ%@
M ,YW2 RG(#G&S@;?V/,1!"A3T/?4=U(B(BP4J-  F)&APT$G(;P)HP)(&,I"
M42Y& 0$-H" @.W@.8=G=;@;BY.5'XULXU\@'L>9].?*F7KXX79GGGKJ].NQW
M!:M\P]7H]@U&O3+#G2E.N/OPQ\X'X]O*TE[N2W"W*7;5*,36:4W(WOU0\C54
M#/8F.C&3^DZ28.!_E.8E-.).K'+EJH4AL(1@L8.:HB:WKGX9]@=A]L93;D;M
M%(0Y_9J1"V=+)*XD.+!G3N3$>/+3$!:(TM,R\(RZ$1(,1*N[F8L-6]#6M"M4
M'M5M[LA/RD_L*=C[.GE(4M2N[2N#,RBE,8,Q+QT+@3<K%B0R50XL-:!$@IB)
MW8L-"TY-1N3J"@+F>2)7%Z1I>0O2KFD)J<K^4EG3PK>&K6?@H>;I^C&L*94L
M5#.HRFY.I6#X$&OQLG)4ZX76=J @DD3YR[?[#V'L;;D:%L!$P=EPY^>E9:-,
MS*YI402P1"A+$16ZG=F-R9CH(0"4[J2H[@Q]9?A%V^V]VP_;4';TS*?F9:3V
M;&@2<G)PI1)A18L<SL=82%18BH,7\A!4\3NX?>_"@&(28$\G.O&/Y+2C-22J
M^I%T:=I.-0.4B[V?F#@S8@F8QBE*FT,H:1>+',5)JP9NG;@Z;=!50G2MR+$*
M84!)7'C*$*"@,ZHB_A2ST#542:!*22P!./7H\Y)[/@1]H;0CIEI"1A+FIR.M
M]V' @C>66 )4I5$0T)!5$B+1#0"I0!EZ85C4J;BDV0?",XV.;L%&SD/AW$6I
M&HE:N8^125 BC-]'*HJ-7[=R5-=NY153<%*H4X6TH 2D) *=P;A200I!0&4E
M8-4J200L%B% OC<+5WJC%2M,5,9HL.+#4E<.,B+\:(L):"41(<5*@N&M!*%I
M4"DD$8Z3<B&BCL*(J6\Q\U,B[O*F4 @EU""51:@J72684XNF!PY_PDM+.ZEJ
M%BKS2D=QLO'N2\](R1Q[_P!E)0PI.--K24KG8@[LY_EH22F$==U:U18J2&="
MT*J"^/D[\;MOHVCVDEMBR\5,26[/RJH4=*5.@;5G%)BSP)!8K@P8<G*Q$U,.
M+ BH+*W@-V]N_P .O$,=O>&W9O&W:2YST-.+\;9^&>7BULM;\&+6\#:^0P>?
M=K9M]+-+/G2^=G%K^;,7&'I?/J]O?!AK7=CN'#9:D9_7CD*Z/D6MH?KKQ;,/
M?#X:P[M86'@]K"G+B,KTU%VFO3^/3X6SJ]]@=0=08^UI06%F\; : W:I<&P.
M+?C\KGB>);YX-;N/OO[M]KGRX>U30@5^1<!UGI\OKE@#=MS[/'++/PL#^?0M
MKG5M&? YVIS\JUIYX,.O77W]G#9CBKF:@N&S'&U3Y/P<8/PZX>'/6[,:RZMN
M0=>WCL'&Q@UWY9$%^-7U<FCOAU7C:IX6TN&P_'R\-<-MIIG0D<V',#.H8>=9
MY>OGUK;!K6L[5O<FQUS9GID;\6JZZZI@[+"'I0T/R\?+Q-CASP:\;.-/J_.S
MGK1UY8+!7EH=7>S7\?KAB(GM-W>]I8EW.E#D^@SO8<'&&7G\OOB'GWZUNQZK
M6N1XU^C?3@PIA1^'76;<<'CQ\M9#OL(%ZU^E/G0T<URP\M/7JHRPMW=M^UID
M:Y4R#-=V;Q%+4&+GXV_7!\M^WKX8;OD%E[G)CX\*$$T]FH#A]<K<-7S^IP[4
M,;$7KQ(:U;9?47F%[X]N_#/'+6S9:#0WS.MV-"XIJV@Q?DW+)Z-7J]\/9OX[
M?'R#&UY\;T/@> >WG0XE\M+>7J6P:UK.P5 >K_2MJ-XD%Z98===4PM>H#H,]
MME?8LP>Q!#VXWU&F+]_D1T:6P^.77VZ^5H;4J[WJYK3PH*V'+$TKPY=?7"X?
M7KV_7;VX6K<79QSIG]_*HQ=?MJ+?:W)\'9X;.[6/I:5:EAKPL1P!K6K6RPY^
M=_'IO?!]O'Y 'K8:'CZ-SI45U+$EF+!^OE]2?;#M0^@ _2V@O]*XF#ACH=GO
M:-X4L6(#^5:D4N+X:MT+_+%J5W15.7D475=W]7QR$M2U:4],4Q/QSE--5)W$
MSC!Q'/DN:H0Y04%NX.*2G-YR2H$5((&( VW,I,QY&:EIV5684S*1H4Q!B)+%
M,6$M*T$D,HC>3:@(!!Q%)"TJ0H.E22D@U!!<$>1/GK7'Q;_AZ7]__!Q<O2\Z
M[.\ \G4]%OI2L;C*S"B4VDZX=SM+5.N2CJKB8XCYHE*+$E8Q:.^#3=#(-XRI
MY8C=DZE44XY;ZK[9;#7V_P"R&S)W9R$09[=E-JR2)HJ@I$.:@#\S*K64**-Y
M"PM*MW<5%EX+J"%;XZ9^TI7L\J=FMI1Q D96%&5-S)!,.#"@DJ5,+W=XB&A*
M28BG:'#*U+HE39&_&,H.@F%XMP_+CY,3B(:7>7P,#-S3U'Q)J=)%WOW:3!W(
M2,E$F8Q;V!JITS!NV?QLG'L9IK.47.#*H)R";H X_P#"^;GC);;['=H$1C/[
M*B$JEYR)WRE;.GH6X8:%[ZT18"5[RD+AK5!5"FX/=$I*6W>T%P(R9/:4A&A1
MI6:AHB09B74%P8M!$A18:T? I*T$%*DGXF)S<YHY<UY%(_B)P]P\Y3M;TJI(
M5#R:VLK&TXVGFLF>ZN^^+J^-?WLPE103)=:4A7$M%OZ3B6#QXP(O*0,4^D8Q
M-VA'KD-K_#C8<7LO%[2R$S*QT1H6U@(,U%@+0F?V5W2T2,6!&6 B,E*TS"HJ
M4*(A18H2L)44G'EWXP=L9[LFGL=VE@)BS6PH.T9J3[0R$LM'?*_/2,1,L2E2
M@E*Y:(A<6$(JH:(D9,&&5I$3>3BKDV4W6W(WIFB;PU9-K4U7W/7@O+RA:PIW
MYF!Z*DV*,#>+1K-9=NT?O6LS1*U1/BHF9H)GJ52,<E:++1K9<_<NT6RI?M'L
MR>V5&=$.<@"&A;)*H4Q"6(TO'2"=T*1&3#SK#"DD@*(QX7L/\7Y.;_&+9FW-
MF2L?9^R-JR$#LY/0YY4.'$G8JE1S(SLW#EXL:#"7!FHLM+)6(L54*33$/>)$
M12$_1A"<K.>.LTD'\'3DO /$T7"9H<[YJNHR<IE51<,W2[U\V6(=(Y%4^>WY
MJQ1  43 _/+\[S'8*2,-2($W.0IE+I>8[J)#W@X*8D-$*$H"A!9?PU.ZHN#]
M70NV,XF*TQ*RZH;G>3"[V'%2Q .ZM<2*'!JQ1\5G3<27*;O-2JME1<=3KQ0:
M7E84*F6(4#(F=/%'[Z-2:/T2F$O2Q"L<Z(9$1,0CI90^*G1H*!N.Q>Q52$;:
M4:<A)$[ F#)ILH0X8A08RHD%3 M,)C(.\P)0D!@Z@<':K:HG(<A"EEG\K%@B
M;5=)7$,9<$(B %G@F$L%-0%DERR2-*%@,(FR\-FW/[;;>CIMX_(-YACXXZ!%
M?*E+\C6W6N,A2[NJJLN=BS.3.Y")NRJ5U&=.8#JA'1=7LF:D8DH;]1B-&;Z!
M=MD3J&YB R3%D02D,W3MQ,&'([/[0Q^[$.%'VU)HC;HW4]]'D(D1,=2;/$BP
MII"U@?$KN8D0N0HXY:+$FYW8L(K*XD#9,S$@[QWE=U!GH<,PDDY(AQ):(A))
M9)BPX8;X1C "Q,QSX!EEQ'K[+=G!?W_3A0U8/D#?' .19GHS@Z@^7O?&SW)J
MN71ODA+WH99^A'F3@8!")<G,54[*H%91>0CGZC4IA6%H5**>QSM4"@8S22=)
MMQ,L \SI?:_M"KL_,[!F$PE10J9FE3" "D1)404PHT,++)[PF/"C(3;?@H4I
M@7/:NS.Q1MJ!M>"N*F&1+P$0E'XMR8,8Q(,4H#G<W8"X2E"NY%7NN0&U^JJX
M6]NGJN<4*O0L[)5&DS)*)M*>8KU 1Q#KNU6"$PBM%$=$)&+.D3H Y<@W%)8!
M1=$07 4P[1)]IMA3<@G:2-I2T*55$, Q)N(B5*)A,-,5<NI,<H_?)AJ"]Q!7
MO N@J37' 3>P=KR\X9$R,Q%F$H$8(ET&8"H)688CI5""FAJ6"-Y8&Z:+"5.#
MN/R.[DY^[&^E-*]" 0CIRH[K:@FJ88N'39VHS11GH:'ED7Z*'3MDY%Q'O<0;
ME<JBC'NETG)"++'20Z!V\[0RNV.SY5L::5%EI3;,K+3D1"%PPM1E8\> J$I6
MZM4),6&V^4)WHJ$E!*4A2NZ=D-C3&S=LI&TI?NXT;9<S&ED%2(A0D3$"!%2L
M))2(AAQ* *44PUJ"QO$A-(ONY#]&N[[Z%IBB9]S0L1>@PK:2216CBS\;$S=*
MHQTHO&13,KV)<-H]]&/G+ANDN^< S48G1;@+8Q$FV;L]^(D^CL[M&<VC+)VE
M'V-%V=!*DQ3*QH\O.*C041H\0PXZ5Q8<:&E*U)AH,01 I7Q@J5HVSV+D_P!M
MR4M)1U24':<*=B)3W8F(<*-*B'%,*$@1()3#B0XA4 I:MPI(3\!"4Y%H+DS4
MYR6[Z^3[(14[*5(^K>1O&I*J)F40;,VAEU:)6EZ?0BHU$5ORXOQ$0^3.*KY\
M[<?$'(9<$B$1)Q.T^UTWVQ[/]IX<>6@RD/9\+94[*0(*EQ%[HVBF!,JCQE;O
M>G<CPR&APT)W =URYY&1[.2_9K;&P5PH\687.1-HRDS&B)2A)4J35&EQ"A)?
MNP50U@DK65;S;P2'&7^5I=Q0]8UGR:GE:4S&ST2_O9/04TFY3407>1U54C4R
ML:T6D&1V\B5LVG8QF\;I)NTTR._U88JG$>"[%[5VA(2':N'(3<67CP]C#:4
MH(4F'%DYV43&B)A1 N$5JEXRD*)024!G^$-S7:>0DYJ;[/KFY>'&AQ-IF1C
M@A2X<S*S*H:#$04Q E,>&A20%@!9>Y+V[>[<K=5<G^X*H+M:$@*0"-Y2=VQ)
MF0C68GDW494+>H*340?2[I1>4=-2KSR'1H.7BB*2AA.0A#&,8=SL7;VV=O\
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M$-!3-1(<-DD(&YN!4)+T_<J/=_"6 2'9\6(Q2,<2%( F.8Q2$(4HF,8V)0*
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MP=M2$YM%:A+P9M,U'6$*B**H1,9(W4A2E;\5*4FA;>)- <:-K0)B+LJ<E9%
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MY]9]'"'CZ=75CGU[QW9X6AX'-J.;/1GJSUS9S=L7A[\>+4X9#.CXHLK/L8G
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MU/C&]2V\:+',*!XL0]7QVWMK#3,;1E>T,%*$R_:J0A;;*80:'"VBM<25VW+
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M36D/RY591)/GI$'#HSX#S2X-O;+1L:=AR*8RHL42,A,3.^E*3!F9N4A3,6
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M$LMJHC&GLO#4C8<E%B?SDV(T_%5_65.QHDR%$G_,B(#G(/CSR9P-(T!+UPH
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M,4=ABG-S3%$,,Q''++(V YB #;8320I"@?ZI(K9@X(/E8BF0=L;N 2%)(_K
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MH&TI( .K\Q))6M:1J8THJ:@)#U7%03;'J_\ 8U]K/V'VWB;#F(I1)=I94RZ
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M7P^N.@[:_P#>(\D>-NW?J*R,Y*U)(TO&.%50,+&C*;5IN=(=SSR*"Y2.X?\
M[/,6P\Q(6#=PGTG-8@BIYDKLNA7;J+M>$!"EH,I!G(R0/YS:$VF;EB$$$;B@
MF%^:B+!*N]4@L\3>'>$]H%CLA#V9$*HDQ&F8DM"4X_=R4L9:9&\[[P*HGY:&
MDL.[2H;PW #BI_?E>_/M9-C,7B5.^8S#1PQD8Y5^8D<Y9NTS).&WY>D5-DBB
MJF<Q.8W;H@0HB!.;EAS</LWL&55!BR^R9.'%@1$1(,40@8R(D-;I5WQ*HBE
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MK"3.R<,D4*Y:'%_*1F_ACR\5! 4D@7S=C-.*6O6J"D%7*B5.WF0XUM#MCKJ
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M^X<LG0I\WI_R1J8X#T91M\=?BAM9&UNV.T!"W3!V4B'LB&H ?'$E5Q(DXHL
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M4Q$C*D*JKSA23,<H**@GS15%,@CSC\P#%$XE >: @)L,0MMPE1!4$DI2V\H
MD)=V<V#L6>[%L95D!@Z7-A0%0%R/ZP (=@P<5IB$<A%"B10A3D$0$2G*!BB)
M1 Q1$I@$!$# !@RR$ $,P"P$I+@D'4$@UH:C44QHO0U&GB_O7GB6?-C.VXMP
M4Z(BATP6$ $3'0 X"JD40$.8*A0YO.$#!@(@)1QQ#)!B"&O?*=XI!W;,%M\*
MB""X!JU*L7IC2I.^DI)8$@*/^:_Q#Q%,>7BAD$2)-R@"JQBMT"AD!,0P$^ ;
M"HI@)N "4H#D-D)(4LJ6Y2@%:S<EK"MRI1 KJ3E@HL&%"JB0+ ZWH *^&(@
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M&:JCQ3 A4RJ^.=L-NR^Q]F3DLJ(D[0G(,26@2P+Q$]\CN8D:(FZ(<)*E$*4
M%Q F&*E6[]Q=F]CS,_M&#$,):964F4QIF*01#WH*@L0$DAEQ(BTA!2'*$DK5
M0 *Z87E7&W;WKBBO5T()Y1NF5!O-QC@\=+IMR"8Q&YW20&([;D$YA30?(NDD
M3&.9 B1E#B;QG8W:7;&PMY,A,M 6=Y4K'AIC2Y4:%8AEC#60 %+AJAJ4WQN
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MN8%%1/GNU.:.!S. $1$0"UV@1#,&20V[*(W8A%0N9B,J.I\P%-##AP$-C3)
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M:&@RLZO?#WJ_0KKPUSP"<A1*!C%*)S<T@&, <XV CS2@(YFP PX!G@ Y8!D
M=R 62"[ D .SY@ &CFSBPI@2S.P>@L'+6&M _F=<0)"04C4VC@Q"&9&=)H/E
M#<[GMTEB]&DN7 <.C(N*95A$##S#?I !Q,&6!!3'*T.H1A"*H*0S1%(JJ&;$
M*5#WBD. " "6OBC1#"W5,.[[P)B*J=Q*G2E7(+*0HEZ&VDG4K986R$FS()W\
M,J+U$H!^IPW O->M!'#'!PVY^10YPJ$3 ,,<;99%:"M<O%+09M @K+_P+8F%
M%/%"PEWH$J4]CC'-)5N)C0P\2 KO$@76EB(D.E?C02P )*@EAA2;5"I((Y&J
MP #M!)W'.@R,@Z3YKAFN _Q)F36*0% # X%Z1,<!$0L@1%R,V\5/\VM4*/#:
MBT$%$5'^<"C>8D,[$.PPBH3-RY"5-OI3$A+%"E89<-8S!"@'S9QF<$2Z;U-3
MPE?(E 72#F.EVA@P,@Z2 S5^W,40$2"50#&3QQ,4ATS@(B("-F(:Y&=_=+)[
MM2(TM$#$+A%HL%8)JK>3N@DL-X*#Y80E)FY8]XEM]*X49#-NQ Z(J#_5(+MF
MS$7?%%@:B)$TY*-YM4?B*,%>/DE3!SE'31LF"L:[33$><89!B=N"0'-SEG'2
M%',;;J;E%3$Y 5*)_=[3"(T 6$.)$44QX1(H.YBA9411""D@$-C;RTP(,M&3
M,J=4@50HJKE:$)"H40 U/>0BE@:J6XOC5!Q>?5C% 6$#)*Q$0V</%(YD1)HY
M5;-G#E9TDU.Z7;'46(V!7HDP "$ @ ',P ,.^)V'(15B+-P4S,RM$),:*51$
M)B+0A*%1!#3$ 2I>Z%$U+U?'4%;6G(0[J6B=Q 05JA0PF&M2$JB%005*0=X)
M"F%!0 6IBM41>(]>0M<4DZ%0TS4S&HY.'=H 1(%9A>*4.[9%;HID304>@W5<
MMSI<PAGICI%3!1P2VUVIL>%"F=E[10$B6D8LE F$*)5NRZ)@"'%*U$J6(14E
M"PIR(3*)W4DC/(;3B1(&T))3F/-PIJ- B)"1O1UP"5P]T !!7NJ6EF!62-W>
M4#C3B\&EHBO:/JFBIU(586K8&4IZ2*&'2%9RS)9BJL@8<.C<H%5%=LL40,BX
M325()3D*8.^RD=<M'@S$([L2!$1$07IO0E!8?@HEB"&(<&AQU$EMPL"Q/PD
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MDSI<R:8&1YQ4TS&64,1),YR^;+BH0@KWDFGP@$'?)_A"15]XL-*N:.<?9,*
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M)#(AAU$V&Z'(H\TBZBX.F2*,7"#QG'-"))*-U4UP<N!$"E*!D3'+TSIPH'/
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M9_+-RMP39CM]G=H-A;+@;"EDP9R9,FB+'F8T*)W$#\UM *A3B(TO%@%<T($
M[B"E2 J&P0202+$@1XAF%?NQOE(2D_$0E!=!"DEAO&I<'=-.?<VY20O+E;HK
MM7]\U.MZ4O;7HJG/WE4^RD8N681U;IQ;=*IB1TE"O9&,=1JTLFZ=1RC9XN ,
MET$U3%7*J0G1YU,LB;FA)+,64$>)^564+0I4 J)A;R5H2L*"-U*G0/B2;ACC
M>IWMU)6P7NC> +_%8YM4UH32ML9/'JV\<-GF&W#=WVVVG*[?<>5<GMC5SMH]
M3Z&SY^&#0CLX]^7=MQ ;36FCDDBS\@XOD'+O8X= 7T\*^-F(P]N@R]=WK:TM
M8@GB1>W,.W#AB6Z-?;/VPL0V^>S'+'+6ZTHSZB^1IQ=AKRJXQ6-O2[5:O6>#
M6O#8'?MM6.IYC[\F8/QN^'77G<^%L/6M>-@J ['5J@W?PY"_#$ZZZ\L'6/7X
M:VV>C4<Z<SX/QS+5<!T<&O70_:P,<APY%_"MRVH?#KVZ'ZX-:\+34_)P7IE>
MP\-'.'77G@V9Z^G7YV<<K$%\G#YT.?F3=UZ=??AZ8-;=:[1P< !G>VAHUK')
MWYX=6ZZY!UNSRQW#AVCY;;#4.YJU/AT?,-Q/*F+G2K9A^0];8T)Y9-W%)4Y=
MBG55*T%1T%TEX5*O;QJ@@Z5A(R6<4X5P]<-W4K*L&"#U=BE6X4D]DUG*YTDT
MD5';LQ4$5U2]3[32<"#LXQI:4EX1,S 5-Q84"&B(8+J4"N(A(44B8[E:R5&V
M\KX03CV_\'-O3LWVNEY':^V-I34-.RY^'L:4G-H34:5AS^Y#1NP8$>,J"B)^
MSC/PX(2E)*E!$/XU)2=!)21".8J.B(J/7!Q3;QS!L457<K)NS A&13!%/%1P
M^DWBB#-F@D!E%5UB%*&8B'1"2WP@J46"$)#J6M1 2A #DJ6H@) J20!7'U05
M(0E<2+$1!A0D+BQHT101#@P8:2N+%BK-$0X2 I:U&B4I)-L34M=Y6%Q)BT;>
M4Q=I/"K.I%E5C2->KTU50S+E67<JQ\JW179EE6KY\YCW\.Y72E"KM@>I-5(Y
MZQ<K[F9V=-;,4($TA=64B.E"U0HW>$K)2M(4D+2I10N&2%@@*"2E25'KNP.V
M6PNUTI^?V9-P$*250IC9\>/"ASLGW)[M!BP5K2LP8L-*8L*.A*H)2HH,01H<
M6&C<ODHW%#/K5)>9>+2S]I'2,>QIR[^,G6\C"RIHHK@\E453'CSG9R4>UGWA
M89C&HOT6SI=I 'D!;?!2#%57O'8I&T-EQ9C:L,KE(DQ!$K+[\)'>&7*A%C+*
M(R%%*8T1$$)!2E2A!W_X2DGY^_';M'LC;PV;V6E(\':,OLZ9B[1VG%EXYB2P
MGS"5+2DO#C0(@AQ8LI B3:HRH:EH2J<$+>[V%%2C?6.HVFH>-?Q</$M8UM)-
MEF;PS8@BY6261.@8%G*QE'"W-(H;F LJ<""8PE  ,-NYQ]I3LS&A3$S,1(ZX
M$5"X0B$;B%(6%_!#0$I3O%*7W4 D 7%1X#"D96!"7!@P$041$*0LH'Q+0I)2
M76HE2B 5-O*(!<  WTWFJ:E:5DU8Z30.F9-0P-G0$,#=ZB!@ CELK_"<BA0
MPDQZ1(W.36*10IBAZ=*STOM"71&@+!< Q(9(WX2B*HB)N""6!_A4/B22"#CS
MZ9DH\C'5"C)(8JW(@!W(B00RT&S$,6?>272H!0(Q=-*1C^57.Y%!12+C4E'T
MF[,!BIIMFB8N%4"K" E%RN5,4D4PYQN<<#F*"1%#EV.T9F#+)2C?2)B86F#
MAN-Y2XJDPTJ*0=[<03O*40  -U)WB =[(P(D=2U[BC @I7$BK (2$0PI92%&
MBEJ W4@$J#[Q^$%JZXFW<Z_7D)!P99TX.81 XB!$BXB)&[<@B)4T4P,()IE'
M(H (XF$1'"B5ARL%,&"@)AH211G4JQ4L@ J4I@22*Y,&&,L2-$F(IBQ5;RU$
MJ-V2'#)2"X #E@/$O7%UP+\S"09*FQ4;D>M55VXF-T2H)G#F'.0! ISH<XRB
M FYW-4 !P$!$#;&:@B- BI#)B&%$2A8 WD[R:@*(<!;!*F(<>&-U*Q.ZCPU?
MQ0^\!4@_PG=LHI< J2[I<,#P)&-@)V2;G69PSAPBV3>&^(?+*JD2*5@@;$4N
M<<Q?UNU2@B4"B8>8541+S0$0ZA)PH@3$F4(4M4,;D%*4E1,98;>8 AH23OEV
M#E(!>F.SS"D;R()4E.^2J(2IFAHND$E)!B*9 N0 HD$%\5=X^3,U13CE45E7
MIP:M#('*=,GZ<550,D(@!&Z("<1#$"FY@"& VP0H1[Q2HZ5)3"'>10L$*-?A
M00IB\13"M2'.6-2U_"!#4DJ6=U!200#<J<%F0D%18W %V!FP!&,9 4@#T;=,
MI"!_.4.(X% < S.JH;$P@'\1A'"V-U1XI)_B622<@!4^"4BG+&L!*$,*)2*"
MY)H*<2>BV/39$44#&5$.F5YRRYA'^>8,1+C_ +5,N!"YX !<0VVD104ID_PI
M9*!P&;7=1K6M:VQJ2""'9W!5D :. ^EFX8\HG,H3GB  4PB) P$!YFX38[QS
M'8&6%HM(2=T%R -[1]!2PQK!H=,@2Q:KTSXVX5L'V]WN-M(#]=?JV;8KE\\L
MQH#H.>E"X <XE3;1[1MF%AQ ]LM6O4Z\L:#<WN;_ #POIKY\>NS3YT>CVU\L
M_&8+/2W._M][88EU1_B[L.\/;;L[,PRT,ZLR*/3R?.P;)L[EV)>VI\F;(5%"
MS<=;M8U %V$L % !QR$?8; 7=Z9EC30.1F .6=[,0-FO#Y6KWX68>F=<OE;"
M_7G]<1$]_=[V<'-.7'4'#$.P7+]/E9M'8D.+5PPNO9W\>/4&/'LV6E<V&9J7
MJXN309L-*9$WA?PTTXEM.=\ ]?RZ]8Y6&E+#AF +'2EWH0+Z!P^O#IJX,\0X
M:ZMW:'>.%CDGVU#AO$.,RQR!^$X48Z]<<^1\ ^'Z]FN.7WM3Y'4@Y6M=WH'J
MYXC$]N?6E?TP=@>V(VC::V=G-KD.:V)N:O;#F?FPP:Z[7S%.>7C9L\R;OAUP
MQY,(@41PQ$ QYO'+,,<^O9Y[!E]U_&S5%>='L_$&F+G0TJ 7KJ#[78<KB&8A
M'"0E'^$Y<!_VQ1XY88&*( /: ;K:@Z5.&^%FH/BL[VH12F51EB=<O/GB"T5,
MH0Z*V KMS"DL&6!\OT* &\JI! V8?Q<X! , M8@"2%)?<6RDD4(JQ10"J2"+
MY"SC$!N"SA@1SJ".!UI5P,QB39#\&Z4C3C@F8#.6 CO1,.*S?,/XD%!$Q2XB
M84C .PN6>+^]0F8'\0:'&%*+ ^%>H$1(#T2-]/'&-!W%F$;-O0ZY/\2?^P32
M_P )I:D%X[+3[Q1\KS@CI%,PN *&/0R+=$RB9P#B]23,C@ 8F7*0QS  XVR0
M8:IV$B"EN_@*3W;FBX"U)2H5+GN%J"@Y_@*F!MC#%6F6B&*IQ!B [S"J8B02
M"UOWB0Q/]<!Z%\88FJADY!XJ_P#B56JBA01*5HH=#F-R',=-$3)"0ZH%,83"
M90QA$PB(   4H=KE9&7@0DP>[3%"25DQ4I6ZR %+ ((22* ) I1S4G@(\Y&B
MQ%Q HPZ)2 A10R Y"24E)402[FY>C,!)MZ@DI-!U3KU87P2:7PK!PZ.!W+5V
M*J"[=(CI3%3X=XNW1;K$4.)"<]-8! J1BFU19*7EU0YZ$GNC+J,2,B&"(<2$
M$K0M1AI^'?A(6N(DI2Y8INH$:8<U&C)7)Q28@C (AJ6?C1$)0I"0L@JW8BTA
M*@31PIV20<6OR*I'416(=)1(QB*)*%$BB:A><4Q3E, '*8H@(&*8 $HX@. V
MYV$4J2E:64E27!20H$$.% AP00RGJ&;(#'$1=\*4E8*2E@0H$$%)#@@L0:E)
M%WN,7%=O!O)>KXQPBD;X2(<(R3UQ@/1) V-TK=(3;!4<KE33(F \\2=*J <Q
M$XEV&WIJ%+[.F$+([R9AJEX2+J48@W5J;^K#02HD_"X2DEU#&YV-+KC3L%:0
M=R7B"-$58#=8H#V=2P P+MO*9DDC/\[==1=0.COGL6*+I8PG768.%F?Q!S&Y
MQCJI)&Z$ZAQQ%14$@54$1,<YASMTZ4V[M.2A)A0IC>AI "$QD)B[@ 8!)(WF
M <!.\4I%@!CM$QL>0F5F)$@;L0DE:H:E0MXNY*PDA))-U$;Q-R^+BIZEH"E6
MAF<#&H,4E#%,N<G.4<.3D 0*9RY6,HNN).<;F =0Q4^<8$RD 3!;93D]-[0B
MB+-QUQE)!"$J80T WW(:0$ $A+[H!) *B2 VZEI27DT%$M"3"!8J(<K6<BM:
MB5*(!+;Q8"P -;@MM7UUXZ/2E=?3&XPO/;Z^&7CEOSLTSO;GY4YN&:M<7TM[
M>=?*N5,/ <-@X=8#LZ\?>T<-<,?$LWCSKR(?!CH? >S?+!PVX;0V@&LL_/;9
M\.H>^G&O+S O<NJ!PMP\/?C?+'GGD W1@8O2<WG@GS@Y_,QYO.YN./-YWZ>=
MAACECC:VRU:EZ M3A878<,2YKXG#W[PRX=O$.O'KRW6C@NQ/DXIIK?F6TQ6(
MN!XWJW%VIX5SP_3/'6/L-J7][@'EGXYN+UQ/?+IOF,+PQ#B&SCAOSQ#?]9Y.
M,RS"E6L='KF.(Q?-CQOH^5&.7V>M:^EK7F7X:-[O7EI.NNON=6A"SA0G0YCJ
M]"[6K1QZ!PNK/AH??WLX5TS]^6?JX;%XTUZ'R^6#S ?/CVXAP#<-IIF["K-1
MW\2'L.=,/0CTTY,=3F, 8>>_$!XX9]NRQP;7KSSH'TTJ!I; OZ<#P>G*^'Z8
M:\/>QAFS!S5LZ^E:<CE2>[]>?RPMGJ.'RVYY\=_58*"IL'R KR<UKJY<Z8M_
M8/\ 6U*/;+CA]^M9^]J1QJQI0Z6=K&O-L3PZZI\L+PUL';LQ\[0ULU?9Z'5A
MDVK@B^+Y]7%KMC7.ON53<Y=G.59 U?)50P<T6V=*S\BWH&M7U,-7[>@'MYY(
M$U8LX)6E$Z@>45'.92/BW,TW6>K"UBD!-+/F3%QOY?9DW,HAQ(28:A%_A28\
M!,52?S"9;O.Z5$$4H1&4$*4E!"1O*_FTJ(TE0%*NX%B0#NE3.S!TURK2^+U>
MW\W&QKV>C)*^>Z>-E*42Z>JXR2O&HYC(TNC\?&11E*D8N9E)U!%+*34/&&-*
M)-"ED9:,8B(.7[5)7$F1GEB$M$E-J3&;N5B6C*$4LI1[HIAD1#N(6KX"H;J%
M%MU*B!4@%3J0-V_QI^%W WG+IK3XF.5\2H<HCD_?G):;_?M<U^T9I*/ABT_^
M]&A_SP9B87%M$Q(1(SOY@,I*. ,A',/A_BWZY3)M453@)0O[/VAW?>_D9T0M
MU:^\$I,;FXA]]>^8>[NH%5+W@!=36P*T!3%:'I0K2]J4!S%@-0!EBX8.]JZJ
MIW-5LZ:O-N\J)Y0B1EJX:P5:TS+NJ,0*K)H&5JUO'R;A:FTBKPLRB8\P1F4J
ML3)IF$#L'94=$24FH7=*BRDQ#$P0("HD"*@1OX"!"*D#O2=]#=V5?Q(-E#%!
M!<!0+7 (+$7< EB!=VL=,44;^[DC1T3)LKW+M)=M44?.R=*EA:ZI:7<U@UIE
M-RI/&I!NPEEU:H4B?@W*;].$*^.T6141<@DH0P!K_(3N\M*I.:3W*H:8I7+Q
M4""8K"%WQ6@"$%[PW2LC><*%,3>22!O)=1+?$&+79C5B[M;%2NNO7HZ^&GG%
M44.[>/(=K**PZJKU@XCE@?),8Z24("#@"G,F#649F!0 YHG.<F.*9K:9J6C2
M<3NHZ4I5N[[)4%4*EI)<9;R%"SYVP"@H%B201P#;H4+\"/:^,DVV[Y"X%KG+
MC5L[OD7Q<%@RRX&ML]?$^0)PP6>;4YT:E+YOY"F&%C[Y;\==>';MM'>HR%C?
MD>;:AJ$OBM\J\*]6?E;!AW^N/D'IYV,U:FNF=0_CJ&U)9S@_A[-ZGW],.U=\
M[=?KI3QF#L\/EKPVVA#5%K-1J/\ ,\*WU#GY_7KSMA;,/8,N' <-OUPQL(L*
M'4-P;0MS.C.UK=_F:ZZA[?9VP;MF?AF.WCW[>^P:L[U%\_,"I.;M9\,[T\Z"
MVGA;PP^SZ?7NL=[<[&F>H/(#V(Q.?W^WCA"(  8B  (@ 8CAF(X  8[QV &T
M1RL<#7+6P8%Q8,[V')\-7Z^O1P\!PWX!OP\.K9PRQX;+'%GM3+P;SK2XR#XU
M,;L:US\>B;:WQ+NFK9\V<,GK9!XS>(*MG31V@FX:NFRY#)+MW""Q3HKH+I&,
MDJBJ0R:A#&*<IBB(6B@E25(4$K"@4J2I.\E0+@A0+C=4*,:-J,:H<2)!B0XT
M):X46&M,2%%AK4B)#B((4A<-:"%)6A0"@I)"DJ (((&,24MR?+DJ*GD*GI6[
M&DH6=9F5-'2#6,(8\.9<ITUA@D5S+-H$5$CJ(G_)D6.*)SH#_)&$@\? V1LN
M6B]_ DH$**DD)6E =#C=)A@NF%0E^[":<*8[-M'MOVNVO)'9NTNT.U)N26$B
M++Q9E6[,!)!2)HIW5S;$)4/S*HOQ *_B#XS"10AP$4SE. &$@B0P& #%_B*(
ME$<#%RQ*.8;PMR5FR<6;*PR! ]+Y5'56.F/0%$<\!''@ CA@ [\-V? ,QW[9
M07(<D$UX<7IEE0MSM6S8>1K^FMM+&O3N]]N%J6I?)O,:YAN8#G$Z]_'Y6?$%
M9!%P04W"*2Z8B BFLD14@B Y#S%"F*(AGN$<\NNA2D'>2I:% 'XT$I4 ^2@Q
M OS'$AQ2E0W5!*@<E,I/B"XTO1Q7-H:K-LJT68BD0K5=!5L=)(I4R@BLF9-0
MI"E "EQ(<P!@&0CC;4F(M,1$4$E:(B8@4JIWDJ"DDF]".>I ?&DH2I"H9 "%
M(4@@!ANJ#$, S,3DV-8)BDY> =*H+M5EFP'-\._11,=NNGSL"&$Q ."*HEPZ
M1!00.0P#S>>GS#F] E=I2LZA*T1$(B;O[R"M03$0K.AW2I.86 00:L72.G3$
MC,2RU)4A2D'^"*E)*%APS[N]NJ:I03O#B&)N.!BI+HCR;EJJ6-CDQ=JG<$,F
M#DZ'ZTFR// IE 64 I%#D 2))F.81Y_,(?9S<W "DR\.(E4>.H0PE!![L++*
MB+(<)*$DE*3\2U, -UR-U+2T4I,>(A0AP05E2@0%E*00E+L5;Q "B*)2Y)!8
M&II2"K]=5R[7,JZ7,)SG5'$3".6!/YI2% .:0A>:4A  I2E* !;08"8*$HAH
M"8:0 D#(!W?,DNY)J2"36N,B(IB+4J(K>6IU$J\;9  9!@ *!G:ZZ;?*L91L
MH0?TG."!P$ $.8L)2&, #L,7])L0P$0+S!$2B(#L)^$(LM$&8&^D\4 J;D:B
MK@.[.,;Z65NQ4-_2^$BAN0E[49]7ID,9:^+3=/P(N()(,1*;$X@4B[LY<2\W
MG" B5NF8# .8=(<,Q !MUW<[N$2GXEQ7!9B40@6-G(*U4/ 9/CE+JJP"&+FC
MK-14T^$5%;G5(Q4'!^G.1J0<C%!5<P;D0'(H#EFJ/Z=O\..X<L2!NI5$4+'=
M0-5YDC1(KE5FKC7<A-*U.='9A0U)I3*ML>C& A2E+@ F_20 V8!ECPP*&?#=
MG;0 Y)-A51/$ZZD^-\9+ ,^88:LQMD&H&#94;'DP88!P#W&TO6U:9"G,Y..0
M?!P7!%]0;TT -6)L';+$L;:/:-LHL-6 OK3/.F8X!\:#4GQ/OH_I3/"M0>9I
MJ#PX/J_'PQ+\,&M8VF5,G:E: CCI?D,,_K\\0%?YW9[:[.K;:*>@\*-P%!IJ
M#2U=6)<-H=MJ:O>Q#U #O5BP8:ARV&!?87K'OV;.[YVTI9R]>0;,N/'CD*L'
M&'77IB5W8X=FAV>UK4FH<7&5<JDN#0NUL[XN;/SZ%_GB*GO[O>VJO ^GR/&^
M)B'H+2U[#5GS%[5;W=L.C@T%J!KX>0^^=CAT<&OKMXV@+T^39W:[ WK0WI9U
MQY6TPNSN^H[\^_ULKEY&NK.3F]ZTMQQ>?CYY#*GA[8-F_',/8/KZ!9XO7RRI
MEK1KGS7R:A^9^WN<&[SX=>_W[-EKK=F?B]\SZ'Q8,[/TUX9?+G?#]/';[:R
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M#NJN7Y%M+\K$J#J\>\U6/IV\2!OHGG,O7BJCBLE%W8(0\(D"D&]6<T\=-N!
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M=L=!VO.&(8I3!2\67B!"(:T0DF7A34&&E,-*PE"-V=C;R0P<)W=T!05J$-(
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MC,6!T :U-6R9AKX/?Z_3G\\2ZO\ .QULP^H^6ZVDN"*L&] 'L03K=SD6>K$
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M@QI>.@P@F"40B(DK#,3O$S"UI*D)7"3N[N$PAOJ6%,HJWQ\+L=U:2_Q?%13
MT 8$I4<6W!_AN4% W=/J68UHZ95Z]DKL?]6.)I.+C*Z0I.A^3M0?)EJ2BDGG
MQ[EP$-6MW5/5N=!+X\&=)3]XKJ>C(YW+03=](ZU]HYB),"*J"E4 (FOY$N*M
M4N8T?:4?:<..4E*05P)B) !^$&-#ETPUJ2B(0F=PD!@H@_ "H,[(AB$4N,E)
M"M6*B0Y Q=DSR!Z.EY 5$:\J2G8:17OC5J6#I6/8PK>H25Y5=YM875E66%9V
M#)7D^S5[U<S%!JMFXD=5$[C)IX@U&(:,K8H>WHZ$@&!"B+ D^ZB1E*681EX4
MK!FF##>_:,.2@)F 2"F&E2 3ODG48*34$I;?!"2 5;RE%-1_BRM6Z:N_ D79
M<!R0F%QE=RU>MZBI55Q,/;RWRM+T#==&W741&J7C4IR6:573@J<CJBGDXQ-B
MGR86,LYQ<.59B5K:6<K*-1CT@?89_:RYV"F 8<5DIEDB),32YN.H2\7:<5)B
M150H95O':2D)^%(AH@H WMXM4("+-=19* A(WMP42"6_@!O<G&Y>/7MSQPRP
M\LN_+'K"W#N.&@HX9V;*FM6!.C8R-PM1GJ_K7PJW X=JWL:7?G5CX^F)@XZ\
M>/RRM-0*%\^#9/4&STI3(8:=>6GUKA:'RQR#'$0R^=CZ7N:Y6L'<T:QS .+T
M/5JEF!K],'9Z89^N?9QZK*#.EZAJ\2SU<,]:.YPY^[T]J<]..#;KUQPW#B(;
MNNPDY"Q]P6>V52"U0-0<+/UY,^88'/AA]VLM#ORV6KZ"OD3F![N]1I7$\>J]
M#*M\&M>F_P!;*^5],]:_0M=CAUU[Y>V#6M;[+-R:[\;9VO<Z8===987W]>.N
MS*SS-[/F]/#G2EJ8OZ>VG7.N'K/O^7AG: DGD[TORKD1Y'Q,Z]OKYTP6I'!W
MIQSS+TY^M!AC 4AR4N2W+U4\KJ6Y-7)_E*WD)I6I'U92-S5W+VJWM1.'0OEY
MYY43JFU9AS-K/3"]6E5GAWZKLQG)UQ6$3COD;5VHB$(*=I;01 2@0DP43LRF
M$F'N[HA"$(FXF&$G="0E( #;H&-!APB7,-!4[DE""2;N[5KJ_,XF:@Y,7)OJ
M>KW%XT]R?[D)F\E>08S0WB3%TEWTO7!9V+(U)#S@U1)T\YFE):(%BP-&OE7I
MG#,6+0$%$RMT@)IA[2VA"A"71M">1+I288ED3<PB!N+?>A]T(@0$K=04AMT@
MG>%3C48:"K>*$%3OO%"2ITU?>9W%W!>W#&.N3ER0:+N%I2]F)GIZ1OLJN_VN
M)F\&^VM[QJ?H]-Q>'-S,8TAE(Y_3-/0472[6F&<6R!LSIY.-7:$4?2JZIUCR
M*X!N=H[7C3T647#A)D8>SY=$O)0):)&(ETH)B!28L2(J*8Q6Q5%"@?A2!_""
M-$."E&^ZM\Q%%412@/B)+%Q8)R .3O?&5[J^3W<-<8>:4N7N7NLNG5J-1(\^
MK=U0-,4:K,] 911N236I^,8*/46JBJQVJ"YE$&IUE1032%503;6;VC/SVX)R
M=FIONB>[$Q'BQA#?^(I[U:@"IF4150 2;!M:8:$ [J4H<5W0D.QH" !3@>)&
MF+E=75W7OW5=OWMV] O'MZ48QA+SGCNCJ=<NKQH6,CG$3&Q%=N%HXZM81<=%
M.W48Q85">1:-(YRY9-T4VRZJ1L:9J92("4S,PE,JHJE4ICQ=V64HA:ER_P 0
M$%2E@*4J'NDJ2"3O $4I'Q.D?%_$X#J:@WZ'>8. %.PX7NB#@H2F(2)INFX>
M+IVG8",90T% P4<TB86$B(ULFSC8J(BX]%NQC8V/9HI-&+!DW0:M&R2:#=%-
M),I PKB+BK7$B1%Q(L12EQ(BUF)%7$42I2U+45*4I1)*E%U$J)-7P#!@   P
M H PL&LU!GBJ:W]^&.P-FP1#=;3R?UNSLQL+9M<4+'%ZR\':YO< YX>RP\J/
MD'.==+MJ<SB7^^%KVRX>?"RX\F/.E'-#H:T9GQ>OG77TUP=VS9EKM^H#:TJ#
M0 B[ ?IY::X>-[UZY?8C#V6A\P[G-[T87(H*T'A@YI5OEY8DI%I\<S7:@(%%
M0H<PPXX H0Q5$Q'#:7GE #=6. #LMF@1>ZBHBLX2HN!5TD,6J'^$FU=YA9\8
MXB!$AJ03_$ W @N'TJ-#0Y'&/TVZ[4YDUTSI*E$<0,& CD <XA@R,&..!B")
M1#8.=N:7$1%3O0U!22 Q'/,7!X'''I2I,1(6""3F+ZMD1RIB[8U=9%(BZQ!
M"B)$C& 0$YQ 1 PERQ*4,3"8, $0  Q$<0XV,I*E%#NX=6Z:@4#$LWQ&G*MP
M,;V&#0D-D 7&O,VKQ.*Z@NHH'/%4YA$0$! 1 ,>!<-FW< 8#EA;"4I + ,.#
MAB:T-2&)-<94O<\.#%J]:OBNIJXD*)Q_FXXAWCF&WCG;:J2RBQUIF18UU\*Y
M.V-8.M X#\K.#<"C^M2,(<Q'#/,;:A84J '<VHU+L6RI>N(;DZGI^O/"UO\
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MQ.RB::;A3Q)LL2\EM\)K8J@A2I*%#4B$%J0DS^[$C?EI])A*)CJ*80CID%?
MI*G5%/>%&^E,*5AV63<#^ ,*,1\-2&5>A!%"6Q2G%*<O2!.1L6N:YKBG%W G
MFG$6KR;XN\I!&)J&^B&IY*B7$Q2T%0:034(2X>J;Q!JUF[,LT"M24D,;.+#2
MQ\B8VP8CDP($O$#A&^-I+E5;Z)1<3OQ#BQ(ZMV)^?ARPA*2 3"[XK1^]&DB,
MG^D5!A8($1W6Q&\ EFW#R!:M#9U$TO\ B 7?1[F;E@O"O-JVI$Z)GJLAUZVN
M'+3*,Q)<DF+HF;C*52DEX ]/K4ERF(@:IJIJR,G2S^CU8N8HX*LG7-6PTAFC
M1=@3*PE"I>5@PN^APEB!M#O5(3M9<>&J-NIB"((VS%]W")!BIC[R(O<P^Y4D
M>]2[ J*B#=  )A@,'W2D"(+/:M7Q69ND/Q&DH"-D8.\9[^T<G6<PC(0HP]R$
MQ'TW!LHF%)0KTR3Y2E@?4>_F7%5O+S@:U-)UXJW;TFRHR&;HH3!GFB%&[.%:
MD198=TF!#4F)OSR%1(BEK,PET][N14H3"$J3"3 <Q51XA)04Q0CNZ5!]Y0(W
M4,D,-TL=UP"Y4YWF8 &KWY7MV/*!D.6) 5Q3;*I?W6HREV3EU,-ZE8,*?;0D
M+%5@TK>*>)!?''RZ OU9&)6-")7$5BQJAVDS2<U93)$S3$+MY::V>-CQ8$14
M,311,)2@PE*BF(M4$P%@_DU(9&ZMEF>@JA#>(A1"R(FM6\5H;>*003\0"0!O
M;P(W@YJ&^"M-:25X,=RZ5E+S2T5(5.U4/7#I6'=-%K@Y")7NV/6CM2EF=RD-
M-A S#6MFM!FBVMYKF_"IXR'6G$IY2@3O2.H=S'ZY9>POY+WZ(1: -\$;12L3
M7<#O53JX?>(,!4<K,J)&$M?=]WW^[\8.E7>_%NO< ?S;%+_T =T[S .5D"[5
M(Q</)SNNY1%.7N2E;WT.D)(9BFI\LW+1DE'H0LC5LM=AR,X==Y&THSF9+\D:
M.JPNRO?4:LTBF;QA07534(UGF*K_  [0FMGQ)5$&224!$6'N(4A:E)A(FMM+
M 5&4A&^4P9J4!4JI< N8:FUH"V=;/NN;!U$0P2 Y8.E98$BM,L;Y]8ZVZ]QM
MPN=??BX-3\G!M08U<!U;KY#"UKSW9[Q"P4]+D\A>Q;A4W;.]=>F=,@<'CLZO
MIGV8!Y65^O&@M4,=+9DBV'E?C]Z<W/KAV>]=#3A:EAE5G>YF#67SR^?"S)O;
M+VMX$M3#JOTK]-<&'RQWX6CL0+FSYZMF:#5AF37!_JV3X0@ Y#GLW /8.&'G
MZ65>]: T\BU=2]J5HV+[5Y=6]+XDWR(JI 8@")DS ?  S$,! >O$,0'L 0PM
MK00E5@ H-6[AF]!:C9YXARX'ZVQ+M3F(!0*(@(ALW#VAMV8[-@8VR*=C_I#+
M)L]:ZX8N)!<ATP*/Z3\W9CB XX@& [^S;VAG;"2Y+Z@VI737AQL[8K'U;R^7
M'SQ[MC9G.0+4HQXWH" '%2]SB8\FQYH]GWW^7K8!<%P7KH3858L7-ZZ\F(-M
M8K6M6ULV=[5TKS<L>@S*;N\L1M"02"[,[9>)J*<.!!+_  X8\VHIEFU<KAGJ
MY#L]'L^&/!]@=OL-J!G6E*^3CGJ+O7@Q! ,.&[6_=L];1K,UM#2E\\@S'D^*
M2^N?66=_;$5/?W>]J+D\O1_;1OH)B%Y?;:/#OPM' U'S+,7RI<U%03B^OZV&
MO@^&&L\=:Z[6PL3;CY?H!RJT/5&ZZX87GW?7 ,<N 9#W2W'PK84=V&1R?2M+
MZ>/V<M74U'B /#?V;.(Y]7;U969.SU<:\"?+1VHQK@1KESOH*<>7&N'[>EJ]
M- U7K1O7B+WX8GS]WP:UWV>3^5ZG/,@GHX==>&#9KC82VEP[\>KZ^)"_6F)5
MQGAF&P?;;G].W.VI-QS'ASOSR^>&G3\L02MDW*)>E 0$#' IBCS38<X=^8#@
M..&(#A;65*0LD'2EQ8=:8$ W#X\MXIHV."A2F.<N93*B!A(/$H% I0,&XPE$
MP9<T0L7'B1 4J+)-PD$;PIQ*B*U#U/EC0(:$G>9U N":MK3CBI6Q Y6:FFN6
ME*>.F->#A[?7Q[O%POD:7\R3G4\#AK\_MY>/D:^0]EH_(Z@%Z:L]!P#NXOAU
M]1SPOGV??OW9VM!K<O?K@!R:K/?IS_3PSIAZ#/UT-E*FE];Y!]*TS\\3HT]N
MAA!ZXY;\\]W?K,9DS\1J;$Z \2+O6Q>GVSY4S\.J $<@ZQ#6_;N[0V;0'QJ1
M]N%<LW(J*$ *G@#UE;/D;V//.\^]'EGQ]X-7P=W=$1J\2@O4+2G!?W53DU!,
M8Y)S=TWHRJ'%=M;Q(ME5BTZE+U[(3E)QT1!2$(2!0C7;N,%FVF*O[!+2FQE2
M\&+,1EA9$(Q.[FT(6HJ_,F/"$ RRE0A#*( 1&4N(E9B%02O>W(.(F(%*  9E
M,"FR@!NDJ"P[E1^&A#$$AG-$2F>60-XDFA5?YS(4^O(71T[!MJ5H22I^FY-M
M2O+-J"G[Q*V6E(ZJY&3I5U+<G52DJN?1DI*KPM41[QX2.0<QT'-0ZFHHV/\
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MK3ZTA#4#>.FY<#2]&59-0$I-,JI4I5.ED6L]&1#%]%3:D1+S$?@YI.*J]:H
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M%K#6.>'7GZ+MK6[:L;/5J>-M+T_34?A3W!ZPQZLO>TM8/H&8V.9/,FY#EQ7
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M:IXJ?IKX^?HPP[!0!V]N0;EQ\\3!9ZFU.J49W+8=5PL,L/,,L.(ZSSM*&GR
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M.)I]O/3DTG'M=OLZ0C1H2%2\^J57.)FTK@0C$AQ(DM*PPN,%D+A0XH65I2B
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M4S2TS$)(B=QW,2"I,PJ-<0DPW(6L_P":H@,0HI*2!+%KMK*QE2H-FDS S\3
MR$F$;.QX,9 B)&BQFT@BB)W"*[<JX)E$>>/-4P*JF!3%$^0[*B0(TBI<26FY
M.9G(, QY2.8L$J,5(7!4I*4+0LH*LA1RE14"VE.T$1H4TE,./+3,&6BQA!F8
M7=Q=T0U%$5*=Y:5(WF'\1^*A2 <6?"574#M_=$DXDE%$ZBC:@7FBBBV#XY5H
MV,HV.<2H *?1& ! &XI%',# (8VY&9V?)PX7:-2( "I*-)HE3OQ#W28L4)B
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M*+@JW; *W@+:8N!NW0:()-FJ"39L@0J2"""9$D44RA@4B:28%(0A0P "D
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FNJ>X?!T8]7G\K4Y<;4M0OZ='#$1-,<\PW>_58//*S6)&O7LQ_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g96328g27d13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g27d13.jpg
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M5'62TC(X07<W471V)7$Y0F%B<GB!E;&V\/_$ !T! 0 " P$! 0$
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M],_ T['T[L6."WE4^N_4TB%B*V=7!AT'<M@5,#YR@D)=9.^NA\2,G:&*]+K
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MY0N NP2" UTJJ<Q&;2MKT*O'&G!G"R76I02W,>FSZA!#<K#ITT&K7;WL\5W
M!S)[D0O&D:NW+"N$VYR#7()-Y<E8BJF18V*DR*T2!%92<!5R"3CKD9!%6"\&
MN&UYL7M!UL':@M=8VEIKP?G@QM=:D>OM&+0+)2T]G>P)D 5V-$'V$0]*#2K"
MQ2=<(DV4?"E.3!,JT8@EV84IIMA?.XG>YMM*U-[V&6TON(N*;F\%M<(T4_J7
MIT<J6Q:-PLBQF>Z*Q,R@.(MR$@DU);;7EBV%62WM43<O4<V0@L ?#P3) )P3
MUQ@9^BOGS>NC3BE.*4XI3BE.*4XI3BE5U](D?IWOZ5?_ '<4IZ1(_3O?TJ_^
M[BE/2)'Z=[^E7_W<4IZ1(_3O?TJ_^[BE/2)'Z=[^E7_W<4IZ1(_3O?TJ_P#N
MXI3TB1^G>_I5_P#=Q2GI$C].]_2K_P"[BE/2)'Z=[^E7_P!W%*>D2/T[W]*O
M_NXI3TB1^G>_I5_]W%*>D2/T[W]*O_NXI3TB1^G>_I5_]W%*>D2/T[W]*O\
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MAKTMT?'DRI4AF$X\J,T_)D/-MI<><4IO?:$WML#%PFX[0Y !<+G 8A0"V,D
M#. *8&<X&2,$XZX]'Z.IZ?+6IL:KUA%",UF-KBA1ZW'-MV5BOL4^O,A&+&T[
MAYH^R);')@-FVWL8=;*HCIG(=QAQ+^%X\?)C=W1<RFYN#(8^49#-(7,7O9<M
MN,?^QG;\E8VKC&U<9SC QGTXQX_+XUR/ZOUI*0/;E:[HTEL0.+"!3;]2 /(&
M"3^5J.BQZ'!ZDPAQI3B\EH4;#48EE:\S&GLJSXPNKH%B+FX!=D=R)I 7>/\
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MDR?3).21&##8F3LR)G^M/YE/.Y=D_P"G<\IW_/YE[B>1%CDFEDC3&Q'D=T3
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M$'#8$5K'C=DS9TQUF+%CMX_.X\^ZVVC'YU*QCFK,J*6=E55&69B%4 >)).
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M;_:7.*5C.*4XI3BE.*4XI3BE.*4XI55N\7_E"[%?^U5J_L*N<[5__P 9??\
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MX;<ITZ^%DFH]FD:Q=F3M,8$D4<BL4,<[1ENSR$C*).(VD4AT#(P8XYB;S'N
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MP\  .E69YR:EJJW>+_RA=BO_ &JM7]A5SG:O_P#C+[_PTO\ \37T?R0?]I_
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M]JMY;02BZLT$KP-;7FXA)'12+:5@7R /="O<$@1 ;SNF"D(VQF&QS@-N3'4
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MJPJ92Y>:0VV5E$:FV#I+$YN%'+&5N_E0%6:*($,P9BTD8+=,84;_  R=Y!#
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MF\J5O5BV/XAG^:;_ *B>*5\Z?^5"_P#Z-,5__,KJS_\ UK8W/I7DJ_ZSR?\
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M20CO*IW ?K_X@%@/ ,?&LMV _P#@GM#_ .S37]E5SXWY;_\ LC\H?_I;5/\
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M/G)QD= ,GY!U&=\'%X(KJYX..ML3:.'3L7>A$;B';]^7(;$5;)N'V\8GB:9
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MI2HTIMUKRU^1Y6>'*G*DDC+H_+=DWQ,'C?:2-T;CHR-C*L/$$' J8'(!P1D
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MTXA:<9QZWR111S0\2131I+%)ZF))'(JO'(C+J(9'1@596!P5(((Z$56U4D-
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M4@6V@LK86EM$KO*PB[1<73&65^])(TUS,Q8*BJI5$154"MXTV;B6W,[;V.
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M= ,*B*H")&@ 5$10J@8 KNQQI$@2-0JCP ^4Y))/4DGJ2>IJ).^7_DW['_\
MM79?[.GGJ?)O_P!>^%?_ #BU_P#D:X7%?_5S6?\ P,W_  %?$;S] J_F>G%*
M<4IQ2G%*<4IQ2OZGR?*QY6<X3X\>5E.,*5A/C_/G"<J3A6<8_/C&5)QG/YLJ
MQ_MX.<''CYLG S\IP<?IP?T4KT>1X1#8XK?%:.UVT[3A]7JN_2J?&ZYO7DJS
M4B.EZK6 U#(U$A5HI/%1R4LE3'3)!%_T-V-FRDWRJW'GL>?5\S/DWTR70+F"
MYM=*?BJZ6^O6XD%E&;N/6KN[FU"*[CNFC[6(K:[E1(AN#"VB6( #NUZOUTW:
M:E#)#/>KH\)M[==*-S(('T^"&.V:!X0Y@+S0(Q=MI!F<R=3UK2Z1V'TI5H77
M&42JEX/DNO6P+I,BUZ>/J,JO6>DVVVRK+"*OD9\V7Z!=JPM]B1 $RJN<K9 I
M C/3)[<13L55Z^X<UV[DXE2*\L+>+B/3K!'N8Y+Q+FUOK.S6UDA6*.-.98W8
M5EDF2Z@N8XI&5(RX#BO;:II\*Z4SP7$KZ7=3L(F6!HIK>:<S+(6=FV7$.04C
M:&6)G4%G"DK6\2>Z=2 HHV1'RU;<+5W<YG9%RM>[K4.<-7ZMVZ@3->VNK16A
MTBPNTM;E>G2H(V3ZWMN$S)<DVM;#:8H%B@O!%[<'4.=ZAZ/#<Z)!IEC::':2
M"#3[FRU!-1M+IS*EN+T=IC5Y5Y-H=B+  QW7#63Q!!'V8IZH7TD6H27=Q/J$
MR<RZAN+8VL\*A#*;?,3,J'F3C<S2=!B(0,!V!U]U?LS2UUUF"VH=30-O539-
MH+WM^M#"TH!6+"$,1:37P-?FD!"Y#21\YR7:R11ETQ+DP6F -=BPY."'H9].
MXBU72];L=4N-)@]4-'N],M(;!;J6)+BZMYX6OKFXN$CF"GF1A;2*$B%5D+3W
M#.O+YD5UI=G=Z?<6D5[)V:^ANYI+DQ)(T4,L<BV\443-'D!&+3NX,C,H$4*J
M=^3B[@TO>J6$INYPFRV6:!L+8-PID_73M97(/UK8TX.6,T.RIL3S#8!Z(7#*
MG"+F*38'(:3Q6-,JI1,4<XW"VBZYI][/>Z)/I;-J&FZ;97L>I"Z"V]UID<T,
M-_:FV5C<*\,VR:RF[.',$3)=1%Y0=UOK"YMX[?4([L"UN;J>W:U,.98KMHWD
MMIA*0(BKQ[H[A.:5YL@:!]J$;UKSM?7ANN FM3-E[%:D"42[W6R4]KK[L)P<
MT9J5VGPBTB@6MLN7#I;F@2,.0L!L1.#TYN,:(QBE4)^CPG$4-2X1N9=2GU."
MUX;UBXO[&QMKQN(M.$A@O+&-X5U"T,,$^8YXG7M&FYMXR\,;17<6Z0&S:ZU$
MMK':23:K8Q6UQ<2VXTNZVB2"X97-K.)'CPT3J3%=>VMB1P\#X4UEGK+HRS=6
MZ?,VJK:43!7M[V:M@F/3#]=M=HB#2NO^M,B0*M+URP/F%)!SQ-QHNP'96'HQ
M .6F2JQ9'9[C N!;77K7BR\32?4IS%P;PQ:3->V]S:6CR1:CQ,JRVBV7,2);
M?W3:>$*M%-$BW5L(PTNYFTZ;18&O.V+OU[5YT6WEBGF5'M-()28W 5G,F-JW
M1;(>.1FAF+%4T:U=DJ5M.L]FQ=["6BL3]N;'UKM#7C-09$V$97Y.J*?MBF56
MBV5\T3 3%!5!]A"(LNTCFII-.0#\G%??<G8:9OVG#%]I-UPM-I\]I=)H^F:G
MI6I&\,UO)<+J]YI5[=W]JL$5P@F$VGS,EI*8XCVA5[0HC):O-JUO>PZPES'/
M"]]=V=Y:" 1RI$;&"^MX;:<R/$QCY5VBM.@9\Q%N42V!4RI.UEBU5I^ZQBLV
MG,GA#UJA@EL-FYE<:GQUFH@AV4ZS&9)R1R9+$%Z0ZAEF2XVZYGR$9QGV%X+I
MK2Z6Q:%+UK>9;1[@,8$N3&P@>8(&=HDD*LZJ"S*"!@G-<2 PB>$W =K<2QF=
M8B!(T08&18RQ #LF0I)P"03X5O.X=KS-Q;AM^U3@J*TU9;'@A$JS;K[0P-5A
MV(XZLTJ$Y$7&DL!JY5AXJKC\QG6'V1P]CS3C;J<+Q0T72$T71;/28)F+6UL8
MWNR%:6:[EW2W5\X<,K37%W)+=2;PRM)(VX$'%6;^]:_OY[V1% FEW+#DA(X4
MPD-NI4J1'# B0I@@A$&"#UJ:V]M=?=>P=FG=*57:<&X[0HEHUW#KMX)5R=4-
M65V_,('W) FPC5KL.QI:J\X2K-<DF@].4-BDU%RB3A.&UAWAG1^(M1?2[?7+
MO29+/2M0M-2>YL(KE+S5;G3V,EGSK:0"VTU!<".ZN%@FO!(\0BBY$3M5_MVE
MVJWDFGPWBSWEM-:K%<O$T%E%<@+/RY4)ENV,6^&(R1P; _,?F.HS_5]E:ZK8
M.+C[.FL1/F<HZU>B>>@^D^T2>L2=$YL7E>=\UZER;QZ[\SY7IWJK_1>:]+_T
M?,CAFY&G=C[3!O\ 7H>)M^)-O9CQ1ZO=FQMSS^1[1G_+YO7=LZUGU7B[6;CE
M2;3H(TC;E<\T:*-,YOCCE\P<W'NMG3&[I4W]/MK5XD;T_578A!DOIG6'9G+4
M2.=J @Q?"^TXRAPJN41J\-SJ06.HA%Y;TVO7T0:KQL1#,1O9ZP3,P1,S@\9Z
M3<Q0:S=AXC#K6J\+@NUO>30Z?#I3<R:YOS8&.^AMR\2!+G3YH;F"9X6[3;)S
M)H^CH5["\EA"0PDT^SU?"B6WC>YDO1LCBMNT[K:23;(Q>*ZCDBDC60<J9ML;
M:1W4"LN!M;6T@3LE3/+E66IQ-#VIG2T"31ZN,P--QK37Z_HD#1ZC6:_9S9XP
MP_$GZYJ) L:'3BL:38D+FR!][@><B?4[.**VN[<);7;Z_:'7'6_NY>; UK<W
M&OW%]>75Q:P6\+*\>I7D4,,B0LMN0BR5^((P8[.=GE@DS- NFS#3T-M"FR19
MHHM-BMH(HII)9 RM:0.\B,X:4%BE >?0Z\Q3BE.*59#7&I:?:]?M'S,^RM6(
MV_OB("0,>%LA1J],:?"[3:E%F94&5.)I./D55]R%#DBLQ&GDF$SW5C\B2OF=
M3UB]L]1-O!':M;0+H+W!E$IGE&M:S/I12%DD2.(P+&+@.ZS;RIA,8$G.BZUK
M9036HED:82R'4Q&$*"-#I]A'>AG#(S/S"YB*J4P#S-V4V28RUZEB40,)M4*R
MPK5+]:ATHKSPX&\Q*7(SF1B/(9&W O-E1UK:3&>C^KVO/H=4VIUA:DIS)::R
M]_/+:26KVB<J8FY$TP9 @QN4R6<2(P!+!N8=I&0&QFM)K(6T:3+*LS;X\1%8
MR&).<%4G=F!Q@KL&02"14V6VIQ:K;>SA>IZU!&++6=Y4RI5FGS*>BPB0U&MT
MW:#AIT93G8[T=IETO7*+5!Y=,53@=NQH@AI,$R7%S6>%9WC7=EPO#>:K<06M
MSH5_=W5ZEZ;:::_LUTL0++>A@Q98;F^NY(2V)C;;YEDABE1NA/"L,^KR06D4
MDT.HV\$4#0"6..WG:\,A6W*D &2*V@63;[6)@D9622-A5+?@*KU'9NZ*R!;4
M[3*S>=A@P[#$U4U:JT&/%X$&.R16ZM4U6!D9IIN>I]696<8DY=SYSR^>GTJY
MGN^'].N[T$W-SH]I<7?=$9:::SCDF.P!1&6=F.P ;"=N!BN9<Q+#JL\%L0J1
M:A+%;DG>%5+EDB);O;P %RW7<!GKFONOU6^#E:PUQ)K$*6-K4BA4]^O#I[OG
MYT &[7AS@F%,?R](R]+BP%1V)#OGW_./-K7YYSRO+5^=%X)!=W0E8-*+F<2,
MHPK2"5@[*,# +9(&!@'P%?U,F-B8Z#:N!\F!BM]Y6K:G%*<4IQ2G%*<4IQ2G
M%*U M-/Q=D:"9#40;<(!#:9F%:3D\6HA)UD 3I/<$YJ]AY6,XP%)2K'"K^O%
ME%84EP5?B8CQ>453G%RU6,PZ@7N&A9;-6AC5]HNI.W62FW<?]XJQ-)<[/]=N
MC_B5HV=T>%!!<Y.,[1RW.X'S$D!<^AB//5O^4ZWIQ2G%*<4IQ2G%*K?Q2G%*
M<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2K%L?Q#/\TW_ %$\4KEXI3BE
M.*4XI4!&O]\%?^8S?[2YQ2L9Q2G%*<4IQ2G%*KEMOJ;H/?&T-/;<V_0!>P+3
MH=JW9UE%LB?6-:!%+G(JL@E8'ZV_A0LN<@KIXK(*469F,A7LOD(,9LHF%/A]
M2RUK4M.L[ZRL;E[:'4N0+MHN[+(D F"1"4=](V$[\P(5,@PC$IN5HGACD='=
M0QCSM!Z@$XR<>!/08SG'B.O6K&\Y=2TXI52>^7_DW['_ /M79?[.GGMO)O\
M]>^%?_.+7_Y&O/\ %?\ U<UG_P #-_P%?$;S] J_F>G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2NVU/G,-H:8FRV6
MF\S,H::D/-MHR0C)A3\H0A>$IS.AH1$F9QC&9,9"6'O+:3A&-#'&Q+,B,QV
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M>FM>[:H-LUK<PGI55NH66 /1H,J0,F/#9J<(D-QY\-;<F(ZI./$EYA:7$?\
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M]PS^2W'TR?\ FI^14Z"?5]<_B;<?Q'CV;O*#\(V7U79?=4]C[AG\EN/ID_\
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M -GQ2GJTC_P$W]5?_9\4IZM(_P# 3?U5_P#9\4IZM(_\!-_57_V?%*>K2/\
MP$W]5?\ V?%*>K2/_ 3?U5_]GQ2GJTC_ ,!-_57_ -GQ2GJTC_P$W]5?_9\4
MIZM(_P# 3?U5_P#9\4IZM(_\!-_57_V?%*G]G&<,M8SC.,X:;QG&?S9QG",>
M/&<?^F<<4KDXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*5@QED#&"EC##YK<@G5)\(:>B)\>'8,HB(@'(27
M,9_VID#B49Y"\>-.59=;_P#&TO&.99:QIVH7VL:;:7*2WN@W5M9ZK;@]^UGO
M-/M-4ME<?Z9K.]@D1AT)+K[I& NW.G7EI;:?>7$+1VVJP37%C*?<SQ6]W/8S
M%3YC'<VTJ,IZ@;6\&%9SG3JE3BE.*4XI3BE.*4XI74GSH@R#-)3WT1H(^)(G
M3)+F?);CQ(C*WY#[F?\ T0TRVMQ>?_1*<YY!=7,%E:W-Y=2K#:VD$US<S.<)
M#!!&TLTKGS+'&C.Q\P!J6"&6YFAMX$:6>XECAAC49:265PD:*/.SNP4#TD5P
MART \(%G!;Z90PR.@EATE/\ X9$ C&:F0WT__NO1WFW,?_L5CD6G7]KJNGV.
MIV,HGLM2L[:_LYE]S-:WD*7%O*/DDBD1Q\AK>[M9[&[NK*Z0Q7-G<36MQ&?&
M.>WD:&5#\J2(RGY161Y<JO3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5P(DQG)#T
M1M]E<J,VP[(CI<0IYAN3EW$=;K>,Y6VE_+#WFE+QC#GFG/)\?DY\42SPO+)
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MDR2:->I--$L898WD599)(;=952XEMD9.=*F6GEAE6"(%I)FCD$2R<MR,"9,
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MULP8<:*AIE%"2*5Y'9+:2)&=F6-4E98U+$JBL^YV" A079F(&6).36X(  +
MD 9)(R?E.,#KX] !Z*RWMU2/IC5?>$1]\YIR)_>9?FW^RLY'I'[17B#X3&U5
M>7X0KP*LJ)9 ,J,/["[U=GR(Y@>\Q":<H-,2VY+>;D*;C-N*2I*%O*0E2DYP
MG.<XSSW?#$4HX:XX!CD!;3].V@HP+8N9\X!&3C(SCPJC<D=HLNH_S'\_R+7M
M][=4CZ8U7WA$??.>$Y$_O,OS;_95[(](_:*>W5(^F-5]X1'WSCD3^\R_-O\
M93(](_:*>W5(^F-5]X1'WSCD3^\R_-O]E,CTC]HI[=4CZ8U7WA$??..1/[S+
M\V_V4R/2/VBGMU2/IC5?>$1]\XY$_O,OS;_93(](_:*>W5(^F-5]X1'WSCD3
M^\R_-O\ 93(](_:*\0?!LVJKQ/"0^&QERK(!C12&Z^M3D"3(,#V8\U#.N+VA
MU<1YR0EN2AI:DI<4RI>$*4E*LXSG&.>[XFBE/#/ P$<A*V.J;@$8E<W5OC<
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MZC6RZG!;>PWYL:U3\MW&R;!F6#-M9MD9H!*W$IFNVO;FUDDE?<DJPW,44-S
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M*ZE].NOO:<F+WJ/]Q?LI\S[J3]EOKI\$M:?NSQZLZQ\*ZE].NOO:<F+WJ/\
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MC_<7[*KGIOIKKLGNQGL?<.NVIM/NZ[(G@_7?656H6O0Y:K1EJD!B>YMA%Z;
MS$*;)N<%+[5-"1B9 5J^BSL--NKN]GM*Q?2O=:N4L3IL.I7EZ+E8WU*ZEN+E
MTE(PZV-ND[96U@;!FD**]W<+DCD0P[XTA4R<QHT0J2(U"KTZX+L5Z%F_%&2$
M7_:+8DLIIT_V2V.4+]AJ?"8T/KBQD1VJ]$61(6Q"]EV(1(?'N;RV\,8>*@3
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MYN1[0@JW#M!JDP8RSET@U^OO0RTFX-&N2\L0EM#+'<75K%&+@%[J:S ,XML
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MA,V8P\/>L0BO,W -YZRT5RSUJ-(+M=";39X8&G+P.(^1SXHI0\MMVE"\'.4
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M2^I[!6]7#*X!H58[);SU#1B.OS=9I53ND4[2@U!JYVRS[W;[N/+U<;=9$N+
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M//"RG6Y#/,TN&VDU:VMI8TO+::Z6V/,,\0>.23EB9>1-%(CA2'13(R!L!UD
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MAQ<*1E-W5-+ETJ40S,[/S)HR6MKB!&,+!&:&29$6>,MG#QY&,'P85I%*)02
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M':-.U-!'=QJT$40[:8C(L0BMEC,K+(BQ!,##Q.J%4QGEQK'M![LD9)0G<3W
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M9DQ_63HU]V.J,F0VEN-=21=4T[4#$Q6Q]1]T6\;I/4RWM(7PVW"\XVQ9<@[
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MEGI,ETQ=9&':+.UEGEC 1>]B1W(;<&DR0%4A!E&D*.3M9@TH3 (SM=PH/7Y
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MVN=ZL])L$:3)CQY,E@JY+:D2&&7WDK=:;6FMVZ]*0Q]LNN7;$-;ISY=D# $
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M>O1><G*23CW"IL5TQMVQ7O;=_"0T,[$(,28#89CMWNMV86,6EU,\L":PEO<
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MQN)+F:5?:NW20O=S+&HNI'861U/=<@K;L&Y<[RQK.65)'B(QO&C)&ZA5!Z[
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MPIP>>!Y^E:I!::?-;DP12M-<23&=+^07=O+:QPQVZQV5S!#*\+K,RQWX-O\
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FI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g96328g52t94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g52t94.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[26(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )6R^E8 X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   ( !P X
M0DE-!"4      !#_^'[:(TV'88>P:G+N>BY<.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0&D            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  @.__C4  @ ".$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              Q@   B(
M 0                         !              (B    Q@
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    Q@    !29VAT
M;&]N9P   B(    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M    5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   ,8     4F=H=&QO;F<   (B     W5R
M;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53
M;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /
M15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N
M9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO
M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M C_P        .$))3001       ! 0 X0DE-!!0       0    $.$))300,
M     !M-     0   *     Z   !X   ;,   !LQ !@  ?_8_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(               $  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( %\!!@,!$0 "$0$#$0'_Q  ?    !04! 0
M        " D*"P(#! 8' 07_Q !!$  !! $# P,"! ,%!@0'   " 0,$!08'
M"!$ $B$)$S$*0105(E%A<8$6(S*1\!<80J&QT20F,U<9)RE#8L+Q_\0 ' $
M 00# 0                ($!08! P<(_\0 0Q$  @$"!0($ P4&!0($!P
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M7\;WX]1)C$AG9M-Q# ??;,FW5WPXM\JRLWN55KBXK+YZJU2C'PUW<*%IJ5*
M [DR XY U)IYF?(*@!4L$) @J6$*2)("%H!(.Q([3AT]&=1UILD7GD>>?L7E
M4517[^4\_MXYX5>.N3("% 80P^;Z]\2JL& 93(/&,CI6%8'1@P.C!CYEM8QZ
MN&_-ER&(L6,P])DR9#B,L1XT<%>D2'G2_2VRRR!N.&1"( )&2]HJJ:ZBW%0+
M3M5UUZCHB)W.I@(  )D\"!R<)9TIJ7J$!%$DGC;?OZ<^P$X9K[E/J;M4L/UY
MU,Q';WHYI9F6D>*91+QO%,PS"=E+=SE;=210['(!8J9S,-NHG682RITX$RA
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M:<9I68$MFRS9V(X3@27FGZZI_%,JVW+E@A=O4NGOAN]XE.ZSLU*=.IM3LZ(
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M_P"<976<9P.C!CYEE:1*J-*FSY,>)#AL.29,F4\W'CQHS+:N/R9#[I"VRPP
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MFO;7!-.G6K5(:DRTJAITRS EU>H$2G)U*6T@A.(RXM42F[@005X$@:G$D;[
M RPXC>"8&&76(9OD^!9'B^H&%6TBFRS![ZGS#%+VN>..]!MZ>4U/KW0<9(25
M%)IM700B!UATV7 ,#,5[A<4J=[95+>X5:])AJ!(\C*W%,C>009$=C$[G$-38
MI4*OMJD$$0>>>#N#(&W:>1B2KT!]2/1[4#9KMYW/Y]>Q,;'5NB"MLXC2FX</
M/:!N3 S.K_#M][K3<.WKIA-]P(*,.QE[O[T%+RUF?2%RN<WV7TJ;5#:Z:B5
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M+-II0*!-R:R!>O4T*2R;:=CC,AJM1]EQ/_49,"\JO*^L>G:!M,BRVT;8T*-
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M#*!R.X&W;8?KM]<3V*NE8,#HP8'1@Q0X"."0J2HA)PO''[_Q14YZQ&X/I/\
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M%)9QW.<-G5H/D/<7MOSD@R4:4N>TCC=W;PI_JYZH-;X3W08^#FE/3,Q4HAF
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M>3T:;5@U)ZES<5''AM*AEI4EIC45@L'J5 =U@B2=]&P--I9AR#"[_J6 .W:
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M$X3G[>/WZVB!L(V''H,8Q[UG!@=&# Y3]T\_'\>B1Z^WY^F# Z,&/.4_=/\
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HZ>24JZ+<5;JM=5?%N;BN!XE5P#$ &% )F/-R=]]C#]5W$[@=&#'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g96328g53o82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g53o82.jpg
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M 0$!              $#! 4&!P(("?_$ %$1  $$ @ $ P0%!@@*"@,! 0$
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MPU:-F&U/._7PL A=((FN/0RR\K&C?4NTTV,=.Q(\-\-[!YND:YK6CUZ@;/\
MFCJ?NZKW4AO@5_#5! :[ $<2.UNS :^&"N]!H?8>S\YMAF6)&QH#M@*JI'0
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MPRS>FVZI*QA>TNLRNYO!DY?"+)'EK'NC<PL'.'^BO\][QI^U?YS_ (S\\_\
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MPSQCBY:D T73Y&2''1L:?YSO?)(7Z\_A8XD=0"%;NN5FGE$H>[TC#I"3VU\
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MQ+2EEL7)(W![(9'L$<=?G;L&0#G=,T'X#X;7?'S!N8QD+VB25P+0\!K >A<
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MZ_\ 0?C/\+Z1_0\?E)Q%_3^:_K2]_?I]$XK^C,?_ /"K?W:?FX^>O_0?C/\
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M].C/N0GOJ0A7VL932_FE._J^:=?*HR:6(.;'+)&'C3PQ[F!P]'!I </L.U!
M.M@'7;8!U]V^RR#*:E,(F$3")A%K7I79.3<;$_CG5^DTCG0O:%K9E7&S" 'W
MS[/Y_4T/9(RF)!*1O>OI1%@-29+J_DAMI:]Z3O)XS"Y?-3>!B<9>R4NP',I5
M9K')OL9#&QS8V^KI"UH'4D!6=S(4<>SQ+UNM49HD&Q-'%S:\F![@Y[O1K YQ
M/0 E>7CXSOJ^J^E!'#V.+S[M8>.5DM='C%RDT>XUGGMEO,V,%CA&09NRB!,6
MQD @:)8]-+AM*3&C%9KL9V3'EJ<1]3>Q3A*WPU-G79J.C7S-J&B(*3;U*UD:
MM&-\[IW3P5IIGUHYYGUMAY!<Z)@<UKF 'CO'^;AR[,<,>ZQ+0A?8,E@UK$-6
M:RYL8C$<DS&"5\<;9M<HZ![B"0[8H8SOZYJO91Y2\==%[)YKX;;>^^K?6+B3
M_,ZG-8YA4>AQN85<=7'A;&JZ),JJP.':K YNO)%NR)9@]HC(>=<<(*?E_4[G
MQ;Q;QEC<+Q/G:G#_  GPD#6RER,Y2WCGY2U+9$K_ 'F:$6YWU*X]X,H:R&OX
M;0T"/3--7>\)@;5_$8V;)YO-ZDIP.%."TVG"R(L;X3)/!C$\I$082Z27F))+
MMNV5+JD_#I\5429^*P?/M*LII2]/OG>E:*]6+R96OEO<QV9TDC:5)E;5KZTN
M,)9TTOY;82UI*=)T^][1^-K[/"DXAO5H-:;7QABQ,#6?Y CQD=0<FNFG<V_Y
MQ)))SE?A3AZL[G;BZ\TA.S);Y[KW._RBZV^;XMC>P!KRTI@!0(.M#V1-="B0
M J-KY1Q@4=#%#V-?+6ODS"@LL1FM?).M?)#:?T:UK_#6LTZ>Q/9D=-9FEL2N
M^M+/(^61WG\3Y'.<>I/<^:SL<44+ R&..)@[,C8UC!]S6@ ?@%VV4E43")A$
MPB81,(F$3")A$PB81,(F$3"* EM_XHO ?]!GK7_Y ^+\V"'_ !5R'^T&'_X=
MG%0=_*8_]1-_O(%/O-?5=,(H/>Y^/='Z16N"=!X_7T7'IGF;TYR[OH*BJ,!J
M^[?  R/9.=]+J,$[8R NOBC$[F'1KB0K\DT0AC5V(6)BRY49B0X\C.X&[6JR
MY"O<D\"KE,7;QTECD?**\CS%9K3.CB:Z5[&VJT+9!&TN\-[W .(T:$['.$;F
M#F=%*R0-V!S ;:X D@ \CG$;Z; [=Q4YR+Q]Z-[IZH[T4VY4.:\/Y-\7CHOI
MU\Q:PMLUU"T'!'F2L4&I;H02>">H-JH).7;EJ(F)QF(W'E@"4>,V=2XJ)&VZ
MYF<;0Q./9J:S?N<&UL4&1/A]TBC?E9K$WO$C9!8AL-;#\+&L<2V1A)CULVC(
M9'RR=FL9<=+L@\Q(C ;R@CE+3S=22/Q\IBT[X;/HH-:ZX5N'OAFZU,>9'RK-
M3XOA/QA1Y-H LR6U%P$>YU/G,.T51\M T_!:L5>EQC0=Q],\:^U+897K"S<3
M8Q\4C8.'O=YG,<(ISGLW.(9"#R2&&:TZ*8,=IQCD!8\#E<-$JLVM(""9P0"-
M@00MV/,<P;L;'38ZCN%IOSI\-SV+S*S>0!'0^H><"_,?AW5CN\+S3/J8GI+=
MXZM9.FT8WSVF3^Y"2K4<%4!%3"&?O16'03EBEEY["D-RF6G4N,WV2XFPMJ+,
MOK5,FRUQ)-CW91LSZQ@J15;#+,[:#V$R3OFD9IAL,A:QIZM.M'Q'6G880Y\?
M)7;((B [F>7M+6^("--#0=GE))*SKL/C7W]9>DP?1O/KWY(UW?JWBISR!Z1!
M6N#UX;RH2]JWV*W0NF\4?%QC]KF2A\BUE8.JG=TPX<R-%AN/&&WWG5,6]/-<
M/1578RQ7S!H5,X,SC)(G4W6WCP8X75+P<Z*%K7"%CO&@YG EVF: !]/AL%PD
M:Z'Q'P>#*"'A@^(D/C^L[?4CE=TZ#KW6AI_PC?4'(:3U+CWESK_")_./4'C+
MAWD/T*>[<$O\2Y5G7(.?VOELSI/)1=*22#%7[-4;O8'VZA:R@A@2:U =_**?
M%:<0K(-XPQ=V>I=RU/(-LXK-W\SCHZ#Z[H)??+$-MM6V^<MD8(IJ\8,T+7E[
M.8>$TD:IFG*T/9$^,LEA9#(9 [F'*TL+F!I(Z@[T2-'S6T_1'P[_ &IU3G=S
M\<5OMW )WB7I('SM4)9J[4HN(]'\FIW%H5#BG@=,52*]&J72IEIET..7#V+H
M]ABEJM^+R@\1QV*.'2T6F-XDPE2S!FI:.1;G:LN2G#*\\;\9;FO.L.B?-X\C
MIJHB%@LDCK1%DO()" 7.:?4M:=[70B2,PO$8)<")6!@;L-Y1IW-R[!<=C9 [
M J6E1\LG>F^K?5_>^\5'82M6*)Q;BW"@>CXB:4)<XXN.OM@)]&)JKI$I'&M7
MF_\ 8K=&!@BDB/8( &KCIAH6+EE-PF\1+EF5,1B,?CYN>6,WKV0D\-[6-M77
MUXF5F>*UA<:]:E"Z21@,;I)GM8]X9S&L(2^6621N@>1D8V"2UG,2XZWKF<\@
M G>FC8&UJ#V5T\%RSU8&+2CU8@DCO!P5:=K]QJ7+[),MT2-8NP7\?5>6QK81
MAW U:K7+H<RND:\$>@@25RG<5%2FS!LT-E536E=:Z'YZ^[^S?Z^WG;UA0F$3
M")A%$?R#_DO?O]7'H[_K^7A2>S?N_:5+C"A,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81>"#XF'PQ.G>\_?GL#J7PY**]U:LT.PU0%
MWA^9:*;4*V_Z4EBW]](JG+#ML-!1%H?KT*&#+]$C22L62!NQXL/:^VCR1+&_
MH'A?BFKP_P /8:IQ+8%26Q'-+CPV*>>48P/'NTMN.&.1\0D<Z1E8AA$D$;7'
M1:\K V*SK%B9U9I>&D"39#1XO\X,+B [70NZ]'$CMI2O^#'\ 3T'Q7T72O5O
MM,4!Y^WR.:[8.:\>@6:OW*RF+TF*_&"V:VE:B0-5<.$JZY.C@B .L!$R1L40
M>HBP*'CWXY?$\;>T/'7L;/B,&^2Q[XT1VKKHI((F5]@R10LF:R9\DNO#>YT;
M6-B+N4O<X%E:G0D9(V68!O(=M9L$EWD3K8 '<==[UO6NOLPSBBS"81,(F$3"
M)A%U\PN)'OQ(L\F.@RB#FVH$:9-C1GYKNMZUMN(R\ZAR2YK:DZVAE*U:VK7Z
M/TZRHR&61KW1Q22-C&Y',8YS6#U>6@AH^UQ 7ATC&%K7O8USSI@<X-+CZ-!(
M+C]@VNPRFO:811U[%ZW\U<"^T9ZUV>C5(JCY?365EDF+F_M7RTC42DU]!6VR
M_K4I*$;C!G4[6M"/G]2TZWL>&X0XFX@T<1A;]R([)M"$PTF@=27WK!BJ,T 2
M>:8'0)\EBK^<Q&,V+V0K0/Z?F>?Q+!WVY:T0?.[?;;8R-Z'<A1T_/0[5U3^X
M\N>-^L7 >_\ ),?I?=9$+S_SC;#G_DF14:QH(7FV"]:VG>V1E;@2G?[24*0E
M"G-;)^16$Q/Q<5<9XBG(T_'B\"U_$.2V.KH97UC'0J2^AELR-'0GT6*_*#(7
M>F&P%Z=I[6\D6XNIH]I&"7GL3L^QD32>NNR_/S>_;W8/[SO'KB%R$!)_1+YW
MY!JFJU*0WO\ 2G[/L_0$&KNT^E&]M.[&A1K+B]J>:TW\FD-CQ%P-A^F X0?F
M+#?J9'C&W[TS?J<+CS!1<TGJ!+/*0/A/-U)CZ+XCO]<GG6T8C]:I@H/!/X9"
MT)+(.NAY(VC>R .FME<U^'_Y0YH6_*AGE8^_WQQ:'YG1>Q3R76KM-G-_+Z2.
MR][DFFQL[]'_ )P.(*2GYJ^AM.UK^K&9/V@\6Y.'W5V5DQ] ;#,;AHXL118P
M]#'X-!D!D9]D[Y2?,G05Y4X8PE1_C"DVU9)#G6[[GWK#GC^?XEDR!COMC:Q;
MK[?P3E/HKFY/E'7*E"L],);CO-PE*=@S Y&$E:!QFODH2V9@8L.2ZZB+,@NM
M[W&>DP)") Z9,B/X3!Y_+<.9.++8>V^K=BYFF0!LC)HI"#+#8CD#F30RZ!>Q
MX/Q!LC2V1C'MR&1QE+*U'TKT#9J[]$-V6NC>T$,DB>TAT;V;(:YI'0N:06.<
MTUK\Q^"!XSYU>8=T)O\ 3^F1A<]L@+IG0;#79=12^P[I^-HM"KU2KLT\Q'>2
MC>H!$@L7-:3N,6'DF''FW.F97VY\:Y+'OHQC%XQTL9CFNXZO89<+7#E=X3[%
MNQ'7<YI(,D48E83S121N (U*G[.\!5LML/-RXUC@YE>U+$Z#8.QXC8H(G2M!
M_F/<6.'PO:\$@W#-MMM-H::0AIII"6VVVTI0VVVA.DH0A"=:2A"$ZTE*4ZTE
M*=:UK6M:SC9))))))))).R2>I))ZDD]23W6^  #0&@.@ [ >B_O(1,(F$3")
MA%Q9LZ$-C.S2,R+ AL:TIZ7-D-18S*=[TG2G7WUMM-ZVK>DZVM>M;WO6M?IW
MK(+FM!+B&@=R2 !]Y/15(HI9GMBACDED>=-CB8Z1[CK>FL:"XG0)Z ]!M?5B
M0Q*9:DQ7V9,=]M+K$AAQ#S+S2]:4AQIUM2FW&UIWK:5H5M*M;UO6]ZP"" 00
M0>H(.P1Z@CNO+V/C<YDC7,>PEKF/:6N:X="US7 $$'H00"%]<E>4PB81,(F$
M3")A$PB810$MO_%%X#_H,]:__('Q?FP0_P"*N0_V@P__  [.*@[^4Q_ZB;_>
M0*?>:^JZ81,(F$3")A$PB81,(F$52OJ*F31_<;",IEE[61-W2BU4N/77NP_$
M',-<!MIVS=*&[ZE H/#J7U7F) 18V]16A?.K8;Y;57T\QG!V&XH$Z;*CB]#\
M.GKR]?GH_CU_1UMJPO*81,(F$41_(/\ DO?O]7'H[_K^7A2>S?N_:5+C"A,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBK)^(GZ6Z14X_
M//'OEB6RY[*]:O$JUS\DG2Y$;AG,(:%-],](VY#&_J@"*&(5):J.I"FW3UV<
MAQQ,8R\(("GMHX;Q=:8V<SEFD83$!LEAO8W[1ZU<9"3T<^P_1FUTC@YB\L#V
MN%K8E<WEAB_CYMAIUL1M'UI'>@:-Z]7= ">AEEY8\T\X\B<(H' N6Q'VZU1Q
M>VI1@AM+I^XV<@ZLA:KS:9NM?40LUN.R)IHO)5O[-#\K4.$W''18<5C$9;)V
M<Q?L9"VX&6=^PQO2.&)HY88(F_S8H8PV-@]&[=MQ<36BB;#&V-@Z-'?S<?-Q
M]2X]3\ATT%(3,<JB81,(F$3")A%HKT[UJ5PCSUV3L,""T2)\]Y]9+&'@2$K7
M$E&X@]U(5F<EI2'?P]15R'^(;;6EQ,+3ZD*2K6MZSW"^(9G^(L+AI)#%%D<C
M6K32-(#V0/D'CEFP1XGA!_A[!'/R[!"QN8O.QN*OWV-#WU:LTL;7;Y72-:?#
M#M:/)SEO/H@\N]$+_/YZ3U#H/8+F9Z%TRVF[G<3TMR81.&YKLJ3M2W%.-QHB
M-[TP.'1-*^Q'"Q[48<-C(;BP8L>.TVTG]"L9BL=AJ,.-QE."G2KL$<<$+ UN
M@-%SS]:61_>260NDD<2Y[G.))^8K=RU?L26KD\EBQ*XN?)(XN=U)(:T=F,;O
M3&,#6,'PL:  %Z!_A7>O?=/5N?6G@',!_->ADN=*%E!_4N^W"U;C42HFM/P8
M5:?%5R#*LMU:8FCICX!.S$-0B-]8EZ1^$H&-#OGCVK\'<"8C(U>(<I)D\=%D
MA+%)BN'Z=3FOW("V22RV:S(RK2YHY6"Q^9?XKOSK6^*9#)T_@S.\27:LV+I,
MIVGU.1[+N3GGY:T$FVMA='"UTU@!S'&+\XTQC;">0,#+7OS,.V=5_O\ U'[(
MZO;A[_S5(YIPB/!\_P#.?L7?_.#%9==40O-M%Z^:DZ=)V.!*=_L;6E"4);SD
MOY:X3$G7"O!F)IR-/PY//N?Q#DN8#39HF61'0J2[ZZBK2-'D3LE;K^3^1N]<
MSG[T[3WJ8T-Q=31[QO=#S69V?:^5I/F.BD7QWR/YIX%]F]R7C%&J95OZOG9T
MB4F;H_M?SVO<N[V!9:VR]N*VI:]23+J5.+6OY?4I6]ZWF>+^)N(-MR^:OVX3
MK57QC!1:!V#*-<0TV:&@.2 = !Y++4,'B,9UHX^M _\ \;D\2P=]^:Q*7SNW
MW.Y#UV5(O-<653")A$PB81,(F$3")A$PB81>(KXF'I_HO??3W4ZX;.E&>><K
MOEFY_1Z4B4^R"',TXM,KDP^X,2I+#YZPS8$LG,(RVW9[3$J.)0\B /BQVN7Y
MN]-;O6&/<X0UYI(8HM_ T1.+"_E[%[R"XN.W:(;L-: /U$]B' N&X1X%P%RK
M4@=F,_B:.7RN4,;'6YW9*O'=BIB?1<VI2BFCKQ01N;"YT;[!:9II)';G^$)Z
MQNO)/1]3XX8MC^^-]5<+!B@$V4^D#6[(V(GE 5F#)G/)BB)THE!9"%/NRXS!
M2$4^N:U+F#Q2H]SP[?EKW8ZSI#[M8YFN8YWP,DY2YDC03IKBYH8[6@YKOBV6
MLUK/\(OV?XSB+@K(<25L>S\I< VO9@MU8-V[M$V(8+=&TZ)IDLPQ02OMUP\/
M=7EKZB=%%/8Y_88A:'$)<;4E:%I2M"T*TI"T*UI25)4G>]*2K6];2K6]ZWK>
MMZW\MYT?OV7YQ$$$@@@@D$$:((Z$$'J"#T(/9?UA0F$3")A$PB81,(F$4!+;
M_P 47@/^@SUK_P#('Q?FP0_XJY#_ &@P_P#P[.*@[^4Q_P"HF_WD"GWFOJNF
M$3")A$PB81,(F$3")A%4S[3(.@?154?B6 E4[G;N=4H!Q\,$OW3*EKOU["77
MH$J1R^W/4?T-RH5705:U8P<H;9CU5F)T_?RRV3%G2(<HSA2->?KU^P?+[?7\
M.RMFPH75'?QG00QNN*&)L/X60_ E&FYCP=)G[H]^&*+,CUM3WAJ9OV&YS4%U
MN6Y%TZB,XAY2%:(J\J#Z9[YTNTD^35_?-@5^$%.U3ORMOW(.F4V 2J_)JQYO
MG0X)7BYCI\6\4 O:+!Z-'J''#-W-19%&JC-PB5F0B\#( ,I(\_+[Q]OF.XZ?
M9^U2KJOHGF)/D_(>JW:VU'ED/L//ZK?0(J^6\!7Y"6;'6PMC?%QY!F6,03DA
M6CL*,0<B-?)M;K*W&V=2&D[)H[T.OW=5JKQ,<"66G]P/5PP+L ,IZQ]&2AAD
M(0B%1)&,KH$U*9$$C >?ARV%*2K27H[SC>]IWK2M[UO"'R^[]I4S,*$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6B/3/HOFGD[AO0^_\
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MH.O-9K1\'(XQF.MQR\O03.DD?OJ[GZ@_S_LL^(=SK^U1/37'NZCVOT,!._\
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M:-G&Y*E)X=FG:C,<T3B YIT=M?'(QS9(I8R^*:)S)8GOC>UQS+*JQJ@);?\
MBB\!_P!!GK7_ .0/B_-@A_Q5R'^T&'_X=G%0=_*8_P#43?[R!3[S7U73")A$
MPB81,(F$3")A$PBJ8]OQ3<SI?1*Y4HO;WR'1?/%- 7L;1(/.H]8L7+*U/]%E
MSFQ5DN7G3LI-OH0LF6'4X%6 YD<]8;;UGFB&&JBRP7NK1>AK777X[WY>0(Z?
M;H]E:=7AL\.$&BREA*6PA!BH8EV0W&!PRQEY'S^J;/BUH0  L2'?GKZVQ08=
M#U\M?9Q4?I^9>5_-EK8.X5\S5;,-CF*_81LL08&2M+^PFCYS*V)+"U-+;>:4
MIM>]MOL.M2([ND/QW6GFVW$D6E97ECA\T,X&F5@[*^\ERILE8)'1^FNWPY-/
M5\54SC5EZ0NXJZ#9Q)FK *[6BH"P68F"( *W6@\L<\.KP6-!*=G]P-?+M^Y]
M5PNX^._*WI<=2@_H#SYR7L GG#)*/01E^I(2PP*=',,"(I2/7(DZ(XP(8G1@
M 6/(9A-M-K9%06OITB,TE) 2.Q(^XD?J6I?A^\YH?(^7=:YKS"H@*'0*=ZF]
M%!JK3ZL-C!Z]7Q3/0I[C0\2,B(;C0HC:W7%I990E&E+5O6OGO>%+B3HD[.NY
M^\A3LPO*81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3>]:UO>
M]ZUK6OGO>_T:UK7^.][_ .6M814BTC7_ 'IOL1CKLS7XGX!\,] G#^+0G/[V
MO^G?6]=4Y .=?VG>MQCO,^%..2 ?/I;.GAQRZ.SSD$G.@H*AXN\S[X4PQI#X
M.(<]7:Z\[M+BL/)\4=+?>.UD!J2RTZ?'!RQO8UQ8\V+?\*FY^]>!Q#!W$LS3
MUD_T8^S>X+MD'H0+NLT97R81,(F$4.>M>\/./*#VZ,W:275NK.+=8A<>X<$F
M=4Z1+F-;^3D%X/6?O$$%+1\];4W9RH/Y(4E>M[3O6][EB. N),M7]_-2/$XD
M .DS.<G9BL:QAZB036N62=I\C5BG)/36U@;W$N)I2^["=UVZ=AM#'1NNVW.'
M=ICAVV)W;I,^/OOLM4?CWQ#?0OS36JU1?$'.YGZ$6&\Z@=E[_,A+_M-2QU,@
M.Q^<U!V0SM2)$"RD3!8:_P#9K2A:D.-YE_=_9UP[_*;-_CG(LWNO0\3"\/L>
M-;9)=D:[)7 UWU9*T<,4K=[(V%8^+Q3E/XF&MP[5=_VMCDR&3<T]G,KM(J0$
MCH63/D>P^NM+-*#\/;@@"PQK_P!4U;?3?56?DO70_1!]WHLF"YM>GMM5VJ36
MVJ/6H,>1K3@Q@;7=2AJ$,M,SU?8I7NQR'M#S]BN_'XGW3A?$NZ?1W#E<8UD@
MZC=FW&3?M/<TD2NELEDI)+HQO2N*W"V,CE;:N^/F+H_[UE93;<WKO44#@*T3
M6GJP,AYF:&G=-J<K334=IIAAIMEAEM#3++2$MM---ITAMIIM&DH;;;0G2$(1
MK24IUI*=:UK6LT4DN)<XESG$ESB2223LDD]22>I)ZDK8P      - #H !V '
MD OA/GPA4&:3)2X\ <.B29Y"=,>;CQ(4*&RN1*ERI#JDM,1XS#;CS[SBDMM-
M(4M:M)3O>O)(:"YQ :T$DDZ  &R2?( =255AAEL2Q001OFGFD9###$USY)99
M'!D<<;&@N>][W!K&M!<YQ  )*\\78?CUBPEZ(!N+\4C7.CB9[L1%NM]GF@)M
MI9CNJ:7.$ X(:6L) D_1MT<\5E3)[\9QIZ:)&R-N0F].L<6!LKFUJHDB:2!)
M+(6.DT=;:QK3RM/=O,2X@_$UIZ+[&X<_@ESVL5#9XFXG?C<K8A;(<=C:,5R*
M@Y[0YL5BW+9C%J9FPV=E>.*%DC7-BLSLY93;!XL]J<W]K<YG7&F0IM9LM8F1
M!=\H964S-(U@A.9>?'OL$([4=HN!+MQIFQ!=,2"N2N!/CR8$*5#>83G\9E(,
MI"Z2(&.2,ALT+B"Z,N!+2'#0>QVCROT-Z<"UI! ^?O:;[,<W[,<S#C<G+%>H
MWHI)\3EJ\;XH+T,+FLF8Z%[GNK6ZSI(O>:WB3",30O9-+'*QYF1F37-DPB81
M,(F$3")A$PBXLV="&0Y1 E,BCQ\)AV5-G39#42'$C,(VX](E27UMLQV&6TJ6
MZ\ZM#;:$[4M6DZWO()#07.(:T DDD  #N23T 'F2JD44L\D<,$<DTTKVQQ11
M,=))(]Q :R-C 7/>XD!K6@DD@ $J"=G]]48R<GT3R_1KAZVZ'!>W#EL\M0Q%
MY=7IBM?-K\L>T&$MT</$<U_NR!<FP+VK^ZVRA>_EK$R9B)SW0T(9<C..A%<
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M;RWN' ?+?\([BGV>PR</\-\58S)9RY&;62+,'E8,?=PT4K(H(GSF>M:CE^D
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M$MSE.GS.#.=S.>-ME$#9E]Y=OPF%S:[".A\G3$'S)V&?9UUL FZO-'5ZH?\
MI#UF*XX5"\HYS5YG:/3%[CK70.+5J2TB6W%5O;:KET,OO:HE%Y^,5\W9QTNI
ME4Q+;C0YM;3)"<-W'AKA&7,Q3Y;)6X\)PS0</I#-66DM+AU%+'0]'W\C+]6.
MO%L,)!D<"8XY,#ELXRA)'2J0NR&7LC_!L?"0' 'I[Q:D^K6JL/5TDFN8 \H(
M#G,QWS]Y+*5ZYK]$^E;1#[+ZA,0UQV3R8SK= XX%E:6I=&XI79GU)!"XJ'7(
MDZT2&M6:Q?5*E3'HNRA1F;<\0\716*0X<X9JOPW"T+P]U<N:<AF9VZ OYNRS
MK/,[0='58?=:XY6L:[PHBREB\&^*P<KEYFY#,R-T)0TBK0C._P#!L?$[^+8
M2'3$>++U<XMYWATLKOT.@\S"JL?1KO4:#7TNICJ.72QAZN(^\+2I2(^B)N9"
MB;D.)0K;;&GMNN:3OZ$*^6\T"6:&!O//+'"S>N>5[8V[/8<SR!L^0WLK=<7A
MLOG+/N6%Q61R]PM+_=<92LW['(T@.>8:L4L@8TD<SRWE&QLA?E(Z)0.F!M6/
MG%XJ%_K^WE1]&Z79 ]H$ZD(2E2XZB(29.B)D-I6G;C"G=.MZ5KZT)^>(IH9V
M\\$L<S-ZYXGMD;L=QS,)&QYC>PF4PV7P=GW+-8K(XBYRA_NN3I6:%CD)(#Q#
M:BBD+"0=/#>4ZZ$K7?:O3'"_/(]F=UWH]?JDF:G6Q%>4\Z5N!]:U_8M-5^G!
MFI]F-*=?^F/IP>+?CM/+0F0\RE7U:HVKU2DWFLSLC)^JS9=*_9T R)H=(_9T
M/A:0">I"S/#' _%?&4SHN',)<R#(B?>;@:V#&TP&\SC<R5ET-&KRLV_EFL,>
MYH)8UVM*+_\ MI]E^B-_=_/_ !N+YSYY,_LI[1Z8A+7=ID-SYI5-I7"A,E4Y
MF4G6VY8V9?2L021BNZVN$TXE3>6'O63NC5.L*4)[6KS3XI'4;BJ-Z@]G-,S@
MUP\AT6]_DQ[-.#?CXOXEDXTS,?4\,\#R@8N*0=1%D^*[#!$]A/-'/%B:\EF"
M1O21S2"LJI?@7ER+#"Z%W^QV[U;U.(K[>/:.V2V2M5 R%[2MYND<JB(:H-5'
M*>0B1'B?A965"?3]I&(H4K>]U(L17YQ-<?+D+ ZB2T0Z-AZ;\*N-0QMV 0.5
MQ:>H(5AD_:[GC3EP_"%+'>S_  $@Y7T.%XG5\A;8 0QV4X@D+LOD)PPNC?+[
MQ79*P\LD) "G,PPS&9:C1F6H\>.TVRPPPVAIEEEI.D-----Z2AMIM"4H;;0E
M*4)UI*=:UK6LRH      &@!T  [ #R 7*GN<]SGO<Y[WN+GO>2YSG.)+G.<2
M2YSB22222223M?7)7E,(F$3")A$PB81,(F$7R?88E,NQI++4B.^VME]A]M#K
M+S3B=H<:=:<TI#C:T[VE:%IVE2=[TK6];WK((!!! ((T0>H(/<$>8*]-<YCF
MO8YS'L<',>TEKFN:=AS7 @M<" 0000>H7"%!@X*)J #%#0T'2UNZA"H,4=$T
MXY\OK<U'B-,LZ6OY:^M>D?4KY:^>]_+(:UK!IC6M'?30&C?KH !5;%FS;D,U
MJQ/9E(#3+8EDFD+1V:7R.<[0V=#>AOHNRSTJ"81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$5*/0;%U.F=K=FW7JLT;0+'UKL
ME/N(\3[A@U&)=R"K_7;-PNK0JR3!EBG"&N7<9)HA=#%<?,<G.VDB<K1?H%@L
M;!!J3/?O^_\ R4^7;TZD??O].];W^&E==A0L5O(JT':7;0E(M3%%N1>M&QE4
MNTFOQ[8Q4+%/&R8H:SN5>7.&1+"D$0=CD_P660AQ">XNH<E]MAYS>$43 7EK
MHM19JIRG]7Y\!Z75Q74ZPJXN\>N-@@64!UU7-BMI-7 =9>_%K;9^I_E7RFHE
MX_03'0I<-P4Q*KDZHRV%PYT$IWWW^P=N@\OT=%UG:_'O4+AS?A7+_//L?LWD
M@!Q*I-TI4CG-9YK<"-]!# -5KU7:M#W0:T::8D5J%6Y"XSX=F#]]?.D%S$.)
M:B)9(#U)(!WZ[_80NO\ AQ4NT<ZXQTND77IEC[):ZUZ?]$#3G4+</!B;+=9S
M?0R"UFS(ZMPAP*',>2XAM;(R%&BZ2TG:6]*VK>REQWH@ =.P[=SZ]58!A>4P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBIB]JV>P^ZO0,3X8/(31(
M;R\&/K_0OB+=.KLMV+(K'*"+J9]/\TA#$56E0K[W7[O]O8D(>8DA^;M2Y7V)
M>'.-"D;K@XH\#CCQ3<8UUN1TM;ANK( 1+<8.6;*2,/UJ^/WJ/H0^T6MVPM8]
M64Y-B3W5A^  .LO'\UIZMBV.SI//J#R^HV!<!5ZQ7J36J_3JB%&UNJU0*+KE
M:KP>(U!$@P(2$P-$"!D)A*&8D = C1XD2,TE+;+#+;:-:2G6LTZ662>62:9[
MI9II'RRR/)<^221Q<][W'J7.<2YQ/4DDJ\ #0&M     '0  :  \@!T"@GV'
MU+?.A7TSYJ\60Q%NZN+6F#U/M!9G\0Y%YTBOJ6T\LU*;2Y%N/3$I0\D)0!ZI
M*6"++CMCU]V%EQJ.@8;A6ACL?!Q-QL^:IB)09,5A87>'F.)'-T0(&DA]/&$E
MOCY"0-+HR!6^*6&0ZO?S-FU9DQ'#[63W6?!=R#QS4<2#L$R. +;%P:/AU6[T
M\$R]&2,&\?-_EJA^<11J4-FE[UU*\R4%NJ]HNKWXGT'HY[>M*7)*$G5.K'A(
MB_FV"JX]Q H-%2A*4RIRY9&7@N).*K_$DL+)60T,51:8L3A*+?"QV-K]@V*(
M:$D[QUGM2 S3O))+6<D;,EB<-6Q+)',=)9NV7>)=R%@\]JW+ZO<=\D;>T4+"
M&1M ^L[F>Z3&:PLNO$7\4KM=YZY[(ZX)LY&?^3O*[24YU1ZXX\[H8#$UYQN!
M-G0HFU?9)EV8C&?.SYVTJDRDRHD93NX4 >Q'Y?G;4MC)66R%W)7D=!$PGX6-
MC/*2T=@9' O)[G8!.FM _43V#\,8KAWV;<.V*,,/OF?H5\UE;K6M\>U8NM,T
M44LFN8QT(9&U(8MB.,QR/#1+-,]^N/!]VZ@&]%\_YUSKJ-[Y=![?::UR^Z%J
M#(@MF%5^PFHD5V7#05A$A\4H*VXN4/.)A;(AD*F.P9#*7Y*'J&+DG;<AA@L3
M5Q:DCKRNA(YN1[P"0' M#F[VU^N9G4CH2#FO:QB\%9X,S&9S.!Q6>EX6H7L]
MC*^79*ZL+E.K(]L<IKRP325['*(YZIE$-HB-LK'%D;F>QKBOCG@/"2#UFJE/
M4?Z-/5MXUUSHA&7?NJ')CB--R)DRYV)<LA"<EH2G4J,"T(&O;0C>X.MIUO.D
M5<;3J.\2.+GG/5UF9QFL/.M$F63;@3YAG*#Z+\W.)_:3Q?Q9"VCD,D*>%A'+
M5X=PT,>(P%2('F9%%C*0CAE;$=^&^V;,[-D"714H<OUHB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A%#V?XNH)-_I^YUZZ;)&]-'WVO;".3:0D=1:9V;I.^I=]IE%
MD,T1HU$$]UL>TL7PI8B]EMPT5%%1.>62C. @LB 4[/[?M[:'7[/)3"PH3")A
M$PBB/Y!_R7OW^KCT=_U_+PI/9OW?M*EQA0F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(H)>_O7)#ROR<- YK7VNA>GN[66/R+RWR=&TN/W/JAYO33!D
MLQIQI4:A<^AO;MM],R'H0R")B,#IA49(-09.L_P]AVY:W(ZU(:V*H1&YE;AZ
M""I&>K&'1W8LN'@UXP'/<\ES6.#'!4+$QB8 T<TLA#(F>;G'S/\ FM'5Q[ =
M">H79^)?*]?\3<!?!VFW1[;T^U$SG8O3O<[#):BR^E]>LJ-EK[>#12=J*F'7
MART*&UZ/*^[1P]7%P]R4ZFK)2Y,9K*39_),->N^.NP14,1C86N?[O481'5K1
M1LYB^9^P7\@<Z29YY=CE \Q,95A<Z21HT'2SS/(8TG6WO<XZ#6M [D@-:.I[
MK21GJG6O>I8E0O-9PYR;RM G2@W1?4L6.X/M_4_NKRXI>F>=&9C25Q!:EH>'
ME^JR6/L&7MOIKZ'5P/L3FZPXK$< PQW^)H(,OQ7)&R;&\*O<)*>*YVA\5WB0
ML=I\H!;)#B6NYG#E-D@/W!JTEV]Q-(^MB)):.%8YT=O,M!9/=T=/@Q/,-M9L
M%DETC0._"V6ZDGQQ[C7->"4(-S3E%5'U&HA$*VQ!A)4N3.FNZ1]\,&B+ZG)Y
MHX16A+I$N3D29TM>D_:O;0VTA&@9G-9//Y";)Y:W)<N3D!TDA ;'&W?)#!&W
M4<$$0)$<,36QL!.F[))V:ACZF,K1TZ4+8((^S6[)<XZYI)'G;I)'Z!?(\ESN
MFSH #%NY>E^+^=1,0AU.YPQ!$NK3%9IXYI\[?+A-<<TQ'@52FB6Y1XR\_*4W
M$T^Q#T.BOO-:GS8;:_M-8"W>JTF@V)0USND<307S2$G0$<3=O<22!L#E!/4@
M+>.%>!^)N,[$D. QDMB&N"Z]DIG,J8G&Q-;SOER&3L&.I6:R,&7D?(9Y&-<8
M8I7#E45OM?:/K/\ 0P@IX@X/.^?S?D)@%O5-U%.__P"J/\Y->XJW+94K7U/;
M+7(5+:2XWIR.]\M8_P#ZTR/;FQ5,^?1V0E:?0$%E38_TY6D;!T5O_+[,O9[]
M<U_:GQ9%_,89J_ &+L-_RG_F[G%!C<!H-]WQEB-Q:[ED8"H4^K_@AUV^NB[+
MYKO2:E:$04Q;8+ZT;M%EA74KMYU]^XSKDED_8(%C(N.KV88T'GB9[GV#L",#
M^Q?;FXR_PNR7E?1E$;]:D;8=(\2N)),IE >]KSL\PY"UW0@,T=].X _A1W<2
MV>EQOBCD:!EY\?/P]5H49<97#&L9C8L874Z<U*%K1[L\V8;$(YFS/M<['19[
M\/[X1F_,G18/;.UW*N7GH5<9F-TFNTYDF[4:U/GQ'H,FQ2BIR ((G"[<&3)B
MBXZ@@V$)<>=(?5/G:@/#:V(X=]QF;:M2LEFCWX4<7,8F.((+RY[6.>X D-'(
MT-)+OB=REN(]KW\(@<<X6;A?AC&7<5A[KHSE+N2= W(W88I&RLI1UZDUB&I7
M=+&R2P\6YY;+6MAU#"9FSW=9M"^74PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3"*(_D'_ "7OW^KCT=_U_+PI/9OW?M*EQA0F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB^,F3&A1I$R9(8B1(C#LF5*DNML1HT9AM3K\B0^ZI#3
M+#+2%..NN*2VVVE2UJTG6]ZD N(:T$N)   ))).@ !U))Z #J2G;NHZ.>QO)
M_P"3O0K5!])<./!>45HU<.C/U;J%,MDFGURNQ7)9@F;'5LR4(PVHC36T[:<B
M?;O2%-1&&G93S3*\D,+E_$K1.QE^-]R5D-82U9X1/+(0&,C=*QC7%V][#M ;
M<2 "52,T6G.\1A# 7.T]IT!W)T56)Y=,#KU9+U\93VI*1R^M&JO,IWC'G]V^
M;;W$O,DY]QR#;=A6]277^T^CE?9GIS(9DD<U5IHNL!YLP454)@[C:HVYGU.
M>&8'Y&V9Q+F9JHV+^4;H.C=*>5K,=BAMG/*YD#9&OGD#7L\1V-FN5J<,V6R,
MK*U>-NHC*?J1G?+RM&R^:?IRQL#GNV&M!WI2 '<^ZW\04A!MO= ]EXUXZC2X
MY2E>>Y$A\-T7NS<9Y$D7:NZ/PGD2:[2W5-LS0W-84A,F<O;<XS*4W$%3I^1D
MR&(]GD<E3 SULUQDYCHKW$3&MGQV!+P6RU,$V1I;9NM!,<V3>WD9U9 P%TK(
M\&RK>XH>V?)1S4,"'-?7Q;B8[62#2',GR1:=Q5R0'1U&D.<=.D=IK'/G=?\
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MJU_CDAF:?]:QC8?]56L2Z_\ Z6&[_1O[%!R?L5I?R7A'CW-Z[?3'$V+Q@?\
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MV=]O/OY^:^U&XKZQJ=GI/2B(@#?I]0Z)T]%=J=^Z97HU[AT+H?*><U>&0O\
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MZ!L]ECT!-:8LA@,,F'6R#D*/MLHV?7]^WZNBRX#R.HUT[7K%$>MA(G50=J
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F81,(F$3")A%DE5_S9/\ [=[_ .N$6S,(F$3")A$PB81,(F$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g96328g63g07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g63g07.jpg
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M.4AR=H>VQT)#H?_$ !X! 0 " P$! 0$!           ! P($!08'"0@*_\0
M7A$  @$# P$$!08("@8$"@L! 0(#  01!1(A$P8B,5$406&1T0<5(S)QH19"
M4F*!E;'2"!<84U:2DY34Y"0S5&/3XS4WEK0)-$-$57)U=K7!)71W@X2RL[;"
MP^'P_]H # ,!  (1 Q$ /P#_ '\4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*_P <_P"%.W?NB(=._>D=B>WMH1>/C\M;]0!QV?RL('8]:U)
MWKKJ8P:6;,FW67CEP[7\RAAYYRNLNIY2JN>>7S?7+NZCU:\2.YN(T5H=J)-(
MJC-M 3A58 9)).!R23XU^D7R"]ENS.H_)-V3O=0[.:%?WDPUSK7=YI&GW5S+
MT^TFL11]6>>W>639$B1IN<[8T5%PJ@#Y\_E)](O_ !^[J_I3G/Z]KD^G7O\
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MBM/[M#^Y7L^M+_.R?UV^-/RY>FQ_EA=*7_6"VS^UU/0+'_8K3^[0_N4ZTO\
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MW6RVMP-<&7%RBY0C8B!U"WL=TT()N>8RB&(-O5>^Q$")]&?,0_(?K]OV<&E
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MTDU@+VC[.:LKW9^;[G99/9:/=VD%P&O7?YRG4P)$)1-F.TMG:PZ?$+F])-I
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M&<@F'48<XXZ:NO<$9!ZNS!520,@L< ]X!3ZL5\VJZ=:]*4I2E*4I2E?Z3/\
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M#J/)MZCOB;O-)L3>S9+;%W$[1C,_)]VG;;N-JVP*J9O"=JKG:JY3NA=QV@8
MR<8R:QMOP,G3(M>U[*:FM>U[7M>T[=VO:]OIM>U[1WC:]K_3:]OJJT_+MV#(
M(+ZN0>"#IW!'D?IZP_BZ[2?D67]Z'_#K+*_@@NG*NF427.Z[62-Y,\S2:NS"
MZF!?,?E?-AD3QS!WQ?Y,L[WS:7=65NVROY2/D7^FJ1\MOR=J8F6/45: .("-
M)0&$2 "3I$3?1]0 !]F-PX.169^3[M00X)M2)-ID!O3B0J<J7&SO;3RN[.#X
M8K$?N,?3'_P]2_IV[_9VKOX]NP?Y>K_J[_GUA_%UVD_(LO[T/^'3]QCZ8_\
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M;6<)A65.F[Z:;".>X:ZC99KB/589%"0S%H+6[F!=E"50ET2(QM#$QAG;=MY
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MT4$+C-8[W4D%@^!"Q. ,]5V0@ 8XP,IXG(P2U=XUYRMBE*4I2E*5-R_>Y/\
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M;-L72]E-BXN[JZ*FYN)IRF[:99&DP7QO;O$]Y]JEW/><J"Q.!6*JJ_54+GR
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MY%)'I!X-86#1,"*.2QX-<$QJ\DL#PB@AY@?.B4U>CIEDU[<%>G+-%!$US/'
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M>RKIK0K.E*4I2E*5->_6U_D3?_9E2E0J4I2E*4I2E<2=)/I.):MV)K6 B9K
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MB8S$S-O#;@58 !@H< J#D[<H03G!!/ P>016?T"7G!\KMU\;GIB>P0+.E(#
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MLX(5S-%\[/1.-LRA#*V.91GAGC;)VM?AGADK;+'*W'AEC>UKXWXVO;C:K0W
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MPP20;H))I)88VQPQM:W"M>222:1Y97>661B\DDC%W=V.69F8DLQ/))))-9
M     8  P /( < 5E>HY]H9=[0^:L*FG4<^T,N]H?-2E.HY]H9=[0^:E*=1S
M[0R[VA\U*5,79Y7:,K>?9V\FSCZ;ND;6OQ5X_P!K?RN%^'U7X?5?Z+TI4/J.
M?:&7>T/FI2G4<^T,N]H?-2E.HY]H9=[0^:E*=1S[0R[VA\U*5BRD7%FN7\W:
MAB/*2C0V,ZXHU7ZB787SNR)-?.7OYEXUNJI=!?#@HGY>7DWMQO6:2/'NV.R;
MT:-]I(W(V-R-CQ4X&0>#BH(!\1G!!'L(\#6H172^MH.:(R.(0Z&QTV53?(NR
M ENP:+8MRI' P6:,;)\$Q;(P933-&&0Q-FU+&4\"Q%%R1PQ<VOFO;NXC2*>X
MEEC3:51W+#**41FSR[1QDQQL^YDC)12%.*@(BDE5 )SR!YG)QY D9('!//C6
M(=='K4;\H>,$H3%"CZ4MB[&27++<U9G6!Y,BB78%1A!TY&OA[Y(L3358N&BC
M2V#YS9-'"RN7&P:E?*D:+<R(L)C:+80C1M$5,;(Z .K*40A@P.5&3Q4=-"22
MH);.<\@YSD$'(P<GC'KK)1S26M(CDR5CL1B@QR/D2LM;/T[HK%/2=:-/H9D=
M<%72JY)Z4QB))[&$7;UTX5;@%N4-\DF*:*">$U_>3[NK<2.'B$+*3A.B)5G$
M810$5.NBS%54 R#><L23(1%\% YW9QSG!7)/B3M.W)]7'A6X@8D'BXA@ CK,
M(%"C$;H,!@W-HU9M4KYYJYXI(I7QQMDJLHHLLI>UU%EU%%E<LU5,\\M>262:
M1I97:21SEG8DLQQCDGR  'J   X%2      / #PK+]1S[0R[VA\U85-.HY]H
M9=[0^:E*=1S[0R[VA\U*4ZCGVAEWM#YJ4J9=EGU!/'S[/\\6OQZVCY/_ )*%
MN''ROK_AX?9]/\-J4J'U'/M#+O:'S4I3J.?:&7>T/FI2G4<^T,N]H?-2E.HY
M]H9=[0^:E*CO R#]HZ8/;C73)ZW7:.VJ[ANH@Y:N4LD7""R>65\5$EDL\TU,
M,K7QRPROC>W"]2K,K*RDJRD,K X(8'((/J((R#3Q\:KE?1&J')X+)UX)!E#T
M>;@&H@E=F.Q6;(Q+.ZL2LIAC;%%XI$EKY.(HL^2<K1ERHJY!J,%U5%,ML:A>
MK')"+J812F4NF\X)G&)\>M1.#B8*5$HXD#  5ATTR#L7(Q@X'&/J_P!7\7\G
MU8J3+=,:^G99B<EH ,:+#$$VP]ZX*.4E&B263W).R&+5\@GAGCS%]A=6V'G<
MDG2R.6=TL[X5C!?75LC1P3-&C$EE 0AB=H.<J2?JKQG' /B*,BL06&2/#D^W
MV^TU,::F@S"2RF8LP()M*)L-;B)6<2=^2_.#&>*N#1B^5ZQ_;-VEEW'5<,+8
M=6NX<9(WPR<+7SQ:[N6AA@:5C#;N7AC.-L;MC<RC'BV!G.<X&? 8D(H+,!RW
M#'GFH\7TWKR%L8Z,BT7C 5A$GI4C&6S/-&R8)\=;.69AR,\ZJIDU4(M7CM!U
M=/*UE$W*V-[?W3+C,UY=7#2O-/)(TZHLQ8\R+&0R!\ 9"E5(SX$#RH$50 !@
M#)'CQGQJ=!]7PW6HIV#@@4'&1+\P3D#Q@-=6Q;N#9IQ=X8**8JKJWN\*/<E'
MI!:U[9.WRSAXOY;IPNJI%S=7%VZR7,K3.J)$K/C(CC&U$& .ZB@*H\%4!1@
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MC-XG[3^VMI? ?8/V5ZU%32E*4I2E*4I7"&JNDLKO+=6Y8#'-FP01&&$)"/\
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MC:27UU#:Q9WRL<D*SE(T1I)9-B N_3B1Y-B!G?;M168@'!W$:ESX#'K R20
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MI()XI)XY*K.5%E<K88XVR454S4SO:^6>>65[Y7TR2Q+'Q8DG@#DG)X& /L
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M 9@_BTH;G(2$$*Q<CC#HY/&;4T\@4AFD(1&$H])A+^/%&<I?)N>9(QQ\Y4E
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MI7+FZY_LO7D[UB\$/,58%*9YKJ"EVZD(0=QT/E,):VC1%U,)LG+KR$82,9F
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M\;96M>U[5:&X'=;P'JJC!]GO'QK%\D=]H$?'@?ZPJ=WYK>ZF#[/>/C3DCOM
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M6666RA:Y-P',::@][<V4L'4BAV01)/ 8@9FW,RG89&81C 3 *S/C 8[=N,E
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M=L[0W&-9FH>;UU'XMJV3ZK:0),C,MBF@DGF^S->R"42$1&7T@=+ R!B(1Z1
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M2F1YCWBGI7%OXR@/C [[S2F1YCWBGI7%OXR@/C [[S2F1YCWBGI7%OXR@/C
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M<8VLRK@JWXS $E\[$QD;002Y[HP2*Q^[>D(2U85FS8>$:DVD'U[KDP[2482
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M$&(&0Q=J]CY^S<7D:#R)%%02W<!W+M^U'3X[-6:*1Y E[<VK%PHW(B0S6TH
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M>P1I%%<E(T:V=5$<9&ZSEFGMBV8SN$<MQ*^&W*Q8;PP1 N!@!))3).X$Y_+
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M7B.2ODK-'S)PNU<)7^A1%7/"_P!%ZSBDDADCFB=HY8G22-U.&21&#(ZGU,K
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M=NQ:((W674465OAY:N>>>665]6>:2XFEN)FW2SRR32M@#=)(Q=S@  99B<
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MBP11RR':J;II4C629MJ+EI&8EMTAS))([Y",KP <>6XD#[ 20H]6  , #P
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M$LV[._) W[E"G.T*.%4 8 P*BL>C4S;DA9@L?G\N+HS>.SB0F)5@)<DY<O"
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M+M1BZR^#P.)=,M]+\K9>@M;6\D?4DE#L;E9!+(@02'HW$44C1*/H>M%((\N
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M<8"T](FX5[LI/9TG<N$.NEY485V5;:Q=D3>J-4T<1QZ2X)#B#9-IYA&(><C
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MU2)1##-Z/=&[@ZV\K'(\72E[L;QL>ILMY P=7CDMHV0C+9AXP^>2-R[6QCD
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MBT'),LFU>9UVM;VA9UM([F0I,6NX;+I]"&=3/TECQ#$)#;QP22; 6<DL6CI
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M)G=RLBWLY72NNLDEY:F.Q:6[7=U;VJ,J-<310AVSM3J.$WMM!;:F=S;03@'
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M-ZYP=K;=RY&<$9JQ6#*K#@, <'Q&1G!]H\#[:W.M>LJ4I2E*4I6X1/\ O_\
MT7_F:4JB3@,TH:,9X!RF>&90AGAG@/=Y8YX9.UKXY8Y61O;+'*U[7QRM>]KV
MO:]K\*N!&!R/ >L5KUB^0'?8I;X<\\&IR/,>\4IR [[%+?#GG@TR/,>\4IR
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MX/&" :MG6NCTM6,#3"/#)0YP/D094DJ2'-\+YO@, A>N6N;5J&"AQK!%8%!
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9<14P\KAUCCP\K&W'AQMQX?5QMQ^NE*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g96328g77q21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g77q21.jpg
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M 0$! ?_  !$( 'H"70,!$0 "$0$#$0'_Q  ?  $  @,  P$! 0
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M;I;39I#;HX:UL!0+!))!*2R LB1FB:088]P[$;F*+.?O[^/L.O=B/3CH<UY
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MDZ>JTA0:3BZ5B)OD$0]5PE3BGT29(GCBLR9HS+'&;>$2%5$IVX*X#D0R[4+
MMTW*Y"DB)CNU+ M+A6"EM[;025&<YR5\2Y(! R,^8KD7<W:#[;VD=P;7TQ8^
MV!VA&EAU%LJ]:P?,TF^MN2)F+F@VAI5&AZB0^P G9K"SE,Y &9@0960LD61
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MG2E.E*=*4Z4K^)?W7#_WA': _P#JU?\ ^#6O.OE^O_[8O?\ I0?^%@K]/_\
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M8U)B+"+I3QLR(T>^6W1W9D(C2N+'VS_31;QZMU"A16^Z:NL= O5DBM-C8\V
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M8%4)=1LXV@MCQ;< @=,]M;W2<;L<O-"9L==C7FB;QJYUR'N"%^;*,EK6OWU
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M2)P&"E:\7W)@T\0.$I,9)9F),&<Z[/K64D6^$;:W>5+^(*?B'H,"2,!#UMS
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MG/2>+?.T&6$L&!GL#/9>%9Y3E:UFRH>-PY,E]YG-<\,K/-THV6\:>1H[CIL
ML)M65,3[=@4'$72W;A+\)LQ\+4D=0%+$&((H,>03O$@).S.22,MNQC:=N?WM
M>KZX[9&L7.GN;=N#5>V=W-]M;V7-]C.-TGW)+4-(VYIV='%'/GVEJ'8 =AIM
M7RNM!V6VBUJ!:E+M?475W3,Z2(#M+PKAW:*59]D,T5NL5N5C6 1L\Z+<K(.E
M-&5D?IRPCJLA4NJ$2$PY7'492F75G+L-Q?($9*$9=6RHR&\.<@9!&&P</YC4
MA&V-2[.IVTD['7K+7FR$%NUQGC256%7T#!IRPN]DJYT-:M;<VJ6QE-8[PA;*
M;/7J5G=]VN)[9IX!PE?J<ETOANC-$\3"19(F27QG?<==5B;<Z 2(-D;AE:39
M -DY5D;+";T97!4JX9?",1[#NX!\).6!!"[GY3((KFCLQC=G>>FNQ-Q(-?M7
MUCVC5ZF.YMULMJ%S3*"QUKM@Q]9JT(@N=;3<DAW$&B=SBSI[(N#/X7+\Q.1V
MI8AVU=&Y#J86D"K$S%41&#N)80%8M&[8Z9D\*%2PR0<J"*HA'CQA3E@,DD$*
M5?) # >>.2#@X'KY@Z+V,9J[1]QN].P2EW:E]H_LZWAPE;YD>4\IU94[9*48
M2PJV"M]S40+Y(DQMDRIFMF$L;/6;$1@$^ 1, <SQB6=(WW"-[:YC#+P5=S"#
MR05WF,,8P0?"LP*E"P*-MJ%AC*R1L0?6 &QQYXW>9!X)4^8!'2FZFR+<%0'O
MM1W"C4[UIEUIV(=+HEB#9,;_ +K&%T92%SE58[#L9MM&W-@$99@*G9PF-NIY
ME@TM?[Y);!7>^AQP=6!6A?IM S0.C_"2*1TH";B0JRK$L2*6 )B^#D"SQQE"
MMMDV.0X#!QU RX4$'<^$48)8L2!QO\2DHQSE^.$^T\54CNTEO\VA9II:27NC
M9Y-4FK> \=;FK\UT=2*IJW&)CB-%79@\HI$44&/$<2G(./'X,>M^U#BVMQ)N
M#B"(.'R7#"-=P?/.\'.[/[[-42$&20C&"[D8\L;CC'S8\JHSJ^H5_29_Y/5_
M\7?_ . O_P"U=>7[2?\ H7_Q/_Z*Z%A_RO\ [O\ _.O]&RQV753W"-1:\4;V
M!4]3NH 'E>E<"@V2INA'E><C0FJR1X7%<L*P!TC:0<<%JFX 3-<1 8+!/A\S
MC>6(EHGDC9DDC9HV9"T<J-'+&2I!*2QLT<BGPNC,K J2#WB5.,[2,@C.."#D
M'!\B" 1ZP:K(BD=D<MNBL!6J]-DOJN]9VBM.R-25^9O7;,ZM0EZ<6)$RDJV1
MBEZVNP -Q9MU\P[ ^U!B6$HB5N/"9AM#4-2"21B^OA'+&L,L8N9PDD20FW2*
M10^UXT@9H%1@56$F, (2M1*1$@E8R0202JY!)W$@XR"6\1(Y)Y\Z\N*7V2^!
MLP^-7:>X#D7DJ9!>-3(>!LU1E<>T\M9G![U_-9+RJE:+-5B0LL.1IZY8GJ26
M/)8W8"D8]T-1SN[[>[MP?=WF?.]98YE;._.Y9HHI0WF)8HY =Z*0V18QMCQR
M,;5Q@@@CR]89@?F)'D344;7O8^#AIHXFHM*"P:ZLS*Z:^@&T]6X(:+<7)N#)
MQ;*;'%5,<*Q9FK&.,]D^28@M#C8\"BBI9\,9.,G4=38S%KZ^)N8E@N";JX)N
M($!5(9B7^%B1256.3<B@D  4"0C;A(QM)9<*OA8^;+QP3ZR,$UMIN'9X944[
M5S&KT$_6;,8P)EKLV@B%45@&P.E:'B'5&=#(@+&.93S,3()U\D1)TTI<V&9$
MF<G-2W-VLZW2W%RMTI5EN5EE$ZLJA599@W4!50%4A@0H & ,5DB,J5(0J?-2
M%*G)R<CR.3SY>=2*F1H.A?\ H,AI-+[J_7*GQ[TZ1!7.ZJT[TK[T:S_YG1A_
M_P"?JWIYY[W$W][D?IEKZ,&%](F>>Q-<75Q_KY[B?X26;X:227X:?9UI?&S?
M"3=./JR?&DZ:;R=JX (OQ0B\ <8'"YP./4,G \ADX\ZK_#5W8OCKS.HQZ5T3
MA5'5MBOSBL8:6JN->;7H?SGF+JS2XU'A:?;8?.R^:L90TKB/SLGD&8^7EW['
MNGJAD28ZAJ!ECA-NDO>[GJ);GS@1^IN6$X&8@0AQ\6H].'!&R+!.XC:F"WRB
M,8)Y//G6D;0[._8LVI5+C5&5#I-2]_U<44FVVK7%)746^N*$K,J4DU"ENJ.L
M06"&GNE%(KE4<IAS88IJJN$4AYA< K9@K[76]5M)H)5N[B;NTKSPPW4DMQ;I
M<.LP%P()',9F1[B69'*DB9F=MVYPV&BA8$;47< I*A58J"OAW 9VD* 0#Y#
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M]4GDBL7$<^EO9K<3W\T AU"SU"[:V@FTR8B:9&AB@$TLI@W0R9E!8DX#LQC
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MRCY0,B)SHN<"II)<IK?7JI+&MU=+'-N$R+<2!)0R"-A*HDVR;D 1MP.4 4\
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M999<1QX^5EESW\\U2RR32R32N7EE=Y)';XSN[%G8_.S$D_.:R    ,   #V
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M)%)YHT,<<C(C2Q3$*<$2PB012*P\2N@ED"LI!\1^:LE02"1D@$?U-C(QY$'
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M>02P9LBRV!Y)!A,\TE,LLD\C2RL7=MH).!PJA$50 %5$151$4!41550%  R
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MYI42.21G1'ED4,<_"3%3+(3YM))L0.[%F8(BD[44#(4 Y  X _J7. /8!DX
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M&3@^*2--SK"0L%.SXV5'!4'!=0WQN.%R><_,"< U/GMFQX=G@M\K86".^P;
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MR)'(6NS!UY# \<A18T("I(@ZLL19F53&\B[,(<$IU!N)X) V;MHW C)/KQY
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M#YE3Y'D^L'(/EZCR/GJM)M#ZH(5&HY*7K7A.PB6PF+HE*N 6:--8'=K3_N<
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M[]SEKJ[8_ X)E?*]WD>6 IXO 89))&B*;3&9'V8#MD(D'D(QY^SG< #GCG(
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M+EP\\>$F,GU*_E8M+=S2L8YXMTKF0A;E.G<;2^[:\\?@ED7$DB$JS$$B@CC
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M652!(&V)M%%;EE!XQSY8R#R/(X(!!/(/EC)S@SNSOI1FC"K+/6VNF5?7&GL
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M>+S)X!XK0DF_=PVRO:DJX;>V'WW+:&UM=;0.H%&I5>LAO%-K\UMJ3D:L[O\
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M\R'_ -V72E0NE*=*4Z4ITI6B;1+=K];WMC6F_H%^MJ3]DI<< !M.5YR]82;
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MO&?@,\Y8EP^'G).9MBTL8+R+1XP.C+>ZQ-I\T^\D=-CIW3<(YV(8A=2>7QL
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MD0+CSXG'=P1\/),7''/?+W_!SY7P_P '/\'/P=*5#\%EZP'[5%\KI2G@LO6
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M"(Q(5<98OD$DCU*  HSYDU5M@[7]L\3VNH4)B_+"C:VVK:-'PXUDSQD+30K
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M9\NN$$=4G:R/.#>'<I["L8<UYP5*PSF=)9S%C?,T,XV&>27UVCF1)F5BABP
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M 6SQY;0"3SZL&J2N\IAO8[192K["$LQJ&I(=D*VR)]7['!K %]38-X 'U]T
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MQ\VC-V55C=UNN[2R3!X-;II9Y6:W8-B+:\574^)/O8N;%8G>6 +C">*>6(;
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MZJ>@)+Z'$=U<M 7D4JJO!8.]J01 [-",$%<#&9F*X0Q@H8><(?$B[@ 03AI
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MQP43VSV[[':)CM#Y@NH+I I8J,R6TTT:MD<H6# %25 929!@>1D<XY4J?J8
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M^:]5UFGCY_M87Q:N^:]*4\?/]K"^+5WS7I2GCY_M87Q:N^:]*5,Y.F\!'EY
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M"$D12FT^ZA5W=$9$B2<R13P3QF&28VPE1X9)%DC%PI@=D+".;$<FUB 0D1B
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M0QQ6-WI4\$L8:2=X["+H3B6*:Y-LKW*XG985B1YD D+!BZQ,3$-XLEUD4@X
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M0%V/?6,\1AN&N4CFBT=W,$4<DD<VDV<VGF';++"A2XBD,ZS*[&)MD9BD\17
M1U(9=I*F8 ,2 5E=9-V0"<J1MVXYY.X<5E@-+;&HR#1"VD\4FQS]G-*HHU7A
MM-E?5N*]TSC4H%&<G/V"RF6O*FV8>R@AM5N*Y3;P3$8)"\DA<6]S(30>_M;B
M747N.\1#5))+B8PPQ2FVG[ZUQ&L2/<0]>$Q,R.6>!ED964,L>) C91&%VGI
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MYKQ,L\\\I<^<LLLN8>><LLN>>><LN>>>>>>>>>>>_K.3[3]9J@^9^D_WU&]
M(ON*I^+@_P"IZ9/M/UFL4] (ON*I^+@_ZGID^T_6:4] (ON*I^+@_P"IZ9/M
M/UFE/0"+[BJ?BX/^IZ9/M/UFE/0"+[BJ?BX/^IZ9/M/UFE/0"+[BJ?BX/^IZ
M9/M/UFE/0"+[BJ?BX/\ J>F3[3]9I3T B^XJGXN#_J>F3[3]9I3T B^XJGXN
M#_J>F3[3]9I3T B^XJGXN#_J>F3[3]9I3T B^XJGXN#_ *GID^T_6:4] (ON
M*I^+@_ZGID^T_6:4] (ON*I^+@_ZGID^T_6:4] (ON*I^+@_ZGID^T_6:4]
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+_P!COY[OL]*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g96328g80a43.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g80a43.jpg
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MUS&4N2,F5G25U"4U0=-14J?1V"0R-)'2_\0 '0$!  $$ P$
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , X)U%XX]D@:8/ 8MU*HZ(/@0,A79(*EPX65.@#V2BQK_?3EPS9
M'7<5C3@JW0WT3>J@Q>SCC?EFCYH'2E*0I]:QT[?5K2%*6>DKHZTG.\>';2/4
M@D!WBJ1CX0Y0]]Y/(Q112*(G^?=-(Q912-IO]0F^S'D,OLF4L T:\/+Y YW]
M=GQ*O^HMVFP<I<J][#S(F\N#B, 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M;32>_MK)+I@XC & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M1CE/+WI.#V<TV_=$CF1H]0P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@&C7AY?('._KL^)5_U%NTV#E+E7O8>9$WEP<1@# & , 8
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MU%4Y\=I?'GZAL\G(N7+SE;GC.Y/XLYYCZU_%XZOC[NI:@#T<N>)6#= 2I'Z
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M.#2B=S ;V"DL:F;".MQ"E8#UU&I$6*MK92P\_%G+Y=^]8;QN33;WX)M\' 8
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M!%1@$ZGDX?K7J3^@]V_=5)\@7&7UHW_?['URB7#2^G*?O:GF,])S-9"4# &
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M48!.IY.'ZUZD_H/=OW52?(%QE]:-_P!_L?7*)<-+Z<I^]J>8STG,UD)0, 8
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MI9A*<,22VMM3C'E3GT2*ELN.<[GC.[<^3MY6_#RN3&&9<SQG,8 P!@# & ,
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M2M;S#:<'[':2^,#Y6'F4L 1F-2LO'I)IR:CWQH%0IH.A_$A8AGK$<7?186*
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M$'[/,EY!(=@(D"#V.&54-R1;8,##">7[EQR.$CF?*+-$<I\O_MAYL20'!Q&
M, 8 P!@'G*W#\KEI>T:;_:8GGT>T;J/I7BVQ]5I&J-]T[>>%7'IIF.<N1Y1@
M%N/QYO4LWY^9NM?W\4YFB' 7K]M._P"K^I7QM)==2EWFV\ZD>:YFRY&Q@$ZG
MDX?K7J3^@]V_=5)\@7&7UHW_ '^Q]<HEPTOIRG[VIYC/2<S60E P!@# & ,
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MQ"$-N4MB,8X2Y4XN$(P;RXQ2SOYN99;>%R++;PEEMF5\\9S& , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M#2GL^:ZL#)"%_9GH6+WC8C$3'G4)$NZLKR<RQ<C+K+BE806+1HQ82@P2'-RZ
M<R]%,3N^D(0 ,'A91)I.;CP,(Z)<BJ;YGCX6OA^V_L9-F*LG$>LJN(3/(HP>
MB8[*8X++"A!)FT8$0K9=MIQ\"D&8YT^&MGH=710:Z3%OWXOA=JI\&OWS'EN[
M6%#OV , 8!HUX>7R!SOZ[/B5?]1;M-@Y2Y5[V'F1-Y<'$8 P!@# & ><K</R
MN6E[1IO]IB>?1[1NH^E>+;'U6D:HWW3MYX5<>FF8YRY'E& 6X_'F]2S?GYFZ
MU_?Q3F:(<!>OVT[_ *OZE?&TEUU*7>;;SJ1YKF;+D;& 3J>3A^M>I/Z#W;]U
M4GR!<9?6C?\ ?['URB7#2^G*?O:GF,])S-9"4# & , 8 P!@# & , 8 P!@%
M(?RC7O!V_P"N/>Z$0.ANR5PU%#'W6: R9Y&(#.#4<"N9"0L*VQSTRLP'.44%
M"+IB(%M%W6VO*JB#!JGMMSJCIQQG3BUT+1M3T"XN-0TRRO*\=4N*4:MQ0IU9
MJG&VLY1@I23:BI3G)+D3DWSEAU.XKTKB,:=6<(]"B\1DTLN4\O=S[EY" O\
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MW;]U4GR!<9?6C?\ ?['URB7#2^G*?O:GF,])S-9"4# & , 8 P!@# & , 8
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M/;];/Z"*9K=QI]=+\76?G5B3:5THN^3^@L-9C@N0P!@# & , 8 P!@# & ,
M8 P#"532&ZCAZSD;6@H6&@1DH3:5HZ&2!$VZD$<;(*BWI0@FW02U8)D"@I:0
M"&SG?X21"2 <S)HH/F:Z?'NNZ=C3IVKM+B=:I*DW=*5-P5.JVIQC%MO:<835
M*;2V'4I3E!N,D=<'4;GMQ44I-0><MI;LM);DVLKGPUG?DS;GA.P8 P!@# &
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MFMZ65FB1Y4]ZQNO?JE5K]Y]V9GSBGZVKGQQ=>J6!']7Z:CWF'GU"M=F3BUC
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M4'&6</$GHY<ED%ZW.2)S+G84Q#7[:LY[8H4@+C*<1,LY>U)<0 B()).I1$5
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MI>28?.%[;>QF$?;=?,0\;W4W2/#J_JY>-'_"UN]KSD7GLP*2 8 P!@# & ,
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M,/G"]MO8S"/MNOF(>-[J;I'AU?U<O&C_ (6MWM><B\]F!20# & , 8 P!@#
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M-?TIOS_1V ?G=YXE>FNVWP'T;Y\W7;;W.)3?GN\^YQSS[G'_ '._X\^Y[G&
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MVOMHBV9LVJ*KARX5WU3113W4WVXUUYYX Y/ & , 8 P!@# & , 8 P!@# &
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M[C;?!08 P!@# & , 8 P!@# & ?A7CGE-3CCCW>>=-^../\ \>>=>>../_\
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M1/#DBD3@%K97$XYX8*%-AXPQN8;#&K-KQJAH*/F[F_ROZ,&S>"@P!@# & ,
M8 P!@# & , Q-;5Q *:#<2*3Q^=E@:(XZ8+%8?$"<G8QP5'6J#XF2DCD?KRD
M%9)LU5'*3AYMHFJBR?J<;<:M%>> ,8/.Y%*,-(XY<KSG0:9AM:SXZ9_8WFO(
MBLHO;RFZ-?OK8?<AN$Z_7++I./A0><X1?PU@V7/SAM&XUIP9V%</DY^3R?;X
M>8VHP4& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M>\A[@5TPIJ,P:0U[5;Z<\"VL6+1Z;"G QGM'YC#E%9!RH0>FAOQ21)CQ2/\
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & 88M&EF%DFXI+F$XGM83R&#)9'@<ZKIS%-3J<4G:D;<3&*NV,ZB4ZB
MCT0>(0R'E55G$;W-#2D8$O 986IJ[]*%<_\ CR_68@6Z/4^B-%1:.EK AU<Z
M0*LZQFE8 #XQ>'VK!ZB2W9P<+83B2 )!,'&R I54!)BL6E<5-6#&]DXY81&4
MA&;!@U#/<SV>PWW/LN8W&P4-&^M7SJ?$8]ME%?JB4;@J^2/<^EF\F"@P!@#
M& , U0[G! TCI9,-))Q6U>QE>S*B>R&0V_'EI/6NXP%8\<D.P.6B?A:/C7 ^
M1.Q+4&DG(#X>/NGSYHP)O-TWFK-U=]$J3I7SG2H75S55K>QI4[*HJ5TIU+6K
M2Z)1GL5)*5*,W4;ITYU%&,I1C[G*Z:Z3IX<H13G#+G':CA33PUE+>TEO:7,^
M4C4O^:3Z4]*+#AT,K35*D(5">UQIY:'5X)&X'64WXJUO('%3N(G'4YXB4C,/
M.3-=S84_,1DK(!AHE6KH.+WD<6L8BBRD^G4+>CKEM6KW6;^O7TBG&TU6I5N+
MJW]N.FKQ5JCMW"K7IT$K:WA5A3G3C=*I+H5:U@Y>2I*4K><8Q2IQA7;G22A"
M6QGH>RMK,8N7NYN+:;AC?&;2D'[12*&V/1TFB)">U_5Y08=ZVS"P1]R#6\E"
M0:+D[GB$C0$V_$ LA:M/B].!T0DT.<HDY.+B1+;8FW*R- $@2>IQS2J=:UOZ
M5:-O<7<)T]3H6\K*4J4Z]6-C7I.=G6G2;Z)0E6I5DX4IUH^X<*;J."?JK.,Z
M<HN48-.E*71$I*,74B\3BI)8DHN.^23WY>,G8^GA]@6KB4A@ NK$X=![-E$0
MA<OI&)LX15-E@4&0,ZXF40C8TL?&,O1)$?/063N!9TJ,*S>%28LP59M7R0MA
MUZS2E"YI3J2N^C5[6E6KT;ZK*O=VM1N=-4*U64*<I9ITZ=>DITX3A0KTJ<E*
M47.5:#3@U%0V8S<8RIQ4836$]J*3:6]N,L-IRC)K<4#?*-_6Q7I]#:1^Z.(Y
ML+Q:]:&G]^O_ %VN1W5.G*GO:?F(@QR>%O& >FUY/MZH;J)_,WI^LM<F:N\8
MO7EK']W_ #58DJTWI*C_ &GI:A,MD)/<, 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M0> E<PG9IJN@/Y;I/U7,E>)NGNBSANDS04T:I"KQ[G'8^EDDF"@P!@# & ,
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M8W<NY167O;R^?"S;GA.P8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M<FW)M-Y;^ RKGD.8P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MAA-6L(XW)@1&DKF;>P:DK*/0]LZ,/='FCXS)KEC[UZ5%B#+2)1(-*95(M63
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MLM<F:N\8O7EK']W_ #58DJTWI*C_ &GI:A,MD)/<, 8 P!@# & , 8 P!@#
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M%L& >AOY+IZM>0?6=M'['U?FN7&MUSTO%5IZ>[)+I/2K[[/Y(ECG,:%S& ,
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MTY[XK#WI<I=M-N:MS"JZK4G&44FHJ.YIM\F.P3]YCTN0P!@# & , 8 P!@#
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M%&MJ,*LZ=>JZ5-4J,:S4U!SRXSG!);*:RFWOQSD=)#Q4?"H+0\37A6A'A.
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M\J/=;Z TS]HI_F&^.#I30_"+[T=N7K1OY=?WM/Y9%W;,%E^& , 8 P!@# &
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M6L>5@8P\+0VJA4[*O0T2(V <24TX&M23L<]=D>1;8RK$(ZCK,IRE&(<Y9GW
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MZ\DE^5'NM] :9^T4_P PWQP=*:'X1?>CMR]:-_+K^]I_+(N[9@LOPP!@# &
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MI:&\</YC!'VJUY^D,9N+Q&]?=+Q5J/FTCXD\8O6W/PVU^6H4T,W/,!# )J?
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M4FINJYI)5)Q;6R^597,1$_M6.X7Y%W;_ /LX6K_IO,O_ 'ZN+W\[77[)U/\
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M4Y2:Q%-M(J!?M:.W'Y&7<#^S9;'^F<QK_!G5_P"@A_C4_P!X^C7\9#BD_/\
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M8>5CER3M>(!V73OKJ#<U25GUP[MF9S,1L7; !COIEV)#MW2HR=Q8X\U4)%(
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M4<-8O$)FP+!GI<* *:(K!)L+:O&KT=HH@59D.$5EVFS=784,ZX P!@# & ,
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MY#N4ECN%R:=1JHY# $F4T>?')*'<\%28RQHMI((5&V['5D]VF+ ,B'4>D#2
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M4UYT4TU4TYYXYYUWUXVUYYUVXVUYYUVXYXYYUVXXVXY]S\&W''/'X>., _6
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
(# & , 8!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g96328g96a22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96328g96a22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1G,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &;"^978X0DE-! 0      #<< 5H  QLE1QP!6@ #&R5'' (   +V\!P"
M!0 ;5F5R82 M(%-C:2!'<F9X("T@5C=B7U!224Y4 #A"24T$)0      $&_9
M<-H SG]D#!G%VU>9U)XX0DE-!#H      .4    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O
M &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU
M;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0
M !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O
M;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O
M;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0               !"
M;&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q =
M  IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             #Y
M!^$          0                         !              ?A   #
MY                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
MY     !29VAT;&]N9P  !^$    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   ^0     4F=H=&QO;F<
M  ?A     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M<A(E?!04_P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!*P)= P$1  (1 0,1 ?_$ !\
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M_P &&R=Q\H;0WCSAYS8_2 W?["G\&_T84.X^1AM)WB_7AXP\YL?I!?T%.O\
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M,XG:&\=<,^JP\YL?I ?H*?P>OLZ\-DYT.Z&T-_'KZ;](><V/T@/T%/9^9O\
M1A0VL;Y0VAOZZ];9P\YL?I ?H*_P8;)W'KVY0VD[QYP\YL?I ?H*_P &&R=Q
M\H;2=X\X><V/T@/T%?X,*'<?*&TDZCV]X><V/T@/T%?X,-E6XQ&TDZCV]X><
MV/T@/T%?X,-D[CY1.TG>/.'G-C](#]!7^#"AW'R,-H;QYP\YL>CR@/T%/?R-
M,-E6X^41M)I6H^OEG#SFQ^D!^@K_  8;*MQ\HG:3O'G'O2=MURG.DH!RIAJ<
M>2<.2&@CKH8H".XH] #T8$$9VA4'*\>CSFQ^D!V_U%/'_4PH=Q\H;0WC=](>
M<V/T@/210/>3"AW'QMQAM#>/"_M#SFQ^D!^@K_!A0[CXVAM#>/.'G1C](#]!
M7^#"AW'RA4;QYB'G1C](#]!7^#"AW&\*@:CSAYS8_2 _05_@PV3N/5X;2=XA
MYS8_2 _05_@P((T-^NOQ#:3O$/.;'Z0'Z"O\&&R=Q^OEGI#:3E4=<<H><V/T
M@/T%/X,-E6X^4-I.\0\YL?I ?H*_P84.X^1AM)WCSAYS8_2 _05_@PH=Q\C#
M:&\></.C ?\ V@/T%?X,*'=Y7]NO*&T-_G;.'G-C](#]!7^#$[*MQB-I.\0\
MYL?I ?H*_P &(H=QB=H;QYP\YL?I ?H*_P &%#N/E#:3O'G#SFQ^D!^@K_!A
MLG<?YZRAM)WCK^.JB'G-C](#]!3^#CT#A0[CY&&TG>.NNJB'G-C](#]!7^#"
MAW'*OA#:&\></.C'Z0'Z"O\ !A0Y4-<X5&\></.;'Z0'Z"O\&&R=Q\H;2=XZ
MMUYY0\YL?I ?H*_P84.X^4-I.\></.;'Z0'Z"O\ !A0[CY&&T-X\X><V/T@/
MT%?X,-D[NNO+.(VD[^'7WRCW(/&SDPE15 Y@+RA "G#\W4 U_.* #O$.CMQ%
M(FH,?3A$PPA#"$4B:^:%^O)^PIC).>70ON/+QM>,%Y#G]XM7?[?4'2 >._L#
M=U[@ULO7/7R&@YFHXD5W"*[>GF<B>5MYOI<TG$[ZC=KF?36PB(;NGU#AN-L[
M9:Y_4V]=5[CS'WB.SU;MW1OZ->.O=A8C0UMPM?*O#(>T3O\ $WOG;.G6EX<#
MT^S3X>'3AGK6ECX<M<LO"AAT,O6OUYY1/KZ.S[NGN]F%>>FF>7#SRI>(\L]_
MYRX^L1\/;X[ONZ_!NUH?IF;6_/*)^OIRO^=.;?OZN-^[W=/;A>GAQ.6>8KR-
M#7/@5N?5K^^6Z)XZPZO;Z-/6&'"WL:6OO)X^M1$=:'7T\:^1B.!W;^[H\=_5
MT]&(I;G8\<Q0TRH3<B)Z%[<<^7/+.'9T[^GU>CV![\-0+Y\Q6F6FXY6!\H;\
MK9>?CZGVB<97TZW]'7A$1'IZ]W;V]8>/;NQC2E;G6FO'7,Z9GPK:?#2^[=H>
M6Z\3Q^/:.[IQ-^O#C?B3>UA>(Z_C<+Y1'=OXUZ_LWANZ,.!Z!K?AJ+'RR$\;
M=4T^]C?.)PX[\J<1GN\Z\-!$0PUSRTM:O0I]81 Z^O=X=._>/W^/4-<\CEOI
M2M\[\+5X:1(IY7YY6L/QRUGCCM\,/;Z4TH-XI2OI2(Z_G=SAIZ->!Z.OOPIF
M!D?*ISU!ZL12D*^-.AGIPAB80Q%#O%;::6M[^>D(<>_U]>!W^QSSX7H+TXG,
M@0Z]O+2*^A_<JWB?]LN*S^_Q'L(L_P"GU_NB@>_W?=NQ9>U0*^UM3I6AK0<-
M+U^WO^;Q ?$=?1N[NSCIPS\20?"HX&N6_AOB3]!3QOQW]91/''J^SKPMYUWY
MWKZ#/=D8CKKS\\](8:TYFXMI[5'WK"'&G;QNP.ZM\]!R'G332ASAU7=U>'9@
M:V-#;SU&GTKRAOA[^->S#W_BU;9Z>T/;JF^&'5=1RMP'0A$>/1Z- [>P??Z,
M14Y^.8H*>%;C@?#.)Y9^-3NWCV\8G7CCQQ-CN/ _;3/=NB*==<HC7J /'L#H
M'X^G#6V\UW#7SN*6.O$Q--2>6\YCZ>$.--/#?VZ]_5Z-<./$6I34 '4UW'++
M+.'YO7G;=3AJ>=(G=\./NZ^_"Q'I>H/+?G;B8B_UZ_.G"(^'IU]?&O;A>G+,
M9^%;9V-_&)^OA3RZINAU>&_=W=G'=T8BEM:"_'+(5N*;CRRAKSM?COZXYQ/9
MQKQ[?#7$\^=JWI^!EPUO$;^J=>G.D->.SO'#6OG<4%*W]*>^4*=;^$/LXW>G
M[<*7SY;Q]+;Z5O0\7WZOX?:''H#X!KA:VE*^0M_!W<X=>)^II$=O&[NZ?O'N
MTPIGQ/'+*U*TX^.0N)W=7XY?@<:P'K$>SN]/K[]V!IF?I3Q)\!G[6#0#?Q\/
M+A>)X[,+#Q-==:#(G2H^T1UOA]W'3W>'COPIIRN3UNX"^MQ#\]9<>?*T5R)^
M;O\ ZL-W_P"17W_#%:\Q?3CY_P ;HL1D;:^?#K?%#XXXT]&+#S(\/"N6A_-C
M%?775?&'2&[T<;L,Q;6AZN+;Q#(W\>KQ&GH\../' #2VE:9<N6>@SWU,23X\
M_KUZ1.G3WX6O7[6T%:\]=<AE$5RX1'Q^SN\ [/=@?QN.F1MN XY5M2)^GWX\
MSO\ >)XW>P/5T^SN9#TKXVM[Y<*:1U?U/G^>+CCV84^NNE_QNYT$.NO6(W^K
MPT'M#IW?#3$&M-^^M*'0C.U3D*9Q-O/G4;B;7^M8G&7777I$0Q'I<[N?'E8Y
M;M$,,N)SXZV]Z"$.../?NCE6PS%"3RK6NGEKHZZZ]KN..WC=B:5S]"1NY5AU
MUNZO#CCV=G;A[#/72O'A:QJ*WU==>N_=$=H\;NGJ^WHW8<=U:>&=M^FO#,Q.
MX=7RU^V=XG"W"PJ/7TIP^D1#QTX]W9AD+^>M<JTI;=K[PY5Z]]\..->-.C"_
MOXW\*4\:C4PZZIU7.'';T_#?X!Z,!<5OGQ^HROR&F58=;LOK;F?&&'\:6W_8
MT^AA##>#^#U>WWA$<>WX;M>SM'#=7,9;MV0W#RKF;Q/7I];TW[A$Z?9W>KHP
M(^V9RB*_?CYYQ683YRK]0;]XGC!S3Q^D6-Z^'UBY\5Q9#"$,(12)KYH7Z\G[
M"F,D9GD:</'3H1@O(<_O%K8M\==VAJ:5Y4^N<50XW[_CAI3W.F\&IX$?31U:
MWTB.W[N.K[![(%M]Z7L<J"AXY^&NZ=WCOZU^XWS^&F[0..CX8GVH<MV=M=UA
MPIOB/YK>IZS^L-_W!]^GPPOP(W9[ZB]!T86_)_%?K#?QX\??ARZX <!R\;PM
MUUUPA[/A[PUUPY[_ !%;<J\K&Y&=(>OU]C2D.OOX^SV84Y$ZZ;^9O0>7A#VZ
M^_K%FYB33ZM4"]62,%(LE7Z;9IN/,N3G40?14(^?M!61Y1052!P@F*B8F#ED
MY1=0UUQ=+-)>FI=I==AQYEM5#0E+C@0H Z&BC0W(/@#@XLH:<4*50A:A4 BJ
M4U'&E1<6M'Y7$OEM]K5YLE93IMX6@);72-LJ68N=3TU3<JTYGLG7Y+*:1H&8
M49!%= W8/[C)[1&6N7;!<'Z[=.PU&]%,0'2111]6'8?"/ZO,[3LQ_1U-.2TD
MD/)2^K%FC-IF)93E"5!A&'S,RH;*26WF2*BQZ5>)OA@40CXA!*W:I5L!BB2A
M8OFM3B4BYH4G0@QW"D/E'\K(0K)[/5"V1$&KM6;1&RS*3"JL:Z2A9/9OH.9V
M8ENOCELU65=.JY(PV5TNG%L&B2LR#AXS!9J %5Y.B([-S2ZI;>96O^E8?BJ4
M;*@7$XB_+L-, GY0XE<R@J*J( 2:&A!CLU3C:;J2H /.,UJ"!W0)*J 7% ;"
MYN=+V>R^4>M*^5F7>9DAL=YQPQ]H>UY6U;9.K#V]Y*+26>9\VZ[:[K7W<@Y8
M7QXVRH"%HM2>7&WHW<$R1$2_C6S!S,S1GT4PO5V<:$W-2R<9DG!AK4V[BSJ9
M>>"9#X1QIA8"5, S@6^\EEHL$[:DJ44H0$J5C\6=A"S+NCO5(2PG;:)=[Q*E
M@V5_;^4;1VJT&9WV%(_*_9>1C_*R#D\EKO5+!<+IF1EMF"VS(N^5^7%;RPS*
MRES&8Y9W3+8N9%FL[?+6ZWQ.7>EGH"$B;8Q;SU2\FDV\DC)/4(0;T]CYE:9I
M:9UAUMEB6F9<RTO,S+DU+3DNJ:8F?A6FU3+#)0GNUK6RK8>JDH*4E<8_'M@H
M!;6DJ4M"MI;: A:%A"T%95L*4*DT"A5(K:M(S!EK\I%E]F+M=N-DY"EKM'[Z
M7SAKM/O41F5E7>8^:G\CE$1NS&P5JE6F9GJ.FNS,X>01YLBCQ15D[A+%'UFR
MM7D(UXDSV:F9;!_ZN7@4I1(N/2RY::86VW/U#!;=?;0A\A5 L)H %!:%.-%*
MS8B;0N8^'"2"2ZE*]I"DJ+5U5"2HIME6M[$ UCI!W_:/LQK9MGZ: <->)Y6I
M6.5P^P]8<#QQUAA:MM,\ZY6UW'.]?"'0ZZT,./1@;\-X-[:CZ:PZ\8C=[=W5
MO'[=>_UX6Y7-*V!)&?OZVK$W]+ZV'VIP\H>SK^WN#T>/7@-^^AS\SN\LZ5K>
MSUT^W$^/+2)U]. -<O;QX&X^G&(IX0XXZ<,P#RX:@_3QAUUE##AUIEN](0^_
MC@<,P<K@BV6M]<];_6'77\17T _XE7\5/:<NN*C965;Y&EZ^E_:+*_)Y>AM%
MO[NWHW]6[O\ 4/JQ945K4;R.>O"F53IXQA?=G;6_#S'G$XGEK>][]<>41$;^
MWC=X\#X87.>_AE8\;UMGO.Z)MNZORZ'.'B/;X:;@T'MW^G7=VAB+;Q<VRH18
M$9W(\]VHAR&[G6YJ-UO"E]QB>S\>.-W8W$GRR-=!??3GEP$;_P".NK[^0/RC
MNTGM=Y#YAT@V6(3V76S>AEE8K;?<^ZILQR^U@:!S$C)PJ;6KYG4NMWJKV3+S
M*=M4D5I^4S#AH>P22[Q96/9IMRQKI0-Q[-X;@\_+O_%%$SB1FFV9?#W<41A.
MW+*;!+LJ\XRXW-39>.PF6<6VD) 42=H \&;=F&EH[NJ&=@J<=2SW]%A1^5:=
MH%MO9H2X 36H%#>+TAOE0,N5G<%14*Q/YE9G35[R%I]699;,42,<WJ5GADLZ
MSQB]H?+B#DI61FVV52=+K&8C]>'DW4A98B2ISNJN5GLLX9N'5"^R\PE*W^];
ME95#$^\\J:42N3?D9T2*\.FG$I2V9LO.RZ0M(2A:70ZE(0#LR)U%0G9*UE30
M2$"SB76RX'4 FNP$I42*D@@ DDTC7.1^6%N=XROH=^R#V;4K%-3FTWD)DI9Z
M'8<VLJ'=Q@8G.66?L6L%8ZLUS"K=BRMS6?*QYX%@RS C$JG#3C@CY>1LL''S
M3B.[%'8YAB:F&,0Q13;:,,Q">:F&I.;#"U224$K;=+#K4S*)"N\6J747EH!"
M4M*4@*K5/K4VE;+&V>^::4E3C84 X2!;:2I*RH;*=L%*34DD @7^E\M1D.ZM
M6:L.PH-IDX"A5_:4E*U8(RV9?2,M<Y39;J=OMUZCY.ALI]>WY<Q-G84*UDRX
MLMRCVK&R&C4!?H0)YB$1D:1V)Q -2BU3#2%S#N&(<;4S,)0PC%GF66%)F%-A
MF96VN89,RTPHJ;VC0N!*B,OZBUM+2$J.R'B#5)VRPE2E#9!VD5"%;!5^ZEPD
MVBIQ/RLZR]D)"V/8_P YZC%L+YLMUBWV21O>2LFRIU9VQ7<5%9'6Q]'P5[DI
M:7>3$Q)G;S]9KS236K3)DN\DI4KE1M'+5K[))[HJ:QF2?4IC%%L-)8GDJ>=P
M<+5/-)4XPE" A*:MO.*0'2H!*2 5 )XUHJ7<2 IG;45-D)2_3NS1*B36M"E-
M=FER":1Y9*?*)W"TL*EEU2<I\VMK#.27D=I"\VI*//DED^O3<GLK]J?,/(B(
M?.#SEMKE/F9(92LGK=-A8QZ$U9HRO+V*UO8-ZZ7,K$]V=:96],/SDIA,DV,-
MEVBOXV<[Z;FL*EY]8'=M./(24.%QYQ:2VVI8;:"@D1+<V5!"4-N/NJ#JR 6V
M]EM+RV@34A)-0$I2#4@5414F-NMH/:QE,H\S,O,D<M,B[UM"9S9@4R[9G)T>
MGV2@TM*OY:9?OZY#V&RR]GS$L5?@1>NYZV0<#6H!HY7<S$FNOY6YB(]L:0-U
M&'X2B<E9J>F9]C#I*7>8E2^\W,/*<F9@.K0TAJ7:<< #;2W'7% )2D"@4JH'
M(=>+:T-(;4\XL%>PDI2 E) )*E$ W(  K6N<:NUG;_L\3GM;,D0R]S0SIN=S
MVKLS\H:/6T4\G*&VRJ@LK\A\CLUK2QDIY2TM&-FK<%'Y@RLVK/NW\G;7[].3
MA(MA+-T*^5[VCO9]E<@S/"9E9)AC"96;>=/QDP9MR:GYV4:4E!;*VEN*80@-
MA*&DIV5K4@ERE"9HAU36PMQ2GUH2/[:-@):;<()K0A.T;_,3>@(I%Q0_RF19
M;).:VFS[,>:T9LY/)6@,,I\TGULRL$V:C+,#/.J9%QDDG2V5N=W.F$6DK4E<
M8Q&QPY"R-0CG:SEQ%3*\?$.\%]F"B>1A?]4E%8D$3"IN52S-_P#*&7D7I]:2
M^6DLO$)9[E9:6-AY:0 M 4I,B<!:+_<N!FJ-A>T@A>TZ&TD)KM)_=M?,,@;C
M6AYB_*)N8C:GJV4\'$D@J'E[FYM*9;9YN[&O6FA[&AE!L;0&T[$2]5L4U.0T
M)4XY)2U1["1D+5(QD>3S>^4DWT;%",@GE+]G@O"W)M:]M^8E,-F9!+8=/=F<
MQAS#%H>;0A:WE$-E24M)4JJ@$!2OE)<ULO=V  E"WD.DE-PVP'04DE(3Q*B!
M3,@5C -C^65M%EH[V0R-V;_RFS!K&?\ LBY=6FM.\T<KK;7'F7NU7:I"#J$O
M7;A6+_#PQ+C/+P,M4V#&1=GBZG9)&OV:P!+T-9S)X[%OL8TT\/C\3[J6=P_%
MYEEU$K--."9PEM"WFW676%K++8=0ZLI&TZVEQIL-OC9BDX@5#^TR5+2\PA:%
M+01L/DA)2H* JJA2,PD_,:B,Q5?Y1*TQD[=\LH#++-/:;SJ=;1>UW 5[+Z,+
MD_EF>F96;-<S46-I!:S/K#&UV8BZ\[NE=K-/>/UW-RO$I)B:6)'HMSO"<-WL
MVT4,33DW*89(C#<&>7,K^,F>_FL30]W1[L-K=;6Z&'''@ EEA*1L[52(S3.*
MJM'=N.N=_,("!W:-E+.R5#:KLD))^474JYKE'S*_+#Y?RL:YO% V?\VKUDY7
M:]LH7#,+-!";RX@$:)6MKF31@**#RH35K0M4_8H6Q+>:)^&K3"38H&9R+OSZ
MFU18J260['3*5)8?Q"38G77,6:EI4MS+OQ"\(3WC^R^VT6FT+;^=M;I0JZ4E
MLJV@D<0;NI+3BFTI84M=4)V1,$I1\I.THA0V2$UR)V@([$B&\0'P$/M]7OQI
MOUTYWO>_"@-*'2.PR\\^6[7H0P-?*NA.[=EZY<#$0]&&1'C7QO77,Z5MQM1X
MPQ,(8@C7=7Q\N0W\LH17(GYN_P#JP_85Q6O,<OJ8M1D><4+IXX^/4/AF*V]Q
MD:#/2W0!%Q7EUU]-1SG$Z#Z97\,N-HB''9W>KQU]V&?@?I3\WKGRAUOX^?*G
MO$:[_3W]&[?T?=TCKTX@$\\MX\<K;J<#4UK$T]CNSO;/\Y"F43[_ &>K7CMQ
M/OZ>^M=]3X1'MZ^=.MT1[ #W!U#KQ\8(IOMN-!0:&II[>D3ZD^YU%.J^D]/7
MQV8FQUO_ !4>U8C+3K?#3CCJ\?LPH,J^OF.(WUK[0KUUKR^\1U:<:>SJX'#3
MARTK?=D+<*7K$ZUZKZZ]"-/]O_.N[[.6Q?M'YYY;*Q2-[RPRRFK75E9N/"5B
M22S$S<&YG\<*R /&X J;EHBLF!MP\H-,=QV?DF,2QK#9&9VRQ-33;+O=JV5;
M"ZUV54-#84-#G:./,N*98=<33:0@J%02*C>+$QSOR]V_,X,YLH9C:;+=$<L\
MM)K;)V=MF3+K*>O4.LS>;=::26=5(RXOSO/MM>'20U*?S45L!W3&K1K-E,9;
M9;RL1/,5K)9)!HLVV*8[.R<E.)PL-?%33>#8CBDS-N3#K<FZ42CS\N)#N$@/
M-R@0 MY94B8F4+;(;;20>(U-N.MAXD(0M]ME+:4I*T_, YWA43LE>B1="2""
MJNT?H??*QW&:M^3>9,!D9<*KLJV_*;;;S@C;-9)#+Z0L&>M/V9J&C8H>3IT;
M$VIY8,N'3R0C955.-NL2T)+Q,S!NTWI3DD&C&!V29;9GI9R?:<Q9B;P.36RT
MF82W(/8G,=TM#REMAJ9"4J2"IA=4*0L%-P53\<HJ:6EI086B9<"R4DN)90%#
M9 )*"36RA<$<8OJ;^6&I5'A+.ZS5V?<QLKK,2)V;Y[+"L6J\Y1G0S'@]J-2\
M(Y>2LC;XJXOZCERUC/Y.+?(70;5*E/!0T6#I DE(N4(@W'1V-??<:3*8A+3;
M07B3<T\VQ.),JYA89^(2EI;*7IHK,PTEKND4<4JGR@%<9*Q!" >\;6VHAHMH
M*VSMAVNP2H*(;L#7:KLT-=T5*.^6.R+"D.;U::%=:O%(Y89\VQ@N$I5;'&VG
M,O9ZL-;A;5DI1YZO2CZ'M]EM<==:;:\MIZ)=*0-MKT^4XJQLK&RD6TA?8W$
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M(NY1&$6F>7&0,-%-33-REV;Z*C%X]%C*3$9MW97LE,=I'775O?!X9*$":FR
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M3 L?D10R%#0[MO,R"IO]8[ZQ2[@AAZQY*!T4P[B% - #':=G4;&#2F]0=78
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M32E?MD*Q->&?5MWK%L7-^I&UJ5<H&$BID4VR9B[C$%VLDU,<HAH)3D(J8Q#
M.I3%*(;PQDD#:&[[#7VI>P$8K)V2==]SF>?&NEZUBQLK8= 4'DXJF4[@'!F+
M7E  \PF1)-1=5/IT.MSY4N4&AP33.4! JI@-DXJA"1NJ1PK2OANU\(P:2*5X
ME(YC,7Y@5T\8V 0_N5?Q/^V7'&K5=]X'E:.1_P!/K?% XX^.OXVB]].C4>?6
MM?77X_B-_'HW^C?ZL*F^EZ9@VM?RO0Q-NO&WC;SC5?;$V7=FC:OR6L5"VIZS
M R^7$,U?6I2SRTFG6G^7"T3'.5G5WA+H*K96I+1$<5TO(22CHL2M&)NFM@;O
MH91VS5[7!L5Q/"9YM_"G7$3*U):#2$EU$R%J ##C%"'@XJR!0J"S5M25A)%$
MPPR^T4OI24 %52=G9I6J@JHV2D9WRS!!,?G$B_D$9*J/964V$?E;+KEQ27T@
M4AX>*G'H.T5';**DVJ4C<\GLU:9%3KQ>)FX)V034V,,JTDXUP4#)/FPF])5V
M_2\E"<?[(L3#Z4V6M HH)4M!*69R4=4A(6VZ*=\L52H$ I5'4C"]DDRD\I*"
M;@&I!H#3:0H!1HH?Z4V(-""*Y.RK_P"#HY:6F[Q.8&VKMR9D[6#U%ZW;$K[6
M2<UU*8<E4.H$#,7>RWG,2YRC%YS*X+,J\XJ,N/-G,VDD3$.8.)-_J/--,KE\
M$P*5PD%)JZI(=4@4%'$,-L2S*2FU%.=\BXJF,T82@J"YF96_<?)D"=VT5%1K
MN 2<[Q^F'+K+FB914>L9:98U.#HU"ID4WA*O5*XP1C8:&C&P&$C=JV1* "=1
M0RCEVY5,J[?/%G#YZNX>.%UU/,YF9?FWW9F:><?F'EE;KSJBI;BU:E1\  *!
M( 2D   =NE*4)"4)"4I%$I38 #0#JO$UB]=WQ^&OPQ0<]*YY5T(O^3>E-(RO
M]/K3ZQJ3G-FJC/-K/0ZG*N&D7$O25O,:R1T0E-RDF[?,GBSK)_*F,<D69VO-
MB<:I$9R#44'3"H1<@L\?E5EDRLVF^=G<#5*N2.*3["%O3#9G,'DWI@RK#*&G
MFTH[0X\^@I<D, E7%%QIS;;>Q%]D-M4EU=XYYSVI[0IFVY_!\.F%ML2[R9'&
MY]F63-S#[CS3JW.S/9Z76%-XCVCFVTAIYONW6<,8>4Z\#,I#3=MM,A,XK=$P
M48YS4E=GS+-K!1[./R8R?:1J,Y6FZ:7(-'N\UE.6_>2!DP!:0591QV!7KERV
M04?D;!+R7-7VI[.X>_-/HP)CM;C*YI]U[M'VA<>5*SJU&H>;P%.RRTT#5+27
MG@[W:$+6&E+,NQP6^Q_:;$I:4EU]HICL7@+<HPTQV7[,M2Z)N00E-"R[VB(+
MSKQ']QY3+!9#SCB$%X-IF7MQH2+)!PT1"D>R4D2(C(^+)(S+Q22F'Y&#5)H5
M[*R"H J_DG8(@N^>J !W3HZJYP QQQY[,O\ Q,S,3*FF&3,/.O*9EF@S+M%Y
MQ3A:8935++"-K9::39#82D&B1'ILK+B4E9:52Z^^F68:ETOS3I?F7@PVEL.S
M#ZJ*>?<"0MYU5%..*4LBJHJG 8HK[[J>%\^8M%\<FV>T=L_5S,Q>ZQ&S9F!6
M[Q-R-=RZK5XLB]*EJFFVD'EHAJVWJU=C<V)M>C1,U&Y#VIT8L%4:RL*-/KWY
M1H$>R$6VQMBL.Q!<J)96)R[S#:79AQAL/I<!3L%TNN+E&P^I"YYM(VW71_>=
M[M6RE:HX*'6>\VTLK2LA*0H[% "#LA(#BM@*2T3\H'[4[0K01=<1\H;EQ.2"
M5;K61=RD:S.N%Z^$9Y?E5$SL]>[7F=E/2B5IE39:Y,8Z3:3:^?%<MT]874TW
MC5(B3<3Y!EX:10FW=3G9V9:27'9YE+J!WFT4S:VT2[,K,OEQ3R6%*24?!.,(
M:#>UMH"*I6"A,IG$K44AI9&1%6@HK4XE.SL;8"@>\2HJ"B DU_;\T8WSWVZ:
M58*A)&J&S+%YJ.ZPBWF).(S,-E%*13>L-LJ-HK-N#,5BQN<^\@)\BNSQ--7U
M9M#2"M5.3E$)-Q67<LFS@I#DR.!/H?1WV**E$NU0ER5^,2I3IF\.E'!M*9:2
MXU2?00ZVI;3VR4!P)VEHP=FDE!*&.\4@!5%AN@'=O."@"E$+!9ND@*2""4U(
MBOH[865]1@+RX=;/T'"YHP4Q;29B-8RM9:-%Y>P5G-JT429+'TVOW.P9K9CR
MLBSRR?3+5_1H"_1SJ68Q4.,VO*1TDSA:E8/-/.,)3B*W)1Q+7PREN31"&WI1
MI]%7G&6Y650E4TE"DON2Z@E2U! 24J5F'VT[0+02X-K; 2BIV5*39*5%;BJ(
MK1 7>@.H%W,ML7(Z.NK2TH9!2;V3=J0T6VOM'K654]/5FL6=OLW*((R\Q"W%
MS+SXO+EM8UF./#Y<FM8G<IVI8C5V=LFZFJC@\\IDM&?0E*>\49>8=FVVW7FC
MB144(6R$-_V<*<4')@-6+0V@#1$B9:VMH-D@% [Q*6R4I6&*5.WM$;4P!1&U
M_J) U^1AM+[.;G+J#S"J6S=5%JI7,]5,F9CFD,BE4*4.9F4T-F;:[77Y"ESU
MMK,H%@BK;!U6RUR&FV]DL=G=R-=>LGCY%LVD2L,Q$3*Y9[$G0Z](?'(J9_:?
M^&FW)5EEQ+S;+J2VXRXZTXM"FFV@AU"@DDH@/L%'>):3LH=[HU#(V2XA*UJ3
MLJ4""E02H)(455014$1M3L\7S*/.IG-YKT/+N*JU@;/$ZA,S:L9EXZL+QI+P
M=:S.0:$N67\U:8N9B'C6[Q,L^:M+*\1:6565:2""<LQ=''K,08FY(MRC\RMY
ML@O(0%3 ;24+=E2KN7TM*0H*EUH0HM@J:"%))0H1>RMMT*<0C9-=DDA-35*7
M "I)(598J*_*JH-""(V6]'IXWXZS7+[6^O&GC:+O'PZM$:>KC7U]?;[U-^7N
M:^&>N_AK-?/JGEIN]GV[^KN[/#L\=,#PM>_MNSRIIX0^UM>._GOY5B<#X D$
M;_I?7/EK$0Q/OUK3*T(KL3\V?_5AX_V:O3QVXJ7F.7C]LZY<ZW$6(UY^'7XB
MA8LL!N%J<K9U\N IEI7#CCC7 TW;KTTJ#GN!TK:E:4AUUU2(W[N/'C?Z]X*&
MU[U%\J@:6\>KQ-K]<NK>5C.&>?/7?;V%;Q$,2.J]&$..SV#VX@UIF?+Z4)\/
M,ZPW_P ^HW0X[?9QZ<#OZ_FE:>L.MWKUX0X^_=]V'#P/'C;\:\(=>N5_S$<<
M:[Q^.%Z4SM?B12WC>^6^HB>NJ6'TAIZ>.D>W?]VF\<+Z_C?72M^7 "YA7PZR
M&ZWYK81.%.6[30GUTSU-M(B'''5QUZ8$5Z^E@=:^QAUUKT<JPXXX[.W#^.M!
MZ:<(===;]T8=S.SB9Y;R<% -J/?<Q;-/05NMJ%:R^95UW+MJ?0U:RVMEE6+:
M+/5&+M&,?W*JQK:"B'TG;IQ].-TH"NRB36478<N6DS,I<<+[$NVVXRR79A3H
M07I@.*9:'<MO*&TEEU16M*&4);47'$;2=K!3@00-E2U*"E;* FNRB@4:J*1;
M:% "5$D;*30TL.P[96S?5F\DZG<P73-")E7D2]43HF8[[DGC&5ZD)>6;%CZ@
M[,_J<$TRPS%4L-W8%<TVO&H]I0FYY@O!R*3?DM8-B3I0$2U2M"5 %^6%U%A*
M$**G@$O.&9EPTPNCSOQ#);0H+37 S#";ES4BR'"33:J0 @DI3L+VE@;*2A84
M04F*//;;FSU"P%LFF]EGY=W4:3<[L_@$:'>(24$E'C\R7TK4W3BV5ZO0E=OK
M@^4.8S&/I5MEJ_8G+NIS/*8)MF*ZZ>3>"8BMQE!90@/OLL(<4_+J1_?7+(0Z
M TZXMR7!FY92WV4.-@/(JJI B%33*4K5MUV$+6I(2L*^1*UE)VD@!=&W E"B
MDDI509F!=NC967(FI'9JEGB*RDE$)!5Z3F-:E#KQ<A38I1Z5*N5"46&!D93,
M.CQ=>LXI_DW:I*T0[&L2TNZ=D2P.!8LDT7**:HA*J.O2S5 H/+ *G7D#O B7
M>4XU7O&DM+4XE 23#XJ7-:.!1J?VI6K+8!LA)H 5HHJR5;0 K6D>X=N+99,\
M4C&N:B4I,IQU:DOR?@J?F!/V54+>ZJ+."B6E;@ZI(3SVTK.K[2T9"F,XY>W0
M1K/"C/0<:5^W,>/Z'BNSMJE%);VG$]ZIZ7;: :#I<4IU;R4):'</$/;09<[I
M?=K5LD0^*EPHI#J2H '9"5*4=JE $A))5\P^6FT-I-0*B,G909ZY>YZ-+1)9
M<NIV3AZK-QT(K.2-6L$!"SPRU5@+E%S%2DYJ.8M;- R$#98MXUE(I1=%5)=%
MT4/('L8\?\6;DIB14RB9"$N.H4ONTNMK6WW;KK*T/(0I1:<#C2TE"KU216J5
M)38AQ#H445*01\Q2H!04$J!02!M)V5#YA:_%-<Q<>_CC?P]:'<*"@W$$V&6G
MID17/KVZZLW=7'7]^)&5J;J4MKI;.H.MLLZP-=?7R_$-WV^'&N%<\K9WTXVY
M]&R_VY]4AN'CC\,,ZY&GO<$96_/FN.NOYBLPGSE7Z@?WB>,%Z>-/3JO&+$:^
M'UBY\5Q9#"$,(12)KYH7Z\G["F,D9ZY=5.@XB\8+R'/[Q:V+>.6_4Z[J[^,5
M0PW9;_'73UXPC0?;P((U_+HX?U2S4Z4W9RE&#$2Z]6NB1M-=_P#6TZ\:9VQ_
MR9+=WKWGL(\A0>ACZ1_PY*']4[3IU,AAY&^B9B8!IPJL5XTC8K9P.53(_+DQ
M>@(,Y.C_ )R4@]2/W:\LAM=_3KWX[S KX1(4K_E'T<6#EQT)\Z4CR[]4TE/Z
M@]J0K/\ J(5X+EF%)_\ M2(S88 , @( (" @.N\!#K 0TWAT@(:]&.V(W 6%
M*UI2GAH1OMH08T :9GA3?^*4L:[J1Y8FN7AIG_&?A>@O$0T >D-<* V-*WM8
MZ\;Z>'@(5(R-(^9V+L&RPL"-E'@$'R<CQ55%L97_ )H+JH)+JD3TWB*:*AM.
M@O8KY[C2O'6F7EK8P^W7K:/IUX^WNW85\[97I6OI:%.OMQO&AVVU?+,YI%IR
MKR]B(M[.M(&G76\6>Q+.RU^BUF8O)8:J:14>*,C;+);9FOV!.,@FTE ,&4/6
MY^8FK)'.25N&M/$QJ6DQ@,U.XBJ8^%#S3+,O)J;1,S;S;LNMU(>>;=:E660Z
MR7'UL3*RIUM#4NX"ZMGT;](USO\ ^T/ V<-5*-SBFL3V7IYMYZ592K"I\%:V
M&'I=Z864)<[ME$Q+A13\[[8IM8RV#\P+766)LO<PXZ#<MKW>+$C2+[5TWT;&
MR5KAJ/%V.3H\Y5I-Y,/8*45J4-,66MRC6QS\?.L*W;49%.L/(J'0LW$[,R^'
M/8/.36%_&-"6FPJ;DYYYF8=;0XF791,,S;#,HV^SWJVFG4+E)=;+CS6S\0E:
MUM;'^O']6:[6X2C&'9!]QSL^RF7F<.EYF49<2G$,464.RDS-3RV'DU6:IG'T
M.-H"R6E$-QT^XZ?CU?#';6H:'QKE]OINCQ;K+Z:_6(U[NSU[NGPW=?1X8C>:
M7MI6_$#<#X@VRB:<=_E?+G?3/G#=N_'M]7</H#$G/UO4TKD=V_6U*#.%[_QN
M\^(\3$[N../3AJ>K<>-:]&(OUUUX0XW\=N!-!7^?#.IKX0ZZ\(<!AEF<ST,\
M^5*PZ,,/6MC^?6V^$,*4],AKJ?J=-80\/;O^.%Z<?/W(\S#GZ6^D0'CK[>[J
MZ-!Z=/$>O#UOS.[3*F1IXYF)/*GIQUSJ-_(:19&8O_).0^M8=7_\^WZ1[-XX
MR1^X>.G/6ULZ5N<]\8+_ &GP]>'UX<H^++#_ )-J=8>='7[EKJ'1V]6OV8.?
MORK\HUXJT_&5>1ANR..VKW%.7/6,R(?W*MU[S_MEQ0;KL:W%_+TZKK%_^C+J
MO1W>$4#VXMW:];[=:17Z1'3X<:>WJ].O5B*DYBQ-,\N-<ZUTMI2AK$Y<^J^F
MOA36+<N51K]_J%JHEL8^=*M=:Y-U*R1GE#EIYP@+%&.H>88^5,UF[MMY7'O'
M"'E#5=%RCSG.(*IJ%(<MK+JY=UI]I6PXRXAUM5 =A;:PM"J&H-% &XH0/FXX
MJ2%I4A0JE0*5#*H4*$5%[CCRCF-M/Y&;#F5L\2=O>SEF)87ENASS3H<H3V%I
M#QR% )6F<>J2%B[W4V44_:G2CGGG:N1QAA>:?VFVRL$W6&97V;#)['9IL(E\
M2EF^X5L#XPM%:@_WJEC;6PXI8^920EU7SU0TT%J&PGAOM2B#5;+AVP2>Z2LT
M*=@"R%IH2 D_*!0@J- -J+IV9MG'98S"7E,PZWL[S^5,KE+FG%4VM>=I^Z13
MZ=2RF-5+C4+8\AE'<8@NDK+/(]9RVEVLLX<OX(Z$I(R! <(8KQ/$L58"99[$
M6YM$U+./.;"&EI1\6767F@LI400A*@"@I 0X"A*?E,2PVPNKB65-%M80-JJ5
M*[L)4E9%M3K4U!J34QTS$1^W<(^@.CUCN#W:P30"U:4!M7C;+ST.D<T ?:X'
MB<_(7/O/CNZ./'JZ1Q-=]L@.AE>VZW&(Y7SZY:Y"+'5RZJ*]RB[VXBRN)^"C
M9".@!54.:-@C3#I5W.2L3%!R6#2?G#*E;RL\5 99TQ2*Q\J(U4=)+]DG%Y]&
M'O86A\HE9IYIZ:"4@/30ET)1+,3$P?[SDI*TVY>4*@PVZHN]V5I0I'5*P7#5
MXG+XNN7"YV48>8DRI1+,I\4XIR;F):7LRU.3=>[F9P(,PXRD,EP-J<2Y9EKH
M5_E;09]7;R,' RIY4TLF)Y,SV+\IIOY-L_,D<V62C)!<)--M.G<32_-,'+1L
M:-9D5/)FE>QD<4PIB2[J;PL3,TR& PH)8#3Y1B)G7?BGEI4^R@L%<J$2R-IU
M#BP\Z0& QU>(X/C,S/EZ1Q?X23F#,F8253!>EPYA8D&C*,-K1+OK$PE$V5S2
MPEE;;:I=H*,P9F[Z#37E+CWK%Y8GMD,X<-!1=/@=@N@TCHIA#,6YQ=2,B*JP
M,(YJ9ZY2.W(]?&<OC-4UG2NO7XIB+>(O(=;E&I,(2L*0UL;*G'GW9EU0#;+(
M2DN/+#2%;9;;[MH+4E"0.SP?#'<+8<9=G79XK6V4./!S:2TS+LRK2"7'WR5A
MJ7;+JTE"7GBX\6T+<57!^T1M1-,@+'0*T>B2]XD;_$7R2BF$%*LTIMZ\I,8Q
MDBU^!@2MGTC,R\R1XH"+A=.)KL8FT.:6GVKAU',WN>'84K$&YAT3"&$2ZY=*
MRX@E($PI2-M;FT$H0V14A.VXK: 0V4I4H<]Y\,E *%+VPLC9(_T $@ YD@U!
M.R!2A-2(UKF/E#(YP]BFU4RNAF[.3)EE<V$WF#<@K4>ODUF#F=3:9$YFOTXV
MJSQZ<TEJYF/6K/ 1]V6@9H#/IUM(1*",%Y1-=DCLX0E2GIM94CXF74W+M=ZL
MSLM+NO*E4E3R \4NR[C3JF4N)HE"DK^?Y*53N02W^[8759V &UK2@.&B24BB
M@4A5-:BHH?IJ&W2A=HRHR]$V8YEZ:=LCY@F5Y8JI$?D[(V"Y9"T^-/)*M8R2
M7C)]6U9_UM/,V)<MF<I3PI.9#Q$;>:"KY;3B_@7PZWD/XHTD):2HE+;J^\0V
MQ/O*"05)"F^ZD'3+. E+H>ETD-;:PW*9HK *&%&IH*D#-32>-%!3H2M) *2E
M7[@*F\LF]LF&S(S A*0IE<:I'OAX.>C2V%>!JDXNSMF6[&X*-8F%=R#UQFE/
M59ZI-H9H2%<&++38B8J;EQ'2B<JX>&HG<&7+2[C_ ,4'@QM(46@XZBJ'RV%*
M<0@"5;<24?#)<*B\M#P"DE 2,FID.+"0@H*J$!=$']M30*-5D$**R  D%-00
M033#;:@2TM'.JKDV%@?.9M2G$AVTQ7GEC925@S?R4RSBH*[2S9U_]T]GA)7-
M,ULS)H5@AYN3AHF%*Z2=JOBG1'(8(4)4'IU+20T7]M2'4LJ0U)SDRM3""DF;
M;6B4[F6?:4A!<<H0$DT@S=:4:4HE010;)553K38"S7^VH%W:6A0KLIME6/>U
MV\: K*L8*;R^0BU+)-R-<C&PVJKR3Q2T%S)RKH89>V:&01*^KV;!T+[(7F;R
MW?H+S414J1)RSE5P1.1-!#@$P$%:)C;[M"7%'N74I#?PTT^)EM9^5R5'PZ6$
M3*2$+>?2@!)*0L)M-0DH-ZC]R3<+;3L* )(<(65E!!(2A2C85& :5MDP=$HL
M!3JAL^97U22=0.668N83&5M36@52NN)NR[,$!;K=;($\%:+%4ZQ%06=3![1[
MK9E7[<8;*:QF< S@ZA& _P"P>P5R8?6\]B$T\D+F)>74VT9AUP(9Q1UEEE>V
MTT\ZIR36)AAO9/>3:*$N/**:FYA*&P$M(;.RA:PI6P$DEE*E*%%*0D!P;"U5
M^5!R2D5SA#[<IFOF^K163+V4M<A-4>#8U^+D(VHKJRV9=RRWAF=JD*RMY_E(
M'*AH?-5BVD<TE%))I(W:KWBM)PZ#]FQ._P""O Z@O+G4(:2V^XIQ:5/ (EF9
ME9:#J>[0Y-GX113* )4EAUAS;(4:6?%$'9[I2E[:$431-UJ0-K9)4H-CO "X
M:@J2H;J[S98W<F967=)S )#2-<"XUB&L1J_+BD,G"*RK%%VM$OCH"9!1S'K*
M':JK(CS2QDA53 "'* =',L_#3#\N5H=[EU;8<179<"%$;:0;T5^X#,5 -Q')
M;7WB$+H4[20JAL145H>(R,7SB@[M^5Z5\1?=IYQG#"GN;>?O8_05,(CH]?;Q
MU]79ZL#EQJ:5WWRKO.7#RB<_+=UIKO\ .)X]/1QW]6!K;PN3X7YZ<8CKPSZ]
MXKL3\V?]']F'C_9J^SL].*UYBVGU/VKXQ8C(YY^'\[_"*#\-0UXUUTZ-1Z]<
M9C(BEP33B<ZU-JVN3D1X1@?>AIU2E<Z#2D3T\=8?9B>=QY^8IG7=ORM$9=:'
M[Q Z!T\<:>K77=K@2*'A;,B^=/N=+\8D5.775?.E+TAQX].[XZZ[]_1A[ [L
MSG;[ZD'*'5],K_2E+6SAN[>OJ[=_9V=>OIQ%AJ=;^^0\QPJ18PONTUW>._AX
M0]GX[_QUZ<2*[J:^9N/SJ;P]?XM_%,HGPXXX <"#>FZE#E_.F8](CGUUT1$?
M;\/L[?L'$6TTSWY:YDD94/'A$_;Z_?=]Q$] >''7\<+@9C+/SO<WK;,\>$1F
M>?6GTAQZ.-,37H5J1Z4._=OO6'7CU6([O>/AWZ]?&[6*C+A2M<_'?<>O,SQ^
MG/A33J])XZ.-/# 4M2N5*\M#Q&[2AB.L^J\X<=7C[>OQQ/7UO:Q->!AUKR]/
MI&-LQ<G\N,VD(YMF#5VUA3C"2;9H8SV4C'!HR=1;MK#7W;N&?1SJ2JMG;-&;
M:TU*16=5FSMV;)"?BI%%FV(ER9><F9,K,NZ6MO8*@ @BK9);6 XE24NMJ42T
MZD)<:*E%M:237!3:'*!:0JE:74*;5 1\I!(4  I)JE5!4&@C2B&NNPG8I.3B
MH++^P6&5O#16<&%9909QS*TO2\P(*T,W-KK4,6O.BQ^5,[$9P6E9Y*UMJPI"
M4EFC,2#L&]@LLJNKW2V<>:2E3LPVVEDA&VJ=DD!#LNZV4M/+[U)5-MKDVP$O
M%3])5"02VTA(XR52A/RHVBJI #;BJ)4BM4I""$M*2[7Y0$'O+_,HDV! 7?87
MM\P7-.WT>=JRN>.5='L:5>O4=;T(Z7#/%_FB@A$/*@Q37J"N8%R-FUF$$>](
M_FIJ6A;/<GE;7C8!.==/N0XQC[*!)LO(=$A-OM;;"V2MOX'X8E:7B0^&&OA)
M<J31"&UM,I>"EEL)P2N342XI)3WR$$A07LJ[T+H"FA1MJ#A%;J6%*V:#:*JO
M"9Q;%<78(RM4?*2UN51CIZP-)*8R_P Q(&O5=LUGME:XQL4B>W,"R5?KLPO=
M<@K+3(^O09J9#G@HZ'32KSQ 8T^+DEC:VE.OSC5-MMHI3,RSCCI+>*LJ51A9
M2XXV&9]IY3B^^6'%J)<2=H$NRB%@(;()2I5>[6D(!5+J .TFH"BIE: D;(V0
M?E- ;EKF9FP1&W.L/*W6Y!C8KNK5+'!+MLM,V$(=>/\ RERECZ1FHLT5@PK\
M5 3\[8\I6$/FDZ:M&D^WC(>-=SSF/I+AK"4NRN/K8<0ZZ%-,!UIQ*IN4*PK8
MFE/2H.V75NMI:FBJ4"B6U*60V%/55FER3)"T@5.R00VY0CY-A9^6B4D%-'+
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M[>%:5]^?M#U]/'HXZ,/.W.OWXZUKNAY9=>/6<:4;<S 5LM:O(%+KY#=6Z)Q
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M\6\.I<M, JU[]/\ GC:6M:BX#1,S4K4I7>E+ZMEMM,RVV@I.-*?MI3_8?VV
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MJN HLD1!,ZR9# RCFXB4RB:/*$>==*AH/)$QE53<@5!2;IE%++Y4#?[G099
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M03\SL[-5U"HRLG )ZH2%RI)-% 3"26P#1:G,BE+:E(2LWH5@)V@%%$"::O\
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M'BV1_P#YP[47K0^!&MZTC[C_ ,*=3B?Z3!)"5?\ #D@$E22H GLPY0E(*2H
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MD_"R+;6B%-MT+U!GWQ6FM2A* =D=C*87*2A[P(+TPJZYE\]X\I1S(*JA%?\
MR &EB3G'0#&L1V,,(0PA&+LVZC'VJIN1=H*J.(D1?ME&ZO-K ER12?(&0%1%
MM+H+LSJCYADUDXF4=I,R/C) DDX0X.(,)?EU;0)+=5I*30TI10(J X"FM6ED
M-K4$[>0(V?LGB\QA6+-EEQ*6YL=PZEQ-4%5=MAP.!*W)-;;P3_S\L@S<JTIY
M3 45*;<X=YO1%1R]S4--Q]4LMIFWJK=K'2"#PSTE>3>OG+T[EZBDS;-5B->6
M14Z3N.8K-P=J(O ;*)IICYQ.H9E)TK0V\ZLD%"]H*[K:6I9) 2$D)_<0I*2-
MJB@,H^SNSDSB6.]G9=J8FI.282VN7FFDMEGXQIMA#%$%3SKC7>56VEQJ8>0X
M6@MI;@)5'2ZI2B]DJ%>EY%L1)Q.0$:]?-3)_S7.2#%)1RF":@G 6ZG.GY":G
M*$43 5341,&/2Y-Y;\K*S"D[+CK#3J@+$*6VE5M0-HDIW6-:BD?$G:3#V,)[
M08WA<J[WTMA^*XA),.$A2ELRTTZRWMJ 2%+"$A+A2 DK"MGY:1H;FW\G+EQ)
MVU7.?9@M4]L>[0[7G%VF8.3I4XVJ6)83 L,;F'EFF=O5;+"/EPYV40;MHQ:1
M7.#F:--I)>1*[YAG;6?98&&XTTUVAP=5 9/$25S#*<@N3GJ%]EQ*?\LJ+@2
M4M]V:KC3YC"&5K+\HM4C-9AUB@;6<Z.L_L6DG.FR2;JVLHJ^2WRAV864M^@-
MG/Y1VIP64N8,\X"*RUVC:N=7_P!'G.M5(Q$4BFEW)$B9?6USRDU'<5-!'QQE
MU157:5-)]!QLAS9SLS)8E*.XQV0F')Z5:'>3N$/T_J^&I-226@3\5+IR2XV5
MJV10*>4AQ2..U/O2[B)7%$)8=79F:03\),&EP%'_ "G+"J5D UK1 *0>P &
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MU^CU=F[U^K$YGEQR.EN()AIX^>^_EYQ0I2LP4R;G)".166TT%P05&[@0 -
MRS<Z2B@%#<4JACE+T &F,@HC(^%:BV=*^OY,8E(.8]P?,4/XX10?Y-ZKJ/\
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MD]2H*.:W'RS!N[;<7%>P;/:%H?TR:E<993M%AV4F&)7%)<+ VD/8=.*#P*J
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MPTV9OG9%!+-("^)U&RN@3)% B[*H_$Q&I7$<YW+!<1PJ6F)"83(XDV4K;EG
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MN%)(!!%P:4O'Y\MLKY/#,G9SLLK:\KJW8;WD,N]-*P$A66LA.VG*M--?RQ&
MM<='E<SQX:O'3*>NYALTGB#>,9HC<GL1-,DIBR?/N-=FI_"YLXAA/>J82LO-
M_#E7Q$HK,A(3\ZFQ6H4-K93\BQ0!1_0[]-?UF[/]J<(:[.=M7I25Q82XDG7,
M2#0PW&V=D-A3BW &&YIP42\P\$H<<^=DG:[MO![;Y0/:TE*,YH##:2M#ZO+L
MEH99\T3HTA;@BQ2,U=L"YBFK3J_)NCIF4(I/DLY;8U5$5FD\T<$35)PG^U^/
M+ES+K=::7387,)EPU,*L4D&A#*#?-MAM05>M8VQG]#OTQ5B*,69PA3B=M+[<
MDG$9AW"BH*"TJ$OWBBMLV!:6\MA2?E+9!BXMA@]J0S#NC*H2T41"NY52-F=Y
M2OT'1SYWUR D6(6:CU<$#%C6=BK-2-+66%,\$)0TJ$0E ,7\.-X>07!P66=F
M3/.-/ O2\N7C**!*YYM*@7TH)^7;0WM+0;J+E$@!!6H<[]3,1D\.9[-RLW(N
ML2\]BJ9&4[2,J;;1V8Q!;.SAC[H%5F4F)E+3$XBB6?@@^M2^^:82?T!Y9T"/
MSRV=)K*N$L#8Z-?L$1?,L+"[(JNT7JMQ8J6"NNG0)!Y2";TLC:8EVLDF8S=<
M%%DVZQ40;'W;#Y9.*X,[()=2%2[Z'Y9:A5(0\"XWM 5("BN802!8G: 52A^?
M>T':9WL;^H.&]LYB1<*<6PR9P;M)(LJ2AT8EA3J)"?;:*_[94R)?"9QE"U .
M-E+:EME?>I^!7*#*C9LRAO+'/7S;?;!FS"R=//6X)1RF9] +($*ZBX5\Y29/
MV*8.%&\C*V4R#(S!=&)*R1._:M ?Y"1D<$D)D8GL33TZA3'<M%55-$#:;;4H
M)4D5(6X\4IV:("05!(7>_P!J.U'ZK=J<(3V+1,8)A/9F9E\45/SX;*69T*5W
M<U.LM+>8>7W:7)>3PY+CW?(5-J><2PZZ9?F?&6+-VIG6;U>_LYF!(8R3"#S*
MK#&S+HL"&-Y*T?6&!<5)]).$4>2DM(.FIE7)P.N=,#GY(>=?TYMM2RPHI;43
M1ET!U.R34))^4&@M9*4G_8-/H69[.X//(;5-R[C,X$I+LWA;SDD%/[([UUF6
M>,XAA"U@J2R'%; H@.* J;,NF9-ZS#<'HMLD&LC&MDT%IZAY*T>Z3<A),14(
MX19V:0%[:'T+ +J))JKP3 8=O*$ @N/*$N2)J^Z9;<"75IJ :,M!Q?RV53YB
MM3:*BI;;V$*^56SM!)&<A@&"8$H8@'5=Z5GN)W&IV190T[L[)<90AJ3:?F4I
M4I*9AX/O- J2A205 Y&R^E8F^1F8U*A'2I'\[EY=:X>/<M'<5+P-A:P3B?KZ
MCR(D$&DA'.VDM"M7#+RALEJHEJ@8P%'3M&'$/I=2TL?,TXFUE(6E)4@D&A24
MK0",KB@CA]J4AB3PS%%;#C.'XSA4Z5H6EQJ8E'9M$A-H2Z@J0MMR6G'4KV5$
M$9Z1W?RQM@7W+;+V]$Y/)NE&J5L*!=>2!;' Q\QH'9H#S300 2B&@]88]GDW
M_BI.5F1E,2S#V1MWK:'#3E6ULX_/G'\..#X[C6$*K7"\6Q+#C7.LE-O2P_\
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M!%E'A(FX]G%EQ;(GY-*VII^34X1-=RIYIYF7#2 F54X/[KBDJ<6V&Z(VDD@
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M*+R;B\QH^US*4),&0AJ_;ZO/'9Y@625\D=5Z2ALPHN;N,ZNWB8/G9,D.?T/
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ME2W)E)E2''4L/%MM:&W%AM12AQPJ2A"CLV4I3:T@$_N!32I C$K0" 5)!()
MVA4@4J:5R%1?*/=.6'+F7BW4!8+!3WT19ZXNHZBY*:B#M9RJS+1TW7<"@J[
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MD-%;CDR7F ^7DR +;JGU_$ =ZAMM25/_  S:DQDXF545.*<J D.J3M)4J@"
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M]Y-MN+4LSDPDAI10V@EUEMLRX=;I4S*_*>_42I8:"@MI9"@ $-V;4$@=VFY
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M&LQQ>3'UV%BH)@3_ %&<0Q;L&I=.KDH-TPTW::8]G9:#++3*;I:;;; M9+:
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M6TH<&*C!)%M&J.';E_",5]6[12RG&%*0:4!>4!M)KW:>[)52H4LH<("_DV
M@E2E-)5[K^C6,,2F*,L3+0<#CB<-;6X6EJ0)]Q4V$M%82XRPE^30MV63WZ7U
MK<FDMM-2\\^WS_V9;-%0$A)4A$TD1H1QYF2=SFB"BLC%^6+I>1+'7YITU>E<
MN2I 5)!;E"P(F@5!5(A>5^G&*MR6(/X4X0E&(; ;<=6$$3,L'5(0BI"5)?2X
MXD #;+B6DI!"@D<W_%!V0F,>[-2':R4;69CLRIY<Q*RK/?AS"\5<E$3,RZ&V
MB\TY(.2TNXM2EF61++FW%J2IM2E;OX]MCX%KF0>9SI3A_&F>LE#4=^F@ (CK
M[/;OQD*4.^U/6MB16VD4N*(2!4U)W7S-!J=.=:7.G$7;8VW\[LM\S\T,KLMY
M>N2-89,:K'2<O^0S640IRDI%OW+Z",ZEU9J&FW]C9RT>,N^EV0L4O)$H6&A6
M3EG*R<M[;V)[#X'BF%X9BF)LS3<RMR;<:9^/6RJ<#;K2&YC882P\PW++9=+#
M;+G>$.%Y]YQ*V6F=7Q'$IJ7>?98+:D)#04YW 6&MI*B4;2RM"E.I4D**TVV=
MEM*2%*5J)LZ[<^>V6$''T)G*P#3+EI8:^=[8U\O6$D%';2%I:R4N\D"P)8,\
MRQGFB<K'RB$F\\^+,G"YZY,Q<DS:JDW#M'V$P+%'W<06U,KQ-<M,!$N,1<:^
M.6W*J:80CXCOPPY+N%IQI33?<!P#XIEYI:TGKI+%)IA"6OD^'0M&TLL!7<A3
M@4LJ*-@K"P%)(4K;(J&UI4 1^G,AP5125!5!?ED+REFI@.W4. :',B8#'U2Y
MP# 74YQ   #&$0$<?,1&?RE-S0*LJEB H4%P#>PKNK01NZ#LJV21G8C+C0U-
MA>AJ18@UK'TM-?*VNG3Y0AIX\Z7'&FO_ +UFJW'PTQ7EW*ZQV>'@_P!0D-G,
M3TGLT-*$3#0%:7)N >&XQD?7\/'KW\=/7CS,5K=/B+W&M,QKIK?C[?'.#Y13
M9\M6;-.HLKDM3)P^=+/,)@O&W6FKQD(_8IN(GS(*=MFROHV99Q*S,C=%C8T#
MNVM>=QK-M,'B8*2>RS#V?])>U4G@L[B+&/XC+HP)6&.!R0GP\^VLH>^(K(L=
MVZPIY*RI3DJH(<FTO.+8#TPRAESS/M]@4Q/M2CV&2CBL1$VFDU+%MM:4J;[H
M"8<!0ZELI"0EZJD,E"4N%#3A6C@_$Y);=#Z]N<HXVJ9^HW%%12<?P"DA:8UD
MU1L<\=TM:9&5=2#:O-HF>LD2=ZI:G4B2+EI>,%X,DX=M 53^E7NT78!O#D8V
M[/\ 9U4B0&&II*91U:U2TN )-II#:IE;\O*O! DT-%YEIW8[I*%T/CC>%]IU
MS:L.1+8J)D5<6R5/H"4O.DE]:U*2TEIUY&T9A2PVM:=K;*@#'Z$OD^<BG63N
M2PC>Z3)Q.;CRZYC*VBUVI&/7L5@-*R\,SE'L.^!=W.MZA,K4^#5:%FSLGME6
MAT+@>.09RT8;'RU^JW:9&.X[LX=B+4Q@J)#"_A9.34Z)67[EA]UI#R-E$LN>
M8$_,)<,N'$2HF%2/>J<8> ]N[!8*O#L/+DY*.,SZIF;[V8F COGMMQI"RVJ[
MR9=Q4NV4!TI6]L"8V0EQ!.-OE'Q\R67Y/2^I:$=UGY0_9^BS+CN$L5:_RD:R
MR(F#?S;@D>V*J #H8I0 0-CI.PW]U/:V4-TO]D<5<V<_[DN9=2"+"Z=L[-^.
M<;/C/RG#'=6\4EA7796%A6FH'6G;?\.-=W7OQIN?MU73?3.FL=E_/5+Z6B ^
MX?9I[^-1P'#QN<\_'._,[S$G\CUK[=4$3AE3HDYZ\ :U\XB*^A_<J_B?]LN*
MS^_7,<[]9;K19_T^M\:H9S[*V4^?<@[=YAH6)XPFH&OUFVU^+L#J)A+K!U&5
MLLW4X^Q)-2 _YJNR=SMKIB>%D8=5R>><EECR1&<06-[63Q6;D$@2Q;!0XXZT
MXI"5K9<>2RAU;1)V:N(8:"MM*P V-D)VE;7&<8;<)*P:D!*@"0%)3MD!5*'Y
M2M5*$&YO819".PGL^%KSVN.(.8<MI-H@VE7B,HE NY)9JUS>9MI)9&JLH"*;
MR:+;.^\ID=Q\8R$14AU5"G5B&JF.0<>Q'O0Z%H24$E *.\2G:^$*D#O%.+*#
M\$Q5*E')8!HN,#*LE&R036E3M$*) 6 HD 7_ +BKUO46M'ODMA_(Z=ME8OEF
M;62UW:M+HK*6:S2;"9>V @6X;[(-YED[ASPK=*7MI&4N[5K<77WC(D<SB()U
M#P0NXMUBG&YY#3K#2FVF5C9#;2"VENC/<I*"E062AHJ2.\4X"5%2PM5"),LT
M5!9"BL4^8J))H0:&MJ$@5H!D*4B\Z%LMY698V6D6NBIV*OR5$J!,OXY-&;4=
M,I.F)T_+NEDK\VUD6[L'3<K'*?+N1!XU.QE1F*PW7&0%I(3#&2IF,5FYIJ8:
M?*'$3#QF%%2 E27R],O=X@BA2=J;F$4(*=ATC9)2A2<D,-MJ;*006T;";U&Q
MLH24FM:@AM"C>M4B]*B,&Q'R=^43&WL7TA,6F3RUKE=BX&G93IS]JCX*+48.
M<GI0\M+OD;2KYUD L61>7]G9+0\;5E0GF3V2GEK&[<-UF?/7VBG"PI"$-(FG
M7%N/3>PT7% B<1LMI[KY 6Y^8;45J>^1:4MAH!053\&T5[2BI2-D -DG9!_M
MFIO?YF6U  )N+[5J9I:[)N3L?4?R(C8Z;8P2+/*2,C4O/;A^K$1&1MH<VG+.
M&CC2Y)%(8FOJNU(,[%ZB]0E*N4L#+%>LQ4!3@JQ>=6_\0I:"X3-E1[L)#BIY
MK8F7%;&P=MP_W M*DE#U7$%*J4M$NT$[(3;^V10U*>Z55 %:@!(&S2A!18YQ
MBI;Y.[9W5CK:T(E=6LA=ZX6A66SLK(BTM<KEDG3[%0DLN)*<2BBN9F#3J5KF
MXG\H)P)3,58'#5ZYNZ\C%Q;QERQVBQ$+955DIEW?B&FE-$LHFN^;F#,H;*J(
M<[UEM>PWL2UB SLJ6#69-FBA10*TA*E!7S% 2I.P3>HV5*!K5=Z[5:&+ESOV
M+\N<V&CES67!\J;:[7ESK6JHMY%@OR;1"VRMVUZ#2OSU54&PSL#=I]DK-K/U
MA,9=OYS92[%$\>O3(8S,2A"70)ID!%&7=DBK3C+K(*G&W0$(6PVHMA(R.RI!
M.T,W9=#EQ_;74_,FN1"TJI0BI4%J&T2;YA0M%3@]BG(:NOEIB+A[&E/OG+5Y
M,SJUMG'3Z>=1N8U-S1A%I=!RY5BE_P GK/0JRE )(QR"$5 -%ZXU2)#O'+56
M',:GW0$N+:* %!#8:0$MA<L_*N!NVV.\:F'2X=LE;BN\/S)21"95E'[0JIIM
M$J-5;*TN(*J4!*5(3LV  % *$B-@<OJ/"Y:TJM42NF?*1%7BF\8V=2C@KR6D
ME$P%1Y+S+PB+<KV9F'RCF5EWA$&Y7<D\=.2H)%5!,O7S#[DT\Z^Y0+=65$)3
MLH2#0!*4FI"$"B4IK4) %Z5-Z$!M(0+@ "I-3Q).1)S)O<^$7EQW^[QX'%-Z
MY6IX\,Z;S;3?>)ZX>_+H1'C[/#J^_"M,ZGD+#+^=_H(GEZ\]?Q$X9\=:6\K^
M=]8B(]?1W?AK[,1:MZUH/K2PL2+G([QE$^6?'^:>L6C?Z3"YDTJT4*Q"]+"6
MV%?P<DK&NA923=N^0,D+J.=@14&[]H<2.6:QTEDB.$DS*H+I =$][#[DL^V^
MUL]XTM*TA:=I)H;A2?\ 4E0^4BHJ*T(.6"T)6E255HH$&AH;^U,_+?&%H'90
MRL@V-KCE5+7/-[@ZKCB1">GQ<F:I5C,J?S@9,8P&31@FV8NLR[79[5()J)N%
M5U)Q:%26;UJ.@X6*YKF+32UM+'=-J9[W9[ML)JIV7;E%*5M%6TH2S33:3H$!
M9!=4M:ZQ+M@*'S$*"0:DV"5*< &5/F4HG?E6@ &$Z-\G3D_",G07N:M^8DNB
MY1"HRBUFM\$G0(Z*@,L*Y5R51J%LF'+>6KS3)ZA2+&6>23Q%I/11W\+%P;5<
M8TG->[1SBU)^';9EFSM%U ;9<,P7%S3CI>466P4.F;?24)2D["]E:UD;45)D
MFDUVRI9HD)J5 ("0@)"1M$A2=@';)))%@D&D;#26S/E-+(-&[V(D5$V*^:[E
MJ(3+XITELZ,V*_G7?#@<#\H!?7ZLQ#]CH/\ Q8R14C68IM%E"#UR,2G$%12M
M(V_A ?E2?ED9-R1E],TR[JTG>HA1J1%_<M_+\O[>](K7_K.I><S)S6D'2@L+
M1B:<V&,JR5V%99=O)FA6NI$B2TNX!*623=U\\55<CZ&*P$BK+59==9W2=GZ@
M5]==I8HQR9)*64475),R3=US&\=FRZM4P$3#3VV'V2EI*7 IZ>F-GYFGD !_
M$)AP MJ .P* H!%9EFZ )JVI)"DJ!42E0;::"@-I-^[:0G,:G,Q[,LM@G9^R
MOHMFH$5$RTM#W/*YME+97$RZ8*RTA6%89E%60PS#2,:2YG=R<L49N>*\?O62
M,H4 @FD-'E*P")G'L0FGVIA:T(<9FC.-[ ("7=M2FOE)*0ED**&]E*%;(^<K
M554$2K3:%( )2I'=J)-20  ;C?0$W(!R %HMO-?Y/K*G, ;S)5B7F,N[5F'.
M664G;3$ J:59,\P(:[0N9,?!2$/(5B>1&Y%O\_*KEGYVQPT=,^0"W@5(5DE!
MXME.T,W+B72ZE$RS+-LI;:7LA"E2ZV%RJG$K0Z@]Q\.VD!#;:E(V@5A9VQBY
M*-KVR"4*45DK%R L*#@2001M[:B:D@$UH0-F+Z4V(,B57#\3LK2:,E+':+K*
M5XUG>#"/[S;GE\6E;DX0YORPLR$;F9=*^U;H/48%.%EDDU85=_%1#]AQ_P"N
M3]O[C6VEIIA+@:3WB6&A+[+(-:!&U+,N$[.WMI)V]E2DG,2K0_TJH5K<IM&A
M6LK*E<?\Q2:94.50"-E*?3H.BP[B"KJ"S>.=66ZVQ5-=PJZ.,SF!<Y^^V54J
MJIA.5%S8[++.&S<!YIFW52:(%*@@F4.L>><>7WCA!4&V6JA.S1N69;EVP16Y
M#32!6GS*!4<XN2D)% +54H\UJ4HGS5Y<;QD6)^;O_JR_NU?OQQUY^'GUPBY&
M7CU](H>+;^G*_KUOBJ'HU^[H]/'9C$TL=#ZURU%"2:USM<B'C3\Y^'6^,#9K
M_P!\L/\ JH/_ !;K%S62O^[_ -J8K<S3_P!O_N/7KQC.B.])+M!-,?\ Y0^_
M@<5&GE0^=A3F?S8Q9?SJ.O2/;@*:'^#U8WKXUA$:!T<=.O7QV84'7.NO6ZD3
M4UKUE33K?$[_ '=& XY^'C3@./K$6]\X8>69.670K?6M<K0B.!^/1UZ^&&F_
M.I%M]3SKG36)Z'TSTISBQ9<H.<SLI&BF@I-GETG2%$!$!=L:HYB$!#JU*A8G
M9BB._4!TZ!TZV<^:<PY)%@N9=_\ 4B74VD\?E?5R,;=@?]OLWVQ>%-MV6P20
M)J*AE_%VIQP;Z%S#60>&>8CPEY!K;LTJVHW5!U"U;+].WQ@B11,CB3OSY[$1
MLH5)4A%2K,H&OSC5'G$R*)I3[DARE,<0#!!3,8@TH&K<O)B8;L1M+FUJ;0X
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M638B)"IAR3*"9XN J&=.0$04\E19HH8+()(3^VI(XUU]+;O.+$)( *OW4 W
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M+44\\2DFZ\FA86-8N).>E(F*0<OT.NQ>95+R3J&E#XR90N6D4?ZG9EQ!2@)
M!IL$EQ:C1MM"2MQ:$ J&W=A\(;Q/'Y*8GVEG ,'?E\6[236RDLR>#RCZ')E3
MI4I(4J82GX:78;[R:FGW4,2DO,S"D,KU4RGVB<B=FNBY=;,-?/;\U,SLOX>-
MK=PJ.3=+F;L\CK>Y<F<7)X\?D3CX)- EI?3#IZ4DPJZ:%YQ-9N"J8IATDEBV
M&X1+2F#M%^=G)9M++[,A+N3!2^HU?4I0V&Z!Y2U*_N52*Z@B/1.T78GM=VZQ
M?&NWLX,-[/8#C,R_/89B/:;%);"FWL,;;",,::9*GILK5(,RS;15+);=)2I*
M]E0,=).CKW!UZZ@(=NO';C;>)-*<;4L;G6^HSUK'AGORUW="(TXU^/3QIT84
MWU-=YKE7RJ,],QNJ)ZI],NJYQ/'V??\ # DWN"*5Y;CZ9WO0TI$=??KWB.X!
MUT_#7QW#\<2#>E[ 9\Z&I S%-]_6)XD4K_-.5Q](G#SY='PSI6^Z(AA]*^O/
MA:UL_!##737R'U!\H0X##7KD*<<Q0<ZBM"Z,1U^OX<='I[5+WX^5K>.>7C3.
M=/+Z]9^&Z>./LZ\-+6SWY5N2<ZTXZUKK$==??2 ;^.SIPK7VWW],O4<X&W6_
M*,!6K_UBM?\ X^ ][/%H_P H_P#:K?QY_6*5?OO_ +D?2D9]]?&_[MVN*N6\
M5X9'CIN_,7>75OS>D/CQ[L+<J^'MKRA].O>&%^NO#ZVI"&%#PK_/XT-+YUK"
M*Y$A_1WX_P#1A[$U?MQ6L7YCCUY>6^U!L1QZ]HH?'''NQ8>L]#E3JNXB*NNN
MO>&H=O' #ZL*Z5%>&\5KGI:E_2%#NZZ(\XP-FM_?+#_JHO\ XIUBUK)7_=_[
M4Q6YFG_M_P#<J,ZH_P!DE]63]D->.W?BKC[:YY^?@;DQ9U]H\^CJUZ_3OUTU
MZ/7UXBE+9Z[M]:;MUCKI$YZTT\+4K3/RTB<3SY\CRO[F(A@+6I0<*ZGE_$(8
M5'+=?/EY]6A$ &GM'U^GCNP I7F3[<;:^N0B2:^@\O#KC%@W0/*9K*^)3U%>
M1S)B'!--XD1KT1.V9VH._P#-)S$,*!C#^;RG!";Q. #UV(75(M_ZG)YI0W49
M:>?40*D@4;H385(&H!VSLL.[9[43BC1N5[,3K:M-I>(SF'X6RBM+GO)T. 9T
M:4<DU'S.Y@]GON5,B9)-%<,J;78Y!)(3&3;'LK_+Y)BW*)M3\A8[*4%(3B(F
M*Q/RM1#%#3A?G9%=*'^G3#ZP*V+RY,(3P!*7*5-]BD=A-2B<+[-=J98*4M"N
MU^$8;+*70*=3ADMVC7,.$#Y=I"7Y0*H+&8%*1<5RJ<+?*C9Z18F_EE?M\!+U
MJ:;<KDF6BYM@O'/2)J:&YM46[A04E-!,FIR3E$!*&.RF&$3+#TLZ-II]M;3@
M)))0XDI50Z&AJG.]](U+"L2FL&Q/#\6DE]U.X9.RT_*KI9,Q*/(?:VTVJDK0
M M-0%)J"#4QQ<N-2L[=:6@;*0Z^9V5C1A 9A)@F)5;76V:0L:9G+#)B(B^@K
M?"M&Y9Q1#^X;(SDXMXFD9HN<OD<Y*/2KSDN^/^8EJ(=-*!UH69FD#5MY &U3
M]C@4@T*3'W/V,[28;,RTJJ4<2C!,=<=F\"6I0*9&==5WN*=F)I634[ATVXM4
MHE=/C)1UIUI2N\:"\-5NP,*-G!2[5+N$F,%/Q,YEW+2SA5-!K$NY=S%3E8=N
M7*O\PR37F(,\.E).A*SCG4PV=NS D0V.DG4 A*R,@4[5ALFJ5)4%'Y4*LI*7
M%_(VI8<4"$4C;^TDB]B."3#,N@NO2K[,^AA*%+4\TVAYB90$(^=T)9?+ZV&Z
MNOH84RW\ZQ&[+XX-N681!,2BBF8/YQN4>8_.01$H:N$#M T4C#$TG((#>2%2
ME8,&[D.E=5L5/[:;((HI ^6Z$D#YTENNU+D'XN4_RPE^5V'!Y6PGO: C:VML
M@G86?[EG5[1HVX'OVS0/_(3Q >*Y2?+C)T[EE7.;V>:3>J<R]C,OJS-04G,
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MD@H1"745ET32/+*1TT4D'9(T5@7CXCSU,O%F:R(M31/1XEA[;S95\VP%]XM
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M#BR=R>$<\=ANM&DKS;+<Y(90M>@D8]%50!,/G&QNS&%8IQUU5*SB7R2@@(F
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MU?;NAU,J81Y_:K&$XSC<U,L@)DF=B1PYI(HEJ1E 6V E-?D2Y1;^S3Y2Z4Z
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MF9-7,U.O4D5PB:\P$0%W(+E*"ZPIQ[+GG[A%+&*C2PH:@^ X:4H#U:,@-38
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M51D;UW4('/@#OWT,9C(7D%(43&.)"@43GT$Y]  !,<2E* F-IJ;D@4!$1T*
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MWA3WA]P<>O#4GD.O$P_)Z\HC?V]GO'7V:![<10U%[>N=:7WB@S'A2D3;=O\
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M@F06LE4DGBCJ&;KB#B3.Z=+'*V"T5&)/OG:!E':?"6^UTBA(Q"42U*=II9H
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MT?\ !W9U6'&B>TG:1E*\2H1WF%X0HE3<FH@U0_.5/?(%"$E:5BK3*UZ^A?\
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MP"6ED]S+X;.SKB!,8OVD*@M_&YX%$JS,K,HPE804R^Y>X T -      -VG0
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MK*C<Z;!.7/++)1ZDF3FDG94PL*+0>2B@#A;,S\(*-A1<*_B/[1:".]!JHM[
M*A'>M_[A^XH)_P!.UL%S]U-D#NP5;5=G<JMHJ,9FYEA,KK(Q5]JS\B-;97 K
MYO,-#PSNKOW<JQ1GHR>YSS++QB3R%D6S]U%2#U.*512)*>1B\9>4PJ4F4"JI
M=U)+A:"5(.V'0$J*%M_YB%$.)4E*TI*Q4MA6RJDA:#4!0-!M$@U&R214&M"
M4FI!L<R*B*G$9BY?6!<6L#>J;-N0?-XP6\19X227"2=-9)\UCQ19OEE/+G+*
M&EWC=IR?*%FL5).$TS),71TL5R[[=.\8>0"DKJMI:1L I!7521\H4M"2K(*4
MD5J1 +2:[*DFAH:*!H;V-#G0$TSH":4!B\=-==?1QINWAVCBBE:UXD7-?2^X
MTOIN$9UI2GCU6]CN$3B?$<.M<B;4B(>G[N_"HO?\<8>'YX1&_C?QOZ] \.O
M$ZC=_&9.>M*4\XFW5NK:5//2*U!C_25?J#?O$]W9QJ&X<5KT\3RZIIGGK4YH
M&?A_._JF8BY\819#"$,(12)KYH73_P!^3]A3&2,_#CPT&?*,%Y#G]#%JCZ?;
MVAV?'OZM<6^]M^\;O2O'2L5^7IQW_3AK2.3FU'RK;M(-JT B<4TZ35$P =0
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M8A@F"TG.S"Y"',UAH5F_E78$,#9FKH<,<[#L+G\6F426&RCTY,+N&VD5V$U
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MXM08ERF:<KW)<EDMOJ 4I+"E%M&ULG$-36TDJ>2 A 20BIVU)V!WB]IM(!4
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M-&M%, [PY$(6)+R>O^J6.TT[0#T^;/\ ][M2*W_\08XV:[L;M C=I'V?A9^
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M,1RGVX2&+FS"*" \E2@10E'3<(DG[.4VG1T#ITCX8\X[6_\ Q)H[Y-OA</3
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M/7EX\.A;D'C@.CQPW"N>N\:Y>]L[7M#KJN?*& -?I>M1O]_*$1N#C<&F_P
M\?NQ&1O0;J[A?D*4SY5O2)N>KFMN9Y<^,3QQQU]>)OU?/Q\[6J- 3$===::0
M_#3LXW8<-*4I3*VOF+&D/R:[^KPP\?"W'EZURA#V?C\?PPW9 WIE:IXTSK>F
M?.D/7^/I_,1I[>G>/LW[O1@!3QK6Y]-U<Z<3<TB:^F5AZVOXQ6H3YRK]0.[_
M +1/?Q^&"]-,[>6ZT9HU\/XZ_FY\5Q9#"$,(12)KYH3Z\G["F,D9^&ZNHSX>
M7.,%Y#G]#%K?;UCQT]08M^ISKQYZVI0YG(15]M!UEJ8Y-9RF"F[6R,XJ/--"
M6Z@603CN 6O,P0OCB.O1SK9Z01Z-2FZ0QYKBG_*]I Z:A/Q,F_4Y[-&2LWUJ
M%WWC6/M#L(/Z[^BKN'H_N/'!NTF%[(S#W>8A\.FE,]AV74 !D0(ZR\:_AXX]
M*MEF=]LJWR'IKYT^+^J?SRAAKO/W-N%K\1XPA]WW^O"_7G?GD/>IA^?QY0P^
M_'PT_ WPAA2_/W&N?+*_T1 "'5QZ>O$9Y5(%,M?$F].?.L20=>O#2.:&WA%F
M2L^7\R)=$Y"OS$3RP#<!HB00=B41ZMTYJ4-=X<KLWZ%VP;(F))VEEL.-^+2P
MJG_^7?'UC_ASG O".TN'U^:6Q*2G*$WI/2SC-0,S?#Z$\M\;]Y;RY9[+VCS1
M3 ?SG4J\\.(#KHLO%-3KE'?_ %B+"H0P=(&*(#T#C<Y!T/24FZ+[<LPHFV9;
M3M#S!!ZI\V=JI(X=VF[0R"AL_"8UB;"12E4-SCR6R."D;*AI0VTB]>...H<<
MNOM>E_SOIXZTCH.NNM1#CCX]N&MQG72WCGIYZY !UUU:&'A7*^OMIU2'YAA>
MUJ#PK_'(URXPA[<*VL:Z5%">?XH>4/2''''QPWYY=4%_+\PZZZ^D,3UNY=>D
M(8@9#CNXWA#IPSWT]Z^H](91'1Z>GI'J^[I'WCAD1QSU-J4/A:M?<Q.?AED-
M?SD/80[NK3C<.OOP\LJ$Z^1!WZG6''6O5Q3VB<+'KS'W^\1$#[.OPT]GM^QO
ML*:[J7N<O'/[3[Z<Z^OI][@0_N5;Q/\ MEQ6;+M:X]<XS_Z?7^Z*!BPTUM?K
MSK2N\T!K%<1T=/?]H[].KJZ-WAAEGN/(7&OMP'")SRX?86KKKG?G$_=WCZ>G
M#P.[>?'/ZYWUB/SP'TAQZ_5Z!PX5TRK?Z<JTJ;7AUY>?B(P#<]$;\V54'DDY
M^$6$QMQ03(= IC^ <V?4>C4HAJ&@Z6I_81_W4IQJ>?5AOJ5^^O\ VY\ !Y6C
M/W:'''V8IS-C8@6U/'?E;GRO;EUJ-+PXX]F)\NL_I[:V==>L. P',9TW4H,A
M]OM#HPXXX^&C+>;^5?6@]*[LG777UJ]_5QZ<#IEP'+=NIXVTA[:]>$!TZ^._
MV]/5A89TS%/0"VGA]87TZX>F6L8XS7E,SX>DR3W)ZK5RX7P%V",3#6J<4K\'
MS3EZBB^?O7J*9U521S0ZKP6*2K59X5(R2#DJXII+<2=7.MRZE2##+\R2D(0\
MX6F]E2@%*4H5*MA)*MD$%6A!H%=[V<E\ FL58:[3XC/89A&P\J8FL/E!.3>T
MVTM33+32B$I+S@2UWJDN):*@5ME&TM'/W--'.^)A:FWVI+C1KS/YHYFTRFY0
M9(9;UV3;95M\P7OG-2+F,UI!^JTN5XR[K3D6,_.U\XJL32$1&F41D2+)$1U:
M>&(H;8&-/R\RY.S;#$AATHTM,FF:)64.3JE4?F)5GY7'6C5)4A-0JH ]F[/+
M[)S,UB2_T_PS%\)D^S^ XGB?:7M7CDZPYV@7@S7<"8ENSS+*7,,PG&Y]L.RD
MI.#9=#,P^$J9*5%6^V5V5[++N.>.WTDI;\PK-Y&\S"S(DF#%E/W66:(F1;*.
MDF*::$?"Q#<XQM9KS418P$0FDT1,NX,\>N]FDI),HA2EK+\T[LJFIM24I<F%
M@4&T$T"&VP=EIH42TV D?ZE*\=[0]H'<;?:;:83AN"R'>-8+@C#SKLGA4LXL
M+<#:G5*6_-3+@[^?G7/[TY,E3BME ::;O>SB4*W81,114@0<L)DT3@FJH4&#
MCE)IG%-8I%#@ E(8450*80$4E  2#V\F"9R5H4I/Q+ "B*I![Q(&V I)(!))
M 4FP_<#>-4G[2,Z2E2A\),52D@*4.Y79)*5@*(LD["J$@[)R.K&RJFS*,B+6
M.D& ADOLQ(F\N=IN0423RZD5&J28)QL?R5F::XMWJFIRN5PYTB#$/Z/C=^W)
M</=!;S+Q_P").VZQW39;(4<99"RHE]TJ0ZI(6VD[.P@[)6Z?GCS[]/0T._[M
MEYFG9?L"E0><#FTE."/EM*:,,@*;2HMNJN%K&T$-#Y(SA>[N9B24@*Z\CB3C
M&/)(V*4D <*15(KRY%A4FY0K4"G>2:J29@@ZV@Y1DI18Q'0 E&MW+D//%$7&
M^E]-#7C:GTX^FI%;GC05N>'"F_SMEK;1[78YVU2N0V6$@ADVPH-;A)T6UIKJ
MTM>I>'LZSA[Y_CVT@X4B56RBSI 9,BBB3V&D9))@X$KA,[=KW$Q@.(2V"8=C
MZNY5AN)S$U*LK:=VW&9F55LJ9FT!([AQY(4ZP@J47&4ERP$='+=H\,F\?Q3L
MV@O)Q7"I:4G'FWF^Z:?E9M 6E^2<*R9AIA2DLS"PA ;>4&QM$DQL31\RJ[+7
M&S90-)B7L]ORO@JNK=; M&MT8P[Z>;K':-EGC,Q6Q)Q=!J9^[8$;)II)+ 1)
M=PX;OTVN<S@.(2.#X7C4REIN3Q=Z;:D4%W_FG4R90EZ8+!2"F6+B^[0X%$E:
M:J0A+C2G,93M%AN(8YBV RBGG9W!69-W$%I:K*,JG@M3,M\0%$&:#: ZMG9
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M[38++&2PG'<4PV4+JWC+RDX\PR7G$H2MPH0H)VUI0A*E$5(2 <HO@  H  :
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MW9VL63!C$M+Y<V3=PI#0"7E):NZ?-VH%9OXIRVB-S[+]GUXYV5QO% Y,(Q;
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M#G?S%3NY4-O:@AU_/F.?.L1X=W':'&X>C G4 Z:'VSUSIYTI$\^/6X]7&<7
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M7&VX'AE#^//KGNB/O#I[/3QUX5''QX<]:$UUH#6XI$_SEO\ #K2'9O\ O^S
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MAT<=_P!N]:HXWL>0KGNZJ16=^G//KA]K3U\<#T^W#4G7D+Y:Z^=(CKK=EZ1
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MF9P(W.<3%,"14S=GA<XB3=>6N;Q64"V%I2YA4P&'5.D@)#UTAQJA4I2=I))
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M!'^DE[OYH0T]1^C\!UPVZ5L-.&7*E1N]:P*..^NM?/7^12)\Q'^DE_5F[_\
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M,3YB/U.2_JC#_P#4Q.V=P]>O#[Q&QO/I2(\Q'^DD_5#_ )F[#;TH,NO#A$[
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G&$(80AA"&$(80AA"&$(80AA"&$(80AA"&$(80AA"&$(80AA"/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
